

405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No oIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerNon-accelerated filerSmaller reporting companyEmerging growth companyXIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. oIndicate by check mark whether the registrant has filed a report on and attestation to its managementâ€™s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. oIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. oIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrantâ€™s executive officers during the relevant recovery period pursuant to Â§240.10D-1(b). oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No xBased on the closing price of the registrantâ€™s common stock as reported on the Nasdaq Global Select Market, the aggregate market value of the registrantâ€™s common stock held by non-affiliates on December 29, 2023 (the last business day of the registrantâ€™s most recently completed second fiscal quarter) was \$114.6 million.As of September 9, 2024, there were 135,620,541 shares of the registrantâ€™s common stock outstanding.DOCUMENTS INCORPORATED BY REFERENCEPortions of the registrantâ€™s proxy statement for the upcoming Annual Meeting of Stockholders to be filed no later than 120 days after the end of the registrantâ€™s fiscal year ended June 30, 2024, are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent described herein.Table of ContentsTABLE OF CONTENTSPART IIItem 1.Business18Item 1A.Risk Factors18Item 1B.Unresolved Staff Comments46Item 1C.Cybersecurity46Item 2.Properties47Item 3.Legal Proceedings47Item 4.Mine Safety Disclosures48PART II49Item 5.Market for Registrantâ€™s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities49Item 6.Reserved49Item 7.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations50Item 7A.Quantitative and Qualitative Disclosures About Market Risk66Item 8.Financial Statements and Supplementary Data67Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure97Item 9A.Controls and Procedures97Item 9B.Other Information97Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections97PART III98Item 10.Directors, Executive Officers and Corporate Governance98Item 11.Executive Compensation98Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters98Item 13.Certain Relationships and Related Transactions, and Director Independence98Item 14.Principal Accounting Fees and Services98PART IV99Item 15.Exhibits, Financial Statement Schedules101Item 16.Form 10-K Summary101Signatures1Table of ContentsCautionary Note About Forward-Looking StatementsThroughout this Annual Report on Form 10-K for the year ended June 30, 2024 (this â€œAnnual Reportâ€), we make â€œforward-looking statementsâ€ within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€) and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). This Annual Report contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this Annual Report are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as â€œanticipate,â€ â€œestimate,â€ â€œexpect,â€ â€œproject,â€ â€œplan,â€ â€œintend,â€ â€œbelieve,â€ â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œcan have,â€ â€œlikelyâ€ and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth opportunities or initiatives, strategies or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including:â€¢the viability of our growth strategy, including our ability to obtain licenses to open our de novo centers in Downey and Bakersfield, California, and our ability to ramp up our de novo centers in Florida;â€¢our ability to identify, successfully complete and integrate acquisitions, joint ventures and strategic partnerships;â€¢our ability to attract new participants and retain existing participants and grow our revenue throughout our new and existing centers;â€¢the impact on our business from ongoing macroeconomic related challenges, including labor shortages, labor competition and inflation; â€¢the results of periodic inspections, reviews, audits and investigations under the federal and state government programs, such as the audit of our Sacramento, California center and the targeted medical review of our San Bernardino, California center, and our ability to sufficiently cure any deficiencies identified by the respective federal and state government programs;â€¢the adverse impact of inspections, reviews, audits, investigations, legal proceedings, enforcement actions and litigation, including the current civil investigative demands initiated by federal and state agencies, as well as the litigation and other proceedings initiated by, or on behalf, of our stockholders;â€¢the risk that the cost of providing services will exceed our compensation under the Program of All Inclusive Care for the Elderly (â€œPACEâ€);â€¢our increased costs and expenditures in the future and our inability to execute or realize the benefits of our clinical value initiatives;â€¢the dependence of our revenues and operations upon a limited number of government payors;â€¢the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants;â€¢the impact on our business of renegotiation, non-renewal or termination of capitation agreements with government payors;â€¢the impact of state and federal efforts to reduce healthcare spending; â€¢the concentration of our presence in Colorado;â€¢our ability to compete in the healthcare industry, including as a result of new or growing market participants;â€¢the difficulty to predict our future results, which could cause such results to fall below any guidance we provide;â€¢our dependence on our senior management team and other key employees;2Table of Contentsâ€¢the impact of failures by our suppliers, or limitations on our ability to access new technology or medical products;â€¢our ability to manage our operations effectively, execute our business plan, maintain effective levels of service and participant satisfaction and adequately address competitive challenges;â€¢our ability to establish a presence in new geographic markets;â€¢the impact on our business of security breaches, loss of data or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;â€¢our ability to accurately estimate incurred but not reported medical expense or the risk scores of our participants;â€¢the impact on our business of the termination of our leases, increases in rent or inability to renew or extend leases;â€¢the effects of a pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, as well as weather and other factors beyond our control;â€¢our ability to adhere to complex and changing government laws and regulations in the healthcare industry, including U.S. healthcare reform, the regulation of the corporate practice of medicine and the Health Information Technology for Economic and Clinical Health Act of 2009 (the â€œHITECH Actâ€), and their implementing regulations (collectively, â€œHIPAAâ€), and other privacy laws and regulations in the healthcare industry;â€¢our status as a â€œcontrolled companyâ€;â€¢the impact of our share repurchase program;â€¢the enhanced requirements of being a public company;â€¢the impact on our business of disruptions in our disaster recovery systems or business continuity planning; andâ€¢other factors disclosed in the section entitled â€œRisk Factorsâ€ and elsewhere in this Annual Report.We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Annual Report are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.3Table of ContentsPART IIItem 1.Â A Â A BUSINESSWho We AreInnovAge is the leading healthcare delivery platform by number of participants focused on providing all-inclusive, capitated care to high-cost, seniors, many of whom are dual-eligible. Our programs are designed to address two of the most pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. Our participant-centered care delivery approach is designed to improve the quality of care our participants receive, while keeping them in their homes for as long as safely possible and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. Through our Program of All-Inclusive Care for the Elderly (â€œPACEâ€) program, we fulfill a broad range of medical and ancillary services for seniors, including in-home care services (skilled, unskilled and personal care), in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. We directly contract with government payors, such as Medicare and Medicaid, and do not rely on third-party administrative organizations or health plans. We believe our model aligns with how healthcare is evolving, namely (i) the shift toward value-based care, in which coordinated, outcomes-driven, quality care is delivered while reducing unnecessary spend, (ii) eliminating excessive administrative costs by contracting directly with the government, (iii) focusing on the patient experience, and (iv) addressing social determinants of health.InnovAge Holding Corp. (formerly, TCO Group Holdings, Inc.) and certain wholly owned subsidiaries were formed as for-profit corporations effective May 13, 2016, for the purpose of purchasing all the outstanding common stock of Total Community Options, Inc. d/b/a InnovAge, which was formed in May 2007. In connection with this purchase, Total Community Options, Inc. and certain of its subsidiaries converted from not-for-profit organizations to for-profit corporations. In connection with our initial public offering (â€œIPOâ€), which occurred in March 2021, we changed the name of our company from TCO Group Holdings, Inc. to InnovAge Holding Corp. (â€œInnovAgeâ€). In this Annual Report, the terms â€œwe,â€ â€œour,â€ â€œour companyâ€ and â€œusâ€ may refer, as the context requires, to InnovAge or collectively to InnovAge and its subsidiaries.InnovAge is headquartered in Denver, Colorado and manages its business as one reportable segment, PACE. PACEAs of June 30, 2024, the Company served approximately 7,020 PACE participants, making it the largest PACE provider in the United States (the â€œU.S.â€) based on participants served, and operated 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania and Virginia.PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, population in a community-based service model. We define dual-eligible seniors as individuals who are 55+ and qualify for benefits under both Medicare and Medicaid. InnovAge provides all needed healthcare services through an all-inclusive, coordinated model of care, and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, Veterans Administration (â€œVAâ€), and private pay sources. Additionally, under the Medicare Prescription Drug Plan, the Centers for Medicare and Medicaid Services (â€œCMSâ€) share part of the risk for providing prescription medication to the Companyâ€™s participants. We deliver our participant-centered care through the InnovAge Platform (as defined herein), which is designed to bring high-touch, comprehensive, value-based care. We believe the traditional fee-for-service reimbursement model in healthcare does not adequately incentivize providers to efficiently manage this complex population. Dual-eligible seniors must navigate a disjointed, separately administered set of Medicare and Medicaid benefits, which often results in uncoordinated care delivered in silos. Our vertically integrated care model and full-risk contracts requires us to coordinate and manage all aspects of a participantâ€™s health, and deliver the necessary care. Costs under the PACE program are estimated to be 12% lower on average than for a comparable dual-eligible population aged 65 and older under Medicaid, based on an analysis of most recently available data by the National PACE Association in January 2024. Importantly, we believe our vertically integrated model can deliver better health outcomes and reduces unnecessary or avoidable medical spend. In addition, as of June 30, 2024, we believe our participants had a lower hospital readmission rate compared to a frail, dual-eligible or disabled waiver population. In addition to reducing spend, we also focus on ensuring our participants are satisfied with the services delivered. Our participant satisfaction is administered quarterly and is measured through a Net Promoter Score (â€œNPSâ€). NPS is a metric used to measure customer satisfaction, loyalty and enthusiasm by asking how likely they are to recommend a company to a friend or colleague, and is reported as a number between negative 100 and positive 100. Based on surveys of our participants administered by a third-party vendor in FY24, our average FY24 NPS was 46. According to Qualtrics, the creator of the NPS, Bain and Company suggests a score above 20 is favorable and above 50 is excellent. We believe our value proposition to each constituency translates into a predictable economic model. We directly contract with Medicare and Medicaid on a per member, per month (â€œPMPmâ€) basis, which creates recurring revenue streams and provides significant visibility into our revenue trajectory. We receive 100% of the pooled capitated payment to directly provide or manage the healthcare needs of our participants. Industry ChallengesUnsustainable and rising healthcare costs. According to data from the Office of the Actuary of CMS, healthcare spending in the United States grew at approximately 5% per year from 2017 to 2022, and in 2022 represented \$4.5 trillion of annual spend, or 17.3% of U.S. GDP. The overall growth rate of healthcare spending is expected to accelerate due to the aging population. We believe government healthcare spend is higher for the dual-eligible population, who typically suffer from multiple chronic conditions and require long-term services and supports. We believe Medicare and Medicaid spend on average three times more per capita on a dual-eligible senior than a Medicare-only senior. Improved care management of dual-eligible seniors is critical to reducing the rapid growth in government healthcare spending in the United States.Highly fragmented, uncoordinated healthcare system. The U.S. healthcare system is complex and highly fragmented, resulting in piecemeal care delivery across different providers who each lack a complete picture of the patient. Furthermore, this dynamic often makes the healthcare system difficult for patients to navigate. Primary, acute, behavioral and long-term care providers need to work together to effectively manage a patientâ€™s care, yet, today, they often work in silos. This lack of care coordination can result in missed or inaccurate diagnoses, gaps in care, unnecessary spend and ultimately sub-optimal patient outcomes.High-cost, dual-eligible seniors are at high risk of falling through the cracks of the U.S. healthcare system. Few government-sponsored programs other than PACE bring together the Medicare and Medicaid benefit for these individuals, creating further barriers to delivering coordinated care. Dual-eligible beneficiaries are among the most medically complex, high-frequency users of healthcare services. Based on InnovAge data as of June 30, 2024, the typical InnovAge participant had, on average, ten chronic conditions and, based on the data most recently available to us from a 2022 modified health outcomes survey, required, on average, assistance with two or more activities of daily living (â€œADLsâ€). A lack of coordination across providers can have severe consequences given the high occurrence of chronic illnesses and other underlying health issues in this population.Prevalence of wasteful spending and sub-optimal outcomes. A 2019 study, published in the Journal of the American Medical Association, estimated that approximately 25% of all annual healthcare spending is for unnecessary services, excessive administrative costs, fraud and other inefficiencies creating waste. Proper management of chronic conditions and targeted interventions to mitigate challenges presented by social determinants of health can significantly reduce the incidence of acute episodes, which are the main driver of emergency room visits and hospitalization among the dual-eligible senior population. Healthcare spending on nursing care facilities and continuing care retirement communities is expected to reach approximately \$216.3 billion in 2024, based on the latest projections made by the Office of the Actuary of CMS, which is a 3.3% increase compared to the current 2023 projection. Similar to spend on hospitals and other high-acuity care settings, we believe many of these dollars can ultimately be saved by providing proactive treatment and investing in proper medical and social supports to enable frail seniors to live in their homes and communities.Despite high levels of spending, the U.S. healthcare system struggles to produce better health outcomes and delivers low levels of patient and provider satisfaction. Payment structures are evolving to address healthcare issues. Policymakers and healthcare experts generally acknowledge that the fee-for-service model is not designed to deliver on the â€œtriple aimâ€ of providing low-cost, high-quality care while improving the patient experience. Historically, healthcare delivery was oriented around reactive care for acute events, which resulted in the development of a fee-for-service payment model. By linking payments to the volume of encounters and pricing for higher complexity interventions, the fee-for-service model does not incentivize providers to practice preventative medicine or manage patients in lower cost settings. Rather, many policymakers and healthcare experts 2Table of Contentsbelieve it unintentionally creates the opposite resultâ€”acute, episodic care delivered in high-cost settings that unnecessarily drive up the total cost of healthcare.High-cost, dual-eligible seniors often require proactive, coordinated care plans to address their medical acuity, need for long term support and risks related to social determinants of health. Without personalized, patient-centered care that removes barriers to preventative or other early treatment, high-cost, dual-eligible seniors would continue to likely over-utilize healthcare in higher-cost settings, such as emergency rooms and nursing homes.PACE is a value-based government-sponsored, provider-led managed care program focused on enabling frail, dual-eligible seniors who have skilled nursing needs to age independently in their homes that can mitigate concerns over utilization of high-cost healthcare. PACE providers receive a monthly risk-adjusted payment for each participant (PMPM) directly from Medicare and Medicaid to oversee the totality of medical care an enrolled participant needs. Fully capitated models, such as PACE, incentivize organizations to better manage chronic conditions to avoid high-cost acute episodes and to invest in services that fall outside the scope of a fee-for-service model. These services, such as care coordination and ancillary support to remove barriers created by

social determinants of health, can have a significant impact on a participant’s overall health. InnovAge participants are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in average Medicare Advantage (MA) programs. As a result, we receive larger payments for our participants compared to MA participants. This is driven by two factors: (i) we believe we provide care for a higher acuity population, with an average Medicare Risk Adjustment Factor (RAF) score of 2.46 based on InnovAge data as of June 30, 2024, compared to an average RAF score of 1.08 for Medicare fee-for-service non-dual enrollees, as calculated in an analysis by Avalere Health in June 2020 of a cohort of individuals enrolled in Medicare Fee-for-Service in 2019, with a higher RAF score indicating poorer health and higher predicted healthcare costs, and (ii) we have Medicaid spend in addition to Medicare. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. Legacy healthcare delivery infrastructure has been slow to transition from fee-for-service to value-based care models. In order for the shift to value-based payment models to drive meaningful results, we believe there must be a corresponding shift in care delivery models. While there has been significant investment by providers, payors and technology companies in developing solutions to enable higher-quality and lower-cost care, the healthcare industry is still heavily reliant on fee-for-service reimbursement models. The COVID-19 pandemic amplified several flaws in the current legacy healthcare delivery system, including the need for integrated, multimodal value-based care delivery models. Traditional healthcare providers faced dwindling fee-for-service visits during the stay-at-home orders, government restrictions and general patient fear of medical settings, reducing their revenue and straining their ability to provide care. Providers that operate comprehensive value-based models, like us, were better positioned to quickly pivot their care delivery approach to safely treat patients in virtual and home-based settings without losing revenue. Our Market Opportunity We are one of the largest healthcare platforms focused on frail, dual-eligible seniors, serving participants exclusively through our PACE program. We have built the largest PACE-focused operation in the country based on number of participants, with 20 operational centers across six states; we are 11% larger than the size of our closest PACE-focused competitor and more than 30 times larger than the typical PACE operator. Given our scale across geographies, we believe we are positioned to capitalize on a significant market opportunity to provide care to frail, high-cost, dual-eligible seniors. Our care model targets the most complex, frail subset of the dual-eligible senior population. We estimated our target population at approximately 2.3 million in 2023 based on data from the U.S. Census Bureau from 2018, representing seniors who we believe are dually eligible for Medicare and Medicaid and meet the nursing home eligibility criteria for PACE. We prioritize growth in high-density urban and suburban areas, where there are sizable numbers of frail dual-eligible seniors who would benefit most from our program. We leverage the InnovAge Platform (as defined herein) which is designed to provide comprehensive, coordinated healthcare to enable our frail, eligible for skilled nursing seniors to live independently in their homes and communities. We believe people want to stay in their home for as long as possible, and the InnovAge Platform is designed to empower seniors to age independently in their own homes, on their own terms, for as long as possible. Table of Contents Based on historical results for the year ended June 30, 2024 and our experience and industry knowledge, we estimate an average annual revenue opportunity of \$113,000 per participant (or \$9,400 PMPM) and a total addressable market opportunity of \$260 billion, based on our estimated market of approximately 2.3 million PACE eligible in the United States in 2023, as described above. Of these estimated PACE eligible participants, only approximately 77,000 are enrolled in a PACE program, based on a June 2024 report from the National PACE Association, and over the next four years, the National PACE Association is targeting a PACE enrollment increase at a compound annual growth rate (CAGR) of approximately 23%. As a result, we believe that, subject to our ability to effectively execute our growth strategy, we have a substantial opportunity to bring our comprehensive value-based model of care to more frail, dual-eligible seniors across the country. The InnovAge Platform Our participant-centered approach is tailored to address the complex medical and social needs of our frail dual-eligible senior population. We leverage the InnovAge Platform to deliver comprehensive, coordinated healthcare to our participants. The InnovAge Platform consists of (1) our Interdisciplinary Care Teams (IDTs) and (2) our community-based care delivery model. The key attributes of the InnovAge Platform include: Our participant focus. Our model is focused on caring for frail, high-cost, dual-eligible seniors. Our target participant population is the frail, nursing home-eligible subset of dual-eligible seniors to whom we refer as high-cost, dual-eligible given their high healthcare acuity and the associated high level of spend. Our participants are among the most frail and medically complex individuals in the U.S. healthcare system. Based on InnovAge data as of June 30, 2024, the typical InnovAge participant had, on average, ten chronic conditions and, based on the data most recently available to us from a 2022 modified health outcomes survey, required, on average, assistance with two or more ADLs. Our platform is designed to enable participants to exercise their preference to age independently in their homes and stay active in their communities for as long as safely possible. All of our participants are certified as nursing home-eligible. As of June 30, 2024, 92% of our participants were able to live safely in their homes and communities. Our interdisciplinary care teams. The IDT structure is core to our clinical model. Our IDTs oversee all aspects of each participant’s unique care plan and function as the core group of care providers to our participants. Our IDT structure is designed to enhance access to care for our participants and eliminate information silos and gaps in care that frequently occur in a fee-for-service model. We are responsible for all of our participants’ medical care, and we direct care delivery across multiple settings. We deliver individualized care for each participant that addresses both his or her specific medical conditions and social determinants of health. We deliver or manage primary and specialist care, in-home care, hospital visits, nutrition, transportation to and from our care centers and to other medical appointments, pharmacy and behavioral health. We leverage a technology suite, which we believe is powered by industry-leading clinical and operational information technology solutions to collect and analyze data, streamline IDT workflows and empower our teams with timely participant insights that improve outcomes. Each IDT convenes, at a minimum, experts across at least 11 disciplines to collectively manage the complex care needs of each participant. IDTs are typically comprised of a primary care provider, registered nurse, master’s level social worker, physical therapist, occupational therapist, recreational therapist or activity coordinator, dietician, center manager, home care coordinator, personal care attendant and driver. The IDTs meet multiple times per week to discuss each participant’s care plan and closely monitor key clinical metrics so that each participant receives optimal treatment based on his or her current conditions. Our community-based care delivery model. Our high-touch model delivers care across a continuum of community-based settings. Our multimodal approach leverages (1) the care center, (2) the home and (3) virtual care capabilities to deliver comprehensive care to our participants. Our capitated payment model gives us the flexibility to invest in care coordination, transportation and other services to mitigate challenges presented by participants’ social determinants of health, regardless of what is traditionally covered by insurance. As a result, our capabilities are not limited to what we are able to offer inside of our centers. Our community-based care centers. Our purpose-built community-based care centers are designed for the specific needs of our target population and serve as a medical and social hub for our participants. Our participants often spend the full day in these centers receiving medical treatment, meals and physical therapy and socializing with peers. Our care centers are larger than those of most other comparable care organizations and include dedicated spaces for medical care, physical therapy, behavioral health and dentistry, in addition to day-rooms and dining spaces for socialization among our participants. We incorporate population-specific design elements, such as grab bars and rounded hallways, to accommodate the frailty and the prevalence of dementia among our participant population. The size and design of our centers enable us to deliver a significant portion of our participants’ care in one location, simplifying the healthcare experience for participants and their families. Our in-home care capabilities. Our in-home care capabilities are designed to enable our participants to live safely in their homes and avoid nursing homes to the extent safely possible. We directly deliver or manage all skilled and unskilled care a participant may require to live independently at home. Additionally, we have dedicated strategic partnerships with hospital-at-home providers to deliver acute care in-home when appropriate. In addition, we manage transportation not only to and from our centers, but also to all third-party medical appointments. Our capitated payment model gives us the flexibility to invest in home modifications, such as ramps, grab bars and shower chairs, to reduce falls and make the home safer for our participants. We believe our presence in our participants’ homes gives us real-time insight into their health and enables us to positively influence many environmentally-driven social determinants of health. Our virtual care capabilities. Our virtual care capabilities give us the flexibility to deliver medical care and social services virtually when appropriate. Our physicians are equipped with several telehealth platforms to provide virtual care and utilize the option best suited for each individual participant’s preferences and needs. We offer telehealth visits when clinically indicated, allowed per regulations and more convenient for the participant. Our aim is to make virtual care access simple and convenient for our participants. Addressing social determinants of health. Our care delivery model is designed to provide services that mitigate challenges presented by participants’ social determinants of health, such as: Economic stability Transportation Physical environment Community and social context Food and nutrition Healthcare literacy Fitness Our technology suite. Our fully capitated care model is operationally complex; it requires coordination among dozens of different providers per participant, real-time integration of clinical data from disparate sources and predictive analytics to enable effective interventions. We license a suite of third-party clinical technologies that we use to create a comprehensive view of our participants’ health, empowering our IDTs to make optimal care decisions. We leverage what we believe to be industry-leading reporting and predictive analytics solutions to collect and analyze data, stratify our population and uncover actionable participant insights. Our Value Proposition We believe that our healthcare model is one where all constituencies involved, including participants, their families, providers and government payors, have the ability to win. Our participants win by enjoying a better participant experience, improved health outcomes and remaining in their homes and communities for longer. We leverage our differentiated care delivery model to improve the health of our participants and help them avoid unnecessary hospitalizations and nursing home care. We enable our participants to remain in their homes as long as possible and age independently. As a result, as of June 30, 2024, approximately 92% of our participants lived in their preferred setting: their home or community. We believe our care model also delivers better clinical outcomes: our participants have fewer hospital admissions and lower hospital readmission rates. Our care model is not one size fits all; it is customized to the unique needs of each participant, which benefits participant health and increases participant satisfaction with our program. Families win as we reduce their caregiving burden and provide peace of mind. We significantly reduce the caregiving burden on the families of our participants. Our model handles all transportation to and from medical appointments and center visits, helps participants with ADLs, and creates social outlets for participants to reduce isolation. Most importantly, we believe we offer peace of mind to our participants’ families who know their loved ones’ complex needs are cared for. Friends and family of participants remain one of our largest referral sources for recruiting new participants. Our providers win as they are able to focus on improving the lives of their participants. We enable our providers to focus on taking care of participants by providing them with meaningful clinical and administrative support. We remove the pressure of trying to optimize visit volume by rewarding quality, not quantity, of care. We estimate that our providers (1) have a smaller number of participants to care for and spend more time with each participant than providers in similar care organizations, and (2) benefit from the support of a multidisciplinary team. Government payors win through fiscal certainty and lower costs. We believe we provide fiscal certainty through our capitated payment arrangements and reduce the cost of both medical and long-term support and services for high-cost, dual-eligible seniors. For states, costs under the PACE program were estimated to be 12% less than the cost of caring for a comparable population through other Medicaid services based on an analysis of most recently available data by the National PACE Association in January 2024. Our Growth Strategy Increase participant enrollment and capacity within our centers For the fiscal year ended June 30, 2024, our participant census was approximately 7,020 across our 20 centers in six states. During fiscal year 2024, we opened or acquired three new centers, two in Florida and one in the Crenshaw neighborhood of Los Angeles, and have two additional planned de novo centers in Bakersfield and Downey, California. During fiscal year 2025, we expect to focus on increasing enrollments and utilization of capacity at our existing centers. Build de novo centers In fiscal year 2024, we expanded into a new geography by opening two de novo centers in Florida (Tampa and Orlando) and acquired one planned de novo center in Bakersfield, California. We also have one additional planned de novo center in Downey, California. We believe de novo centers generate compelling long-term unit economics and the potential for robust internal rates of return. We have operated our platform across different geographies and we expect to prioritize a list of target markets that we believe are optimal environments to launch the InnovAge Platform. Our approach to de novo developments includes building centers to our experience-based specifications, with flexibility for future center expansion factored into the blueprints where possible. Execute tuck-in acquisitions and partnerships Over the past six fiscal years, we have acquired and integrated four PACE organizations for a total of eight operational centers (excluding the PACE center in Bakersfield, California, which is not yet operational). These acquisitions represent expansion of our InnovAge Platform into one new state and five new markets. By bringing acquired organizations under the InnovAge Platform, we hope to further realize revenue growth and improve operational efficiency and care delivery post-integration. We believe there is a robust landscape of potential tuck-in acquisitions to supplement our organic growth. In fiscal year 2024, we completed an acquisition of two PACE programs in California from ConcertoCare, which included one operating center in the Crenshaw neighborhood of Los Angeles and a second program that is a planned de novo in Bakersfield. We remain disciplined in our approach to acquisitions and in the past have executed multiple types of transactions, including turnarounds and non-profit conversions. When integrating acquired programs, we work closely with key constituencies, including local governments, health systems and senior housing providers, to enable continuity of high-quality care for participants. We also have pursued and intend to pursue additional relationships with key stakeholders, existing organizations and other care providers in order to form partnerships in target geographies. In fiscal year 2024, we opened the Orlando PACE center as a joint venture with Orlando Health, a healthcare system broadly recognized for its care programs, services and extensive community outreach and support with the goal of magnifying the impact and extend the reach of PACE services for eligible seniors in the Orlando market. Reinvest in the InnovAge Platform to optimize performance We believe that our ongoing investment in the InnovAge Platform drives greater efficiency across our business, creating a virtuous cycle that allows us to continue providing necessary care to our participants. Our platform is the largest among PACE providers based on participants served and one of the most geographically diverse. We plan to continually invest in technology improvements and seek to unlock new insights through enhanced data analytics capabilities that will advance our care model. We have begun to invest in building capabilities to increase our sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends. We believe our investments will ultimately result in better health outcomes and lower medical costs for participants. In the long-term, we intend to reduce medical costs in order to generate savings for reinvestment to support continuous improvement of the InnovAge Platform. Regulation Our operations are subject to extensive federal, state and local governmental laws and regulations. These laws and regulations require us to meet various standards relating to, among other things, arrangement and provision of covered healthcare services to our participants, operation and management of PACE centers, dispensing of pharmaceuticals, personnel qualifications, maintenance of proper records, and quality assurance programs. If any of our operations are found to violate applicable laws or regulations, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price, including: suspension, termination or exclusion of our participation in government payor programs; loss of our licenses required to operate healthcare facilities or administer prescription drugs in the states in which we operate; criminal or civil liability, fines, damages or monetary penalties for violations of healthcare fraud and abuse laws, including the federal Anti-Kickback Statute, Civil Monetary Penalties Law, the False Claims Act (FCRA) and/or state analogs to these federal enforcement authorities, or other regulatory requirements; enforcement actions by governmental agencies and/or state law claims for monetary damages by patients or employees relating to breach of, impermissible use or disclosure of, or other incident relating to protected health information (PHI) and other types of personal data or personally identifiable information (collectively, PII) and, together with PHI, PII) that we collect, use, and disclose, in violation of federal or state privacy laws, including, for example and without limitation, the Health Insurance Portability and Accountability Act of 1996, as amended by HITECH Act (HIPAA), or state data privacy and security laws; mandated changes to our practices or procedures that significantly increase operating expenses or decrease our revenue; imposition of and compliance with corporate integrity agreements that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our business practices which could lead to potential fines, among other things; termination of various relationships and/or contracts related to our business, including joint venture arrangements, contracts with government payors, and real estate leases or contracts with clinical providers; changes in and reinterpretation of rules and laws by a regulatory agency board, or court, such as state corporate practice of medicine laws, that could affect the structure and management of our business; changes in payor reimbursement, including negative adjustments to government payment models including, but not limited to, Medicare Parts C and D and Medicaid; and harm to our reputation, which could negatively impact our business relationships, the terms of government payor contracts, our ability to attract and retain participants, physicians, and other clinicians, our ability to obtain financing and our access to new business opportunities, among other things. Table of Contents We expect that our industry will continue to be subject to substantial regulation, the scope and effect of which are difficult to predict. Our activities have been and could continue to be subject to investigations, audits and

inquiries by various government and regulatory agencies with whom we contract at any time in the future. See Item 1A. Risk Factors, “Risks Related to Regulation.”Federal and State Regulation of PACE ProvidersWe are subject to a complex array of federal and state laws, regulations, and guidance, including legal requirements directly applicable to PACE providers as well as Medicare and Medicaid laws and regulations. These laws and guidance relate to our organizational structure, governance, fiscal soundness, marketing activities, participant enrollment and disenrollment, charges to participants, provision of healthcare and other services to participants, care planning activities, service delivery settings and maintenance of centers, participant rights, employment and contractual arrangements with healthcare providers and other staff, quality assessment and performance improvement activities, participant grievances and appeals, medical records documentation, compliance program activities, and other aspects of our operations and financing. As a PACE provider that provides qualified prescription drug coverage, we are also subject to Medicare laws, regulations, and requirements applicable to Medicare Part D plan sponsors. The regulations and contractual requirements applicable to PACE providers are complex and subject to change, making it necessary for us to invest significant resources in complying with these requirements. Scrutiny through federal and state government audits, oversight and enforcement and the highly technical regulatory scheme in which we operate require us to allocate significant resources to our compliance efforts. In addition, new centers that we may acquire in the future may have less developed compliance and quality infrastructures, which may require us to allocate additional resources to making any required enhancements. CMS and state regulatory authorities regularly audit our performance to determine our compliance with CMS’s regulations and our contracts with CMS and state authorities, and to assess the quality of the services we provide to our participants. Such audits have in the past, and may in the future, result in the identification of deficiencies in connection with our compliance with regulatory requirements, participant quality of care, care plan development and implementation, grievance and appeal processes, clinicians acting outside of their scope of practice, and other issues. See Item 1A. Risk Factors, “Risks Related to Regulation.” Whether identified through such audits or other avenues, our failure to comply with the federal and state laws applicable to our business could result in significant or material retroactive adjustments to and/or withholding of capitation payments, fines, criminal liability, civil monetary penalties, requirements to make significant changes to our operations, corrective action plans, CMS imposed sanctions (including suspension or exclusion from participation in government programs), loss of contracts, or cessation of our services. Licensing LawsWe, our healthcare professionals, and our centers are subject to various federal, state and local licensure and certification requirements in connection with our provision of healthcare and other services. Specifically, in some of the states in which we operate, we are required to maintain licensure or certification as an adult day health center, home health or home care provider, diagnostic and treatment center, pharmacy provider, clinical laboratory and/or other type of facility, and our affiliated physicians and other clinicians also must be licensed or certified, as applicable, in the states in which they are providing services. In addition, certain of the states where we currently operate regulate the operations and financial condition of risk bearing providers and impose capital requirements, licensing or certification, governance controls, and other obligations. While the states in which we operate do not currently impose these regulations on entities solely bearing risk under the PACE program, these states may seek to license or otherwise regulate our operations and financial solvency in the future; further, states in which we expand in the future may impose similar requirements on our operations. In addition to state requirements, we, our centers, and our healthcare professionals are in some cases subject to federal licensing and certification requirements, such as certification or waiver under the Clinical Laboratory Improvement Amendments of 1988 for performing laboratory services and Drug Enforcement Administration registrations for prescribing, storing, and dispensing controlled substances. Failure to comply with federal, state and local licensing and certification laws, regulations and standards could result in a variety of consequences, including cessation of our services, loss of our contracts, prior payments by payors being subject to recoupment, requirements to make significant changes to our operations, or civil or criminal penalties. We routinely take the steps we believe are necessary to retain or obtain all requisite licensure and operating authorities. While we endeavor to comply with federal, state and local licensing and certification laws and regulations and standards as we interpret them, the laws and regulations in these areas are complex, changing and often subject to varying interpretations. Any failure to satisfy applicable laws and regulations could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation. Corporate Practice of MedicineThe laws and regulations relating to our operations vary from state to state, and some states in which we operate prohibit general business corporations, such as us, from practicing medicine, directly employing physicians, controlling physicians’ or other clinicians’ medical decisions, or engaging in some practices such as splitting professional fees with physicians or other clinicians. In certain states, we contract with physicians to provide healthcare services that are required to be provided by licensed physicians to comply with such requirements. While we believe that we are in substantial compliance with state laws prohibiting the corporate practice of medicine, regulatory agencies and other parties may assert that we could be engaged in the corporate practice of medicine. Further, many such state laws are often vague or have otherwise only been infrequently interpreted by courts or regulatory agencies and are subject to change. The consequences associated with violating corporate practice of medicine laws vary by state and may result in physicians or other clinicians being subject to disciplinary action, as well as forfeiture of revenues from government payors for services rendered. However, if allegations are successfully asserted before the appropriate judicial or administrative forums, we could be subject to adverse judicial or administrative penalties, certain of our contracts could be determined to be unenforceable, and we may be required to restructure our organization or our contractual arrangements. Any allegations or findings that we have violated these laws could have a material adverse impact on our reputation, business, results of operations and financial condition. See Item 1A. Risk Factors, “Risks Related to Our Business.” Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business, and the failure to comply with such laws could subject us to penalties or require a restructuring of our business. Federal Anti-Kickback StatuteThe federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in cash or kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. Court decisions have held that the statute may be violated even if only one purpose of remuneration is to induce referrals. In addition, a defendant need not have actual knowledge of, or the specific intent to violate, the federal Anti-Kickback Statute in order to have the requisite intent to support an Anti-Kickback Statute violation. Federal criminal penalties for the violation of the federal Anti-Kickback Statute include imprisonment, fines and exclusion of the provider from future participation in federal healthcare programs, including Medicare and Medicaid. Violations of the federal Anti-Kickback Statute are punishable by imprisonment for up to ten years, fines of up to \$100,000 per kickback or both. Larger fines can be imposed upon corporations under the provisions of the U.S. Sentencing Guidelines and the Alternate Fines Statute. Individuals and entities convicted of a criminal violation of the federal Anti-Kickback Statute are subject to mandatory exclusion from participation in Medicare, Medicaid, and other federal healthcare programs for a minimum of five years. Civil penalties for violation of the Anti-Kickback Statute include up to \$120,816 in monetary penalties per violation, fines, or penalties of up to three times the total payments between the parties to the arrangement and potential exclusion from participation in Medicare and Medicaid. In addition, the federal Anti-Kickback Statute provides that any claims for items or services resulting from a violation of the federal Anti-Kickback Statute are considered false or fraudulent for purposes of the FCA, which is further discussed below. Any findings that we have violated these laws could have a material adverse impact on our business, results of operations, financial condition, cash flows, reputation and stock price. The federal Anti-Kickback Statute includes statutory exceptions and regulatory safe harbors that protect certain arrangements. These exceptions and safe harbors are voluntary. To receive safe harbor protection, business transactions and arrangements must meet all the requirements of a safe harbor. However, transactions and arrangements that do not satisfy all elements of a relevant safe harbor do not necessarily render the arrangement per se illegal. When an arrangement does not satisfy a safe harbor, the arrangement must be evaluated upon all facts and circumstances, on a case-by-case basis in light of among other things, the parties’ intent, and the arrangement’s potential for abuse. Arrangements that do not satisfy a safe harbor may be subject to greater scrutiny by enforcement agencies. Additionally, some states have enacted statutes and regulations similar to the federal Anti-Kickback Statute. Unlike the federal Anti-Kickback Statute, however, certain state laws may be applicable regardless of the payor source for the patient. 9Table of Contents Moreover, these state laws may contain exceptions and safe harbors that are different from and/or more limited than those of federal law and that may vary from state to state. We have entered, and may continue to enter, into several arrangements that may not fit squarely within enumerated safe harbors and could potentially implicate the Anti-Kickback Statute if the requisite intent were present, such as: Joint Ventures. We operate two of our centers, our Sacramento, California center, and Orlando, Florida center, under joint ventures, each with a not-for-profit healthcare provider. We may enter other joint ventures with providers and payors in the future. The Office of Inspector General (the “OIG”) of the Department of Health and Human Services (the “HHS”) has warned healthcare entities in the past that certain joint venture relationships have a potential for abuse. We have endeavored to structure our joint ventures to satisfy as many elements of the applicable safe harbor for investments in small entities as we believe are commercially reasonable. For example, we believe that these investments are offered and made by us on a fair market value basis and provide returns to the investors in proportion to their actual investment in the venture. 4cDiscounts. Our centers sometimes acquire certain items and services at a discount that may be reimbursed by a federal healthcare program. We endeavor to structure our vendor contracts that include discount or rebate provisions to comply with the federal Anti-Kickback Statute safe harbor for discounts. 5cSales Force and Participant Recruitment. We employ our own sales force and attempt to meet the Anti-Kickback safe harbor for bona fide employment. As noted in the examples above, we have endeavored to structure our business arrangements to fit within applicable federal Anti-Kickback Statute safe harbors and to otherwise operate in material compliance with the federal Anti-Kickback Statute and state analogs. Many of our arrangements are structured to provide for compensation that is fair market value for services actually rendered and in a manner that does not reflect the volume or value of referrals generated between the parties. In structuring our relationships with providers, including our physician partners, and other healthcare entities, we endeavor to comply with the regulatory requirements of such safe harbors and exceptions. On January 19, 2021, the OIG issued regulations under the Anti-Kickback Statute that added new safe harbors and modified existing safe harbors that protect certain payment practices and business arrangements from sanctions under the Anti-Kickback Statute in order to remove potential barriers to more effective coordination and management of patient care and delivery of value-based care. Among other changes, these regulations contained safe harbors for value-based arrangements centering around value-based enterprises, which are enterprises, such as ours, composed of participants collaborating to achieve one or more value-based purposes, including coordinating, and managing the care of a target patient population and coordinating and managing the care of a target population. These new and modified value-based care safe harbors may allow our business to pursue new value-based arrangements with safe harbor protections under the Anti-Kickback Statute. However, compliance with these new Anti-Kickback Statute safe harbors is complex and, to the extent that one of our value-based arrangements does not squarely fit within the relevant safe harbors, it could be subject to greater scrutiny by enforcement agencies. Federal Self-Referral ProhibitionThe federal Ethics in Patient Referral Act (the “Stark Law”) generally prohibits a physician who has (or whose immediate family member has) a financial relationship with certain types of entities from making referrals to that such entities for “designated health services” if payment for the services may be made under Medicare or Medicaid. “Designated health services” include clinical laboratory services, inpatient and outpatient hospital services, physical and occupational therapy services, outpatient speech-language pathology services, certain radiology services, radiation therapy services and supplies, durable medical equipment and supplies, parenteral and enteral nutrients equipment and supplies, prosthetics, orthotics and prosthetic devices and supplies, home health services, and outpatient prescription drugs. To the extent we fall within the types of entities to which the Stark Law applies, then we need to ensure that any financial relationships that we have with a referring provider would satisfy a statutory or regulatory exception to the Stark Law prohibition. Providers are prohibited from billing Medicare and Medicaid for services related to a prohibited referral and a provider that has billed for prohibited services is obligated to notify and refund the amounts collected from the Medicare program or to make a self-disclosure to CMS under its Self-Referral Disclosure Protocol. Penalties for violation of the Stark Law include denial of payment, recoupment, refunds of amounts paid in violation of the law, exclusion from the Medicare or Medicaid programs, and substantial civil monetary penalties (\$29,899 per prohibited item or service and \$199,338 if there is a circumvention scheme; penalty amounts reflect current 2023 levels and are adjusted for inflation from time to time). 10Table of Contents Claims filed in violation of the Stark Law may be deemed false claims under the FCA. In addition to the Stark Law, various states in which we operate have adopted their own self-referral prohibition statutes. In parallel with OIG’s regulations on value-based care discussed above, on January 19, 2021, CMS issued a sweeping set of regulations that introduce significant new value-based terminology and exceptions to the Stark Law, including new exceptions for certain remuneration exchanged between or among eligible participants in value-based arrangements. These exceptions and their various requirements apply based on the level of risk assumed by the arrangement’s participants. These regulations purport to ease the compliance burden for healthcare providers across the industry while maintaining strong safeguards to protect patients and programs from fraud and abuse. To the extent that we rely on the new value-based exceptions to the Stark Law for our value-based arrangements, we intend to fully comply with such safeguards. However, if we were to be found as out of compliance with such exceptions, we could be subject to penalties, as discussed above. The False Claims ActAmong other things, the FCA authorizes the imposition of up to three times the government’s damages and significant per claim civil penalties on any “person” (including an individual, organization or company) who, among other acts: “knowingly presents or causes to be presented to the federal government a false or fraudulent claim for payment or approval; knowingly makes, uses or causes to be made or used a false record or statement material to a false or fraudulent claim; knowingly makes, uses or causes to be made or used a false record, report or statement material to an obligation to pay the government, or knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the federal government; or conspires to commit the above acts. The federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs, including but not limited to coding errors, billing for services not rendered, the submission of false cost or other reports, billing for services at a higher payment rate than appropriate, billing under a comprehensive code as well as under one or more component codes included in the comprehensive code, billing for care that is not considered medically necessary and false reporting of risk-adjusted diagnostic codes, encounter data or other information used to determine capitated payments. The Affordable Care Act (the “ACA”) provides that claims for payment that are tainted by a violation of the federal Anti-Kickback Statute (which could include, for example, illegal incentives or remuneration in exchange for enrollment or referrals) are false for purposes of the FCA. In addition, amendments to the FCA and Social Security Act impose severe penalties for the knowing and improper retention of overpayments from government payors. This could be relevant to our business the extent we receive payments on account of RAF determinations that are based on improper or erroneous records or reports. Failure to return overpayments could subject us to liability under the FCA, exclusion from government healthcare programs and penalties under the federal Civil Monetary Penalty Statute. The penalties for a violation of the FCA may include per claim penalties, plus up to three times the amount of damages caused by each false claim, which can be as much as the amounts received directly or indirectly from the government for each such false claim. As of February 12, 2024, the minimum False Claims Act penalty increased from \$13,508 to \$13,946 per claim. The maximum penalty has increased from \$27,018 to \$27,894 per claim. In addition to civil enforcement under the FCA, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government. Private parties may initiate qui tam whistleblower lawsuits against any person or entity under the FCA in the name of the federal government, as well as under the false claims’ laws of several states, and may share in the proceeds of a successful suit. Generally, federal and state governments have made investigating and prosecuting healthcare fraud and abuse a priority. Any allegations or findings that we have violated the FCA could have a material adverse impact on our reputation, business, results of operations and financial condition. In addition to the FCA, the various states in which we operate have adopted their own analogs of the FCA. States are becoming increasingly active in using their false claims laws to police the same activities listed above, particularly with regard to capitated government-sponsored healthcare programs, such as Medicaid managed care and PACE. Under Section 6031 of the Deficit Reduction Act of 2005, as amended, if a state enacts a false claims act that is at least as stringent as the 11Table of Contents federal statute and that also meets certain other requirements, the state will be eligible to receive a greater share of any monetary recovery obtained pursuant to certain actions brought under the state’s false claims act. As a result, more states are expected to enact laws that are similar to the federal FCA in the future along with a corresponding increase in state false claims enforcement efforts. For additional information regarding allegations against us under Federal and State FCA statutes, see Item 1A. Risk Factors, “Risks Related to Our Business.” We are subject to legal proceedings, enforcement actions and litigation, malpractice and privacy disputes, which are costly to defend and could materially harm our business and results of operations. Civil Monetary Penalties StatuteThe Civil Monetary Penalties Statute, 42 U.S.C. §§ 1320a-7a, authorizes the imposition of civil monetary penalties, assessments and exclusion against an individual or entity based on a variety of prohibited conduct,

including, but not limited to:â€¢presenting, or causing to be presented, claims, reports or records relating to payment by Medicare, Medicaid or other government payors that the individual or entity knows or should know are for an item or service that was not provided as reported, is false or fraudulent or was presented for a physicianâ€™s service by a person who knows or should know that the individual providing the service is not a licensed physician, obtained licensure through misrepresentation or represented certification in a medical specialty without in fact possessing such certification;â€¢offering remuneration to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to influence the beneficiary to order or receive healthcare items or services from a particular provider, unless an exception applies;â€¢arranging contracts with or making payments to an entity or individual excluded from participation in the federal healthcare programs or included on CMSâ€™s preclusion list;â€¢violating the federal Anti-Kickback Statute;â€¢making, using or causing to be made or used a false record or statement material to a false or fraudulent claim for payment for items and services furnished under a federal healthcare program;â€¢making, using or causing to be made any false statement, omission or misrepresentation of a material fact in any application, bid or contract to participate or enroll as a provider of services or a supplier under a federal healthcare program; andâ€¢failing to report and return an overpayment owed to the federal government.We could be exposed to a wide range of allegations to which the federal Civil Monetary Penalty Statute would apply. We perform monthly checks on our employees and certain affiliates and vendors using government databases to confirm that these individuals have not been excluded from federal programs or otherwise ineligible for payment. We have also implemented processes to ensure that we do not make payments to contracted or noncontracted providers listed on CMSâ€™s preclusion list nor make payments for drugs prescribed by individuals on the preclusion list. However, should an individual or entity be excluded, on the preclusion list, or otherwise ineligible for payment and we fail to detect it, a federal agency could require us to refund amounts attributable to all claims or services performed or sufficiently linked to such individual or entity. Due to this area of risk and the possibility of other allegations being brought against us, we cannot foreclose the possibility that we could face allegations of noncompliance with the Civil Monetary Penalty Statute that have the potential for a material adverse impact on our business, results of operations and financial condition.Privacy and SecurityHIPAA requires covered entities, and the business associates with whom such covered entities contract for services involving the use or disclosure of protected health information to provide certain protections to their patients or participants and their health information. Through our various service offerings, the Company acts primarily as a covered entity under HIPAA but may also act as a business associate of other covered entities. The HIPAA privacy and security regulations extensively regulate the use and disclosure of PHI and require covered entities and their business associates, to develop and maintain policies and procedures and implement and maintain administrative, physical, and technical safeguards to protect 12Table of Contentsthe security of such information. Additional security requirements apply to electronic PHI. These regulations also provide our participants with substantive rights with respect to their health information.The HIPAA privacy and security regulations also require covered entities to enter into written agreements with their business associates. Covered entities may be subject to fines and penalties for, among other activities, failing to enter into a business associate agreement where required by law or as a result of a business associate violating HIPAA. Business associates are also directly subject to liability under certain HIPAA privacy and security regulations. In instances where we act as a business associate to a covered entity, there is the potential for additional liability beyond our status as a covered entity.Covered entities must notify affected individuals of breaches of unsecured PHI without unreasonable delay but no later than 60 days after discovery of the breach. Reporting must also be made to the HHS Office for Civil Rights (â€œOCRâ€) and, for breaches of unsecured PHI involving more than 500 residents of a state or jurisdiction, to the media in accordance with HIPAA requirements. All impermissible uses or disclosures of unsecured PHI are presumed to be breaches unless an exception to the definition of breach applies or the covered entity or business associate establishes that there is a low probability the PHI has been compromised. Additionally, beginning in December 2022, OCR has issued guidance on the use of tracking technologies on websites and mobile applications by covered entities and business associates, indicating that certain information collected by tracking technology vendors from websites and applications may cause a breach under HIPAA.Violations of HIPAA by covered entities and business associates, including, but not limited to, failing to implement appropriate administrative, physical and technical safeguards, have resulted in enforcement actions and in some cases triggered settlement payments or civil monetary penalties. Penalties for impermissible use or disclosure of PHI were increased by the HITECH Act by imposing tiered penalties of more than \$50,000 (not adjusted for inflation) per violation and up to approximately \$1.9 million (not adjusted for inflation) per year for identical violations. In addition, HIPAA provides for criminal penalties of up to \$250,000 and ten years in prison, with the severest penalties for obtaining and disclosing PHI with the intent to sell, transfer or use such information for commercial advantage, personal gain or malicious harm. Further, state attorneys general may bring civil actions seeking either injunction or damages in response to violations of the HIPAA privacy and security regulations that threaten the privacy of state residents. There can be no assurance that we will not be the subject of an investigation (arising out of a reportable breach incident, audit or otherwise) alleging non-compliance with HIPAA regulations in our maintenance of PHI.We may also be subject to other laws governing the privacy and security of data, such as the California Consumer Privacy Act of 2018 (â€œCCPAâ€) and data breach notification laws. Additionally, many states also enacted laws that protect the privacy and security of confidential, personal and health information, which may be even more stringent than HIPAA and may add additional compliance costs and legal risks to our operations. Some state privacy and security laws overlap with federal law, some of which are preempted, in part by federal laws, whereas others are not. States have also passed privacy and security laws and regulations that apply across sectors and go beyond federal law, such as data security laws, secure destruction, Social Security number privacy, online privacy biometric information privacy, and data breach notification laws. Some of these state laws impose fines and penalties on violators and afford private rights of action to individuals who believe their personal information has been misused. Various state laws and regulations also require us to notify affected individuals in the event of a data breach involving personal information without regard to the probability of the information being compromised.Looking ahead, it is possible that Congress could pursue a federal privacy bill to harmonize privacy regimes across states. Various other federal and state laws restrict the use and protect the privacy and security of individually identifiable information, as well as employee personal information, including certain state laws modeled to some extent on the European Unionâ€™s General Data Protection Regulation. Federal and state consumer protection laws, including laws that do not on their face specifically address data privacy or security, have been applied to data privacy and security matters by a range of government agencies and courts.Healthcare Reform EffortsThe U.S. federal and state governments continue to enact and consider many broad-based legislative and regulatory proposals that have had a material impact on or could materially impact various aspects of the healthcare system and our business, operating results and/or cash flows. In addition, state and federal budgetary shortfalls and constraints pose potential risks for our revenue streams. We cannot predict how government payors or healthcare consumers might react to federal and state healthcare legislation and regulation, whether already enacted or enacted in the future, nor can we predict 13Table of Contentswhat form such legislation or regulations will take. Some examples of legislative and regulatory changes impacting our business include:â€¢In March 2010, broad healthcare reform legislation was enacted in the United States through the ACA. There have since been numerous political and legal efforts to repeal, replace or modify the ACA, some of which have been successful, in part, in modifying the law. Although some provisions of the ACA have been and may be modified, the reforms, particularly those relating to Medicare and Medicaid programs, could continue to have an impact on our business. These and other provisions of the ACA remain subject to ongoing uncertainty due to developing regulations as well as continuing political and legal challenges at both the federal and state levels.â€¢There have in recent years been congressional efforts to move Medicaid from an open-ended program with coverage and benefits set by the federal government to one in which states receive a fixed amount of federal funds, either through block grants or per capita caps, and have more flexibility to determine benefits, eligibility or provider payments. If these types of changes are implemented in the future, we cannot predict whether the amount of fixed federal funding to the states will be based on current payment amounts, or if it will be based on lower payment amounts, which would negatively impact those states that expanded their Medicaid programs in response to the ACA.â€¢Legislation enacted in 2011 requires CMS to sequester or reduce all Medicare payments, including payments to PACE organizations, by two percent per year beginning on April 1, 2013. â€¢The Inflation Reduction Act of 2022 includes a few provisions intended to lower the costs of some drugs covered under Medicare Part D and to limit Medicare beneficiariesâ€™ out-of-pocket spending under the Medicare Part D benefit. It is not yet clear what effect, if any, these legislative changes and any subsequent implementing regulations and guidance will have on our business.â€¢The â€œMedicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderlyâ€ final rule (â€œPACE Final Ruleâ€) set out a number of changes for PACE organizations, including (i) clarifying that CMS has enforcement discretion to impose civil monetary penalties or an intermediate sanction in the event CMS has made a determination that could lead to the termination of a PACE program; and (ii) reinstating the requirement that PACE organizations enter into written contracts with each outside organization, agency, or individual that furnishes administrative or care-related services not furnished directly by the PACE organization, including 25 medical specialties enumerated by the PACE Final Rule.â€¢The remaining provisions of the PACE final rule from 2024 were issued alongside the new PACE Final Rule for 2025. In this new final rule, CMS sets out changes which include but are not limited to: (i) implementation of past performance guidelines used to evaluate new PACE organization applications; (ii) personnel medical clearance guidelines; (iii) updates to service delivery timeframes by which participants must receive services; (iv) guidelines on IDT care coordination across all service settings with timeframes applied to external provider recommendations; (v) new content and documentation guidelines for participant plans of care; (vi) expansion of participant rights in care settings; and (vii) revisions to existing grievance process to align with standard determination request guidance.CMS and state Medicaid agencies also routinely adjust the RAF which is central to payment under PACE and Managed Medicaid programs in which we participate. The monetary â€œcoefficientâ€ values associated with diseases that we manage in our population are subject to change by CMS and state agencies. Such changes could have a material adverse effect on our financial condition. See Item 1A. Risk Factors, â€œRisks Related to Our Businessâ€â€¢â€¢â€¢Our records and submissions to government payors may contain inaccurate or unsupportable information regarding risk adjustment scores of participants, which could cause us to overstate or understate our revenue and subject us to payment obligations or penalties.â€¢Other RegulationsOur operations are subject to various state hazardous waste and non-hazardous medical waste disposal laws. These laws do not classify as hazardous most of the waste produced from medical services. Occupational Safety and Health Administration regulations require employers to provide workers who are occupationally subject to blood or other potentially infectious materials with prescribed protections. These regulatory requirements apply to all healthcare facilities, including our participant centers, and require employers to make a determination as to which employees may be exposed to blood or other potentially infectious materials and to have in effect a written exposure control plan. In addition, employers 14Table of Contentsare required to provide or employ hepatitis B vaccinations, personal protective equipment and other safety devices, infection control training, post-exposure evaluation and follow-up, waste disposal techniques and procedures and work practice controls. Employers are also required to comply with various record-keeping requirements.Federal and state law also governs the purchase, handling, and dispensing of controlled substances by physicians and other clinicians. If we are unable to maintain our registrations this could limit or affect our ability to purchase, handle, or dispense controlled substances and other violations of these laws could subject us to criminal or other sanctions. In addition, certain laws may apply to activities of our affiliated physicians and clinicians. For example, the Prescription Drug Marketing Act governs the provision of drug samples to physicians and other clinicians, and physicians and other clinicians are required to report relationships they have with the manufacturers of drugs, medical devices and biologics through the Open Payments Program database. Clinical laboratories may be subject to oversight by CMS and state regulators, including the Eliminating Kickbacks in Recovery Act of 2018. If our laboratories or laboratories that we partner with are not in compliance with the applicable CMS or state laws or regulations, they could be subject to enforcement action, which could negatively affect our business. We have in the past and continue to intend to grow our business through acquisitions in the states in which we currently operate or in new states that we seek to enter. Several states, including California, have adopted laws focused on competition, quality, access, and cost that authorize state agencies to review and approve healthcare transactions, and many other states, including Pennsylvania, are considering similar legislation. California is also considering additional legislation that would provide the California attorney general with approval authority with respect to certain health care transactions. Such laws may negatively affect our ability to grow our business.Any allegations or findings that we or our providers have violated any of these laws or regulations could have a material adverse impact on our reputation, business, results of operations and financial condition. Certain states in which we do business or may desire to do business in the future have certificate of need programs regulating the establishment or expansion of healthcare facilities, including our participant centers. These regulations can be complex and time-consuming to ensure compliance with. Any failure to comply with such regulatory requirements could adversely impact our business, results of operations and financial condition.CompetitionThe U.S. healthcare industry is highly competitive. We compete directly with national, regional and local providers of healthcare for participants and clinical providers. We also compete with payors and other alternate managed care programs for participants. Of these providers, there are many other companies and individuals currently providing healthcare services, many of which have been in business longer and/or have substantially more resources. Given the regulatory environment, there may be high barriers to entry for PACE providers; however, since there are relatively modest capital expenditures required for providing healthcare services, there are less substantial financial barriers to entry in the healthcare industry generally. Other companies could enter the healthcare industry in the future and divert some or all of our business. Our principal competitors for dual-eligible seniors vary considerably in type and identity by market. Our growth strategy and our business could be adversely affected if we are not able to compete efficiently, including penetrating existing markets or new markets, recruit qualified physicians or if we experience significant participant attrition to our competitors. See Item 1A. Risk Factorsâ€¢Risks Related to Our Businessâ€¢â€¢The healthcare industry is highly competitive and, if we are not able to compete effectively, our business could be harmed.â€¢We believe the principal competitive factors for serving adults dually-eligible for Medicare and Medicaid and who meet nursing home eligibility criteria include: participant experience, quality of care, health outcomes, total cost of care, brand identity and trust in that brand.SeasonalityOur business experiences some variability depending upon the time of year. Medical costs will vary seasonally depending on a number of factors, but most significantly the weather. Certain illnesses, such as the influenza virus and COVID-19, are far more prevalent during colder months of the year, which results in an increase in medical expenses during these time periods. We therefore see higher levels of per-participant medical costs in our second and third fiscal quarters. Medical costs also depend upon the number of business days in a period, with shorter periods generally having lower medical costs, all else being equal. There is also increased variability of participant enrollment during the open enrollment period, which occurs during our third fiscal quarter. 15Table of ContentsIn addition, the retrospective capitation payments we receive for each participant are determined by a participantâ€™s RAF score, which is calculated twice per year and is based on the evolving acuity and chronic conditions of a participant. We estimate and accrue for the expected true-up payments of our participants. Though no assurances can be made in the future, we have historically used our best estimate for accruing for this payment, and we received net positive true-up payments during the fiscal years ended June 30, 2024 and 2023. Historically, these true-up payments typically occur between May and August, but the timing of these payments is determined by CMS, and we have neither visibility nor control over the timing of such payments. Human Capital ResourcesAs of June 30, 2024, we had approximately 2,350 employees, including over 1,300 clinical professionals (excluding contract labor). Approximately 1% of our workforce is represented by a union, all of which are located in Pennsylvania. Collective bargaining commenced in March 2024. We are unable to predict the terms or timing of any resulting collective bargaining agreement. We believe our efforts in managing our workforce have been effective, evidenced by improved retention, lower turnover, and employee satisfaction during fiscal year 2024. Our people are our product at InnovAge, and their commitment to our participants propels our mission of enabling seniors to age at home, with dignity, for as long as is safely possible. We believe that our employees are drawn to this mission and our values, which is why our voluntary retention rate was 68% over fiscal year 2024. Additionally, in our most recent employee engagement survey conducted in February 2024, 75% of our employees indicated that they feel engaged by their work at InnovAge.Attracting and retaining top talent is critical to the success of InnovAge's mission and one of the highest priorities to leadership. To keep leadership informed of the health of our employee base, we report weekly on key hiring and retention metrics. We launched employee engagement surveys in fiscal year 2022, and we implemented action plans with all staff groups based on survey findings and opportunities uncovered. We continue to evaluate talent needs at the senior management level, aiming to hire ahead of the curve as the business evolves and to assess and respond to any gaps in our capabilities. DiversityAt InnovAge, we strive to be a reflection of the diverse communities that we serve. We are steadfastly dedicated to fostering an atmosphere that champions diversity, equity, and inclusion throughout all sectors of InnovAge. Our commitment remains in building a culture where individual distinctions are not just acknowledged but deeply valued. In our previous engagement survey from February 2024, 76.6% of employees indicated that they feel that they can be their authentic selves at work. As part of our continuous journey to engage and understand our teams better, we plan to conduct our annual engagement survey during September 2024. As of June 30, 2024, our employed workforce

was comprised of individuals who identified as women â€” 76%, and minorities â€” 52%. Four of eleven members of our leadership team identify as women as of June 30, 2024. Training and Development We aim to provide our employees opportunities to grow and advance in their careers at InnovAge with learning and development programs. Each year we conduct soft skills training for managers and supervisors, the content of which is informed by gap assessment surveys. A quarterly training series for front-line leaders enables them to develop their management skills. Our clinical leaders also conduct separate physician leadership trainings quarterly, with a new topic for each installment (e.g., email / phone etiquette). We also conduct a periodic training needs assessment surveys to hear directly from employees and managers where they think they could use more support and learning content in the coming year. These assessment surveys, allow the Company to develop trainings tailored to the most prevalent needs identified by our employees. Implications of being an emerging growth company and a smaller reporting company We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). We will remain an emerging growth company until the earlier of (1) June 30, 2026, (2) the last day of the 16th calendar year in which we have total annual gross revenue of at least \$1.235 billion, (3) the date on which we are deemed to be a large accelerated filer or (4) the date on which we have issued more than \$1.0 billion in non-convertible debt securities during the prior three-year period. Additionally, we qualify as a “smaller reporting company,” and even after we no longer qualify as an “emerging growth company,” we may still qualify as a “smaller reporting company” based on the aggregate worldwide market value of common equity securities held by non-affiliates assessed on an annual basis and measured as of the last business day of our most recently completed second fiscal quarter. As an emerging growth company and a smaller reporting company, we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: (a) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”); (b) a requirement to present only two years of audited financial statements, plus unaudited condensed consolidated financial statements for any interim period and related discussion in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; (c) reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and (d) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the longer phase-in periods for the adoption of new or revised financial accounting standards under the JOBS Act until we are no longer an emerging growth company. Our election to use the phase-in periods permitted by this election may make it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the longer phase-in periods permitted under the JOBS Act and who will comply with new or revised financial accounting standards. If we were to subsequently elect instead to comply with public company effective dates, such election would be irrevocable pursuant to the JOBS Act. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. Available Information Our internet website is www.innovage.com. We include our website address on this Annual Report for reference only. The information contained on our website is not incorporated by reference into this Annual Report or any other report or document we file with, or furnish to, the SEC. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports are available free of charge through our website at www.investor.innovage.com as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. Our SEC filings are also available to the public at the SEC’s website at www.sec.gov. 17 Item 1A. Risk Factors Our business, results of operations, and financial condition are subject to numerous risks and uncertainties. You should carefully consider the following risk factors before making a decision to invest in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, financial condition, operating results and prospects could be materially and adversely affected. You should read these risk factors in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and our consolidated financial statements and related notes in Item 8 of this Annual Report. Summary of Risk Factors There are a number of risks related to our business, regulation, our indebtedness and our common stock that you should consider. Some of the principal risks related to our business include the following: Our growth strategy may not prove viable. Our ability to grow depends upon a number of factors, including results of audits, investigations and remediation efforts, recruiting new participants, finding suitable geographies, entering into government payor arrangements in new jurisdictions, ensuring compliance with regulatory and contractual requirements, identifying appropriate locations or existing centers, purchasing centers or obtaining leases, completing build-outs of new centers within proposed timelines and budgets and hiring members of our IDTs and other employees. Our growth strategy depends upon our ability to identify and complete acquisitions, joint ventures and other strategic partnerships. Our growth strategy involves identifying and successfully completing acquisitions, joint ventures and strategic partnerships, which involve numerous risks, including failure to consummate negotiated transactions, difficulties in successfully integrating the operations and personnel, navigating the necessary regulatory approval requirements and difficulties in entering new markets. If we are unable to attract new participants and retain existing participants, our revenue growth will be adversely affected. To increase our revenue, we plan to expand the number of centers and participants in our network, requiring recruitment and retention. Our inability to identify and recruit new eligible participants, including due to the impact of enrollment sanctions, and retain existing participants has, and could continue to, harm our ability to execute our growth strategy and have a material adverse effect on our business. Our overall business results have been and we expect will continue to be impacted by ongoing macroeconomic and industry-related challenges. Macroeconomic and industry challenges, including labor shortages, labor competition and high inflation, have impacted and we expect will continue to impact our business operations. High inflation has increased the cost of living, and consequently, wage pressure, which has contributed to an increasingly competitive labor market. We have faced, and continue to face inspections, reviews, audits and investigations under federal and state government programs and contracts. As a result of PACE contracts with various federal and state government programs, we are regularly subject to various routine and non-routine governmental inspections, reviews, audits, requests for information and investigations to verify our compliance with applicable laws, assess the quality of our services and evaluate the accuracy of our submitted risk adjustment data. Our centers are subject to, and will continue to be subject, to future audits and we are unable to guarantee the outcomes. We are subject to legal proceedings, enforcement actions and litigation, malpractice and privacy disputes, which are costly and could materially harm our business. We are party to lawsuits and legal proceedings from various parties in the normal course of business. These matters are often expensive and disruptive to normal business operations. Among others, we are currently subject to civil investigative demands and stockholder lawsuits. There can be no assurance that these matters will be resolved in our favor or without significant cash settlements and the time necessary to litigate could harm our reputation, business, financial condition, and results of operations. Under PACE contracts, we assume all of the risk that the cost of providing services will exceed our compensation. Most of our revenue was derived from capitation agreements with government payors in which we receive fixed PMPM fees. To the extent that our participants require more care than anticipated and/or the cost of care increases, aggregate fixed capitation payments may be insufficient to cover the costs. If, in aggregate, our expenses exceed the underlying capitation payment received, we will not be able to fund operations and pursue growth. We have experienced and expect to continue experiencing increased costs and expenditures in the future. In fiscal year 2024, we continued several initiatives intended to lower our costs, however, we expect increased costs in the foreseeable future. We may not succeed in increasing our revenue sufficiently to improve our profit margins and if we are not able to execute or realize the benefits of our clinical value initiatives, our profitability could continue to decline. Our revenues and operations are dependent upon a limited number of government payors, particularly Medicare and Medicaid. When aggregating the revenue associated with Medicare and Medicaid by state, a majority of our revenue was derived from a limited number of government payors. We expect a majority of our revenues will continue to be derived from a limited number of key payors, who are able to terminate their contracts with us upon the occurrence of certain events, adversely affecting our operating results and limiting our expansion. Reductions in PACE reimbursement rates or changes in the rules governing PACE programs could have a material adverse effect on our financial condition and results of operations. We receive nearly all of our revenue through the PACE program, which accounted for 99.9% and 99.8% of our revenue for the years ended June 30, 2024 and 2023, respectively. As a result, our operations are dependent on government funding levels for PACE programs. Any changes that limit or reduce general PACE rates could have a material adverse effect on our business. Our records and submissions to government payors may contain inaccurate or unsupportable information regarding risk adjustment scores of participants, which could subject us to repayment obligations or penalties. The submission of erroneous data could result in inaccurate revenue and risk adjustment payments, which may be subject to correction or retroactive adjustment in later periods. CMS may audit PACE organizations’ risk adjustment data submissions. We could be required to refund a portion of the revenue that we received, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. Renegotiation, non-renewal or termination of capitation agreements with government payors could have a material adverse effect on our business, results of operations, financial condition and cash flows. If we enter into, or amend, capitation contracts which include unfavorable economic terms, we could suffer losses. Some states in which we operate undergo periodic reconciliations with respect to enrollments that present a risk to our business. Allegations of failure and failure to adhere to complex government laws and regulations, have had and could in the future have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price. Our operations are subject to extensive federal, state and local government laws and regulations. Allegations of violation, or actual violations of the legal requirements implicated by our business may have material adverse consequences on our business. Ignite Aggregator LP (an investment vehicle owned by certain funds advised by Apax Partners LLP) and funds affiliated with Welsh, Carson, Anderson & Stowe (together, our “Principal Shareholders”) control us. Our Principal Shareholders beneficially own approximately 83% of our common stock, which means that together they control the vote of all matters submitted to a vote of our stockholders, including the election of members of the Board of Directors of the Company (the “Board”) and all other corporate decisions. For such period of time as our Principal Shareholders beneficially own a majority of the voting power, they will have significant influence. Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause such results to fall below any guidance, targets or goals we provide. If the guidance we provide falls short or we are unable to meet the expectations of analysts or investors, the trading price of our common stock could decline substantially. Risks Related to Our Business Our growth strategy may not prove viable, and we may not realize expected results therefrom. Our ability to grow depends upon a number of factors, including results of audits, investigations and ongoing or new remediation efforts, recruiting new participants, finding suitable geographies that have aging populations and viable rate structures, entering into government payor arrangements in new jurisdictions, ensuring compliance with regulatory and contractual requirements, identifying appropriate locations or existing centers, purchasing centers or obtaining leases, completing build-outs of new centers within proposed timelines and budgets and hiring members of our IDTs and other employees. Our growth strategy involves a number of risks and uncertainties, including that: we may be subject to sanctions as a result of audits and other regulatory processes and proceedings that could include temporary or permanent suspension of enrollments, debarment or exclusion from participation in federal health care programs, and the revocation of a center’s license and suspension or revocation of required attestations to open de novo centers, which may in turn result in participant attrition and preclude us from opening de novo centers and conducting tuck-in acquisitions. As a result of an ongoing audit of our center in Sacramento, California initiated in 2023 and the subsequent medical review of our center in San Bernardino, California, DHCS revoked the state-required attestations for a planned de novo center in Downey and for the de novo center we acquired in Bakersfield, California. There is no guarantee that such attestations will be reinstated or that similar situations will not occur in the future; we may not be able to successfully enter into contracts with government payors and/or other healthcare providers on terms favorable to us or at all. In addition, we compete for government payor relationships with other potential players, some of whom may have greater resources than we do. This competition has intensified due to the availability to seniors of other programs similar to PACE and the ongoing consolidation in the healthcare industry, which may increase our costs to pursue such opportunities; we may not be able to recruit or retain a sufficient number of new participants to execute our growth strategy or offset costs relating to recruiting new participants or opening de novo centers or executing acquisitions; we may not be able to hire sufficient numbers of physicians and other clinical staff, particularly in the current labor market characterized by heightened demand for healthcare personnel and labor shortages; when expanding our business into new states, we may be required to comply with laws and regulations that may differ from states in which we currently operate; we may face larger than expected costs and legal, community or other obstacles in the construction and opening of de novo centers, such as the revocation of state-required attestations, or expanding capacity in existing centers; and we may have difficulty identifying appropriate acquisition targets, be precluded from acquiring targets as a result of audits or sanctions or due to other legal restrictions (e.g. federal or state antitrust laws), may fail to satisfy closing conditions or make investments in acquisitions that we are unable to effectively integrate, involve associated risks or liabilities that we are unable to uncover in advance, or that require greater resources than anticipated and that could include deficient quality of service. As an element of our growth strategy is to build de novo centers, in fiscal year 2024, we opened two de novo centers in the State of Florida. As we are in the early stages of operation of these two de novo centers in a new geography, there is no guarantee about the timing or our ability to enroll enough participants, hire and train enough skilled and non-skilled staff, develop necessary community relationships, and otherwise ramp up these centers to maturity. If we are unable to increase utilization of capacity at our centers through enrollment, ramp up de novo centers, build new de novo centers, manage our external provider costs, expand into new geographies, or find, evaluate and execute on new business opportunities, we may be unable to grow and our business and results of operations will be materially adversely affected. In addition, as we grow our business and open or acquire new centers, we expect to continue to increase our headcount and to hire or contract with more physicians, nurses and other specialized medical personnel. We will need to continue to hire, train and manage additional qualified information technology, operations and marketing staff, and improve and maintain our technology and information systems to properly manage our growth. If our new hires perform poorly, if we 20 are unsuccessful in hiring, training, managing and integrating these new employees, if we are not successful in retaining our existing employees, or if we are unable to provide the care and services that our participants require in compliance with regulatory requirements, our business will be adversely affected. Additional risks include, but are not limited to, our ability to effectively manage growth, process, store, protect and use personal data in compliance with governmental regulations and contractual obligations and manage our obligations as a provider of healthcare services under Medicare, Medicaid and PACE. There can be no assurance that we will be able to successfully capitalize on growth opportunities, which will negatively impact our business, revenues, results of operations and financial condition. Our growth strategy is partially dependent upon our ability to identify and successfully complete acquisitions, joint ventures and other strategic partnerships. An element of our growth strategy is to identify, pursue and successfully complete and integrate tuck-in acquisitions, joint ventures and other strategic partnerships to expand our operations. Since the Company was released from sanctions in fiscal year 2023, we have recommenced our efforts to pursue tuck-in acquisitions. In December 2023, we acquired all of the issued and outstanding membership interests of two California-based PACE programs, ConcertoCare PACE of Bakersfield, LLC and ConcertoHealth PACE of Los Angeles, LLC (collectively, “Concerto”). In May 2024, we entered into a joint venture with Orlando Health with respect to the InnovAge Florida PACE “Orlando (InnovAge Orlando)” center in Florida. We intend to continue pursuing relationships with key stakeholders, existing organizations and other care providers in order to form partnerships in target geographies. However, acquisitions, joint ventures and other strategic partnerships, involve numerous risks, including failure to consummate negotiated transactions, difficulties in successfully integrating the operations and personnel, navigating the necessary regulatory approval requirements, including securing regulatory safe harbors necessary for healthcare related joint ventures under the Anti-Kickback Statute, distraction of management while overseeing the transactions, and disruption of, our existing operations, difficulties in entering new markets in which we have no or limited direct prior experience, and difficulties in achieving the synergies we anticipated. For example, in 2023, CMS and DHCS initiated a routine audit of our Sacramento, California center. Subsequently, DHCS notified us it would also be conducting a targeted medical review of our center in San Bernardino, and that it would be suspending its state-required attestations in support of the planned de novo centers in California, including for one of the acquired centers in Bakersfield, California. Until such time as the attestations are reinstated, we are precluded from opening such center. In addition, we incur costs associated with potential acquisitions that we pursue or fail to close, including as a result of litigation related to a failed transaction. We also may need to expend resources to ensure target and acquired centers are operating in compliance with regulatory and contractual requirements, as well as any corrective action plans. Any failure to select suitable opportunities at fair prices, conduct appropriate due diligence, acquire and

successfully integrate the acquired center, including particularly when acquired centers operate in new geographic markets, could materially and adversely impact our growth strategies, financial condition and results of operations. These transactions may also cause us to significantly increase our interest expense, leverage and debt service requirements if we incur additional debt to pay for an acquisition or investment, issue common stock that would dilute our current stockholders' percentage ownership or incur asset write-offs and restructuring costs and other related expenses that could have a material adverse impact on our operating results. Acquisitions, joint ventures and strategic investments also involve numerous other risks, including potential exposure to assumed litigation, as well as undetected internal control, regulatory or other issues, or additional costs not anticipated at the time the transaction was completed. If we are unable to attract new participants and retain existing participants, our revenue growth will be adversely affected. To increase our revenue, our business strategy includes expanding the number of centers and participants in our network. In order to support such growth, we must recruit and retain a sufficient number of new participants. Our ability to do so was affected in fiscal years 2022 and 2023 as a result of the enrollment sanctions we were subject to in the states of California and Colorado, which have had and may continue to have an impact on our reputation. We are focused on frail, dual-eligible senior population and face competition from other healthcare providers and payors in the recruitment of potential participants. Therefore, we must demonstrate that our services provide a viable solution for potential participants. If we are unable to convince the frail, dual-eligible senior population of the benefits of the InnovAge Platform or if potential or existing participants prefer the healthcare provider model of one of our 21 competitors, we may not be able to effectively implement our growth strategy, which depends on our ability to attract new participants. In addition, participant enrollment for PACE is ongoing each month and requires states to verify eligibility, a process which can result in delays in enrollment. Since the national emergency and public health emergency declarations related to COVID-19 expired, we have experienced an increase in gaps of eligibility with redetermination applications. While participants continue to receive care and remain enrolled with us during this time, the effect of such delays temporarily halts Medicaid revenue related to any closed application and simultaneously increases our risk of revenue recovery. Even though our results of operations have not suffered a material adverse effect from these delays, there is no guarantee that further delays may not adversely impact our results. Our inability to identify and recruit new eligible participants and retain existing participants has and could continue to harm our ability to execute our growth strategy and has and may continue to have a material adverse effect on our business operations and financial position. Our overall business results have been and we expect will continue to be impacted by ongoing macroeconomic and industry-related challenges, including labor shortages, labor competition and inflation. Macroeconomic and industry challenges, including labor shortages, labor competition and high inflation, have impacted and we expect will continue to impact our business operations and our overall business results. The healthcare sector continues to experience a complex set of challenges in hiring additional professionals due to higher demand for healthcare services and systemic challenges related to workforce training and the pipeline of qualified professionals. Furthermore, high inflation has increased the cost of living, and consequently, wage pressure for healthcare professionals, which has contributed to an increasingly competitive labor market. We compete with other healthcare providers, primarily hospitals and other centers, in attracting physicians, nurses and medical staff to support our centers, and recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our centers. Additionally, on October 13, 2023, California passed into law California Senate Bill No. 525 (â€œSB 525â€), which would raise the minimum wage for many California healthcare workers. SB 525 becomes effective when certain financial metrics within the State of California are met. Even though SB 525 is not yet effective and PACE centers are not covered by it, many of our contractors and other third-party providers are expected to be impacted by SB 525, and we believe that due to this and other macroeconomic factors, our California centers have received provider requests to increase rates to cover their increased costs. In addition, as a result of competition generated by SB 525, we have increased our wages for healthcare workers in the California market. Because the vast majority of our revenue consists of prospective monthly capitated, or fixed, payments per participant, our ability to pass along increased costs is limited. In particular, if labor costs rise at an annual rate greater than our net annual consumer price index basket update from Medicare, our results of operations and cash flows will likely be adversely affected. Cost of care and related cost per participant increased for fiscal year 2024 compared to 2023, partially as a result of increased salaries, wages and benefits associated with increased headcount, higher wage rates and other factors. Additionally, external provider costs increased in fiscal year 2024 compared to 2023 as a result of annual increases in assisted living and nursing facility unit cost and general medical inflation. To date, we believe that macroeconomic and industry conditions, including labor shortages and inflation, have not had a material effect on our operating results. However, there can be no assurance that continued challenges will not have an adverse impact on our operating results and financial condition. In addition, if labor market conditions continue to disrupt our ability to recruit healthcare professionals, we may not be able to execute our growth plan and grow capacity in our existing centers or open de novo centers or we may have to do so at costs higher than originally budgeted, which, in turn, could increase our capital needs during a time of high interest rates and when conditions in the credit and capital markets are volatile. During periods of high unemployment, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. These budget deficits at federal, state and local government entities have decreased, and may continue to decrease, spending for health and human service programs, including Medicare, Medicaid, PACE and similar programs, which represent nearly all of the payor sources for our centers and which may have a material effect on our results of operations and financial condition. We have faced and continue to face inspections, reviews, audits and investigations under federal and state government programs and contracts. These audits require corrective actions and have resulted in adverse findings that have negatively affected and continue to affect our business, including our results of operations, liquidity, financial condition and reputation. 22As a result of our PACE contracts with CMS and state government agencies, state licenses, and participation in Medicaid, we are regularly subject to, and will continue to be subject to, various routine and non-routine governmental inspections, reviews, audits, requests for information and investigations to verify our compliance with requirements of these programs and applicable laws and regulations, assess the quality of the services we are providing to our participants, and evaluate the accuracy of the risk adjustment data we have submitted to the government. Starting in 2021, we underwent federal and state audits in our centers in California, Colorado and New Mexico. Based on deficiencies detected in the audits, CMS and regulatory authorities in the states of California and Colorado suspended new enrollments at our Sacramento center and our centers in Colorado. In addition, as a result of the enrollment sanctions, various states suspended our ability to open de novo centers or we committed to proactively pause steps with respect to planned de novo centers. Largely as a result of these sanctions and actions, our census decreased during the sanction period. We were released from the enrollment sanctions in Colorado and California in 2023, and resumed enrollments in those states as well as resumed activities to open de novo centers in other states. In October 2023, CMS and the DHCS conducted a joint routine audit of our Sacramento center and DHCS is currently conducting a medical review of our San Bernardino center. In response to both of these matters, DHCS suspended its state-required attestations for our planned de novo centers in California. In April 2024, CMS officially closed its portion of the Sacramento audit. DHCS's process is ongoing. Audits have and will continue to increase our regulatory compliance costs and have required and may require further change to our business practices, which could negatively impact our participant and revenue growth. Managing audits, even if we achieve favorable outcomes, is costly, time-consuming and diverts management's attention from our business. Our centers will continue to be subject to federal and state audits, including our centers that have undergone the recent audits described above, as well as the centers that did not and centers we open or acquire in the future. Even though we believe we are applying best practices learned from our recent audits to all our centers, there is no guarantee that future audits will not find deficiencies similar to, or different from, the ones found in connection with the recent audits. In general, inspections, reviews, audits, requests for information or investigations with adverse findings, and in particular the audits described above, have resulted in and may further result in: â€¢ temporary or permanent enrollment sanctions in the affected center(s), as was the case with our Sacramento, California center and our centers in the State of Colorado; â€¢ refunding amounts we have been paid by the government; â€¢ state or federal agencies imposing corrective action plans, fines, penalties, training, policies and procedures, monitoring, and other requirements; â€¢ temporary suspension of payments; â€¢ debarment or exclusion from participation in federal healthcare programs; â€¢ self-disclosure of violations to applicable regulatory authorities; â€¢ damage to our reputation; â€¢ the revocation of a center's license or suspension of state attestations to open de novo centers; and â€¢ loss of certain rights under, or termination of, our contracts with government payors. Any of the results noted above could have further material adverse effects on our business and operating results. Furthermore, the legal, document production and other costs associated with complying with these inspections, reviews, audits, requests for information or investigations is significant. If we are unable to effectively remediate the deficiencies raised by any audits, implement corrective action plans, or otherwise satisfy the regulators' concerns, we could be subject to new sanctions, and our business, financial results and operations could be adversely impacted. We are subject to legal proceedings, enforcement actions and litigation, malpractice and privacy disputes, which are costly to defend and could materially harm our business and results of operations. We are party to lawsuits and legal proceedings in the normal course of business from participants, employees, or other third parties for various actions. These matters are often expensive and disruptive to normal business operations. We face 23 and may in the future face allegations, lawsuits, including class actions, and regulatory inquiries, requests for information, audits and investigations regarding care and services provided to participants, the FCA, data privacy, security, labor and employment, consumer protection or intellectual property. We also have faced and may in the future face allegations or litigation related to our potential and completed acquisitions, securities issuances or business practices, including public disclosures about our business. We are currently party to a putative class action complaint alleging violations of the Securities Act and the Exchange Act for making allegedly inaccurate and misleading statements and omissions in connection with our IPO, and a stockholder lawsuit asserting derivative claims for breach of fiduciary duty generally relating to alleged failures by the defendants to take remedial actions to address the matters that resulted in sanctions by CMS at certain of our centers and alleged misstatements in our public filings relating to those matters. We are currently unable to predict the outcome of these matters. See Part I, Item 3 â€¢ Legal Proceedings for more information. Litigation and regulatory proceedings are protracted and expensive, and the results are difficult to predict. Certain of these matters include claims for substantial or indeterminate amounts of damages and may include claims for injunctive relief. Additionally, our litigation costs are and will continue to be significant. Adverse outcomes with respect to any of the legal proceedings described above or other litigation may result in significant settlement costs or judgments, penalties, fines and sanctions. For example, in the fourth quarter of fiscal year 2024, the Company settled a wage and hour class action lawsuit in the State of California for a cash payment of \$1.3 million. Managing legal proceedings, regulatory inquiries, litigation and audits, even if we achieve favorable outcomes, is costly, time-consuming and diverts management's attention from our business. The results of regulatory proceedings, investigations, inquiries, litigation, claims, and audits cannot be predicted with certainty, and determining reserves for pending litigation and other legal, regulatory and audit matters requires significant judgment and assumptions. There can be no assurance that our expectations will prove correct, and even if these matters are resolved in our favor or without significant cash settlements, these matters, and the time and resources necessary to litigate or resolve them, cause harm to our reputation, business, financial condition, results of operations and the market price of our common stock. We are also subject to lawsuits under the FCA and comparable state laws for submitting allegedly fraudulent, inadequately supported or otherwise inappropriate bills for services to the Medicare and Medicaid programs. These lawsuits, which may be initiated by government authorities as well as private party relators, can involve significant monetary damages, fines, attorney fees and the award of bounties to private plaintiffs who successfully bring these suits, as well as to the government programs. In recent years, government oversight and law enforcement have become increasingly active and aggressive in investigating and taking legal action against potential fraud and abuse. In July 2021, the Company received a civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act. The demand requests information and documents regarding Medicaid billing, patient services and referrals in connection with the Company's PACE program in Colorado. We continue to fully cooperate with the Attorney General. We are currently unable to predict the outcome of this investigation. In February 2022, the Company received a civil investigative demand from the Department of Justice (â€œDOJâ€) under the Federal False Claims Act on similar subject matter. The demand requests information and documents regarding audits, billing, orders tracking, and quality and timeliness of patient services in connection with the Company's PACE programs in the states of California, Colorado, New Mexico, Pennsylvania, and Virginia. In December 2022, the Company received a supplemental civil investigative demand from the DOJ requesting supplemental information on the same matters. We continue to fully cooperate with the DOJ. We are currently unable to predict the outcome of this investigation. Furthermore, our business exposes us to potential medical malpractice, professional negligence or other related actions or claims that are inherent in the provision of healthcare services. These claims, whether or not they have merit, could cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business, harm our reputation and adversely affect our ability to attract and retain participants, any of which could have a material adverse effect on our business, financial condition and results of operations. Although we maintain third-party professional liability insurance coverage, it is possible that claims against us may exceed the coverage limits of our insurance policies. Even if any professional liability loss is covered by an insurance policy, these policies typically have substantial deductibles for which we are responsible. Professional liability claims in excess of applicable insurance coverage could have a material adverse effect on our business, financial condition and results of operations. In addition, any professional liability claim brought against us, whether or not they have merit, could result in an increase of our professional liability insurance premiums. Insurance coverage varies in cost and can be difficult to obtain, and we cannot guarantee that we will be able to obtain insurance coverage in the future on terms acceptable to us or at all. If our costs of insurance and claims increase, then our earnings could decline. 24 Under our PACE contracts, we assume all of the risk that the cost of providing services will exceed our compensation. Approximately 99.9% and 99.8% of our revenue for the years ended June 30, 2024 and 2023, respectively, was derived from capitation agreements with government payors in which we receive fixed PMPM fees. While there are variations specific to each agreement, we generally contract with government payors to receive a fixed PMPM fee to provide or manage all healthcare services a participant may require while assuming financial responsibility for the totality of our participants' healthcare expenses. This type of contract is often referred to as an â€œeat-riskâ€ or a â€œcapitationâ€ contract. To the extent that our participants require more care than is anticipated and/or the cost of care increases, aggregate fixed capitation payments may be insufficient to cover the costs associated with treatment. The risk pool of our population became more acute beginning in fiscal year 2023, as we were not able to replenish our population mix with newer, lower-acuity participants due to enrollment sanctions. As a result of this dynamic, together with increased salaries, wages and benefits, increased fleet and contract transportation costs, annual increases in assisted living and nursing facility unit cost and general medical inflation, our external provider costs and cost of care, excluding depreciation and amortization, represented approximately 83% of our revenue in the fiscal year 2024. If medical costs and expenses exceed the underlying capitation payment received, we will not be able to correspondingly increase our capitated payment and we could suffer losses with respect to such agreements. Changes in our anticipated ratio of medical expense to revenue can significantly impact our financial results. Accordingly, the failure to adequately predict and control medical costs and expenses, execute or realize the benefits of our clinical value initiatives, and to make reasonable estimates and maintain adequate accruals for incurred but not reported claims, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Additionally, the Medicare and Medicaid expenses of our participants may be outside of our control in the event that participants take certain actions that increase such expenses, such as emergency room visits or preventable hospital admissions. Historically, our medical costs and expenses as a percentage of revenue have fluctuated. Factors that may cause medical expenses to exceed estimates include: â€¢ the health status of participants requiring higher levels of care, such as nursing home care or higher incidents of hospitalization; â€¢ higher than expected utilization of new or existing healthcare services; â€¢ more frequent catastrophic medical cases (e.g. transplants); â€¢ an increase in the cost of healthcare services and supplies, whether as a result of inflation, wage increases, purchases of vaccines and personal protective equipment as a result of a pandemic or epidemic, other health emergencies, or otherwise; â€¢ emergence of new high-cost medications to treat conditions that are common in our population, such as lecanemab for Alzheimer's Dementia; â€¢ changes to mandated benefits or other changes in healthcare laws, regulations and practices; â€¢ increased costs attributable to specialist physicians, hospitals and ancillary providers; â€¢ changes in the demographics of our participants and medical trends; â€¢ contractual or claims disputes with providers, hospitals or other service providers; â€¢ the occurrence of catastrophes, health emergencies, including epidemics or pandemics or acts of terrorism; and â€¢ the reduction of government payor payments. We have experienced and expect to continue experiencing increased costs and expenditures in the future. In fiscal year 2024, we continued several initiatives intended to lower certain of our costs, including limiting corporate staffing and certain other expenses, effecting a reduction in workforce, and optimizing working capital. However, we have made and expect to continue making significant investments in growing our business and increasing our participant base, 25 building capabilities to increase our sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends, expanding our operations, hiring additional employees for growing or new centers, introducing or improving technology, and operating as a public

company. As a result of these increased expenditures, we may not succeed in increasing our revenue sufficiently to improve our profit margins. We finance our operations principally from revenue from our participant services and the incurrance of indebtedness. We may not continue to generate positive cash flow from operations or have access to sufficient capital, and our variable results may make it difficult for you to rely on our historical results as indicative of future performance. We have encountered and will continue to encounter risks and difficulties frequently experienced by growing companies in rapidly changing and highly regulated industries, including increasing expenses as we continue to grow our business. Our operating expenses have and we expect them to continue to increase over the next several years as we continue to hire additional personnel, expand our operations and infrastructure, and continue to provide services to an increasing number of participants. If we are not able to execute or realize the benefits of our clinical value initiatives, including as a result of our EMR system, Epic, not operating as expected, our profitability could continue to decline. In addition to the expected costs to grow our business, we also expect to continue to incur compliance costs, as a result of audits and maintaining high quality of care across our centers, as well as additional legal, accounting and other expenses as we continue to operate as a public company. These investments may be more costly than we expect, and if we do not achieve the benefits anticipated from these investments, or if the realization of these benefits is delayed, our profitability could continue to decline. If our growth rate were to decline significantly or become negative, it could adversely affect our financial condition and results of operations. If we are not able to maintain positive cash flow in the long term, we may require additional financing, which may not be available on favorable terms or at all and/or which would be dilutive to our stockholders. If we are unable to successfully address these risks and challenges as we encounter them, our business, results of operations and financial condition would be adversely affected. Accordingly, we may not be able to be profitable or improve our income in the future, which could negatively impact the value of our common stock. Our revenues and operations are dependent upon a limited number of government payors, particularly Medicare and Medicaid. Our operations are dependent on a limited number of government payors, particularly Medicare and Medicaid, with whom we directly contract to provide services to participants. We generally manage our contracts on a state-by-state basis, entering into a separate contract in each state. When aggregating the revenue associated with Medicare and Medicaid by state, Colorado, California and Virginia accounted for a total of approximately 84.3% and 83.0% of our capitation revenue for the years ended June 30, 2024 and 2023, respectively. We believe that majority of our revenues will continue to be derived from a limited number of key government payors, which may terminate their contracts with us upon the occurrence of certain events, including as a result of inspections, reviews, audits, requests for information or investigations with adverse findings. The sudden loss of any of our government contracts or the renegotiation of any of such contracts could adversely affect our operating results. In the ordinary course of business, we engage in active discussions and renegotiations with government payors in respect of the services we provide and the terms of our agreements. As the states respond to market dynamics and financial pressures, and as government payors make strategic budgetary decisions in respect of the programs in which they participate, certain government payors may seek to renegotiate or terminate their agreements with us. Any reduction in the budgetary appropriations for our services, whether as a result of fiscal constraints due to recession, or economic downturn, emergency situations such as the COVID-19 pandemic, changes in policy or otherwise, could result in a reduction in our capitated fee payments, changes to the scope of services and possibly loss of contracts and could negatively impact our revenues, business and prospects. See Item 1A. Risk Factors, “Risks Related to Our Business” A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, such as COVID-19, as well as weather and other factors have affected, and could in the future adversely affect our business and “Risks Related to Our Business” We conduct a significant percentage of our operations in the State of Colorado and, as a result, we are particularly susceptible to any reduction in budget appropriations for our services or any other adverse developments in that state. Because we rely on a limited number of government-funded agencies, namely CMS and state Medicaid agencies, for a significant portion of our revenues, we depend on federal funding, as well as the financial condition of the states in which we operate, and each state’s commitment to its participation in the PACE program. Government-funded healthcare programs in the states in which we operate face a number of risks, including higher than expected healthcare costs and lack of predictability of tax basis and budget needs. If the financial condition of the states in which we operate declines, our credit risk could increase. Reductions in PACE reimbursement rates or changes in the rules governing PACE programs could have a material adverse effect on our financial condition and results of operations. We receive nearly all of our revenue through the PACE program, which accounted for 99.9% and 99.8% of our revenue for the years ended June 30, 2024 and 2023, respectively. As a result, our operations are dependent on government funding levels for PACE programs. Any changes that limit or reduce general PACE funding, such as reductions in or limitations of reimbursement amounts or rates under programs, reductions in funding of programs, expansion of benefits, services or treatments under programs without adequate funding, could have a material adverse effect on our business, results of operations, financial condition and cash flows. The PACE programs and their respective reimbursement rates, payment structures and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the PACE rates at which we are compensated for our services. Budget pressures can lead federal and state governments to reduce or place limits on reimbursement rates and payment structures under PACE. Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins. Legislation enacted in 2011 requires CMS to sequester or reduce all Medicare payments, including payments to PACE organizations, by 2% per year for a period of years. We cannot predict what other deficit reduction, other payment reduction or budget enforcement initiatives may be proposed by Congress, which could impact our business, including whether Congress will attempt to increase, restructure or suspend sequestration. Each year, CMS establishes the Medicare PACE benchmark payment rates by county for the following calendar year. Because nearly all of our revenue is through the PACE program, any negative changes to the PACE benchmark payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, our PACE revenues may become volatile in the future, which could have a material adverse impact on our business, results of operations, financial condition and cash flows. Reductions in reimbursement rates could have a material, adverse effect on our financial condition and results of operations or even result in rates that are insufficient to cover our operating expenses. For example, our external provider costs are driven by rates set by Medicare and Medicaid, which are outside of our control and may be negotiated in a manner unfavorable to us. Additionally, any delay or default by state governments in funding our capitated payments could materially and adversely affect our business, financial condition and results of operations. Recent legislative, judicial and executive efforts to enact further healthcare reform legislation have caused the future state of reforms under the ACA and many core aspects of the current U.S. healthcare system to be unclear. While specific changes and their timing are not yet apparent, enacted reforms and future legislative, regulatory, judicial, or executive changes, particularly any changes to the PACE program, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Our records and submissions to government payors may contain inaccurate or unsupportable information regarding risk adjustment scores of participants, which could cause us to overstate or understate our revenue and subject us to repayment obligations or penalties. The claims and encounter records that we submit to government payors involve data that support the RAF scores attributable to participants. These RAF scores determine the payment we are entitled for the provision of medical care to such participants. The data submitted to CMS is based on diagnosis codes and medical charts that our employed, contracted, and noncontracted providers identify, record and prepare. Any issues with recording and documenting identified medical conditions, such as those that were present during the COVID-19 pandemic and could be presented during a future pandemic or epidemic, could adversely impact Medicare RAF scores and our resulting revenue for future periods. CMS periodically audits PACE organizations’ risk adjustment submissions. The submission of inaccurate, incomplete or erroneous data could result in inaccurate revenue and risk adjustment payments, which may be subject to correction or retroactive adjustment in later periods. This corrected or adjusted information may be reflected in financial statements for periods subsequent to the period in which the revenue was recorded. We could be required to refund a portion of the revenue that we received, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. Historically, these true-up payments typically occur between May and August, but the timing of these payments is determined by CMS, and we have neither visibility nor control over the timing of such payments. From time to time, we may experience reconciliation issues as government payors modify or adopt new systems. If CMS seeks repayment from us for payment adjustments as a result of its audits, we could also be subject to liability for penalties for inaccurate or unsupportable RAF scores provided by us or our providers. In addition, we could be liable for penalties to the federal government under the FCA, which may include per claim penalties, plus up to three times the amount of damages caused by each false claim, which can be as much as the amounts received directly or indirectly from the government for each such false claim. As of February 12, 2024, the minimum False Claims Act penalty increased from \$13,508 to \$13,946 per claim. The maximum penalty has increased from \$27,018 to \$27,894 per claim. There is a high potential for substantial penalties in connection with any alleged FCA violations. Elements of the risk adjustment mechanism continue to be challenged, reevaluated, and revised by the U.S. DOJ, the OIG, and CMS. On February 1, 2023, CMS published the Medicare Advantage RADV Program Final Rule, which took effect on April 3, 2023. The final rule includes major updates to the Risk Adjustment Data Validation (“RADV”) audit methodology used by CMS to address overpayments to MA plans based on the submission of unsupported risk-adjusting diagnosis codes, which are used to determine payments under MA. Most notably, the final rule allows CMS to extrapolate RADV audit findings beginning with payment year 2018. CMS intends to initiate audits with the new methodology in calendar year 2025 beginning with payment year 2018. If CMS recovers overpayments from MA plans, those plans may seek to recover payments from us that the plans believe are attributable to risk adjustment data. There can be no assurance that a PACE organization, including us, will not be randomly selected or targeted for review by CMS or that the outcome of such a review will not result in a material adjustment in our revenue and profitability, even if the information we submitted to CMS is accurate and supportable. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions, could materially affect our capitated reimbursement. Renegotiation, non-renewal or termination of capitation agreements with government payors could have a material adverse effect on our business, results of operations, financial condition and cash flows. Under most of our capitation agreements with government payors, the state is generally permitted to adjust certain terms of the agreements from time to time. If a government payor exercises its right to adjust certain terms of the agreements, we are generally allowed a period of time to object to such adjustment. If we enter into capitation contracts with unfavorable economic terms, or a capitation contract is adjusted to include unfavorable terms, we could suffer losses with respect to such contract. In addition, some states in which we operate undergo periodic reconciliations with respect to enrollments that present a risk to our business, results of operations, financial condition and cash flows. Our contracts with government payors may be terminated to the extent that state or federal funds are not appropriated at sufficient levels to fund our contracts or PACE programs in general. Certain of our contracts are terminable immediately upon the occurrence of certain events. Government payors may terminate, suspend or cancel our contracts, in whole or in part, for cause in the event of our noncompliance with the terms, conditions or responsibilities under the contracts, or if we are debarred or suspended from providing services by state or federal government authorities. CMS may also impose sanctions for noncompliance with regulatory or contractual requirements, including the suspension of enrollment of participants, the occurrence of which would adversely affect our operating results and our ability to pursue our growth strategies. If any of our contracts with government payors are terminated or if the government payors seek to renegotiate their contract rates with us, we may suffer a significant loss of revenue, which may adversely affect our operating results. State and federal efforts to reduce healthcare spending could adversely affect our financial condition and results of operations. Most of our participants are dually-eligible, meaning they are qualified for coverage under both Medicare and Medicaid when enrolled in our PACE program, and nearly all our revenue is derived from government payors. Medicaid is a joint federal and state funded program for healthcare services for low income as well as certain higher-income individuals who qualify for nursing home level of care. Under broad federal criteria, states establish rules for eligibility, services and payment. PACE programs are administered at the state level and are financed by both state and federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets. This increase, combined with slower state revenue growth, has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending. Due to budget constraints, including resulting from a potential recession, we may experience negative Medicaid capitated rate payment pressure from certain states where we operate, such as Colorado, where we conduct a significant percentage of our operations. In addition, as part of past attempts to repeal, replace or modify the ACA and as a means to reduce the federal budget deficit, there have in recent years been congressional efforts to move Medicaid from an open-ended program with coverage and benefits set by the federal government to one in which states receive a fixed amount of federal funds, either through block grants or per capita caps, and have more flexibility to determine benefits, eligibility or provider payments. If those changes are implemented, we cannot predict whether the amount of fixed federal funding to the states will be based on current payment amounts, or if it will be based on lower payment amounts, which would negatively impact those states that expanded their Medicaid programs in response to the ACA. We expect state and federal efforts to reduce healthcare spending to continue for the foreseeable future. We depend on our senior management team and other key employees, and the loss of one or more of these employees or an inability to attract and retain other highly skilled employees could harm our business. Our future success depends largely upon the services of our senior management team and other key employees. We rely on our leadership team in the areas of operations, provision of medical services, information technology and security, marketing, and general and administrative functions. Changes to our business strategy resulting from senior executive officer transitions could have a disruptive impact on our ability to implement our business strategy and could have a material adverse effect on our business. Our employment agreements with our executive officers and other key personnel do not require them to continue to work for us for any specified period and, therefore, they could terminate their employment with us at any time. The loss, whether as a result of voluntary termination or illness, of one or more of the members of our senior management team, or other key employees, could harm our business. Changes in our executive management team may also cause disruptions in, and harm to, our business. Labor relations matters could have a material adverse effect on our business, reputation, prospects, results of operations and financial condition. In fiscal year 2024, the nurses in our Pennsylvania centers voted to unionize and collective bargaining commenced in late 2024. These employees represent approximately 1% of our total workforce. Even though we are currently unaware of other unionization efforts, it is possible that additional employees in our Pennsylvania centers or in other geographies may follow. As we negotiate collective bargaining agreements for the two new bargaining units at the Pennsylvania centers, and any other units that may organize in the future, employees may threaten and/or engage in work stoppages and strikes, and our labor costs may continue to increase as a result. The unavailability of staff, or the inability of the Company to control labor costs related to these matters and future efforts to unionize, could have a material adverse effect on our business, reputation, prospects, results of operations and financial condition. If certain of our suppliers do not meet our needs, if we are not reimbursed or adequately reimbursed for medical products we purchase or if we are unable to effectively access new technology or medical products, our ability to effectively provide the services we offer could be negatively impacted. We have significant suppliers that may be the sole or primary source of products critical to the services we provide, or to which we have committed obligations to make purchases, sometimes at particular prices. If any of these suppliers do not meet our needs for the products they supply, including as a result of price increases, a product recall, product shortage or other supply chain issues, or a dispute, and we are not able to find adequate alternative sources, our business, results of operations, financial condition and cash flows could be materially adversely impacted. In addition, the technology related to the products critical to the services we provide is subject to new developments which may result in the availability of superior products. If we are not able to access superior products or new medical products, including biopharmaceuticals or medical devices, on a cost-effective basis or if suppliers are not able to fulfill our requirements for such products, we could face attrition with respect to our participants or health care providers and other personnel and other negative consequences which could have a material adverse effect on our business, results of operations, financial condition and cash flows. We conduct a significant percentage of our operations in the State of Colorado and, as a result, we are particularly susceptible to regulatory issues and reduction in budget appropriations for our services or any other adverse developments in that state. For the fiscal year ended June 30, 2024 and 2023, 23.7% and 23.6% of our total revenues were derived from contracts with government agencies in the State of Colorado. Accordingly, any regulatory issues and developments in the State, such as the enrollment sanctions we were subject to in fiscal years 2022 and 2023, a reduction in Colorado’s budgetary appropriations for our services, whether as a result of fiscal constraints due to recession, emergency situations, such as the COVID-19 pandemic, changes in policy or otherwise, have and could in the future result in a reduction in our capitated fee payments and possibly the loss of contracts, and materially adversely impact our results. If we fail to manage our operations effectively, we may be unable to execute our business plan, maintain effective levels of service and participant satisfaction or adequately address competitive challenges. We have experienced, and may continue to experience, organizational change and growth, which has placed, and may continue to place, significant demands on our management and our operational and financial

resources. Additionally, our organizational structure continues to become more complex as we grow and expand our operational, financial and management controls, as well as our reporting systems and procedures as a public company. We may require significant capital expenditures and the allocation of valuable management resources to grow and evolve our operational and financial operations and grow. We must ensure our personnel have the necessary licenses and competencies and continue to effectively train and manage our employees. We will be unable to manage our business effectively if we are unable to alleviate the strain on resources caused by growth in a timely and efficient manner. As we expect that our participant base will continue to grow following the lifting of sanctions in the states of California and Colorado, the planned expansion of capacity of our existing de novo centers, the opening of de novo centers, and the execution of tuck-in acquisitions, we will need to maintain best practices throughout all our centers. If we fail to effectively manage our potential growth and change or fail to ensure that the level of care and services provided by our employees complies with regulatory and contractual requirements, and levels of patient service and satisfaction, our brand and reputation, could suffer, adversely affecting our ability to attract and retain participants and employees and lead to the need for corrective actions or sanctions. The healthcare industry is highly competitive and, if we are not able to compete effectively, our business could be harmed. We compete directly with national, regional and local providers of healthcare for participants and clinical providers, including new or growing participants and providers. We also compete directly with payors and other alternate managed care programs for participants. There are many other companies and individuals currently providing healthcare services, many of which have been in business longer and/or have substantially more resources. Given the regulatory environment, there may be high barriers to entry for PACE providers; however, since there are relatively modest capital expenditures required for providing healthcare services, there are less substantial financial barriers to entry in the healthcare industry generally. Other companies could enter the healthcare industry in the future and divert some or all of our business. Our ability to compete successfully varies from location to location and depends on a number of factors, including the number of payors who run competitive programs in the local market, our local reputation for quality participant care, the commitment and expertise of our medical staff or contracted healthcare providers, our local service offerings and community programs, the cost of care in each locality, and the physical appearance, location and condition of our centers. If we are unable to attract participants to our centers our revenue and profitability will be adversely affected. Some of our competitors may have greater brand recognition and be more established in their respective communities than we are, and may have greater financial and other resources than we have. Further, our current or potential competitors may be acquired by third parties with greater available resources. Competing providers may also offer different programs or services than we do, which, combined with the foregoing factors, may result in our competitors being more attractive to our current participants, potential participants and referral sources. For example, additional offerings by MA and other competitors during 2024 resulted in higher than expected disenrollments during fiscal year 2024. Furthermore, while we budget for routine capital expenditures at our centers to keep them competitive in their respective markets, to the extent that competitive forces cause those expenditures to increase in the future, our financial condition may be negatively affected. In addition, our contracts with government payors are not exclusive for PACE programs in California, and competitors in California could seek to establish contracts with the state Medicaid agency and CMS to serve PACE eligible participants in our service areas. For example, the service area for our Sacramento, California center overlaps with an existing PACE program in the region. Additionally, as we expand into new geographies, such as Florida, we may encounter competitors with stronger local community relationships or brand recognition, which could give those competitors an advantage in attracting new participants. Individual physicians, physician groups and companies in other healthcare industry segments, some of which have greater financial, marketing and staffing resources, may become competitors in providing healthcare services, and this competition may have a material adverse effect on our business operations and financial position. Our presence is currently limited to Colorado, California, Florida, New Mexico, Pennsylvania and Virginia, and we may not be able to successfully establish a presence in new geographic markets. Prior to fiscal year 2024, we operated in Colorado, California, New Mexico, Pennsylvania and Virginia, and in fiscal year 2024, we opened two de novo centers in Florida. For the year ended June 30, 2024, almost half of our revenue was driven by our businesses in Colorado. As a result, our exposure to many of the risks described in these risk factors are not mitigated by a diversification of geographic focus. To continue to expand our operations to other regions of the United States, including in connection with the ramp up of our Florida de novo centers, we devote significant resources to identifying and exploring perceived opportunities. Thereafter, we have to, among other things, recruit and retain qualified 30personnel, develop new centers and establish new relationships or contracts with physicians and other healthcare and services providers. In addition, we are required to comply with laws and regulations of states that may differ from the ones in which we currently operate, and could face competitors with greater knowledge of such local markets. We anticipate that further geographic expansion will require us to make a substantial investment of management time, capital and/or other resources. There can be no assurance that we will be able to continue to expand our operations in any new geographic markets. Security breaches, loss of data and other disruptions have in the past and could in the future compromise sensitive information related to our business or our participants, or prevent us from accessing critical information and expose us to liability, and could adversely affect our business and our reputation. In the ordinary course of our business, we create, receive, maintain, transmit, collect, store, use, disclose, share and process (collectively, "Process") sensitive data, including PHI/PII relating to our employees, participants and others. We also Process and contract with third-party service providers to Process sensitive information, including PHI/PII, confidential information and other proprietary business information. We manage and maintain PHI/PII and other sensitive data and information using both on premise and cloud-based systems. Third-party service providers that serve our participants Process PHI/PII data either in their own on-site systems, at managed or co-located data centers, or in the cloud. We are highly dependent on information technology networks and systems, including our EMR system, Epic, and the internet, to securely Process PHI/PII and other sensitive data and information. Security breaches of this infrastructure, whether ours or of our third-party service providers, including physical or electronic break-ins, computer viruses, ransomware, attacks by hackers and similar breaches, and employee or contractor error, negligence or malfeasance, have occurred in the past, and have in the past and could in the future, create system disruptions, shutdowns or unauthorized access, acquisition, use, disclosure or modifications of such data or information, and could cause PHI/PII to be accessed, acquired, used, disclosed or modified without authorization, to be made publicly available, or to be further accessed, acquired, used or disclosed. We use third-party service providers for important aspects of the Processing of employee and participant PHI/PII and other confidential and sensitive data and information, and therefore rely on third parties to manage functions that have material cybersecurity risks. Because of the sensitivity of the PHI/PII and other sensitive data and information that we and our service providers Process, the security of our technology platform and other aspects of our services, including those provided or facilitated by our third-party service providers, are important to our operations and business strategy. We have implemented certain administrative, physical and technological safeguards through our Cybersecurity Program to address these risks; however, such policies and procedures may not address certain HIPAA requirements or address situations that could lead to increased privacy or security risks, and agreements with contractors and other third-party service providers who handle this PHI/PII and other sensitive data and information for us. However, some PACE organizations that we have acquired in the past or may acquire in the future may not have implemented such agreements with their third-party service providers, which may expose us to legal claims or proceedings, liability, and penalties. We may be required to expend significant capital and other resources to protect against security breaches, to safeguard the privacy, security, and confidentiality of PHI/PII and other sensitive data and information, to investigate, contain, remediate, and mitigate actual or potential security breaches, and/or to report security breaches to participants, employees, regulators, media, credit bureaus, and other third parties in accordance with applicable law and to offer complimentary credit monitoring, identity theft protection, and similar services to participants and/or employees where required by law or otherwise appropriate. Cyber-attacks are becoming more sophisticated, and frequent, and we or our third-party service providers may be unable to anticipate these techniques or to implement adequate protective measures against them or to prevent future attacks. The prevalence of smart/handheld devices and the remote work environment has increased these risks. We exercise limited control over our third-party service providers and, in the case of some third-party service providers, may not have evaluated the adequacy of their security measures, which increases our vulnerability to problems with services they provide. A security breach, security incident, or privacy violation that leads to unauthorized use, disclosure, access, acquisition, loss or modification of, or that prevents access to or otherwise impacts the confidentiality, security, or integrity of, participant or employee information, including PHI/PII that we or our third-party service providers process, could harm our reputation and business, compel us to comply with breach notification laws, cause us to incur significant costs for investigation, containment, remediation, mitigation, fines, penalties, settlements, notification to individuals, regulators, media, credit bureaus, and other third parties, complimentary credit monitoring, identity theft protection, training and similar services to participants and/or employees where required by law or otherwise appropriate, for measures intended to 31repair or replace systems or technology and to prevent future occurrences. We may also be subject to potential increases in insurance premiums, resulting in increased costs or loss of revenue. Even in the case of cybersecurity incidents on our third-party service-providers, we remain responsible under HIPAA for our participants' PHI/PII and any failure on our part to comply with HIPAA in connection with such data could be subject to civil penalties, resolution agreements, monitoring or similar agreements or other enforcement action. For example, on February 21, 2024, Change Healthcare, a subsidiary of UnitedHealth Group, was the subject of a well-publicized cyberattack. Change Healthcare is the largest clearinghouse for medical claims in the U.S. and this event has caused significant delays and disruptions in payments to hospitals, physicians, pharmacists, and other health care providers across the country, including us. This cyberattack did not have a material impact on us or our operations. However, future cyber attacks on our third-party providers could have a material impact on our business.If we or our third-party service providers are unable to prevent or mitigate security breaches, security incidents or privacy violations, or if we or our third-party service providers are unable to implement satisfactory remedial measures with respect to known or future security incidents, or if it is perceived that we have been unable to do so, our operations could be disrupted, we may be unable to provide access to our systems, and we could suffer a loss of participants, loss of reputation, adverse impacts on participant and investor confidence, financial loss, governmental investigations or other actions, regulatory or contractual penalties, and other claims and liability. In addition, security breaches and incidents and other compromise or inappropriate access to, or acquisition or processing of, PHI/PII or other sensitive data or information can be difficult to detect, and any delay in identifying such breaches or incidents or in providing timely notification of such incidents may lead to increased harm and increased penalties. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident. A failure to accurately estimate incurred but not reported medical expenses could adversely affect our results of operations. External provider costs include estimates of future medical claims that have been incurred by the participant but for which the provider has not yet billed. These claim estimates are made utilizing actuarial methods and are continually evaluated and adjusted by management, based upon our historical claims experience and other factors, including an independent assessment by a nationally recognized actuarial firm. Positive or negative adjustments, if necessary, are made when the assumptions used to determine our claims liability change and when actual claim costs are ultimately determined. Due to uncertainties associated with the factors used in these estimates and changes in the patterns and rates of medical utilization, materially different amounts could be reported in our financial statements for a particular period under different conditions or using different, but still reasonable, assumptions. It is possible that our estimates of this type of claim may be excessive or inadequate in the future and we may be obligated to repay certain amounts to CMS. In such event, our results of operations could be adversely impacted. Further, the inability to estimate these claims accurately may also affect our ability to take timely corrective actions, further exacerbating the extent of any adverse effect on our results of operations. In addition, our operational and financial results will experience some variability depending upon the time of year in which they are measured. For example, medical costs vary seasonally depending primarily on the weather because certain illnesses, such as the influenza virus, are far more prevalent during colder months of the year. Historically, we have seen higher levels of per-participant medical costs in the second and third quarters of our fiscal year. We lease half of our centers and may experience risks relating to lease termination, lease expense escalators, lease extensions and special charges. We currently lease 10 of our 20 centers. Our leases typically have terms of nine years, and generally provide for renewal or extension options for an average total potential term of approximately 23 years. However, there can be no assurance that these rights will be exercised in the future or that we will be able to satisfy the conditions precedent to exercising any such renewal or extension. Each of our lease agreements provides that the lessor may terminate the lease, subject to applicable cure provisions, for a number of reasons, including the defaults in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. If a lease agreement is terminated or if we are unable to renew or extend any of our leases, we may lose the center subject to that lease agreement. If we are not able to renew or extend our leases at or prior to the end of the existing lease terms, or if the terms of such options are unfavorable or unacceptable to us, our business, financial condition and results of operation could be adversely affected.32A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, such as COVID-19, as well as weather and other factors, have affected, and could in the future adversely affect our business.Any future pandemic, epidemic or outbreak of an infectious disease may adversely affect our business if one or all of the geographies we serve is affected by such outbreak, particularly at the onset of any such outbreak before response protocols have been developed. Specifically, if our participants fall ill due to an outbreak, such as during the COVID-19 pandemic, we may experience a high level of unexpected deaths, increased costs, difficulties adhering to the complex government laws and regulations that apply to our business (including difficulties enrolling participants as was the case during the COVID-19 pandemic), and other effects, including a loss of revenue, negative publicity, litigation and inquiries from government regulators.In addition, our results of operations have been and may in the future be negatively impacted by adverse conditions affecting our centers, including severe weather events such as tornadoes, hurricanes and widespread winter storms, earthquakes, violence or threats of violence or other factors beyond our control that cause disruption in provision of participant services, displacement of our participants, employees and care teams, or force certain of our centers to close temporarily. Our insurance coverage may not compensate us for losses that may occur in the event of an earthquake or other significant natural disaster. In certain geographic areas, we have a large concentration of centers that may be simultaneously affected by health emergencies, adverse weather conditions or other events. Our future operating results may be adversely affected by these and other factors that disrupt the operation of our centers.Risks Related to Regulation Allegations that we have failed to adhere to all of the complex government laws and regulations that apply to our business have had and could in the future have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price. Our operations are subject to extensive federal, state and local government laws and regulations, such as: the federal Medicare, federal and state Medicaid, and federal and state PACE statutes and regulations, which are continuously changing and evolving; the federal and state anti-kickback and self-referral laws, which prohibit, among other things, the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback or remuneration, whether in cash or in kind, for referring an individual, in return for ordering, leasing, purchasing or recommending or arranging for or to induce the referral of an individual or the ordering, purchasing or leasing of items or services covered, in whole or in part, by federal healthcare programs, such as Medicare and Medicaid, or by any payor; the federal civil false claims laws, including the FCA and associated regulations, which impose civil penalties through governmental, whistleblower or qui tam actions, on individuals or entities for, among other things, knowingly submitting false or fraudulent claims for payment to the government or knowingly making, or causing to be made, a false statement in order to have a claim paid. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties ranging from \$13,946 to \$27,894 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; the federal false claims laws, which impose criminal penalties on individuals who make or present a false, fictitious, or fraudulent claim to the government that the individual knew was false, fictitious, or fraudulent, and was made with the specific intent to violate the law or with a consciousness of wrongdoing; the state false claims laws, which generally follow the FCA and apply to claims submitted to state healthcare programs, and state health insurance fraud laws that impose penalties for the submission of false or fraudulent claims by providers to commercial insurers or other payors of healthcare services; the federal Civil Monetary Penalties Statute and associated regulations, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know such remuneration is likely to influence the beneficiary's selection of a particular provider or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies, and which authorize assessments and program exclusion for various forms of fraud and abuse involving the Medicare and Medicaid programs; the federal healthcare fraud statute and its implementing regulations, which created federal criminal laws that prohibit, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; federal and state laws regarding the collection, use, disclosure and, protection of personal identifiable information or PII and protected health information or PHI (e.g., HIPAA and the CCPA) and the storage, handling, shipment, disposal and/or disposing of

pharmaceuticals and blood products and other biological materials, and many other applicable state and federal laws and requirements; state and federal statutes and regulations that govern workplace health and safety; federal and state laws and policies that require healthcare providers to maintain licensure, certification or accreditation to provide services to patients or to enroll and participate in the Medicaid programs, to report certain changes in their operations to the agencies that administer these programs and, in some cases, to re-enroll in these programs when changes in direct or indirect ownership occur; federal and state scope of practice and other laws pertaining to the provision of services by qualified healthcare providers, including those pertaining to the provision of services by nurse practitioners and physician assistants in certain settings and requirements for physician supervision of those services; state laws restricting the corporate practice of medicine; and federal or state consumer protection laws that regulate various trade practices (e.g. consumer communications or consumer-facing activities). In addition to the above, PACE contracts also impose complex and extensive requirements upon our operations. Federal and state manuals, policies, and other guidance may also affect our operations. The various laws, regulations, and agency guidance that apply or relate to our operations are often subject to varying interpretations, and additional laws and regulations potentially affecting healthcare organizations continue to be promulgated and issued. A violation or departure from any of the legal requirements applicable to our business may result in, among other things, government audits, decreased payment rates, significant fines and penalties, the potential loss of licensure or certification, recoupment efforts or retractions of reimbursement previously paid, voluntary repayments, exclusion from governmental healthcare programs, written warnings, corrective action plans, monitoring, reputational harm, suspension of new enrollment or the restriction of current enrollment, the withholding of payments under the PACE program agreement, and termination of the PACE program agreement. These legal requirements may be civil or administrative in nature. We are subject to federal and state regulations that require PACE organizations to maintain fiscally sound operations, as defined by CMS and applicable state agencies. We submit regular financial reports to governmental authorities and are subject to routine financial reviews and audits by both CMS and state agencies. For example, federal and state governments evaluate our assets and liabilities, cash flows, and net operating surpluses against specific regulatory requirements. From time to time, federal and state authorities may identify aspects of the finances of our PACE organizations that do not comply with federal or state requirements and may require us to submit clarifications and/or take action to adjust the capitalization or other financial status of such entities. As state agencies promulgate additional regulations applicable to PACE and issue sub-regulatory guidance, we will have to allocate sufficient resources to ensure compliance with both federal and state regulations. We endeavor to comply with all legal requirements. We further endeavor to structure our relationships with physicians, providers, and other third parties to comply with state and federal anti-kickback laws and other applicable healthcare laws. We utilize considerable resources to monitor laws and regulations and implement necessary changes. However, the laws and regulations in these areas are complex, changing and often subject to varying interpretations, and any failure to satisfy applicable laws and regulations could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation. We may face penalties, including penalties under the FCA, if we fail to report and return government overpayments within 60 days of when the overpayment is identified and quantified. See Item 1A. Risk Factors, "Risks Related to Our Business." We are subject to legal proceedings, enforcement actions and litigation, malpractice and privacy disputes, which are costly to defend and could materially harm our business and results of operations. Additionally, the federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare, Medicaid, and other federally funded healthcare programs. Moreover, following amendments to the federal Anti-Kickback Statute under the ACA, claims that are implicated by Anti-Kickback Statute violations are also subject to liability under the FCA, including qui tam or whistleblower suits. In recent years, the number of suits brought in the medical industry by private individuals has increased dramatically. Given the high volume of claims processed by our various operating units, the potential is high for substantial penalties in connection with any alleged FCA violations. In addition to the provisions of the FCA, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government. If any of our operations are found to violate these or other government laws or regulations, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price, including: suspension, termination or exclusion of our participation in government payment programs; refunds of amounts received in violation of law or applicable payment program requirements dating back to the applicable statute of limitation periods; criminal or civil liability, fines, damages or monetary penalties for violations of healthcare fraud and abuse laws, including the Anti-Kickback Statute, Civil Monetary Penalties Statute and FCA, or other failures to meet regulatory requirements; enforcement actions by governmental agencies and/or state law claims for monetary damages for patients or employees relating to breach or impermissible use or disclosure of, or other incident relating to PHI and other types of personal data or PII that we collect, use, and disclose, in violation of federal or state privacy laws, including, for example and without limitation, HIPAA or state data privacy and security laws; mandated changes to our practices or procedures that could significantly increase operating expenses; imposition of and compliance with corporate integrity agreements, monitoring agreements or corrective action plans that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices; termination of various relationships and/or contracts related to our business, including joint venture arrangements, real estate leases and consulting agreements; harm to our reputation, which could negatively impact our business relationships, affect our ability to attract and retain participants and healthcare professionals, affect our ability to obtain financing and decrease access to new business opportunities, among other things. We are, from time to time, and may in the future continue to be, a party to various lawsuits, demands, claims, governmental investigations, audits (including investigations or other actions resulting from our obligation to self-report suspected violations of law), and other legal matters. Responding to subpoenas, requests for information, investigations and other lawsuits, claims, and legal proceedings as well as defending ourselves in such matters has required management's attention and caused us to incur significant legal expense. It is possible that criminal proceedings may be initiated against us and/or individuals in our business in connection with investigations by the federal government. The results of such lawsuits cannot be predicted. Qui tam actions are filed under seal and impose a mandatory duty on the U.S. DOJ to investigate such allegations, and because qui tam suits are filed under seal, we could be subject to suits of which we are not aware or have been ordered by the presiding court not to discuss or disclose. We, our healthcare professionals, and the centers in which we operate, are subject to various federal, state and local licensing, certification and other laws and regulations, relating to, among other things, the quality of medical care, equipment, privacy of health information, physician relationships, telehealth, personnel and operating policies and procedures. Failure to comply with these licensing and certification laws, regulations and standards could result in cessation of our services, recoupment of prior payments by government payors, corrective action plans, the suspension of participant enrollment or requirements to make significant changes to our operations and can give rise to civil or, in certain cases, criminal penalties. We routinely take the steps we believe are necessary to retain or obtain requisite licensure and operating authorities. While we endeavor to comply with federal, state and local licensing and certification laws and regulations and standards as we interpret them, the laws and regulations in these areas are complex, changing and often subject to varying interpretations. Any failure to satisfy applicable laws and regulations could have a material adverse impact on our business, results of operations, financial condition, cash flows, and reputation. If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting U.S. healthcare reform, our business could be harmed. Due to the importance of the healthcare industry in the lives of all Americans, federal, state, and local legislative bodies frequently pass legislation and administrative agencies promulgate regulations relating to healthcare reform or that affect the healthcare industry. As has been the trend in recent years, it is reasonable to assume that there will continue to be increased government oversight and regulation of the healthcare industry in the future. We cannot assure our stockholders as to the ultimate content, timing or effect of any new healthcare legislation or regulations, nor is it possible at this time to estimate the impact of potential new legislation or regulations on our business. Since nearly all of our revenue is derived from government payors, we are always subject to regulatory changes. Federal and state legislators routinely introduce and consider proposed legislation that would impact Medicare, Medicaid, and PACE funding and operations, and state and federal agencies also consider and implement regulations and guidance that impact our business. Similarly, changes in private payor reimbursement policies could lead to adverse changes in Medicare, Medicaid and other governmental healthcare programs, which could have a material adverse effect on our business, financial condition and result of operations. We cannot predict with certainty the impact that any particular federal and state healthcare legislation or regulation will have on us, but such changes could impose new and/or more stringent regulatory requirements on our activities or result in reduced payment rates, any of which could adversely affect our business, financial condition, and results of operations. While we believe that we have structured our agreements and operations in material compliance with applicable healthcare laws and regulations, there can be no assurance that regulators will agree with our approach or that we will be able to successfully address changes in the current legislative and regulatory environment. Moreover, some of the healthcare laws and regulations applicable to us are subject to limited or evolving interpretations, and a review of our business or operations by a court, law enforcement or a regulatory authority might result in a determination that could have a material adverse effect on us. Furthermore, the healthcare laws and regulations applicable to us may be amended or interpreted in a manner that could have a material adverse effect on our business, prospects, results of operations and financial condition. Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business, and the failure to comply with such laws could subject us to penalties or require a restructuring of our business. Some of the states in which we currently operate have laws that prohibit business entities, such as us, from practicing medicine, employing physicians or other clinicians to practice medicine, exercising control over medical decisions by physicians or other clinicians or engaging in certain arrangements, such as fee-splitting, with physicians or other clinicians (such activities generally referred to as the "corporate practice of medicine"). In some states, these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition is a matter of judicial or regulatory interpretation. For example, in Pennsylvania, the statutes that pertain to the employment of healthcare practitioners by healthcare centers do not explicitly include a PACE organization in the list of healthcare centers by which a healthcare practitioner may be employed. Other states in which we may operate in the future may also generally prohibit the corporate practice of medicine. While we endeavor to comply with state corporate practice of medicine laws and regulations as we interpret them, the laws and regulations in these areas are complex, changing, and often subject to varying interpretations. The interpretation and enforcement of these laws vary significantly from state to state. Penalties for violations of the corporate practice of medicine vary by state and may result in physicians being subject to disciplinary action, as well as forfeiture of revenues from payors for services rendered. For business entities, such as us, violations may also bring both civil and, in more extreme cases, criminal liability for engaging in medical practice without a license, as well as obligations to restructure the implicated arrangements. Any of these outcomes may have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation. Laws governing the review and approval of healthcare transactions could limit our ability to grow our business. Several states, including California, have adopted laws focused on competition, quality, access, and cost that authorize state agencies to review and approve healthcare transactions, and many other states, including Pennsylvania, are considering similar legislation. California is also considering additional legislation that would provide the California attorney general with approval authority with respect to certain health care transactions. We have in the past and continue to intend to grow our business through acquisitions, and these laws could negatively affect our ability to grow in implicated states in the future. Our use, disclosure, and other processing of PHI/PII is subject to HIPAA, CCPA as amended by the CPRA and other federal and state privacy and security regulations, and our failure to comply with those laws and regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our participant base and revenue. Numerous state and federal laws and regulations govern the collection, dissemination, use, disclosure, destruction, retention, privacy, confidentiality, security, availability, integrity and other processing of PHI/PII. These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of PHI by health plans, healthcare clearinghouses, and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. A business associate is any person or entity (other than members of a covered entity's workforce) that performs a service for or on behalf of a covered entity involving the use or disclosure of protected health information. HIPAA requires covered entities, such as ourselves, and their business associates to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims. HIPAA imposes mandatory penalties for certain violations. Under a notice of enforcement discretion issued by HHS in 2019, penalties for violations of HIPAA and its implementing regulations start at \$100 (not adjusted for inflation) per violation and are not to exceed approximately \$63,000 (not adjusted for inflation) per violation, subject to a cap of approximately \$1.9 million (not adjusted for inflation) for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. In addition, HIPAA provides for criminal penalties of up to \$250,000 and ten years in prison, with the severest penalties for obtaining and disclosing PHI with the intent to sell, transfer or use such information for commercial advantage, personal gain or malicious harm. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys' fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates for compliance with the HIPAA Privacy and Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty fine paid by the violator. HIPAA further requires that individuals be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals. HIPAA specifies that such notifications must be made without unreasonable delay and in no case later than 60 calendar days after discovery of the breach. If a breach affects 500 individuals or more, it must be reported to HHS without unreasonable delay, and in no case later than 60 calendar days after discovery, and HHS will automatically investigate the breach and post the name of the entity on its public breach portal. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS at least annually. Breaches affecting more than 500 residents in the same state or jurisdiction must also be reported to the local media. Looking ahead, it is possible that Congress could pursue a federal privacy bill to harmonize privacy regimes across states. In addition to HIPAA, numerous other federal and state laws and regulations protect the confidentiality, privacy, availability, integrity and security of individually identifiable information. State statutes and regulations vary from state to state, and these laws and regulations in many cases are more restrictive than, and may not be preempted by, HIPAA and its implementing rules. These laws and regulations are often uncertain, contradictory, and subject to changing or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. For example, the CCPA provides certain exceptions for PHI, but is still applicable to certain PII we process in the ordinary course of our business. The effects of the CCPA are wide-ranging and afford consumers certain rights with respect to PII, including a private right of action for data breaches involving certain personal PII of California residents. In addition, the California Privacy Rights Act of 2020, or CPRA, expands the CCPA's requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states have enacted similar privacy laws that impose new obligations or limitations in areas affecting our business and we continue to assess the impact of this state legislation on our business as additional information and guidance becomes available. Efforts at the federal level to enact similar laws have been ongoing. As new data security laws are implemented, we may not be able to timely comply with such requirements, or such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to implement required changes in a timely manner could subject us to liability for non-compliance. Consumers may also be afforded a private right of action for certain violations of privacy laws. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance issues for us and potentially restricts our ability to process data and may expose us to additional expense, adverse publicity, and liability. While we believe we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations, and we have implemented measures to require our third-party service providers to maintain reasonable data privacy and security measures, we cannot guarantee that these efforts will be adequate, and we may be subject to cybersecurity, ransomware or other security incidents. Further, it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of our third-party service providers. If we or these

third parties are found to have violated such laws, rules or regulations, it could result in regulatory investigations, litigation awards or settlements, government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business. Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business. We also publish statements to our participants that describe how we handle and protect PHI. If federal or state regulatory authorities, such as the FTC, or private litigants consider any portion of these statements to be untrue, we may be subject to claims of deceptive practices, which could lead to significant liabilities and consequences, including, without limitation, costs of responding to investigations, defending against litigation, settling claims, and complying with regulatory or court orders. The FTC sets expectations for failing to take appropriate steps to keep consumers’ personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section 5(a) of the Federal Trade Commission Act (‘FTC Act’). The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers’ personal information; any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. Any of the foregoing consequences could seriously harm our business and our financial results.

Risks Related to Our IndebtednessOur existing indebtedness could adversely affect our business and growth prospects. As of June 30, 2024, we had total outstanding debt of (i) \$63.8 million principal amount under the Term Loan Facility (as defined in Note 7, ‘Long-term Debt’ to the consolidated financial statements) and (ii) \$2.2 million principal amount under the convertible term loan. Our indebtedness, or any additional indebtedness we may incur, could require us to divert funds identified for other purposes for debt service, impairing our liquidity position. If we cannot generate sufficient cash flow from operations to service our debt, we may need to refinance our debt, dispose of assets or issue equity to obtain necessary funds. We do not know whether we will be able to take any of these actions on a timely basis, or on terms satisfactory to us or at all. Our indebtedness and the cash flow needed to satisfy our debt have important consequences, including: limiting funds otherwise available for financing our capital expenditures and pursuing our growth strategies by requiring us to dedicate a portion of our cash flows from operations to the repayment of debt and the interest on this debt; making us more vulnerable to rising interest rates; and making us more vulnerable in the event of a downturn in our business. Our level of indebtedness may place us at a competitive disadvantage to our competitors that are less leveraged. Fluctuations in interest rates can increase borrowing costs. Increases in interest rates directly impact the amount of interest we are required to pay and reduce earnings accordingly. In addition, developments in tax policy, such as the disallowance of tax deductions for interest paid on outstanding indebtedness, could have an adverse effect on our liquidity and our business, financial conditions and results of operations. We expect to use cash flow from operations to meet current and future financial obligations, including funding our operations, debt service requirements and capital expenditures necessary to grow and maintain our businesses. The ability to make these payments depends on our financial and operating performance, which is subject to prevailing economic, industry and competitive conditions and to certain financial, business, economic and other factors beyond our control. In addition, the 2021 Credit Agreement (as defined in Note 7, ‘Long-term Debt’ to the consolidated financial statements) contains a number of restrictive covenants that impose significant operating and financial restrictions on us and may limit our ability to engage in acts that may be in our long-term best interests. A breach of the covenants or restrictions under the 2021 Credit Agreement could result in an event of default under such document. Such a default may allow the creditors to accelerate the related debt and terminate all commitments to extend credit thereunder and may result in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. In the event the holders of our indebtedness accelerate the repayment, we may not have sufficient assets to repay that indebtedness or be able to borrow sufficient funds to refinance it. Even if we are able to obtain new financing, it may not be on commercially reasonable terms or on terms acceptable to us. Our failure to raise additional capital or generate cash flows necessary to expand our operations and invest in participant services in the future could reduce our ability to compete successfully and harm our results of operations. We may need to raise additional funds, and we may not be able to obtain additional debt or equity financing on favorable terms or at all. If we raise additional equity financing, our security holders may experience significant dilution of their ownership interests. If we engage in additional debt financing, we may be required to accept terms that restrict our operational flexibility and our ability to incur additional indebtedness, force us to maintain specified liquidity or other ratios or restrict our ability to pay dividends or make acquisitions. If we need additional capital and cannot raise it on acceptable terms, or at all, we may not be able to, among other things: develop and enhance our participant services; continue to expand our business either by increasing enrollment or building de novo centers; hire, train and retain employees; respond to competitive pressures or unanticipated working capital requirements; or pursue acquisition opportunities.

Risks Related to Our Common StockOur Principal Shareholders control us, and their interests may conflict with ours or yours in the future. Our Principal Shareholders own approximately 83% of our common stock, which means that they control the vote of all matters submitted to a vote of our shareholders, which enables them to control the election of the members of the Board and all other corporate decisions. This concentration of ownership may delay, deter or prevent acts that would be favored by our other shareholders. The interests of the Principal Shareholders may not always coincide with our interests or the interests of our other shareholders. Even when the Principal Shareholders cease to own shares of our stock representing a majority of the total voting power, for so long as the Principal Shareholders continue to own a significant percentage of our stock, the Principal Shareholders will still be able to significantly influence the composition of our Board and the approval of actions requiring shareholder approval. Accordingly, for such period of time, the Principal Shareholders will have significant influence with respect to our management, business plans and policies, including the appointment and removal of our officers, decisions on whether to raise future capital and amend our charter and bylaws, which govern the rights attached to our common stock. In particular, for so long as the Principal Shareholders continue to own a significant percentage of our stock, the Principal Shareholders will be able to cause or prevent a change of control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of us. The concentration of ownership could deprive you of an opportunity to receive a premium for your shares of common stock as part of a sale of us and ultimately might affect the market price of our common stock. In addition, this concentration of ownership may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in a company with significant stockholders. In addition, we are party to a Director Nomination Agreement (defined herein) with the Principal Shareholders that provides the Principal Shareholders the right to designate: (i) all of the nominees for election to our Board for so long as the Principal Shareholders collectively beneficially own at least 40% of the Original Amount (as defined therein); (ii) 40% of the nominees for election to our Board for so long as the Principal Shareholders collectively beneficially own less than 40% but at least 30% of the Original Amount; (iii) 30% of the nominees for election to our Board for so long as the Principal Shareholders collectively beneficially own less than 30% but at least 20% of the Original Amount; (iv) 20% of the nominees for election to our Board for so long as the Principal Shareholders collectively beneficially own less than 20% but at least 10% of the Original Amount; and (v) one of the nominees for election to our Board for so long as the Principal Shareholders collectively beneficially own at least 5% of the Original Amount. If TCO Group Holdings, L.P., the investment vehicle through which the Principal Shareholders hold their investment is dissolved, then each of the Principal Shareholders will be permitted to nominate (i) up to three directors so long as it owns at least 25% of the Original Amount, (ii) up to two directors so long as it owns at least 15% of the Original Amount and (iii) one director so long as it owns at least 5% of the Original Amount. The Principal Shareholders may also assign such right to their affiliates. The Director Nomination Agreement also provides for certain consent rights for each of the Principal Shareholders so long as such shareholder owns at least 5% of the Original Amount, including for any changes to the size of our Board. The Principal Shareholders and their affiliates engage in a broad spectrum of activities, including investments in the healthcare industry generally. In the ordinary course of their business activities, the Principal Shareholders and their affiliates may engage in activities where their interests conflict with our interests or those of our other shareholders, such as investing in or advising businesses that directly or indirectly compete with certain portions of our business or are suppliers or customers of ours. Our certificate of incorporation provides that neither the Principal Shareholders, any of their affiliates or any director who is not employed by us (including any non-employee director who serves as one of our officers in both her or his director and officer capacities) or its affiliates have any duty to refrain from engaging, directly or indirectly, in the same business activities or similar business activities or lines of business in which we operate. The Principal Shareholders also may pursue business and investment opportunities that may be complementary to our business, and, as a result, those opportunities may not be available to us. In addition, the Principal Shareholders may have an interest in pursuing acquisitions, divestitures and other transactions that, in their judgment, could enhance their investment, even though such transactions might involve risks to you. We are a controlled company within the meaning of the rules of Nasdaq and, as a result, we qualify for, and intend to continue relying on, exemptions from certain corporate governance requirements. Therefore, you do not have the same protections as those afforded to stockholders of companies that are subject to such governance requirements. The Principal Shareholders control a majority of the voting power of our outstanding common stock. As a result, we are a controlled company within the meaning of the corporate governance standards of the Nasdaq Global Select Market (‘Nasdaq’). Under these rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a controlled company and may elect not to comply with certain corporate governance requirements, including: the requirement that a majority of our Board consist of independent directors; the requirement that nominees to our Board are to be selected, or recommended for the Board’s selection, either by independent directors constituting a majority of the Board’s independent directors or by a nominations committee that is composed entirely of independent directors; the requirement that we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and the requirement for an annual performance evaluation of the Board and its committees. We currently utilize and intend to continue utilizing certain of these exemptions as long as they are available to us, and in the future, we could utilize additional exemptions. Accordingly, you do not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq.

40We qualify as an emerging growth company and a smaller reporting company and we have elected to comply with reduced public company reporting requirements, which could make our common stock less attractive to investors. We are an emerging growth company, as defined in the JOBS Act and a smaller reporting company as defined by the Exchange Act. For as long as we continue to qualify as an emerging growth company, we are eligible for certain exemptions from various public company reporting requirements. These exemptions include, but are not limited to, (i) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (ii) reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, (iii) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved, and (iv) an extended transition period to comply with new or revised accounting standards applicable to public companies. Additionally, as long as we qualify as a smaller reporting company, we are required to present only the two most recent fiscal years of audited financial statements in our Annual Reports on Form 10-K. We could be an emerging growth company for up to five years after the first sale of our common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the ‘Securities Act’), which first occurred in March 2021. However, if certain events occur prior to the end of such five-year period, including if we become a large accelerated filer, our annual gross revenue exceeds \$1.235 billion or we issue more than \$1.0 billion of non-convertible debt in any three-year period, we would cease to be an emerging growth company prior to the end of such five-year period. Additionally, even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company if the market value of our common stock held by non-affiliates is below \$250 million (or \$700 million if our annual revenue is less than \$100 million) as of December 31 in any given year, which would allow us to continue taking advantage of certain of these exemptions. As a result, the information that we provide to holders of our common stock may be different than you might receive from other public reporting companies in which you hold equity interests. We cannot predict if investors will find our common stock less attractive as a result of reliance on these exemptions. If some investors find our common stock less attractive as a result of any choice we make to reduce disclosure, there may be a less active trading market for our common stock and the market price for our common stock may be more volatile. The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we no longer qualify as an emerging growth company or a smaller reporting company. As a public company, we are subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Compliance with these rules and regulations creates legal and financial compliance costs, makes some activities more difficult, time-consuming and costly and increase demand on our systems and resources, particularly after we no longer qualify as an emerging growth company or a smaller reporting company. Furthermore, the need to maintain the corporate infrastructure demanded of a public company may divert our management’s attention from implementing our business strategy, which could prevent us from improving our business, financial condition and results of operations. We have made, and will continue to make, changes to our internal controls and procedures for financial reporting and accounting systems to meet our reporting obligations as a public company. However, the measures we take may not be sufficient to satisfy our obligations as a public company. These additional obligations could have a material adverse effect on our business, financial condition and results of operations. The Sarbanes-Oxley Act requires, among other things, that we establish and maintain effective internal controls and procedures for financial reporting. If we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. The existence of any material weaknesses or significant deficiency in internal controls over financial reporting would require management to devote significant time and incur significant expenses to remediate any such issue and management may not be able to remediate the issue in a timely manner. The existence of any material weaknesses or significant deficiency could cause us to reissue our financial statements, fail to meet reporting deadlines or undermine shareholders’ confidence in our reported financial statements, all of which could materially and adversely impact our stock price. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, such as disclosures related to climate emissions, are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We invest in resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations. Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our shareholders to replace or remove our current management, even if beneficial to our shareholders. In addition to the Principal Shareholders’ beneficial ownership of a combined 83% of our common stock, our Director Nomination Agreement, certificate of incorporation and bylaws and the Delaware General Corporation Law (the ‘DGCL’), contain provisions that could make it more difficult for a third party to acquire us without the consent of our Board or the Principal Shareholders, even if doing so might be beneficial to our shareholders. Among other things, these provisions: allow us to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without shareholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of shareholders; provide for a classified board of directors with staggered three-year terms; prohibit shareholder action by written consent from and after the date on which the Principal Shareholders beneficially own, in the aggregate, less than 35% of our common stock then outstanding; provide that, from and after the date on

which the Principal Shareholders beneficially own less than 50% of our common stock then outstanding, any amendment, alteration, rescission or repeal of our bylaws by our shareholders will require the affirmative vote of the holders of at least 66⅔% in voting power of all the then-outstanding shares of our stock entitled to vote thereon, voting together as a single class; and we establish advance notice requirements for nominations for elections to our Board or for proposing matters that can be acted upon by shareholders at shareholder meetings, provided, however, that at any time when a Principal Shareholder beneficially owns at least 5% of our common stock then outstanding, such advance notice procedure will not apply to such Principal Shareholder. Our certificate of incorporation contains a provision that provides us with protections similar to Section 203 of the DGCL, and prevents us from engaging in a business combination with a person (excluding the Principal Shareholders and any of their direct or indirect transferees and any group as to which such persons are a party) who acquires at least 85% of our common stock for a period of three years from the date such person acquired such common stock, unless Board or shareholder approval is obtained prior to the acquisition. These provisions could discourage, delay or prevent a transaction involving a change in control of our Company. These provisions could also discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us to take other corporate actions you desire, including actions that you may deem advantageous, or negatively affect the trading price of our common stock. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our shareholders to replace current members of our management team. These and other provisions in our certificate of incorporation, bylaws and Delaware law could make it more difficult for shareholders or potential acquirers to obtain control of our Board or initiate actions that are opposed by our then-current Board, including delay or impede a merger, tender offer or proxy contest involving our Company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction. Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our shareholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our shareholders' ability to obtain a favorable judicial forum for disputes with us. Pursuant to our certificate of incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim of breach of fiduciary duty owed by, or other wrongdoing by, any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents, or a claim of aiding and abetting any such breach of fiduciary duty, (iii) any action asserting a claim against us or any of our directors or officers or other employees arising pursuant to any provision of the DGCL or our certificate of incorporation or our Bylaws (as either may be amended, restated, modified, supplemented or waived from time to time), (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws, (v) any action asserting a claim against us or any of our directors or officers or other employees governed by the internal affairs doctrine or (vi) any action asserting an internal corporate claim as that term is defined in Section 115 of the DGCL. Our certificate of incorporation also provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. However, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce a duty or liability created by the Securities Act or the rules and regulations thereunder; accordingly, we cannot be certain that a court would enforce such provision. Our certificate of incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the provisions of our certificate of incorporation described above; however, our shareholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The forum selection provisions in our certificate of incorporation may have the effect of discouraging lawsuits against us or our directors and officers and may limit our shareholders' ability to obtain a favorable judicial forum for disputes with us. If the enforceability of our forum selection provision were to be challenged, we may incur additional costs associated with resolving such a challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find our forum selection provision to be inapplicable or unenforceable, we may incur additional costs associated with having to litigate in other jurisdictions, which could have an adverse effect on our business, financial condition and results of operations and result in a diversion of the time and resources of our employees, management and Board. Our operating results have fluctuated and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause such results to fall below any guidance, targets or goals we provide. Our quarterly and annual operating results have fluctuated and may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may be driven by a variety of factors, many of which are outside of our control, including, but not limited to: our ability to execute our growth strategy, including our ability to identify and successfully complete acquisitions and expand via de novo centers within existing and new markets; our inability to control expenses and increases to the cost of care, including as a result of the composition of our participant pool, macroeconomic factors such as such as labor shortages, high inflation, and health emergencies; the results of current and future, routine and non-routine inspections, reviews, audits and investigations under federal and state government programs and contracts, and any resulting sanctions or remediation efforts as a result of such government actions; legal proceedings, enforcement actions and litigation, malpractice and privacy disputes to which we are currently and may in the future be party to. The impact of any one of the factors discussed above or any other factors discussed in this Risk Factors section, or the cumulative effects of a combination of such factors, could result in significant fluctuations and unpredictability in our quarterly and annual operating results. As a result of such variability and unpredictability, our revenue or operating results could fall short of our expectations or any guidance we provide and we may also fail to meet the expectations of industry or financial analysts or investors for any period. If the guidance we provide falls short or we are unable to meet the expectations of analysts or investors, the trading price of our common stock could decline substantially. Our operating results and stock price are volatile. The price of our common stock has significantly fluctuated since our IPO. In addition, securities markets worldwide have experienced, and are likely to continue to experience, significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could continue to subject the market price of our shares to wide price fluctuations regardless of our operating performance. In addition, our operating results and the trading price of our shares may fluctuate in response to various factors, including: developments and results of audits, sanctions, investigations and litigation; market conditions in our industry or the broader stock market; actual or anticipated fluctuations in our quarterly financial and operating results; introduction of new solutions or services by us or our competitors; issuance of new or changed securities analysts' reports or recommendations; sales, or anticipated sales, of large blocks of our stock; additions or departures of key personnel; regulatory or political developments; litigation and governmental investigations; changing economic and macroeconomic conditions; inflationary pressures, increased interest rates, weather, public health events, such as the COVID-19 pandemic, and war, including uncertainties surrounding the Russia and Ukraine war and the Israel-Hamas war; investors' perception of us and our prospects; and any default on our indebtedness. These and other factors, many of which are beyond our control, may cause our operating results and the market price and demand for our shares to fluctuate substantially. Fluctuations in our quarterly operating results could limit or prevent investors from readily selling their shares and may otherwise negatively affect the market price and liquidity of our shares. A significant portion of our total outstanding shares may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. We are party to a registration rights agreement with TCO Group Holdings, L.P., the investment vehicle through which the Principal Shareholders hold their investment, which requires us to effect the registration of the Principal Shareholders' shares in certain circumstances. The Principal Shareholders are also entitled to participate in certain of our registered offerings, subject to the restrictions in the registration rights agreement. These registration rights would facilitate the resale of such securities into the public market, and any such resale would increase the number of shares of our common stock available for public trading. In addition, we have registered shares of common stock that we may issue under our equity compensation plans. Such shares can be freely sold in the public market upon issuance, subject to vesting, and Rule 144 under the Securities Act. In the future, we may also issue our securities in connection with investments or acquisitions. The number of shares issued in connection with an investment or acquisition could constitute a material portion of our then-outstanding common stock. Because we have no plans to pay regular cash dividends on our common stock for the foreseeable future, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it. We do not anticipate paying any regular cash dividends on our common stock for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our Board and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our Board may deem relevant. In addition, our ability to pay dividends is, and may be, limited by covenants of existing and any future outstanding indebtedness we or our subsidiaries incur. Therefore, any return on investment in our common stock is solely dependent upon the appreciation of the price of our common stock on the open market, which may not occur. Our Board of Directors has approved a share repurchase program that may subject us to certain risks, which can be exacerbated because our stock is thinly traded. Our Board of Directors approved a repurchase program to repurchase shares of our common stock. Our share repurchase program does not obligate us to acquire any common stock, and we may discontinue the program at any time. If we fail to meet any expectations related to share repurchases, we may lose market and investor confidence. In addition, our common stock is thinly traded. Thinly traded stocks pose several risks for investors because they have wider spreads and less displayed size than other stocks that trade in higher volumes. Other risks posed by thinly traded stocks include difficulty selling the stock, challenges attracting market makers to make markets in the stock, and difficulty with financings. Because our common stock is thinly traded, repurchases under the repurchase program can impact the price of our common stock on a given day or period. If securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendations regarding our shares or if our results of operations do not meet their expectations, our stock price and trading volume could decline. The trading market for our shares is influenced by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over these analysts. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, analysts have in the past downgraded, and may in the future downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline. We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock. Our certificate of incorporation authorizes us to issue one or more series of preferred stock. Our Board has the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our shareholders. Our preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock may delay or prevent a change in control of us, discouraging bids for our common stock at a premium to the market price, and materially adversely affect the market price and the voting and other rights of the holders of our common stock. Future offerings of debt or equity securities by us may materially adversely affect the market price of our common stock. In the future, we may attempt to obtain financing or to further increase our capital resources by issuing additional shares of our common stock or offering debt or other equity securities, including senior or subordinated notes, debt securities convertible into equity or shares of preferred stock. In addition, we may seek to expand operations in the future to other markets which we would expect to finance through a combination of additional issuances of equity, corporate indebtedness and/or cash from operations. Issuing additional shares of our common stock or other equity securities or securities convertible into equity may dilute the economic and voting rights of our existing stockholders or reduce the market price of our common stock or both. Upon liquidation, holders of such debt securities and preferred shares, if issued, and lenders with respect to other borrowings would receive a distribution of our available assets prior to the holders of our common stock. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred shares, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends to the holders of our common stock. Our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, which may adversely affect the amount, timing or nature of our future offerings. Thus, holders of our common stock bear the risk that our future offerings may reduce the market price of our common stock and dilute their stockholdings in us. General Risk Factors Disruptions in our disaster recovery systems or business continuity planning could limit our ability to operate our business effectively. Our information technology systems facilitate our ability to conduct our business. While we have disaster recovery systems and business continuity plans in place, any disruptions in our disaster recovery systems or the failure of these systems to operate as expected could, depending on the magnitude of the problem, adversely affect our operating results by limiting our capacity to effectively monitor and control our operations. Despite our implementation of a variety of security measures, our information technology systems could be subject to physical or electronic break-ins, ransomware and other cybersecurity incidents and similar disruptions from unauthorized tampering or any weather-related disruptions in Denver, Colorado, where our headquarters is located. In addition, in the event that a significant number of our management personnel were unavailable in the event of a disaster, our ability to effectively conduct business could be adversely affected. Item 1B. A. A. A. UNRESOLVED STAFF COMMENTS None. Item 1C. A. A. A. CYBERSECURITY Risk Management and Strategy Our Cybersecurity Program (the Program) is designed from a risk- and compliance-based approach for resilience and protection across our operations and the appropriate access, use, and/or disclosure of PHI and PII. Our Program employs the National Institute of Standards Technology (NIST) cybersecurity framework and strategy to deliver multi-layered defenses and relevant technologies that are designed to control, audit, monitor, and protect access to sensitive information. We also leverage government partnerships, industry and government associations, third-party benchmarking, audits, threat intelligence feeds and other similar resources to inform our cybersecurity efforts and allocate resources. We maintain our Program with physical, administrative and technical safeguards, and we maintain plans and procedures whose objective is to help us prevent and respond to cybersecurity incidents. Elements of our Program include: (i) required training for our employees (including onboarding and annual training), exercises (including advanced phishing exercises), and awareness for our employees to promote vigilance of cybersecurity risks and (ii) compliance audits and assessments, which include routine technical and non-technical audits and assessments internally and in collaboration with independent third parties at least annually. In addition, we engage various third-party consultants to assist us in assessing, enhancing, implementing and monitoring our Program and responding to incidents. As a company managing the use and disclosure of PHI and PII, we annually undergo internal and/or third-party HIPAA Security Rule risk assessments of our administrative, physical, and technical safeguards. In addition, external assessors periodically evaluate our safeguards against multiple frameworks, including NIST Cyber Security Framework (CSF). Our Program is integrated into our Enterprise Risk Management (ERM) program and includes a vendor risk management program supported by our security and compliance teams. We assess vendor cybersecurity risks according to HIPAA and NIST CSF standards and have established an oversight process to manage cybersecurity risks related to the products and services we procure. During the fiscal year ended June 30, 2024, we did not identify risks from cybersecurity threats, including as a result of previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. While prior incidents have not had a material impact on us, future incidents could have a material impact on our business, operations, and reputation. See the Security breaches, loss of data and other disruptions have in the past and could in the future compromise sensitive information related to our business or our participants, or prevent us from accessing critical information and expose us to liability, and could adversely affect our business and our reputation in Item 1A. the Risk Factors in this Annual Report. 46 Governance While our full Board of Directors has overall responsibility for risk oversight, it has delegated primary oversight of certain risks to its committees. Our Audit Committee monitors cybersecurity risks, and the steps our management has taken to monitor and control exposures. Our Chief Information Officer (CIO) and Chief Information Security Officer (CISO) brief the Audit Committee quarterly on cybersecurity risks, updates on the regulatory and cyber landscape and significant cybersecurity events, as needed. Our Audit Committee reports to the Board of Directors on cybersecurity matters quarterly, or more often as the need arises. We have an Information Security Team to strengthen our cybersecurity risk management activities across the Company. The Information Security Team reports to our CISO who works in collaboration with our CIO, Chief Compliance Officer and General Counsel. The Information Security Team is responsible for the oversight and operation of our Program, and the management of our security standards and operating procedures. Cole

we are our CISO. Mr. Naus holds over 20 years of experience in the cybersecurity industry. Mr. Naus holds a degree in Cybersecurity Assurance and holds other cybersecurity certifications. Mr. Naus reports directly to Cara Babachicos, our CIO. Ms. Babachicos has over 20 years of experience in the cybersecurity industry, having previously worked as Chief Information Officer at other companies in the healthcare industry.

Item 2.A. A) A PROPERTIESAs of June 30, 2024, we operated an aggregate of 20 centers, of which ten were owned and ten were leased, representing approximately 410,000 and 240,000 gross square feet, respectively. Our centers are located in 14 markets and six states. Our principal executive offices are located in Denver, Colorado, where we own facilities totaling approximately 290,000 square feet across the state. We occupy a 69,000 square foot facility for administration, sales and marketing, technology and development and professional services in Denver, Colorado. We also own and lease properties for operational PACE centers in Denver, Colorado; Loveland, Colorado; Pueblo, Colorado; Albuquerque, New Mexico; Los Angeles, California; Sacramento, California; San Bernardino, California; Philadelphia, Pennsylvania; Charlottesville, Virginia; Newport News, Virginia; Richmond, Virginia; Roanoke, Virginia; Orlando, Florida; and Tampa, Florida . We do not have any PACE centers or properties located outside of the United States.Our leases typically have terms of nine years, and generally provide for renewal or extension options for an average total potential term of approximately 23 years. Our lease obligations often include annual fixed rent escalators ranging between 2.0% and 3.0%. Generally, our leases are “modified gross” leases, which require us to pay the cost of insurance, taxes, maintenance and utilities, but not for costs related to the structure of the building. We generally cannot cancel these leases at our option. We believe that our facilities and centers are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations.

Item 3.A. A) A LEGAL PROCEEDINGSFrom time to time, we may be involved in various legal proceedings and be subject to claims.Civil Investigative DemandsIn July 2021, the Company received a civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act. The demand requests information and documents regarding Medicaid billing, patient services and referrals in connection with the Company’s PACE program in Colorado. The Company continues to fully cooperate with the Attorney General. In February 2022, the Company received a civil investigative demand from the DOJ under the Federal False Claims Act on similar subject matter. The demand requests information and documents regarding audits, billing, orders tracking, and quality and timeliness of patient services in connection with the Company’s PACE programs in the states of California, Colorado, New Mexico, Pennsylvania, and Virginia. In December 2022, the Company received a supplemental civil investigative demand requesting supplemental information on the same matters. The Company continues to fully cooperate with the DOJ. We are currently unable to predict the outcome of these investigations.

47Stockholder LawsuitsOn October 14, 2021, and subsequently amended on June 21, 2022, the Company was named as a defendant in a putative class action complaint filed in the District Court for the District of Colorado on behalf of individuals who purchased or acquired shares of the Company’s common stock during a specified period (the “Securities Action”). Through the complaint, plaintiffs are asserting claims against the Company, certain of the Company’s officers and directors, Apax Partners, L.P., Welsh, Carson, Anderson & Stowe, and the underwriters in the Company’s IPO, alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 for making allegedly inaccurate and misleading statements and omissions in connection with the Company’s IPO and subsequent earnings calls and public filings, and seeking compensatory damages, among other things. On September 13, 2022, the Company and the officer and director defendants and Apax Partners, L.P. and Welsh, Carson, Anderson & Stowe filed a motion to dismiss the amended complaint for failure to state a claim upon which relief can be granted. On December 22, 2023, the District Court granted in part and denied in part the motion to dismiss. The action is now in discovery.On April 20, 2022, the Board of Directors of the Company received a books and records demand pursuant to Section 220 of the Delaware General Corporation Law, from a purported stockholder of the Company, Brian Hall, in connection with the stockholder’s investigation of, among other matters, potential breaches of fiduciary duty, mismanagement, self-dealing, corporate waste or other violations of law by the Company’s Board with respect to these matters. On May 15, 2023, Mr. Hall filed a lawsuit in the Delaware Court of Chancery asserting derivative claims for breach of fiduciary duty against certain of the Company’s current and former officers and directors generally relating to alleged failures by the defendants to take remedial actions to address the matters that resulted in sanctions by CMS at certain of the Company’s centers, and alleged misstatements in the Company’s public filings relating to those matters. On June 28, 2023, upon stipulation of the parties, the court entered an order staying the litigation pending the resolution of the motion to dismiss in the Securities Action or upon fifteen days’ notice by any party to the litigation. We are currently unable to predict the outcome of these matters.

Other MattersIn the third fiscal quarter of 2023, the Company agreed to settle a wage and hour class action lawsuit in the State of California for a cash payment of \$1.2 million. Subsequently, the Company was notified of certain additional individual claims and agreed to include such claims within the class. In October 2023, the Company agreed to increase the settlement amount to a total of \$1.3 million, reflecting the additional individual claims. The Court entered the final approval of the settlement on April 2, 2024 and the payout occurred on June 7, 2024. The matter will remain open for 180 days to allow the class members to settle their checks, after which time the case is expected to officially close. Because the results of legal proceedings and claims are inherently unpredictable and uncertain, we are currently unable to predict whether the legal proceedings we are involved in will, either individually or in the aggregate, have a material adverse effect on our business, financial condition, or cash flows. The outcomes of legal proceedings and claims could be material to the Company’s operating results for any particular period, depending in part, upon the operating results of such period. Regardless of the outcome, litigation has the potential to have an adverse impact on us due to any related defense and settlement costs, diversion of management resources, and other factors. Refer to Note 9 – Commitments and Contingencies to the Consolidated Financial Statements included in this Annual Report for more information.

Item 4.A. A) A MINE SAFETY DISCLOSURESNot applicable.

48PART IIItem 5.A. A) A MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIESOur common stock is listed on the Nasdaq Global Select Market under the symbol “INNV.” As of September 30, 2024, there were approximately ten stockholders of record for our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by economic banks, brokers and other financial institutions. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.Dividend PolicyWe have not paid cash dividends since our initial public offering and currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness and, therefore, we do not anticipate paying any cash dividends in the foreseeable future. Additionally, because we are a holding company, our ability to pay dividends on our common stock may be limited by restrictions on the ability of our subsidiaries to pay dividends or make distributions to us. Any future determination to pay dividends will be at the discretion of our Board, subject to compliance with covenants in current and future agreements governing our and our subsidiary’s indebtedness, and will depend on our results of operations, financial condition, capital requirements and other factors that our Board may deem relevant.Recent Sales of Unregistered SecuritiesThere were no unregistered sales of equity securities during the year ended June 30, 2024.Issuer Purchases of Equity SecuritiesStock repurchases during the three months ended June 30, 2024 were as follows:

	(a)	(b)	(c)
Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
(a)April 1st–June 1st, 2024	\$5.02384	145,023	\$0.735
(b)Total		145,023	

(a)On June 10, 2024, the Company’s Board of Directors announced the approval of a share repurchase program authorizing the repurchase of up to \$5 million of the Company’s common stock, with no expiration date. For further information regarding stock repurchase activity, see Note 16 Share Repurchase Program to the consolidated financial statements in this Annual Report.(b)Average price paid per share does not include costs associated with the repurchases.

Item 6.A. A) A [Reserved]

49Item 7.A. A) A MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSThe following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this Annual Report. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Our historical results are not necessarily indicative of the results that may occur in the future and actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and in the sections entitled “Risk Factors” and “Forward-Looking Statements” included in this Annual Report.

OverviewGeneralInnovAge Holding Corp. (“InnovAge”) became a public company in March 2021. The Company served approximately 7,020 PACE participants as of June 30, 2024, making it the largest PACE provider in the U.S. based upon participants served, and operates 20 PACE centers across Colorado, California, Florida, New Mexico, Pennsylvania and Virginia. During the year ended June 30, 2024, the Company opened two de novo centers in Tampa and Orlando, Florida, and acquired two PACE centers in California from ConcertoCare, which include one operating center in the Cresshaw neighborhood of Los Angeles, and a second program that is a planned de novo in Bakersfield, California.OperationsInnovAge’s programs are designed to allow frail seniors to live life on their terms by aging in place, in their own homes and communities, for as long as safely possible. Through our Program of All-Inclusive Care for the Elderly (“PACE”) program, we fulfill a broad range of medical and ancillary services for seniors, including in-home care services (skilled, unskilled and personal care), center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. The Company manages its business as one reportable segment, PACE. We are the leading healthcare delivery platform by number of participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Our programs are designed to directly address two of the most pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. Our participant-centered care delivery approach is designed to improve the quality of care our participants receive, while keeping them in their homes for as long as safely possible and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. Our participant-centered approach is led by our Interdisciplinary Care Teams (“IDTs”), who oversee all aspects of each participant’s unique care plan and function as the core group of care providers to our participants. We directly manage and are responsible for all healthcare needs and associated costs for our participants, including housing costs, where applicable. We directly contract with government payors, such as Medicare and Medicaid, and do not rely on third-party administrative organizations or health plans. We believe our model aligns with how healthcare is evolving, namely (i) the shift toward value-based care, in which coordinated, outcomes-driven, quality care is delivered while reducing unnecessary spend, (ii) eliminating excessive administrative costs by contracting directly with the government, (iii) focusing on the patient experience and (iv) addressing social determinants of health.Trends and Uncertainties Affecting the CompanyMacroeconomic conditions. During fiscal year 2024, the U.S. continued to wrestle with inflation and the health industry continued to face increased wages due to labor shortages and increased competition among healthcare professionals. In fiscal year 2023 and 2024, in response to high levels of inflation, we implemented various mitigation strategies to reduce costs of operation, including consolidating services, price negotiations with providers and vendors and limiting corporate staffing, and effecting a reduction in workforce in December 2022 and October 2023. Inflationary pressures eased significantly during the second half of fiscal year 2024 and abated to normalized levels. The effects of inflation, after accounting for these mitigation strategies, were immaterial to our financial results for fiscal year 2024. Increased cost of care. In fiscal year 2024, operating expenses increased \$49.6 million, or 6.7%, compared to 2023 due to (i) the increased cost of care and related cost per participant as a result of increased salaries, wages and benefits associated with increased headcount and higher wage rates and (ii) increased fleet and contract transportation due to an increase in external appointments related to growing census. Additionally, external provider costs increased in the fiscal year 2024 compared to 2023 due to annual increases in assisted living and nursing facility unit cost and general medical inflation. In an effort to mitigate the effects of these rising costs, in fiscal years 2023 and 2024, we implemented and continued certain clinical value initiatives designed to manage participant expenses and reduce low-value utilization of services and an infrastructure to ensure accurate reimbursement of services. During fiscal year 2024, we continued to strengthen our payer capabilities and reduced external provider costs, which we believe to be a result of our maturing clinical value initiatives. Additionally, in fiscal year 2024 we introduced operational value initiatives to complement our clinical value initiatives. These initiatives are focused on identifying value-creation opportunities at the center operating level and the selling, general and administrative level to drive staff productivity, operating efficiency and vendor unit economics from better leveraging people, process and technology. While we expect to continue to experience elevated operating expenses during fiscal year 2025 for similar reasons, we also expect that our clinical value initiatives will help offset increasing cost of care.Census and capitation revenue. On May 11, 2023, President Biden allowed the national emergency and public health emergency declarations related to the COVID-19 pandemic to expire, which ended certain Medicaid waivers. While states have resumed processing new Medicaid applications and redeterminations of beneficiary eligibility, the healthcare industry, including the Company, experienced increased delays in the processing of such applications. As a result of such delays, the Company experienced an increase in gaps of eligibility with redetermination applications during fiscal year 2024, which is expected to continue through fiscal year 2025. While participants continue to receive care and remain enrolled with the Company during this time, the effect of such delays temporarily halts Medicaid revenue related to any closed application and simultaneously increases our risk of revenue recovery. In an effort to mitigate these risks, the Company utilizes State approved third-party eligibility partners to expedite applications, escalate delayed cases to State administrators, and pursue safe discharges for individuals who are truly ineligible. There has not been a material effect on the Company’s financial statements or operations due to this situation. The Company has experienced aging report accounts and financial losses being normalized to pre-public health emergency levels. The Company expects to continue these mitigating measures during fiscal year 2025 and will continue to assess the situation as it evolves.Labor market. The healthcare sector continues to experience a complex set of challenges in hiring additional professionals. Specifically, the demand for healthcare services has been steadily increasing due to an aging population and a greater focus on health and wellness in society. In addition, there are systemic challenges related to workforce training and the pipeline of qualified professionals, which have not kept pace with this growing demand. Furthermore, high inflation experienced during fiscal year 2023, which continued through fiscal year 2024 increased the cost of living, and subsequently, wage pressure for healthcare professionals, with a shift towards an employee-centric market with an emphasis on competitive compensation, flexibility and professional growth opportunities, which contributed to an increasingly competitive labor market. In an effort to mitigate the effects of these challenges, we adopted strategies to offer competitive compensation packages. Partially as a result of increased competition and other market trends, in conjunction with increased staffing related to compliance and remediation efforts in our centers, there was an increase in the cost of care for the fiscal year 2024 compared to 2023, as discussed in “Results of Operations” below.Additionally, on October 13, 2023, California passed into law California Senate Bill No. 525 (“

to an average RAF score of 1.08 for Medicare fee-for-service non-dual enrollees, as calculated in an analysis by Avalere Health in June 2020 of a cohort of individuals enrolled in Medicare Fee-for-Service in 2019; and (ii) we have Medicaid spend in addition to Medicare. Our participants are managed on a capitated, or at-risk basis, where InnovAge is financially responsible for all participant medical costs. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. For dual-eligible participants, we receive PMPM payments directly from Medicare and Medicaid, which provides recurring revenue streams and significant visibility into our revenue. The Medicare portion of our capitated payment is risk-based on the underlying medical conditions and frailty of each participant. In fiscal year 2023, we began working on expanding payer capabilities which we continued to strengthen in fiscal 2024 so that our revenue more accurately reflects the acuity of the populations we serve. Our ability to grow enrollment and capacity within existing centers. We believe all seniors should have access to the type of all-inclusive care offered by the PACE model. Several factors can affect our ability to grow enrollment and capacity within existing centers, including sanctions issued by regulators or suspensions of State attestations required to open new de novo centers. Our ability to maintain high participant satisfaction and retention. Our comprehensive individualized care model and frequency of interaction with participants generates high levels of participant satisfaction. We achieved an average NPS score of 46 for fiscal year 2024 and average participant tenure of 3.6 years as of June 30, 2024, measured as tenure from enrollment to disenrollment, among our centers that have been operated by us for at least five years. Furthermore, we experience low levels of voluntary disenrollment, averaging 6.9% annually over the last three fiscal years. Effectively managing the cost of care for our participants. We receive capitated payments to manage the totality of a participant's medical care across all settings. The risk pool of our population became more acute in fiscal year 2023 as we were not able to replenish our population mix with newer, lower-acuity participants as a result of State sanctions. Together with the factors disclosed above (increased salaries, wages and benefits, increased fleet and contract transportation costs, annual increases in assisted living and nursing facility unit cost and general medical inflation), our external provider costs and cost of care, excluding depreciation and amortization, represented approximately 83% of our revenue in the year ended June 30, 2024. Center-level Contribution Margin. The Company's management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. As we serve more participants in existing centers, we expect to leverage our fixed cost base at those centers and increase the value of a center to our business increases over time. Our ability to expand via de novo centers within existing and new markets. Several factors can affect our ability to open de novo centers, including sanctions issued by regulators, legal, community or other obstacles in the construction of such centers, and our ability to hire and train enough workers to ramp up these centers to maturity. In response to an audit to our Sacramento center and a medical review of our San Bernardino center, which have been previously disclosed, the California Department of Health Care Services (DHCS) notified us that it was suspending its attestations in support of the planned de novo center in Downey and the recently acquired planned de novo center in Bakersfield. CMS has closed its process and DHCS's process is ongoing. While the planned California de novo centers are precluded from opening at this time, DHCS notified us that it would consider restoring the State Attestations upon our successful remediation of the deficiencies raised in our Sacramento center. Execute tuck-in acquisitions and partnerships. Over the past six fiscal years, we have acquired and integrated four PACE organizations for a total of eight operational centers (excluding the PACE center in Bakersfield, California, which is not yet operational). These acquisitions represent expansion of our InnovAge Platform into one new state and five new markets. By bringing acquired organizations under the InnovAge Platform, we hope to further realize revenue growth and improve operational efficiency and care delivery post-integration. We also have pursued and intend to continue pursuing additional relationships with key stakeholders, existing organizations and other care providers in order to form partnerships in target geography, such as the joint venture we entered into at our Orlando PACE center with Orlando Health during the fourth quarter of fiscal year 2024. Our ability to maintain high quality of regulatory compliance. The Company's priority is to continue to maintain high quality of regulatory compliance in all its centers. Contracting with government payors. Our economic model relies on our capitated arrangements with government payors, namely Medicare and Medicaid. We view the government not only as a payer but also as a key partner in our efforts to expand into new geographies and access more participants in our existing markets. Maintaining, supporting and growing these relationships, in existing markets as well as new geographies, is critical to our long-term success. Investing to support growth. We intend to continue investing in our centers, value-based care model, and sales and marketing organization to support long-term growth. We expect our expenses to increase in absolute dollars for the foreseeable future to support our growth due, partially, to additional costs we incur in connection with audits to our centers, remediation plans and current and potential legal and regulatory proceedings. We plan to invest in future growth judiciously and maintain focus on managing our results of operations. We are investing to increase our sophistication as a payer to drive clinical value, improve outcomes, and manage cost trends. Accordingly, in the short term we expect the activities noted above to increase our expenses as a percentage of revenue, but in the longer term, we anticipate that these investments will positively impact our business and results of operations. Seasonality to our business. Our operational and financial results, including medical costs and per-participant revenue true-ups, will experience some variability depending upon the time of year in which they are measured. Medical costs vary most significantly as a result of (i) the weather, with certain illnesses, such as the influenza and COVID-19 viruses, being more prevalent during colder months of the year, which generally increases per-participant costs and (ii) the number of business days in a period, with shorter periods generally having lower medical costs all else equal. Per-participant revenue true-ups represent the difference between our estimate of per-participant capitation revenue to be received and actual revenue received from CMS, which is based on CMS's determination of a participant's RAF score as measured twice per year and is based on the evolving acuity of a participant. Where there is a difference between our estimate and the final determination from CMS, we may record either an increase or decrease in true up revenue. Historically, these true-up payments typically occur between May and August, but the timing of these payments is determined by CMS, and we have neither visibility into nor control over the timing of such payments. The variability of participant enrollments during the open enrollment period has also been impacted by additional offerings by MA and other competitors. We believe that, as a result of these additional offerings, we experienced higher than expected disenrollments during fiscal year 2024. Components of Results of Operations Revenue Capitation Revenue. In order to provide comprehensive services to manage the totality of a participant's medical care across all settings, we receive fixed or capitated fees per participant that are paid monthly by Medicare, Medicaid, Veterans Affairs (VA) and private pay sources. The concentration of capitation revenue from our various payors was: 2024 2023 Medicaid 54% 54% Medicare 46% 46% Private pay and other 0% 0% Total 100% 100% Denotes less than 1% Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. The PACE state contracts between us and the respective state Medicaid administering agency are amended annually each June 30 in all states other than California and Pennsylvania, which contract on a calendar-year basis. We are currently operating in good standing under each of our PACE state contracts. For a discussion of our revenue recognition policies, please see Critical Accounting Estimates below and Note 2 Summary of Significant Accounting Policies of our consolidated financial statements included in this Annual Report. Other Service Revenue. Other service revenue primarily consists of revenues derived from state food grants and rent revenues. For a discussion of our revenue recognition policies, please see Critical Accounting Estimates below and Note 2 Summary of Significant Accounting Policies of our consolidated financial statements included in this Annual Report. Operating Expenses External Provider Costs. External provider costs consist primarily of the costs for medical care provided by non-InnovAge providers. We separate external provider costs into four categories: inpatient (e.g., hospital), housing (e.g., assisted living and skilled nursing facility), outpatient and pharmacy. In aggregate, external provider costs represent the largest portion of our expenses. Cost of Care, Excluding Depreciation and Amortization. Cost of care, excluding depreciation and amortization, includes the costs we incur to operate our care delivery model. This includes costs related to salaries, wages and benefits for IDT and other center-level staff, participant transportation, medical supplies, occupancy, insurance and other operating costs. IDT employees include medical doctors, registered nurses, social workers, physical, occupational, and speech therapists, nursing assistants, and transportation workers. Other center-level employees include clinic managers, dietitians, activity assistants and certified nursing assistants. Cost of care excludes any expenses associated with sales and marketing activities incurred at a local level as well as any allocation of our corporate, general and administrative expenses. A portion of our cost of care, including our employee-related costs, is directly related to the number of participants cared for in a center. The remainder of our cost of care is fixed relative to the number of participants we serve, such as occupancy and insurance expenses. As a result, as revenue increases due to census growth, cost of care, excluding depreciation and amortization, moderately decreases as a percentage of revenue. As we open new centers, we expect cost of care, excluding depreciation and amortization, to increase in absolute dollars due to higher census and facility related costs. Sales and Marketing. Sales and marketing expenses consist of employee-related expenses, including salaries, commissions, and employee benefits costs, for all employees engaged in marketing, sales, community outreach and sales support as well as financial eligibility support for both prospective and existing participants. These employee-related expenses capture all costs for both our field-based and corporate sales and marketing teams. Sales and marketing expenses also include local and centralized advertising costs, as well as the infrastructure required to support our marketing efforts. We expect these costs to increase in absolute dollars over time as we continue to grow our participant census. We evaluate our sales and marketing expenses relative to our participant growth and will invest more heavily in sales and marketing from time-to-time to the extent we believe such investment can accelerate our growth without negatively affecting profitability. Corporate, General and Administrative Expenses. Corporate, general and administrative expenses include employee-related expenses, including salaries and related costs. In addition, general and administrative expenses include all corporate technology and occupancy costs associated with our corporate office. We expect our general and administrative expenses to increase in absolute dollars due to the additional legal, accounting, insurance, investor relations and other costs that we incur as a public company, as well as other costs associated with compliance and continuing to grow our business. However, we anticipate general and administrative expenses to decrease as a percentage of revenue over the long term, although such expenses may fluctuate as a percentage of revenue from period to period due to the timing and amount of these expenses. Depreciation and Amortization. Depreciation and amortization expenses are primarily attributable to our buildings and leasehold improvements and our equipment and vehicles. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful life or lease terms, to the extent the assets are being leased. For more information relating to the components of our results of operations, see Results of Operations below and Note 2 Summary of Significant Accounting Policies of our consolidated financial statements included in this Annual Report for more detailed information regarding our significant accounting policies. Results of Operations The following table sets forth our consolidated results of operations for the periods presented. Year Ended June 30, 2024 2023 in thousands Revenues Capitation revenue \$762,570A \$686,836A Other service revenue 1,285A 1,251A Total revenues \$763,855A \$688,087A Expenses External provider costs \$403,010A \$374,528A Cost of care, excluding depreciation and amortization 228,781A 212,271A Sales and marketing 24,957A 19,627A Corporate, general and administrative 111,337A 115,637A Depreciation and amortization 18,950A 15,419A Total expenses \$787,035A \$737,482A Operating Loss (23,180) (49,395) Other Income (Expense) Interest expense, net (4,023) (1,522) Gain on cost and equity method investments 2,842A 2,842A Other income 2,542A 1,244A Total other income (expense) 1,361A (1,398) Loss Before Income Taxes (21,819) (50,793) Provision (Benefit) for Income Taxes 1,402A (7,241) Net Loss (23,221) (43,552) Less: net loss attributable to noncontrolling interests (1,883) (2,879) Net Loss Attributable to InnovAge Holding Corp. \$21,338 \$(40,673) Loss Before Income Taxes as a % of revenue 2.9% (7.4)% Net Loss as a % of revenue (3.0)% (6.3)% Revenues Year Ended June 30, % Change % Change 2024 2023 in thousands Capitation revenue \$762,570A \$686,836A 75,734A 11.0A % Other service revenue 1,285A 1,251A 34A 2.7A % Total revenues \$763,855A \$688,087A 75,768A 11.0A % Capitation revenue. Capitation revenue was \$762.6 million for the year ended June 30, 2024, an increase of \$75.7 million, or 11.0%, compared to \$686.8 million for the year ended June 30, 2023. This increase was driven by a \$30.8 million, or 4.5% increase in member months (as defined below under Key Business Metrics and non-GAAP Measures) coupled with a \$44.9 million, or 6.3%, increase in capitation rates. The increase in member months was primarily due to the release of sanctions at our Sacramento, California center and at our Colorado centers. The increase in capitation rates was primarily driven by an annual increase in both Medicaid capitation rates as determined by the States and Medicare capitation rates as a result of increased risk score and county rates. Expenses Year Ended June 30, % Change % Change 2024 2023 in thousands External provider costs \$403,010A \$374,528A \$28,482A 7.6A % Cost of care, excluding depreciation and amortization 228,781A 212,271A 16,510A 7.8A % Sales and marketing 24,957A 19,627A 5,330A 27.2A % Corporate, general and administrative 111,337A 115,637A (4,300) (3.7)% Depreciation and amortization 18,950A 15,419A 3,531A 22.9A % Total operating expenses \$787,035A \$737,482A \$49,553A 6.7A % External provider costs. External provider costs were \$403.0 million for the year ended June 30, 2024, an increase of \$28.5 million, or 7.6%, compared to \$374.5 million for the year ended June 30, 2023. The increase was primarily driven by an increase of \$16.8 million, or 4.5% in member months coupled with an increase of \$11.7 million, or 3.0%, in cost per participant. The increase in cost per participant was primarily driven by a \$9.6 million increase associated with increased assisted living utilization and unit cost and a \$3.6 million increase associated with higher professional services utilization. This was partially offset by a \$5.1 million reduction in permanent nursing facility utilization. Cost of care, excluding depreciation and amortization. Cost of care, excluding depreciation and amortization expense was \$228.8 million for the year ended June 30, 2024, an increase of \$16.5 million, or 7.8%, compared to \$212.3 million for the year ended June 30, 2023, primarily due to an increase of \$7.0 million, or 3.1%, in cost per participant coupled with an increase of \$9.5 million, or 4.5%, in member months. The increase in cost per participant was driven by (i) a \$12.8 million increase in salaries, wages and benefits associated with increased headcount to support growth and higher wage rates, (ii) a \$2.3 million increase in contract provider expense in California, (iii) \$1.9 million in increased fleet expense and contract transportation as a result of higher average daily attendance, an increase in external appointments, and higher fuel costs, (iv) \$1.2 million in increased building maintenance and security, (v) \$1.8 million in software license fees, and (vi) \$1.8 million in de novo occupancy and administrative costs inclusive of the Concerto acquisition in December 2023. This was partially offset by a \$3.9 million reduction in third party audit and compliance support. Sales and marketing. Sales and marketing expenses were \$25.0 million for the year ended June 30, 2024, an increase of \$5.3 million, or 27.2%, compared to \$19.6 million for the year ended June 30, 2023, primarily due to a \$1.6 million increase in marketing spend and a \$2.8 million increase in salaries, wages and benefits, both associated with sanction release in our Colorado and Sacramento, California centers as well as opening new centers in Florida. Corporate, general and administrative expenses. Corporate, general and administrative expenses were \$111.3 million for the year ended June 30, 2024, a decrease of \$4.3 million, or 3.7% compared to \$115.6 million for the year ended June 30, 2023. The decrease was primarily due to (i) \$2.7 million reduction in third party legal expense, (ii) \$2.3 million reduction in insurance expense, (iii) \$4.5 million reduction in consulting expense associated with improving organizational capabilities including the transition to a new electronic medical record (EMR), (iv) \$2.2 million reduction in contract staff augmentation, and (v) \$1.0 million reduction in recruiting expense. These decreases were partially offset by (i) a \$3.5 million increase in employee compensation and benefits as the result of an increase in headcount to support compliance and bolster organizational capabilities, (ii) \$3.7 million in bad debt expense, and (iii) \$1.2 million in consulting costs including Sarbanes-Oxley Act of 2002 compliance, internal audit support, and public relations. Depreciation and amortization. Depreciation and amortization expense was \$19.0 million for the year ended June 30, 2024, an increase of \$3.5 million, or 22.9%, compared to \$15.4 million for the year ended June 30, 2023. The increase in depreciation expense was a result of capital additions in the normal course of business. Other Income (Expense) Year Ended June 30, 2024 2023 in thousands Interest expense, net (4,023) (1,522) (2,501) 164.3% Gain on cost and equity method investments 2,842A 2,842A Other income 2,542A 1,244A 2,418A 195.0% Total other income (expense) \$1,361A \$(1,398) \$2,759A (197.4)% Net Meaningful Interest expense. Net interest expense, net consists primarily of interest payments on our outstanding borrowings, net of interest income earned on our cash and cash equivalents and restricted cash. Interest expense, net was \$4.0 million for the year ended June 30, 2024, an increase of \$2.5 million, or 164.3%, compared to \$1.5 million for the year ended June 30, 2023. The increase was primarily due to interest expense of \$7.5 million partially offset by interest income of \$3.5 million from money market funds during the year ended June 30, 2024. Interest income during the year ended June 30, 2023 was \$3.4 million from money market funds offsetting interest expense of \$4.9 million. Gain on cost and equity method investments. Gain on cost and equity method investment was \$2.8 million for the year ended June 30, 2024 compared to no gain or loss for the year ended June 30, 2023. On March 13, 2024, Pinewood Lodge, LLLP (a PWD), a variable interest entity of the Company, entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including its senior housing unit, which was used in our operations. On May 2, 2024, PWD closed on the sale of the property. In June 2024, the partnership was dissolved and we recognized a gain of \$4.8 million from the dissolution of the partnership. See Note 4 Cost and Equity Method Investments of our consolidated financial statements included in this Annual Report for further discussion. The gain was partially offset by impairment losses of \$2.0 million in conjunction with our minority interest investment in Jetdoc, Inc. ("Jetdoc") during the year ended June 30, 2024. No observable price changes or impairments were recorded during the year ended June 30, 2023. Other

Other income consists primarily of the proceeds received from the sale of or disposal of equipment, unrealized gains and losses and investment income related to short-term investments. Other income was \$2.5 million for the year ended June 30, 2024, an increase of \$2.4 million, compared to \$0.1 million for the year ended June 30, 2023, due to \$2.4 million in investment income related to short-term investments. Investment income during the year ended June 30, 2023 was \$1.2 million offset by \$1.1 million loss on disposal of capital assets.Provision (Benefit) for Income Taxes. The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Senior Housing Thornton, LLC (â€œSH1â€) and InnovAge Sacramento have elected to be taxed as partnerships, and no provision (benefit) for income taxes for SH1 or InnovAge Sacramento is included in these consolidated financial statements. Further, the Company entered into a joint venture called InnovAge Florida PACE â€” Orlando on May 28, 2024 and its members elected to be taxed as a partnership. No provision (benefit) for income taxes for InnovAge Orlando is included in these consolidated financial statements for activity occurring from joint venture formation date through the balance of the fiscal year.57A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.During the years ended June 30, 2024 and 2023, we reported provision (benefit) for income taxes of \$1.4 million and \$(7.2) million, respectively. The decrease of \$8.6 million is primarily due to (i) pretax book loss recognized during the year ended June 30, 2024, as compared to the pretax book loss recognized during the year ended June 30, 2023 and (ii) the change in our valuation allowance. Net Loss Attributable to Noncontrolling Interests. InnovAge Senior Housing Thornton, LLC is a variable interest entity (â€œVIEâ€). The Company is the primary beneficiary of SH1 and consolidates SH1. The Company is the primary beneficiary of SH1 because it has the power to direct the activities that are most significant to SH1 and has an obligation to absorb losses or the right to receive benefits from SH1. The most significant activity of SH1 is the operation of the housing facility. The Company has provided a subordinated loan to SH1 and has provided a guarantee for the convertible term loan held by SH1. The SH1 interest is reflected within equity as noncontrolling interests. Our share of earnings is recorded in the consolidated statements of operations as net loss attributable to noncontrolling interests.Net LossDuring the years ended June 30, 2024 and 2023, we reported net loss of \$23.2 million and \$43.6 million, respectively, consisting of (i) operating loss of \$23.2 million and \$49.4 million, respectively, (ii) other income of \$1.4 million and other expense of \$1.4 million, respectively, and (iii) provision for income taxes of \$1.4 million and benefit for income taxes of \$7.2 million, respectively, each as described above. 58Key Business Metrics and Non-GAAP MeasuresIn addition to our GAAP financial information, we review a number of operating and financial metrics, including the following key metrics and non-GAAP measures, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. We believe these metrics provide additional perspective and insights when analyzing our core operating performance from period to period and evaluating trends in historical operating results. These key business metrics and non-GAAP measures should not be considered superior to, or a substitute for, and should be read in conjunction with, the GAAP financial information presented herein. These measures may not be comparable to similarly-titled performance indicators used by other companies.Year Ended June 30, 20242023dollars in thousandsKey Business Metrics:Â A Centers(a)2017Census(b)(7),0206,400Total Member Months(b)(8),84077,370Non-GAAP Measures:Center-level Contribution Margin(c)\$132,064Â A \$101,288Â A Center-level Contribution Margin as a % of revenue(c)17.3Â A %14.7Â A %Adjusted EBITDA(c)\$16,474Â A \$(3,425)Adjusted EBITDA Margin(c)2.2Â A % (0.5)% (a)Includes InnovAge Sacramento and InnovAge Orlando, which the Company owns and controls through joint ventures and are consolidated in our financial statements. During the fiscal year ended June 30, 2024, the Company opened the Orlando and Tampa centers and acquired an operational center from Concerto in Los Angeles. (b)Amounts are approximate.(c)Center-level Contribution Margin, Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the period indicated, see below.CentersWe define our centers as those centers open for business and attending to participants at the end of a particular period. CensusOur census is comprised of our capitated participants for whom we are financially responsible for their total healthcare costs.Total member monthsWe define Total Member Months as the total number of participants as of period end multiplied by the number of months within a year in which each participant was enrolled in our program. We believe this is a useful metric as it more precisely tracks the number of participants we serve throughout the year.Center-level Contribution MarginThe Companyâ€™s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs. For purposes of evaluating 59Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expense or corporate, general and administrative expenses across our centers. Center-level Contribution Margin was \$132.1 million and \$101.3 million for the years ended June 30, 2024 and 2023, respectively. The increase in Center-level Contribution Margin for fiscal year 2024 was primarily due to a year-over-year increase of 11.0% in total revenue and 7.7% in center level expense during the same period. For more information relating to Center-level Contribution Margin, see Note 14 â€œSegment Reportingâ€ to our consolidated financial statements. A reconciliation of Center-level Contribution Margin to loss before income taxes, the most directly comparable GAAP measure, for each of the periods is as follows:June 30, 2024June 30, 2023in thousandsPACEAll other(1)TotalsPACEAll other(1)TotalsCenter-Level Contribution Margin131,667Â A 397Â A 132,064Â A 100,948Â A 340Â A 101,288Â A Overhead costs(2)136,284Â A 10Â A 136,294Â A 135,264Â A Â A 135,264Â A Depreciation and amortization18,477Â A 473Â A 18,950Â A 14,959Â A 460Â A 15,419Â A Interest expense, net3,845Â A 178Â A 4,023Â A 1,342Â A 180Â A 1,522Â A Gain on cost and equity method investments(2,842)Â A 2(2,842)Â A 2(2,842)Â A 2(2,542)(124)Â A 124Loss Before Income Taxes\$21,555\$(264)\$(21,819)\$(50,493)\$(300)\$(5,793) (1)Center-level Contribution Margin from a segment below the quantitative thresholds is attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.(2)Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.Adjusted EBITDA and Adjusted EBITDA MarginWe define Adjusted EBITDA as net loss adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, litigation costs and settlement, M&A diligence, transaction and integration, business optimization, EMR implementation and gain on cost and equity method investments. For the years ended June 30, 2024 and 2023, our net loss was \$23.2 million and \$43.6 million, respectively, representing a year-over-year improvement of 47%, and Adjusted EBITDA was \$16.5 million and \$(3.4) million, respectively, representing a year-over-year increase of 585%. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue. For the year ended June 30, 2024, our net loss margin was 3.0%, compared to our net loss margin of 6.3% for the year ended June 30, 2023. For the year ended June 30, 2024, our Adjusted EBITDA margin was 2.2%, compared to our Adjusted EBITDA margin for the year ended June 30, 2023 of (0.5%).Adjusted EBITDA and Adjusted EBITDA margin are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net loss and net loss margin, respectively, as determined by GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA margin are appropriate measures of operating performance because the metrics eliminate the impact of expenses that do not relate to our ongoing business performance and certain noncash expenses, allowing us to more effectively evaluate our core operating performance and trends from period to period. We believe that Adjusted EBITDA and Adjusted EBITDA margin help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net loss and net loss margin. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. Our use of the term Adjusted EBITDA varies from others in our industry. Effective for the year ended June 30, 2024, the Company has revised its 60calculation of Adjusted EBITDA to no longer exclude de novo center development costs and to reflect the impact of other investment income. The presentation for the year ended June 30, 2023 has been recast to conform to the current presentation.A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, for each of the periods is as follows:Year Ended June 30, 20242023in thousandsNet Loss\$(23,221)\$(43,552)Interest expense, net4,023Â A 1,522Â A Other investment income(a)(2,385)(1,170)Depreciation and amortization18,950Â A 15,419Â A Provision (benefit) for income tax item1,402Â A (7,241)Stock-based compensation6,832Â A 4,993Â A Litigation costs and settlement(b)4,878Â A 9,782Â A M&A diligence, transaction and integration(c)778Â A 140Â A Business optimization(d)4,399Â A 10,535Â A EMR implementation(e)3,660Â A 6,147Â A Gain on cost and equity method investments(f)(2,842)Â A 2Adjusted EBITDAs\$16,474Â A \$(3,425) (a)Reflects investment income related to short term investments included in our consolidated statement of operations. Effective for the year ended June 30, 2024, the Company has revised the calculation for Adjusted EBITDA to reflect the impact of investment income in 2024 and 2023.(b)Reflects a \$1.2 million reserve for a California wage and hour class action settlement for the year ended June 30, 2023, and each of the years ended June 30, 2023 and 2024 included charges/(credits) related to litigation by stockholders, litigation related to de novo center, and civil investigative demands. See Item 3, â€œLegal Proceedingsâ€ included in this Annual Report. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy.(c)Reflects charges related to M&A transaction and integrations, including the Concerto acquisition in December 2023. Effective for the year ended June 30, 2024, the Company has revised the calculation for Adjusted EBITDA to no longer exclude de novo center development costs in 2024 and 2023. De novo center development costs were \$1.0 million for each of the years ended June 30, 2024 and 2023.(d)Reflects charges related to business optimization initiatives. Such charges related to one-time investments in projects designed to enhance our technology and compliance systems, improve and support the efficiency and effectiveness of our operations, and third party support to address efforts to remediate deficiencies in audits. For the year ended June 30, 2024 costs include (i) \$3.1 million associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing payor capabilities, and strengthen our enterprise capabilities, (ii) \$0.3 million of costs related to severance and other organizational costs, and (iii) \$0.9 million related to charges for technology improvements, environmental sustainability, governance reporting, and other non-recurring projects aimed at reducing costs and improving efficiencies. For the year ended June 30, 2023, costs included (i) \$1.8 million related to consultants and contractors performing audit and other related services at sanctioned centers, (ii) \$5.7 million of costs associated with third party consultants to strengthen enterprise capabilities, (iii) \$0.6 million related to the consolidation of the Germantown, Pennsylvania center, (iv) \$1.1 million related to organizational restructuring, and (v) \$1.4 million related to other non-recurring projects aimed at reducing costs and improving efficiencies.61(e)Reflects non-recurring expenses relating to the implementation of a new EMR vendor.(f)Reflects \$4.8 million net benefit associated with the dissolution of the PWD partnership partially offset by \$2.0 million impairment in Jetdoc investment.Liquidity and capital resourcesGeneralTo date, we have financed our operations principally through cash flows from operations and through borrowings under our credit facilities, from the sale of common stock in our IPO that occurred in March 2021. As of the years ended June 30, 2024 and 2023, we had cash and cash equivalents of \$56.9 million and \$127.2 million, respectively, a decrease of \$70.3 million primarily due to the Concerto acquisition, deferred revenue due to the timing of payments received during the prior fiscal year, and a decrease in working capital. Our cash and cash equivalents primarily consist of highly liquid investments in demand deposit accounts and cash.Our capital resources are generally used to fund (i) debt service requirements, the majority of which relate to the quarterly principal payments of the Term Loan Facility (as defined in Note 7 â€œLong-term Debtâ€ to the audited consolidated financial statements) due 2026, (ii) finance and operating lease obligations, which are generally paid on a monthly basis and include maturities through 2028 and 2032, respectively, (iii) the operations of our business, (iv) income tax payments, which are generally due on a quarterly and annual basis, (v) capital additions, which include acquisition and de novo centers, and (vi) share repurchases authorized under the \$5.0 million Board approved program. We will also continue investing in resources and initiatives to provide

for the year ended June 30, 2024 compared to a net loss of \$43.6 million during the prior year, as described further above, (ii) a decrease of \$28.1Å million in deferred revenue during fiscal year 2024 due to timing of payments received during the prior year, and (iii) an increase of \$38.6Å million in accounts receivable, net of allowance primarily due to timing for the receipt of payments in 2024.

Investing Activities. Net cash used in investing activities in 2024 was primarily made up of \$23.9Å million for the Concerto acquisition and approximately \$7.9 million in purchases of property and equipment. In 2023, net cash used in investing activities was primarily due to \$23.4 million in purchases of property and equipment and \$46.2 million for purchases of short-term investments, consisting primarily of managed income funds invested in investment grade short-term fixed and floating rate debt securities aimed at creating income while maintaining low volatility on principal. Our investment in managed income funds regularly pay dividends which are reinvested into the funds. Financing activities. The decrease in net cash used in financing activities was primarily due to a contribution from a joint venture partner in 2024.

Emerging Growth Company and Smaller Reporting CompanyWe qualify as an Åœemerging growth companyÅ pursuant to the provisions of the Jumpstart Our Business Startups (ÅJOBSÅ) Act and a Åsmaller reporting companyÅ as defined by the Exchange Act. For as long as we are an Åemerging growth companyÅ or a Åsmaller reporting company,Å we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not Åemerging growth companiesÅ or Åsmaller reporting companies,Å including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, only being required to present two years of audited financial statements, plus unaudited 63 condensed consolidated financial statements for applicable interim periods and the related discussion in the section titled ÅManagementÅs Discussion and Analysis of Financial Condition and Results of Operations,Å Åreduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, exemptions from the requirements of holding non-binding advisory Åsay-on-payÅ votes on executive compensation and shareholder advisory votes on golden parachute compensation. In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the longer phase-in periods for the adoption of new or revised financial accounting standards under the JOBS Act until we are no longer an emerging growth company. Our election to use the phase-in periods permitted by this election may make it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the longer phase-in periods permitted under the JOBS Act and who will comply with new or revised financial accounting standards. If we were to subsequently elect instead to comply with public company effective dates, such election would be irrevocable pursuant to the JOBS Act.

Critical Accounting EstimatesThe discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates under different assumptions or conditions, impacting our reported results of operations and financial condition. Certain accounting policies involve significant judgments and assumptions by management, which have a material impact on the carrying value of assets and liabilities and the recognition of income and expenses. We consider these accounting policies to be critical accounting policies. The estimates and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. While our significant accounting policies are described in more detail in Note 2 ÅSummary of Significant Accounting Policies,Å to our audited Consolidated Financial Statements, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require management to make subjective and complex judgments and estimates in the preparation of our consolidated financial statements.

Revenue recognitionWe recognize revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606). Our PACE operating unit provides comprehensive healthcare services to participants on the basis of estimated PMPM amounts we expect to be entitled to receive from the capitated fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. We recognize capitation revenues based on the estimated PMPM transaction price to transfer the service for a distinct increment of the series (i.e. month). We recognize revenue in the month in which participants are entitled to receive comprehensive care benefits during the contract term. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program, and Medicare rates can fluctuate throughout the contract based on the acuity of each individual participant. In certain contracts, PMPM rates also include Årisk adjustments,Å based on various factors. For additional information see Note 3 ÅRevenue Recognition.Å For certain capitation payments, the Company is subject to retroactive premium risk adjustments based on various factors. The Company estimates the amount of the adjustment based on participant medical status and historical experience. Such estimates are then recorded monthly on a straight-line basis. We review our assumptions and adjust these estimates accordingly on a quarterly basis. Our consolidated financial statements could be materially impacted if actual risk scores are different from the estimated risk scores. If our accrual estimates for risk scores at June 30, 2024 were to differ by 5%, the impact on revenues would be approximately \$0.5 million. Certain third-party payor contracts include a Medicare Part D payment related to pharmacy claims, which is subject to risk sharing through accepted risk corridor provisions. Under certain agreements the fund risk allocation is established whereby we, as the contracted provider, receive only a portion of the risk and the associated surplus or deficit. We estimate and recognize an adjustment monthly to Part D capitation revenues related to these risk corridor provisions based upon pharmacy claims experience to date, as if the annual risk contract were to terminate at the end of the reporting period.

GoodwillGoodwill represents the excess of consideration paid over the fair value of net assets acquired through business acquisitions. Goodwill is not amortized but is tested for impairment at least annually. We test goodwill for impairment annually on April 1 or more frequently if triggering events occur or other impairment indicators arise which might impair recoverability. These events or circumstances would include a significant change in the business climate, legal factors, operating performance indicators, competition, sale, disposition of a significant portion of the business, or other factors. Impairment of goodwill is evaluated at the reporting unit level. A reporting unit is defined as an operating segment (i.e. before aggregation or combination), or one level below an operating segment (i.e. a component). For purposes of the annual goodwill impairment assessment, the Company has identified two reporting units, East and West. There were no indicators of impairment identified and no goodwill impairments recorded during the years ended June 30, 2024 and 2023. In determining the fair value of our reporting units, we estimate a number of factors including anticipated future cash flows and discount rates. Although we believe these estimates are reasonable, actual results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Reported and estimated claims Reported and estimated claims expenses are costs for third-party healthcare service providers that provide medical care to our participants for which we are contractually obligated to pay (through our full-risk capitation arrangements). The estimated reserve for unpaid claims liability is included in the liability for reported and estimated claims in the consolidated balance sheets and requires estimates including actual member utilization of healthcare services, unit cost trends, participant acuity, changes in net census, known outbreaks of disease or increased incidence of illness such as influenza or COVID-19 and other factors. We periodically assess our estimates with an independent actuarial expert to ensure our estimates represent the best, most reasonable estimate given the data available to us at the time the estimates are made. We have included incurred but not reported claims of approximately \$55.4 million and \$43.0 million on our balance sheet as of June 30, 2024 and 2023, respectively. Our recorded medical claims expense estimate is approximately within +/- 5-10% of actual medical claims expense incurred, or less than 1% of our total operating expense. The following tables provide information about incurred and paid claims reporting and development as of June 30, 2024 (except as otherwise noted). The expenses recorded table reflects the amount of claims reported in our consolidated statements of operations as of the end of the applicable fiscal year based on our best and most reasonable estimates and actuarial assessment at the time of such determination. The cumulative actual incurred claims table represents the actual amount of claims incurred by the Company with the benefit of the passage of time. The cumulative actual paid claims table represents the actual amount of claims paid by the Company during the period. The variance between the expense recorded and the cumulative actual incurred claims ranges between approximately 1% and 3% of actual total incurred claims over the periods presented, and such variance may vary based on the factors described above in this section.

	Fiscal Years Ended June 30, 2020	2021	2022	2023	2024in thousands
Claims incurred year:	FY 2020\$211,381Å	FY 2021\$234,070Å	FY 2022\$299,432Å	FY 2023\$291,988Å	\$315,148Å
Pharmacy expense	\$8,786Å	\$10,650Å	\$12,550Å	\$12,550Å	\$12,550Å
External provider costs	\$403,010Å	\$465,000Å	\$520,000Å	\$520,000Å	\$520,000Å
Cumulative Actual Incurred Claims for the Fiscal Year Ended June 30,	2020\$211,381Å	2021\$445,461Å	2022\$744,913Å	2023\$1,040,893Å	2024\$1,355,941Å
Actual Incurred Claims for the Fiscal Year Ended June 30,	2020\$211,381Å	2021\$445,461Å	2022\$744,913Å	2023\$1,040,893Å	2024\$1,355,941Å
Paid claims for the Fiscal Year Ended June 30,	2020\$211,381Å	2021\$445,461Å	2022\$744,913Å	2023\$1,040,893Å	2024\$1,355,941Å

Our recent accounting pronouncements See Note 2 to our consolidated financial statements ÅSummary of Significant Accounting Policies,Å "Recently Adopted Accounting Pronouncements" and ÅRecent Accounting Pronouncements Not Yet Adopted,Å for more information.

Item 7.A. Å QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes. Interest rate risk As of June 30, 2024, we had total outstanding borrowings of (i) \$63.8 million principal amount under the Term Loan Facility (as defined in Note 7 to the audited consolidated financial statements) and (ii) \$2.2 million principal amount under the convertible term loan. As of June 30, 2023, we had total outstanding debt of \$67.5 million in principal amount under the Term Loan Facility and \$2.3 million under the Convertible Term Loan. As of June 30, 2024 and 2023, the interest rate on the Term Loan Facility was 7.18% and 6.95%, respectively. We are exposed to changes in interest rates as a result of our variable-rate borrowings under the 2021 Credit Agreement. Generally, the Company may designate specific borrowings under the 2021 Credit Agreement as either base rate borrowings or Secured Overnight Financing Rate (ÅSOFR,Å) borrowings. We amended our 2021 Credit Agreement during the fourth quarter ended June 30, 2024 to replace the London Interbank Offered Rate (ÅLIBOR,Å) reference rate with SOFR prior to the discontinuance of LIBOR. As of June 30, 2024, based on our secured net leverage ratio, the margins of our borrowings under the Term Loan and Revolving Credit Facility (as defined in Note 7 to the audited consolidated financial statements) were (a) 0.75% for alternate base rate borrowings and (b) 1.75% for Term SOFR borrowings. Our cash and cash equivalents and interest payments in respect of our debt are subject to market risk due to changes in interest rates. We had cash and cash equivalents of \$56.9 million as of June 30, 2024, which are deposited with high credit quality financial institutions and are primarily in demand deposit accounts. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on our business, financial condition or results of operations. We had short-term investments of \$45.8 million and \$46.2 million as of June 30, 2024 and 2023, respectively, which are primarily invested in managed income funds managed by major financial institutions. The funds mainly invest in investment grade, U.S. denominated short-term fixed and floating rate debt securities. Securities are subject to market risk and sensitive to changes in interest rates. While the instruments held by the funds are generally less sensitive to interest rate changes than instruments with longer maturities due to their short-term nature, the funds may face a heightened level of interest rate risk due to changes in monetary policy. During periods when interest rates are low or negative, the funds yields, and total returns may also be low, or the funds may be unable to maintain positive returns. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on these short-term investments.

Inflation riskBased on our analysis of the periods presented, we believe that inflation has not had a material effect on our operating results. See more information under Item 7. Management's Discussion of Financial Condition and Results of Operations. Trends and Uncertainties Affecting the Company. There can be no assurance that future inflation will not have an adverse impact on our operating results and financial condition.

Item 8. Å FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA(a) Index to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm (PCAOB ID: 34) 68 Consolidated Balance Sheets as of June 30, 2024 and 2023 69 Consolidated Statements of Operations for the years ended June 30, 2024 and 2023 70 Consolidated Statements of Stockholders' Equity for the years ended June 30, 2024 and 2023 71 Consolidated Statements of Cash Flows for the years ended June 30, 2024 and 2023 72 Notes to Consolidated Financial Statements 72 76 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and the Board of Directors of InnovAge Holding Corp. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of InnovAge Holding Corp. and subsidiaries (the "Company") as of June 30, 2024 and 2023, the related consolidated statements of operations, stockholders' equity, and cash flows, for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility

[illegible]

probable that the performance condition will be achieved. We analyze if a performance condition is probable for each reporting period through the settlement date for awards subject to 76performance vesting. Stock-based compensation is included in corporate, general and administrative expenses on our consolidated statements of operations.Shares issued pursuant to our equity incentive plan are issued from authorized but unissued shares or from shares held by the Company as treasury stock, if any. See Note 10 to our consolidated financial statements.

Income Taxes. The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Senior Housing Thornton, LLC (the "SH1") and InnovAge Sacramento have elected to be taxed as partnerships, and no provision (benefit) for income taxes for SH1 or InnovAge Sacramento is included in these consolidated financial statements. Further, InnovAge Orlando entered into a joint venture on May 28, 2024 and its members elected to be taxed as a partnership. No provision (benefit) for income taxes for InnovAge Orlando is included in these consolidated financial statements for activity occurring from joint venture formation date through the balance of the fiscal year.A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.Variable Interest Entities (VIE)A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk or whose equity owners lack certain decision-making and economic rights. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity. The primary beneficiary is required to consolidate the VIE. InnovAge Senior Housing Thornton, LLC (the "SH1") and Pinewood Lodge, LLP (the "PWL") are considered to be VIEs. The Company is not considered the primary beneficiary of PWL but is considered the primary beneficiary of SH1. On March 13, 2024, PWL entered into a Purchase and Sale Agreement for the sale of all of PWL's property, including the Senior Housing unit. The sale closed on May 2, 2024, and as a result, the Company ceased providing senior housing services through PWL. Emerging Growth Company StatusThe Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company's consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Adopted Accounting Pronouncements.Financial InstrumentsIn April 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (the "ASU 2019-04"), which requires entities to use a current expected credit loss (the "CECL") model to measure impairment for most financial assets that are not recorded at fair value through net income. Under the CECL model, an entity will estimate lifetime expected credit losses considering available relevant information about historical events, current conditions and supportable forecasts. The CECL model does not apply to available-for-sale debt securities. The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the standard on July 1, 2023. Our adoption of the standard did not have a material impact on the consolidated financial statements. The Company makes estimates of expected credit losses based on a combination of factors, including historical losses adjusted for current market conditions, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Recent Accounting Pronouncements Not Yet Adopted.Segment ReportingIn November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual segment disclosures be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is evaluating the impact of ASU 2023-07 on our consolidated financial statements. Income TaxesIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires additional disclosures related to rate reconciliation, income taxes paid, and other disclosures. ASU 2023-09 requires public companies to annually (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. Additionally, ASU 2023-09 requires public companies to annually disclose the amount of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as the amount of income taxes paid by individual jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2025. The Company is currently evaluating the impact of ASU 2023-09 on our consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

Note 3: A Revenue Recognition.Capitation Revenue and Accounts ReceivableOur capitation revenue relates to contracts with participants in which our performance obligation is to provide healthcare services to the participants. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type. The Company contracts directly with Medicare and Medicaid on a PMPM basis. We receive 100% of the pooled capitated payment to directly provide or manage the healthcare needs of our participants. Fees are recorded gross in revenues because the Company is acting as a principal in providing for or overseeing comprehensive care provided to the participants. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers. In general, a participant enrolls in the PACE program and is considered a customer of InnovAge. The Company considers all contracts with participants as a single performance obligation to provide comprehensive medical, health, and social services that integrate acute and long-term care. The Company identified that contracts with customers in the PACE program have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied over time as the Company provides comprehensive care to its participants. Our revenues are based on the estimated PMPM amounts we expect to be entitled to receive from the capitated fees per participant that are paid monthly by Medicaid, Medicare, the VA, and private pay sources. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. VA is included in the Private Pay and other and is also capitated. Private pay includes direct payments from participants who do not qualify for the full capitated rate and have to pay all or a portion of the capitated rate. Costs to obtain contracts consist of sales commissions for new enrollees and are included in deposits and other on our consolidated balance sheets. These costs are amortized over a three- to seven-year period which corresponds to the average time a participant is enrolled in the PACE program. As of June 30, 2024 and 2023, contract assets included within deposits and other were \$2.8 million and \$1.0 million, respectively. The Company disaggregates capitation revenue from the following sources for the year ended June 30, 2024: 2023 Medicaid 54% 54% Medicare 46% 46% Private pay and other 0% 0% Total 100% 100% Less than 1% The Company determined the transaction price for these contracts is the amount we expect to be entitled to, which is the most likely amount. For certain capitation payments, the Company is subject to retroactive premium risk adjustment payments according to the CMS risk adjustment payment timeline. Specifically, there is a mid-year true up payment based on updated risk score calculations and a final true up payment to allow for complete diagnosis submission. The Company estimates the amount of the adjustment and records it monthly on a straight-line basis. These adjustments are not expected to be material. The capitation revenues are recognized based on the estimated PMPM transaction price to transfer the service for a distinct increment of the series (i.e. month). We recognize revenue over time in the month in which participants are entitled to receive comprehensive care benefits during the contract term. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component. The Company also provides prescription drug benefits in accordance with Medicare Part D. Monthly payments received from CMS and the participants represent the bid amount for providing prescription drug coverage. The portion received from CMS is subject to risk sharing through Medicare Part D risk-sharing corridor provisions. These risk-sharing corridor provisions compare costs targeted in the Company's bid to actual prescription drug costs. The Company estimates and records a monthly adjustment to Medicare Part D revenues associated with these risk-sharing corridor provisions. Medicare Part D comprised (i) 12% and 13% of capitation revenues for the years ended June 30, 2024 and 2023, respectively, and (ii) 24% and 23% of external provider costs for the years ended June 30, 2024 and 2023, respectively. The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. The concentration of net receivables from participants and third-party payers as of June 30, 2024 and 2023 was as follows: 2024 2023 Medicaid 71% 61% Medicare 22% 29% Private pay and other 7% 10% Total 100% 100% The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company's best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. The balance of the allowance for uncollectible accounts was \$6.7 million as of June 30, 2024, compared to \$4.2 million as of June 30, 2023. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts. Other Service Revenue and Accounts ReceivableOther service revenue primarily consists of revenues derived from state food grants and rent revenues. Accounts receivable related to other service revenue were not significant as of both June 30, 2024 and June 30, 2023.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to change, as well as government review. Failure to comply with these laws can expose the entity to significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. See Note 9, Commitments and Contingencies.

Note 4: A Cost and Equity Method Investments.The Company holds cost method and equity method investments as of June 30, 2024: 2023 in thousands Cost method investments \$2,645.4 \$4,645.4 Equity method investments \$4.8 \$4.8 Total investments \$2,645.4 \$4,645.4 Nonconsolidated Entities Cost Method Investments As of June 30, 2024 and 2023, the Company maintained one investment and two investments, respectively, that were accounted for using the cost method. The Company's ownership interests are less than 20% of the voting stock of the investments and the Company does not have the ability to exercise significant influence over the operating and financial policies of the investments. The investments do not have a readily determinable fair value and the Company has elected to record the investments at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. JetDocIn August 2021, the Company acquired a minority interest equal to 806,481 shares of the outstanding common stock of JetDoc, Inc. (the "JetDoc"), a telehealth and virtual urgent care app dedicated to effectively connecting users with medical professionals, for cash consideration of \$2.0 million. We determined that indicators of impairment were present as of December 31, 2023, and recognized an impairment loss of \$1.9 million during the three months then ended. During the three months ended March 31, 2024, we determined that the remaining balance of our investment in JetDoc was impaired and recognized an additional impairment loss of \$0.1 million. Impairment losses are included in gain on cost and equity method investments on our consolidated statements of operations. During the year ended June 30, 2023, there were no observable price changes or impairments recorded. As of June 30, 2024, the Company does not have any ownership interest in JetDoc.

Dispatch HealthOn June 14, 2019, the Company invested \$1.5 million in Dispatch Health Holdings, Inc., ("Dispatch Health") through the purchase of a portion of its outstanding Series B Preferred Stock. On April 2, 2020, the Company invested an additional \$1.1 million through the purchase of a portion of its outstanding Series C Preferred Stock. As of June 30, 2024, the balance of the Company's investment was \$2.6 million which represents the maximum exposure to loss. The investment does not have a readily determinable fair value and the Company has elected to record the investment at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. During the years ended June 30, 2024 and 2023, there were no observable price changes or impairments. Equity Method InvestmentsPinewood LodgeThrough May 2, 2024, the Company's operations included a Senior Housing unit that primarily included the accounts of Continental Community Housing (the "CCH"), a wholly-owned subsidiary of the Company and the general partner of PWD, which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older. PWD was a VIE, but the Company was not the primary beneficiary. The Company did not have the power to direct the activities that most significantly impacted the economic performance of PWD. Accordingly, the Company did not consolidate PWD. PWD was accounted for using the equity method of accounting. The equity earnings of PWD were not significant. As of June 30, 2023, the balance of the Company's investment in PWD was \$0.8 million, which represented the maximum exposure to loss.

On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including the Senior Housing unit. On May 2, 2024, PWD closed on the sale of its Senior Housing property for \$9.5 million. Upon completion of the sale, PWD ceased providing senior housing services and in June 2024 was dissolved. Following the dissolution, the remaining proceeds from the sale were distributed in accordance with the partnership agreement and as otherwise agreed by the partners.

Consolidated Entities.Controlling InterestInnovAge Florida PACE. On May 28, 2024, the Company entered into a Joint Venture Agreement with Orlando Health (the "OHI") to develop and manage PACE centers to serve communities in Orlando, Florida. In connection with the joint venture, the joint venture, InnovAge Florida PACE, was formed. The Company contributed \$26.1 million for its controlling membership interest of 90%. As a result, the joint venture's results are consolidated in the Company's consolidated financial statements. OHI contributed \$2.9 million in cash for its 10% interest. Noncontrolling InterestSenior HousingThe Company's operations include a 0.01% partnership interest in SH1, which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older. SH1 is a VIE. The Company is the primary beneficiary of SH1 and consolidates SH1. The Company is the primary beneficiary of SH1 as it has the power to direct the activities that are most significant to SH1 and has an obligation to absorb losses or the right to receive benefits from SH1. The most significant activity of SH1 is the operation of the senior housing facility. The Company has provided a subordinated loan to SH1 and has provided a guarantee for a convertible term loan held by SH1. The following table shows the assets and liabilities of SH1 as of June 30, 2024: 2023 in thousands Assets Cash and cash equivalents \$816.4 \$648.4 Prepaid expenses and other \$5.1 \$1.4 Property, plant and equipment, net \$9,465.9 \$9,333.4 Deposits and other, net \$409.4 \$402.4 Liabilities Accounts payable and accrued expenses \$295.4 \$268.4 Noncurrent liabilities \$456.4 \$454.4 Long-term debt, net of debt issuance costs \$3,739.4 \$3,784.4 Redeemable Noncontrolling InterestInnovAge SacramentoOn March 18, 2019, in connection with the formation of InnovAge Sacramento, the joint venture with Adventist Health System/West (the "Adventist") and Eskaton Properties, Incorporated (the "Eskaton"), the Company contributed \$9.0 million in cash and land valued at \$4.2 million for a 59.9% membership interest in the joint venture. Further, Adventist contributed \$5.8 million in cash and Eskaton contributed \$3.0 million in cash for membership interests of 26.4% and 13.7%, respectively. In fiscal year 2021, the Company made an additional contribution of \$52,000 and obtained an additional 0.1% membership interest in the joint venture, which resulted in the Company obtaining control and consolidating InnovAge Sacramento as of January 1, 2021. The InnovAge California PACE-Sacramento LLC Limited Liability Company Agreement (the "JV Agreement") includes numerous provisions whereby, if certain conditions are met, the joint venture may be required to purchase, at fair market value, certain members' interests or certain members may be required to purchase, at fair market value, the interests of certain other members. The Company's investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As of June 30, 2024, none of the conditions specified in the JV Agreement had been met. Accordingly, these put rights held by the noncontrolling interests of the joint venture are required to be presented as temporary equity. As of June 30, 2024 and 2023, the Company's redeemable noncontrolling interest was recorded at fair value of \$22.2 million and carrying value of \$12.7 million, respectively.

Note 5: A Goodwill and Intangible Assets.Goodwill represents the excess of cost over the fair value of net assets acquired. Goodwill amounted to \$139.9 million and \$124.2 million as of June 30, 2024 and June 30, 2023, respectively. The Company had one acquisition resulting in goodwill during the year ended June 30, 2024, see additional information in Note 1: Acquisitions, and did not have any acquisitions resulting in goodwill during the year ended June 30, 2023. Goodwill is not amortized. Pursuant to ASC 350, Intangibles, the

Goodwill and Other, we review the recoverability of goodwill annually as of April 1 or whenever significant events or changes occur which might impair the recovery of recorded amounts. For purposes of the annual goodwill impairment assessment for fiscal year 2024, the Company identified two reporting units, East and West. There were no indicators of impairment identified and no goodwill impairments recorded during the years ended June 30, 2024 and 2023. The following table summarizes the changes in goodwill for the fiscal years ended June 30: in thousands 2024 2023 Balance as of beginning of period 124,217 124,217 Goodwill acquired during the period 15,732 124,217 A Balance as of end of period 139,949 124,217 Intangible assets consisted of the following as of June 30: in thousands 2024 2023 Definite-lived intangible assets Customer relationships \$6,600 \$6,600 Indefinite-lived intangible assets Permits 2,000 2,000 Total intangible assets 8,600 8,600 Accumulated amortization (4,062) (3,402) Balance as of end of period 4,538 \$5,198 A Intangible assets with a finite useful life continue to be amortized over their useful lives. The Company recorded amortization expense of \$0.7 million for each of the years ended June 30, 2024 and 2023. The total expected future annual amortization expense for the next 5 years ended June 30, is as follows: in thousands Amortization Expense 2025 \$660 2026 \$660 2027 \$630 2028 \$540 2029 \$480 2030 \$420 2031 \$360 2032 \$300 2033 \$240 2034 \$180 2035 \$120 2036 \$60 2037 \$0 The recoverability of other intangible assets in conjunction with long-lived assets whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. There were no intangible asset impairments recorded during the years ended June 30, 2024 and 2023. Note 6: A A A Leases Leasing Arrangements as Lessee The Company leases certain property and equipment under various third-party operating and finance lease agreements. The Company determines if an arrangement is or contains a lease at the lease inception date by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. The leases are noncancelable and expire on various terms from 2024 through 2034. We determine if an arrangement is a lease upon commencement of the contract. If an arrangement is determined to be a long-term lease (greater than 12 months), we recognize a right-of-use ("ROU") asset and lease liability based on the present value of the future minimum lease payments over the lease term at the commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Our lease terms may also include options to extend or terminate the lease when it is reasonably certain that we will exercise those options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have elected to apply the short-term lease exception for contracts that have a lease term of twelve months or less and do not include an option to purchase the underlying asset. Therefore, we do not recognize a ROU asset or lease liability for such contracts. We recognize short-term lease payments as expense on a straight-line basis over the lease term. Variable lease payments that do not depend on an index or rate are recognized as expense. Certain leases include escalations based on inflation indexes and fair market value adjustments. Operating lease liabilities are calculated using the prevailing index or rate at lease commencement for such leases. On March 20, 2023, we consolidated our Germantown center in Pennsylvania with two of our existing centers. Upon consolidation, we terminated our Germantown center lease and recognized lease termination costs of \$0.6 million. Lease termination costs are included in other income (expense) on our consolidated statements of operations. The following table presents the components of our ROU assets and their classification in our Balance Sheet as of June 30. Component of Lease Balances Balance Sheet Line Items 2024 2023 in thousands Assets: Operating lease assets \$28,416 \$21,210 A Finance lease assets Property and equipment, net 15,908 16,378 A Total leased assets \$44,324 \$37,588 A The following table presents the components of our lease cost and the classification of such costs in our Statement of Operations for the years ended June 30. 83 Component of Lease Cost Statement of Operations Line Items 2024 2023 in thousands Operating lease cost Cost of care excluding depreciation and amortization and Corporate, general and administrative \$5,402 \$4,642 A Finance lease expense Amortization of leased assets Depreciation and amortization 1,984 3,080 A Interest on lease liabilities Interest expense, net 1,255 A Variable lease cost Cost of care excluding depreciation and amortization and Corporate, general and administrative 938 82 A Short-term lease cost Cost of care excluding depreciation and amortization and Corporate, general and administrative 172 108 A Total lease expense: \$7,651 \$9,167 A The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of June 30. Weighted average remaining lease term: 2024 2023 Operating leases 7.7 years 7.9 years Finance leases 3.5 years 3.9 years Weighted average discount rate: 2024 2023 Operating leases 6.86% 6.60% Finance leases 7.80% 7.80% The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to June 30, 2024. in thousands Operating Lease Finance Lease Total 2025 \$6,023 1,455 7,478 2026 6,311 1,455 7,766 2027 6,544 1,455 8,000 2028 6,655 1,455 8,110 2029 6,744 1,455 8,199 2030 6,811 1,455 8,266 2031 6,866 1,455 8,321 2032 6,900 1,455 8,355 2033 6,922 1,455 8,377 2034 6,933 1,455 8,388 2035 6,933 1,455 8,388 2036 6,933 1,455 8,388 2037 6,933 1,455 8,388 2038 6,933 1,455 8,388 2039 6,933 1,455 8,388 2040 6,933 1,455 8,388 2041 6,933 1,455 8,388 2042 6,933 1,455 8,388 2043 6,933 1,455 8,388 2044 6,933 1,455 8,388 2045 6,933 1,455 8,388 2046 6,933 1,455 8,388 2047 6,933 1,455 8,388 2048 6,933 1,455 8,388 2049 6,933 1,455 8,388 2050 6,933 1,455 8,388 2051 6,933 1,455 8,388 2052 6,933 1,455 8,388 2053 6,933 1,455 8,388 2054 6,933 1,455 8,388 2055 6,933 1,455 8,388 2056 6,933 1,455 8,388 2057 6,933 1,455 8,388 2058 6,933 1,455 8,388 2059 6,933 1,455 8,388 2060 6,933 1,455 8,388 2061 6,933 1,455 8,388 2062 6,933 1,455 8,388 2063 6,933 1,455 8,388 2064 6,933 1,455 8,388 2065 6,933 1,455 8,388 2066 6,933 1,455 8,388 2067 6,933 1,455 8,388 2068 6,933 1,455 8,388 2069 6,933 1,455 8,388 2070 6,933 1,455 8,388 2071 6,933 1,455 8,388 2072 6,933 1,455 8,388 2073 6,933 1,455 8,388 2074 6,933 1,455 8,388 2075 6,933 1,455 8,388 2076 6,933 1,455 8,388 2077 6,933 1,455 8,388 2078 6,933 1,455 8,388 2079 6,933 1,455 8,388 2080 6,933 1,455 8,388 2081 6,933 1,455 8,388 2082 6,933 1,455 8,388 2083 6,933 1,455 8,388 2084 6,933 1,455 8,388 2085 6,933 1,455 8,388 2086 6,933 1,455 8,388 2087 6,933 1,455 8,388 2088 6,933 1,455 8,388 2089 6,933 1,455 8,388 2090 6,933 1,455 8,388 2091 6,933 1,455 8,388 2092 6,933 1,455 8,388 2093 6,933 1,455 8,388 2094 6,933 1,455 8,388 2095 6,933 1,455 8,388 2096 6,933 1,455 8,388 2097 6,933 1,455 8,388 2098 6,933 1,455 8,388 2099 6,933 1,455 8,388 2100 6,933 1,455 8,388 2101 6,933 1,455 8,388 2102 6,933 1,455 8,388 2103 6,933 1,455 8,388 2104 6,933 1,455 8,388 2105 6,933 1,455 8,388 2106 6,933 1,455 8,388 2107 6,933 1,455 8,388 2108 6,933 1,455 8,388 2109 6,933 1,455 8,388 2110 6,933 1,455 8,388 2111 6,933 1,455 8,388 2112 6,933 1,455 8,388 2113 6,933 1,455 8,388 2114 6,933 1,455 8,388 2115 6,933 1,455 8,388 2116 6,933 1,455 8,388 2117 6,933 1,455 8,388 2118 6,933 1,455 8,388 2119 6,933 1,455 8,388 2120 6,933 1,455 8,388 2121 6,933 1,455 8,388 2122 6,933 1,455 8,388 2123 6,933 1,455 8,388 2124 6,933 1,455 8,388 2125 6,933 1,455 8,388 2126 6,933 1,455 8,388 2127 6,933 1,455 8,388 2128 6,933 1,455 8,388 2129 6,933 1,455 8,388 2130 6,933 1,455 8,388 2131 6,933 1,455 8,388 2132 6,933 1,455 8,388 2133 6,933 1,455 8,388 2134 6,933 1,455 8,388 2135 6,933 1,455 8,388 2136 6,933 1,455 8,388 2137 6,933 1,455 8,388 2138 6,933 1,455 8,388 2139 6,933 1,455 8,388 2140 6,933 1,455 8,388 2141 6,933 1,455 8,388 2142 6,933 1,455 8,388 2143 6,933 1,455 8,388 2144 6,933 1,455 8,388 2145 6,933 1,455 8,388 2146 6,933 1,455 8,388 2147 6,933 1,455 8,388 2148 6,933 1,455 8,388 2149 6,933 1,455 8,388 2150 6,933 1,455 8,388 2151 6,933 1,455 8,388 2152 6,933 1,455 8,388 2153 6,933 1,455 8,388 2154 6,933 1,455 8,388 2155 6,933 1,455 8,388 2156 6,933 1,455 8,388 2157 6,933 1,455 8,388 2158 6,933 1,455 8,388 2159 6,933 1,455 8,388 2160 6,933 1,455 8,388 2161 6,933 1,455 8,388 2162 6,933 1,455 8,388 2163 6,933 1,455 8,388 2164 6,933 1,455 8,388 2165 6,933 1,455 8,388 2166 6,933 1,455 8,388 2167 6,933 1,455 8,388 2168 6,933 1,455 8,388 2169 6,933 1,455 8,388 2170 6,933 1,455 8,388 2171 6,933 1,455 8,388 2172 6,933 1,455 8,388 2173 6,933 1,455 8,388 2174 6,933 1,455 8,388 2175 6,933 1,455 8,388 2176 6,933 1,455 8,388 2177 6,933 1,455 8,388 2178 6,933 1,455 8,388 2179 6,933 1,455 8,388 2180 6,933 1,455 8,388 2181 6,933 1,455 8,388 2182 6,933 1,455 8,388 2183 6,933 1,455 8,388 2184 6,933 1,455 8,388 2185 6,933 1,455 8,388 2186 6,933 1,455 8,388 2187 6,933 1,455 8,388 2188 6,933 1,455 8,388 2189 6,933 1,455 8,388 2190 6,933 1,455 8,388 2191 6,933 1,455 8,388 2192 6,933 1,455 8,388 2193 6,933 1,455 8,388 2194 6,933 1,455 8,388 2195 6,933 1,455 8,388 2196 6,933 1,455 8,388 2197 6,933 1,455 8,388 2198 6,933 1,455 8,388 2199 6,933 1,455 8,388 2200 6,933 1,455 8,388 2201 6,933 1,455 8,388 2202 6,933 1,455 8,388 2203 6,933 1,455 8,388 2204 6,933 1,455 8,388 2205 6,933 1,455 8,388 2206 6,933 1,455 8,388 2207 6,933 1,455 8,388 2208 6,933 1,455 8,388 2209 6,933 1,455 8,388 2210 6,933 1,455 8,388 2211 6,933 1,455 8,388 2212 6,933 1,455 8,388 2213 6,933 1,455 8,388 2214 6,933 1,455 8,388 2215 6,933 1,455 8,388 2216 6,933 1,455 8,388 2217 6,933 1,455 8,388 2218 6,933 1,455 8,388 2219 6,933 1,455 8,388 2220 6,933 1,455 8,388 2221 6,933 1,455 8,388 2222 6,933 1,455 8,388 2223 6,933 1,455 8,388 2224 6,933 1,455 8,388 2225 6,933 1,455 8,388 2226 6,933 1,455 8,388 2227 6,933 1,455 8,388 2228 6,933 1,455 8,388 2229 6,933 1,455 8,388 2230 6,933 1,455 8,388 2231 6,933 1,455 8,388 2232 6,933 1,455 8,388 2233 6,933 1,455 8,388 2234 6,933 1,455 8,388 2235 6,933 1,455 8,388 2236 6,933 1,455 8,388 2237 6,933 1,455 8,388 2238 6,933 1,455 8,388 2239 6,933 1,455 8,388 2240 6,933 1,455 8,388 2241 6,933 1,455 8,388 2242 6,933 1,455 8,388 2243 6,933 1,455 8,388 2244 6,933 1,455 8,388 2245 6,933 1,455 8,388 2246 6,933 1,455 8,388 2247 6,933 1,455 8,388 2248 6,933 1,455 8,388 2249 6,933 1,455 8,388 2250 6,933 1,455 8,388 2251 6,933 1,455 8,388 2252 6,933 1,455 8,388 2253 6,933 1,455 8,388 2254 6,933 1,455 8,388 2255 6,933 1,455 8,388 2256 6,933 1,455 8,388 2257 6,933 1,455 8,388 2258 6,933 1,455 8,388 2259 6,933 1,455 8,388 2260 6,933 1,455 8,388 2261 6,933 1,455 8,388 2262 6,933 1,455 8,388 2263 6,933 1,455 8,388 2264 6,933 1,455 8,388 2265 6,933 1,455 8,388 2266 6,933 1,455 8,388 2267 6,933 1,455 8,388 2268 6,933 1,455 8,388 2269 6,933 1,455 8,388 2270 6,933 1,455 8,388 2271 6,933 1,455 8,388 2272 6,933 1,455 8,388 2273 6,933 1,455 8,388 2274 6,933 1,455 8,388 2275 6,933 1,455 8,388 2276 6,933 1,455 8,388 2277 6,933 1,455 8,388 2278 6,933 1,455 8,388 2279 6,933 1,455 8,388 2280 6,933 1,455 8,388 2281 6,933 1,455 8,388 2282 6,933 1,455 8,388 2283 6,933 1,455 8,388 2284 6,933 1,455 8,388 2285 6,933 1,455 8,388 2286 6,933 1,455 8,388 2287 6,933 1,455 8,388 2288 6,933 1,455 8,388 2289 6,933 1,455 8,388 2290 6,933 1,455 8,388 2291 6,933 1,455 8,388 2292 6,933 1,455 8,388 2293 6,933 1,455 8,388 2294 6,933 1,455 8,388 2295 6,933 1,455 8,388 2296 6,933 1,455 8,388 2297 6,933 1,455 8,388 2298 6,933 1,455 8,388 2299 6,933 1,455 8,388 2300 6,933 1,455 8,388 2301 6,933 1,455 8,388 2302 6,933 1,455 8,388 2303 6,933 1,455 8,388 2304 6,933 1,455 8,388 2305 6,933 1,455 8,388 2306 6,933 1,455 8,388 2307 6,933 1,455 8,388 2308 6,933 1,455 8,388 2309 6,933 1,455 8,388 2310 6,933 1,455 8,388 2311 6,933 1,455 8,388 2312 6,933 1,455 8,388 2313 6,933 1,455 8,388 2314 6,933 1,455 8,388 2315 6,933 1,455 8,388 2316 6,933 1,455 8,388 2317 6,933 1,455 8,388 2318 6,933 1,455 8,388 2319 6,933 1,455 8,388 2320 6,933 1,455 8,388 2321 6,933 1,455 8,388 2322 6,933 1,455 8,388 2323 6,933 1,455 8,388 2324 6,933 1,455 8,388 2325 6,933 1,455 8,388 2326 6,933 1,455 8,388 2327 6,933 1,455 8,388 2328 6,933 1,455 8,388 2329 6,933 1,455 8,388 2330 6,933 1,455 8,388 2331 6,933 1,455 8,388 2332 6,933 1,455 8,388 2333 6,933 1,455 8,388 2334 6,933 1,455 8,388 2335 6,933 1,455 8,388 2336 6,933 1,455 8,388 2337 6,933 1,455 8,388 2338 6,933 1,455 8,388 2339 6,933 1,455 8,388 2340 6,933 1,455 8,388 2341 6,933 1,455 8,388 2342 6,933 1,455 8,388 2343 6,933 1,455 8,388 2344 6,933 1,455 8,388 2345 6,933 1,455 8,388 2346 6,933 1,455 8,388 2347 6,933 1,455 8,388 2348 6,933 1,455 8,388 2349 6,933 1,455 8,388 2350 6,933 1,455 8,388 2351 6,933 1,455 8,388 2352 6,933 1,455 8,388 2353 6,933 1,455 8,388 2354 6,933 1,455 8,388 2355 6,933 1,455 8,388 2356 6,933 1,455 8,388 2357 6,933 1,455 8,388 2358 6,933 1,455 8,388 2359 6,933 1,455 8,388 2360 6,933 1,455 8,388 2361 6,933 1,455 8,388 2362 6,933 1,455 8,388 2363 6,933 1,455 8,388 2364 6,933 1,455 8,388 2365 6,933 1,455 8,388 2366 6,933 1,455 8,388 2367 6,933 1,455 8,388 2368 6,933 1,455 8,388 2369 6,933 1,455 8,388 2370 6,933 1,455 8,388 2371 6,933 1,455 8,388 2372 6,933 1,455 8,388 2373 6,933 1,455 8,388 2374 6,933 1,455 8,388 2375 6,933 1,455 8,388 2376 6,933 1,455 8,388 2377 6,933 1,455 8,388 2378 6,933 1,455 8,388 2379 6,933 1,455 8,388 2380 6,933 1,455 8,388 2381 6,933 1,455 8,388 2382 6,933 1,455 8,388 2383 6,933 1,455 8,388 2384 6,933 1,455 8,388 2385 6,933 1,455 8,388 2386 6,933 1,455 8,388 2387 6,933 1,455 8,388 2388 6,933 1,455 8,388 2389 6,933 1,455 8,388 2390 6,933 1,455 8,388 2391 6,933 1,455 8,388 2392 6,933 1,455 8,388 2393 6,933 1,455 8,388 2394 6,933 1,455 8,388 2395 6,933 1,455 8,388 2396 6,933 1,455 8,388 2397 6,933 1,455 8,388 2398 6,933 1,455 8,388 2399 6,933 1,455 8,388 2400 6,933 1,455 8,388 2401 6,933 1,455 8,388 2402 6,933 1,455 8,388 2403 6,933 1,455 8,388 2404 6,933 1,455 8,388 2405 6,933 1,455 8,388 2406 6,933 1,455 8,388 2407 6,933 1,455 8,388 2408 6,933 1,455 8,388 2409 6,933 1,455 8,388 2410 6,933 1,455 8,388 2411 6,933 1,455 8,388 2412 6,933 1,455 8,388 2413 6,933 1,455 8,388 2414 6,933 1,455 8,388 2415 6,933 1,455 8,388 2416 6,933 1,455 8,388 2417 6,933 1,455 8,388 2418 6,933 1,455 8,388 2419 6,933 1,455 8,388 2420 6,933 1,455 8,388 2421 6,933 1,455 8,388 2422 6,933 1,455 8,388 2423 6,933 1,455 8,388 2424 6,933 1,455 8,388 2425 6,933 1,455 8,388 2426 6,933 1,455 8,388 2427 6,933 1,455 8,388 2428 6,933 1,455 8,388 2429 6,933 1,455 8,388 2430 6,933 1,455 8,388 2431 6,933 1,455 8,388 2432 6,933 1,455 8,388 2433 6,933 1,455 8,388 2434 6,933 1,455 8,388 2435 6,933 1,455 8,388 2436 6,933 1,455 8,388 2437 6,933 1,455 8,388 2438 6,933 1,455 8,388 2439 6,933 1,455 8,388 2440 6,933 1,455 8,388 2441 6,933 1,455 8,388 2442 6,933 1,455 8,388 2443 6,933 1,455 8,388 2444 6,933 1,455 8,388 2445 6,933 1,455 8,388 2446 6,933 1,455 8,388 2447 6,933 1,455 8,388 2448 6,933 1,455 8,388 2449 6,933 1,455 8,388 2450 6,933 1,455 8,388 2451 6,933 1,455 8,388 2452 6,933 1,455 8,388 2453 6,933 1,455 8,388 2454 6,933 1,455 8,388 2455 6,933 1,455 8,388 2456 6,933 1,455 8,388 2457 6,933 1,455 8,388 2458 6,933 1,455 8,388 2459 6,933 1,455 8,388 2460 6,933 1,455 8,388 2461 6,933 1,455 8,388 2462 6,933 1,455 8,388 2463 6,933 1,455 8,388 2464 6,933 1,455 8,388 2465 6,933 1,455 8,388 2466 6,933 1,455 8,388 2467 6,933 1,455 8,388 2468 6,933 1,455 8,388 2469 6,933 1,455 8,388 2470 6,933 1,455 8,388 2471 6,933 1,455 8,388 2472 6,933 1,455 8,388 2473 6,933 1,455 8,388 2474 6,933 1,455 8,388 2475 6,933 1,455 8,388 2476 6,933 1,455 8,388 2477 6,933 1,455 8,388 2478 6,933 1,455 8,388 2479 6,933 1,455 8,388 2480 6,933 1,455 8,388 2481 6,933 1,455 8,388 2482 6,933 1,455 8,388 2483 6,933 1,455 8,388 2484 6,933 1,455 8,388 2485 6,933 1,455 8,388 2486 6,933 1,455 8,388 2487 6,933 1,455 8,388 2488 6,933 1,455 8,388 2489 6,933 1,455 8,388 2490 6,933 1,455 8,388 2491 6,933 1,455 8,388 2492 6,933 1,455 8,388 2493 6,933 1,455 8,388 2494 6,933 1,455 8,388 2495 6,933 1,455 8,388 2496 6,933 1,455 8,388 2497 6,933 1,455 8,388 2498 6,933

ofunitsWeighted average grant date fair valueOutstanding balance, June 30, 20232,118,558\$0.57Â Granted1,106,850\$1.78Â Forfeited(1,853,737)\$0.57Â Vestedâ€“\$â€“Â As of June30, 2024,371,671\$1.55Â The total unrecognized compensation cost related to profits interests units outstanding as of June30, 2024 was \$3.9 million, comprised (i) \$1.8 million related to time-based unit awards expected to be recognized over a weighted-average period of 2.8 years and (ii) \$2.1 million related to performance-based unit awards, which will be recorded when it is probable that the performance-based criteria will be met.2021 Omnibus Incentive PlanIn March 2021, the Compensation Committee of the Board of Directors approved the InnovAge Holding Corp. 2021 Omnibus Incentive Plan (â€œ2021 Omnibus Incentive Planâ€), pursuant to which various stock-based awards may be granted to employees, directors, consultants, and advisers. The total number of shares of the Companyâ€™s common stock authorized under the 2021 Omnibus Incentive Plan is 14,700,000. The Company has issued time-based restricted stock units under this plan to its employees which generally(i) vested on March 4, 2023, the second anniversary of the grant date, or (ii) vest over a three-year period with one-third vesting on each anniversary of the date of grant. Certain other vesting periods have also been used. The grant date fair value of restricted stock units with time-based vesting is based on the closing market price of our common stock on the date of grant. Certain other awards, including units and stock options under this plan vest upon achieving specific share price performance criteria and are determined to have performance-based vesting conditions. The Company has also issued time-based vesting stock options under this plan to its employees which generally vest in equal parts over a three-year period.89Restricted Stock UnitsA summary of time-based vesting restricted stock units activity for the year ended June30, 2024, was as follows:Restricted stock units - time basedNumber of awardsWeighted average grant-date fair value per shareOutstanding balance, June 30, 20231,873,794\$10.10Â Forfeited(143,935)\$5.49Â Vested(720,326)\$5.25Â Granted1,854,786\$4.84Â Outstanding balance, June 30, 2024,864,319\$8.15Â The total unrecognized compensation cost related to time-based restricted stock units outstanding as of June30, 2024, was \$11.3 million and is expected to be recognized over a weighted-average period of 2.0 years.A summary of performance-based vesting restricted stock units activity for the year ended June30, 2024, was as follows:Restricted stock units - performance basedNumber of awardsWeighted average grant-date fair value per shareOutstanding balance, June 30, 2023258,767\$5.18Â Forfeitedâ€“\$â€“Â Vestedâ€“\$â€“Â Grantedâ€“\$â€“Â Outstanding balance, June 30, 2024258,767\$5.18Â The total unrecognized compensation cost related to performance-based vesting restricted stock units outstanding as of June30, 2024, was \$0.4 million and is expected to be recognized over a weighted-average period of 1.5 years. Nonqualified Stock OptionsA summary of time-based vesting stock option activity for the year ended June30, 2024, was as follows:Stock options - time basedNumber of awardsWeighted average grant-date fair value per shareOutstanding balance, June 30, 2023716,661\$1.43Â Grantedâ€“\$â€“Â Forfeited(108,108)\$0.31Â Exercised(54,054)\$0.19Â Expiredâ€“\$â€“Â Outstanding balance, June 30, 2024554,499\$1.77Â Exercisable balance, June 30, 2024346,560\$0.17Â The total unrecognized compensation costs related to time-based vesting stock options outstanding as of June30, 2024, was \$0.09 million and is expected to be recognized over a weighted-average period of 1.4 years.90The fair value of the time-based stock options granted during the year ended June 30, 2023, was based upon the Black-Scholes option pricing model using the assumptions in the following table:2023Expected volatility34.5Â %Weighted-average expected life (years) - time vesting units2.9Interest rate1.56Â %Dividend yield0Â %Weighted-average fair values\$0.80Â Fair value of underlying stocks\$3.70Â A summary of performance-based vesting stock option activity for the year ended June30, 2024, was as follows:Stock options - performance basedNumber of awardsWeighted average grant-date fair value per shareOutstanding balance, June 30, 2023776,299\$3.08Â Grantedâ€“\$â€“Â Forfeitedâ€“\$â€“Â Vestedâ€“\$â€“Â Outstanding balance, June 30, 2024776,299\$3.08Â The total unrecognized compensation cost related to performance-based vesting stock options outstanding as of June30, 2024, was \$0.8 million and is expected to be recognized over a weighted-average period of 1.6 years. Note 11: AcquisitionsOn December 1, 2023, the Company acquired all of the issued and outstanding membership interests of two California-based PACE programs, ConcertoCare PACE of Bakersfield, LLC and ConcertoHealth PACE of Los Angeles, LLC (collectively “Concerto”), from Perfect Health, Inc. d/b/a ConcertoCare, a tech-enabled, value-based provider of at-home, comprehensive care for seniors and other adults with unmet health and social needs, for \$23.9 million. We believe the Concerto acquisition complements our California PACE centers. The acquisition was funded through cash on hand. Results of operations from the acquired centers are included in our consolidated statements of operations for the year ended June30, 2024 beginning with the date of acquisition and were not significant to our results. We incurred costs related to the acquisition of approximately \$0.1 million during the year ended June30, 2024. Acquisition related costs were expensed as incurred and have been recorded in corporate, general and administrative expenses in our consolidated statements of operations.The Concerto acquisition was accounted for using the purchase method of accounting. The purchase price has been preliminarily allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. The fair values of assets acquired and liabilities assumed may change as the valuation of intangible assets, working capital adjustments, and overall purchase price allocation are being finalized. Goodwill represents the excess of the purchase price over the fair value of net assets acquired. Goodwill recognized represents the 91estimated future economic benefits arising from expected growth opportunities for the Company and is not deductible for income tax purposes. The following table presents a preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:Preliminary allocationMeasurement period adjustmentsAdjusted allocationin thousandsCash Consideration\$23,916Â \$â€“Â \$23,916Â Total Consideration\$23,916Â \$â€“Â \$23,916Â Accounts receivable, net\$563Â \$(124)\$439Â Prepaid expenses\$330Â 739Â 1,069Â Property and equipment, net7,969Â â€“Â 7,969Â Operating lease assets\$6,892Â 923Â 7,815Â Goodwill17,348Â 1,616Â 15,732Â Deposits and other\$343Â â€“Â 343Â Accounts payable and accrued expenses(353)78Â (275)Reported and estimated claims(111)â€“Â (111)Operating lease obligations(8,941)â€“Â (8,941)Finance lease obligations(124)â€“Â (124)Fair value of assets and liabilities\$23,916Â \$â€“Â \$23,916Â As of June30, 2024, we recognized a measurement period adjustment for lease incentives related to tenant improvements. The adjustment resulted in an increase of \$0.7 million to prepaid expenses and \$0.9 million to operating lease assets, a decrease of \$0.1 million to accounts receivable and \$0.1 million to accounts payable and accrued expenses, and a corresponding decrease of \$1.6 million to goodwill. Note 12:Â Â Â Â Â Income TaxesThe Companyâ€™s effective income tax rate for the years ended June30, 2024 and 2023 was (6.4)% and 14.3%, respectively, which differed from the amount computed by applying the applicable U.S. federal statutory corporate income tax rate of 21% in each period as a result of the following factors:Year ended June 30,20242023in thousandsStatutory rate\$(4,581)\$ (10,667)IRC Section 162(m) limitation (A)504Â 588Â Change in valuation allowance\$6,543Â 4,297Â Permanent adjustments\$614Â 457Â Prior year true-up and other(349)157Â Income from entities not subject to taxation404Â 605Â State tax 1,733(2,678)Provision (benefit) for income taxes\$1,402Â \$(7,241) (a)Reflects the permanent addback for the Section 162(m) limitation, which limits the deduction of compensation for the five highest paid officers to \$1.0 million per officer. 92Provision (benefit) for income taxes consisted of the following for the years ended June30, 2024 and 2023:Year ended June 30,20242023in thousandsCurrent:Federal\$â€“Â \$3,709Â State178Â 575Â Total current tax expense178Â 4,284Â Deferred:Federal445Â (10,263)State779Â (1,262)Total deferred tax expense1,224Â (11,525)Total provision (benefit) for income taxes\$1,402Â \$(7,241)The significant components of deferred tax assets and liabilities were as follows for the years ended June30, 2024 and 2023:Year ended June 30,20242023in thousandsDeferred tax assets:Amortization\$573Â \$629Â Federal net operating losses22,873Â 17,147Â State net operating losses8,053Â 5,701Â Provision for uncollectible accounts1,755Â 1,114Â Accrued vacation469Â 835Â Reported and estimated claims1,505Â 1,164Â Stock-based compensation511Â 449Â Accrued bonuses1,180Â 582Â Interest Expense1,943Â 791Â Lease liability9,260Â 6,784Â Total deferred tax assets48,122Â 35,196Â Valuation allowance(15,948)(8,347)Deferred tax assets, net of valuation allowance32,174Â 26,849Â Deferred tax liabilities:Goodwill(9,207)(6,697)Depreciation(16,288)(13,137)Equity investment(4,696)(5,019)Prepaid expenses(705)(1,792)ROU asset(8,684)(6,436)Other(54)(4)Total deferred tax liabilities(39,634)(33,085)Net deferred tax liability\$(7,460)\$(6,236)CarryforwardsThe Company had state net operating loss carryforwards of \$185.8 million and \$117.9 million at June30, 2024 and 2023, respectively, which will begin to expire in 2037 if not utilized. Included in this is a city net operating loss which will 93begin to expire in 2025 if not utilized. Additionally, the Company has federal net operating loss carryforwards of \$108.9 million and \$81.7 million as of June30, 2024 and 2023, respectively which do not expire.Valuation AllowanceThe Company has provided \$15.9 million and \$8.3 million at June30, 2024 and June30, 2023, respectively, as a valuation allowance against its deferred tax assets for federal and state net operating losses and state 163(j) interest expense limitations where there is not sufficient positive evidence to substantiate that these deferred tax assets will be realized at a more-likely-than-not level of assurance.OtherThe Company had no uncertain tax positions at June30, 2024 and 2023.The Company files income tax returns as a consolidated group, excluding SH1, InnovAge Sacramento, and InnovAge Orlando, in the U.S. federal jurisdiction and various states and is subject to examination by taxing authorities in all of those jurisdictions. From time to time, the Companyâ€™s tax returns are reviewed or audited by U.S. federal and various U.S. state-taxing authorities.The Company believes that adjustments, if any, resulting from these reviews or audits would not be material, individually or in the aggregate, to the Companyâ€™s consolidated financial position, results of operations, or liquidity. The Company is subject to income tax examinations by U.S. federal and state jurisdictions for the period ended June 30, 2021 and forward. The Company is subject to income tax examinations by California, Colorado and New Mexico state jurisdictions for the period ended June 30, 2020 and forward.Note 13:Â Â Â Â Â Related PartiesPWD VIE. Pursuant to the PWD Amended and Restated Agreement of Limited Partnership, CCH helped fund operating deficits and shortfalls of PWD in the form of a loan (the “PWD Loan”). The PWD Loan did not accrue interest. Additionally, CCH was paid an administration fee of \$35,000 per year. At June 30, 2023, \$0.7 million was recorded in Deposits and other related to the PWD Loan. On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD’s property, including the Senior Housing unit.On May 2, 2024, PWD closed on the sale of its Senior Housing property for \$9.5 million. Upon completion of the sale, PWD ceased providing senior housing services and was dissolved. Following the dissolution, the remaining proceeds from the sale were distributed in accordance with the partnership agreement and as otherwise agreed by the partners. The Company received net proceeds of \$4.8Â million in connection with the dissolution.Note 14:Â Â Â Â Â Segment ReportingThe Company applies ASC Topic 280, “Segment Reporting,” which establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about operations, major customers and the geographies in which the entity holds material assets and reports revenue. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the Companyâ€™s chief executive officer, who is the chief operating decision maker (â€œCODMâ€), and for which discrete financial information is available. The Company has determined that it has three operating segments, two of which are related to the Companyâ€™s PACE offering. The PACE-related operating segments are based on two geographic divisions, which are East and West. Due to the similar economic characteristics, nature of services, and customers, we have aggregated our East and West operating segments into one reportable segment for PACE. The Companyâ€™s remaining operating segment primarily relates to Senior Housing, which is an immaterial operating segment, and shown below as “Other.” Along with certain corporate unallocated expenses.As of June30, 2024, the Company served approximately 7,020 PACE participants, making it the largest PACE provider in the U.S. based upon participants served, and operated 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania and Virginia. PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, in a community-based service model. InnovAge provides all needed healthcare services through an all-inclusive, coordinated model of care and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, VA and private pay sources. Additionally, under the Medicare Prescription Drug Plan, CMS shares part of the risk for providing prescription medication to the Companyâ€™s participants.94The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The Company does not review assets by segment and therefore assets by segment are not disclosed below. For the periods presented, all of the Companyâ€™s long-lived assets were located in the United States and all revenue was earned in the United States.The CODM uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. Center-level Contribution Margin is defined as total segment revenues less external provider costs and cost of care (excluding depreciation and amortization). The Company allocates corporate level expenses to its segments with a majority of the allocation going to the PACE segment.The following table summarizes the operating results regularly provided to the CODM by segment for the years ended June 30, 2024 and 2023:June 30, 2024June 30, 2023in thousandsPACEAll other(1)TotalsPACEAll other(1)TotalsCapitalization revenues\$762,570Â \$â€“Â \$762,570Â \$686,836Â \$â€“Â \$686,836Â Other service revenue\$310Â 975Â 1,285Â 347Â 904Â 1,251Â Total revenues\$762,880Â 975Â 763,855Â 687,183Â 904Â 688,087Â External provider costs\$403,010Â â€“Â 403,010Â 374,528Â â€“Â 374,528Â Cost of care, excluding depreciation and amortization228,203Â 578,228,781Â 211,707Â 564Â 212,717Â Center-Level Contribution Margin\$131,667Â 397Â 132,064Â 101,948Â 340Â 101,288Â Overhead costs(2)136,284Â 10Â 136,294Â 135,264Â â€“Â 135,264Â Depreciation and amortization18,477Â 473Â 18,950Â 14,959Â 460Â 15,419Â Interest expense, net\$3,845Â 178Â 4,023Â 1,342Â 180Â 1,522Â Gain on cost and equity method investments(2,842)â€“Â (2,842)â€“Â â€“Â 0Â Other income(2,542)â€“Â (2,542)(124)â€“Â (124)Loss Before Income Taxes\$(21,555)\$(264)\$(21,819)\$(50,493)\$(300)\$(50,793) (1)Center-level Contribution Margin from a segment below the quantitative thresholds is attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.(2)Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items. Note 15:Â Â Â Â Â Earnings per ShareBasic earnings (loss) per share (â€œEPSâ€) is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options and other equity awards, using the treasury stock method and the average market price of the Companyâ€™s common stock during the applicable period. When a loss from continuing operations exists, all dilutive securities and potentially dilutive securities are anti-dilutive and are therefore excluded from the computation of diluted earnings per share. When net income from continuing operations exists, performance-based units, are omitted from the calculation of diluted EPS until it is determined that the performance criteria has been met at the end of the reporting period. As of June30, 2024 and 2023, there were 1,035,066 performance-based awards excluded from the calculation of diluted EPS. 95The following table sets forth the computation of basic and diluted net loss per common share:Year ended June 30,in thousands, except share values20242023Net loss attributable to InnovAge Holding Corp. \$(21,338)\$(40,673)Weighted average common shares outstanding (basic)135,902,214135,593,824EPS (basic)\$(0.16)\$(0.30)Share Repurchase ProgramOn June 14, 2024, our Board authorized up to \$5.0 million of share repurchases. As of June30, 2024, the Company had repurchased approximately 45,023 shares of its common stock for \$0.2 million, of which 36,559 were placed in Treasury. Note 17:Â Â Â Â Â Subsequent EventThe Company has evaluated subsequent events through September10, 2024, the date on which the consolidated financial statements were issued.96Item 9.Â Â Â Â Â CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURENone.Item 9A.Â Â Â Â Â CONTROLS AND PROCEDURSEvaluation of Disclosure Controls and ProceduresUnder the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Actâ€)), as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of June30, 2024.Managementâ€™s Annual Report on Internal Control Over Financial ReportingManagement is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. In order to evaluate the effectiveness of internal control over financial reporting, management has conducted an assessment, including testing, using the criteria set forth by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission in Internal Control â€“ Integrated Framework (2013 Framework). The Companyâ€™s internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act, is a process designed to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Based on our assessment under the criteria established in Internal Control â€“ Integrated Framework (2013 Framework) issued by the COSO, management has concluded that the Company maintained effective internal control over financial reporting as of June30, 2024. This Form 10-K does not include an attestation report on internal controls over financial

reporting of the Company's registered public accounting firm. Additionally, our auditors will not be required to formally opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 until we are no longer an accelerating growth company as defined in the JOBS Act. Changes to our Internal Control over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Item 9B. A. A. OTHER INFORMATION Insider Trading Arrangements and policies On June 13, 2024, Nicole D'Amato, the Company's Chief Legal Officer and Corporate Secretary, adopted a Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the sale of up to 47,574 shares of the Company's common stock through September 16, 2025, or upon the earlier completion of all authorized transactions under the plan. Item 9C. A. A. A. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS Not applicable. 97 PART III Item 10. A. A. A. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE The information required by this item, other than the information regarding the code of ethics and business conduct set forth below, will be set forth in the Proxy Statement relating to our upcoming Annual Meeting of Stockholders (the "Proxy Statement"), which is expected to be filed with the Securities and Exchange Commission (the "SEC") within 120 days of the fiscal year ended June 30, 2024, and is incorporated in herein by reference. Code of Ethics We have adopted a written Code of Ethics that applies to our directors, executive officers and employees, including our Chief Executive Officer, Chief Financial Officer and officers responsible for financial reporting. A current copy of the code is publicly available under "Governance" on the Investor Relations section of our website, <https://investor.innovage.com>. Any substantive amendments to or waivers from the Code of Ethics (to the extent applicable to our Chief Executive Officer, Chief Financial Officer or officers responsible for financial reporting) will be disclosed on this page of the Company's website. Item 11. A. A. A. EXECUTIVE COMPENSATION The information required by this item will be set forth in the Proxy Statement, which is expected to be filed with the SEC no later than 120 days after the end of our fiscal year ended June 30, 2024, and is incorporated herein by reference. Item 12. A. A. A. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The information required by this item will be set forth in the Proxy Statement, which is expected to be filed with the SEC no later than 120 days after the end of our fiscal year ended June 30, 2024, and is incorporated herein by reference. Item 13. A. A. A. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE The information required by this item will be set forth in the Proxy Statement, which is expected to be filed with the SEC no later than 120 days after the end of our fiscal year ended June 30, 2024, and is incorporated herein by reference. Item 14. A. A. A. PRINCIPAL ACCOUNTANT FEES AND SERVICES The information required by this item will be set forth in the Proxy Statement, which is expected to be filed with the SEC no later than 120 days after the end of our fiscal year ended June 30, 2024, and is incorporated herein by reference. 98 PART IV Item 15. A. A. A. EXHIBITS, FINANCIAL STATEMENT SCHEDULES The following documents are filed as part of this Annual Report: (a) (1) FINANCIAL STATEMENTS The financial statements required under this item begin on page 69 of this Annual Report. (a) (2) FINANCIAL STATEMENT SCHEDULES All schedules are omitted because the required information is either inapplicable or presented within the consolidated financial statements or related notes. (a) (3) EXHIBITS Exhibit Index Exhibits not filed herewith are incorporated by reference to exhibits previously filed with the SEC, as reflected in the table below. Exhibit No. Description 3.1 Second Amended and Restated Certificate of Incorporation of InnovAge Holding Corp., filed March 3, 2021 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on March 8, 2021). 3.2 Amended and Restated Bylaws of InnovAge Holding Corp., effective March 3, 2021 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed with the SEC on March 8, 2021). 4.1 Description of Securities (incorporated by reference to Exhibit 4.1 to the Company's Annual Report on Form 10-K filed with the SEC on September 22, 2021). 4.2 Registration Rights Agreement, dated as of March 8, 2021, by and among the Company and the other signatories party thereto (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on March 8, 2021). 10.1 Director Nomination Agreement, dated as of March 8, 2021, by and among the Company and the other signatories party thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on March 8, 2021). 10.2 Credit Agreement, dated as of March 8, 2021, by and among Total Community Options, Inc., the Borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on March 12, 2021). 10.3 Amendment No. 1 to the Credit Agreement, dated as of June 14, 2023, among TCO Intermediate Holdings, Inc., Total Community Options, Inc., each subsidiary loan party thereto, and JPMorgan Chase Bank, N.A., as administrative agent and as collateral agent (incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K filed with the SEC on September 12, 2023). 10.4 Form of Director and Officer Indemnification Agreement between the Company and each of its directors and executive officers (incorporated by reference to Exhibit 10.2 to the Company's Registration Statement on Form S-1 filed with the SEC on February 8, 2021). 10.5 Employment Agreement, effective as of December 1, 2021, by and between InnovAge Holding Corp. and Patrick Blair (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on November 12, 2021). 10.6 Class B Unit Award Agreement, effective August 30, 2023, by and between TCO Group Holdings, L.P. and Patrick Blair (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on September 1, 2023). 99 10.7 Transition and Separation Agreement, dated as of July 3, 2023, by and between Total Community Options Inc. and Barbara Gutierrez (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the SEC on July 5, 2023). 10.8 Letter Agreement relating to Class B Units, dated as of July 3, 2023, by and between TCO Group Holdings, L.P. and Barbara Gutierrez (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the SEC on July 5, 2023). 10.9 Employment Agreement, dated as of July 3, 2023, by and between Total Community Options, Inc. and Benjamin C. Adams (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on July 5, 2023). 10.10 Class B Unit Award Agreement, effective as of July 10, 2023, by and between TCO Group Holdings, L.P. and Benjamin C. Adams (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on July 5, 2023). 10.11 Employment Agreement, dated as of November 30, 2021, by and between Nicole D'Amato and Total Community Options, Inc. (incorporated by reference to Exhibit 10.6 to the Company's Annual Report on Form 10-K filed with the SEC on September 13, 2022). 10.12 Class B Unit Award Agreement, dated as of December 18, 2023, by and between TCO Group Holdings, L.P. and Nicole D'Amato (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on December 19, 2023). 10.13 Employment Agreement, dated February 28, 2023, by and between InnovAge Holding Corp. and Christine Bent (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on February 28, 2023). 10.14 Employment Agreement, dated as of August 15, 2022, by and between Richard Feifer and Total Community Options, Inc. (incorporated by reference to Exhibit 10.9 to the Company's Annual Report on Form 10-K filed with the SEC on September 13, 2022). 10.15 InnovAge Holding Corp. 2021 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Registration Statement on Form S-8 filed with the SEC on March 5, 2021). 10.16 TCO Group Holdings, Inc. 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company's Registration Statement on Form S-1 filed with the SEC on February 8, 2021). 10.17 TCO Group Holdings, L.P. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.20 to the Company's Annual Report on Form 10-K filed with the SEC on September 12, 2023). 10.18 Form of Stock Option Grant Notice and Agreement (incorporated by reference to Exhibit 10.9 to the Company's Registration Statement on Form S-1/A filed with the SEC on February 24, 2021). 10.19 Form of Restricted Stock Unit Grant Notice and Agreement 10.20 Form of Non-Employee Director Restricted Stock Unit Grant Notice and Agreement 21 Subsidiaries of InnovAge Holding Corp. 23 Consent of Deloitte & Touche LLP 24 Powers of Attorney (included on signature page) 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 Certification of Chief Financial Officer Pursuant to Section 306 of the Sarbanes-Oxley Act of 2002 32.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 97* Clawback Policy 101.INS* Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) 100 101. SCH* Inline XBRL Taxonomy Extension Schema Document 101. CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document 101. DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document 101. LAB* Inline XBRL Taxonomy Extension Label Linkbase Document 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) A. A. A. Management contract or compensatory plan or arrangement* A. A. A. Filed herewith A. A. A. Furnished (and not filed) herewith pursuant to Item 601(b)(32)(ii) of the SEC's Regulation S-K Item 16. A. A. A. FORM 10-K SUMMARY None 101 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 10, 2024 INNOVAGE HOLDING CORP. By: /s/ Benjamin C. Adams Name: Benjamin C. Adams Title: Chief Financial Officer Power of Attorney KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Patrick Blair, Benjamin C. Adams and Nicole D'Amato, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with any and all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated as of September 10, 2024. Signature Title/s Patrick Blair President and Chief Executive Officer (principal executive officer) Patrick Blair/s Benjamin C. Adams Chief Financial Officer (principal financial officer and principal accounting officer) Benjamin C. Adams/s John Ellis Bush Director John Ellis Bush/s James Carlson Director, Chair of the Board James Carlson/s Andrew Cavanna Director Andrew Cavanna/s Patricia Fontneau Director Patricia Fontneau/s Edward Kennedy, Jr. Director Edward Kennedy, Jr./s Thomas Scully Director Thomas Scully/s Teresa Sparks Director Teresa Sparks/s Marilyn Tavenner Director Marilyn Tavenner/s Richard Zoretic Director Richard Zoretic EX-10.19 2 ex1019-revised form of restr.htm EX-10.19 Document INNOVAGE HOLDING CORP. RESTRICTED STOCK UNIT NOTICE (2021 OMNIBUS INCENTIVE PLAN) InnovAge Holding Corp. (the "Company"), pursuant to its 2021 Omnibus Incentive Plan (the "Plan"), hereby grants to Participant an Award of Restricted Stock Units for the number of shares of Stock set forth below (the "Award"). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Notice (this "Grant Notice") and in the RSU Agreement (attached hereto as Attachment I) and the Plan, both of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein but defined in the Plan or the RSU Agreement will have the same meaning as in the Plan or the RSU Agreement. If there is any conflict between the terms in this Grant Notice and the Plan, the terms of the Plan will control. Name of Participant: Date of Grant: Vesting Commencement Date: Number of Shares of Stock Subject to the Award: Vesting Schedule: A. A. A. [Time or performance vesting criteria to be inserted]. Issuance Schedule: A. A. A. Subject to any adjustment as provided in Section 10(a) of the Plan, one share of Stock will be issued for each Restricted Stock Unit that vests, with the time of issuance set forth in Section 6 of the RSU Agreement. Additional Terms/Acknowledgements: Participant acknowledges receipt of, and understands and agrees to, this Grant Notice, the RSU Agreement and the Plan. Participant acknowledges and agrees that this Grant Notice and the RSU Agreement may not be modified, amended or revised except as provided in the Plan. Participant further acknowledges that, as of the Date of Grant, this Grant Notice, the RSU Agreement and the Plan set forth the entire agreement and understanding between Participant and the Company regarding the acquisition of Stock pursuant to the Award specified above and supersede all prior oral and written agreements, promises and/or representations on that subject, with the exception of (i) Awards previously granted and delivered to the Participant, and (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law. By accepting this Award, Participant consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. InnovAge Holding Corp. By: A. A. A. Signature Title: A. A. A. Date: A. A. A. Participant: A. A. A. Signature Date: A. A. A. ATTACHMENTS: RSU Agreement 2 ATTACHMENT INNOVAGE HOLDING CORP. 2021 OMNIBUS INCENTIVE PLAN RSU AGREEMENT Pursuant to the Restricted Stock Unit Grant Notice (the "Grant Notice") and this RSU Agreement (this "Agreement"), InnovAge Holding Corp. (the "Company") has granted you an Award of Restricted Stock Units under its 2021 Omnibus Incentive Plan (the "Plan"), with respect to the number of shares of Stock indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement or in the Grant Notice but defined in the Plan will have the same meaning as in the Plan. If there is any conflict between the terms in this Agreement and the Plan, the terms of the Plan will control. The details of your Award of Restricted Stock Units (this or your "Award"), in addition to those set forth in the Grant Notice and the Plan, are as follows: 1. Grant of the Award. This Award represents the right to be issued on a future date one (1) share of Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 below) as indicated in the Grant Notice. As of the Date of Grant, the Company will credit to a bookkeeping account maintained by or on behalf of the Company for your benefit (the "Account") the number of shares of Stock subject to the Award. This Award was granted in consideration of your services to the Company. 2. Vesting. Subject to the limitations contained herein, your Award will vest as provided in your Grant Notice. Vesting will cease upon your Termination. Upon your Termination, the Restricted Stock Units credited to the Account that were not vested on the date of such Termination will be forfeited at no cost to the Company, and you will have no further right, title or interest in or to such underlying shares of Stock. 3. Number of Shares. The number of shares of Stock subject to your Award may be adjusted from time to time for capitalization adjustments, as provided in the Plan. Any additional Restricted Stock Units, shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Committee, to the same forfeiture restrictions, restrictions on transferability and time and manner of delivery as applicable to the other Restricted Stock Units covered by your Award. Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Stock shall be created pursuant to this Section 3. Any fraction of a share will be rounded down to the nearest whole share. 4. Securities Law Compliance. You may not be issued any shares of Stock under your Award unless the shares of Stock underlying the Restricted Stock Units are then registered under the Securities Act or, if not registered, the Company has determined that such issuance of the shares would be exempt from the registration requirements of the Securities Act. The issuance of shares of Stock must also comply with all other applicable laws and regulations governing the Award and the Company's policies, and you shall not receive such Stock if the Company determines that such receipt would not be in material compliance with such laws, regulations or Company policies, if applicable. 5. Transfer Restrictions. Prior to the time that shares of Stock have been delivered to you, you may not transfer, pledge, sell or otherwise dispose of this Award or the shares issuable in respect of your Award, except that, upon receiving written permission from the Committee or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company, designate a third party who, on your death, will thereafter be entitled to receive the shares issuable in respect of your Award, and in the absence of such a designation, your executor or administrator of your estate will be entitled to receive any Stock or other consideration that vested but was not issued before your death. For example, you may not use shares that may be issued in respect of your Restricted Stock Units as security for a loan. The restrictions on transfer set forth herein will lapse upon delivery to you of shares in respect of your vested Restricted Stock Units. 6. Date of Issuance. a. The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulation Section 1.409A-1(b)(4) and will be construed and administered in such a manner. The Company shall issue to you one (1) share of Stock for each Restricted Stock Unit that vests, if any, as soon as practicable following the applicable vesting date(s) (subject to any adjustment under Section 3 above) and in any event within thirty (30) days following the vesting date. b. The form of delivery (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. 7. Dividends. You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from the adjustment provided in Section 10(a) of the Plan. 8. Restrictive Legends. The shares of Stock issued under your Award shall be endorsed with appropriate legends, if applicable, as determined by the Company. 9. Award Not a Service Contract. This Agreement is not an employment or service contract, and nothing in this Agreement will be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment or service. 10. Withholding Obligations. a. On or before the time you receive a distribution of the shares of Stock underlying your Award, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, you hereby authorize any required withholding from the shares of Stock issuable to you and/or otherwise agree to

AAAAAAAAAAAAAAAAAA Signature: _____ Title: _____ AAAAAAAAAAAAAAAAAA Date: _____ (Date: _____)
 ATTACHMENTS: RSU Agreement Attachment INNVOAGE HOLDING CORP. 2021 INNVOAGE INCENTIVE PLANRSU AGREEMENT Pursuant to the Restricted Stock Unit Grant Notice (the “Grant Notice”) and this RSU Agreement (this “Agreement”), InnovaAge Holding Corp. (the “Company”) has granted you an Award of Restricted Stock Units under its 2021 Omnibus Incentive Plan (the “Plan”), with respect to the number of shares of Stock indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement or in the Grant Notice but defined in the Plan will have the same meaning as in the Plan. If there is any conflict between the terms in this Agreement and the Plan, the terms of the Plan will control. The details of your Award of Restricted Stock Units (this or your “Award”), in addition to those set forth in the Grant Notice and the Plan, are as follows: 1. Grant of the Award. This Award represents the right to be issued on a future date one (1) share of Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 below) as indicated in the Grant Notice. As of the Date of Grant, the Company will credit to a bookkeeping account maintained by or on behalf of the Company for your benefit (the “Account”) the number of shares of Stock subject to the Award. This Award was granted in consideration of your services to the Company. 2. Vesting. Subject to the limitations contained herein, your Award will vest as provided in your Grant Notice. Vesting will cease upon your Termination. Upon your Termination, the Restricted Stock Units credited to the Account that were not vested on the date of such Termination will be forfeited at no cost to the Company, and you will have no further right, title or interest in or to such underlying shares of Stock. 3. Number of Shares. The number of shares of Stock subject to your Award may be adjusted from time to time for capitalization adjustments, as provided in the Plan. Any additional Restricted Stock Units, shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Committee, to the same forfeiture restrictions, restrictions on transferability and time and manner of delivery as applicable to the other Restricted Stock Units covered by your Award. Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Stock shall be created pursuant to this Section 3. Any fraction of a share will be rounded down to the nearest whole share. 4. Securities Law Compliance. You may not be issued any shares of Stock under your Award unless the shares of Stock underlying the Restricted Stock Units are then registered under the Securities Act or, if not registered, the Company has determined that such issuance of the shares would be exempt from the registration requirements of the Securities Act. The issuance of shares of Stock must also comply with all other applicable laws and regulations governing the Award and the Company’s policies, and you shall not receive such Stock if the Company determines that such receipt would not be in material compliance with such laws, regulations or Company policies, if applicable. 5. Transfer Restrictions. Prior to the time that shares of Stock have been delivered to you, you may not transfer, pledge, sell or otherwise dispose of this Award or the shares issuable in respect of your Award, except that, upon receiving written permission from the Committee or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company, designate a third party who, on your death, will thereafter be entitled to receive the shares issuable in respect of your Award, and in the absence of such a designation, your executor or administrator of your estate will be entitled to receive any Stock or other consideration that vested but was not issued before your death. For example, you may not use shares that may be issued in respect of your Restricted Stock Units as security for a loan. The restrictions on transfer set forth herein will lapse upon delivery to you of shares in respect of your vested Restricted Stock Units. 6. Date of Issuance. a. The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulation Section 1.409A-1(b)(4) and will be construed and administered in such a manner. The Company shall issue to you one (1) share of Stock for each Restricted Stock Unit that vests, if any, as soon as practicable following the applicable vesting date(s) (subject to any adjustment under Section 3 above) and in any event within thirty (30) days following the vesting date. b. The form of delivery (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. 7. Dividends. You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from the adjustment provided in Section 10(a) of the Plan. 8. Restrictive Legends. The shares of Stock issued under your Award shall be endorsed with appropriate legends, if applicable, as determined by the Company. 9. Award Not a Service Contract. This Agreement is not a service contract, and nothing in this Agreement will be deemed to create in any way whatsoever any obligation on your part to continue in the service of the Company or an Affiliate, or of the Company or an Affiliate to continue your service. 10. Withholding Obligations. You hereby acknowledge and agree that you are and shall be solely responsible for the payment of all applicable U.S. federal, state, local or non-U.S. tax withholding and other similar charges or fees that may arise in connection with the grant, vesting or settlement of the Restricted Stock Units. Unless such tax withholding obligations are satisfied, the Company shall have no obligation to deliver to you any shares of Stock. 11. Tax Consequences. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its officers, directors, employees or Affiliates, related to tax liabilities arising from your Award or your other compensation. 12. Notices. Any notices provided for in your Award or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this Award, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 13. Unsecured Obligation. Your Award is unfunded, and as a holder of a vested Award, you shall be considered a general, unsecured creditor of the Company with respect to the Company’s obligation, if any, to issue shares or other property pursuant to this Agreement. 14. Governing Plan Document. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan will control. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE. ANY DISPUTE, CONTROVERSY OR CLAIM BETWEEN YOU AND THE COMPANY ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL BE RESOLVED BY ARBITRATION IN ACCORDANCE WITH THE PROVISIONS RELATING TO ARBITRATION SET FORTH IN THE PLAN. 15. Clawback/Recoupment Policy. You hereby acknowledge and agree that your Award (and any compensation paid or shares issued under your Award) and any other compensation received in respect of your services to the Company or any of its Affiliates on or after the date hereof is subject to recoupment in accordance with any clawback policy adopted by the Company pursuant to Rule 10D-1 of the Exchange Act, Nasdaq Listing Rule 5608, or other applicable law, and any other compensation recovery policy adopted by the Company. 16. Other Documents. You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. 17. Voting Rights. You will not have voting or any other rights as a stockholder of the Company with respect to the shares of Stock to be issued pursuant to this Award until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this Award, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. 18. Severability. If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. 19. Data Privacy. You explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of personal data as described in Section 20(g) of the Plan (such Section 20(g) of the Plan is incorporated herein by reference and made a part hereof) by and among, as applicable, the Company, its Affiliates, third-party administrator(s) and other possible recipients for the exclusive purpose of implementing, administering and managing the Plan and Awards and your participation in the Plan. You acknowledge, understand and agree that Data may be transferred to third parties, which will assist the Company with the implementation, administration and management of the Plan. 20. Miscellaneous. a. The rights and obligations of the Company under your Award

will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by, the Company's successors and assigns. You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award. You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award. This Agreement will be subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. All obligations of the Company under the Plan and this Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation or other acquisition of all or substantially all of the business and/or assets of the Company. * * * This RSU Agreement will be deemed to be signed by you upon the signing by you of the Restricted Stock Unit Grant Notice to which it is attached. 6 EX-21 4 ex21-subidiarylistx2024 .htm EX-21 DocumentEntity NameDBASate of IncorporationConcertoCare PACE of Bakersfield, LLCInnovAge California PACE - BakersfieldDelawareConcertoHealth PACE of Los Angeles, LLCInnovAge California PACE - CrenshawDelawareInnovAge California PACE - Inland Empire, LLCDelawareInnovAge California PACE - Los Angeles, LLCDelawareInnovAge California PACE - Sacramento, LLCDelawareInnovAge Florida PACE II, LLCInnovAge Florida PACE - OrlandoDelawareInnovAge Florida PACE, LLCInnovAge Florida PACE - TampaDelawareInnovAge Greater Colorado PACE - Loveland, LLCInnovAge Greater Colorado PACE - LovelandColoradoInnovAge Holding Corp.DelawareInnovAge Investment Holdings, LLCDelawareInnovAge Pennsylvania LIFE, LLCInnovAge Pennsylvania LIFE - AlleghenyInnovAge Pennsylvania LIFE - PennypackInnovAge Pennsylvania LIFE - Henry Ave.InnovAge Pennsylvania LIFE - St Bart'sPennsylvaniaInnovAge Senior Housing - Thornton (Managing Member), LLCColoradoInnovAge Senior Housing Thornton II, LLCColoradoInnovAge Senior Housing, Thornton LLCColoradoInnovAge Virginia PACE - Charlottesville, LLCInnovAge Virginia PACE - Blue RidgeVirginiaInnovAge Virginia PACE - Roanoke Valley, LLCInnovAge Virginia PACE - RoanokeVirginiaInnovAge Virginia PACE II, LLCInnovAge Virginia PACE - RichmondInnovAge Virginia PACE - PeninsulaVirginiaInnovative Care Management, Inc.InnovAge Care ManagementDelawareSenior Life at Home II, LLCColoradoSenior Life at Home, LLCColoradoSeniors! Inc.ColoradoTCO Eastern Holdings, LLCDelawareTCO Intermediate Holdings, Inc.DelawareTCO Midwestern Holdings, LLCDelawareTCO Western Holdings, LLCDelawareTLC Inland, LLCDelawareTotal Community Care, LLCInnovAge New Mexico PACEColoradoTotal Community Options, Inc.InnovAgeColoradoTotal Longterm Care Solutions, LLCInnovAge - LowryColoradoTotal Longterm Care, Inc.InnovAge Colorado PACE - DenverInnovAge Colorado PACE - LakewoodInnovAge Colorado PACE - ThorntonInnovAge Colorado PACE - AuroraInnovAge Colorado PACE - LovelandInnovAge Colorado PACE - PuebloInnovAge California PACE - Inland EmpireColorado EX-23 5 ex23consent.htm EX-23 DocumentCONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-253902 on Form S-8 of our report dated September 10, 2024, relating to the financial statements of InnovAge Holding Corp. appearing in this Annual Report on Form 10-K for the year ended June 30, 2024./s/ DELOITTE & TOUCHE LLPDenver, COSeptember 10, 2024Á Á Á EX-31.1 6 innv-20240630xex311.htm EX-31.1 DocumentEXHIBIT 31.1Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002I, Patrick Blair, certify that:1.I have reviewed this Annual Report on Form 10-K of InnovAge Holding Corp.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: September 10, 2024/s/ Patrick BlairPatrick BlairPresident and Chief Executive Officer EX-31.2 7 innv-20240630xex312.htm EX-31.2 DocumentEXHIBIT 31.2Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002I, Benjamin C. Adams, certify that:1.I have reviewed this Annual Report on Form 10-K of InnovAge Holding Corp.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: September 10, 2024/s/ Benjamin C. AdamsBenjamin C. AdamsChief Financial Officer EX-32.1 8 innv-20240630xex321.htm EX-32.1 DocumentEXHIBIT 32.1Certification of the Chief Executive OfficerPursuant to Rule 18 U.S.C. Section 1350In connection with the Annual Report on Form 10-K of InnovAge Holding Corp. (the "Company") for the year ended June 30, 2024, as filed with the U.S. Securities and Exchange Commission (the "Report"), I, Patrick Blair, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: September 10, 2024/s/ Patrick BlairPatrick BlairPresident and Chief Executive Officer EX-32.2 9 innv-20240630xex322.htm EX-32.2 DocumentEXHIBIT 32.2Certification of the Chief Financial OfficerPursuant to Rule 18 U.S.C. Section 1350In connection with the Annual Report on Form 10-K of InnovAge Holding Corp. (the "Company") for the year ended June 30, 2024, as filed with the U.S. Securities and Exchange Commission (the "Report"), I, Benjamin C. Adams, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: September 10, 2024/s/ Benjamin C. AdamsBenjamin C. AdamsChief Financial Officer EX-97 10 innv-20240630xex97clawbackpolicy.htm EX-97 DocumentPurpose:InnovAge Holding Corp. (the "Company") believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's pay-for-performance compensation philosophy. The Company's Board of Directors (the "Board") has therefore adopted this policy, which provides for the recoupment of certain executive compensation in the event that the Company is required to prepare an accounting restatement of its financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws (this "Policy"). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the rules promulgated thereunder, and the listing standards of the national securities exchange on which the Company's securities are listed.Policy:ADMINISTRATIONThis Policy shall be administered by the Compensation Committee of the Board (the "Compensation Committee"). Any determinations made by the Compensation Committee shall be final and binding on all affected individuals.COVERED EXECUTIVESThis Policy applies to the Company's current and former executive officers (as determined by the Compensation Committee in accordance with Section 10D of the Exchange Act, the rules promulgated thereunder, and the listing standards of the national securities exchange on which the Company's securities are listed) and such other senior executives or employees who may from time to time be deemed subject to this Policy by the Compensation Committee (collectively, the "Covered Executives"). This Policy shall be binding and enforceable against all Covered Executives.RECOUPMENT; ACCOUNTING RESTATEMENTIn the event that the Company is required to prepare an accounting restatement of its financial statements due to the Company's material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement (i) to correct an error in previously issued financial statements that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (each an "Accounting Restatement"), the Compensation Committee will reasonably promptly require reimbursement or forfeiture of the Overpayment (as defined below) received by any Covered Executive (x) after beginning service as a Covered Executive, (y) who served as a Covered Executive at any time during the performance period for the applicable Incentive-Based Compensation (as defined below), and (z) during the three (3) completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement and any transition period (that results from a change in the Company's fiscal year) within or immediately following those three (3) completed fiscal years.INCENTIVE-BASED COMPENSATIONFor purposes of this Policy, "Incentive-Based Compensation" means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure, including, but not limited to:(i)non-equity incentive plan awards that are earned solely or in part by satisfying a financial reporting measure performance goal; (ii) bonuses paid from a bonus pool, where the size of the pool is determined solely or in part by satisfying a financial reporting measure performance goal; (iii) other cash awards based on satisfaction of a financial reporting measure performance goal; (iv) restricted stock, restricted stock units, stock options, stock appreciation rights, and performance share units that are granted or vest solely or in part based on satisfaction of a financial reporting measure performance goal; and (v) proceeds from the sale of shares acquired through an incentive plan that were granted or vested solely or in part based on satisfaction of a financial reporting measure performance goal.Compensation that would not be considered Incentive-Based Compensation includes, but is not limited to: (i) salaries; (ii) bonuses paid solely based on satisfaction of subjective standards, such as demonstrating leadership, and/or completion of a specified employment period; (iii) non-equity incentive plan awards earned solely based on satisfaction of strategic or operational measures; (iv) wholly time-based equity awards; and (v) discretionary bonuses or other compensation that is not paid from a bonus pool that is determined by satisfying a financial reporting measure performance goal.A financial reporting measure is: (i) any measure that is determined and presented in accordance with the accounting principles used in preparing financial statements, or any measure derived wholly or in part from such measure, such as revenues, EBITDA, or net income or (ii) stock price and total shareholder return. Financial reporting measures include, but are not limited to: revenues; net income; operating income; profitability of one or more reportable segments; financial ratios (e.g., accounts receivable turnover and inventory turnover rates); net assets or net asset value per share; earnings before interest, taxes, depreciation and amortization; funds from operations and adjusted funds from operations; liquidity measures (e.g., working capital, operating cash flow); return measures (e.g., return on invested capital, return on assets); earnings measures (e.g., earnings per share); sales per square foot or same store sales, where sales is subject to an accounting restatement; revenue per user, or average revenue per user, where revenue is subject to an accounting restatement; cost per employee, where cost is subject to an accounting restatement; any of such financial reporting measures relative to a peer group, where the Company's financial reporting measure is subject to an accounting restatement; and tax basis income.OVERPAYMENT; AMOUNT SUBJECT TO RECOVERYThe amount to be recovered will be the amount of Incentive-Based Compensation received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts, and must be computed without regard to any taxes paid (the "Overpayment"). Incentive-Based Compensation is deemed "received" in the Company's fiscal period during which the financial reporting measure specified in the incentive-based compensation award is attained, even if the vesting, payment or grant of the incentive-based compensation occurs after the end of that period.For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the exchange on which the Company's securities are listed.METHOD OF RECOUPMENTThe Compensation Committee will determine, in its sole discretion, the method or methods for recouping any Overpayment hereunder which may include, without limitation: requiring reimbursement of cash Incentive-Based Compensation previously paid; seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards granted as Incentive-Based Compensation; offsetting any or all of the Overpayment from any compensation otherwise owed by the Company to the Covered Executive; cancelling outstanding vested or unvested equity awards; and/or taking any other remedial or recovery action permitted by law, as determined by the Compensation Committee.LIMITATION ON RECOVERY; NO ADDITIONAL PAYMENTSThe right to recovery will be limited to Overpayments received during the three (3) completed fiscal years prior to the date on which the Company is required to prepare an Accounting Restatement and any transition period (that results from a change in the Company's fiscal year) within or immediately following those three (3) completed fiscal years. In no event shall the Company be required to award Covered Executives an additional payment if the restated or accurate financial results would have resulted in a higher Incentive-Based Compensation payment.NO INDEMNIFICATIONThe Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive-Based Compensation.INTERPRETATIONThe Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and the applicable rules or standards adopted by the Securities and Exchange Commission or any national securities exchange on which the Company's securities are listed.EFFECTIVE DATEThis Policy shall be effective as of the date it is adopted by the Board (the "Effective Date") and shall apply to Incentive-Based Compensation (including Incentive-Based Compensation granted pursuant to arrangements existing prior to the Effective Date). Notwithstanding the foregoing, this Policy shall only apply to Incentive-Based Compensation received (as determined pursuant to this Policy)

on or after the effective date of NASDAQ Listing Rule 5608.AMENDMENT; TERMINATIONThe Board may amend this Policy from time to time in its discretion. The Board may terminate this Policy at any time.OTHER RECOUPMENT RIGHTSThe Board intends that this Policy will be applied to the fullest extent of the law. The Compensation Committee may require that any employment or service agreement, cash-based bonus plan or program, equity award agreement, or similar agreement entered into on or after the adoption of this Policy shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, cash-based bonus plan or program, or similar agreement and any other legal remedies available to the Company.IMPRACTICABILITYThe Compensation Committee shall recover any Overpayment in accordance with this Policy except to the extent that the Compensation Committee determines such recovery would be impracticable because:(A)The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered;(B)Recovery would violate home country law of the Company where that law was adopted prior to November 28, 2022; or(C)Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26U.S.C. 411(a) and regulations thereunder.SUCCESSORSThis Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives. EX-101.SCH 11 innv-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Cost and Equity Method Investments link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Share Repurchase Program link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Cost and Equity Method Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Revenue Recognition - Schedule of Source of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Revenue Recognition - Schedule of Concentration of Net Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Cost and Equity Method Investments - Schedule of Equity Method and Cost Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Cost and Equity Method Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Cost and Equity Method Investments - Schedule of Variable Interest Entity (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Asset (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Goodwill and Intangible Assets - Schedule of Expected Future Annual Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Leases - Schedule of Assets and Liabilities Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Leases - Schedule of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Leases - Schedule of Weighted Average Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Leases - Schedule of Future Maturities of Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Leases - Schedule of Future Maturities of Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Leases - Schedule of Future Maturities of Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Long-term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Long-term Debt - Schedule of Aggregate Maturities of the Total Debt Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Cash, Cash Equivalents and Marketable Securities by Significant Investment Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Stock-based Compensation - Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Stock-based Compensation - Schedule of Weighted-Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Stock-based Compensation - Schedule of Profits Interests Transactions and Number of Units Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Stock-based Compensation - 2021 Omnibus Incentive Plan and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Stock-based Compensation -Schedule of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Stock-based Compensation - Schedule of Time-based Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Stock-based Compensation - Schedule of Black-Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Stock-based Compensation - Schedule of Performance-based Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Income Taxes - Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Segment Reporting - Schedule of Operating Results by Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Share Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 innv-20240630 .cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 innv-20240630 .def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 innv-20240630 .lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT InnovAge Sacramento InnovAge Sacramento Represents information relating to InnovAge Sacramento. Operating Lease Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Adjustments to reconcile net loss to net cash provided by (used in) operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Interest Expense Deferred Tax Asset, Interest Carryforward Related Parties Related Party Transactions Disclosure [Text Block] Principal payments on long-term debt Repayments of Long-Term Debt Amortization Expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Adventist Health System/West Joint Venture Adventist Health System/West Joint Venture Represents the information pertaining to Adventist Health System/West Joint Venture. Schedule of Profits Interests Transactions and Number of Units Outstanding Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Other income Other income Other Nonoperating Income Cover [Abstract] Cover [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five DECREASE IN CASH, CASH EQUIVALENTS & RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Future Maturities of Lease Payments for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Percentage of additional membership interest Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol ROU asset Deferred Tax Liabilities Rights of Use of Asset Deferred Tax Liabilities Rights of Use of Asset External provider costs External Provider Costs Amount of external provider costs. Non-NEOs Non-NEOs [Member] Goodwill and Intangible Assets Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Accounts receivable, net Increase (Decrease) in Accounts Receivable Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Land Land [Member] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Service, Other Service, Other [Member] 2026 Lease Liability, Payments Due, Year Two Lease Liability, Payments Due, Year Two Component of Lease Cost Lease, Cost [Abstract] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Overhead costs Cost, Overhead Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] Dilutive shares (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Leases [Abstract] Leases [Abstract] Definite-lived intangible assets Finite-Lived Intangible Assets, Gross Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Prior year true-up and other Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] State net operating losses Deferred Tax Assets, Operating Loss Carryforwards, State and Local Prepaid expenses Prepaid Expense, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Finance leases Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Legal settlement, settlement period Legal Settlement, Settlement Period Legal Settlement, Settlement Period Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Potentially anti-dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Percentage of Vesting, Second Anniversary Share-Based Payment Arrangement, Tranche One [Member] Less liability accretion / imputed interest Finance Lease, Liability, Undiscounted Excess Amount Credit Facility [Domain] Credit Facility [Domain] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Goodwill Balance as of beginning of period Balance as of end of period Goodwill Accounts receivable, net of allowance Accounts Receivable, Allowance for Credit Loss Taxes paid related to net settlements of stock-based compensation awards Payment, Tax Withholding, Share-Based Payment Arrangement Share repurchase program, authorized, amount Share Repurchase Program, Authorized, Amount Reported and estimated claims Reported and Estimated Claims, Current Carrying value as of the balance sheet date of the portion of reported and estimated claims due within one year or the operating cycle, if longer. Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Stock options Share-Based Payment Arrangement, Option [Member] Depreciation Depreciation Reported and estimated claims Deferred Tax Assets, Reported and Estimated Claims Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible reported and estimated claims. 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Finance leases Finance Lease, Weighted Average Discount Rate, Percent 2021 Omnibus Incentive Plan 2021 Omnibus Incentive Plan Represents information pertaining to omnibus incentive plan 2021. 2025 Finance Lease, Liability, to be Paid, Year One Award Type [Axis] Award Type [Axis] Dispatch Health Holdings, Inc. Dispatch Health Holdings, Inc. Represents information pertaining to Dispatch Health Holdings, Inc. Net deferred tax liability Deferred Tax Liabilities, Net Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Property, plant and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Exercisable balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Convertible term loan Convertible Debt [Member] Number of reporting units Number of Reporting Units Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-

Based Payment Award [Table] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Intangible Assets, Net (Including Goodwill) [Abstract] Intangible Assets, Net (Including Goodwill) [Abstract] Current portion of operating lease obligations Less: Current lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Nicole Daë™ Amato [Member] Nicole Daë™ Amato Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted average grant-date fair value per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Less accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Cash Cash [Member] Weighted-average number of common shares outstanding - diluted (in shares) Weighted average common shares outstanding (diluted) (in shares) Weighted Average Number of Shares Outstanding, Diluted Loans and leases receivable, related parties Loans and Leases Receivable, Related Parties MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total InnovAge Holding Corp. Equity, Attributable to Parent Total deferred tax assets Deferred Tax Assets, Gross Restricted stock units - performance based Performance-Based Restricted Stock Units Represents the information pertaining to performance based restricted stock units. Schedule of Changes in Goodwill Schedule of Goodwill [Table Text Block] Software Software and Software Development Costs [Member] Deposits and other Deposits and other, net Deposits and Other Assets , Noncurrent The amount of non current portion of deposits and other assets as at the end of the reporting period. Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Equity Method and Cost Method Investments Investment Holdings, Schedule of Investments [Table Text Block] Capitation revenue Capitation revenue Represents information pertaining to capitation revenue. Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Document Fiscal Period Focus Document Fiscal Period Focus Property and equipment purchased under capital leases Property and Equipment Purchased Under Capital Leases Property and equipment purchased under capital leases. Costs incurred related to the acquisition Business Combination, Acquisition Related Costs 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Goodwill expected to be deductible for income tax purposes Business Acquisition, Goodwill, Expected Tax Deductible Amount Assets Assets [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Revolving credit facility fee Line of Credit Facility, Commitment Fee Percentage Schedule of Operating Results by Reportable Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] 2029 Lease Liability, Payments Due, Year Five Lease Liability, Payments Due, Year Five Capitalized interest Accumulated Capitalized Interest Costs Lease liability Deferred Tax Asset, Lease Liability Deferred Tax Asset, Lease Liability Schedule of Expected Future Annual Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Term Loan Facility Senior Loans [Member] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Equity investment Deferred Tax Liabilities, Equity Method Investments Amount of deferred tax liability attributable to taxable temporary differences from equity investment. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Total leased assets Right-of-Use Asset Right-of-Use Asset Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Schedule of Weighted-Average Assumptions and Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Administrative fee per year Related Party Transaction, Amounts of Transaction Total lease expense: Lease, Cost 2021 Credit Agreement 2021 Credit Agreement Represents information pertaining to 2021 credit agreement . Noncurrent Assets Assets, Noncurrent [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Name Outstanding Recovery, Individual Name Revenue Recognition Disaggregation of Revenue [Line Items] Variable lease cost Variable Lease, Cost Goodwill, impairment charges Impairment of goodwill Goodwill, Impairment Loss Fair value of assets and liabilities Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Award Timing Predetermined Award Timing Predetermined [Flag] Cash contributions Proceeds from Contributions from Parent Investment, Name [Axis] Investment, Name [Axis] Net loss per share - diluted (in dollars per share) EPS (diluted) (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] State and Local Jurisdiction State and Local Jurisdiction [Member] Total current tax expense Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Ownership [Axis] Ownership [Axis] Percentage of vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Customer [Axis] Customer [Axis] Measurement period, adjustments accounts receivable, net Measurement period, adjustments accounts receivable, net Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable, Net Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable, Net Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Other Deferred Tax Liabilities, Other Sales and marketing Selling and Marketing Expense Net Loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Provision (Benefit) for Income Taxes Provision (benefit) for income taxes Income Tax Expense (Benefit) Weighted-average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Percentage of obligation for health care costs Percentage of Health Care Costs Incurred Percentage of health care cost incurred. Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] 2027 Lease Liability, Payments Due, Year Three Lease Liability, Payments Due, Year Three Other Other Operating Activities, Cash Flow Statement All Adjustments to Compensation All Adjustments to Compensation [Member] Prepaid expenses Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Other intangible assets, net Other Intangible Assets, Net Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest expense, net Interest expense, net Interest Income (Expense), Nonoperating Time-Based Options Awards Time-Based Options Awards [Member] Time-Based Options Awards Medicare Part D Medicare Part D Represents the information pertaining to Medicare Part D. Related Party Transaction [Axis] Related Party Transaction [Axis] Number of acquisition resulting in goodwill Number of Acquisition Resulting In Goodwill Number of Acquisition Resulting In Goodwill Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Deposits and other Increase (Decrease) in Deposit Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Vesting [Domain] Vesting [Domain] Unvested balance, beginning (in dollars per share) Unvested balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Restatement Determination Date Restatement Determination Date Provision for uncollectible accounts Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Monthly principal and interest payments Debt Instrument, Periodic Payment Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] 2020 Equity Incentive Plan 2020 Equity Incentive Plan Represents the information pertaining to 2020 equity incentive plan. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding balance, beginning (in dollars per share) Outstanding balance, ending (in dollars per share) Outstanding balance, beginning (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease assets Operating lease assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding balance, beginning (in shares) Outstanding balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Measurement period adjustments, fair value of assets and liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Earnings per Share Earnings Per Share [Text Block] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Schedule of Future Maturities of Lease Payments for Finance Leases Finance Lease, Liability, to be Paid, Maturity [Table Text Block] PEO PEO [Member] Name Trading Arrangement, Individual Name Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Entity Public Float Entity Public Float Treasury stock at cost, 36,559 shares as of June 30, 2024 Treasury Stock, Common, Value Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Permanent adjustments Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Percentage of vesting Year 2 Share-Based Payment Arrangement, Tranche Three [Member] Other Income (Expense) Other Nonoperating Income (Expense) [Abstract] Reported and estimated claims Increase (Decrease) in Reported and Estimated Claims The increase (decrease) during the reporting period in the amounts of reported and estimated claims. Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash and Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Maximum exposure to loss of the cost method investments Cost Method Investment, Maximum Exposure to Loss The amount of maximum exposure to loss under the cost method investments. Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Total intangible assets Intangible Assets, Gross (Excluding Goodwill) Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Share repurchase program, number of shares repurchased (in shares) Share Repurchase Program, Number of Shares Repurchased Share Repurchase Program, Number of Shares Repurchased Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Weighted average discount rate Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate Noncurrent Liabilities Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Due to Medicaid and Medicare Due to State and Federal Health Programs Amounts payable to state and federal health programs such as Medicare and Medicaid. Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Entity Ex Transition Period Entity Ex Transition Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Capital Stock Common Stock Common Stock [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Segment Reporting [Abstract] Segment Reporting [Abstract] Tax withholding related to the net share settlements of stock-based compensation awards (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key Property and equipment included in accounts payable Property and Equipment Included in Accounts Payable Intangibles and property and equipment included in accounts payable. Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Share Repurchase Program Equity [Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Orlando Health InnovAge Florida PACE â€” Orlando [Member] InnovAge Florida PACE â€” Orlando Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting Segment Reporting Disclosure [Text Block] Current portion of long-term debt Less current maturities Long-Term Debt, Current Maturities Title Trading Arrangement, Individual Title Consolidated Entities [Axis] Consolidated Entities [Axis] Uncertain tax positions Unrecognized Tax Benefits Variable Interest Entities (VIE) Consolidation, Variable Interest Entity, Policy [Policy Text Block] City Area Code City Area Code Current Liabilities Liabilities, Current [Abstract] Auditor Location Auditor Location Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Purchases of short-term investments Payments to Acquire Short-Term Investments Loss on disposal of assets Gain (Loss) on Disposition of Assets Payments for repurchase of common stock Payments for Repurchase of Common Stock Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Long-term debt, net of debt issuance costs Noncurrent maturities Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] June 2024 Repurchase Program June 2024 Repurchase Program [Member] June 2024 Repurchase Program Weighted average grant date fair value Weighted average grant-date fair value per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Shares acquired (in shares) Shares Acquired The number of shares acquired. Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Retained deficit Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Net loss Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Corporate, general and administrative General and Administrative Expense Deferred income taxes Deferred Income Taxes and Tax Credits Settlement agreement amount subject to court approval Litigation Settlement, Amount Awarded to Other Party 2026 Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total lease liabilities Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Stock options - performance based Performance Shares [Member] Cost and Equity Method Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Measurement period adjustments, accounts payable and accrued expenses Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities, Accounts Payable Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities, Accounts Payable Pooled capitated payment Percentage of pooled Capitated Payment Received Percentage of pooled capitated payment received. 2029 Finance Lease, Liability, to be Paid, Year Five Amendment Flag Amendment Flag Accounts receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Redeemable Noncontrolling Interests (Temporary Equity) Increase (Decrease) in Temporary Equity [Roll Forward] Amortization of leased assets Finance Lease, Right-of-Use Asset, Amortization Subsequent Events [Abstract] Subsequent Events [Abstract] Long-term Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Nondeductible compensation paid Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Paid Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible compensation paid. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Loan amount Debt Instrument, Face Amount Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising expenses Advertising Expense Weighted average remaining lease term: Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Land Land Due to Medicaid and Medicare Increase (Decrease) in Due to State and Federal Health Programs The increase (decrease) during the reporting period in the amounts of due to Medicaid and Medicare. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Finance lease obligations Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Finance Lease Obligation Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Finance Lease Obligation Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Estimated Useful Lives Property, Plant and Equipment, Useful Life Number of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote

[Text Block] Property and equipment, net Total property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Payments for finance lease obligations Finance Lease, Principal Payments Equipment and vehicles Equipment and vehicles Tangible personal property used to produce goods and services and equipment used primarily for road transportation. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Advertising Costs Advertising Cost [Policy Text Block] Income tax receivable Income Taxes Receivable, Current Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Schedule of Assets and Liabilities Related to Leases Schedule of Lease Assets and Liabilities Classification in Balance Sheet [Table Text Block] Schedule of Lease Assets and Liabilities Classification in Balance Sheet Commitments and Contingencies (See Note 9) Commitments and Contingencies Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date Business Business Description and Basis of Presentation [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Long-Term Debt, Maturity, Year One Accrued vacation Deferred Tax Assets, Accrued Vacation Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible accrued vacation. Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Net Loss Attributable to InnovAge Holding Corp. Net loss attributable to InnovAge Holding Corp. Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Less liability accretion / imputed interest Lease Liability Undiscounted Excess Amount Lease Liability Undiscounted Excess Amount Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Lease termination costs Operating Lease, Lease Termination Costs Operating Lease, Lease Termination Costs Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Consolidated Entities [Domain] Consolidated Entities [Domain] Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Federal Current Federal Tax Expense (Benefit) Entity Address, Address Line Two Entity Address, Address Line Two Name Forgone Recovery, Individual Name Operating leases Operating Lease, Weighted Average Remaining Lease Term Investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Personal-Needs Account Personal-needs account Represents information pertaining to cash held for specific purpose. Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Deferred revenue Increase (Decrease) in Deferred Revenue Total Lease Liability, Payments Due [Abstract] Lease Liability, Payments Due Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] Less: net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Maximum exposure amount in VIE Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount 2028 Lease Liability, Payments Due, Year Four Lease Liability, Payments Due, Year Four Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Related Party [Axis] Related and Nonrelated Parties [Axis] Weighted-average number of common shares outstanding - basic (in shares) Weighted average common shares outstanding (basic) (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Total stockholders' equity Beginning, balances Ending, balances Equity, Including Portion Attributable to Noncontrolling Interest Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Property and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Goodwill acquired during the period Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Lease Cost Lease, Cost [Table Text Block] Mutual funds Mutual Fund [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Time-based stock options Time Based Stock Options [Member] Time Based Stock Options Cost of care excluding depreciation and amortization and Corporate, general and administrative Direct Operating Costs and General and Administrative Expense [Member] Direct Operating Costs and General and Administrative Expense Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Measurement period adjustments, goodwill Measurement period adjustments, goodwill Goodwill, Measurement Period Adjustment Equity method investments Equity Method Investments Cost of Goods and Service, Product and Service Benchmark Cost of Goods and Service, Product and Service Benchmark [Member] Pay vs Performance Disclosure [Line Items] Redeemable Noncontrolling Interests (See Note 4) Beginning balance Ending balance Redeemable noncontrolling interest, equity, carrying amount Redeemable Noncontrolling Interest, Equity, Carrying Amount Fair value adjustment for redeemable noncontrolling interests Redeemable Noncontrolling Interest, Fair Value, Carrying Amount Redeemable Noncontrolling Interest, Fair Value, Carrying Amount Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Depreciation and amortization Depreciation, Depletion and Amortization [Member] Depreciation, Depletion and Amortization Time-based restricted stock units (RSUs) Restricted Stock Units (RSUs), Time Based [Member] Restricted Stock Units (RSUs), Time Based Operating lease liabilities Increase (Decrease) in Operating Lease Liability Medicare Medicare Represents information pertaining to Medicare customer. Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Schedule of Intangible Assets Schedule of Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table Text Block] Tabular disclosure of amortizable finite-lived intangible assets, including the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization. excluding goodwill. Leases Lessee, Operating Leases [Text Block] Common stock outstanding (in shares) Beginning, balances (in shares) Ending, balances (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Operating lease cost Operating Lease, Cost Operating lease obligations Total long-term lease liabilities Operating Lease, Liability, Noncurrent Observable price changes Equity Securities, Increase (Decrease) from Observable Price Changes The amount of increase (decrease) from observable price changes in equity securities. Contribution from joint venture partner Contribution From Joint Venture Partner Contribution From Joint Venture Partner Total noncurrent assets Assets, Noncurrent Interest on lease liabilities Finance Lease, Interest Expense Deferred revenue Contract with Customer, Liability, Current Proceeds from sale of real estate Proceeds from Sale of Real Estate Entity Tax Identification Number Entity Tax Identification Number Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Shares repurchased at cost (in shares) Treasury Stock, Shares, Acquired Money market funds Money Market Funds [Member] Number of PACE centers excluding non-consolidating joint ventures Number of Centers Excluding Non-consolidating Joint Ventures Represents information pertaining to number of centers excluding non-consolidating joint ventures. Treasury Stock Treasury Stock, Common [Member] Income tax payable Taxes Payable, Current Redeemable noncontrolling interests Redeemable Noncontrolling Interest, Equity, Fair Value Plan Name [Axis] Plan Name [Axis] Thereafter Finance Lease, Liability, to be Paid, after Year Five Equity Components [Axis] Equity Components [Axis] Total lease payments Finance Lease, Liability, to be Paid Accounts Receivable Accounts Receivable [Policy Text Block] Total expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating lease rentals Operating Lease, Expense Eskaton Eskaton Represents the information pertaining to Eskaton. CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Equity securities, FV-NI, current Equity Securities, FV-NI, Current Current Assets Assets, Current [Abstract] 2025 Lease Liability, Payments Due, Year One Lease Liability, Payments Due, Year One Auditor Information [Abstract] Auditor Information Treasury stock at cost (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Short-term lease cost Short-Term Lease, Cost Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Pending litigation, motion to dismiss resolution, notice period Loss Contingency, Pending Litigation, Motion to Dismiss Resolution, Notice Period Loss Contingency, Pending Litigation, Motion to Dismiss Resolution, Notice Period Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Assets: Assets, Lessee [Abstract] Assets, Lessee Security Exchange Name Security Exchange Name Related Party Transaction [Domain] Related Party Transaction [Domain] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Concerto Concerto [Member] Concerto Number of units Number of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Income from entities not subject to taxation Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount State Current State and Local Tax Expense (Benefit) Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Number of PACE participants Number of Participants Number of participants. Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Professional Liability Claims Professional Liability Claims Policy [Policy Text Block] Disclosure of accounting policy relating to professional liability claims. Common stock issued (in shares) Common Stock, Shares, Issued Income taxes payable Increase (Decrease) in Income Taxes Payable Entity [Domain] Entity [Domain] Risk percentage Concentration Risk, Percentage Loss Before Income Taxes Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Stock-based Compensation Compensation Related Costs, Policy [Policy Text Block] Common stock authorized (in shares) Common Stock, Shares Authorized Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Prepaid expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Entity Voluntary Filers Entity Voluntary Filers Related Party Related Party [Member] Total deferred tax expense Deferred Income Tax Expense (Benefit) Proceeds from sale of short-term investments Proceeds from Sale of Short-Term Investments Accounts receivable, net of allowance \$6,729 â€” JuneÂ 30, 2024 and \$4,161 â€” JuneÂ 30, 2023) Accounts Receivable, after Allowance for Credit Loss, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Impairment charges Asset Impairment Charges Total debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Operating lease assets Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Operating Lease Assets Business Combination, Recognized Identifiable Asset Acquired And Liability Assumed, Operating Lease Assets Thereafter Long-Term Debt, Maturity, after Year Five Restricted cash Restricted Cash, Current Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Measurement period adjustments, prepaid expenses Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses Document Annual Report Document Annual Report Accrued bonuses Deferred Tax Assets, Accrued Bonuses Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible accrued bonuses. 2027 Finance Lease, Liability, to be Paid, Year Three Gain on cost and equity method investments Gain on cost and equity method investments Equity Method Investment, Realized Gain (Loss) on Disposal Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Amortization expense Amortization of Intangible Assets Liabilities Liabilities [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Revenues Revenues [Abstract] Fair value adjustment for redeemable noncontrolling interests Fair Value Adjustment For Redeemable Noncontrolling Interests Fair Value Adjustment For Redeemable Noncontrolling Interests Net loss Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Acquisitions Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less liability accretion / imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Short-term investments Short-Term Investments PEO Name PEO Name Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Stock-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Intangible assets, useful life (in years) Finite-Lived Intangible Asset, Useful Life Additional Paid-in Capital Additional Paid-in Capital [Member] Finance lease obligations Total long-term lease liabilities Finance Lease, Liability, Noncurrent Schedule of Concentration of Net Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restricted stock units - time based Time-Based Restricted Stock Units Represents the information pertaining to time based restricted stock units. 2028 Finance Lease, Liability, to be Paid, Year Four Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Less: Current lease liabilities Lease Liability, Current Lease Liability, Current Membership interest (as a percent) Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest Number of operating segments Number of Operating Segments Deferred tax assets: Components of Deferred Tax Assets [Abstract] Deposits and other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deposits And Other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deposits And Other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deposits And Other Income taxes paid Income Taxes Paid Amortization Deferred Tax Assets, Amortization Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible amortization. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Percentage of vesting Year 1 Share-Based Payment Arrangement, Tranche Two [Member] Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Supplemental Cash Flows Information Supplemental Cash Flow Information [Abstract] Repurchase of equity securities Proceeds from (Repurchase of) Equity Series C Preferred Stock Series C Preferred Stock [Member] Total other income (expense) Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Short-term Investments Short Term Investments, Fair Value Disclosure Short Term Investments, Fair Value Disclosure Auditor Firm ID Auditor Firm ID Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Operating Loss Operating Income (Loss) Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Number of reportable segments Number of Reportable Segments Total liabilities and stockholders' equity Liabilities and Equity Subsequent Event Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Medicaid Medicaid Represents information pertaining to Medicaid customer. Other service revenue Other service revenue Represents information pertaining to other service revenue. 2026 Finance Lease, Liability, to be Paid, Year Two Schedule of Aggregate Maturities of the Total Debt Outstanding Schedule of Maturities of Long-Term Debt [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Tax withholding related to the net share settlements of stock-based compensation awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected life (years) - time vesting units Weighted-average expected life (years) - time vesting units Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions,

Expected Term Product and Service [Axis] Product and Service [Axis] Summary of Significant Accounting Policies Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Stock options - time based Time-based options awards Represents the information pertaining to Time Vesting Awards. Expenses Operating Expenses [Abstract] Number of geographic divisions Number of Geographic Divisions Number of geographic divisions. Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Number of programs acquired Business Acquisition, Number of Programs Acquired Business Acquisition, Number of Programs Acquired Total Consideration Business Combination, Consideration Transferred Less unamortized debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Minimum Minimum [Member] Adoption Date Trading Arrangement Adoption Date Related Party Transactions [Abstract] Related Party Transactions [Abstract] Income tax receivable Increase (Decrease) in Income Taxes Receivable Short-term Investments Short-Term Investments [Policy Text Block] Short-Term Investments Nonconsolidated Entities Variable Interest Entity [Line Items] Provision for uncollectible accounts Accounts Receivable, Credit Loss Expense (Reversal) Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Total debt Outstanding borrowings Long-Term Debt, Gross Exercise Price Award Exercise Price Schedule of Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Arrangement Duration Trading Arrangement Duration Net operating loss carryforwards Operating Loss Carryforwards Leases Lessee, Finance Leases [Text Block] Amortized Cost Marketable Securities, Amortized Cost Marketable Securities, Amortized Cost Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Schedule of assets and liabilities Variable Interest Entity [Table] Domestic Tax Authority Domestic Tax Jurisdiction [Member] Investments Total investments Long-Term Investments Buildings and leasehold improvements Buildings and leasehold improvements Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and additions or improvements to assets held under a lease arrangement. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Total lease liabilities Finance Lease, Liability 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Cost method investments Cost Method Investment Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments. Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Balance as of end of period Intangible Assets, Net (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Operating lease obligations Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease Obligation Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease Obligation Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Other Segments All other Other Operating Segment [Member] Total lease payments Lease Liability, Payments Due Lease Liability, Payments Due Thereafter Lease Liability, Payments Due, After Year Five Lease Liability, Payments Due, After Year Five Related Party [Domain] Related and Nonrelated Parties [Domain] Noncurrent liabilities Liabilities, Noncurrent Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Depreciation and amortization Cost, Depreciation and Amortization Amortization of term of cost to obtain contract Amortization Term of Cost to Obtain Contract Amortization Term of Cost to Obtain Contract Deferred tax liability, net Deferred Income Tax Liabilities, Net Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Maximum interest rate Interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Schedule of Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Interest expense, net Interest Expense [Member] Federal Deferred Federal Income Tax Expense (Benefit) Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Intangible assets, impairment charges Intangible asset impairments Impairment of Intangible Assets, Finite-Lived Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Measure: Measure [Axis] Total long-term lease liabilities Lease Liability, Noncurrent Lease Liability, Noncurrent Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Fair value of underlying stock (in dollars per share) Share Price Entity Emerging Growth Company Entity Emerging Growth Company Percentage of aggregate outstanding principal amount Debt Instrument, Periodic Payment, Principal, Percent Percentage of the required periodic payments applied to principal. 2029 Long-Term Debt, Maturity, Year Five Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Minimum expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Equity Component [Domain] Equity Component [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Controlling membership interest Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest Entity Shell Company Entity Shell Company Reported and estimated claims Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reported and Estimated Claims Amount of reported and estimated claims assumed at the acquisition date. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Variable Interest Entity Schedule of Variable Interest Entities [Table Text Block] Changes in operating assets and liabilities, net of acquisitions Increase (Decrease) in Operating Assets [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Property and equipment gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Private pay and other Private pay and other Represents information pertaining to private pay and other customer. Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Exercisable balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Letters of credit, issued amounts Line Of Credit Facility Issued Amount Issued amounts under letters of credit. 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Fair Value Marketable Securities Weighted-average fair values (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value The estimated weighted average fair value. Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Deferred financing costs amortized Accumulated Amortization, Debt Issuance Costs Total lease liabilities Lease Liability Lease Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four IRC Section 162(m) limitation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Measurement period adjustments, operating lease assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Debt Issuance Costs Debt, Policy [Policy Text Block] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Proceeds from dissolution of equity method investments Proceeds from Sale of Equity Method Investments Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Credit Facility [Axis] Credit Facility [Axis] Cost of care, excluding depreciation and amortization Direct Operating Costs Entity Registrant Name Entity Registrant Name Acquisition of business Acquisition of business Cash Consideration Payments to Acquire Businesses, Gross Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Center-Level Contribution Margin Gross Profit State Deferred State and Local Income Tax Expense (Benefit) Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Stockholdersâ€™ Equity Entity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Schedule of Source of Revenue Disaggregation of Revenue [Table Text Block] Profits interests units Profits Interests Units Represents the information pertaining to profits interests units. Basis of Preparation and Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, \$0.001 par value; 500,000,000 authorized as of JuneÂ 30, 2024 and 2023; 136,152,858 issued and 136,116,299 outstanding as of June 30, 2024 and 135,639,845 issued and outstanding as of JuneÂ 30, 2023. Common Stock, Value, Issued Document Financial Statement Error Correction Flag Document Financial Statement Error Correction [Flag] Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Highest compensation paid, officers Number of Officers, Highest Compensation Paid The number of officers whom highest compensation paid. Impairment loss in investments Cost method investment, impairment losses Cost Method Investment, Impairment Loss Cost Method Investment, Impairment Loss Jctdoc, Inc. Jctdoc, Inc. Represents information pertaining to Jctdoc, Inc. Reported and Estimated Claims Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block] Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] State tax Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Performance-based unit awards Performance Vesting Units Represents the information pertaining to performance vesting units of profit interests. Long-term debt Long-Term Debt, Fiscal Year Maturity [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total deferred tax liabilities Deferred Tax Liabilities, Gross Net loss per share - basic (in dollars per share) EPS (basic) (in dollars per share) Earnings Per Share, Basic Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Federal net operating losses Deferred Tax Assets, Operating Loss Carryforwards, Domestic Ownership [Domain] Ownership [Domain] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Total current liabilities Liabilities, Current Share Repurchase Program [Axis] Share Repurchase Program [Axis] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Percentage of vesting Year 3 Share-Based Payment Arrangement, Tranche Four [Member] Share-Based Payment Arrangement, Tranche Four 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Profits interests granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Contribution from joint venture partner Noncontrolling Interest, Increase from Subsidiary Equity Issuance Schedule of Fair Value of Cash, Cash Equivalents and Marketable Securities by Significant Investment Category Fair Value, Assets Measured on Recurring Basis [Table Text Block] Minimum interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Maximum expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Stock-based Compensation Share-Based Payment Arrangement [Text Block] Schedule of Stock-based Compensation Expense Schedule of Allocated Share Based Compensation Expenses [Table Text Block] Tabular disclosure of allocated share based compensation expenses. Entity Address, City or Town Entity Address, City or Town Goodwill Deferred Tax Liabilities, Goodwill Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Finance Lease Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Series B Preferred Stock Series B Preferred Stock [Member] Revenue Recognition Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Shares repurchased at cost Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Partnership interest (as a percent) Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Current portion of finance lease obligations Less: Current lease liabilities Finance Lease, Liability, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Unvested balance, beginning (in shares) Unvested balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Schedule of Weighted Average Lease Terms and Discount Rates Schedule of Weighted Average Lease Term and Discount Rates of Leases [Table Text Block] Schedule of Weighted Average Lease Term and Discount Rates of Leases Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Depreciation Deferred Tax Liabilities, Depreciation Amount of deferred tax liability attributable to taxable temporary differences from depreciation. 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Number of investments Number of Investments Accounted Under Cost Method The number of investments held by company which are accounted under cost method. Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Schedule of Preliminary Allocation of the Purchase Price Schedule of Business Acquisitions, by Acquisition [Table Text Block] PACE PACE Represents information pertaining to Program of All-inclusive Care for the Elderly Operating Segments. Prepaid expenses and other Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Administrative Fee Per Year Administrative Fee Per Year [Member] Administrative Fee Per Year Retained Earnings (Deficit) Retained Earnings [Member] Amortization of deferred financing costs Amortization of Debt Issuance Costs Pinewood Lodge L L P Pinewood Lodge L L P [Member] Pinewood Lodge L L P Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Restricted stock units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Time-based unit awards Time Vesting Units Represents the information pertaining to time vesting units of profit interests. Executive Category: Executive Category [Axis] Payments to acquire investments Payments to Acquire Investments Schedule of Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EQU-101.PRE 15 invnv-20240630 pre.xml XBL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_0.jpg begin 644 image_0.jpg MB51.1PT*®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

[illegible]

MT,>E03\0,1P=IY_"M:525&2G='!CL%2S##SPU=>[)'Y*.;J.L?#OQ(MU:R7 M.A:W82D;L&.6-@<%64]NQ!X=7XW.:\$\\<_ \$31O[*UOQ TNG-CS+>WC2 2X_ O M[- P]CQ[5^D&K>-\$="U];>74]%T[492!E[NUCE8 BP-5['X<>\$K2Y\R#POHL, MBGAX]/A4C\0M>\L5&HE4E"[_ *C\>EP]B,+.>\$HXN2@W]J.K.S^2D?!GP* 9J MU[X]ZI9ZA? 6DFG>\$U=9);N=2INE!&4B!Y.>F[H* _1FQM4M+>&&-0D42"-\$ P M% & !26T:N15"HIV]H& !Z"K*];? \$8B>(E>1^F9)DF'R6A[.B[N6K;Z_Y" ;&,\$Y[_6D,*GKS]:DHKD/!/%&T8S12T4 ? _9 end XML 21 R1.htm IDEA: XBRL DOCUMENT

Cover - USD (\$) \$ in Millions	12 Months Ended Jun. 30, 2024		Sep. 09, 2024	Dec. 29, 2023
Cover [Abstract]				
Document Type	10-K			
Document Annual Report	true			
Document Period End Date	Jun. 30, 2024			
Current Fiscal Year End Date	--06-30			
Document Transition Report	false			
Entity File Number	001-40159			
Entity Registrant Name	InnovAge Holding Corp			
Entity Incorporation, State or Country Code	DE			
Entity Tax Identification Number	81-0710819			
Entity Address, Address Line One	8950			
Entity Address, Address Line Two	E. Lowry Boulevard			
Entity Address, City or Town	Denver			
Entity Address, State or Province	CO			
Entity Address, Postal Zip Code	80230			
City Area Code	844			
Local Phone Number	803-8745			
Title of 12(b) Security	Common Stock, \$0.001 par value			
Trading Symbol	INNV			
Security Exchange Name	NASDAQ			
Entity Well-known Seasoned Issuer	No			
Entity Voluntary Filers	No			
Entity Current Reporting Status	Yes			
Entity Interactive Data Current	Yes			
Entity Filer Category	Accelerated Filer			
Entity Small Business	true			
Entity Emerging Growth Company	true			
Entity Ex Transition Period	false			
ICFR Auditor Attestation Flag	false			
Document Financial Statement	false			
Error Correction Flag	false			
Entity Shell Company	false			
Entity Public Float				
				\$ 114.6
Entity Common Stock, Shares Outstanding	135,620,541			
Documents Incorporated by Reference	Portions of the registrant's proxy statement for the upcoming Annual Meeting of Stockholders to be filed no later than 120 days after the end of the registrant's fiscal year ended June 30, 2024, are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent described herein.			
Entity Central Index Key	0001834376			
Document Fiscal Year Focus	2024			
Document Fiscal Period Focus	FY			
Amendment Flag	false			
XML 22 R2.htm IDEA: XBRL DOCUMENT				
Audit Information	12 Months Ended Jun. 30, 2024			
Auditor Information [Abstract]				
Auditor Name	Deloitte & Touche LLP			
Auditor Firm ID	34			
Auditor Location	Denver, Colorado			
XML 23 R3.htm IDEA: XBRL DOCUMENT				
Consolidated Balance Sheets - USD (\$) \$ in Thousands		Jun. 30, 2024	Jun. 30, 2023	
Current Assets				
Cash and cash equivalents		\$ 56,946	\$ 127,249	
Short-term investments		45,833	46,213	
Restricted cash		14	16	
Accounts receivable, net of allowance (\$6,729 – June 30, 2024 and \$4,161 – June 30, 2023)		48,106	24,344	
Prepaid expenses		18,919	17,145	
Income tax receivable		3,324	262	
Total current assets		173,142	215,229	
Noncurrent Assets				
Property and equipment, net		193,022	192,188	
Operating lease assets		28,416	21,210	
Investments		2,645	5,493	
Deposits and other		5,949	3,823	
Goodwill		139,949	124,217	
Other intangible assets, net		4,538	5,198	
Total noncurrent assets		374,519	352,129	
Total assets		547,661	567,358	
Current Liabilities				
Accounts payable and accrued expenses		55,459	54,935	
Reported and estimated claims		55,404	42,999	
Due to Medicaid and Medicare		15,197	9,142	
Income tax payable		0	1,212	
Current portion of long-term debt		3,795	3,795	
Current portion of finance lease obligations		4,599	4,722	
Current portion of operating lease obligations		4,145	3,530	
Deferred revenue		0	28,115	
Total current liabilities		138,599	148,450	
Noncurrent Liabilities				
Deferred tax liability, net		7,460	6,236	
Finance lease obligations		12,743	13,114	
Operating lease obligations		26,275	18,828	
Other noncurrent liabilities		1,298	1,086	
Long-term debt, net of debt issuance costs		61,478	64,844	
Total liabilities		247,853	252,558	
Commitments and Contingencies (See Note 9)				
Redeemable Noncontrolling Interests (See Note 4)		22,200	12,708	
Stockholders' Equity				
Common stock, \$0.001 par value; 500,000,000 authorized as of June 30, 2024 and 2023; 136,152,858 issued and 136,116,299 outstanding as of June 30, 2024 and 135,639,845 issued and outstanding as of June 30, 2023.		136	136	

Treasury stock at cost, 36,559 shares as of June 30, 2024	(179)	0
Additional paid-in capital	337,615	332,107
Retained deficit	(68,311)	(35,944)
Total InnovAge Holding Corp.	269,261	296,299
Noncontrolling interests	8,347	5,793
Total stockholders' equity	277,608	302,092
Total liabilities and stockholders' equity	\$ 547,661	\$ 567,358

XML 24 R4.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets	12 Months Ended	
(Parenthetical) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023
\$ in Thousands		

Statement of Financial Position [Abstract]

Accounts receivable, net of allowance	\$ 6,729	\$ 4,161
Common stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Common stock authorized (in shares)	500,000,000	500,000,000
Common stock issued (in shares)	136,152,858	135,639,845
Common stock outstanding (in shares)	136,116,299	135,639,845
Treasury stock at cost (in shares)	36,559	

XML 25 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD (\$)	12 Months Ended	
\$ in Thousands	Jun. 30, 2024	Jun. 30, 2023

Revenues

Total revenues	\$ 763,855	\$ 688,087

Expenses

External provider costs	403,010	374,528
Cost of care, excluding depreciation and amortization	228,781	212,271
Sales and marketing	24,957	19,627
Corporate, general and administrative	111,337	115,637
Depreciation and amortization	18,950	15,419
Total expenses	787,035	737,482
Operating Loss	(23,180)	(49,395)

Other Income (Expense)

Interest expense, net	(4,023)	(1,522)
Gain on cost and equity method investments	2,842	0
Other income	2,542	124
Total other income (expense)	1,361	(1,398)
Loss Before Income Taxes	(21,819)	(50,793)
Provision (Benefit) for Income Taxes	1,402	(7,241)
Net Loss	(23,221)	(43,552)
Less: net loss attributable to noncontrolling interests	(1,883)	(2,879)
Net Loss Attributable to InnovAge Holding Corp.	\$ (21,338)	\$ (40,673)
Weighted-average number of common shares outstanding - basic (in shares)	135,902,214	135,593,824
Weighted-average number of common shares outstanding - diluted (in shares)	135,902,214	135,593,824
Net loss per share - basic (in dollars per share)	\$ (0.16)	\$ (0.30)
Net loss per share - diluted (in dollars per share)	\$ (0.16)	\$ (0.30)

Capitation revenue

Revenues

Total revenues	\$ 762,570	\$ 686,836
Other service revenue		

Revenues

Total revenues	\$ 1,285	\$ 1,251

XML 26 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - USD (\$)	Total	Capital Stock	Additional Paid-in Capital	Retained Earnings (Deficit)	Treasury Stock	Noncontrolling Interests
\$ in Thousands						

Redeemable Noncontrolling Interests (Temporary Equity)

Treasury stock at cost (in shares)					0	
Beginning, balances (in shares) at Jun. 30, 2022		135,532,811				
Beginning, balances at Jun. 30, 2022	\$ 338,466	\$ 136	\$ 327,499	\$ 4,729	\$ 0	\$ 6,102
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Stock-based compensation (in shares)		107,034				
Stock-based compensation	4,608		4,608			
Net loss	\$ (40,982)			(40,673)		(309)
Ending, balances (in shares) at Jun. 30, 2023		135,639,845			0	
Ending, balances at Jun. 30, 2023	\$ 302,092	\$ 136	332,107	(35,944)	\$ 0	5,793
Beginning balance at Jun. 30, 2022	15,278					

Redeemable Noncontrolling Interests (Temporary Equity)

Net loss	(2,570)					
Ending balance at Jun. 30, 2023	12,708					
Redeemable Noncontrolling Interests (Temporary Equity)						
Net loss	(43,552)					
Stock-based compensation (in shares)		800,515				
Stock-based compensation	6,832		6,832			
Tax withholding related to the net share settlements of stock-based compensation awards (in shares)		(287,502)				
Tax withholding related to the net share settlements of stock-based compensation awards	(1,324)		(1,324)			
Contribution from joint venture partner	2,900					2,900
Shares repurchased at cost (in shares)		36,559			36,559	
Shares repurchased at cost	(179)				\$ (179)	
Fair value adjustment for redeemable noncontrolling interests	(11,029)			(11,029)		
Net loss	\$ (21,684)			(21,338)		(346)
Ending, balances (in shares) at Jun. 30, 2024		136,116,299				
Ending, balances at Jun. 30, 2024	\$ 277,608	\$ 136	\$ 337,615	\$ (68,311)	\$ (179)	\$ 8,347

Redeemable Noncontrolling Interests (Temporary Equity)

Fair value adjustment for redeemable noncontrolling interests	11,029					
Net loss	(1,537)					
Ending balance at Jun. 30, 2024	22,200					
Redeemable Noncontrolling Interests (Temporary Equity)						
Net loss	\$ (23,221)					
Treasury stock at cost (in shares)	36,559				36,559	

XML 27 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash	12 Months Ended	

Method Investments” for more information.

Short-term Investments

Short-term investments consist of investments in managed income fund securities managed by major financial institutions. These securities are measured at fair value on a recurring basis with changes in fair value recognized in earnings. The estimated fair value of the short-term investments is valued using quoted market prices in active markets and classified as Level 1 of the fair value hierarchy. Dividend income is reported within other income (expense) in the Company’s consolidated statement of operations. Dividends received are reinvested in fund securities. We may sell these securities at any time for use in current operations. As a result, we classify our short-term investments as current assets on the Company’s consolidated balance sheets.

Restricted Cash

Restricted cash includes cash held for participants who have established a personal-needs account to pay for nonmedical personal expenses, payment of which only occurs upon participant authorization, in the amount of approximately \$0.01 million and \$0.02 million as of June 30, 2024 and 2023, respectively. The Company records a related deposit liability for any participant contributions to these personal-needs accounts in accounts payable and accrued expenses in the consolidated balance sheets.

Accounts Receivable

The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company’s best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts. See additional information in Note 3 “Revenue Recognition.”

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful lives or lease terms, if the assets are being leased.

Property and equipment were comprised of the following as of June 30:

dollars in thousands	Estimated Useful Lives	2024	2023
Land	N/A	\$ 11,970	\$ 11,970
Buildings and leasehold improvements	10 - 40 years	156,064	124,262
Software	3 - 5 years	30,678	26,656
Equipment and vehicles	3 - 7 years	69,495	57,754
Construction in progress	N/A	12,234	42,223
		280,441	262,865
Less accumulated depreciation and amortization		(87,419)	(70,677)
Total property and equipment, net		\$ 193,022	\$ 192,188

Depreciation of \$18.3 million and \$14.8 million was recorded during the fiscal years ended June 30, 2024 and 2023, respectively. Land is not depreciated, and construction in progress is not depreciated until ready for service. Costs of enhancements or modifications that substantially extend the capacity or useful life of an asset are capitalized and depreciated accordingly. Ordinary repairs and maintenance are expensed as incurred.

The costs of acquiring or developing internal-use software, including directly related payroll costs for internal resources, are capitalized. Software maintenance and training costs are expensed in the period incurred.

Interest is capitalized on construction projects, including internal-use software development projects, while in progress. During the fiscal years ended June 30, 2024 and 2023, the Company capitalized interest of approximately \$0.01 million and \$1.0 million, respectively.

When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets, and the resulting gain or loss, if any, is reflected in the consolidated statements of operations. Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. No impairment charges were recorded in the fiscal years ended June 30, 2024 or 2023.

Goodwill and Intangible Assets

Intangible assets primarily consist of customer relationships acquired through business acquisitions. Goodwill represents the excess of consideration paid over the fair value of net assets acquired through business acquisitions. Goodwill is not amortized but is tested for impairment at least annually.

The Company tests goodwill for impairment annually on April 1st or more frequently if triggering events occur or other impairment indicators arise which might impair recoverability. These events or circumstances would include a significant change in the business climate, legal factors, operating performance indicators, competition, sale, disposition of a significant portion of the business, or other factors. Impairment of goodwill is evaluated at the reporting unit level. A reporting unit is defined as an operating segment (i.e. before aggregation or combination), or one level below an operating segment (i.e. a component). A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component. The Company has two reporting units, East and West, for evaluating goodwill impairment.

ASC 350, Intangibles—Goodwill and Other (“ASC 350”), allows entities to first use a qualitative approach to test goodwill for impairment. When the reporting units where the Company performs the quantitative goodwill impairment are tested, the Company compares the fair value of the reporting unit, which the Company primarily determines using an income approach based on the present value of discounted cash flows, to the respective carrying value, which includes goodwill. If the fair value of the reporting unit exceeds its carrying value, the goodwill is not considered impaired. If the carrying value is higher than the fair value, the difference would be recognized as an impairment loss. There were no goodwill impairments recorded during the years ended June 30, 2024 and 2023.

Customer relationships represent the estimated values of customer relationships of acquired businesses and have definite lives. The Company amortizes these intangible assets on a straight-line basis over their ten-year estimated useful life. Intangible assets are reviewed for impairment in conjunction with long-lived assets. There were no intangible asset impairments recorded during the years ended June 30, 2024 and 2023.

Reported and Estimated Claims

Reported and estimated claims consist of unpaid claims reported as of the balance sheet date and estimates of claims incurred on or before June 30 that have not been reported by that date (IBNR). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of healthcare services, historical payment patterns, cost trends, and other factors. These complex estimation methods and the resulting reserves are continually reviewed and updated, and any adjustments deemed necessary to contemplate new or updated information are reflected in current operations.

Debt Issuance Costs

Debt issuance costs are those costs that have been incurred in connection with the issuance of long-term debt and are offset against long-term debt in the consolidated balance sheets. Such costs are being amortized over the term of the underlying debt using the straight-line method, as the difference between that and the effective interest method are immaterial.

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performed the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation. Medicaid and Medicare capitation revenues are based on a per member, per month (“PMPM”) capitation rates under the PACE program. For a discussion of our revenue recognition policies, please see Note 3 “Revenue Recognition.”

Professional Liability Claims

The Company records a liability for medical malpractice claims based on estimated probable losses and costs associated with settling these claims and a receivable to reflect the estimated insurance recoveries, if any. See Note 9 “Commitments and Contingencies.”

Advertising Costs

The Company’s purchased services and contracts expenses include media advertising, tactical advertising, and promotion costs. The creative portion of these activities is expensed as incurred. Production costs of advertising and promotional materials are expensed when the advertising is first run, unless such costs support direct-response advertising campaigns. In that case, these costs are capitalized and amortized over the period estimated to benefit from the campaign. Total advertising expenses were \$6.8 million and \$5.6 million for the fiscal years ended June 30, 2024 and 2023, respectively.

Stock-based Compensation

The Company and its principal shareholder have long-term equity incentive plans that provide for stock-based compensation, including the granting of stock options, profits interests units and restricted stock units to employees, directors, consultants, or advisers, as determined by each of the respective plans.

The Company utilizes the Black-Scholes option-pricing model to determine the fair value of the stock options on the date of grant. This model derives the fair value of the options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate, and dividend yield. The Company uses the Monte Carlo option model to determine the fair value of the granted profits interests units.

For service-vesting awards (i.e., restricted stock units), we recognize stock-based compensation expense over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. If the award was, in substance, multiple awards, we recognize stock-based compensation expense over the requisite service period for each separately vesting portion of the awards. For performance-vesting awards (i.e., performance stock units), we recognize stock-based compensation expense when it is probable that the performance condition will be achieved. We analyze if a performance condition is probable for each reporting period through the settlement date for awards subject to

performance vesting. Stock-based compensation is included in corporate, general and administrative expenses on our consolidated statements of operations.

Shares issued pursuant to our equity incentive plan are issued from authorized but unissued shares or from shares held by the Company as treasury stock, if any. See Note 10 “Stock-based Compensation.”

Income Taxes

The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Senior Housing Thornton, LLC (“SH1”) and InnovAge Sacramento have elected to be taxed as partnerships, and no provision (benefit) for income taxes for SH1 or InnovAge Sacramento is included in these consolidated financial statements. Further, InnovAge Orlando entered into a joint venture on May 28, 2024 and its members elected to be taxed as a partnership. No provision (benefit) for income taxes for InnovAge Orlando is included in these consolidated financial statements for activity occurring from joint venture formation date through the balance of the fiscal year.

A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.

Variable Interest Entities (VIE)

A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk or whose equity owners lack certain decision-making and economic rights. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity. The primary beneficiary is required to consolidate the VIE. InnovAge Senior Housing Thornton, LLC (“SH1”) and Pinewood Lodge, LLP (“PWD”) are considered to be VIEs. The Company is not considered the primary beneficiary of PWD but is considered the primary beneficiary of SH1. On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD’s property, including the Senior Housing unit. The sale closed on May 2, 2024, and as a result, the Company ceased providing senior housing services through PWD.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging

growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company's consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Adopted Accounting Pronouncements

Financial Instruments

In April 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-04, *Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments* ("ASU 2019-04"), which requires entities to use a current expected credit loss ("CECL") model to measure impairment for most financial assets that are not recorded at fair value through net income. Under the CECL model, an entity will estimate lifetime expected credit losses considering available relevant information about historical events, current conditions and supportable forecasts. The CECL model does not apply to available-for-sale debt securities. The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the standard on July 1, 2023. Our adoption of the standard did not have a material impact on the

consolidated financial statements. The Company makes estimates of expected credit losses based on a combination of factors, including historical losses adjusted for current market conditions, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Recent Accounting Pronouncements Not Yet Adopted

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*. ASU 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual segment disclosures be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is evaluating the impact of ASU 2023-07 on our consolidated financial statements.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. ASU 2023-09 requires additional disclosures related to rate reconciliation, income taxes paid, and other disclosures. ASU 2023-09 requires public companies to annually (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. Additionally, ASU 2023-09 requires public companies to annually disclose the amount of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as the amount of income taxes paid by individual jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2025. The Company is currently evaluating the impact of ASU 2023-09 on our consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

XML 30 R10.htm IDEA: XBRL DOCUMENT

Revenue Recognition

Revenue from
Contract with
Customer [Abstract]
Revenue Recognition

Revenue Recognition

Capitation Revenue and Accounts Receivable

Our capitation revenue relates to contracts with participants in which our performance obligation is to provide healthcare services to the participants. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type. The Company contracts directly with Medicare and Medicaid on a PMPM basis. We receive 100% of the pooled capitated payment to directly provide or manage the healthcare needs of our participants.

Fees are recorded gross in revenues because the Company is acting as a principal in providing for or overseeing comprehensive care provided to the participants. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.

In general, a participant enrolls in the PACE program and is considered a customer of InnovAge. The Company considers all contracts with participants as a single performance obligation to provide comprehensive medical, health, and social services that integrate acute and long-term care. The Company identified that contracts with customers in the PACE program have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied over time as the Company provides comprehensive care to its participants.

Our revenues are based on the estimated PMPM amounts we expect to be entitled to receive from the capitated fees per participant that are paid monthly by Medicaid, Medicare, the VA, and private pay sources. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. VA is included in "Private Pay and other" and is also capitated. Private pay includes direct payments from participants who do not qualify for the full capitated rate and have to pay all or a portion of the capitated rate. Costs to obtain contracts consist of sales commissions for new enrollees and are included in deposits and other on our consolidated balance sheets. These costs are amortized over a three-

year period which corresponds to the average time a participant is enrolled in the PACE program. As of June 30, 2024 and 2023, contract assets included within deposits and other were \$2.8 million and \$1.0 million, respectively.

The Company disaggregates capitation revenue from the following sources for the year ended June 30:

	2024	2023
Medicaid	54 %	54 %
Medicare	46 %	46 %
Private pay and other	*%	*%
Total	100 %	100 %

* Less than 1%

The Company determined the transaction price for these contracts is the amount we expect to be entitled to, which is the most likely amount. For certain capitation payments, the Company is subject to retroactive premium risk adjustment payments according to the CMS risk adjustment payment timeline. Specifically, there is a midyear true up payment based on updated risk score calculations and a final true up payment to allow for complete diagnosis submission. The Company estimates the amount of the adjustment and records it monthly on a straight-line basis. These adjustments are not expected to be material.

The capitation revenues are recognized based on the estimated PMPM transaction price to transfer the service for a distinct increment of the series (i.e. month). We recognize revenue over time in the month in which participants are entitled to receive comprehensive care benefits during the contract term. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company also provides prescription drug benefits in accordance with Medicare Part D. Monthly payments received from CMS and the participants represent the bid amount for providing prescription drug coverage. The portion received from CMS is subject to risk sharing through Medicare Part D risk-sharing corridor provisions. These risk-sharing corridor provisions compare costs targeted in the Company's bid to actual prescription drug costs. The Company estimates and records a monthly adjustment to Medicare Part D revenues associated with these risk-sharing corridor provisions. Medicare Part D comprised (i) 12% and 13% of capitation revenues for the years ended June 30, 2024 and 2023, respectively, and (ii) 24% and 23% of external provider costs for the years ended June 30, 2024 and 2023, respectively.

The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. The concentration of net receivables from participants and third-party payers as of June 30, 2024 and 2023 was as follows:

	2024	2023
Medicaid	71 %	61 %
Medicare	22 %	29 %
Private pay and other	7 %	10 %
Total	100 %	100 %

The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company's best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. The balance of the allowance for uncollectible accounts was \$6.7 million as of June 30, 2024, compared to \$4.2 million as of June 30, 2023. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts.

Other Service Revenue and Accounts Receivable

Other service revenue primarily consists of revenues derived from state food grants and rent revenues. Accounts receivable related to other service revenue were not significant as of both June 30, 2024 and June 30, 2023.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to change, as well as government review. Failure to comply with these laws can expose the entity to significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. See Note 9, "Commitments and Contingencies."

XML 31 R11.htm IDEA: XBRL DOCUMENT

Cost and Equity
Method Investments
Investments, Debt
and Equity Securities
[Abstract]
Cost and Equity Method
Investments

Cost and Equity Method Investments

The Company holds cost method and equity method investments as of June 30:

	2024	2023
<i>in thousands</i>		
Cost method investments	\$ 2,645	\$ 4,645
Equity method investments	—	848
Total investments	\$ 2,645	\$ 5,493

Nonconsolidated Entities

Cost Method Investments

As of June 30, 2024 and 2023, the Company maintained one investment and two investments, respectively, that were accounted for using the cost method. The Company's ownership interests are less than 20% of the voting stock of the investments and the Company does not have the ability to exercise significant influence over the operating and financial policies of the investments. The investments do not have a readily determinable fair value and the Company has elected to record the investments at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.

JetDoc

In August 2021, the Company acquired a minority interest equal to 806,481 shares of the outstanding common stock of Jetdoc, Inc. ("Jetdoc"), a telehealth and virtual urgent care app dedicated to

12 Months Ended
Jun. 30, 2024

12 Months Ended
Jun. 30, 2024

effectively connecting users with medical professionals, for cash consideration of \$2.0 million. We determined that indicators of impairment were present as of December 31, 2023, and recognized an impairment loss of \$1.9 million during the three months then ended. During the three months ended March 31, 2024, we determined that the remaining balance of our investment in Jetdoc was impaired and recognized an additional impairment loss of \$0.1 million. Impairment losses are included in gain on cost and equity method investments on our consolidated statements of operations. During the year ended June 30, 2023, there were no observable price changes or impairments recorded. As of June 30, 2024, the Company does not have any ownership interest in JetDoc.

Dispatch Health

On June 14, 2019, the Company invested \$1.5 million in DispatchHealth Holdings, Inc., ("DispatchHealth") through the purchase of a portion of its outstanding Series B Preferred Stock. On April 2, 2020, the Company invested an additional \$1.1 million through the purchase of a portion of its outstanding Series C Preferred Stock. As of June 30, 2024, the balance of the Company's investment was \$2.6 million which represents the maximum exposure to loss. The investment does not have a readily determinable fair value and the Company has elected to record the investment at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. During the years ended June 30, 2024 and 2023, there were no observable price changes or impairments.

Equity Method Investments

Pinewood Lodge

Through May 2, 2024, the Company's operations included a Senior Housing unit that primarily included the accounts of Continental Community Housing ("CCH"), a wholly-owned subsidiary of the Company and the general partner of PWD, which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older.

PWD was a VIE, but the Company was not the primary beneficiary. The Company did not have the power to direct the activities that most significantly impacted the economic performance of PWD. Accordingly, the Company did not consolidate PWD. PWD was accounted for using the equity method of accounting. The equity earnings of PWD were

insignificant. As of June 30, 2023, the balance of the Company's investment in PWD was \$0.8 million, which represented the maximum exposure to loss.

On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including the Senior Housing unit. On May 2, 2024, PWD closed on the sale of its Senior Housing property for \$9.5 million. Upon completion of the sale, PWD ceased providing senior housing services and in June 2024 was dissolved. Following the dissolution, the remaining proceeds from the sale were distributed in accordance with the partnership agreement and as otherwise agreed by the partners.

Consolidated Entities

Controlling Interest

InnovAge Florida PACE – Orlando

On May 28, 2024, the Company entered into a Joint Venture Agreement with Orlando Health ("OHI") to develop and manage PACE centers to serve communities in Orlando, Florida. In connection with the joint venture, the joint venture, InnovAge Florida PACE – Orlando was formed. The Company contributed \$26.1 million for its controlling membership interest of 90%. As result, the joint venture's results are consolidated in the Company's consolidated financial statements. OHI contributed \$2.9 million in cash for its 10% interest.

Noncontrolling Interest

Senior Housing

The Company's operations include a 0.01% partnership interest in SH1, which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older. SH1 is a VIE. The Company is the primary beneficiary of SH1 and consolidates SH1. The Company is the primary beneficiary of SH1 as it has the power to direct the activities that are most significant to SH1 and has an obligation to absorb losses or the right to receive benefits from SH1. The most significant activity of SH1 is the operation of the senior housing facility. The Company has provided a subordinated loan to SH1 and has provided a guarantee for a convertible term loan held by SH1.

The following table shows the assets and liabilities of SH1 as of June 30:

	2024	2023
	in thousands	
Assets		
Cash and cash equivalents	\$ 816	\$ 648
Prepaid expenses and other	5	1
Property, plant and equipment, net	9,465	9,933
Deposits and other, net	409	402
Liabilities		
Accounts payable and accrued expenses	295	268
Noncurrent liabilities	456	454
Long-term debt, net of debt issuance costs	3,739	3,784

Redeemable Noncontrolling Interest

InnovAge Sacramento

On March 18, 2019, in connection with the formation of InnovAge Sacramento, the joint venture with Adventist Health System/West ("Adventist") and Eskaton Properties, Incorporated ("Eskaton"), the Company contributed \$9.0 million in cash and land valued at \$4.2 million for a 59.9% membership interest in the joint venture. Further, Adventist contributed \$5.8 million in cash and Eskaton contributed \$3.0 million in cash for membership interests of 26.4% and 13.7%, respectively. In fiscal year 2021, the Company made an additional contribution of \$52,000 and obtained an additional 0.1% membership interest in the joint venture, which resulted in the Company obtaining control and consolidating InnovAge Sacramento as of January 1, 2021.

The InnovAge California PACE-Sacramento LLC Limited Liability Company Agreement (the "JV Agreement") includes numerous provisions whereby, if certain conditions are met, the joint venture may be required to purchase, at fair market value, certain members' interests or certain members may be required to purchase, at fair market value, the interests of certain other members. The Company's investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As of June 30, 2024, none of the conditions specified in the JV Agreement had been met. Accordingly, these put rights held by the noncontrolling interests of the joint venture are required to be presented as temporary equity. As of June 30, 2024 and 2023, the Company's redeemable noncontrolling interest was recorded at fair value of \$22.2 million and carrying value of \$12.7 million, respectively.

XML 32 R12.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill represents the excess of cost over the fair value of net assets acquired. Goodwill amounted to \$139.9 million and \$124.2 million as of June 30, 2024 and June 30, 2023, respectively. The Company had one acquisition resulting in goodwill during the year ended June 30, 2024, see additional information in Note 11 "Acquisitions," and did not have any acquisitions resulting in goodwill during the year ended June 30, 2023. Goodwill is not amortized.

Pursuant to ASC 350, "Intangibles — Goodwill and Other," we review the recoverability of goodwill annually as of April 1 or whenever significant events or changes occur which might impair the recovery of recorded amounts. For purposes of the annual goodwill impairment assessment for fiscal year 2024, the Company identified two reporting units, East and West. There were no indicators of impairment identified and no goodwill impairments recorded during the years ended June 30, 2024 and 2023.

The following table summarizes the changes in goodwill for the fiscal years ended June 30:

	2024	2023
in thousands		
Balance as of beginning of period	\$ 124,217	\$ 124,217
Goodwill acquired during the period	15,732	—
Balance as of end of period	\$ 139,949	\$ 124,217

Intangible assets consisted of the following as of June 30:

	2024	2023
in thousands		
Definite-lived intangible assets		
Customer relationships	\$ 6,600	\$ 6,600
Indefinite-lived intangible assets		
Permits	2,000	2,000
Total intangible assets	8,600	8,600
Accumulated amortization	(4,062)	(3,402)
Balance as of end of period	\$ 4,538	\$ 5,198

Intangible assets with a finite useful life continue to be amortized over their useful lives. The Company recorded amortization expense of \$0.7 million for each of the years ended June 30, 2024 and 2023.

The total expected future annual amortization expense for the next 5 years ended June 30, is as follows:

	Amortization Expense
in thousands	
2025	\$ 660
2026	660
2027	630
2028	540
2029	48

We review the recoverability of other intangible assets in conjunction with long-lived assets whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. There were no intangible asset impairments recorded during the years ended June 30, 2024 and 2023.

XML 33 R13.htm IDEA: XBRL DOCUMENT

Leases

Leases [Abstract]

Leases

Leases

Leasing Arrangements as Lessee

The Company leases certain property and equipment under various third-party operating and finance lease agreements. The Company determines if an arrangement is or contains a lease at the lease inception date by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct

12 Months Ended Jun. 30, 2024

the use of the asset. The leases are noncancelable and expire on various terms from 2024 through 2034. We determine if an arrangement is a lease upon commencement of the contract. If an arrangement is determined to be a long-term lease (greater than 12 months), we recognize a right-of-use ("ROU") asset and lease liability based on the present value of the future minimum lease payments over the lease term at the commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Our lease terms may also include options to extend or terminate the lease when it is reasonably certain that we will exercise those options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have elected to apply the short-term lease exception for contracts that have a lease term of twelve months or less and do not include an option to purchase the underlying asset. Therefore, we do not recognize a ROU asset or lease liability for such contracts. We recognize short-term lease payments as expense on a straight-line basis over the lease term. Variable lease payments that do not depend on an index or rate are recognized as expense. Certain leases include escalations based on inflation indexes and fair market value adjustments. Operating lease liabilities are calculated using the prevailing index or rate at lease commencement for such leases.

On March 20, 2023, we consolidated our Germantown center in Pennsylvania with two of our existing centers. Upon consolidation, we terminated our Germantown center lease and recognized lease termination costs of \$0.6 million. Lease termination costs are included in other income (expense) on our consolidated statements of operations.

The following table presents the components of our ROU assets and their classification in our Balance Sheet as of June 30.

Component of Lease Balances	Balance Sheet Line Items	2024	2023
		<i>in thousands</i>	
Assets:			
Operating lease assets	Operating lease assets	\$ 28,416	\$ 21,210
Finance lease assets	Property and equipment, net	15,908	16,378
Total leased assets		\$ 44,324	\$ 37,588

The following table presents the components of our lease cost and the classification of such costs in our Statement of Operations for the years ended June 30.

Component of Lease Cost	Statement of Operations Line Items	2024	2023
		<i>in thousands</i>	
Operating lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	\$ 5,402	\$ 4,642
Finance lease expense:			
Amortization of leased assets	Depreciation and amortization	1,984	3,080
Interest on lease liabilities	Interest expense, net	—	1,255
Variable lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	93	82
Short-term lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	172	108
Total lease expense:		\$ 7,651	\$ 9,167

The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of June 30.

Weighted average remaining lease term:		2024	2023
Operating leases		7.7 years	7.9 years
Finance leases		3.5 years	3.9 years

Weighted average discount rate		2024	2023
Operating leases		6.86 %	6.60 %
Finance leases		7.80 %	7.80 %

The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to June 30, 2024.

<i>in thousands</i>	Operating Lease		Finance Lease		Total
2025	\$	6,023	\$	6,631	\$ 12,654
2026		5,988		5,389	11,377
2027		5,742		4,514	10,256
2028		4,952		2,461	7,413
2029		4,097		555	4,652
Thereafter		11,582		—	11,582
Total lease payments		38,384		19,550	57,934
Less liability accretion / imputed interest		(7,964)		(2,208)	(10,172)
Total lease liabilities		30,420		17,342	47,762
Less: Current lease liabilities		4,145		4,599	8,744
Total long-term lease liabilities	\$	26,275	\$	12,743	\$ 39,018

Leases

Leasing Arrangements as Lessee

The Company leases certain property and equipment under various third-party operating and finance lease agreements. The Company determines if an arrangement is or contains a lease at the lease inception date by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. The leases are noncancelable and expire on various terms from 2024 through 2034. We determine if an arrangement is a lease upon commencement of the contract. If an arrangement is determined to be a long-term lease (greater than 12 months), we recognize a right-of-use ("ROU") asset and lease liability based on the present value of the future minimum lease payments over the lease term at the commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Our lease terms may also include options to extend or terminate the lease when it is reasonably certain that we will exercise those options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have elected to apply the short-term lease exception for contracts that have a lease term of twelve months or less and do not include an option to purchase the underlying asset. Therefore, we do not recognize a ROU asset or lease liability for such contracts. We recognize short-term lease payments as expense on a straight-line basis over the lease term. Variable lease payments that do not depend on an index or rate are recognized as expense. Certain leases include escalations based on inflation indexes and fair market value adjustments. Operating lease liabilities are calculated using the prevailing index or rate at lease commencement for such leases.

On March 20, 2023, we consolidated our Germantown center in Pennsylvania with two of our existing centers. Upon consolidation, we terminated our Germantown center lease and recognized lease termination costs of \$0.6 million. Lease termination costs are included in other income (expense) on our consolidated statements of operations.

The following table presents the components of our ROU assets and their classification in our Balance Sheet as of June 30.

Component of Lease Balances	Balance Sheet Line Items	2024	2023
		<i>in thousands</i>	
Assets:			
Operating lease assets	Operating lease assets	\$ 28,416	\$ 21,210
Finance lease assets	Property and equipment, net	15,908	16,378
Total leased assets		\$ 44,324	\$ 37,588

The following table presents the components of our lease cost and the classification of such costs in our Statement of Operations for the years ended June 30.

Component of Lease Cost	Statement of Operations Line Items	2024	2023
		<i>in thousands</i>	
Operating lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	\$ 5,402	\$ 4,642
Finance lease expense:			
Amortization of leased assets	Depreciation and amortization	1,984	3,080
Interest on lease liabilities	Interest expense, net	—	1,255
Variable lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	93	82
Short-term lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	172	108
Total lease expense:		\$ 7,651	\$ 9,167

The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of June 30.

Weighted average remaining lease term:		2024	2023
Operating leases		7.7 years	7.9 years
Finance leases		3.5 years	3.9 years

Weighted average discount rate		2024	2023
Operating leases		6.86 %	6.60 %
Finance leases		7.80 %	7.80 %

The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to June 30, 2024.

<i>in thousands</i>		Operating Lease		Finance Lease		Total
2025	\$	6,023	\$	6,631	\$	12,654
2026		5,988		5,389		11,377
2027		5,742		4,514		10,256
2028		4,952		2,461		7,413
2029		4,097		555		4,652
Thereafter		11,582		—		11,582
Total lease payments		38,384		19,550		57,934
Less liability accretion / imputed interest		(7,964)		(2,208)		(10,172)
Total lease liabilities		30,420		17,342		47,762
Less: Current lease liabilities		4,145		4,599		8,744
Total long-term lease liabilities	\$	26,275	\$	12,743	\$	39,018

XML 34 R14.htm IDEA: XBRL DOCUMENT

Long-term Debt

Debt Disclosure

[Abstract]

Long-term Debt

12 Months Ended

Jun. 30, 2024

Long-term Debt

The components of our long-term debt are as follows:

	June 30, 2024	June 30, 2023
<i>in thousands</i>		
Senior secured borrowings:		
Term Loan Facility	\$ 63,750	\$ 67,500
Convertible term loan	2,239	2,284
Total debt	65,989	69,784
Less unamortized debt issuance costs	716	1,145
Less current maturities	3,795	3,795
Noncurrent maturities	\$ 61,478	\$ 64,844

2021 Credit Agreement

On March 8, 2021, the Company entered into a credit agreement (as amended, the “2021 Credit Agreement”) that replaced its prior credit agreement. The 2021 Credit Agreement consists of a senior secured term loan (the “Term Loan Facility”) of \$75.0 million principal amount and a revolving credit facility (the “Revolving Credit Facility”) of \$100.0 million maximum borrowing capacity, each with a maturity date of March 8, 2026. Borrowing capacity under the Revolving Credit Facility is subject to (i) any issued amounts under our letters of credit, which as of June 30, 2024 was \$3.9 million, and (ii) applicable covenant compliance restrictions and any other conditions precedent to borrowing. Loans under the 2021 Credit Agreement are secured by substantially all of the Company’s assets. Principal on the Term Loan Facility is paid each calendar quarter in an amount equal to 1.25% of the initial term loan on closing date.

Outstanding principal amounts under the 2021 Credit Agreement accrue interest at a variable interest rate. As of June 30, 2024 and 2023, the interest rate on the Term Loan Facility was 7.18% and 6.95%, respectively. Under the terms of the 2021 Credit Agreement, the Revolving Credit Facility fee accrues at 0.25% of the average daily unused amount and is paid quarterly. As of June 30, 2024, we had no borrowings outstanding, \$3.9 million of letters of credit issued, and \$96.1 million of remaining capacity under the Revolving Credit Facility.

The 2021 Credit Agreement requires the Company to meet certain operational and reporting requirements, including, but not limited to, a secured net leverage ratio. Additionally, annual capital expenditures and permitted investments, including acquisitions, are limited to amounts specified in the 2021 Credit Agreement. The 2021 Credit Agreement also provides certain restrictions on dividend payments and other equity transactions and requires the Company to make prepayments under specified circumstances. The Company was in compliance with the covenants of the 2021 Credit Agreement as of June 30, 2024 and 2023.

The deferred financing costs of \$2.0 million are amortized over the term of the underlying debt and unamortized amounts have been offset against long-term debt in the consolidated balance sheets. Total amortization of deferred financing costs was \$0.4 million and \$0.4 million for the years ended June 30, 2024 and 2023, respectively.

Convertible Term Loan

On June 29, 2015, SH1 entered into a convertible term loan. Principal and interest payments of \$0.02 million are due monthly. The loan bears interest at an annual rate of 6.68%, with the remaining principal balance due upon maturity at August 20, 2030. The loan is secured by a deed of trust to Public Trustee, assignment of leases and rents, security agreements, and SH1’s fixture filing.

Aggregate maturities of our debt as of June 30, 2024 were as follows:

	Long-term debt
<i>in thousands</i>	
Year ending June 30:	
2025	\$ 3,795
2026	60,059
2027	63
2028	67
2029	72
Thereafter	1,933
Total debt	\$ 65,989

XML 35 R15.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

Fair Value Disclosures

[Abstract]

Fair Value Measurements

12 Months Ended

Jun. 30, 2024

Fair Value Measurements

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company’s own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant.

The three levels of inputs that may be used to measure fair value are:

- Level 1** Unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date
- Level 2** Quoted prices in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the assets or liabilities
- Level 3** Unobservable inputs to the valuation techniques that are significant to the fair value measurements of the assets or liabilities

The following table shows the Company’s cash, cash equivalents and marketable securities by significant investment category as of June 30, 2024.

<i>in thousands</i>	Amortized Cost	Fair Value	Cash and Cash Equivalents	Short-term Investments
Cash	\$ 25,793	\$ 25,793	\$ 25,793	\$ —
Level 1				
Money market funds	31,153	31,153	31,153	—
Mutual funds	45,556	45,833	—	45,833
Total	\$ 102,502	\$ 102,779	\$ 56,946	\$ 45,833

Recurring Measurements

The Company’s investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As a result, at each fiscal period end the Company reports this put right at the greater of (i) carrying value of the redeemable noncontrolling interest or (ii) fair value of the redeemable noncontrolling interest. Because this asset does not have observable inputs, Level 3 inputs are used to measure fair value. The fair value of the redeemable noncontrolling interest is determined utilizing a discounted cash flow model. As of June 30, 2024 and 2023, the Company’s redeemable noncontrolling interest was recorded at carrying value of \$22.2 million and \$12.7 million, respectively.

There were no transfers in and out of Level 3 during the fiscal years ended June 30, 2024 and 2023. The Company’s policy is to recognize transfers as of the actual date of the event or change in circumstances.

XML 36 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

Commitments and Contingencies

Disclosure [Abstract]

Commitments and Contingencies

12 Months Ended

Jun. 30, 2024

Commitments and Contingencies

Professional Liability

The Company pays fixed premiums for annual professional liability insurance coverage under a claims-made policy. Under such policy, only claims made and reported to the insurer are covered during the policy term, regardless of when the incident giving rise to the claim occurred. The Company records claim liabilities and expected recoveries, if any, at gross amounts. The Company is not currently aware of any unasserted claims or unreported incidents that are expected to exceed medical malpractice insurance coverage limits.

Litigation

From time to time, the Company may be involved in various legal proceedings and be subject to claims. The Company regularly evaluates the status of claims and legal proceedings in which it is involved in order to assess whether a loss is probable or there is a reasonable possibility that a loss may have been incurred, and to determine whether accruals are appropriate. The Company expenses legal costs as such costs are incurred.

Civil Investigative Demands

In July 2021, the Company received a civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act. The demand requests information and documents regarding Medicaid billing, patient services and referrals in connection with the Company's PACE program in Colorado. We continue to fully cooperate with the Attorney General . We are currently unable to predict the outcome of this investigation.

In February 2022, the Company received a civil investigative demand from the Department of Justice ("DOJ") under the Federal False Claims Act on similar subject matter. The demand requests information and documents regarding audits, billing, orders tracking, and quality and timeliness of patient services in connection with the Company's PACE programs in the states where the Company operated as of 2022 (California, Colorado, New Mexico, Pennsylvania, and Virginia). In December 2022, the Company received a supplemental civil investigative demand requesting supplemental information on the same matters. The Company continues to fully cooperate with the DOJ. We are currently unable to predict the outcome of this investigation.

Stockholder Lawsuits

On October 14, 2021, and subsequently amended on June 21, 2022, the Company was named as a defendant in a putative class action complaint filed in the District Court for the District of Colorado on behalf of individuals who purchased or acquired shares of the Company's common stock during a specified period (the "Securities Action"). Through the complaint, plaintiffs are asserting claims against the Company, certain of the Company's officers and directors, Apax Partners, L.P., Welsh, Carson, Anderson & Stowe and the underwriters in the Company's IPO, alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 for making allegedly inaccurate and misleading statements and omissions in connection with the Company's IPO and subsequent earnings calls and public filings, and seeking compensatory damages, among other things. On September 13, 2022, the Company and the officer and director defendants and Apax Partners, L.P. and Welsh, Carson, Anderson & Stowe filed a motion to dismiss the amended complaint for failure to state a claim upon which relief can be granted. On December 22, 2023, the District Court granted in part and denied in part the motion to dismiss. The action is now in discovery.

On April 20, 2022, the Board of Directors of the Company received a books and records demand pursuant to Section 220 of the Delaware General Corporation Law, from a purported stockholder of the Company, Brian Hall, in connection with the stockholder's investigation of, among other matters, potential breaches of fiduciary duty, mismanagement, self-dealing, corporate waste or other violations of law by the Company's Board with respect to these matters. On May 15, 2023, Mr. Hall filed a lawsuit in the Delaware Court of Chancery asserting derivative claims for breach of fiduciary duty against certain of the Company's current and former officers and directors generally relating to alleged failures by the defendants to take remedial actions to address the matters that resulted in sanctions by CMS at certain of the Company's

centers, and alleged misstatements in the Company's public filings relating to those matters. On June 28, 2023, upon stipulation of the parties, the court entered an order staying the litigation pending the resolution of the motion to dismiss in the Securities Action or upon fifteen days' notice by any party to the litigation. On January 22, 2024, upon stipulation of the parties, the court entered an order further staying the litigation pending the close of fact discovery in the Securities Action.

We are currently unable to predict the outcome of these matters.

Other Matters

In the third fiscal quarter of 2023, the Company agreed to settle a wage and hour class action lawsuit in the State of California for a cash payment of \$1.2 million. Subsequently, the Company was notified of certain additional individual claims and agreed to include such claims within the class. In October 2023, the Company agreed to increase the settlement amount to a total of \$1.3 million, reflecting the additional individual claim. The Court entered the final approval of the settlement on April 2, 2024 and the payout occurred on June 7, 2024. The matter will remain open for 180 days to allow the class members to settle their checks, after which time the case is expected to officially close.

Because the results of legal proceedings and claims are inherently unpredictable and uncertain, we are currently unable to predict whether the legal proceedings we are involved in will, either individually or in the aggregate, have a material adverse effect on our business, financial condition, or cash flows. The outcomes of legal proceedings and claims could be material to the Company's operating results for any particular period, depending in part, upon the operating results of such period. Regardless of the outcome, litigation has the potential to have an adverse impact on us due to any related defense and settlement costs, diversion of management resources, and other factors.

XML 37 R17.htm IDEA: XBRL DOCUMENT

**Stock-based
Compensation**
[Share-Based Payment
Arrangement
\[Abstract\]](#)
[Stock-based
Compensation](#)

**12 Months Ended
Jun. 30, 2024**

Stock-based Compensation

A summary of our aggregate stock-based compensation expense is set forth below. Stock-based compensation expense is included in corporate, general and administrative expenses on our consolidated statements of operations.

	Year ended June 30,	
	2024	2023
	<i>in thousands</i>	
Stock options	\$ 802	\$ 1,010
Profits interests units	861	867
Restricted stock units	5,169	3,116
Total stock-based compensation expense	\$ 6,832	\$ 4,993

2020 Equity Incentive Plan

Profits Interests

TCO Group Holdings, L.P. (the "LP"), the Company's largest shareholder and prior to the IPO, the Company's parent, maintains the TCO Group Holdings, L.P. Equity Incentive Plan (the "2020 Equity Incentive Plan") pursuant to which interests in the LP in the form of Class B Units (profits interests) may be granted to employees, directors, consultants, advisers, and other services providers (including partners) of the LP or any of its affiliates, including the Company. A maximum number of 16,162,177 Class B Units are authorized for grant under the 2020 Equity Incentive Plan. Both performance-based and time-based units were issued under the plan. As of June 30, 2024, a total of 15,222,837 profits interests units have been granted under the 2020 Equity Incentive Plan.

The Company used the Monte Carlo option model to determine the fair value of the granted profits interests units at the time of the grant. Expected stock price volatility is based on consideration of indications observed from several publicly traded peer companies. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the unit. The dividend yield percentage is zero because the Company neither currently pays dividends nor intends to do so during the expected term. The expected term of the units represents the time the units are expected to be outstanding. During the fiscal year ended June 30, 2024, a total of 2,213,700 Class B Units were awarded to the Company's

Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer. The assumptions under the Monte Carlo model related to the profits interests units for fiscal 2024, presented on a weighted-average basis, are provided below:

	2024
Expected volatility	68.0 - 76.0 %
Expected life (years) - time vesting units	2.7 - 3.1
Interest rate	4.23 - 4.57 %
Dividend yield	—
Weighted-average fair value	\$ 1.59 - 2.17
Fair value of underlying stock	\$ 5.52 - 7.27

A summary of profits interests activity for the year ended June 30, 2024, was as follows:

	Number of units	Weighted average grant date fair value
Time-based unit awards		
Outstanding balance, June 30, 2023	1,264,337	\$ 1.28
Granted	1,106,850	\$ 6.21
Forfeited	(380,679)	\$ 1.28
Vested	(703,395)	\$ 1.28
Outstanding balance, June 30, 2024	1,287,113	\$ 5.52
Performance-based unit awards		
Outstanding balance, June 30, 2023	2,118,558	\$ 0.57
Granted	1,106,850	\$ 1.78
Forfeited	(1,853,737)	\$ 0.57
Vested	—	\$ —
Outstanding balance, June 30, 2024	1,371,671	\$ 1.55

The total unrecognized compensation cost related to profits interests units outstanding as of June 30, 2024 was \$3.9 million, comprised (i) \$1.8 million related to time-based unit awards expected to be recognized over a weighted-average period of 2.8 years and (ii) \$2.1 million related to performance-based unit awards, which will be recorded when it is probable that the performance-based criteria will be met.

2021 Omnibus Incentive Plan

In March 2021, the Compensation Committee of the Board of Directors approved the InnovAge Holding Corp. 2021 Omnibus Incentive Plan ("2021 Omnibus Incentive Plan"), pursuant to which various stock-based awards may be granted to employees, directors, consultants, and advisers. The total number of shares of the Company's common stock authorized under the 2021 Omnibus Incentive Plan is 14,700,000. The Company has issued time-based restricted stock units under this plan to its employees which generally(i) vested on March 4, 2023, the second anniversary of the grant date, or (ii) vest over a three-year period with one-third vesting on each anniversary of the date of grant. Certain other vesting periods have also been used. The grant date fair value of restricted stock units with time-based vesting is based on the closing market price of our common stock on the date of grant. Certain other awards, including units and stock options under this plan vest upon achieving specific share price performance criteria and are determined to have performance-based vesting conditions. The Company has also issued time-based vesting stock options under this plan to its employees which generally vest in equal parts over a three-year period.

Restricted Stock Units

A summary of time-based vesting restricted stock units activity for the year ended June 30, 2024, was as follows:

Restricted stock units - time based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	1,873,794	\$ 10.10
Forfeited	(143,935)	\$ 5.49
Vested	(720,326)	\$ 5.25
Granted	1,854,786	\$ 4.84
Outstanding balance, June 30, 2024	2,864,319	\$ 8.15

The total unrecognized compensation cost related to time-based restricted stock units outstanding as of June 30, 2024, was \$11.3 million and is expected to be recognized over a weighted-average period of 2.0 years.

A summary of performance-based vesting restricted stock units activity for the year ended June 30, 2024, was as follows:

Restricted stock units - performance based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	258,767	\$ 5.18
Forfeited	—	\$ —
Vested	—	\$ —
Granted	—	\$ —
Outstanding balance, June 30, 2024	258,767	\$ 5.18

The total unrecognized compensation cost related to performance-based vesting restricted stock units outstanding as of June 30, 2024, was \$0.4 million and is expected to be recognized over a weighted-average period of 1.5 years.

Nonqualified Stock Options

A summary of time-based vesting stock option activity for the year ended June 30, 2024, was as follows:

Stock options - time based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	716,661	\$ 1.43
Granted	—	\$ —
Forfeited	(108,108)	\$ 0.31
Exercised	(54,054)	\$ 0.19
Expired	—	\$ —
Outstanding balance, June 30, 2024	554,499	\$ 1.77
Exercisable balance, June 30, 2024	346,560	\$ 0.17

The total unrecognized compensation costs related to time-based vesting stock options outstanding as of June 30, 2024, was \$0.09 million and is expected to be recognized over a weighted-average period of 1.4 years.

The fair value of the time-based stock options granted during the year ended June 30, 2023, was based upon the Black-Scholes option pricing model using the assumptions in the following table:

	2023
Expected volatility	34.5 %
Weighted-average expected life (years) - time vesting units	2.9
Interest rate	1.56 %
Dividend yield	0 %
Weighted-average fair values	\$ 0.80
Fair value of underlying stock	\$ 3.70

A summary of performance-based vesting stock option activity for the year ended June 30, 2024, was as follows:

Stock options - performance based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	776,299	\$ 3.08
Granted	—	\$ —
Forfeited	—	\$ —
Vested	—	\$ —
Outstanding balance, June 30, 2024	776,299	\$ 3.08

The total unrecognized compensation cost related to performance-based vesting stock options outstanding as of June 30, 2024, was \$0.8 million and is expected to be recognized over a weighted-average period of 1.6 years.

XML 38 R18.htm IDEA: XBRL DOCUMENT

Acquisitions

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Acquisitions

12 Months Ended
Jun. 30, 2024

Acquisitions

On December 1, 2023, the Company acquired all of the issued and outstanding membership interests of two California-based PACE programs, ConcertoCare PACE of Bakersfield, LLC and ConcertoHealth PACE of Los Angeles, LLC (collectively "Concerto"), from Perfect Health, Inc. d/b/a ConcertoCare, a tech-enabled, value-based provider of at-home, comprehensive care for seniors and other adults with unmet health and social needs, for \$23.9 million. We believe the Concerto acquisition complements our California PACE centers. The acquisition was funded through cash on hand. Results of operations from the acquired centers are included in our consolidated statements of operations for the year ended June 30, 2024 beginning with the date of acquisition and were not significant to our results. We incurred costs related to the acquisition of approximately \$0.1 million during the year ended June 30, 2024. Acquisition related costs were expensed as incurred and have been recorded in corporate, general and administrative expenses in our consolidated statements of operations.

The Concerto acquisition was accounted for using the purchase method of accounting. The purchase price has been preliminarily allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. The fair values of assets acquired and liabilities assumed may change as the valuation of intangible assets, working capital adjustments, and overall purchase price allocation are being finalized. Goodwill represents the excess of the purchase price over the fair value of net assets acquired. Goodwill recognized represents the

estimated future economic benefits arising from expected growth opportunities for the Company and is not deductible for income tax purposes.

The following table presents a preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:

	Preliminary allocation	Measurement period adjustments	Adjusted allocation
		<i>in thousands</i>	
Cash Consideration	\$ 23,916	\$ —	\$ 23,916
Total Consideration	\$ 23,916	\$ —	\$ 23,916
Accounts receivable, net	\$ 563	\$ (124)	\$ 439
Prepaid expenses	330	739	1,069
Property and equipment, net	7,969	—	7,969
Operating lease assets	6,892	923	7,815
Goodwill	17,348	(1,616)	15,732
Deposits and other	343	—	343
Accounts payable and accrued expenses	(353)	78	(275)
Reported and estimated claims	(111)	—	(111)
Operating lease obligations	(8,941)	—	(8,941)
Finance lease obligations	(124)	—	(124)
Fair value of assets and liabilities	\$ 23,916	\$ —	\$ 23,916

As of June 30, 2024, we recognized a measurement period adjustment for lease incentives related to tenant improvements. The adjustment resulted in an increase of \$0.7 million to prepaid expenses and \$0.9 million to operating lease assets, a decrease of \$0.1 million to accounts receivable and \$0.1 million to accounts payable and accrued expenses, and a corresponding decrease of \$1.6 million to goodwill.

XML 39 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

Income Tax Disclosure [Abstract] Income Taxes

12 Months Ended
Jun. 30, 2024

Income Taxes

The Company’s effective income tax rate for the years ended June 30, 2024 and 2023 was (6.4)% and 14.3%, respectively, which differed from the amount computed by applying the applicable U.S. federal statutory corporate income tax rate of 21% in each period as a result of the following factors:

	Year ended June 30,	
	2024	2023
	<i>in thousands</i>	
Statutory rate	\$ (4,581)	\$ (10,667)
IRC Section 162(m) limitation (a)	504	588
Change in valuation allowance	6,543	4,297
Permanent adjustments	614	457
Prior year true-up and other	(349)	157
Income from entities not subject to taxation	404	605
State tax	(1,733)	(2,678)
Provision (benefit) for income taxes	\$ 1,402	\$ (7,241)

(a) Reflects the permanent addback for the Section 162(m) limitation, which limits the deduction of compensation for the five highest paid officers to \$1.0 million per officer.

Provision (benefit) for income taxes consisted of the following for the years ended June 30, 2024 and 2023:

	Year ended June 30,	
	2024	2023
	<i>in thousands</i>	
Current:		
Federal	\$ —	\$ 3,709
State	178	575
Total current tax expense	178	4,284
Deferred:		
Federal	445	(10,263)
State	779	(1,262)
Total deferred tax expense	1,224	(11,525)
Total provision (benefit) for income taxes	\$ 1,402	\$ (7,241)

The significant components of deferred tax assets and liabilities were as follows for the years ended June 30, 2024 and 2023:

	Year ended June 30,	
	2024	2023
	<i>in thousands</i>	
Deferred tax assets:		
Amortization	\$ 573	\$ 629
Federal net operating losses	22,873	17,147
State net operating losses	8,053	5,701
Provision for uncollectible accounts	1,755	1,114
Accrued vacation	469	835
Reported and estimated claims	1,505	1,164
Stock-based compensation	511	449
Accrued bonuses	1,180	582
Interest Expense	1,943	791
Lease liability	9,260	6,784
Total deferred tax assets	48,122	35,196
Valuation allowance	(15,948)	(8,347)
Deferred tax assets, net of valuation allowance	32,174	26,849
Deferred tax liabilities:		
Goodwill	(9,207)	(6,697)
Depreciation	(16,288)	(13,137)
Equity investment	(4,696)	(5,019)
Prepaid expenses	(705)	(1,792)
ROU asset	(8,684)	(6,436)
Other	(54)	(4)
Total deferred tax liabilities	(39,634)	(33,085)
Net deferred tax liability	\$ (7,460)	\$ (6,236)

Carryforwards

The Company had state net operating loss carryforwards of \$185.8 million and \$117.9 million at June 30, 2024 and 2023, respectively, which will begin to expire in 2037 if not utilized. Included in this is a city net operating loss which will

begin to expire in 2025 if not utilized. Additionally, the Company has federal net operating loss carryforwards of \$108.9 million and \$81.7 million as of June 30, 2024 and 2023, respectively which do not expire.

Valuation Allowance

The Company has provided \$15.9 million and \$8.3 million at June 30, 2024 and June 30, 2023, respectively, as a valuation allowance against its deferred tax assets for federal and state net operating losses and state 163(j) interest expense limitations where there is not sufficient positive evidence to substantiate that these deferred tax assets will be realized at a more-likely-than-not level of assurance.

Other

The Company had no uncertain tax positions at June 30, 2024 and 2023.

The Company files income tax returns as a consolidated group, excluding SH1, InnovAge Sacramento, and InnovAge Orlando, in the U.S. federal jurisdiction and various states and is subject to examination by taxing authorities in all of those jurisdictions. From time to time, the Company’s tax returns are reviewed or audited by U.S. federal and various U.S. state-taxing authorities.

The Company believes that adjustments, if any, resulting from these reviews or audits would not be material, individually or in the aggregate, to the Company’s consolidated financial position, results of operations, or liquidity. The Company is subject to income tax examinations by the U.S. federal and state jurisdictions for the period ended June 30, 2021 and forward. The Company is subject to income tax examinations by California, Colorado and New Mexico state jurisdictions for the period ended June 30, 2020 and forward.

XML 40 R20.htm IDEA: XBRL DOCUMENT

Related Parties

[Related Party Transactions \[Abstract\]](#)
[Related Parties](#)

Related Parties

PWD VIE. Pursuant to the PWD Amended and Restated Agreement of Limited Partnership, CCH helped fund operating deficits and shortfalls of PWD in the form of a loan (the “PWD Loan”). The PWD Loan did not accrue interest. Additionally, CCH was paid an administration fee of \$35,000 per year. At June 30, 2023, \$0.7 million was recorded in Deposits and other related to the PWD Loan. On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD’s property, including the Senior Housing unit.

On May 2, 2024, PWD closed on the sale of its Senior Housing property for \$9.5 million. Upon completion of the sale, PWD ceased providing senior housing services and was dissolved. Following the dissolution, the remaining proceeds from the sale were distributed in accordance with the partnership agreement and as otherwise agreed by the partners. The Company received net proceeds of \$4.8 million in connection with the dissolution.

XML 41 R21.htm IDEA: XBRL DOCUMENT

Segment Reporting

[Segment Reporting \[Abstract\]](#)
[Segment Reporting](#)

Segment Reporting

The Company applies ASC Topic 280, “Segment Reporting,” which establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about operations, major customers and the geographies in which the entity holds material assets and reports revenue. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the Company’s chief executive officer, who is the chief operating decision maker (“CODM”), and for which discrete financial information is available. The Company has determined that it has three operating segments, two of which are related to the Company’s PACE offering. The PACE-related operating segments are based on two geographic divisions, which are East and West. Due to the similar economic characteristics, nature of services, and customers, we have aggregated our East and West operating segments into one reportable segment for PACE. The Company’s remaining operating segment primarily relates to Senior Housing, which is an immaterial operating segment, and shown below as “Other” along with certain corporate unallocated expenses.

As of June 30, 2024, the Company served approximately 7,020 PACE participants, making it the largest PACE provider in the U.S. based upon participants served, and operated 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania and Virginia.

PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, in a community-based service model. InnovAge provides all needed healthcare services through an all-inclusive, coordinated model of care and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, VA and private pay sources. Additionally, under the Medicare Prescription Drug Plan, CMS shares part of the risk for providing prescription medication to the Company’s participants.

The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The Company does not review assets by segment and therefore assets by segment are not disclosed below. For the periods presented, all of the Company’s long-lived assets were located in the United States and all revenue was earned in the United States.

The CODM uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. Center-level Contribution Margin is defined as total segment revenues less external

provider costs and cost of care (excluding depreciation and amortization). The Company allocates corporate level expenses to its segments with a majority of the allocation going to the PACE segment.

The following table summarizes the operating results regularly provided to the CODM by segment for the years ended June 30, 2024 and 2023:

in thousands	June 30, 2024			June 30, 2023		
	PACE	All other ⁽¹⁾	Totals	PACE	All other ⁽¹⁾	Totals
Capitation revenue	\$ 762,570	\$ —	\$ 762,570	\$ 686,836	\$ —	\$ 686,836
Other service revenue	310	975	1,285	347	904	1,251
Total revenues	762,880	975	763,855	687,183	904	688,087
External provider costs	403,010	—	403,010	374,528	—	374,528
Cost of care, excluding depreciation and amortization	228,203	578	228,781	211,707	564	212,271
Center-Level Contribution Margin	131,667	397	132,064	100,948	340	101,288
Overhead costs ⁽²⁾	136,284	10	136,294	135,264	—	135,264
Depreciation and amortization	18,477	473	18,950	14,959	460	15,419
Interest expense, net	3,845	178	4,023	1,342	180	1,522
Gain on cost and equity method investments	(2,842)	—	(2,842)	—	—	—
Other income	(2,542)	—	(2,542)	(124)	—	(124)
Loss Before Income Taxes	\$ (21,555)	\$ (264)	\$ (21,819)	\$ (50,493)	\$ (300)	\$ (50,793)

(1) Center-level Contribution Margin from a segment below the quantitative thresholds is attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.

(2) Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.

XML 42 R22.htm IDEA: XBRL DOCUMENT

Earnings per Share

12 Months Ended
Jun. 30, 2024

Earnings Per Share
[Abstract]
Earnings per Share

Earnings per Share

Basic earnings (loss) per share ("EPS") is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options and other equity awards, using the treasury stock method and the average market price of the Company's common stock during the applicable period. When a loss from continuing operations exists, all dilutive securities and potentially dilutive securities are anti-dilutive and are therefore excluded from the computation of diluted earnings per share. When net income from continuing operations exists, performance-based units, are omitted from the calculation of diluted EPS until it is determined that the performance criteria has been met at the end of the reporting period. As of June 30, 2024 and 2023, there were 1,035,066 performance-based awards excluded from the calculation of diluted EPS.

The following table sets forth the computation of basic and diluted net loss per common share:

in thousands, except share values	Year ended June 30,	
	2024	2023
Net loss attributable to InnovAge Holding Corp.	\$ (21,338)	\$ (40,673)
Weighted average common shares outstanding (basic)	135,902,214	135,593,824
EPS (basic)	\$ (0.16)	\$ (0.30)
Dilutive shares	—	—
Weighted average common shares outstanding (diluted)	135,902,214	135,593,824
EPS (diluted)	\$ (0.16)	\$ (0.30)

XML 43 R23.htm IDEA: XBRL DOCUMENT

Share Repurchase
Program

12 Months Ended
Jun. 30, 2024

Equity [Abstract]
Share Repurchase
Program

Share Repurchase ProgramOn June 14, 2024, our Board authorized up to \$5.0 million of share repurchases. As of June 30, 2024, the Company had repurchased approximately 45,023 shares of its common stock for \$0.2 million, of which 36,559 were placed in Treasury.

XML 44 R24.htm IDEA: XBRL DOCUMENT

Subsequent Event

12 Months Ended
Jun. 30, 2024

Subsequent Events [Abstract]
Subsequent Event

The Company has evaluated subsequent events through September 10, 2024, the date on which the consolidated financial statements were issued.

XML 45 R25.htm IDEA: XBRL DOCUMENT

Pay vs Performance
Disclosure - USD (\$)
\$ in Thousands

12 Months Ended
Jun. 30, 2024Jun. 30, 2023

Pay vs Performance Disclosure

Net loss attributable to InnovAge Holding Corp. \$ (21,338) \$ (40,673)

XML 46 R26.htm IDEA: XBRL DOCUMENT

Insider Trading
Arrangements

3 Months Ended
Jun. 30, 2024
shares

12 Months Ended
Jun. 30, 2024
shares

Trading
Arrangements, by
Individual

Non-Rule 10b5-1
Arrangement Adopted

false

Rule 10b5-1
Arrangement
Terminated

false

Non-Rule 10b5-1
Arrangement
Terminated

false

Nicole D'Amato
[Member]

Trading
Arrangements, by
Individual

Material Terms of
Trading Arrangement

On June 13, 2024, Nicole D'Amato, the Company's Chief Legal Officer and Corporate Secretary, adopted a Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the sale of up to 47,574 shares of the Company's common stock through September 16, 2025, or upon the earlier completion of all authorized transactions under the plan.

Name
Title

Nicole D'Amato
Chief Legal
Officer and
Corporate
Secretary

Rule 10b5-1
Arrangement Adopted

true

Adoption Date

June 13, 2024

Expiration Date

September 16,
2025

Arrangement Duration

460 days

Aggregate Available

47,574 47,574

XML 47 R27.htm IDEA: XBRL DOCUMENT

Summary of
Significant
Accounting Policies
(Policies)
Accounting Policies
[Abstract]

12 Months Ended
Jun. 30, 2024

Basis of Preparation and
Principles of
Consolidation

Basis of Preparation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). The consolidated financial statements include the

accounts of the Company, its wholly owned subsidiaries, and variable interest entities (VIEs) for which it is the primary beneficiary and entities for which it is the controlling general partner. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in accounting for, among other things, the allowance for uncollectible accounts; revenue reserves; useful lives of property and equipment and the valuation of goodwill and intangible assets; risk-score adjustments to participant revenues; reported and estimated claims; accruals; the determination of assumptions for stock-based compensation costs; deferred taxes, including the determination of a need for a valuation allowance; legal contingencies, including medical malpractice claims; the determination of fair value of net assets acquired in a business combination; and other fair value measurements. Actual results may differ from previously estimated amounts.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and financial instruments issued by major financial institutions that have an original maturity of less than three months. Amounts are reported in the consolidated balance sheets at cost, which approximates fair value.

The Company's cash and cash equivalents are deposited with high credit quality financial institutions and are primarily in demand deposit accounts. The FDIC insurance coverage is \$250,000 on the aggregate of interest bearing and non-interest bearing accounts. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Investments

Investments

Cost method investments do not have a readily determinable fair value and are carried at cost, less impairment plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.

The Company uses the equity method to account for investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. The Company's investments in these nonconsolidated entities are reflected in the Company's consolidated balance sheets under the equity method, and the Company's proportionate net income (loss), if any, is included in the Company's consolidated statements of operations under the equity method.

The Company evaluates its investments for impairment whenever events or changes in circumstances indicate that a decline in value has occurred that is other than temporary. Evidence considered in this evaluation includes, but would not necessarily be limited to, the financial condition and near-term prospects of the investee, recent operating trends and forecasted performance of the investee, market conditions in the geographic area or industry in which the investee operates and the Company's strategic plans for holding the investment in relation to the period of time expected for an anticipated recovery of its carrying value. If the investment is determined to have a decline in value deemed to be other than temporary it is written down to estimated fair value.

Short-term Investments

Short-term Investments

Short-term investments consist of investments in managed income fund securities managed by major financial institutions. These securities are measured at fair value on a recurring basis with changes in fair value recognized in earnings. The estimated fair value of the short-term investments is valued using quoted market prices in active markets and classified as Level 1 of the fair value hierarchy. Dividend income is reported within other income (expense) in the Company's consolidated statement of operations. Dividends received are reinvested in fund securities. We may sell these securities at any time for use in current operations. As a result, we classify our short-term investments as current assets on the Company's consolidated balance sheets.

Restricted Cash

Restricted Cash

Restricted cash includes cash held for participants who have established a personal-needs account to pay for nonmedical personal expenses, payment of which only occurs upon participant authorization, in the amount of approximately \$0.01 million and \$0.02 million as of June 30, 2024 and 2023, respectively. The Company records a related deposit liability for any participant contributions to these personal-needs accounts in accounts payable and accrued expenses in the consolidated balance sheets.

Accounts Receivable

Accounts Receivable

The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company's best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful lives or lease terms, if the assets are being leased.

Property and equipment were comprised of the following as of June 30:

dollars in thousands	Estimated Useful Lives	2024	2023
Land	N/A	\$ 11,970	\$ 11,970
Buildings and leasehold improvements	10 - 40 years	156,064	124,262
Software	3 - 5 years	30,678	26,656
Equipment and vehicles	3 - 7 years	69,495	57,754
Construction in progress	N/A	12,234	42,223
		280,441	262,865
Less accumulated depreciation and amortization		(87,419)	(70,677)
Total property and equipment, net		\$ 193,022	\$ 192,188

Depreciation of \$18.3 million and \$14.8 million was recorded during the fiscal years ended June 30, 2024 and 2023, respectively. Land is not depreciated, and construction in progress is not depreciated until ready for service. Costs of enhancements or modifications that substantially extend the capacity or useful life of an asset are capitalized and depreciated accordingly. Ordinary repairs and maintenance are expensed as incurred.

The costs of acquiring or developing internal-use software, including directly related payroll costs for internal resources, are capitalized. Software maintenance and training costs are expensed in the period incurred.

Interest is capitalized on construction projects, including internal-use software development projects, while in progress. During the fiscal years ended June 30, 2024 and 2023, the Company capitalized interest of approximately \$0.01 million and \$1.0 million, respectively.

When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets, and the resulting gain or loss, if any, is reflected in the consolidated statements of operations. Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable.

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Intangible assets primarily consist of customer relationships acquired through business acquisitions. Goodwill represents the excess of consideration paid over the fair value of net assets acquired through business acquisitions. Goodwill is not amortized but is tested for impairment at least annually.

The Company tests goodwill for impairment annually on April 1st or more frequently if triggering events occur or other impairment indicators arise which might impair recoverability. These events or circumstances would include a significant change in the business climate, legal factors, operating performance indicators, competition, sale, disposition of a significant portion of the business, or other factors. Impairment of goodwill is evaluated at the reporting unit level. A reporting unit is defined as an operating segment (i.e. before aggregation or combination), or one level below an operating segment (i.e. a component). A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component. The Company has two reporting units, East and West, for evaluating goodwill impairment.

ASC 350, Intangibles—Goodwill and Other ("ASC 350"), allows entities to first use a qualitative approach to test goodwill for impairment. When the reporting units where the Company performs the quantitative goodwill impairment are tested, the Company compares the fair value of the reporting unit, which the Company primarily determines using an income approach based on the present value of discounted cash flows, to the respective carrying value, which includes goodwill. If the fair value of the reporting unit exceeds its carrying value, the goodwill is not considered impaired. If the carrying value is higher than the fair value, the difference would be recognized as an impairment loss. There were no goodwill impairments recorded during the years ended June 30, 2024 and 2023.

Customer relationships represent the estimated values of customer relationships of acquired businesses and have definite lives. The Company amortizes these intangible assets on a straight-line basis over their ten-year estimated useful life. Intangible assets are reviewed for impairment in conjunction with long-lived assets.

Reported and Estimated Claims

Reported and Estimated Claims

Reported and estimated claims consist of unpaid claims reported as of the balance sheet date and estimates of claims incurred on or before June 30 that have not been reported by that date (IBNR). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of healthcare services, historical payment patterns, cost trends, and other factors. These complex estimation methods and the resulting reserves are continually reviewed and updated, and any adjustments deemed necessary to contemplate new or updated information are reflected in current operations.

Debt Issuance Costs

Debt Issuance Costs

Debt issuance costs are those costs that have been incurred in connection with the issuance of long-term debt and are offset against long-term debt in the consolidated balance sheets. Such costs are being amortized over the term of the underlying debt using the straight-line method, as the difference between that and the effective interest method are immaterial.

Revenue Recognition

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performed the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation. Medicaid and Medicare capitation revenues are based on a per member, per month ("PMPM") capitation rates under the PACE program.

Professional Liability Claims

Professional Liability Claims

The Company records a liability for medical malpractice claims based on estimated probable losses and costs associated with settling these claims and a receivable to reflect the estimated insurance recoveries, if any.

Advertising Costs

Advertising Costs

The Company's purchased services and contracts expenses include media advertising, tactical advertising, and promotion costs. The creative portion of these activities is expensed as incurred. Production costs of advertising and promotional materials are expensed when the advertising is first run, unless such costs support direct-response advertising campaigns. In that case, these costs are capitalized and amortized over the period estimated to benefit from the campaign.

Stock-based Compensation

Stock-based Compensation

The Company and its principal shareholder have long-term equity incentive plans that provide for stock-based compensation, including the granting of stock options, profits interests units and restricted stock units to employees, directors, consultants, or advisers, as determined by each of the respective plans.

The Company utilizes the Black-Scholes option-pricing model to determine the fair value of the stock options on the date of grant. This model derives the fair value of the options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate, and dividend yield. The Company uses the Monte Carlo option model to determine the fair value of the granted profits interests units.

For service-vesting awards (i.e., restricted stock units), we recognize stock-based compensation expense over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. If the award was, in substance, multiple awards, we recognize stock-based compensation expense over the requisite service period for each separately vesting portion of the awards. For performance-vesting awards (i.e., performance stock units), we recognize stock-based compensation expense when it is probable that the performance condition will be achieved. We analyze if a performance condition is probable for each reporting period through the settlement date for awards subject to

performance vesting. Stock-based compensation is included in corporate, general and administrative expenses on our consolidated statements of operations. Shares issued pursuant to our equity incentive plan are issued from authorized but unissued shares or from shares held by the Company as treasury stock, if any.

Income Taxes

Income Taxes

The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Senior Housing Thornton, LLC ("SH1") and InnovAge Sacramento have elected to be taxed as partnerships, and no provision (benefit) for income taxes for SH1 or InnovAge Sacramento is included in these consolidated financial statements. Further, InnovAge Orlando entered into a joint venture on May 28, 2024 and its members elected to be taxed as a partnership. No provision (benefit) for income taxes for InnovAge Orlando is included in these consolidated financial statements for activity occurring from joint venture formation date through the balance of the fiscal year.

A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.

Variable Interest Entities (VIE)

Variable Interest Entities (VIE)
A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk or whose equity owners lack certain decision-making and economic rights. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity. The primary beneficiary is required to consolidate the VIE. InnovAge Senior Housing Thornton, LLC ("SH1") and Pinewood Lodge, LLP ("PWD") are considered to be VIEs. The Company is not considered the primary beneficiary of PWD but is considered the primary beneficiary of SH1. On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including the Senior Housing unit. The sale closed on May 2, 2024, and as a result, the Company ceased providing senior housing services through PWD.

Recently Adopted Accounting Pronouncements

Financial Instruments

In April 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-04, *Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments* ("ASU 2019-04"), which requires entities to use a current expected credit loss ("CECL") model to measure impairment for most financial assets that are not recorded at fair value through net income. Under the CECL model, an entity will estimate lifetime expected credit losses considering available relevant information about historical events, current conditions and supportable forecasts. The CECL model does not apply to available-for-sale debt securities. The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the standard on July 1, 2023. Our adoption of the standard did not have a material impact on the

consolidated financial statements. The Company makes estimates of expected credit losses based on a combination of factors, including historical losses adjusted for current market conditions, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Recent Accounting Pronouncements Not Yet Adopted

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*. ASU 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual segment disclosures be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is evaluating the impact of ASU 2023-07 on our consolidated financial statements.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. ASU 2023-09 requires additional disclosures related to rate reconciliation, income taxes paid, and other disclosures. ASU 2023-09 requires public companies to annually (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. Additionally, ASU 2023-09 requires public companies to annually disclose the amount of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as the amount of income taxes paid by individual jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2025. The Company is currently evaluating the impact of ASU 2023-09 on our consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

Fair Value Measurements
Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company's own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant.

The three levels of inputs that may be used to measure fair value are:

- Level 1** Unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date
- Level 2** Quoted prices in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the assets or liabilities
- Level 3** Unobservable inputs to the valuation techniques that are significant to the fair value measurements of the assets or liabilities

XML 48 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

12 Months Ended Jun. 30, 2024

Accounting Policies [Abstract] Schedule of Property and Equipment

Property and equipment were comprised of the following as of June 30:

<i>dollars in thousands</i>	Estimated Useful Lives	2024	2023
Land	N/A	\$ 11,970	\$ 11,970
Buildings and leasehold improvements	10 - 40 years	156,064	124,262
Software	3 - 5 years	30,678	26,656
Equipment and vehicles	3 - 7 years	69,495	57,754
Construction in progress	N/A	12,234	42,223
		280,441	262,865
Less accumulated depreciation and amortization		(87,419)	(70,677)
Total property and equipment, net		\$ 193,022	\$ 192,188

XML 49 R29.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

12 Months Ended Jun. 30, 2024

Revenue from Contract with Customer [Abstract] Schedule of Source of Revenue

The Company disaggregates capitation revenue from the following sources for the year ended June 30:

	2024	2023
Medicaid	54 %	54 %
Medicare	46 %	46 %
Private pay and other	*%	*%
Total	100 %	100 %

* Less than 1%

Schedule of Concentration of Net Receivable

The concentration of net receivables from participants and third-party payers as of June 30, 2024 and 2023 was as follows:

	2024	2023
Medicaid	71 %	61 %
Medicare	22 %	29 %
Private pay and other	7 %	10 %
Total	100 %	100 %

XML 50 R30.htm IDEA: XBRL DOCUMENT

Cost and Equity Method Investments (Tables)

12 Months Ended Jun. 30, 2024

Investments, Debt and Equity Securities [Abstract] Schedule of Equity Method and Cost Method Investments

The Company holds cost method and equity method investments as of June 30:

<i>in thousands</i>	2024	2023
Cost method investments	\$ 2,645	\$ 4,645
Equity method investments	—	848
Total investments	\$ 2,645	\$ 5,493

Schedule of Variable Interest Entity

The following table shows the assets and liabilities of SH1 as of June 30:

	2024	2023
<i>in thousands</i>		
Assets		
Cash and cash equivalents	\$ 816	\$ 648
Prepaid expenses and other	5	1
Property, plant and equipment, net	9,465	9,933
Deposits and other, net	409	402
Liabilities		
Accounts payable and accrued expenses	295	268
Noncurrent liabilities	456	454
Long-term debt, net of debt issuance costs	3,739	3,784

XML 51 R31.htm IDEA: XBRL DOCUMENT

Goodwill and
Intangible Assets
(Tables)
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Goodwill

12 Months Ended
Jun. 30, 2024

The following table summarizes the changes in goodwill for the fiscal years ended June 30:

<i>in thousands</i>	2024	2023
Balance as of beginning of period	\$ 124,217	\$ 124,217
Goodwill acquired during the period	15,732	—
Balance as of end of period	\$ 139,949	\$ 124,217

Schedule of Intangible Assets

Intangible assets consisted of the following as of June 30:

<i>in thousands</i>	2024	2023
Definite-lived intangible assets		
Customer relationships	\$ 6,600	\$ 6,600
Indefinite-lived intangible assets		
Permits	2,000	2,000
Total intangible assets	8,600	8,600
Accumulated amortization	(4,062)	(3,402)
Balance as of end of period	\$ 4,538	\$ 5,198

Schedule of Expected Future Annual Amortization Expense

The total expected future annual amortization expense for the next 5 years ended June 30, is as follows:

<i>in thousands</i>	Amortization Expense
2025	\$ 660
2026	660
2027	630
2028	540
2029	48

XML 52 R32.htm IDEA: XBRL DOCUMENT

Leases (Tables)
Leases [Abstract]
Schedule of Assets and Liabilities Related to Leases

12 Months Ended
Jun. 30, 2024

The following table presents the components of our ROU assets and their classification in our Balance Sheet as of June 30.

Component of Lease Balances	Balance Sheet Line Items	2024	2023
<i>in thousands</i>			
Assets:			
Operating lease assets	Operating lease assets	\$ 28,416	\$ 21,210
Finance lease assets	Property and equipment, net	15,908	16,378
Total leased assets		\$ 44,324	\$ 37,588

Schedule of Lease Cost

The following table presents the components of our lease cost and the classification of such costs in our Statement of Operations for the years ended June 30.

Component of Lease Cost	Statement of Operations Line Items	2024	2023
<i>in thousands</i>			
Operating lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	\$ 5,402	\$ 4,642
Finance lease expense:			
Amortization of leased assets	Depreciation and amortization	1,984	3,080
Interest on lease liabilities	Interest expense, net	—	1,255
Variable lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	93	82
Short-term lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	172	108
Total lease expense:		\$ 7,651	\$ 9,167

Schedule of Weighted Average Lease Terms and Discount Rates

The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of June 30.

Weighted average remaining lease term:	2024	2023
Operating leases	7.7 years	7.9 years
Finance leases	3.5 years	3.9 years
Weighted average discount rate	2024	2023
Operating leases	6.86 %	6.60 %
Finance leases	7.80 %	7.80 %

Schedule of Future Maturities of Lease Payments for Operating Leases

The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to June 30, 2024.

<i>in thousands</i>	Operating Lease	Finance Lease	Total
2025	\$ 6,023	\$ 6,631	\$ 12,654
2026	5,988	5,389	11,377
2027	5,742	4,514	10,256
2028	4,952	2,461	7,413
2029	4,097	555	4,652
Thereafter	11,582	—	11,582
Total lease payments	38,384	19,550	57,934
Less liability accretion / imputed interest	(7,964)	(2,208)	(10,172)
Total lease liabilities	30,420	17,342	47,762
Less: Current lease liabilities	4,145	4,599	8,744
Total long-term lease liabilities	\$ 26,275	\$ 12,743	\$ 39,018

Schedule of Future Maturities of Lease Payments for Finance Leases

The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to June 30, 2024.

<i>in thousands</i>	Operating Lease	Finance Lease	Total
2025	\$ 6,023	\$ 6,631	\$ 12,654
2026	5,988	5,389	11,377
2027	5,742	4,514	10,256
2028	4,952	2,461	7,413
2029	4,097	555	4,652
Thereafter	11,582	—	11,582
Total lease payments	38,384	19,550	57,934
Less liability accretion / imputed interest	(7,964)	(2,208)	(10,172)
Total lease liabilities	30,420	17,342	47,762
Less: Current lease liabilities	4,145	4,599	8,744
Total long-term lease liabilities	\$ 26,275	\$ 12,743	\$ 39,018

XML 53 R33.htm IDEA: XBRL DOCUMENT

Long-term Debt
(Tables)
[Debt Disclosure \[Abstract\]](#)
[Schedule of Long-term Debt](#)

12 Months Ended
Jun. 30, 2024

The components of our long-term debt are as follows:

	June 30, 2024	June 30, 2023
<i>in thousands</i>		
Senior secured borrowings:		
Term Loan Facility	\$ 63,750	\$ 67,500
Convertible term loan	2,239	2,284
Total debt	65,989	69,784
Less unamortized debt issuance costs	716	1,145
Less current maturities	3,795	3,795
Noncurrent maturities	\$ 61,478	\$ 64,844

[Schedule of Aggregate Maturities of the Total Debt Outstanding](#)

Aggregate maturities of our debt as of June 30, 2024 were as follows:

	Long-term debt <i>in thousands</i>
Year ending June 30:	
2025	\$ 3,795
2026	60,059
2027	63
2028	67
2029	72
Thereafter	1,933
Total debt	\$ 65,989

XML 54 R34.htm IDEA: XBRL DOCUMENT

Fair Value
Measurements
(Tables)
[Fair Value Disclosures \[Abstract\]](#)
[Schedule of Fair Value of Cash, Cash Equivalents and Marketable Securities by Significant Investment Category](#)

12 Months Ended
Jun. 30, 2024

The following table shows the Company’s cash, cash equivalents and marketable securities by significant investment category as of June 30, 2024.

<i>in thousands</i>	Amortized Cost	Fair Value	Cash and Cash Equivalents	Short-term Investments
Cash	\$ 25,793	\$ 25,793	\$ 25,793	\$ —
Level 1				
Money market funds	31,153	31,153	31,153	—
Mutual funds	45,556	45,833	—	45,833
Total	\$ 102,502	\$ 102,779	\$ 56,946	\$ 45,833

XML 55 R35.htm IDEA: XBRL DOCUMENT

Stock-based
Compensation
(Tables)
[Share-Based Payment Arrangement \[Abstract\]](#)
[Schedule of Stock-based Compensation Expense](#)

12 Months Ended
Jun. 30, 2024

A summary of our aggregate stock-based compensation expense is set forth below. Stock-based compensation expense is included in corporate, general and administrative expenses on our consolidated statements of operations.

	Year ended June 30,	
	2024	2023
<i>in thousands</i>		
Stock options	\$ 802	\$ 1,010
Profits interests units	861	867
Restricted stock units	5,169	3,116
Total stock-based compensation expense	\$ 6,832	\$ 4,993

[Schedule of Weighted-Average Assumptions and Black-Scholes Option Pricing Model](#)

The assumptions under the Monte Carlo model related to the profits interests units for fiscal 2024, presented on a weighted-average basis, are provided below:

	2024
Expected volatility	68.0 - 76.0 %
Expected life (years) - time vesting units	2.7 - 3.1
Interest rate	4.23 - 4.57 %
Dividend yield	—
Weighted-average fair value	\$ 1.59 - 2.17
Fair value of underlying stock	\$ 5.52 - 7.27

The fair value of the time-based stock options granted during the year ended June 30, 2023, was based upon the Black-Scholes option pricing model using the assumptions in the following table:

	2023
Expected volatility	34.5 %
Weighted-average expected life (years) - time vesting units	2.9
Interest rate	1.56 %
Dividend yield	0 %
Weighted-average fair values	\$ 0.80
Fair value of underlying stock	\$ 3.70

[Schedule of Profits Interests Transactions and Number of Units Outstanding](#)

A summary of profits interests activity for the year ended June 30, 2024, was as follows:

Time-based unit awards	Number of units	Weighted average grant date fair value
Outstanding balance, June 30, 2023	1,264,337	\$ 1.28
Granted	1,106,850	6.21
Forfeited	(380,679)	1.28
Vested	(703,395)	1.28
Outstanding balance, June 30, 2024	1,287,113	\$ 5.52
Performance-based unit awards	Number of units	Weighted average grant date fair value
Outstanding balance, June 30, 2023	2,118,558	\$ 0.57
Granted	1,106,850	1.78
Forfeited	(1,853,737)	0.57
Vested	—	—
Outstanding balance, June 30, 2024	1,371,671	\$ 1.55

Schedule of Restricted Stock Units Activity

A summary of time-based vesting restricted stock units activity for the year ended June 30, 2024, was as follows:

Restricted stock units - time based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	1,873,794	\$ 10.10
Forfeited	(143,935)	\$ 5.49
Vested	(720,326)	\$ 5.25
Granted	1,854,786	\$ 4.84
Outstanding balance, June 30, 2024	2,864,319	\$ 8.15

A summary of performance-based vesting restricted stock units activity for the year ended June 30, 2024, was as follows:

Restricted stock units - performance based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	258,767	\$ 5.18
Forfeited	—	\$ —
Vested	—	\$ —
Granted	—	\$ —
Outstanding balance, June 30, 2024	258,767	\$ 5.18

Schedule of Stock Option Activity

A summary of time-based vesting stock option activity for the year ended June 30, 2024, was as follows:

Stock options - time based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	716,661	\$ 1.43
Granted	—	\$ —
Forfeited	(108,108)	\$ 0.31
Exercised	(54,054)	\$ 0.19
Expired	—	\$ —
Outstanding balance, June 30, 2024	554,499	\$ 1.77
Exercisable balance, June 30, 2024	346,560	\$ 0.17

A summary of performance-based vesting stock option activity for the year ended June 30, 2024, was as follows:

Stock options - performance based	Number of awards	Weighted average grant-date fair value per share
Outstanding balance, June 30, 2023	776,299	\$ 3.08
Granted	—	\$ —
Forfeited	—	\$ —
Vested	—	\$ —
Outstanding balance, June 30, 2024	776,299	\$ 3.08

XML 56 R36.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables)

12 Months Ended
Jun. 30, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation
[Abstract]
Schedule of Preliminary Allocation of the Purchase Price

The following table presents a preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:

	Preliminary allocation	Measurement period adjustments	Adjusted allocation
	<i>in thousands</i>		
Cash Consideration	\$ 23,916	\$ —	\$ 23,916
Total Consideration	\$ 23,916	\$ —	\$ 23,916
Accounts receivable, net	\$ 563	\$ (124)	\$ 439
Prepaid expenses	330	739	1,069
Property and equipment, net	7,969	—	7,969
Operating lease assets	6,892	923	7,815
Goodwill	17,348	(1,616)	15,732
Deposits and other	343	—	343
Accounts payable and accrued expenses	(353)	78	(275)
Reported and estimated claims	(111)	—	(111)
Operating lease obligations	(8,941)	—	(8,941)
Finance lease obligations	(124)	—	(124)
Fair value of assets and liabilities	\$ 23,916	\$ —	\$ 23,916

Schedule of Assets Acquired and Liabilities Assumed

The following table presents a preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:

	Preliminary allocation	Measurement period adjustments	Adjusted allocation
	<i>in thousands</i>		
Cash Consideration	\$ 23,916	\$ —	\$ 23,916
Total Consideration	\$ 23,916	\$ —	\$ 23,916
Accounts receivable, net	\$ 563	\$ (124)	\$ 439
Prepaid expenses	330	739	1,069
Property and equipment, net	7,969	—	7,969
Operating lease assets	6,892	923	7,815
Goodwill	17,348	(1,616)	15,732
Deposits and other	343	—	343
Accounts payable and accrued expenses	(353)	78	(275)
Reported and estimated claims	(111)	—	(111)
Operating lease obligations	(8,941)	—	(8,941)
Finance lease obligations	(124)	—	(124)
Fair value of assets and liabilities	\$ 23,916	\$ —	\$ 23,916

XML 57 R37.htm IDEA: XBRL DOCUMENT

Income Taxes
(Tables)
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate
Reconciliation

12 Months Ended
Jun. 30, 2024

The Company’s effective income tax rate for the years ended June 30, 2024 and 2023 was (6.4)% and 14.3%, respectively, which differed from the amount computed by applying the applicable U.S. federal statutory corporate income tax rate of 21% in each period as a result of the following factors:

	Year ended June 30,	
	2024	2023
	<i>in thousands</i>	
Statutory rate	\$ (4,581)	\$ (10,667)
IRC Section 162(m) limitation (a)	504	588
Change in valuation allowance	6,543	4,297
Permanent adjustments	614	457
Prior year true-up and other	(349)	157
Income from entities not subject to taxation	404	605
State tax	(1,733)	(2,678)
Provision (benefit) for income taxes	\$ 1,402	\$ (7,241)

(a) Reflects the permanent addback for the Section 162(m) limitation, which limits the deduction of compensation for the five highest paid officers to \$1.0 million per officer.

Schedule of Provision for Income Taxes

Provision (benefit) for income taxes consisted of the following for the years ended June 30, 2024 and 2023:

	Year ended June 30,	
	2024	2023
	<i>in thousands</i>	
Current:		
Federal	\$ —	\$ 3,709
State	178	575
Total current tax expense	178	4,284
Deferred:		
Federal	445	(10,263)
State	779	(1,262)
Total deferred tax expense	1,224	(11,525)
Total provision (benefit) for income taxes	\$ 1,402	\$ (7,241)

Schedule of Components of Deferred Tax Assets and Liabilities

The significant components of deferred tax assets and liabilities were as follows for the years ended June 30, 2024 and 2023:

	Year ended June 30,	
	2024	2023
	<i>in thousands</i>	
Deferred tax assets:		
Amortization	\$ 573	\$ 629
Federal net operating losses	22,873	17,147
State net operating losses	8,053	5,701
Provision for uncollectible accounts	1,755	1,114
Accrued vacation	469	835
Reported and estimated claims	1,505	1,164
Stock-based compensation	511	449
Accrued bonuses	1,180	582
Interest Expense	1,943	791
Lease liability	9,260	6,784
Total deferred tax assets	48,122	35,196
Valuation allowance	(15,948)	(8,347)
Deferred tax assets, net of valuation allowance	32,174	26,849
Deferred tax liabilities:		
Goodwill	(9,207)	(6,697)
Depreciation	(16,288)	(13,137)
Equity investment	(4,696)	(5,019)
Prepaid expenses	(705)	(1,792)
ROU asset	(8,684)	(6,436)
Other	(54)	(4)
Total deferred tax liabilities	(39,634)	(33,085)
Net deferred tax liability	\$ (7,460)	\$ (6,236)

XML 58 R38.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

Segment Reporting [Abstract]
Schedule of Operating Results by Reportable Segments

12 Months Ended Jun. 30, 2024

The following table summarizes the operating results regularly provided to the CODM by segment for the years ended June 30, 2024 and 2023:

<i>in thousands</i>	June 30, 2024			June 30, 2023		
	PACE	All other ⁽¹⁾	Totals	PACE	All other ⁽¹⁾	Totals
Capitation revenue	\$ 762,570	\$ —	\$ 762,570	\$ 686,836	\$ —	\$ 686,836
Other service revenue	310	975	1,285	347	904	1,251
Total revenues	762,880	975	763,855	687,183	904	688,087
External provider costs	403,010	—	403,010	374,528	—	374,528
Cost of care, excluding depreciation and amortization	228,203	578	228,781	211,707	564	212,271
Center-Level Contribution Margin	131,667	397	132,064	100,948	340	101,288
Overhead costs ⁽²⁾	136,284	10	136,294	135,264	—	135,264
Depreciation and amortization	18,477	473	18,950	14,959	460	15,419
Interest expense, net	3,845	178	4,023	1,342	180	1,522
Gain on cost and equity method investments	(2,842)	—	(2,842)	—	—	—
Other income	(2,542)	—	(2,542)	(124)	—	(124)
Loss Before Income Taxes	\$ (21,555)	\$ (264)	\$ (21,819)	\$ (50,493)	\$ (300)	\$ (50,793)

- (1) Center-level Contribution Margin from a segment below the quantitative thresholds is attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.
- (2) Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.

XML 59 R39.htm IDEA: XBRL DOCUMENT

Earnings per Share (Tables)

Earnings Per Share [Abstract]
Schedule of Earnings per Share

The following table sets forth the computation of basic and diluted net loss per common share:

<i>in thousands, except share values</i>	Year ended June 30,	
	2024	2023
Net loss attributable to InnovAge Holding Corp.	\$ (21,338)	\$ (40,673)
Weighted average common shares outstanding (basic)	135,902,214	135,593,824
EPS (basic)	\$ (0.16)	\$ (0.30)
Dilutive shares	—	—
Weighted average common shares outstanding (diluted)	135,902,214	135,593,824
EPS (diluted)	\$ (0.16)	\$ (0.30)

XML 60 R40.htm IDEA: XBRL DOCUMENT

Business (Details)

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Number of reportable segments segment	1
Number of PACE participants participant	7,020
Number of PACE centers excluding non-consolidating joint ventures center	20
Percentage of obligation for health care costs	100.00%

12 Months Ended Jun. 30, 2024 participant center segment

12 Months Ended		
Summary of Significant Accounting Policies - Investments (Details) - USD (\$)		
	Jun. 30, 2024	Jun. 30, 2023
\$ in Millions		

Accounting Policies [Abstract]

Impairment loss in investments	\$ 2.0	\$ 0.0

12 Months Ended		
Summary of Significant Accounting Policies - Restricted Cash (Details) - USD (\$)		
	Jun. 30, 2024	Jun. 30, 2023
\$ in Thousands		

Restricted Cash and Cash Equivalents Items [Line Items]

Restricted cash	\$ 14	\$ 16

Personal-Needs Account

Restricted Cash and Cash Equivalents Items [Line Items]

Restricted cash	\$ 10	\$ 20

12 Months Ended		
Summary of Significant Accounting Policies - Property and Equipment (Details) - USD (\$)		
	Jun. 30, 2024	Jun. 30, 2023

Summary of Significant Accounting Policies

Property and equipment gross	\$ 280,441,000	\$ 262,865,000
Less accumulated depreciation and amortization	(87,419,000)	(70,677,000)
Total property and equipment, net	193,022,000	192,188,000
Depreciation	18,300,000	14,800,000
Capitalized interest	10,000.00	1,000,000.0
Impairment charges	0	0

Land

Summary of Significant Accounting Policies

Property and equipment gross	11,970,000	11,970,000

Buildings and leasehold improvements

Summary of Significant Accounting Policies

Property and equipment gross	\$ 156,064,000	124,262,000

Buildings and leasehold improvements | Minimum

Summary of Significant Accounting Policies

Estimated Useful Lives	10 years

Buildings and leasehold improvements | Maximum

Summary of Significant Accounting Policies

Estimated Useful Lives	40 years

Software

Summary of Significant Accounting Policies

Property and equipment gross	\$ 30,678,000	26,656,000

Software | Minimum

Summary of Significant Accounting Policies

Estimated Useful Lives	3 years

Software | Maximum

Summary of Significant Accounting Policies

Estimated Useful Lives	5 years

Equipment and vehicles

Summary of Significant Accounting Policies

Property and equipment gross	\$ 69,495,000	57,754,000

Equipment and vehicles | Minimum

Summary of Significant Accounting Policies

Estimated Useful Lives	3 years

Equipment and vehicles | Maximum

Summary of Significant Accounting Policies

Estimated Useful Lives	7 years

Construction in progress

Summary of Significant Accounting Policies

Property and equipment gross	\$ 12,234,000	\$ 42,223,000

12 Months Ended		
Summary of Significant Accounting Policies - Goodwill and Intangible Assets (Details)		
	Jun. 30, 2024 USD (\$) reporting_unit	Jun. 30, 2023 USD (\$)

Accounting Policies [Abstract]

Number of reporting units | reporting_unit

Goodwill, impairment charges	\$ 0	\$ 0

Intangible assets, useful life (in years)	10 years

Intangible assets, impairment charges	\$ 0	\$ 0

12 Months Ended		
Summary of Significant Accounting Policies - Advertising Costs (Details) - USD (\$)		
	Jun. 30, 2024	Jun. 30, 2023
\$ in Millions		

Accounting Policies [Abstract]

Advertising expenses	\$ 6.8	\$ 5.6

12 Months Ended		
Revenue Recognition - Narrative (Details) - USD (\$)		
	Jun. 30, 2024	Jun. 30, 2023
\$ in Thousands		

Revenue Recognition

Pooled capitated payment	100.00%

Amortization of term of cost to obtain contract

Contract assets	3 years

Accounts receivable, net of allowance	\$ 2,800	\$ 1,000

Revenue from Contract with Customer Benchmark Customer Concentration Risk	\$ 6,729	\$ 4,161

Revenue Recognition

Risk percentage	100.00%	100.00%

\$

Variable Interest Entity, Not Primary Beneficiary | Orlando Health

Nonconsolidated Entities

Cash and cash equivalents	\$ 2,900,000
Membership interest (as a percent)	10.00%

Variable Interest Entity, Not Primary Beneficiary | InnovAge Sacramento | Adventist Health System/West Joint Venture | Related Party

Nonconsolidated Entities

Membership interest (as a percent)	26.40%
Variable Interest Entity, Not Primary Beneficiary InnovAge Sacramento Eskaton Related Party	

Nonconsolidated Entities

Membership interest (as a percent)	13.70%
Variable Interest Entity, Primary Beneficiary	

Nonconsolidated Entities

Cash and cash equivalents	\$ 816,000	648,000
Partnership interest (as a percent)	0.01%	
Jetdoc, Inc.		

Nonconsolidated Entities

Shares acquired (in shares) shares	806,481		
Payments to acquire investments	\$ 2,000,000.0		
Cost method investment, impairment losses		\$ 100,000	\$ 1,900,000

Observable price changes

Dispatch Health Holdings, Inc.

Nonconsolidated Entities

Observable price changes	\$ 0	\$ 0
Maximum exposure to loss of the cost method investments	\$ 2,600,000	

Dispatch Health Holdings, Inc. | Series B Preferred Stock

Nonconsolidated Entities

Equity securities, FV-NI, current	\$ 1,500,000

Dispatch Health Holdings, Inc. | Series C Preferred Stock

Nonconsolidated Entities

Equity securities, FV-NI, current	\$ 1,100,000

XML 71 R51.htm IDEA: XBRL DOCUMENT

Cost and Equity Method Investments - Schedule of Variable Interest Entity (Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Mar. 18, 2019
\$ in Thousands			

Assets

Cash and cash equivalents	\$ 56,946	\$ 127,249	\$ 9,000
Deposits and other, net	5,949	3,823	

Liabilities

Accounts payable and accrued expenses	55,459	54,935	
Long-term debt, net of debt issuance costs	61,478	64,844	

Variable Interest Entity, Primary Beneficiary

Assets

Cash and cash equivalents	816	648	
Prepaid expenses and other	5	1	
Property, plant and equipment, net	9,465	9,933	
Deposits and other, net	409	402	

Liabilities

Accounts payable and accrued expenses	295	268	
Noncurrent liabilities	456	454	
Long-term debt, net of debt issuance costs	\$ 3,739	\$ 3,784	

XML 72 R52.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Narrative (Details)	12 Months Ended Jun. 30, 2024 USD (\$)	Jun. 30, 2023 USD (\$)	Jun. 30, 2022 USD (\$)
	reporting_unit acquisition		

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill	\$ 139,949,000	\$ 124,217,000	\$ 124,217,000
Number of acquisition resulting in goodwill acquisition	1		
Goodwill acquired during the period	\$ 15,732,000	0	
Number of reporting units reporting_unit	2		
Impairment of goodwill	\$ 0	0	
Amortization expense	700,000	700,000	
Intangible asset impairments	\$ 0	\$ 0	

XML 73 R53.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023

Goodwill [Roll Forward]

Balance as of beginning of period	\$ 124,217,000	\$ 124,217,000
Goodwill acquired during the period	15,732,000	0
Balance as of end of period	\$ 139,949,000	\$ 124,217,000

XML 74 R54.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Schedule of Intangible Asset (Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023
\$ in Thousands		

Intangible Assets, Net (Including Goodwill) [Abstract]

Definite-lived intangible assets	\$ 6,600	\$ 6,600
Indefinite-lived intangible assets	2,000	2,000
Total intangible assets	8,600	8,600
Accumulated amortization	(4,062)	(3,402)
Balance as of end of period	\$ 4,538	\$ 5,198

XML 75 R55.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets -

Schedule of Expected Jun. 30, 2024
Future Annual USD (\$)
Amortization Expense
(Details)
\$ in Thousands
Amortization Expense
2025 \$ 660
2026 660
2027 630
2028 540
2029 \$ 48

XML 76 R56.htm IDEA: XBRL DOCUMENT

Leases - Narrative
(Details) Mar. 20, 2023
\$ in Millions USD (\$)

Leases [Abstract]
Lease termination costs \$ 0.6

XML 77 R57.htm IDEA: XBRL DOCUMENT

Leases - Schedule of
Assets and Liabilities
Related to Leases
(Details) - USD (\$)
\$ in Thousands

Jun. 30, 2024

Jun. 30,
2023

Assets:
Operating lease assets \$ 28,416
Finance lease assets \$ 15,908
Finance Lease, Right-of-Use Asset, Statement of Financial Position Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated
[Extensible Enumeration] Depreciation and Amortization
Total leased assets \$ 44,324

\$ 21,210
16,378

\$ 37,588

XML 78 R58.htm IDEA: XBRL DOCUMENT

Leases - Schedule of
Lease Cost (Details) -
USD (\$)
\$ in Thousands

12 Months Ended

Jun. 30, 2024 Jun. 30, 2023

Component of Lease Cost
Total lease expense: \$ 7,651 \$ 9,167
Cost of care excluding depreciation and amortization and Corporate, general and administrative
Component of Lease Cost
Operating lease cost 5,402 4,642
Variable lease cost 93 82
Short-term lease cost 172 108
Depreciation and amortization
Component of Lease Cost
Amortization of leased assets 1,984 3,080
Interest expense, net
Component of Lease Cost
Interest on lease liabilities \$ 0 \$ 1,255

XML 79 R59.htm IDEA: XBRL DOCUMENT

Leases - Schedule of
Weighted Average
Lease Terms and
Discount Rates
(Details)

Jun. 30, 2024

Jun. 30, 2023

Weighted average remaining lease term:

Operating leases 7 years 8 months 12 days 7 years 10 months 24 days
Finance leases 3 years 6 months 3 years 10 months 24 days
Weighted average discount rate
Operating leases 6.86% 6.60%
Finance leases 7.80% 7.80%

XML 80 R60.htm IDEA: XBRL DOCUMENT

Leases - Schedule of
Future Maturities of
Lease Payments
(Details) - USD (\$)
\$ in Thousands

Jun. 30, 2024 Jun. 30, 2023

Operating Lease
2025 \$ 6,023
2026 5,988
2027 5,742
2028 4,952
2029 4,097
Thereafter 11,582
Total lease payments 38,384
Less liability accretion / imputed interest (7,964)
Total lease liabilities 30,420
Less: Current lease liabilities 4,145 \$ 3,530
Total long-term lease liabilities 26,275 18,828
Finance Lease
2025 6,631
2026 5,389
2027 4,514
2028 2,461
2029 555
Thereafter 0
Total lease payments 19,550
Less liability accretion / imputed interest (2,208)
Total lease liabilities 17,342
Less: Current lease liabilities 4,599 4,722
Total long-term lease liabilities 12,743 \$ 13,114
Total
2025 12,654
2026 11,377
2027 10,256
2028 7,413
2029 4,652
Thereafter 11,582
Total lease payments 57,934
Less liability accretion / imputed interest (10,172)
Total lease liabilities 47,762
Less: Current lease liabilities 8,744
Total long-term lease liabilities \$ 39,018

Long-term Debt - Schedule of Long-term Debt (Details) - USD (\$) \$ in Thousands		
Debt Instrument [Line Items]		
Total debt	\$ 65,989	\$ 69,784
Less unamortized debt issuance costs	716	1,145
Less current maturities	3,795	3,795
Noncurrent maturities	61,478	64,844
Term Loan Facility		
Debt Instrument [Line Items]		
Total debt	63,750	67,500
Convertible term loan		
Debt Instrument [Line Items]		
Total debt	\$ 2,239	\$ 2,284

Long-term Debt - Narrative (Details) - USD (\$)	Mar. 08, 2021	Jun. 29, 2015	Jun. 30, 2024	Jun. 30, 2023
12 Months Ended				
Debt Instrument [Line Items]				
Outstanding borrowings			\$ 65,989,000	\$ 69,784,000
Revolving Credit Facility				
Debt Instrument [Line Items]				
Letters of credit, issued amounts			3,900,000	
Remaining borrowing capacity			96,100,000	
Term Loan Facility				
Debt Instrument [Line Items]				
Outstanding borrowings			63,750,000	67,500,000
Convertible term loan				
Debt Instrument [Line Items]				
Interest rate (as a percent)	6.68%			
Outstanding borrowings			2,239,000	2,284,000
Monthly principal and interest payments		\$ 20,000.00		
2021 Credit Agreement Revolving Credit Facility				
Debt Instrument [Line Items]				
Loan amount	\$ 100,000,000.0			
Revolving credit facility fee	0.25%			
Outstanding borrowings			0	
Deferred financing costs amortized			2,000,000.0	
Amortization of deferred financing costs			\$ 400,000	\$ 400,000
2021 Credit Agreement Term Loan Facility				
Debt Instrument [Line Items]				
Loan amount	\$ 75,000,000.0			
Percentage of aggregate outstanding principal amount	1.25%			
Interest rate (as a percent)			7.18%	6.95%

Long-term Debt - Schedule of Aggregate Maturities of the Total Debt USD (\$) Outstanding (Details) \$ in Thousands	
Long-term debt	
2025	\$ 3,795
2026	60,059
2027	63
2028	67
2029	72
Thereafter	1,933
Total debt	\$ 65,989

Fair Value Measurements - Schedule of Fair Value of Cash, Cash Equivalents and Marketable Securities by Significant Investment Category (Details) \$ in Thousands		Jun. 30, 2024 USD (\$)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]		
Amortized Cost		\$ 102,502
Fair Value		102,779
Cash and Cash Equivalents		56,946
Short-term Investments		45,833
Cash		
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]		
Amortized Cost		25,793
Fair Value		25,793
Cash and Cash Equivalents		25,793
Short-term Investments		0
Money market funds Level 1		
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]		
Amortized Cost		31,153
Fair Value		31,153
Cash and Cash Equivalents		31,153
Short-term Investments		0
Mutual funds Level 1		
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]		
Amortized Cost		45,556
Fair Value		45,833
Cash and Cash Equivalents		0
Short-term Investments		\$ 45,833

Fair Value Measurements - Narrative (Details) - USD (\$) \$ in Thousands		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022

Fair Value Disclosures [Abstract]

Redeemable noncontrolling interest, equity, carrying amount \$ 22,200 \$ 12,708 \$ 15,278

XML 86 R66.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD (\$) \$ in Millions	1 Months Ended 3 Months Ended		
	Jun. 28, 2023	Oct. 31, 2023	Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Pending litigation, motion to dismiss resolution, notice period 15 days

Settlement agreement amount subject to court approval

\$ 1.3 \$ 1.2

Legal settlement, settlement period

180 days

XML 87 R67.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Stock- based Compensation Expense (Details) - USD (\$) \$ in Thousands	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Total stock-based compensation expense

\$ 6,832 \$ 4,993

Stock options

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Total stock-based compensation expense

802 1,010

Profits interests units

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Total stock-based compensation expense

861 867

Restricted stock units

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Total stock-based compensation expense

\$ 5,169 \$ 3,116

XML 88 R68.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Equity Incentive Plan (Details)	12 Months Ended	
	Jun. 30, 2024	
	shares	

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Profits interests granted (in shares)

2,213,700

2020 Equity Incentive Plan

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of shares authorized (in shares)

16,162,177

Profits interests granted (in shares)

15,222,837

XML 89 R69.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Weighted-Average Assumptions (Details) - Profits interests units	12 Months Ended	
	Jun. 30, 2024	
	\$ / shares	

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Minimum expected volatility

68.00%

Maximum expected volatility

76.00%

Minimum interest rate

4.23%

Maximum interest rate

4.57%

Dividend yield

0.00%

Minimum

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expected life (years) - time vesting units

2 years 8 months 12 days

Weighted-average fair values (in dollars per share)

\$ 1.59

Fair value of underlying stock (in dollars per share)

\$ 5.52

Maximum

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expected life (years) - time vesting units

3 years 1 month 6 days

Weighted-average fair values (in dollars per share)

\$ 2.17

Fair value of underlying stock (in dollars per share)

\$ 7.27

XML 90 R70.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Profits Interests Transactions and Number of Units Outstanding (Details) \$ / shares in Units, \$ in Millions	12 Months Ended	
	Jun. 30, 2024	
	USD (\$) \$ / shares shares	

Number of units

Granted (in shares)

2,213,700

Time-based unit awards

Number of units

Unvested balance, beginning (in shares)

1,264,337

Granted (in shares)

1,106,850

Forfeited (in shares)

(380,679)

Vested (in shares)

(703,395)

Unvested balance, ending (in shares)

1,287,113

Weighted average grant date fair value

Unvested balance, beginning (in dollars per share) | \$ / shares

\$ 1.28

Granted (in dollars per share) | \$ / shares

6.21

Forfeited (in dollars per share) | \$ / shares

1.28

Vested (in dollars per share) | \$ / shares

1.28

Unvested balance, ending (in dollars per share) | \$ / shares

\$ 5.52

Unrecognized compensation cost | \$

\$ 1.8

Weighted-average period (in years)

2 years 9 months 18 days

Performance-based unit awards

Number of units

Unvested balance, beginning (in shares)

2,118,558

Granted (in shares)

1,106,850

Forfeited (in shares)

(1,853,737)

Vested (in shares)

0

Unvested balance, ending (in shares)

1,371,671

Weighted average grant date fair value

Unvested balance, beginning (in dollars per share) | \$ / shares

\$ 0.57

Granted (in dollars per share) | \$ / shares

1.78

Forfeited (in dollars per share) \$ / shares	0.57	
Vested (in dollars per share) \$ / shares	0	
Unvested balance, ending (in dollars per share) \$ / shares	\$ 1.55	
Unrecognized compensation cost \$	\$ 2.1	
Profits interests units		
Weighted average grant date fair value		
Unrecognized compensation cost \$	\$ 3.9	
XML 91 R71.htm IDEA: XBRL DOCUMENT		
Stock-based Compensation - 2021 Omnibus Incentive Plan and Restricted Stock Units (Details) - USD (\$)		1 Months Ended 12 Months Ended
\$ in Millions		
Restricted stock units - performance based		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Unrecognized compensation cost		\$ 0.4
Weighted-average period (in years)		1 year 6 months
2021 Omnibus Incentive Plan		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Number of shares authorized (in shares)	14,700,000	
2021 Omnibus Incentive Plan Time-based restricted stock units (RSUs)		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Vesting period (in years)	3 years	
2021 Omnibus Incentive Plan Time-based stock options		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Vesting period (in years)	3 years	
2021 Omnibus Incentive Plan Restricted stock units		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Unrecognized compensation cost		\$ 11.3
Weighted-average period (in years)		2 years
2021 Omnibus Incentive Plan Percentage of Vesting, Second Anniversary Time-based restricted stock units (RSUs)		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Percentage of vesting	100.00%	
2021 Omnibus Incentive Plan Percentage of vesting Year 1 Time-based restricted stock units (RSUs)		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Percentage of vesting	33.33%	
2021 Omnibus Incentive Plan Percentage of vesting Year 2 Time-based restricted stock units (RSUs)		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Percentage of vesting	33.33%	
2021 Omnibus Incentive Plan Percentage of vesting Year 3 Time-based restricted stock units (RSUs)		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Percentage of vesting	33.33%	
XML 92 R72.htm IDEA: XBRL DOCUMENT		
Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details)	12 Months Ended	
	Jun. 30, 2024	
	\$ / shares	
	shares	
Number of awards		
Granted (in shares)	2,213,700	
Restricted stock units - time based		
Number of awards		
Unvested balance, beginning (in shares)	1,873,794	
Forfeited (in shares)	(143,935)	
Vested (in shares)	(720,326)	
Granted (in shares)	1,854,786	
Unvested balance, ending (in shares)	2,864,319	
Weighted average grant-date fair value per share		
Unvested balance, beginning (in dollars per share) \$ / shares	\$ 10.10	
Forfeited (in dollars per share) \$ / shares	5.49	
Vested (in dollars per share) \$ / shares	5.25	
Granted (in dollars per share) \$ / shares	4.84	
Unvested balance, ending (in dollars per share) \$ / shares	\$ 8.15	
Restricted stock units - performance based		
Number of awards		
Unvested balance, beginning (in shares)	258,767	
Forfeited (in shares)	0	
Vested (in shares)	0	
Granted (in shares)	0	
Unvested balance, ending (in shares)	258,767	
Weighted average grant-date fair value per share		
Unvested balance, beginning (in dollars per share) \$ / shares	\$ 5.18	
Forfeited (in dollars per share) \$ / shares	0	
Vested (in dollars per share) \$ / shares	0	
Granted (in dollars per share) \$ / shares	0	
Unvested balance, ending (in dollars per share) \$ / shares	\$ 5.18	
XML 93 R73.htm IDEA: XBRL DOCUMENT		
Stock-based Compensation - Schedule of Time-based Awards (Details) - Stock options - time based \$ / shares in Units, \$ in Thousands	12 Months Ended	
	Jun. 30, 2024	
	USD (\$)	
	\$ / shares	
	shares	
Number of awards		
Outstanding balance, beginning (in shares) shares	716,661	
Granted (in shares) shares	0	
Forfeited (in shares) shares	(108,108)	
Exercised (in shares) shares	(54,054)	
Expired (in shares) shares	0	
Outstanding balance, ending (in shares) shares	554,499	
Exercisable balance (in shares) shares	346,560	
Weighted average grant-date fair value per share		
Outstanding balance, beginning (in dollars per share) \$ / shares	\$ 1.43	
Granted (in dollars per share) \$ / shares	0	
Forfeited (in dollars per share) \$ / shares	0.31	

Exercised (in dollars per share) \$ / shares	0.19
Expired (in dollars per share) \$ / shares	0
Outstanding balance, ending (in dollars per share) \$ / shares	1.77
Exercisable balance (in dollars per share) \$ / shares	\$ 0.17
Unrecognized compensation cost \$	\$ 90
Weighted-average period (in years)	1 year 4 months 24 days

XML 94 R74.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Black-Scholes Option Pricing Model (Details) - Time-Based Awards	12 Months Ended
	Jun. 30, 2023
	\$ / shares

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expected volatility	34.50%
Weighted-average expected life (years) - time vesting units	2 years 10 months 24 days
Interest rate	1.56%
Dividend yield	0.00%
Weighted-average fair values (in dollars per share)	\$ 0.80
Fair value of underlying stock (in dollars per share)	\$ 3.70

XML 95 R75.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Performance-based Awards (Details) - Stock options - performance based - USD (\$)	12 Months Ended
	Jun. 30, 2024
	Jun. 30, 2023
\$ / shares in Units, \$ in Millions	

Number of awards

Outstanding balance, beginning (in shares)	776,299
Granted (in shares)	0
Forfeited (in shares)	0
Vested (in shares)	0
Outstanding balance, ending (in shares)	776,299

Weighted average grant-date fair value per share

Outstanding balance, beginning (in dollars per share)	\$ 3.08	\$ 3.08
Granted (in dollars per share)	0	
Forfeited (in dollars per share)	0	
Vested (in dollars per share)	0	
Outstanding balance, ending (in dollars per share)	\$ 3.08	
Unrecognized compensation cost	\$ 0.8	
Weighted-average period (in years)	1 year 7 months 6 days	

XML 96 R76.htm IDEA: XBRL DOCUMENT

Acquisitions - Narrative (Details)	Jun. 30, 2024	Dec. 01, 2023	7 Months Ended	12 Months Ended
	USD (\$)	USD (\$)	Jun. 30, 2024	Jun. 30, 2024
		program	USD (\$)	Jun. 30, 2023
				USD (\$)

Business Acquisition [Line Items]

Acquisition of business				\$ 23,916,000	\$ 0
Measurement period, adjustments accounts receivable, net Concerto			\$ 124,000		

Business Acquisition [Line Items]

Number of programs acquired program	2				
Acquisition of business	\$ 23,916,000	\$ 23,916,000			
Costs incurred related to the acquisition				\$ 100,000	
Goodwill expected to be deductible for income tax purposes		\$ 0			
Measurement period adjustments, prepaid expenses			739,000		
Measurement period adjustments, operating lease assets			923,000		
Measurement period, adjustments accounts receivable, net			100,000		
Measurement period adjustments, accounts payable and accrued expenses			78,000		
Measurement period adjustments, goodwill			\$ 1,616,000		

XML 97 R77.htm IDEA: XBRL DOCUMENT

Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) - USD (\$)	7 Months Ended	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
	Dec. 01, 2023	Jun. 30, 2023
\$ in Thousands		

Business Acquisition [Line Items]

Cash Consideration			\$ 23,916	\$ 0	
Measurement period, adjustments accounts receivable, net			\$ (124)		
Goodwill	\$ 139,949		139,949	139,949	\$ 124,217
Concerto					\$ 124,217

Business Acquisition [Line Items]

Cash Consideration	23,916	\$ 23,916			
Total Consideration	23,916	23,916			
Accounts receivable, net	439	563	439	439	
Measurement period, adjustments accounts receivable, net			(100)		
Prepaid expenses	1,069	330	1,069	1,069	
Measurement period adjustments, prepaid expenses			739		
Property and equipment, net	7,969	7,969	7,969	7,969	
Operating lease assets	7,815	6,892	7,815	7,815	
Measurement period adjustments, operating lease assets			923		
Goodwill	15,732	17,348	15,732	15,732	
Measurement period adjustments, goodwill			(1,616)		
Deposits and other	343	343	343	343	
Accounts payable and accrued expenses	(275)	(353)	(275)	(275)	
Measurement period adjustments, accounts payable and accrued expenses			78		
Reported and estimated claims	(111)	(111)	(111)	(111)	
Operating lease obligations	(8,941)	(8,941)	(8,941)	(8,941)	
Finance lease obligations	(124)	(124)	(124)	(124)	
Fair value of assets and liabilities	\$ 23,916	\$ 23,916	23,916	\$ 23,916	
Measurement period adjustments, fair value of assets and liabilities			\$ 0		

XML 98 R78.htm IDEA: XBRL DOCUMENT

Income Taxes - Effective Income Tax	12 Months Ended

Reconciliation Jun. 30, 2024 Jun. 30, 2023
(Details)

Income Tax Disclosure [Abstract]

Effective tax rate (as a percent) (6.40%) 14.30%

XML 99 R79.htm IDEA: XBRL DOCUMENT

Income Taxes - 12 Months Ended
Schedule of Effective

Income Tax Jun. 30, 2024 Jun. 30, 2023
Reconciliation USD (\$) officer USD (\$)
(Details)
\$ in Thousands

Income Tax Disclosure [Abstract]

Statutory rate \$ (4,581) \$ (10,667)
IRC Section 162(m) limitation 504 588
Change in valuation allowance 6,543 4,297
Permanent adjustments 614 457
Prior year true-up and other (349) 157
Income from entities not subject to taxation 404 605
State tax (1,733) (2,678)
Provision (benefit) for income taxes \$ 1,402 \$ (7,241)
Highest compensation paid, officers | officer 5
Nondeductible compensation paid \$ 1,000

XML 100 R80.htm IDEA: XBRL DOCUMENT

Income Taxes - 12 Months Ended
Schedule of Provision

for Income Taxes Jun. 30, 2024 Jun. 30, 2023
(Details) - USD (\$) officer
\$ in Thousands

Current:

Federal \$ 0 \$ 3,709
State 178 575
Total current tax expense 178 4,284

Deferred:

Federal 445 (10,263)
State 779 (1,262)
Total deferred tax expense 1,224 (11,525)
Provision (benefit) for income taxes \$ 1,402 \$ (7,241)

XML 101 R81.htm IDEA: XBRL DOCUMENT

Income Taxes -
Schedule of
Components of
Deferred Tax Assets Jun. 30, 2024 Jun. 30, 2023
and Liabilities
(Details) - USD (\$) officer
\$ in Thousands

Deferred tax assets:

Amortization \$ 573 \$ 629
Federal net operating losses 22,873 17,147
State net operating losses 8,053 5,701
Provision for uncollectible accounts 1,755 1,114
Accrued vacation 469 835
Reported and estimated claims 1,505 1,164
Stock-based compensation 511 449
Accrued bonuses 1,180 582
Interest Expense 1,943 791
Lease liability 9,260 6,784
Total deferred tax assets 48,122 35,196
Valuation allowance (15,948) (8,347)
Deferred tax assets, net of valuation allowance 32,174 26,849

Deferred tax liabilities:

Goodwill (9,207) (6,697)
Depreciation (16,288) (13,137)
Equity investment (4,696) (5,019)
Prepaid expenses (705) (1,792)
ROU asset (8,684) (6,436)
Other (54) (4)
Total deferred tax liabilities (39,634) (33,085)
Net deferred tax liability \$ (7,460) \$ (6,236)

XML 102 R82.htm IDEA: XBRL DOCUMENT

Income Taxes -
Carryforwards Jun. 30, 2024 Jun. 30, 2023
(Details) - USD (\$) officer

Operating Loss Carryforwards [Line Items]

Valuation allowance \$ 15,948,000 \$ 8,347,000
Uncertain tax positions 0 0
State and Local Jurisdiction

Operating Loss Carryforwards [Line Items]

Net operating loss carryforwards 185,800,000 117,900,000
Domestic Tax Authority

Operating Loss Carryforwards [Line Items]

Net operating loss carryforwards \$ 108,900,000 \$ 81,700,000

XML 103 R83.htm IDEA: XBRL DOCUMENT

Related Parties 12 Months Ended
(Details) - USD (\$) officer May 02, 2024 Jun. 30, 2024 Jun. 30, 2023
\$ in Thousands

Related Party Transaction [Line Items]

Proceeds from sale of real estate \$ 4,800
Pinewood Lodge L L P

Related Party Transaction [Line Items]

Proceeds from sale of real estate \$ 9,500
Service, Other

Related Party Transaction [Line Items]

Loans and leases receivable, related parties \$ 700
Administrative Fee Per Year

Related Party Transaction [Line Items]

Administrative fee per year \$ 35

XML 104 R84.htm IDEA: XBRL DOCUMENT

Segment Reporting - 12 Months Ended
Narrative (Details) Jun. 30, 2024
center
division
segment

participant

Segment Reporting Information [Line Items]		
Number of operating segments		3
Number of reportable segments		1
Number of PACE participants participant		7,020
Number of PACE centers excluding non-consolidating joint ventures center		20
PACE		
Segment Reporting Information [Line Items]		
Number of operating segments		2
Number of geographic divisions division		2
Number of reportable segments		1

XML 105 R85.htm IDEA: XBRL DOCUMENT

Segment Reporting - Schedule of Operating Results by Reportable Segments (Details) - USD (\$) \$ in Thousands		12 Months Ended	
		Jun. 30, 2024	Jun. 30, 2023

Segment Reporting Information [Line Items]			
Total revenues	\$ 763,855	\$ 688,087	
External provider costs	403,010	374,528	
Cost of care, excluding depreciation and amortization	228,781	212,271	
Center-Level Contribution Margin	132,064	101,288	
Overhead costs	136,294	135,264	
Depreciation and amortization	18,950	15,419	
Interest expense, net	4,023	1,522	
Gain on cost and equity method investments	(2,842)	0	
Other income	(2,542)	(124)	
Loss Before Income Taxes	(21,819)	(50,793)	

Capitation revenue			

Segment Reporting Information [Line Items]			

Total revenues	762,570	686,836	

Other service revenue			

Segment Reporting Information [Line Items]			

Total revenues	1,285	1,251	

PACE			

Segment Reporting Information [Line Items]			

Total revenues	762,880	687,183	

External provider costs	403,010	374,528	

Cost of care, excluding depreciation and amortization	228,203	211,707	

Center-Level Contribution Margin	131,667	100,948	

Overhead costs	136,284	135,264	

Depreciation and amortization	18,477	14,959	

Interest expense, net	3,845	1,342	

Gain on cost and equity method investments	(2,842)	0	

Other income	(2,542)	(124)	

Loss Before Income Taxes	(21,555)	(50,493)	

PACE Capitation revenue			

Segment Reporting Information [Line Items]			

Total revenues	762,570	686,836	

PACE Other service revenue			

Segment Reporting Information [Line Items]			

Total revenues	310	347	

All other			

Segment Reporting Information [Line Items]			

Total revenues	975	904	

External provider costs	0	0	

Cost of care, excluding depreciation and amortization	578	564	

Center-Level Contribution Margin	397	340	

Overhead costs	10	0	

Depreciation and amortization	473	460	

Interest expense, net	178	180	

Gain on cost and equity method investments	0	0	

Other income	0	0	

Loss Before Income Taxes	(264)	(300)	

All other Capitation revenue			

Segment Reporting Information [Line Items]			

Total revenues	0	0	

All other Other service revenue			

Segment Reporting Information [Line Items]			

Total revenues	\$ 975	\$ 904	

XML 106 R86.htm IDEA: XBRL DOCUMENT

Earnings per Share (Details) - USD (\$) \$ / shares in Units, \$ in Thousands		12 Months Ended	
		Jun. 30, 2024	Jun. 30, 2023

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]			
Net loss attributable to InnovAge Holding Corp.	\$ (21,338)	\$ (40,673)	
Weighted average common shares outstanding (basic) (in shares)	135,902,214	135,593,824	
EPS (basic) (in dollars per share)	\$ (0.16)	\$ (0.30)	
Dilutive shares (in shares)	0	0	
Weighted average common shares outstanding (diluted) (in shares)	135,902,214	135,593,824	
EPS (diluted) (in dollars per share)	\$ (0.16)	\$ (0.30)	
Stock options - performance based			

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]			
Potentially anti-dilutive shares (in shares)	1,035,066	1,035,066	

XML 107 R87.htm IDEA: XBRL DOCUMENT

Share Repurchase Program (Details) - USD (\$) \$ in Millions		12 Months Ended	
		Jun. 30, 2024	Jun. 14, 2024

June 2024 Repurchase Program			

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			

Share repurchase program, authorized, amount			\$ 5.0

Common Stock			

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			

Shares repurchased at cost (in shares)	36,559		

Common Stock June 2024 Repurchase Program			

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			

Share repurchase program, number of shares repurchased (in shares)	45,023		

Shares repurchased at cost (in shares)

36,559

[illegible]

[illegible]

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l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b21=46H9C=8^<2^<7#B3D1^<D&=>@<H&F^<F1J3.MQ7^<61H1WBX^<31FD^<T351^<M^<DK71D.46121@<H1NB+<Z^<Q4H8=81\$M.MU1\$51^<W^<#R^<P5+1HA00>U.LEP19Z6VZ>Z^<Y4^<G1Z4^<O1P@<6V1M0A1Y^<4LNE0R>?

[illegible]

UKS,UDLGUD?9>@3^JA,X^%6%B:Z"Q6'7G(^W:'TWM*O+7+RK MJ^ R&A;Q>,X6NNE 99L^8YCDY'J33#Z84I)=X8V_J(\$?V>)FIY3:7OZR.(MW7&)W>L2TWDHU%:333_!F-C8-

2025-01-27 14:00:00

PPD:UHGUM4*4I=EH/HK6+1&FG8+30M?26I U M +=466I?80/4X\$3?E?7I?DX=4Q MBX&=E!+/-<CT>OEQ/MYQ?87B6Q_MV(EPS)"N"00+NRWKE4DL&V9X9+7.02
/OT-HC*MBY6Z0\$1V13VB89BZMLIE3SV?IB3<+XB<+9I?T5N9N?H"AAIV?>#16Q?38/JX?>T:TON_KC8?WH?==H*O1D%0%?1+0WHSM/M/J?>OFXSFP\$1#R\$9K57\$YJ
!#3\$0<=<P#PBBG+AS=M4+WANJO+!>=R2BM\$5N1Z+52J?H?>EL@SV4M@+V2P?>ABKS0+L&KD:0A
MV4?711N^FOP&7^>K/JYVM+FS>Q?CIGU688M(M<+1JHJGHUV MWY+H4@B/JY5M6.D0?>6"0%?%PT.9R:SN0NJBNWXA0+8^>D8I MWVW&E^T\$P067N0M^EDZ
7P3R=>CV5E8H\$5R PAHV17C.VP.51.3X-M+00Q.7R?Q?>SELYWZ+7J&C<1NM0?CY>#S=>MEDBB^>0<6IXK?U^>M7P7FH?YJG:0#>JHJH\$33UJ^&662N
M0IKN=H#6I?>HN0N^KQDH+ATVZW5\$?D1<=>HCO@NYG&N09LX.G&SY?>MX\$Z+VOIW+IU9Y1=J6S.J?>D.GC4YR&:WSH(L)O?>S.KHINTJN-06\$S1\$S=>
MTPJ5-7&IN.PK?JA/ARJUXC21%\$)H@<+N1?>9V1EC(VT)?>2.G@<N?>S+MFGI?>J=>K800B.U?>V6?>3R56.FI B?YVW7ZJ.SV+O?>S^KIK+<V70>0<R-MW&A/M?H:AS1<+<R?>
F?>OU:B*#>AULB<+Y.L.CR.2AR?R?>H/LM?V9BY8J3JN?RWB(A53#R.3#>#0<A?>V6Q.GCA\$>A+>N0?>PFF0D?B7G&+4B:(LXJH56G10P/H2Q M@>9C<+V/62)B5J?>
WDN0?>X87?>IGD1&I?>D?>SUWY.9Z?E?PWLMAQJ M8YQ<=>W8 K09W-ZBNJ?>97NM10Q?>I?>?D?>MG/GFG722Z8\$1L4LMQ?>T M10\$P\$V?>T\$53P1\$>S- Z- Q4&-D9I2N<+>
(7IR=FI)>0+>S1>5P\$NPSQJ1 MBXTV J?>1YH65<=>F?>YHJ94?>9?>EUIR?>P1S5XMB W?>ON36W5\$>8XBS MRX?>IXK0.L?>L?>CXF?>L?>C?>D?>65SD?>=>2U&N?>
XWKFES2M\$A@>M.5U MVJH\$>3XUFC?>ATW8D+AI B?>YB0(F-G)?>D<Y?>G6PY(K22FI.O M6<C2G4.00%>PJHHDVX?>800B?>@9D?2V?>H.7H%>MNZ=>A<+>V2Z ZVH?>L?>
R?>H2P\$>F=>J.DLA.BF1.S83.ABK A7Q(N?>B/A4ZK.VRY0\$>2&W&XG@>OYOK\$>L&7+J?>MSC-B&7?>6S8LA80HJY.N.Y.N?>W754F?>PUS&01-R?>W2%>@>+>J?>7LZ
MHAQY8KWKHL.RS(R\$S\$A.328Y&?>E?>P?>D?>H?>DDIMN?>Z>?>VJAW?>E?>A.M."H\$90 Y?>P. \$>S-1^>6+>FRSTICIR.L/IX?>P?>NYBJS&CAVHTKT.6J M1?>P>
<3EF\$2(NZ&R 50KS&WJFE15N@>0Q\$9+>C1J37?>P?>BDR1@>K?>M-92M7.J&H\$>W.L?>YOB2D)J04HJ?>WH1=5020<+>I+Z?>B?>W0.O&J?>D1G?>E\$ M3.66&E
H?>U&S.QCQW53B?>6<BZ>AB.B.JZ?>LTOQM9P1?>0A4H@>0KRXH.M?>D<HBKY+3UOLHT4UU0.J5@>H1?>R7NYEY&A.M?>FIM.M.AO?>1V?>7INU?>A&Q
=>XIQAYY&+3^>G5D@>F.L.ZEL.JZ1(056B+>M.8JH1N8X&G\$AA\$B1.(MDDP?>M6?>M?>D-9?>C@>R.K869QJ?>M.MN<=>9G8T2G&X?>P?>A?>(DXF6G016T.LKIOYS.MX?>Y?>O+>3?
55%>M.&DWT?>+>A?>+>I?>#>X&A.D.T.MFF930X?>T?>FKYBJ.7G%>+<MDCLS.5I&N&DXLOID<3.C?>QOS/R?>D?>W?>+>I64?>B2IR<+>I05.4D19>AFH<0 M%>T>+>4&RF
7%>W&W?>T=>E?>1ZB0?>6U=>+>0Z&?>67KYDGS?>1MLEW&?>B7?>3?>I2Z3M?>S6+>+>S&WDMU?>HIG(LOI1050G&4E.J2HIM?>
M.A?>X?>0?>71A1Q0?>1.H%>K%=>79C?>=>=>2?>E%>?>GJRR2?>4GZ?>6RHM?>X MRIE?>7G&S?>+>C?>?>J?>C?>+>O?>U?>F?>X?>P?>+>E?>N?>+>A3I2?>7?>HXYL.L?>MYE28?>?>J&I?>V70
H1QWV?>L0J3Q0?>I=>B1=>S&S?>H?>C?>T?>LH?>F5G\$1.4H<+>C?>M.Z?>H?>H?>8?>E9\$K?>+>COXASL?>2?>K?>YBJ92?>?>TR?>+>BUU?>O?>X?>0?>J5T?>M?>M.4
B.>Z&Z&?>C?>X?>2?>@>X?>4Z2PWB?>H?>G.4M9?>#>N?>=>9<K9 X?>=>44X5?>2?>I MN?>=>MOH1.L?>C?>G?>I?>W?>M?>26TRQ.P55\$WIBU@>DW5\$A)N?>O?>U?>CASH?>3?>1%>O M1+A00.95XP
13607?>F52<+>CE+>P?>L?>+>L5N?>6?>0W1?>L?>C?>H?>P9Q0?>Q?>L.MLX?>C?>F?>O?>K?>=>R5I0K?>1?>L?>V?>P?>A?>W?>98PGVBN1.EWGC(HLSC0S.G.69H?>Y.MY?>3?>U?>UBX8.9?>7?>4P0?>I?>E?>1
#57?>H0I.DZ4?>+>J?>U?>X?>T02K6I.A9Y?>ML5@>+>1%>3 N7H\$?>1 HLBV(D?>21)6E6B?>ZK:U?>D0=>#4P21=>KN?>H875Y?>P?>MR90+>S?>Z?>J?>V?>Y8216Z?>V1.9?>55C?>+>F?>E?>L?>F?>T?>I21-G
M.>IBY-V2HJ.G9GLV?>M?>MPV?>Q?>S?>G&A&H<G?>G?>O?>P?>HBD?>K47-8.B1X?>I.M.5BXP01%Y?>34 61PG-KRA>+>M.TJW?>507D1?>F3<0?>B90?>L?>IS?>@>L?>+>1?>+>F
M<8CIGQ?>ISULJ?>K?>XP.G&A?>4?>XRSK?>?>P17?>=>#>15%>JX?>+>S2N?>O?>J?>W?>U?>M?>YN?>M?>N?>1?>EZI?>P?>+>CMPTM?>=>WXS&3Q8D.9H?>@>H?>B90?>S?>D?>ALLR?>A?>G5 M?>B?>@>9?>Z7R?>55 K
#3KL?>72A?>M.282?>T?>5?>+>1?>S8S16?>?>7?>G&+>8I?>M?>Y%>8)5H8CKI?>X?>01.B5\$MKN?>J?>F?>W?>D?>C?>+>7?>+>1?>2?>S?>B?>7?>K?>E?>G.P44?>9H?>M?>J?>2<+>U?>+>EMH@>C?>BZ

H(7D94FE,CS) MOI62C08 *S1K82SD3UFTZMJ5(WL6B)4<B*0.6>*BX&.3T/+4LJ=>YVW MUM@<O@W/21%?>B?G1#/S+6>UYDQW1)IPGN5)F>21FH*98Y#?2[XI
 M2AZK1+&Z1@HFAD105<G&K1<=87%R*R@6B6%#S1.7<8>GY+3?L@O*P6M%>M+VAEOW5?F=5?FOHOR?+1OCLN0?<K6%>=>ISS5,LE@<XF
 M1#W1E+1SBL (615AY?>PHEINR9YBYDR)U1UHH+1X>Y434A+1?>B53 ML#EJN:WRMWJL?Y13@C(PGEINRWRXN0VGE=1MU6FH@OP>25ID/R?Y*4 MNC ME(N+1)MSI/ZA
 L1.HCJINUBJ01)1\$100=>4T...?>1?>8&A&LG @<3Y3S M&<NIDEN.N.6?>0>1%NWPB>#B6RKE6.(5<=<#FY>3<1K40?>T9G&M. M1P1W?>##<81@>=>
 13SF42QK1W24?A1=A2=>S/AHK< 7&Z175T1+DEPWV1H M141%2P=5?W7H91Y(4T1+34-64*BT?A4)XR1U?B3.WG&00F?H2/EMKY<E M#J1K6H/271.S1&MWL
 KORT?EWE1L.C.7?#>5=>*<AQ2<?>J. MOOBKS.Q.V MR=>=<UK.OVWU1V?2ED<+22+5U>+>ORR2.M<3DW.YU?Z<1X<12>W&KCI<YK<1U1>OWOW7H1RV.YGOG4I2.T<M?>
 Q5>=>UFSZEFIR6PIW<1?W79<?>61&5.0)3?EW1+>J#MEALJRI< MCJCAD1RM<G3T.F?>^>2?W2&OB614Z?QPD@F<=>M+OQGI1.31X25V6<0&N\$H.M5DU>=>
 *QOLFH61#1+2HVUX&<=<M?6.8)AY5.25=>?TQ#>+1H-W#P14@/9&S?<C&9T.98<Z.N:RC.<4N2.M1#H+HBX&=>^>Y<O>9.J1<EM2HB(8?>2.N6N1NHYXOU1AS?%QO)
 M17.0>40WV154Z?EAP8W1V5YQ14U1?>M1%>ML249H145E?P04?H5U9M@315?1.UHOFW1U?P1DFW.K.R.GZW8<9Z.%TBZU
 M004.P1%U1<?>1?7%<=>WDE4R14CC4J3N<@B1<VZ1M1%<SGN6>26>=>S@S?T.Z?D74@8@1?YX+1>=>N.IG4409JWJ3HQZT4QOMSB<F<17>K1@<Q#>0MT%<V.MDPLSH1#F<
 #SUHF01.GY<3?V1.315H1.H.T1ZM&BR>+J1.QO15.S&S@D&B&C(PW%>G2AZ&CB8%55IOV2V)+32.M3MP?S1Y>OQ&C.OG7PS>#ZEX.Y3W+1+L1JN02T&QJ8H&U?Z1?EA1J6S
 MAA#9%<BP64?>7.8.CD119/DV20N9H9-2D1&KAL8>+S%0?>5KUP1<3Z5&M.R.VJ.K?>+GL+1T.6T.MCJTGCI/9R>+3IS16105?110DYX1?A1(67?1A<C1PZ=>7Y&QLXR9M8#
 M21C@<XFB6?>R0B49D&O?C.Z?J&C&DJ.YK1N2FJ2RA1J1K?#?>2?1?FJX8?>MMO?KIDT#F1+>461+27DNKMO@>2U+11?>5?B1A<=>31B&K.E&31819M9APUV.M
 1+L@<LH1DWNX<22B1R1C1<90D1.6EEZ?H1@<AOZ60?B1@H0<5XTM44?M&W1JY1?>+8Y.<1?YH44HCWQK1GFEY?FGGDRRVV/HFOA<3X.Y<6?>PDSU1U1
 M1<1@>1?>D@HOG?>W.A.81C.<?>D15A11?>12@>51%01E(3SY<+O?#Z.A.GY.M4@=>P.O1QC.NM15<HNEX16017M2?M?FJ1V?>5D.M1.2HB113?1X1<=>=>F.M1.H8P08-L0@<
 <1ZN5M154?>1?>#ZEH?CV3?<K?>3089?F6L7C1HMRW0?>2T&1.M1QY?X(NF8M2PXM.M..WLHB17(1?>IOXU?YZ1N.35ZX2XO&S=>M1Y?Y<3H1M<B01W?>5'
 E>..U.VW51?>1.2W4LSA1A1U?>#X.NM2?H1.QVC@<K&EA1B.MIBS1<XSHUM9B0?P1Q?H0?>R&X+1A#>8?F6N1V12-TJ2?>8.74O?90<AD?E>.MY/G6.GA7?
 ZSAV=>88..FLH863?<=>4?9C1W1.O?>O?TH8TE?>L&P<=>2VM?1S@<?>1D>+1?>L1.TMSS?>L&D+TA>U0VVD1F1HVL1R?V2?>0%2+5M686&K&U&M?TA007?>WCK
 MC+8L1OY?>7?>08>KW&Z?>R1D?>1&E.MP?>F42=>8Y<+?>Y011?=>=>O?X9&2M.M<U.VU?>O?WVWZ4AH=>1J1P1<OER101?>=>#>61?2M12/<1A4Z1HNM91Z&E.MDQ
 HEF1@OYJ0.G?>5?>A1.<J0&Z4Y1?>6U(51?>1?>1GYZ?>=<1?>IKK063SEGHQ.MHO14?>4?>8MD41B1V8/YL9/EW2HLRS<6^>#3.SY41<#>G1+5AY&KNES?1U1BYFW?>R6B?>F<6>1+M1W7K
 M2S.IK>2.2VS1+>OPOP.3.7X1.P1GY(1YR76.9?>40?>F&3Y<1.S+>1?>O60F1M.TS<Y1?>41S#>1V1L1S+>0ADUA=5GLW?>E5W371?>7.2IV1?>1OZC8XQ?>U5E>2A.M?>ZSHG5.2PK0Y<?>2
 WOW1=>G01(8KD=VW>M?2&K1.N.#?#H1.KUL5.9?>M?>O10H6.FTT2R3?>B6S82N65?>A1B(01<=>6?>90&D?>91C&881=>+V6.A4&MB1FH8Q@J17?>V.O4Z14Z?>1H-0T42U
 >6^>SXX&R9?>2D?>X2P>1.%Y?>P1V1?>MW?>26^>279.PG=>=>M14B(1?>13+16&?>7?>P.O?>P1&J19&N51.O1CQ<K5W61.M?>FY?>L.73HX>RO>Y4GX4A<H5KDP64R&1?>F.5%L&F?>O?
 &8?>1/1<=>18.M1K4U<1845V?>1W?>POV1H@G>1.F&VYW8O2ZR7R1P4?>=>EN.6?>4&E99@<M18@>2WH&X1L5N?>=>P5..>A2?>6KK.<F12?>2>=>W4?>PP&N(C1)?>5VE.7967H605
 MB&<=>@G1W2?>=<H0<4B15SBC1?>(NGH5?>16U14X&X?>JLM15AY?>=>Z?>L1.0L&R.M.H1H1?>1YALA0UHC4&1&B?>UOM144?>3&X&Z66L73XDL1F?>Y1Y1Y1M1R4X?>=<7Y5<
 N>1K.7+VZ<N6?>W57U1A6C38?>6?>ZT1K?>=>Z?>11?>9&<+>M2F45?>PYR?>1Y00A?>5.G8?>F&G?>UW6G?>2&1X(056?>S?>X?>=>1Y?>M?>Z.YCK.M5TV1B?>=>VDS5A?
 M45?>1V.<KDD<@155X&WS7?>H1H?>W-M.G.Z0?>K?>P?>PTT1F?>Z2VZ+?>M&V1MR7D1?>KHL1?>12?>=>Z#>S1.F1-IOUB1?>C8>0Z?>?>L52?>6<=>1W=N)21D158
 MMC@G6V1W16L1?>T@<K.P1M?>261VY1Y86PK?>Y1DZ.O1O.KV1#?>=<K&WA?>F4MMT?>U9PIONWKQ?>?>TKR<3LT<1DAX0ZV1?>?>5M52RE?>15AIO&6<1MY+?>TH5?>1/LB
 T58.S0?>M#<1?>C.S?>HJMD1P1M1SR9?>11.Q8?>P.M?>M?>G&ZS.E12?>4?>W1?>P.YB?>X(R61+4001B?>#Z?>N.C1B&W&X?>=<@>ANK1U0BZ1M1J2?
 777.7?>6W1&S9<@>LS1?>1?>L&DLBGA0

[illegible]

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s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

Y-ATOTERLPD MX08IEJLH(CVCOA=5&Z&R THOQJUDICXC2L=5%6&7&T M79S=8AIIJ<LTI THVU2661R-CS2-1-N-C-M+TDY0S?CLXGK01ELXCH)TIG9 XS=V3
RX%=>DU2Y14F(CV=U2TWN7F-FM#2GJ1=187CMQ0+5IN>7%HO2<6&10X TOYQGSQ=1@W TVRHJ MUG6MA<CUHFIH\$>D4M,DG LG L<53AID4L<L<1FV198S6Y
M<0>SV9C<#31U0U7P%#>9B0%>X6CM+L P-0 XMR+2RAFW K<0&XGHD9Y?<2L K&GJG<6SWX43GRE-R U0Z05>4# MWEV YJ WG) RXIK&F454-U040AYVX<Y
U>6518%#>T3<#Q81>A1B# MTY1L0#>4XE25#1 MKICB6X7 MVD&5K8C<84892P>5%#9I-F2 JKB(C12EX2<PSJ52)>% MJCS0#L=STF01H1+1+3S
K&S=ZDAF<F(CST6F+M=HTYB1L%>KEZ MA<20&6&178)+>PHI90C45 QSM&7BFA2&9(+>3%>E5N B-KZKTQY<M+L=7J3K0EY<Y+(9>+>L
FN246GQ&5LU<#N) Q+T84QQH9<0DMDGX M10BUU />ZNY3G1G5<ZMTZ3M7ID0VX9I&0+>(P&.)@V3&DND19X&6M MO M1LOOZHCB1<#ICH 0:RH8R WV<6H (<?U
J3XK B<7G0H MPJMN<V6HW ION<#BGL1R1 U1JRYMF@>2A:51C<SL4M+>UEHDIKCH M%4+J05<1G65%79UZ4U6<+>NEJ#7/8W9K15V7B JVYXFIAM12N01 MKKY1Y?
TN>+>V%#H3>IXVNHMK>V/TIX">R>V%#YOKK %YD<#2=>#(F486TMR&FMZ<#>KJPH1G=>M<#N4W40Z2-9V6&4D#>M#>S0.5X<B2I2H1NHIR
57Y5>1C<S&M0+CC B M93G<OV #11#3FE MCD30X2CC2A0 Q<7<=>4&6YIG<0 Q<10M1R1I6/>22F16 P10 I35=EXP>R MW20C 51<56GFIWCB32?>553CT6?>4455M3W0?
2(BM0<6 P2W1L%>P<XZ1H<@ME) Q0FE1 K MM4IM26 6<11TOCWF4NO+Y<S%>C1P<F1UV9R04V4H+Y2<#>0@/M-F RH78BV9<K4WF1G1%=>TX<8<F2L%>
ZDB50H1H<HLLU1K& MWAET2MLL X2Q04=D9<T8-IN NHFF<@QBW<0EXI>8Q<FEMDMQB G V&8D/LMS<AN4LJ7E9B<S<Q<=>K<=>F272>@>A4D1H E<4BFB=OH8_0X
<R@M>5=C M+OB1ZK06<TV-LPV<=>PP<#91C<0EB3K1B<69#D<=>#RP H7I6<#15A)W M5>43HU24<647XCQ&+9GIU<10B<@>9<87<72%G<6N1RDI+>F6G0
MB>MR<0>#>E2NM5 10W1>1ZRG<F83<L MC-#M-9C<GH<#>7K61#9W16 K M1A1W7 5IW<#15 7V F M6URIEY<EQ>20YGH3W M1FC18S861<1F9F6W1S<3VLOF1
14SRXS V12F(72=>=IR0<#5#>2 MX2<5 B=00H& Y<FF741 L O4C4MX45%>+F&K M8<6<Z02<P1919<#>HU2<2BQF M1UOZQF 4D<N1J LIGGNW1L(X42G51&S%N<@/T=Z Y<#
C<69<#>2 P1L5A1&#>4X2GT8 OT8AMZK1/@>1EEEN UV<@>+GA<#>@<2BQ B&B&M<F&U(F41 U2G1V3YF T13C18SFS M1%>#>6<S0H0Y1KIC6S<#>PG?
BX0Y1<3G1>86PR&R<PB1Q 07BP 20<+>VGM% M1 196GA0&V1>H V79B#>54KQ CY2 C MAK<K1H2 C 2XZC JPB89T JYF F00DK<2=3JVD TBFPS @.8 P AZZ%>=>1%>ZQ M1%>99V<+>6#>
#9G 90QB8M=>D GW1#T M7U0UW 52 JHT<#K18H78IC CVUYJ83Q J1M XF11+>[POW]S K<D 02 MB&9 3<1XV81S=1&JG<=>AR M&OF7C/261?=>T1(EN29VAD3E)B<#>
#A4P1WLU<2Y2Y1 R FM+V<+>1NA1=>#150GBNAY4.5 J1N2T MZ SKG B WUPP1Q1Q1<675=AF< EOUH+>540Y7G 6<WGI4K>1@SSRD MJOC&J=PWZ2 C41C7<+>
1QD<+>10G ILLRG&FFC1NZXPB<=>01L04 6 6 M%>0GYZ<+>1L04<51L GH1G 6<26ON7XLVU0A1&9KW&U<55>OL<2 MTC2T1H0K7<+>B712 M
X1#1<6Y60MPDCT<S36V%>@ J1B1N65SXI46P1 MG410EG<SSBSK<4YJ41<0Q Z&S M1Y<#>MG531YX1T1TDT<U<R&5MG0DKK B2 M1+Z9P60U4GA74G<9 J<17&2K13A122
GDK<=>L2+>PAV6N NMA1100 MH138L=N NRR&D<AW42Z4Y17Y2&5DKV<B<=>(QMI)<0 Q/R=>5.59/L MQG<01 M1%>0M V1TG&A 4LXH<@&K OJKC J2=>S1Z1PWH51?<
16PW#5<19V MYGME TVRIR K1CEX<K13 D>U0W0M1Q54<5<@M VV1NKT<#>N1 IO1 K&SUNHM<L<L W<@>2 0EKOV4S3TX<#9U51H7<4YDQ?>G&7Z1<1MREA
E<#HM21+>#<C M1A1H1<=>N1 M1H1&7K<@>(HG7X&Y=2ZWAABA7T20B)F1S<#>X<5T#>#(OZ1+>71<7V<#>M21+>JUEF<1 O A1!M&S&EL FEMIE=8W)1+9Y<#>
(C1XM)=>X OH<=>L M<OL594 F5 L1W18 F1HJ<#>@AD<@>1<CQD L M5A1 (9J&AFC9/PTMK2TG&B D10 01&6 E>B1<4&1E1E AG M238H HUE<@>1 B1 FAKB1J1D<8TG SEIH<2<=>OO1
(H1F<@&S<#>L1 M6<1JG8 M1%>31 8X917 B94<13FPMV 9M1<L F751&HEV M104 GGM&D M1M1 B00<#>H>43ZOL<@>H1R=>ZKJU<+>KUG<@&G F2 V W&U7+TSS)1+3*
MW O&B<B<ZJUK<U>@>MM<92H FPMO QZV1H<#>K1 80<8 SDA0 Q06X<#>1M<#>3 M4E 55% F1H U<PH+>B6&1Q 1.63 KUXY15%>5Y2?>Y19K<WTR1915>YF M04DUUL<
1GUW85FMG<BFT>(<ZZTF&K>3120 GV5KVG1P RNF9IPDA1 XNIE MBU<X LK61Z15<1 J9RNBV186C XUWA14 H=>M4C JUR39&6 L1 GBLH1T5N2
ME)91LOO=>O1K39/M KJM413280R3.8Y%>YKFFRWTVN<+>Y1 99JL3) MRX<U M1LF<@>0RF3C8X<=>C)AS) MFYJK35 MML9+>6<+>5>CB>2+>4VVA%V 3Q7 V9?
MM5<S Z0F<+>WD6>25/81<91 RZB#>K19U<R R14<G93)14PZ1S N1MU M9+>1423DKBDCT V1<1 A-D<QQF%SQC AYIYEO&S4AB3C64X<@>EU<PBO 0 M1)10-<
#F<#>0807H1QI&QSN<POMH1<@>+>51+>13 JG171+>9S EY<#>2<#>K M&XAZCF G1N01T19RYH<R PGJ1P MX45 M0W1ANBYE0>2 L14B34T22?>10S) R MMR>23HP&L<+>7K16?<
Z1#&0P61EAD P6<+>14>M1J FQ<V<S LAGK21 Q2 M00V31 BWKDXDN W78K3&W78Y KAM<4D B21 2FV1<=>@&#>R R2>3 GU15 MD4H N1T<6S Y%>U#>Q1>7&1VX<
0HIC<CF HE F41=>20QLE1<G191 J1 MOX19P2<0 BA0B<+>Y192A) IRK6J3<B J1W1 L1Z1+>=>#>PP73QNG2<0 D6031&R MB<G21E1<@>SUT55<#>B1B<
J1A<@>TXU<B J)>S R4W=08&S XEIVXC9K8H53 JDA8%>VY M'N E0K1S W HUWTR YU<EF1408=>ZUV<+>61 JHJ#M1 X1D4P<Q Q329S3 N1X8F WQ G2L6C L1
MBY

3.RFFYOPLF[XEHUJIN#IN#ZW5]LK-W'Q'Q(C5-K=M:H8.L1Vt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

[illegible]

+Zs'0B'2'5G>+JB M62-VNMC6YAX'>Q'2'2W3SS'7MM2.Hs>#3'>DEJ+/-V/85Y'>FQ1Q'ORY&:(RC&RJT M6H)-5J3.E.ZW3.Q3'0+TQDR(@)/M0&1Y.KH&7'>E9+D1\$>N9>L4OI.
 (NS'M'>Y1Q1'GET\$3'1'1'GDPFR.PT(C'IMX'2)1'>U19'-q'2F'K0.CS'7+L1-#(SRLM'>90'>7L-/IN/Q'PT:6BK+&'B'=ONL>+>'RK8+>U)WV#>PASI09'&J2R2)>
 MGXN.NP5YME:1'>ZGVS'4'0YS+>=1J3F6'0)M.QG'65UVL-16Q20SSPLH+>_MI9J_+>*G21_1HSH+UJ/M<19>+A2UYZ(C'>(.4#1#6E.3@+1+>+>1.9'6XZ
 >G+VYY2)>G<2VWZ'>GZC'&C'DNF2R9+P'DIA_>#M%YUHH35C'>@JHQP>+3C.M'GK'76B0L'>+1#>ZGN_U'1HK.9CU'>N-VH>+SH>+3515X'>PXL'R3U7 M7_715_0'
 3C=6MEQ2'>A15M1M'>#>O).K6<5'>F966&(-7F4)'>K'-A'+8DF6DW+JUSYA.M0+_Q.MP'HQ'>+Y0_>#1FAU5V'4_I.Q'RWVW_9F1H.TIZ(GCSHXH_>H23>+>1.4
 M(B>Q'2'S_>Z01H1L6+>F'Q'>'F5L'>F9'>3'>BBHHBYH&LGMG44:AL:RI4HJGVN_M9B2U=>050L'+>P3>9UP_-Rj5>#>X#>+2'>ATAQIA_>A'>2HGJ/VJVLH'>B:G'Y
 MOVPE'>HVTV'>QOXQ(VAC.M0/L6'>)=3'+4VC+PYL'+>SJ/>599B&B.PPIMN86_>'>MUQ'>ESP8B/B:1'>#>OIA1U'>AHO14+8'40'>9X'>216W'>8.3(>(.S44M3)>)1VIVCG
 M'F7A10>=HBRZ'>Q'>HRS0<1ES'>K31U5412>#>MWAJET46P'>[MWP:4=Q-ET4E#6UVYT:1>1DYC1(VD:5>0HDL&1E2D:J.MF.68Z4<=9>#>Y5VDNJDZ'>F9#C_L'WX>TV'>#>5>
 B5N7'>0.SZIO(H'>KO_1'>NS>2Y'>6RXRSR91E=HRC.M.1YC>+>BAs'>+TVR'>[FRE.YMS:LH21A1U'>=>AGD32C'>T1'>58XXF5'>@1'>94YD.M.YF(E'+450>#>G4W3'>UNZ'>#>EMS->
 US=I41K'H_>H1'>02'>216CM55'7FYA2Z'>M'>2R1.3LV83F'>#>ZR=M'>W'>10N(MJSF(SS&7%>K0&6'>EGS1H'>F2PGC2_1'>O'>W'M4'>SN_-D&1L'>DMMH'>V%>_3484>#>B>
 >_UAI&E'>T-XGZPE32J_>2.2%>M0N'>#6.VLX4(U'>F0<S'>A'>7SH(Q9A'>E&(UEM&A'>41M19R'+>HEF72U&L+FF-B'>M6KBDXQ'>F'>R12'>718C'>HZH)51'>D'>9'>1'>4'>Q9'>'M18DFA2'>+YC.M+>A?

 1542_>GS'>96FK+>'>KCS:BBK_A'>ORHIFGLW'>6W/L)HC'>SOZ'>PRID8Q.M_>LDV'>U6%<-(G1>S0E+>X9IG'>3'>SFE'>#>H&Q'>1'>4G1PA91S1.848\$>SUL'MCX.M.=>MWL>+MXH4?

 N2'>12>_AG.V>+>#(>C'>X'>AY=LPK7JP'>#>LH.Q'>+>CV7'>SOZT.NY5'>M'>PLE#40%>1A186>40>E7>LE'>N'-QL'>#61'>1GX#>U'>F'>#>3'>7JWCAS_1FfZ>+>#>SC_1UOLC'>#>T8DBDBM'>(GKK

 >D:HDRCU>A^2'>CWS'>B&A'>+T'>U'>#>C4Y7'>Z'D_#>M1)Q17>+>@>C'>CONGZMU9'>UN'>1U'>+>KG9_C'>Q_>41'>(>C'd.NJL8TW'>#>Q'>D55_-M9LIXB2'>P'>GZ3MD41F2'>+961>+>KXFK'

 U>31'>642'>4GL'>@>#>G>_>R:R076SPP.MOYN'>T'>21XQ1QER-(L%1#>A)U'>UM'>#>+XGfV0<6>+>1'>J'>P:67'>8&1X3G093B'>1'>MHZD'>5'>#>F'>P\$'>S'>+T4L_>O_>

W(8HM%>L&R1VZ4Q>9N1YLVGKIF(MP2C%>UEJ& CY90N)1#>J Z MR90VPI7U2EC%>HGFZ182X"E-1:56HGK7+<O+H|ISO^6 KJ8WJ9H>M#>U@>B5>G6CMCH\$FMK<14#092@>U0HEBSFD01H.6=1*50*7HXS#P20.M5%>X61+>K=28"BB^1K24A1|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

[illegible]

[illegible]

[illegible]

[illegible]

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

[illegible][illegible]

PMK'IN'LLC:584-DDIVABZG:C3>E<0"5" T:MU:123:XIBE9WGSUC04P2E2UF:1GL&LBI761HKFVX=BEZ7Z(RI&PK8 MZP-UK9'X#J516)P2B%-Z%U-
D66USKONZ#M.ORM6PDSN5P7L4B<+5 M9B92F4BIM7OVR8N5C5Y<@AIDR13+Z:GJ/MN80C(BR+EW)P3#87ED1MG,KWYNK<@JHSC7F
HHVYMO8E&WHIT7BACEM,SNWYF7SK=75P%<R&M1J7+7UJH69HREFBYX0X2>40V(F)J3<K<4KC.M)Y,ZZ.M5OYIS=16Q1QX168P3J+JH6R=@IM29W7>0'G70BF
MOFOQ=Z>425H8695P6D8XDP7P.#6N#O3W.MLJ<@KWZ37J>.000M.ME=S3(CGK7A*ACGM&N8.BX14<=>D8D.39W'H=26N793H'US'+07'IXN.MW4627&ZC.@3RC-
/#@1'UB=>45EJ1B17>2AU698DHP.#6H.82V6K.HZ.M%U'1(CD12LFXOH-IX<=>WOISD1VHVHGM%ZYM92C^15=>1J91L6L4I.M&6-<
FEV&2(FI'X2U2O)LYMVH=SQ<U@'DNGN'V^SC19V2?AXO/GV4.4878E.MRM2SLEB77RKS521BZ6.62TE2(Q8DN7XA10IR'Y'FH#9M08U#B1MW&*>@R%Q.M'5T<5S?<
+R79AF@0FRE65.84/6@I97P76'J(5L'YHVDUT1<OY'Y1<+MP16&4.IQS#R1P+R.R159SFB92H>7.75%-JOLCS&UJBJ#H'1PH R4I(TN4MFHD4)21X9P#@G3YDY8=N61A0-0-
K(1@P25N>ZV4.SG0@1.GZ2RP2E5JWGUENO1'X61YV1H1J<CRP1FVYXIR-R-S+T'CO-1A'J'JG=3=>1@>4@3#M'HH'GZ10D4I(81P1#)S8IA
G6<6GK6Z:Z1X2EFFE>Z2LOIY'WROX3S=6V1%U+O.MD=3U'W+2TRTE3XBE.M.O)F39D2GD'VA'F<=>0-R&8R'4Y1YA>=>O-CUJY#M-K1>15YR1S(RVZ)F1I'V6:ZK0-2=A'IZI
H1W1P61(MXX'X'FU#JZRB4UO/G+G19M4H7F9+MWR2P.G4A.MWC<D01+>@'E.BFZR.J&L33D0>@C<=>I2N4D>=>H&42<=>W'IL%=>3.MMVU4M0)S1R14CS
H#G1H=3A'YND.F.KM.K1>5%TJHFKRLN+U7IOGLKM.M1'6-2.1.6D'0'3VIA.T(CB2?#23R)<=>R'P'DG9ZT'CR1Q@/G'W#T0.737.MJU2T&8C\$229*8S.5M6GE<G1BH(3/TOWOY
'WU:IGJL+P&6@.1#K1'UO.MG4L8K&>0G6CZ17S<+26<75ZAP72QOQ'U#Y#P%O%>ZNLCS@XP)<=>M1H<=>M>A>A'FZ8DAU:
W>L<=>J7>=>NSU'1A'XKOF<=>Z.O1MHRFP7BOW(+6B+5P'P2H2USRY7293B1>5E1D.R@R'U.C5'MATHX>H67F74P
Y_9F2F7M'Z<=>FM>W96.Z2JXQ70-Q0'>3&C<=>WJU.WMHVOI2JF8B2Z.SX1+21LHRBM#)1'2DHI+Y4-0G57J5UHL1W/HR1R.M.YP&CW6'XLD0*0T(YV)00-.8A%CB*3'S@<
MG61N'BD66Z.B.V6U&D/2M1J.S1XQ0'Y&E.F1E:877B876>TV1>3EC:U.MS0>1LNFUFEFO'U'Q0S'YB.540.51FV6CZU#K01H&S.M0N.V.M9S197C2/1.5-
Y.WV.DV4018W.E.K1#(6AJ).166M&RM8A1Y0)0A(C1.MQ1+<#C%(<=JKZCFBDM.MK>>1Z@U<S1&SDC'.20UKN/@R>AX.IDX+<W5N7
MP>A9=P3H'1T@/EWD.8.20X7RFA1A(H%)<=>C1V=FGS&YI8C0-H&0<=>MKE>Z4C-64.NA2<=>#FSA=-9D)E(R'&'H&H1A.K9-HCI)SB-NK70:0:1%F2"=8H7U
M)Y.HSGJ(YG+59YI'@#DXX+1'.S07)HBLD(C1V70.G?P%#X'1T3M.M1J>J2C3S1S7.V'K700.X.36Z&C1<=>GWNJ8<4U+W1>U'<S1@.16L=>U
MHM<6W<6V57J0J1JTF5E9YQV7=1'<1C8D00201H6H(PU).P1'=>F9J&K.MO@TBD^1Y9=92=U6VY.M.9#JG=-BR&=4<=>VK4H30W'UQYI08QOT4'<
(576KX65.59F2N.M1.60D98L>341YN.IVMQ0@)B=F'UKYP4V5Q&VMRL.H7(8F+UAP#877D.M0)9A(HU3EST974JF0K521OUBE.MW7>Q'<C9M=9K=WAQO<
'Q0Q0&ZZ3'@I0.33BG(SB)224687B8M3S0DZS.M1<03<20HOQ)%(K0&K&#P=P'X1<U>4'8D-.QY+5UG516UP<3>U'G.J17.MX1UWYHSTSR/567<=>H=&=>U4-
7MO<+W&M0<0.Y1LVKA1A'<(&'TDX#H1=<=>#MR.R>=<C'VPX%LYZS.IV@Z-87P1Y.X.60F-ODH.D8VK=4X<=>6.HC4'EQ.M43@9.3.QWYVU:8J=<=>P.AE562K0H.Y156\$1PEXL1-
M1/SW3<1HHDWEZ1A'<M=NGN(C7)S.RXD9=+FVPL6HB30-TN10Q.F1&=<=>R'EF1M0NYH1D-01NX<=>MES13B6(H&>=>M5&BNC5FOR:UC.B.W5.M9S197C2/1.5-
(K5XN1VYR4W61618X1A'F57866@)C1'<2'<LL.M1>J.UJW:1ANI=N7NY'XP1K322V76762'JM/9>JA(SK@U.M.H1J12
X'NU'NG.F.&0%NL&1"=B.Y%N'=<(&'EUNR'.YUWVPV)M'>A/4MR0+U+Y3C1.3W2Y1J?>=>#&AZ'W'66U60P@.U1U1T.FJ(2.1%)V=0Z'(#R8N)'MRO&8N>1#*JW+155A?U-0
M1.WZA7X3YR5<=>8A&K6H.H.M5L'LC9N.1N1>1.C1B6.M9?5.AY3\$3(1AG&)<=>L1M12.ATMH.YOINWAW3D.LS1<P>15VM*N.HD748.L152.Z=D+5%CHYM.M@I(29.1'<+Y'EW%
'QZGA'Y'<THKK#Y9'<LLEO.F.H.M%P9X.GCH4J.%<=>C6B.M9?=>M0Z7A'F3=ZEZW'1Q.O.U)HF@0P'FN'DL9'<DX81R@8U5TD72+O1G.7%5X<89.E5\$U89A3&6(S
M#1SAPFOECORM?>ZIQ(S.F71@1+41'<@HV005.H15S76=0IG8ONW.C'G2W\$Z22.MX1.0Z'P@=<=>17LYZ.RBPBV.R.E=8N7M.M'A.NK9Y00>=>Q%BA%14QIA'R:5W\$?
1AAXH1K.M.B15721=>NIG2F16S8NZCCL&7W+OHE\$5.2.D7J3V5M52.2=2RM2M1<+>R(1+D8E)E1.95R1W%MY@/L#R.N.CY'PQRP2B151>?<
X3J1E1J687J>3E1'47'KX+M+>77K.6M.MW4A0ARR12.D'<B'<OG6M.NTD'<B'X4Y2660K7'P6163VF.91M1V>I3'P@<=>C.9<=>6NIG6V1U8H1A'M&69OIB.91/UUD1?<
LG6N>QM.N10870@=<=>SDO.MG'17100MLT'<C+3B16'R(B&F.HH7&5B+4&=>M.N.A.M79.MWQUA43#0:GW1U75.7Q<=>1ACWAMH1.Q3ABD+K@U>=>7@F12'BTRH1
M1FOKE1.T@X#M'VHIROS'D7KH.W5.Y+N<6=V19'K500'@I9231QAZ'L1L'&8W7<#N+<C1CM'6BSE1MF7J6G1OA>=>V.D108'<=>17@G=>0Z/BAPWK618A1?<
'P\$Y/HP.#JH'<M'<A3P1A'<2=2BQ'2A(BJ8VAI=IK61A0GHV'<=>#Q1QV&01.MHF8W758.M1T2ZRP8G'UO.7L9C.(8Z+<5')8R1U4'<=>H&=0'<C1<64MDL-66M.Z.M#5?<
'Q<=>2>2>W'H0F'<=>KZ7@<=>74T'X'M1J>4T.NYNC1'<=>CG3M>SA18H1'<73D1'=>6LYK'<=>HL03F1'<=>GJ9J.EPL.M76KIT3?<
'Z705S1LZ6>191U=NK778C1JLMX1+1.25HIZT7J'<0'2HP62'<=>M.W6836&=<3'<U1+5.2.5SP>=>QOKIP.W.DZA.EBAF+5K.AWJM.T
2D2BRIS1327=K4RS31@E2'5.56=CP3ENZ8'U.W.OKEFK'Y1K@OFYX#H.L'EMRUY1UT'F1I.RA1FN<P<=>W.T.H1L.BHD034W'<V'<GQP'<=>K'<=>44216.M6=RPZPCV>2>-
SD.RP.'4E)O'<=>G4'Z'X'<=>Z%N.GTMH1'U+5M.R'&lt

LR^?2,M6^5N.06+X^Z MO9DO1\|WE!0Y6%(G6K9^5+&\$V2E#8XP^R+!)/9DCZP,*1@Y&C^!S@UR+?7CH MX(=|@.8T,|L|AU,|L|@ABE&6G&-HFN<E8H0!15N,H9)9^QC7
MSBR\ZHEx92?0PHFS,|L^?<5J OW218ZG^SV0B04N0Y9%2CB(C7BCL<|8 M5R6^,M1%,MO_YY#UP0C_7^?^=ANX,(G_!QY<L^CXV-3B^C)R&H!Y^MX%J07A
|@HLN4,ZA)U|&R^|B^7@S#Q0^OA&N9!E^UVE0_UJG2_V0T^& MUVR^DWK^=D^1L1,5A1ZNY,N9Y2UH@^#T+P3JM^X1C%Z\$19),M_6KD=C00,JKB\$=(|B:6,(08Y,
<1FTR9B=|7LJVM|=ETE6^X^PE&L5_M0^?5_ABE>|J4I2YWE7+ER6K<^*_,=|W^?|(H19Q|U|^A=TQOP^*7 MP/S,R6K2^C@9+5GP^OS_7J5)(^=)#8K<|H1D!#04|QD|H=
T:E,04FY8:\$V#26&|0D24-L)7Q*6<61Z348<^<^&^M!^94E MJOT%_=?^L?@4/KAZ5FV51_Q,D-FU!<\$!^G+K1-BCZB^FX3U|Z?BDCKRM9_MJ2C\$|B2K^<^,E7^*X=D/5\$|RH-H%>^"1
|W_,=PSEHK^!C:Y|>EY9_MLEK^!^L^6^H0L8_9+|2,1>|30^7K4E-2G|H:&47<_U9+K@|I|N3,LLR08E_>|Y>_!V^B_XP7VOA0N|9Z_//^#Q&F^,X-B=0\$%G/_
MCSC^0B&J,LLF5%HK1W<8Z0IV^|QEB)Q^4\$2LKNN^|48@X21L_S/17)9_M,@EKEFG^,T7N|23XLLDCQYXFM,%2_JR^2TL-0DN3(94FWR_U|H@6427_Y% MD|0B,D\$E|V12
RUVO_Q,Z5L_Y5>7ED\$YJZS9YGA_!HC>TP0X|HOK\$1&_1,HL3_L2_M2_P_(0<=>ETB>24O-P6_ZF22@ (M%FY2L_YOP(2#%E8+?2\$A&H3V_,EW03XR^FX+|S^D7%,^U
M0@G/G2?8V|AH&9^0%YF&E(P_@&FC^#_92F2\$GRSK95(O^Y|H<=>2%\$ MEUDYTH|HP|^#6\$%SSQ3R|K@_Q|<14-U33WN^2=M_MM%?^"K\$;5|O^UQ09G_MVP;J
DT5R@O^|&R6M<^&@/(|?K+Z>|^0=<^M@2H=X8EQ34-|D3JP^25^2,<#P@+9K4(X^TTC@SM^R^V|^78|+G|%,?)_M2?FZK^E_U&(R#C&^(@_7BLQ#%D?6|TV^PZ<C?<
AT\$RQ?_2X0XW_M^#F|3:6_WGZGX7\$+6N^<^E4>@MX/F9=V_KU:K39A(6_7E46A<3Y51_4OR_2_MV+&^6\$8R(C_PFD|A|UQ^U+^CPSR_U|<^%?SUUXSA)=_1_HQ|^\$X&G|3
MH0F\$N_81Q^>G^0/B>A_23^100B|P_WO+P|^?)2N^M^V7H6K5BZ^|YXBJH_-M8QP^DX014^|&OHTI3JL3\$S+&5?H2A|00|T^<SD3X(H1CQ|^0<5H^AA_M^
3CS6N|<=N0_42T|T^Q|3_XY^<5\$7:6|WB|GMAFQ7^1L|DIK^RVG#X_OX_MW:L@T^N3K_Y^EG3^W(8:6^UF0&>55|Z2I90^T_UEZ|JR_!FWT|L_VNYF\$>Z_M65GL<7|6(X^2)WWZ+
+|&|<17&B_XND;WQ(6>|<9^?0Q^Y|H\$3|(P^K|L|7(PK|L|7^H\$31(CR^#G#A^:A=RMH_135|80_Y|>|Q|A^E_XZ_MM0XBZ^3Z^UHG42+7^|W|N|X(|H|FXD+
^9%+|O@#_!|R|9,C_8D|<6B>|1_M%\$<#++(N39R)L&^_G?4+5)L8%Z|>|LG=P^,|LH609J9/?C4|/PO?F6_MYD|_@SML312A76;Q^0|F=K=&=#9K_TB?/
A^PU_CBT|HAME9H&F(6D2G)^_MA\$^TIDMSN^4ERU8|HCH5F51^|7BN<|QX2^10F^7HZ@8^78E#&C^MD@&X4)M1^#T(BDU#|>|>9P|H^6|LK^5T&<6N2&H%)WS<^&|?
R2F+|0E^<P5FCX3_MH_!<3BQRU|7Q0P\$E@X6^4P8|GMW32_!V>26+|4^<REP6GNM3>TV>^?2=&_M8=%0)B|E_!<Z5_DUN>7@Y4_8:0_!9N7FZZ2|0L^<X^7|
(OY<^NH1UQO:551T_MN^<^7YEP4%Z9^44^BZ^M^U|H|H6W<^C(U^?^ITER_M5>>,Q295_MH32>|705@L\$|YBOX_SIBVGB202W^9_>2MQX4K%7^<D9|
M:LZ5H3^MC0Q<^+|YX|L:A5H02?7H25#>6DKZ_8-4D|<N=<_N|U8R^FY2_M:W:3A#3A)|B22_X9_J|W|C^RDJ&X|M|74|X^F@8_NKGP<Y25H0|M:2_M2^#K8+|H|M@|FS
PL1|C_G@2H25FM0P_Q_L^K_H|&R^NPX<G\$T6_0K2+|^@594<H^|/+>XX533_M:|O\$E(#=&0&||UXAHG&C+|=1V^PNR3^TE56(Y60R_W952>^N#4FKC9<4CH4_M^#&X4Y
U|YX|Y8V07NMGP\$T|3WTKV_@B|<4^?>M^>CX=^CA3V&N\$

X|JR*LXF#'\$5+RXL4E.R9% MK;=51/OE/JL:Q7+ZO^ON*UXP%PTW*(ID%A@ED4|FJ|"+>
<(FY|A5U+!WL|4 M#E;D1|4=A<\$5-(M|L9F'/E5MU|TQB|5M;!=_F(7OWL(1D)93-
R%2RX9@CRA_MJ0Z&P2F)D-"FLBE"EI(-9+Q?P29A4,6H|G@N9!|7<+YQ..:V,"U:QQ'=-5.
M4T2.3"K|_&^"VX<(|FK>4ZEM7",HR8Q|1W#JMY_|G>:|D)7-SS;>U6==_\$_C MI-
>B%|XM;LRLNR^R>|H|NWK8W=AE0|GKD=)/J!18:61\$TR#FDQ/?1(XU5\$Z M.*|4Y
X^Y|H%V;JU A)^7MQKM#C3^H/_W;B-382%\$*.)B\$6K\$<,LU3Y^B;D MBBGN..|6EL?^E+9
K6SVYT#V%PZ2_K%9O;T!59421ZT1C:FV8ZZL4@9#Q<# MP50%|X3T_1*AC_AHV;JSB#!
<":X\$2K/AD/*.)L."2TH%BT(-NHDW^RI;W5;H(CZ%R16J MS |S6#M583WRS2;*
<8&!6V"1@O_S2L\$VU98C^EGT3&#*F|%R8?;15;8F|OPJ M;3
VM=E|J^|@|IYW#)|1QZ72,2%#P?AAAL)5H).*<1L<8P_"+D_33T^|4KF0|
MLWX:P,.*U5/WZZ+M0,F2AGO--=(AD%22+I^6V"(MC_3EZY2+N>>.,;>D|.S'M
F;5|0:4DAV5E|JA!=D3=#KF:G)8*(-EP%IKW/GFR2JRO9>.,;"PC8_M0&BJ:
(7R8E.IY|HCOK\$J1-0T\$78AF\$'6^TB"SEXU|INZBBLE
M|F>.#\$6GMD#6H_T|&F@"7HB97TWO9Y|<#QV/Q#GK@D?I;1_Q314R)'HXPI(''
M^A4XFWAO%*/!<8<:05+->21(\$R<0=208IB08*T<_HQ|^<^;)6I(F<0JQPHU.83 M/-
K>IT7X;J9W\$8IN0IV/C0X<-3HE:6%A\$+#+-(*R"D)P|C-E8A5Y|":LRC^,|
M%^80B&K5;9^G5|2,___>ALHK;M=/0JU\$?T5)E?,9:(#09DL(R-\$1IXO)DH=-8-|Z\$%?"
3:680)019%2.-EN@X MYF/ML7)5IO)TP M:|J|G%J^QZD^?EF-
DJ2O=NF3N>M^#)=^A#K1QBL(6H5;M\$ 0F/4:.88>*Y_70QYQ0|5:6B
MM(8BKQWL@D>.5_B@71U.;R7@=%@WUMEY0DE9(=M>F^E|
MDM^<;2IRR&C<"%+G;H<-@AN):|ECL;YW|H%RV5**(!..|4G1.87H^P/*G<
M^|<^Q;3S4Y=P^5M(#?|!+R D)\27R)E#C"2_':!&I=:EH30>)Q;"QT@J391
M.@7W=CP0*I"INZ+E-ZDD;G&|V80ES#\$6+8K22D*LR^Z4
M;2.DDJR&G/(SG.\$52,WNBQY|H/!A&:Z|B>>@KXUSR_LEX;(G&L^1,"BFK^V*
M#24AMS_1@ZRR\$C6F@90;DZK%,*Y:@AIX.!9:1'SQB_E6\$ F|JVQQLV+\$|L1
M|:M6J_M\$X^L+UE\$HU)9TM3,)5C;2,)V11H/O%))%P/7E&JDC(+PH,9JCCPT M|F
XLHC8|EQJ4+8_CY?!=>S:?.N|K871GDQ%CM&NT%L<|&&89|'J0D>
M6Q^=-9;D+JK804K9-^<QA2H'_S,*4N9W|H|AEF|7Y%P^Z^VQ?^*|L;=@|9;
M+|N/OG3|=6^FG5DY90_1."*Y<)9@)&^,B7(D(N41=PPH77_N,G>Y.4038/?M
S9M)B_CKB_|1L|HJEA&F_^(JMY1\$(T H/_I!;YC:ZO7/!&B9(J#RK7&
?/2|&4G&Q0EX3%X\$HS/70*V MAYRRDG8&86C^0:9>(=N|TU"II%;&(Z"
O=\$.Z0%=@AS&A2FR@1"SB-F;RL M9X_|GSB=@\$'ILOD+?SV=3Y."3|^*WX?
P*2S^\$<3)17"/CWMAM0K_MSWN.):8&>:D\$0*0L=7C.U5*R2EHMN.PMJ^4=(OEY-.B35-
J+Q=?PN+^U(75_M^?18\$6L1D**".*9)%D)7J\$7^,C+0._>|PN|Y=|F'@?+=7
M%M|7(3NI0^%F!|WF8"<\$*Q3_W_+4HZ%:M9OP,1*0QKF!6MZU?3U\$Z^7!)11_M.GDP?
2D@_QE<@6&SH7Z55+S1D_E M%<7E9"BT\$UVQ87PN^"D^3">_A2LS>S=?WF5)8*>IH-
ZBAJ0V@D11!!P@*\$9#_MJ8P:X|VS'+K@_NVJ_?'OL/1:N_7#T*QY8-
EWP_/=-<,Y75A,5E3O3DMCACI_MFA_1|Q10,FDX:Q|L16@2C;|VGU-T6\$8>?
ZV_NA@,5YN!=Z6=F4_3>?BC;?UO MK;^*O_WVZ3|3@!-
*F4>|>V49,48JTM2N@Q!F8^_H|=2F=?OZY0_':@V+|@A)4C4#6&9'J"@*_W^6?
_SPO(|=E9DQ6N%K-;|P_MIV%4K|Q=7*^:K5_&1S^;Q_BB|^#8=7
UJ(+R%"/D33*!6*QT4WN|(TCR*OR_M>9\$N>CY|H|L4I_KDH<62\$^)F:D/8_"6\$3\$YYZ-
LX^>LH|J_*5#89L(I4YT>-+ MN\$J=6;3_Z;S|X|FL7Y%Y#S<7#-+D?QU&>*1/D^4?
O(8F,(L;QY")('M\$&TRJV13B"S<"P^A^SLSO88!ZP*KL)544RB_1>;#I1Z
MUVTVTZV>7@P6TLG&(DTX;(^AF++:/9)>1ZFY-(G|E>XEZ!|CU&\$H=M!4M9_ML^E|T-
^T;UY#^"5"20%L18PA%ABXWSY-9A(2,^*\$MB2|2GM,0&%!R@?LBZ#(
MJ5PN_NBY:*|6Y0HR7LQF'^9N!ISY\$=X_|^WBWY|U?,>NS1.?"J_M4@QHE0?#-

:'UTJ%FF #|=Q;<\$ Z/8R>3\$,5E\IJ+?GAZ "900;7,4-G^T" M7JU*E\$@36L;9S%'NB\$\$@?
X6X,PTGMKH>V4?91E\$&5XZ87D;4
MGHJ4<:WE%Y*LO*U(XZPYE93RO;13YV5T2B(KG4^Y&!Q9HC\$2.O @&VPCSQU
MWDU-X1RF<^F<@3#4HG16L2(W_6XV6M-0\I0\$U>MR5U(8I(X@JN?VN"U,(?
MI6T>KUXX'^\$L:N9D;M8B#F!'&M780?L3_\$R?(@QIGNR\;V=30H@_I.=SI>_MPU^Z?
PFP0F"-5%(T@#^I<,4&0^I?04#,\$3XGV\84?)RU.?+MN\$^CT"-A|=K
MB<I=.2OM@Y7W.70W<#G9VY2/I5!./G90,/8M+I=V\$@9\$HIRV6&EJD8APT%BC--
+4,429M\%Y@7G?*"HF?(AAX%.J9@H"0%"!M,MH1L.+4!!>X12KU5&".,\$60;!::#8H\HAE"?
O<J_<'4\0I(Y^+-H?;6?),MV?418:B8@:LRB"!*=;C\JY\+H04M-JNE?<0F!
<&R@+YZMM(&4EH\$\$. \$F&M:F#BT3:4(X<549\$+Y67013-3I)X"A,>S40.(;I2V?-^;
I=,WIS^%'F-^\$MC9;DTDAITC0J)@ABRC.4BA>1L);+&24SWLR\;K=GR@N!;O;W-
S,32@K"Y M*E<,>;H+ZS%SDF/\$HZ;:@0;E!5@>'FN@,J0W1&N->HK#S\$V5NE9&\$ (0\ C*
I!3M^!4!;!.XCQA)%P5BAFAD##6(*Q=#\$PF-V5/8LJ4AG:'=Q)G>:G(C58'T;8Y.
MJM5ZTY7SZG-5U^>W/3+=OKL+B/&Z4FT/#?U+9W0H1GA%.&P(Y7:8ZB1\$;R
ME\$1(&&G2(\$22>U+S"616X:YGE)47A7Z1R<3/"K35V^DB@&-QMIT"UWH/BW)8-!
(X:L1LLAZK1!G1AL1K'X^SC<+72\AK2E?IF,.LK\$)I?M%VW7P0&(T^7\$\$. \ (YP\$1IX
7J790.8)1PZ(1U A"6>ZNVX\^_QIRF08(RZF,
M/EU&LDU%3H)\&7/M6_86_G2SOSEC\#X%HR?>*|=85R"@Z\$<7*-.@/MK4EJ.1
M,1#E&-\$R\UBWPU2\AF2F1*5&98JQI'LWM/;%2YZ1J^N;^X3ESI\W\5O)^2MJ\;
(!K9)8)LV9072U)X##A/(O@2;05_*283V\$DCQ\$PID+OJN#_L3;T"W7M@?>_?
D\ S+OPL9VW=V; QI"<:&Y!QTN,. \$ \ STJQ22\$NLD-#. <3 !HO>YWR;Z MT-5+_N2KE;_LT
R=*IJ%X-J\ V:ZO/U;6'YK_8?Y#J C?FHMFEF8&_6JF\ S2:
MZ'+^=MH;SLSFX"3@B51)J7,IQSI2)#Q*J(@D6^45&HW'ESQ\+82Q#5JO7\$M42\$;*I1?
|XT^3._C\7^N!-J/(-#<K'IJ,F&<<7"!CD2!!IE \$9S3W=;R# ME%YRIE^MG.4H!YQ6A.?
3L8J'R>JU'U*C .PELO%U-ZL,K*_MK\AEY\WVMEL MM>6UTH@'^&PP*&1W?8M*!
(>VZ1-LYAYRPX5KFE;AC%_5YC\;N5SC/BFEIJI1\$DF\2.+L\$%?
@!0<|R^WVQ=8I44I2AM#;/AD,J0"/TM3GP&HN%8ZP#J
MW^<>/3OB=FJIW3B_E#Y\BJU\$9*H\1_-==BD (DH37!:(=S(U'^(.62H!3WE M25#\$\$
I'^-.T1363FN1GAZ"?6)2%8@F<"PE1\B;R)FB!";M(E9-1!;L<|1-C\$ \$2PW3VGD\
I2*E1#D_%^WF7Z S,KT"&!I\5!^>3IVI^12R2 M(>W;::?-58H!J)3&H9U.G<+EERTUU*M_
IO=.\$X?4?@06P"\B;K;::<|3P MU.[SD-3I)F@4HV**D#D@%TO1?87KU;1G\Q8^P M,%?
AKG_/VC:ZO%EV2S-/K\J_F&\JTF06S\#3**7L IND1AI+CDQ4Q'\$KA6*Y
MGP^/(K!L,F05TC@>H%4D+[WP.E?;(\$9ZT4B?BFU2?HMMP"/OP#|+L&0T:&VR
MA^.W\$5(VOI(*^1L.4!5RMO4804W,#?I%6;KP_WVSSC^8:->(&\$R#1)-Z AE! MD.%PON
X264T929\DN;:D);-W*Q"5L!;.*G\Z4ZUG-!Y9XP1RF"DN3)JYG?U M\J\$@8Q?-C?D:?
#I*8=YM#O?"S*|6+=:Z7VX?_LXG,/10QA9-)3I>I/7TVSPAG!4;??2/-3/3-MGMOY?2-
&R+P37GD'4F3_QA#2CJ)G&@\$. \ 3348_6?7;:0;5D<)Q52;UY!R, M6
7B\VP\F\AM\$R6E4G,DM8TIRLJ0265)CF"P0,%.L#1WSL560BKIT3DZ"!XFX*:LEK*6\$+9<2
"PR<,FGIK5&M.=M8+'JE^ITD8Z7I=,;"I Z#(G,#LTNVG_O-F'A*\$+_R4;'1BPA<("R(1&C
MA"#E%\$=!\48%1:F@_?J1'_A0;=)Q"I3M2'RMP\$0^J)IW;>:'=U;TAL*:Y!0 M!%A)(Y@
4FK0S@\$. 'P;=C';U,.IKJ;Q8\EG@O-B7_H:35;FR\OB9OFM7:1"
M_W4.'YD(QYUGBB"N@(^,VP'.+62Q\ S=AIE698;M1\YA=|7SBPA\;APE;Z3-MMH
(3Q.K'O\83YCUV(/+ QZ0AKUIUR KO\$&2&66T=. F\>NH?.2""_L-981N M=
(0JN.TWW.K>MXN'75S&1R\X\$R.L\8Z!-=*>KN)8+\(PE(OH:+P(Q_/FIY
M>.W00:H*W\9E!'(DT"H0PR'^>3,%2B9P9JB-T2 X2RF'WC*DO->(M,Q)2GY!1N7D_G
M5V^GG9NUL-EGUNJV=(PG\O9XT;6H.? \ @8=N_<&1^QLG\$YYIX>K*+LJ81/G,Q
MIYIF9OZH/OG,_N D) X<%!>GR^ZN/4IW\GT?FQ6'X-MW\^O^RX<(S/Y\ P=
MXN#)>F669_! MUQ,74J13/IQ1=_G+W_?!G*&Z0\OE7W'95!((YB>1FI6,DL MJ./P.I
(.GE%VUJ&\T7XB\/?;Z6R'9/I0F.XFI\J\U!;@C!\$KWO)Y+B,\$P?G)>B07JX?
T^|#)R8_ ^NU?,0.+?YM^G;=&O MX<_E+L,4&LU!YLM5BZ2=','3B3J)Z<:1@H/)?;O!
(IGQ>K9FD7R-TI#;SHU*ML/H\$GUTNKN?^_K9DD8C*R=KO M)2\J>H_VC\>Z,NK
7O>S-HN?&WOR5T-I LEW^@ZL7R3^E:O\$<"<8R\$85,
MZ%4"VH>YG_Z8^ALS6\5@#@J\ V5)EG;+I/&\;:#T49K-'N@Z_,+3XO!M6\8
M0CMXWO9C0_4YP0_/2?L/S4E=TI^L7=99\G6*|C(E.UAG\B^=5?'%J<->9@L
M+^|OKK_/VML0'H6T1WEUWQV=N@O+,CX\V1U!>*PHNWB^V<|<^D)V?WY>+S
MEU'\$XO#WZBX!RR@>O5E?VH#9=GO-C9YVF-;N%NX2,;)<'_@&5J@. \ O<|^8
MW5X\&F=VO1R.V\95RR2('_-/I;4-F\Q?NTV+J,IROAZ7*9'4<#\Z+S=>MR*|P RS?
FF5X;Z;+W\WL)@,T6\8LDYIQ/\$: \ V5\$8K*

<6JLFAR/*7#QZ*!L9AD\LLF>4CZP='+/9I+43_:=MQLBRD)/3TCMBZ8,&7U\$-8/-
;E^YA1^Y^(&UP'+94L6PVE8\^RQ43TN"OX,&.*7\2)JAO/M4I7*I9->JR)M&7IM4#R
M=;H<;+T^6:I8ZNB)H#QA0&%4/M_ L&6DV0T^/;I,@SA-VU9K%,T>-P.L"2
MPH!I;=C8+9GV6)9HL?!=I@Q52C %5W O/2\$G\$)\$/EFN6!IH*8IP&R,J4H9? M%I)?
S95Y=^&C)8CF?IZO"EPRI2Q-FFSWJL7B\H/T8'6PW3D,B^OIW&34A,I7 M+!>1/T4;
IN!'%5B\^_/I=)\$3JF<+E@O/GX+4=FY4=3;FS5A&2"Z7ZI<7/X4 M<)YSH
I8'B7;7%U= ##3V= I'WKEHO&GP+87M\4&H\ MU@5HHW4P?CEZEFB M\I>
(SA!T_QO<^R,L,B_CBV^ID(33C.D^'QAP7#>KWGUF>)AUZX+%WN*/P>?Q
M2=W'EM(>6^CNYK&FVWAPQ&C;>L7PVLLOWMA<3_HKEE0+EKX\OX*-QSYG? QM
M#E">KE1U>MC.C5=TKX1EQK>*00L74VJG6@9IV%1.Y5U=+3>;&ES\72I8K'@
M4I'.SHK"^P1-#>SVV\Y*!99/1?48MA5&^/F"3I^OGK1R;==*Z\;+I*18'&53/M!BQ7?
XCW_4(5=_L#X?!!::SG!9'F1,883?PZ+M/-SM-\$?6VXXEBX6M3T5Q M/VOJPNWM3?
C:OOLSU=X'V.<IM@NW,JV*MMCOE,LR)T)X3Y,K!#VWZ?M;7F MR_@?
I75XDP8M+VY_W^,@?W>CY4+F^>4@#I\K%,8,?_O#&S:9RZ#?5?S9^_
MA'E(<_G&\$(6#'RP7F\I#GWY6I=(@I;F?F&X_7WQ?&+6\$#>CJ;+F_SV&ZG M?;%<3D
FH3B.L_5X8#E-O#W+EDLAR."\$U6GK;2\$PLQ_I?E>(%;UUG681Q5% M!=K0@5_X.:R&
<H' L,HY2,^TPODJZ^CN=AK5E_GWZ,E0'T=.4LV3\B,V0 M^?)W/I/>9HUDSOQA_Z
XU,&=XKL_I(L4"KD>@V\A\$/M\JZ8#0G\'+*<_MPAM0\$U?MXG9PZLCV%DS?
M;BK5Q+))H7+95_MA:(I_MCB^%H?L4MO88.E;#A1I:#AWF=;MGX^63?
("DCUG@>+Y6N2;1X*R@PE_Y2J> MZ;Y*S_QK_S\$X\#Q_VU7?GC0X_TY6*15'M.OU;-
UL:@_GLGJP\1^/Y3?_W<#A_7)S2;U^M^J6\Z\I\KY=7'R?V=D_%CDP
M_IK)2VU78BU&=A7>R)9MAB\^6'>I,M,Z&I==&2EEU/\$/_+P72(Q_U3;UBMF M&?
93>WM84_LX(YLCOWRGW#O>'IBVH?EJ;) G&WOWIYM=@07U^?MBZ5\N(?<) M\?>Y)
I/_KO;UIY\Y\ MNX!Y)*<3"04*RS-(T=Y@2@L56\>-I+=BZ7WQ;O@,+ND\^+%;?
FD>,\$)2>[!!RHL;A0\$ZQ2V=?('+/ M1DL_I&ZHS9,K_7*U=-^;/_@EL%09&APQ7_2G^/A?
K,L:I@W7?S_.L6LWU/U;.'>51:HWY+\$\?V/>Y4-RW;C&+U3M>IA'Q<I B^I5=FEF.IKWG
M:Q7KDG+RF=O*B_((7;CEC9G;C^9J<I\$U+8EB_5#.1VO/9PIC5.50NY XK.ES\UT>?
N\F=VL60GN MS?5Z\>Z1+Y\RY\;V? Y<_+ M7)\D<9\JUV+DY+>[4UA9'?X?
P_+ #W+77F=I0>WV@7*>1;%CO9EMU"+IX9\X+ MZ3T?ZH5X56\)'I"Q\I
("PE^HG\7SS^)'4\I+I?Z(5W3;I/1S*OND-^N?P6%B.? M\^W?Z_5U30\71S*O*DV\I9F%K\I-
NV7&4/?N57O\6=-SUD\$&E0;PI689/+)Q M^Y*ILA5J>LS:SYKB+_IWRCL_@(?
6\H5D34\9/9E5\$-;#ET9\WUR;I C_UG;I M\K6BZ>R*B,T_W" Y6W9W/WF
=/O:O4"LY0%K+WN*6SO/+.^AQV_K@KW@JND!
M:A\;2G>H3095VE\$FP+;MUPNOFAZ,IC"EAB?^+%/-'B_4"Z":7GFVL:&X\$=(
M3I6\6Z,7'C6\I3S;?!UIWH/A.#9?M:GIF:3"--5V_BL8+AO"WH;+::K,\$RF
M/-7#R_<"L:8'D/XL*WXO^6FBR\I8;GX\I"Y7^/G0ZKV0K>DMI#?#2EI\K\I\^
MRSPN4PE1MOSC'6OVJ@FHZ57D'.*9Q\5'_E2Q78OF8OZ&IZ!CG_G%JG#WR8 M=U-
@YM>%2?,R/K6SJ9N&[M.B=4\I'SB*8,I\GLPEZ+N-#\$,*=G_JA7R/E\IPI?
=E\I\GYBHA3M7+I@UMS=N3QL<I^17;I3V^C\I"XW ML.91U_V_4JQ^,BO.>_@WOD;?
_\$Z/VNZ\/_W_!4\$L#!0 (\$+*EDH M2H#RF@<(XF 7:6YN=BTR,#
(T,#8S,'AE>#;Q,2YH=&WM6FUO&S<2 M_GZ_@F?CT@209*UL)
I;L&'!>BAH'7(LD0.;@;OD6CQSR2W)E:S^>CY#I\EJR
M)3=RG2;J40.6M.OAS'#X\DA=TIGH=)GIQ)Q=D_3O_9\I-WMF@J:0(KG.1!
M"M9X92\9ST+Z*!OMU)O;3UWZG(2V&@X.F_6W>EICRU!Q6T\OTG.ZEZ\I
M;.0TMV)^=BK4E"GQ>D>-
Q'%Q>'QTE(^.I@IXD?'R^/#HU&I_WTJDR"7KUJTO&XN4L^?I*>K0RLAM/-J)!O/_O#Q=O
M+CZO_6R0W\I!9KX7B+QTW\CYM\(%5;J"!V4-^ZEQON'P(ECV41;QWOYPQ&S) M/G*7?
LO AT=S0)B=_^F#/E@I\Z(L>^XD'IXHK\I9S
MY7JLB&&8LS#AX=GNX=)QH.JN1!8='TM2Z@_6CO,=\$L9@9D>I\TGH&PT\&W3C
M^OK6\I1J.#BD,%RP"9*YN14R1D8+\$R49^?&-%RS#I*V#C_S\I'OK*18-^_I\MS%T88Z?
GEY+I8#4I!&Y>H!9.WZBLS;:NEE\PSWF"A-3S=F5L3,MQ:7LI&<3-
GC0FND1@!LE5,7)A.SBI<.84)+SFQBF.V4I&"HMR* M@)&%I)Z\I.8E4_\$K"
I\I.CWL"SL"DCED/_DB@4 Y9#F(&W>&)D(I-)J\8,_0 MQZ+_3#K9*J\$!5;IKI\$-
"VDR%"0;H;W_C62>I-5RS L.2<(+:Y!TA",UNJ5V9\$F23TJ\$RA6X\$=)+2Y/: PZ5TW-6 PJ\$
M8D*WU@N8M@CQ=TQC)0A%BGLDT6@(-)L6 (KF?/2GX'I"2FUGO@.NDY?*!T=I MF=-/
Y#>I\WASW?.K'C\A"%XL'40_'1KOI\H'HVR5R>^!5E;9!"1V!(U%V\I
M3%XP\IF3\$#=#"@SPZ?RQ>Q;W8HTE6Z5%23F@1:
MTL^(W\PG+!%OFQLJ+QEJ(0A&N==A\$."*H)'%&I+I<;M7Q\4)L-A\H#N^D

M1Z0P@3\$5?AY=/822&DMI01L&P<%H+"I\$8(25-U\$.E^()2 MEVG92*!J!2G1 3A2%-C:?
<M'5>JCXD^TJCU\$@YA6QP/U1R8+QK-B?TOK.C\$H@9 CU11+!=""^)^5+\$@1!H!4
MCR#D;8=VOCW0;@GY-K(W9K45@&_AQOC'&MCJ@3!EWMK.!\$ _JX ^%:B\$:>Y\$
MAR\@70%<:17F5!6L,TNK+4(QHBPME%NB2P5NS" 7!8#JQM5 N8!53%%8)Z(#
ML=2!E,:%B0;8T2)K6D4D@C(^ 1JK3=6@^"<,Z6)!(VQ!LIUTVD-)IP699T M4C/%5/DU-
>--#;(!1:?!+!65DA# Z@EY!E9SVX3!/= @DB? ;:4F5>/GY_13+ MNOH_KDJ9(@%_(@+)P-
\$H=@>%';\$FN9W%2>TSV!+P-BR%HP/H%,J VQ1-(!0 ML)1SUVBMK
^X3P>JT.4+*/JE0G6<>S%9#RBH_.+>"25 M_!J1O)IP?
U.@@\$7&92!%S!TQ'BVOSYE65U*WYQ5WY'N/#M\$CH; MF!S#K8/^
M'!ODQ7-.T:V:WH+)B%B7D;L@-<+> TJ6E7+XQC6.DCA8YV^JA'@#*JM*A2#E M!Z2-W*
(.H7:AX%!4\ASX!DM!R@+XIL*!6Y3RET;!:_@ &Q.?(!@7?^ _EOF9U M<*Y1ZR%6!D:?
**!>:\$DT-)F^!)L!U4SR*TK9J?+:23M6K?\$(MCN5>A &V^U/ M.L!8PWY>\$VP M?
9NM@""C'0(*,4S!9SO90YE9E:/964/@V_;!%N)9!955K.Y=H MG4ULHDU^"J%
X!>I+0:/>W(9XI:M!9\$#I-+U\$7W-.R 'W8!3,'ZM^7RL3(QA M!32ZL!M"+8:TU/Q*:4-
E""ME6@P-2!>F ^&Z:%Y6V>1";!H)8;3LX M&AP!V!>#K)
!V!Z0VKWHZ#BV8QJ/ZFF6WPTWXNAN<%)?E MMP>^!M)
!ISC'K,8^TJZXRJ5!MIN!')YDPUYR^+.FPQM?'YGC\$,,:^)^UP=3*=
MZ;C&'J+GX2:_H/J'3N:WF,=GNP=@C/AY^XV F_G!LK%I62+R2HW1TMDDHV&>
M_)6B!C4BM67QB!K'*L!:L4F\$' HI*A!BC?)VHF3)WE_+HJ%3\$09CVA>L1FXO
M9HADNNO VB_5!+ P04 " !#BRI9F5 !#H! ' " +)@ %P &EN;G8M,C R-# V
M,S!X97@S,3(N:'1M!5IK;!LX%OV^OX*;8#L-8#M^)&WJI 72QV""!786;8'9
M;PM*O(HYH4@-
*=GQ_OH!EY1C)W:FSJ3;>H(MT"02+^^+A^=>2CJ;U*5YROW:YX!_*F)%N+W).L28DF:'LI:
E\$4KD2WVTJJ<!7'Z?KL,!HYRYR:OSE3>BJT>KVGB>2+H!IV1!>'ZF7 MHY-B-
J5J=%1<92I_&3P!\$>ID!S0GUW-#K05+;!H38_OCHN*I/9UK5D_&@
MW_;;7!H!H=_ISS2+62IS7S!PV==4A#_H)GXZ\$H?^@\$.4,WD-=%%\$@SZ/Y2,Q,M9
M!O!E!AM:1/8,A!/?/C73Q=O+SZ+T: WO!W!=K!GR#SY!^3!_*U+G0N: ^VL M^&?
C0R/A1>W\$)!KCO5%_*%PA/DF?24NA^_.UH;DXSVN^_.^SW_U#,OS8!9N?_M!Z"/-
@9!T1%OR?X*U5!ZXES)!OEH>!4_*"WB.O;6!^3J7!OF--P(29R2L+35-.,+%9/=!#G
MUC;2B!J4.0^H6?&C\Z48!+M_9!Q=6.NFYRL#U@H+4!|!%E74S0^J2.FGQ?
%HUY>""=:A/L""QV:2=B!;6OB%\$@ (H5BQ>6 M4XH25UYCP00)S.*%*W6DH2BW)F
HQ"DGI-(*)!(=E=T!MQ3<8F3:Q!L,\$" MN?:H=! "SF Y/%'DQF^A!
(D+#!/Y;S9^2I5<(!E#H8E\$1&VDS7\$P08*O-C6V>|
M%5QS"F%.,4V);+Z:AB>,RM&?!Y4D"FVQ!@RAY3IW \$F(8!BOC&M;@&Q22=0V M-
XV"3F!I95\$!P*V9BXJ0(%1S.@V9@G3%B'ACFGL!*59<8A!5G;9#"1N
)!%V!Q2EX(Z2EB!AC0F2%>6T\$:F9TF+ XBY4@4292 MOE8ZY,:%!O.87KTS"3R5=SDIW
!B;,"B".!+@/APG4^D1='DYNUC8R Q&,GN MX/@Y'<2I@V.5KM*EYK!4)M"R?
LTMH+EA"WV96M#Q2U#Q<\$!AWD7X!#@AN 1 M/=CH06Z#5NX.:
>|_DO.PWL*R!36+U;"+X.KPT4ZETW8?@I7RXP E-92JK^N M!5
!HOJ\$'D14F2C'N!\$EXRZRLJ>C(S(:POP\$CZ=EK%Y4(-=X4MP1JMX/@Y- M%K32TFL.0*K7
%Q"O9::KN?<%&PRR!LM0C&B+&V46Z(K_6TL M+! =M0%7C*Z
!Q"8FSYU7T8'8Z5Z216!B _;4,6!B\$70Q2=8?!I"@S_A"&= M!PZD%VS!82I-\$RF-
%YR*@A_63+%484/+>-.:"\$!1Z7)S%QDAC(F@UY!ZU:%-\$Y(TT<2-
>?/DX);)%BQ!W);5,P)^ (0#;P-%&H=@>% "V)-Z!N.\$S!F MMQU@-'D(Q@?0*;
<|!_T=L:+CSG58M=TEDS&Q+J*W"6L,?8>T+*LM<,W
MKDFTQ+7SX:9+B#>@LBQU71/I3MG(!/H0'E<:_D4ESX%OL'3@*H#?W)@O-B7!
MUFBX'S=@8^,!A'#P_!0JOMB!3WPTSS4!+6V%OSE3S4A><VU!44@ XM:2?U#0%-
M0VA*0 99BL&T16?CX!LGWA/LWF'K'*6 _."6#H! D0X!I?@(O<5<)U5,:? M3(G+IY67!9L
WS(HE95Q<|+H;.(2;M_LS5M2O' _&)\RF4#+4AK)1L,P!MWYKU^
M>F!>>_Q7"!OM<"!.'=9J?>SH!>J?_!POS>X=^PKJ3V,+B>WD9E02?MZ;!2W MF-
"";3RLKL7@=KH97W>3D_*R^@!M!YZ!P'G6-7\$)SX5EOGY9_N#%_W30;!3
M!/2X!S%#FY_?";W/@=)UT)F83KNL8?H>;C)KZC^H8OY/=;QV?X1&"/^7AH MX&8-
OVY^6J;(W%(A8GX^*3C4TS!3YKY5MG8L)U'C6->PEF^1H7<3387X!;T
M_)Q.!NY.HOU84,E6OUXJG(AOCT^ MP&I_IH_!#N-'A%4\$L#!!0 (
\$.+*EG:EN#;R,2YH=&W=6%MOVS84?M^OX!PL30!)EF39<20G0.IV M;#9@+9(W=M
BY3-A2(UDDJB_?H=4I*=ZYIL:=K.#X:E<_.IW,HSU:FY(>S M%<7D!+O9HZ/WLB!+JDP*%
<4&T!0K9E8HH^\$ZG/D^YW67%:-8LN507\$8)^BC M5.?L K=RPPRGA!V?V;"!G@U=D-
E"DN9P1M@%8N1@P.()S@L2C@HR39)Q/IXF M49Z,DFA")!;C<1+!@W

%-1;&VT:3@!&)1/^BMKX:3*N3;)B%FE41C^,!Z MA[-""@/!%!BW/UL?
=SUAM01G1E9@#IX,O3(^YFPI4E??H'75J^>22Y5NA>Z3 M68E?
X)+Q)GUUQDJJT2_T\$IW(\$HM7GL9"^YHJ5K2*FOU%VR#N|K+-?P_|<"9H
M7T\4VR+>_O;N^/7Q&1K%072S@L?EG@/R5'VAY.=4&5:P'!LF!9(%,BN*YBM&
M"3VBN:U81<402|@ZIOKK@/M=(UAKA&HL:4Q1-T:_!3/T"G-7<71;!S^
MF|K^J#7@UGSVPI|["SL6*)="=#5<,K-R?
3L2HL8)MV'JM#QQ|Z@ (UB^3EZS3%3WD.|7-.VS=Y#*ZKHHD&YXS9<5]=X<#|% M7
V8R,I.T>OJO=)^..G#G&*UP(OJ_T5IPTZRHV5Q&\$8>R#'OK-V98/.A;P\$ M4)8
UWB:/9ID%2:V.SZGA4E'DWMIU|YBT!!A4C^:5H_JMU/Q"CHZWKYZ#>1
MBL)@;&\$X@PYU#T!1LV1-C!NP@H'XUWR.ZZ
MW1L6KQG<|3S:|7LQZ5|. *#1^YGE^O^SV?%7V6PF8\$J5|?Z"H6@P6!*XZYK7
M,P'&!U"A4E3;IGM6C#E'8;)P,@\$004LT)ZS*IC (K?WP2%ASK6=8*!5|Y8S
MLJ+*Q=2WID_PW|:)P0084YW%0BI"E0\ (Q(SHJ?IX=|1O=/:>:7 MZ./V5K*7:?
=|P"S|M_S8M--"3=7*JA6 MPN^M0|VAJYH=L.|^RCZR_EE=1NS:6*2U+,I89>
(D:,>PQ')\4%V M,!Z/LB\$F>!'&9#2(#R:#<8:'9/AGU
-34&JLM*DY/>H53/@K:N,GPU%ITBM& MS"J)PO"GGM.:37,I# 138-S|:7QL>|J"XZI3
MSR27*MD)W2^U\$C_!'>-U|NJ<%52C7^D5.I4%%J|C87V-54L;Q0U^YLV0=SM M5:/^
_#F:!=/E%LDWC|Q_N3UR?G:!'>T,'K?V#)"GZBLM?DZ583G+L&%2
M)DCLZ)HOF(T1^&8P")CF*,/.6A0|=TE|UNE=(4AKI'HM.(418?H| ^ LF ?H
MC&8NXV@P"O|+7I|J#;C57SROX;V)G0B422':*Z86;FZ'0M10;E.:2F502|Y
M)U6!HM#_Q5;V1 AY>;RDZ+WDQ/:)N51E@/:LY>|.81R'Z5P6)1:UNXO2?91+
MY1S7%"M\$!8\$6|W,EZ.Y.- [30>BYCN(AK%'.. C7*|H6XPKQ0R#O+\$@Z.UU
MML("XD.4@FEME|X90%EV%|M#)OYZ3<4GP\$|@J-@QP87V'N+FFKI!AY:4447 M-6
B2|M)-|4|H4DX|L*<8;7 @FK_PS6G-3K.C)7\$81A| M(,?&LW9%C2Z\$O_)@E@#9Z#!|-
%*3&R%?\$YS DPS&|U*O><2@*,(D?G18?OG^
M=S|9HZ#+Z^6CWT8J"H.1A>\$<*M1N@KSB'%@ K."6AVN"*OI7Q12U4T_-TMT0
M80_O(Z|!-HC^&MRWS|YS>*VYM%DT.P 7+@-H6>D;O_|BQ|HDL9F 3E4T
M,PP:H|%@2>"I*U|!,P44*%45-NB>U:,.4=@!HN!3@*" \$EB@/6>5KSL,. "3,
MN;9=#+0JWG!&EE2YF/A.|PFV:C^;&KR=3BM9"*4.4#;!R7FB;=GY0P77)<
M)TRXY)U1VA)F(8V116+/4)>VJV68MR1QY&C\$-|>K(&R.6:;589TD5MOX\$1| M0|9EP|-
@\$CXL#H/H0=DSN>V|)3?+!F0T0'K4&_0Z@Y8%25Q>H^CV;K'\$N M.
M@|OF6?.E|P;8)CK_|!8+@4"ZJ:"1JU\$ _3.N:;%YU|2#VWB=^#J=+K0;G_|
MQ<_30SZC^Z<6|VO4<7=G>)|J=|T^F:QK^+SXM)W"#8L2,I:<\$6133;|GY%X*
MK6|,\$^F^|&??>|XA|02P\$"% ,4 " !#BRI9^0_19GL< M !-J@ '@ @ \$
97@Q,#\$Y+7)E=FES961F;W)M;V9R M97-T CE-9%&0 X9H !X M (-!MQP &5X,3!O#
(S8VIN&UL4\$! A0#% @ 0XLJ62*2;B*T% @ 3Q< !0 M (-!Z H\$ &EN;G8M,C R-# V,S!?
9S\$N;G!G4\$! A0#% @ 0XLJ M66OPT>P=70\$ <8\$- !4 (-!SB\$ \$ &EN;G8M,C R-# V,S!?
M; &%B+GAM; %!+ 0(4 Q0 (-\$.+*EDX5-JX'- \$ #X4"@ 5 M " 1Y !0!L;FYV+3(P,C0P-
C,P7W!R92YX;6Q02P\$"% ,4 " !#BRI9 M*\$J|IH' ").) @ %P @ %M4 8 :6YN=BTR,#
(T,#8S,'AE M># ,Q,2YH=&U02P\$"% ,4 " !#BRI9F5 !#H|' " +) @ %P M @ \$16 8
:6YN=BTR,#(T,#8S,'AE># ,Q,BYH=&U02P\$"% ,4 " !# MBRI9VI;G.3<\$ #C\$ %P @ \$ 8 8
:6YN=BTR,#(T,#8S M,'AE># ,R,2YH=&U02P\$"% ,4 " !#BRI9Q5,B430\$ "V\$ %P M @ %L9
8 :6YN=BTR,#(T,#8S,'AE># ,R,BYH=&U02P4& !, \$! \$! U6@& end XML 117 innv-
20240630_htm.xml IDEA: XBRL DOCUMENT 0001834376 2023-07-01 2024-06-30
0001834376 2023-12-29 0001834376 2024-09-09 0001834376 2024-06-30 0001834376
2023-06-30 0001834376 innv:CapitationRevenueMember 2023-07-01 2024-06-30
0001834376 innv:CapitationRevenueMember 2022-07-01 2023-06-30 0001834376
innv:OtherServiceRevenueMember 2023-07-01 2024-06-30 0001834376
innv:OtherServiceRevenueMember 2022-07-01 2023-06-30 0001834376 2022-07-01
2023-06-30 0001834376 us-gaap:CommonStockMember 2022-06-30 0001834376 us-
gaap:AdditionalPaidInCapitalMember 2022-06-30 0001834376 us-
gaap:RetainedEarningsMember 2022-06-30 0001834376 us-
gaap:TreasuryStockCommonMember 2022-06-30 0001834376 us-
gaap:NoncontrollingInterestMember 2022-06-30 0001834376 2022-06-30 0001834376
us-gaap:CommonStockMember 2022-07-01 2023-06-30 0001834376 us-
gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-06-30 0001834376 us-
gaap:RetainedEarningsMember 2022-07-01 2023-06-30 0001834376 us-
gaap:NoncontrollingInterestMember 2022-07-01 2023-06-30 0001834376 us-

gaap:CommonStockMember 2023-06-30 0001834376 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001834376 us-
gaap:RetainedEarningsMember 2023-06-30 0001834376 us-
gaap:TreasuryStockCommonMember 2023-06-30 0001834376 us-
gaap:NoncontrollingInterestMember 2023-06-30 0001834376 us-
gaap:CommonStockMember 2023-07-01 2024-06-30 0001834376 us-
gaap:AdditionalPaidInCapitalMember 2023-07-01 2024-06-30 0001834376 us-
gaap:NoncontrollingInterestMember 2023-07-01 2024-06-30 0001834376 us-
gaap:TreasuryStockCommonMember 2023-07-01 2024-06-30 0001834376 us-
gaap:RetainedEarningsMember 2023-07-01 2024-06-30 0001834376 us-
gaap:CommonStockMember 2024-06-30 0001834376 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001834376 us-
gaap:RetainedEarningsMember 2024-06-30 0001834376 us-
gaap:TreasuryStockCommonMember 2024-06-30 0001834376 us-
gaap:NoncontrollingInterestMember 2024-06-30 0001834376
innv:SpecificPurposeRestrictedCashMember 2024-06-30 0001834376
innv:SpecificPurposeRestrictedCashMember 2023-06-30 0001834376 us-
gaap:LandMember 2024-06-30 0001834376 us-gaap:LandMember 2023-06-30
0001834376 srt:MinimumMember innv:BuildingAndLeaseholdImprovementsMember
2024-06-30 0001834376 srt:MaximumMember
innv:BuildingAndLeaseholdImprovementsMember 2024-06-30 0001834376
innv:BuildingAndLeaseholdImprovementsMember 2024-06-30 0001834376
innv:BuildingAndLeaseholdImprovementsMember 2023-06-30 0001834376
srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-
06-30 0001834376 srt:MaximumMember us-
gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0001834376 us-
gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0001834376 us-
gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-06-30 0001834376
srt:MinimumMember innv:EquipmentAndVehiclesMember 2024-06-30 0001834376
srt:MaximumMember innv:EquipmentAndVehiclesMember 2024-06-30 0001834376
innv:EquipmentAndVehiclesMember 2024-06-30 0001834376
innv:EquipmentAndVehiclesMember 2023-06-30 0001834376 us-
gaap:ConstructionInProgressMember 2024-06-30 0001834376 us-
gaap:ConstructionInProgressMember 2023-06-30 0001834376
innv:MedicaidCustomerMember us-gaap:RevenueFromContractWithCustomerMember
us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
innv:MedicaidCustomerMember us-gaap:RevenueFromContractWithCustomerMember
us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376
innv:MedicareCustomerMember us-gaap:RevenueFromContractWithCustomerMember
us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
innv:MedicareCustomerMember us-gaap:RevenueFromContractWithCustomerMember
us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376 us-
gaap:RevenueFromContractWithCustomerMember us-
gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376 us-
gaap:RevenueFromContractWithCustomerMember us-
gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376
innv:MedicarePartDMember us-gaap:RevenueFromContractWithCustomerMember us-
gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
innv:MedicarePartDMember us-gaap:RevenueFromContractWithCustomerMember us-
gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376
innv:MedicarePartDMember us-gaap:CostOfGoodsProductLineMember us-
gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
innv:MedicarePartDMember us-gaap:CostOfGoodsProductLineMember us-
gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376
innv:MedicaidCustomerMember us-gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
innv:MedicaidCustomerMember us-gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376

innv:MedicareCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
innv:MedicareCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376
innv:PrivatePayAndOtherCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
innv:PrivatePayAndOtherCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376
us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0001834376
us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0001834376
innv:JetdocInc.Member 2021-08-31 0001834376 innv:JetdocInc.Member 2021-08-01 2021-08-31 0001834376
innv:JetdocInc.Member 2023-10-01 2023-12-31 0001834376
innv:JetdocInc.Member 2024-01-01 2024-03-31 0001834376 innv:JetdocInc.Member 2022-07-01 2023-06-30 0001834376
innv:DispatchhealthHoldingsIncMember us-gaap:SeriesBPreferredStockMember 2019-06-14 0001834376
innv:DispatchhealthHoldingsIncMember us-gaap:SeriesCPreferredStockMember 2020-04-02 0001834376
innv:DispatchhealthHoldingsIncMember 2024-06-30 0001834376
innv:DispatchhealthHoldingsIncMember 2023-07-01 2024-06-30 0001834376
innv:DispatchhealthHoldingsIncMember 2022-07-01 2023-06-30 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-06-30 0001834376
innv:PinewoodLodgeLLPMember 2024-05-02 2024-05-02 0001834376
innv:InnovAgeFloridaPACEOrlandoMember 2024-05-28 2024-05-28 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
innv:InnovAgeFloridaPACEOrlandoMember 2024-05-28 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
innv:InnovAgeFloridaPACEOrlandoMember 2024-05-28 2024-05-28 0001834376
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-07-01 2024-06-30 0001834376
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-06-30 0001834376
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-06-30 0001834376
2019-03-18 0001834376 innv:InnovageSacramentoMember 2019-03-18 2019-03-18 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
innv:AdventistHealthSystemWestJointVentureMember us-gaap:RelatedPartyMember 2019-03-18 2019-03-18 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember innv:EskatonMember us-gaap:RelatedPartyMember 2019-03-18 2019-03-18 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
innv:AdventistHealthSystemWestJointVentureMember
innv:InnovageSacramentoMember us-gaap:RelatedPartyMember 2019-03-18 2019-03-18 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
innv:EskatonMember innv:InnovageSacramentoMember us-gaap:RelatedPartyMember 2019-03-18 2019-03-18 0001834376
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2020-07-01 2021-06-30 0001834376
innv:InnovageSacramentoMember 2021-06-30 0001834376 2023-03-20 2023-03-20 0001834376
innv:DirectOperatingCostsAndGeneralAndAdministrativeExpenseMember 2023-07-01 2024-06-30 0001834376
innv:DirectOperatingCostsAndGeneralAndAdministrativeExpenseMember 2022-07-01 2023-06-30 0001834376
innv:DepreciationDepletionAndAmortizationMember 2023-07-01 2024-06-30 0001834376
innv:DepreciationDepletionAndAmortizationMember 2022-07-01 2023-06-30 0001834376
us-gaap:InterestExpenseMember 2023-07-01 2024-06-30 0001834376
us-gaap:InterestExpenseMember 2022-07-01 2023-06-30 0001834376
us-gaap:SeniorLoansMember 2024-06-30 0001834376
us-gaap:SeniorLoansMember 2023-06-30 0001834376
us-gaap:ConvertibleDebtMember 2024-06-30 0001834376
us-gaap:ConvertibleDebtMember 2023-06-30 0001834376
innv:CreditAgreement2021CreditFacilityMember us-gaap:SeniorLoansMember 2021-03-08 0001834376
us-gaap:RevolvingCreditFacilityMember
innv:CreditAgreement2021CreditFacilityMember 2021-03-08 0001834376
us-

gaap:RevolvingCreditFacilityMember 2024-06-30 0001834376
innv:CreditAgreement2021CreditFacilityMember us-gaap:SeniorLoansMember 2021-03-08 2021-03-08 0001834376 innv:CreditAgreement2021CreditFacilityMember us-gaap:SeniorLoansMember 2024-06-30 0001834376
innv:CreditAgreement2021CreditFacilityMember us-gaap:SeniorLoansMember 2023-06-30 0001834376 us-gaap:RevolvingCreditFacilityMember
innv:CreditAgreement2021CreditFacilityMember 2021-03-08 2021-03-08 0001834376 us-gaap:RevolvingCreditFacilityMember
innv:CreditAgreement2021CreditFacilityMember 2024-06-30 0001834376 us-gaap:RevolvingCreditFacilityMember innv:CreditAgreement2021CreditFacilityMember
2023-07-01 2024-06-30 0001834376 us-gaap:RevolvingCreditFacilityMember
innv:CreditAgreement2021CreditFacilityMember 2022-07-01 2023-06-30 0001834376 us-gaap:ConvertibleDebtMember 2015-06-29 2015-06-29 0001834376 us-gaap:ConvertibleDebtMember 2015-06-29 0001834376 us-gaap:CashMember 2024-06-30 0001834376 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-06-30 0001834376 us-gaap:FairValueInputsLevel1Member us-gaap:MutualFundMember 2024-06-30 0001834376 2023-06-28 2023-06-28 0001834376 2023-01-01 2023-03-31 0001834376 2023-10-01 2023-10-31 0001834376 us-gaap:EmployeeStockOptionMember 2023-07-01 2024-06-30 0001834376 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0001834376 innv:ProfitsInterestsUnitsMember 2023-07-01 2024-06-30 0001834376 innv:ProfitsInterestsUnitsMember 2022-07-01 2023-06-30 0001834376 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-06-30 0001834376 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2023-06-30 0001834376 innv:EquityIncentivePlan2020Member 2024-06-30 0001834376 innv:EquityIncentivePlan2020Member 2023-07-01 2024-06-30 0001834376 srt:MinimumMember innv:ProfitsInterestsUnitsMember 2023-07-01 2024-06-30 0001834376 srt:MaximumMember innv:ProfitsInterestsUnitsMember 2023-07-01 2024-06-30 0001834376 srt:MinimumMember innv:ProfitsInterestsUnitsMember 2024-06-30 0001834376 srt:MaximumMember innv:ProfitsInterestsUnitsMember 2024-06-30 0001834376 innv:TimeVestingUnitsProfitInterestsMember 2023-06-30 0001834376 innv:TimeVestingUnitsProfitInterestsMember 2023-07-01 2024-06-30 0001834376 innv:TimeVestingUnitsProfitInterestsMember 2024-06-30 0001834376 innv:PerformanceVestingUnitsProfitInterestsMember 2023-06-30 0001834376 innv:PerformanceVestingUnitsProfitInterestsMember 2023-07-01 2024-06-30 0001834376 innv:PerformanceVestingUnitsProfitInterestsMember 2024-06-30 0001834376 innv:ProfitsInterestsUnitsMember 2024-06-30 0001834376 innv:OmnibusIncentivePlan2021Member 2021-03-31 0001834376 innv:RestrictedStockUnitsRSUsTimeBasedMember innv:OmnibusIncentivePlan2021Member 2021-03-01 2021-03-31 0001834376 innv:TimeBasedStockOptionsMember innv:OmnibusIncentivePlan2021Member 2021-03-01 2021-03-31 0001834376 innv:TimeBasedRestrictedStockUnitsMember 2023-06-30 0001834376 innv:TimeBasedRestrictedStockUnitsMember 2023-07-01 2024-06-30 0001834376 innv:TimeBasedRestrictedStockUnitsMember 2024-06-30 0001834376 us-gaap:RestrictedStockUnitsRSUMember innv:OmnibusIncentivePlan2021Member 2024-06-30 0001834376 us-gaap:RestrictedStockUnitsRSUMember innv:OmnibusIncentivePlan2021Member 2023-07-01 2024-06-30 0001834376 innv:PerformanceBasedRestrictedStockUnitsMember 2023-06-30 0001834376 innv:PerformanceBasedRestrictedStockUnitsMember 2023-07-01 2024-06-30 0001834376 innv:PerformanceBasedRestrictedStockUnitsMember 2024-06-30 0001834376 innv:TimeVestingAwardsMember 2023-06-30 0001834376 innv:TimeVestingAwardsMember 2023-07-01 2024-06-30 0001834376 innv:TimeVestingAwardsMember 2024-06-30 0001834376 innv:TimeBasedOptionsAwardsMember 2022-07-01 2023-06-30 0001834376 innv:TimeBasedOptionsAwardsMember 2023-06-30 0001834376 us-gaap:PerformanceSharesMember 2023-06-30 0001834376 us-gaap:PerformanceSharesMember 2023-07-01 2024-06-30 0001834376 us-gaap:PerformanceSharesMember 2024-06-30 0001834376

innv:RestrictedStockUnitsRSUsTimeBasedMember
innv:OmnibusIncentivePlan2021Member-us-
gaap:ShareBasedCompensationAwardTrancheOneMember 2021-03-01 2021-03-31
0001834376 innv:RestrictedStockUnitsRSUsTimeBasedMember
innv:OmnibusIncentivePlan2021Member-us-
gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-03-01 2021-03-31
0001834376 innv:RestrictedStockUnitsRSUsTimeBasedMember
innv:OmnibusIncentivePlan2021Member-us-
gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-03-01 2021-03-31
0001834376 innv:RestrictedStockUnitsRSUsTimeBasedMember
innv:OmnibusIncentivePlan2021Member
innv:ShareBasedPaymentArrangementTrancheFourMember 2021-03-01 2021-03-31
0001834376 innv:ConcertoMember 2023-12-01 2023-12-01 0001834376
innv:ConcertoMember 2023-07-01 2024-06-30 0001834376 innv:ConcertoMember
2023-12-01 0001834376 innv:ConcertoMember 2024-06-30 2024-06-30 0001834376
2023-12-02 2024-06-30 0001834376 innv:ConcertoMember 2024-06-30 0001834376
innv:ConcertoMember 2023-12-02 2024-06-30 0001834376 us-
gaap:StateAndLocalJurisdictionMember 2024-06-30 0001834376 us-
gaap:StateAndLocalJurisdictionMember 2023-06-30 0001834376 us-
gaap:DomesticCountryMember 2024-06-30 0001834376 us-
gaap:DomesticCountryMember 2023-06-30 0001834376
innv:AdministrativeFeePerYearMember 2023-07-01 2024-06-30 0001834376 us-
gaap:ServiceOtherMember 2023-06-30 0001834376 2024-05-02 2024-05-02
0001834376 innv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember
2023-07-01 2024-06-30 0001834376 innv:CapitationRevenueMember
innv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember 2023-07-01
2024-06-30 0001834376 innv:CapitationRevenueMember us-
gaap:AllOtherSegmentsMember 2023-07-01 2024-06-30 0001834376
innv:CapitationRevenueMember
innv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember 2022-07-01
2023-06-30 0001834376 innv:CapitationRevenueMember us-
gaap:AllOtherSegmentsMember 2022-07-01 2023-06-30 0001834376
innv:OtherServiceRevenueMember
innv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember 2023-07-01
2024-06-30 0001834376 innv:OtherServiceRevenueMember us-
gaap:AllOtherSegmentsMember 2023-07-01 2024-06-30 0001834376
innv:OtherServiceRevenueMember
innv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember 2022-07-01
2023-06-30 0001834376 innv:OtherServiceRevenueMember us-
gaap:AllOtherSegmentsMember 2022-07-01 2023-06-30 0001834376 us-
gaap:AllOtherSegmentsMember 2023-07-01 2024-06-30 0001834376
innv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember 2022-07-01
2023-06-30 0001834376 us-gaap:AllOtherSegmentsMember 2022-07-01 2023-06-30
0001834376 us-gaap:PerformanceSharesMember 2022-07-01 2023-06-30 0001834376
us-gaap:PerformanceSharesMember 2023-07-01 2024-06-30 0001834376
innv:June2024RepurchaseProgramMember 2024-06-14 0001834376
innv:June2024RepurchaseProgramMember us-gaap:CommonStockMember 2023-07-01
2024-06-30 0001834376 innv:June2024RepurchaseProgramMember us-
gaap:TreasuryStockCommonMember 2023-07-01 2024-06-30 0001834376 2024-04-01
2024-06-30 0001834376 innv:NicoleDAmatoMember 2023-07-01 2024-06-30
0001834376 innv:NicoleDAmatoMember 2024-04-01 2024-06-30 0001834376
innv:NicoleDAmatoMember 2024-06-30 iso4217:USD shares iso4217:USD shares
innv:segment innv:participant innv:center pure innv:reporting_unit innv:investment
innv:acquisition innv:program innv:officer innv:division 0001834376 2024 FY false
[http://fasb.org/us-](http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumu)
[gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumu](http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumu)
1 0.3333 0.3333 0.3333 P460D 10-K true 2024-06-30 --06-30 false 001-40159 InnovAge
Holding Corp DE 81-0710819 8950 E. Lowry Boulevard Denver CO 80230 844 803-8745

Common Stock, \$0.001 par value INNV NASDAQ No No Yes Yes Accelerated Filer true true false false false false 114600000 135620541 <div style="margin-top:6pt;text-align:center;text-indent:18pt">Portions of the registrant's proxy statement for the upcoming Annual Meeting of Stockholders to be filed no later than 120 days after the end of the registrant's fiscal year ended June 30, 2024, are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent described herein.</div> 34 Deloitte & Touche LLP Denver, Colorado 56946000 127249000 45833000 46213000 14000 16000 6729000 4161000 48106000 24344000 18919000 17145000 3324000 262000 173142000 215229000 193022000 192188000 28416000 21210000 2645000 5493000 5949000 3823000 139949000 124217000 4538000 5198000 374519000 352129000 547661000 567358000 55459000 54935000 55404000 42999000 15197000 9142000 0 1212000 3795000 3795000 4599000 4722000 4145000 3530000 0 28115000 138599000 148450000 7460000 6236000 12743000 13114000 26275000 18828000 1298000 1086000 61478000 64844000 247853000 252558000 22200000 12708000 0.001 0.001 500000000 500000000 136152858 136116299 135639845 135639845 136000 136000 36559 179000 0 337615000 332107000 -68311000 -35944000 269261000 296299000 8347000 5793000 277608000 302092000 547661000 567358000 762570000 686836000 1285000 1251000 763855000 688087000 403010000 374528000 228781000 212271000 24957000 19627000 111337000 115637000 18950000 15419000 787035000 737482000 -23180000 -49395000 -4023000 -1522000 2842000 0 2542000 124000 1361000 -1398000 -21819000 -50793000 1402000 -7241000 -23221000 -43552000 -1883000 -2879000 -21338000 -40673000 135902214 135593824 135902214 135593824 -0.16 -0.30 -0.16 -0.30 135532811 136000 327499000 4729000 0 0 6102000 338466000 15278000 107034 4608000 4608000 -40673000 -309000 -40982000 -2570000 -43552000 135639845 136000 332107000 -35944000 0 0 5793000 302092000 12708000 135639845 136000 332107000 -35944000 0 0 5793000 302092000 12708000 800515 6832000 6832000 287502 1324000 1324000 2900000 2900000 36559 36559 179000 179000 -11029000 -11029000 11029000 -21338000 -346000 -21684000 -1537000 -23221000 136116299 136000 337615000 -68311000 36559 -179000 8347000 277608000 22200000 -23221000 -43552000 -78000 -1107000 7010000 3340000 18950000 15419000 5339000 4604000 2842000 0 429000 429000 6832000 4608000 1224000 -11525000 1449000 167000 30333000 -8223000 703000 3303000 3062000 -6499000 2829000 1263000 1370000 6786000 12294000 4545000 6054000 12000 -1212000 1212000 -5610000 -5187000 -28115000 28115000 -36898000 20236000 7914000 23354000 2385000 46167000 3000000 0 4842000 0 23916000 0 -26373000 -69521000 4637000 4103000 3795000 3793000 -179000 0 -2900000 0 1323000 0 -7034000 -7896000 -70305000 -57181000 127265000 184446000 56960000 127265000 4063000 3997000 4452000 13000 181000 882000 4142000 9131000 Business<div style="margin-top:12pt;text-align:justify;text-indent:18pt">InnovAge Holding Corp. and its subsidiaries ("InnovAge" or the "Company"), are headquartered in Denver, Colorado. The Company's participant-centered care delivery approach is designed to improve the quality of care the Company's participants receive, while keeping them in their homes for as long as safely possible. Through the Company's Program of All-Inclusive Care for the Elderly ("PACE") program, the Company fulfills a broad range of medical and ancillary services for seniors, including in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. The Company manages its business as one reportable segment, PACE.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">As of June 30, 2024, the Company served approximately 7,020 PACE participants, making it the largest PACE provider in the United States of America (the

U.S.) based upon participants served, and operated 20 PACE centers across Colorado, California, Florida, New Mexico, Pennsylvania and Virginia.

PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, population in a community-based service model. We define dual-eligible seniors as individuals who are 55+ and qualify for benefits under both Medicare and Medicaid. InnovAge provides all needed healthcare services through an all-inclusive, coordinated model of care, and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, Veterans Administration ("VA"), and private pay sources. Additionally, under the Medicare Prescription Drug Plan, the Centers for Medicare and Medicaid Services ("CMS") share part of the risk for providing prescription medication to the Company's participants.

The Company's common stock is traded on the Nasdaq Stock Market LLC ("NASDAQ") under the ticker symbol "INN".

1 7020 20 1 Summary of Significant Accounting Policies

Basis of Preparation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (VIEs) for which it is the primary beneficiary and entities for which it is the controlling general partner. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in accounting for, among other things, the allowance for uncollectible accounts; revenue reserves; useful lives of property and equipment and the valuation of goodwill and intangible assets; risk-score adjustments to participant revenues; reported and estimated claims; accruals; the determination of assumptions for stock-based compensation costs; deferred taxes, including the determination of a need for a valuation allowance; legal contingencies, including medical malpractice claims; the determination of fair value of net assets acquired in a business combination; and other fair value measurements. Actual results may differ from previously estimated amounts.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and financial instruments issued by major financial institutions that have an original maturity of less than three months. Amounts are reported in the consolidated balance sheets at cost, which approximates fair value.

The Company's cash and cash equivalents are deposited with high credit quality financial institutions and are primarily in demand deposit accounts. The FDIC insurance coverage is \$250,000 on the aggregate of interest bearing and non-interest bearing accounts. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Investments

Cost method investments do not have a readily determinable fair value and are carried at cost, less impairment plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.

The Company uses the equity method to account for investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. The Company's investments in these nonconsolidated entities are reflected in the Company's consolidated balance sheets under the equity method, and the Company's proportionate net income (loss), if any, is included in the Company's consolidated statements of operations under the equity method.

The Company evaluates its investments for impairment whenever events or changes in circumstances indicate that a decline in value has occurred that is other than temporary. Evidence considered in this evaluation includes, but would not necessarily be limited to, the financial condition and near-term prospects of the investee, recent operating trends and forecasted performance of the investee, market conditions in the geographic area or industry in which the investee operates and the Company's strategic plans for holding the investment in relation to the period of time expected for an anticipated recovery of its carrying value. If the investment is determined to have a decline in value deemed to be other than temporary it is written down to estimated fair value. During the fiscal year ended June 30, 2024, we noted indicators of impairment in one of our investments and recorded \$2.0 million of impairment charges. There were no write-downs in the fiscal year ended June 30, 2023. See Note 4 "Cost and Equity Method Investments" for more information.

Short-term Investments

Short-term investments consist of investments in managed income fund securities managed by major financial institutions. These securities are measured at fair value on a recurring basis with changes in fair value recognized in earnings. The estimated fair value of the short-term investments is valued using quoted market prices in active markets and classified as Level 1 of the fair value hierarchy. Dividend income is reported within other income (expense) in the Company's consolidated statement of operations. Dividends received are reinvested in fund securities. We may sell these securities at any time for use in current operations. As a result, we classify our short-term investments as current assets on the Company's consolidated balance sheets.

Restricted Cash

Restricted cash includes cash held for participants who have established a personal-needs account to

pay for nonmedical personal expenses, payment of which only occurs upon participant authorization, in the amount of approximately \$0.01 million and \$0.02 million as of June 30, 2024 and 2023, respectively. The Company records a related deposit liability for any participant contributions to these personal-needs accounts in accounts payable and accrued expenses in the consolidated balance sheets.

Accounts Receivable

The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company's best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts. See additional information in Note 3 "Revenue Recognition."

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful lives or lease terms, if the assets are being leased.

Property and equipment were comprised of the following as of June 30:

	2024	2023
Land	\$1,000	\$1,000
Buildings	\$1,000	\$1,000
Leasehold improvements	\$1,000	\$1,000
Equipment	\$1,000	\$1,000
Other	\$1,000	\$1,000
Total	\$5,000	\$5,000

dollars in thousands

Estimated Useful Lives

2024

2023

Land

	N/A	
	\$	11,970
	\$	11,970
Buildings and leasehold improvements	10 - 40 years	
		156,064
		124,262
Software	3 - 5 years	
		30,678
		26,656
Equipment and vehicles		

3 - 7 years </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,495 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,754 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:top">Construction in progress</td><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,234 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42,223 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">280,441 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">262,865 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:top">Less accumulated depreciation and amortization</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(87,419)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

	(70,677)	
Total property and equipment, net		
\$	193,022	
\$	192,188	

Depreciation of \$18.3 million and \$14.8 million was recorded during the fiscal years ended June 30, 2024 and 2023, respectively. Land is not depreciated, and construction in progress is not depreciated until ready for service. Costs of enhancements or modifications that substantially extend the capacity or useful life of an asset are capitalized and depreciated accordingly. Ordinary repairs and maintenance are expensed as incurred.

The costs of acquiring or developing internal-use software, including directly related payroll costs for internal resources, are capitalized. Software maintenance and training costs are expensed in the period incurred.

Interest is capitalized on construction projects, including internal-use software development projects, while in progress. During the fiscal years ended June 30, 2024 and 2023, the Company capitalized interest of approximately \$0.01 million and \$1.0 million, respectively.

When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets, and the resulting gain or loss, if any, is reflected in the consolidated statements of operations. Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. No impairment charges were recorded in the fiscal years ended June 30, 2024 or 2023.

Goodwill and Intangible Assets

Intangible assets primarily consist of customer relationships acquired through business acquisitions. Goodwill represents the excess of consideration paid over the fair value of net assets acquired through business acquisitions. Goodwill is not amortized but is tested for impairment at least annually.

The Company tests goodwill for impairment annually on April 1st or more frequently if triggering events occur or other impairment indicators arise which might impair recoverability. These events or circumstances would include a significant change in the business climate, legal factors, operating performance indicators, competition, sale, disposition of a significant portion of the business, or other factors. Impairment of goodwill is evaluated at the reporting unit level. A reporting unit is defined as an operating segment (i.e. before aggregation or combination), or one level below an operating segment (i.e. a component). A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component. The Company has two reporting units, East and West, for evaluating goodwill impairment.

ASC 350, Intangibles — Goodwill and Other (“ASC 350”), allows entities to first use a qualitative approach to test goodwill for impairment. When the reporting units where the Company performs the quantitative goodwill impairment are tested, the Company compares the fair value of the reporting unit, which the Company primarily determines using an income approach based on the present value of discounted cash flows, to the respective carrying value, which includes goodwill. If the fair value of the reporting unit exceeds its carrying value, the goodwill is not considered impaired. If the carrying value is higher than the fair value, the difference would be recognized as an impairment loss. There were no goodwill impairments recorded during the years ended June 30, 2024 and 2023.

Customer relationships represent the estimated values of customer relationships of acquired businesses and have definite lives. The Company amortizes these intangible assets on a straight-line basis over their ten-year estimated useful life. Intangible assets are reviewed for impairment in conjunction with long-lived assets. There were no intangible asset impairments recorded during the years ended June 30, 2024 and 2023.

Reported and Estimated Claims

Reported and estimated claims consist of unpaid claims reported as of the balance sheet date and estimates of claims incurred on or before June 30 that have not been reported by that date (IBNR). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of healthcare services, historical payment patterns, cost trends, and other factors. These complex estimation methods and the resulting reserves are continually reviewed and updated, and any adjustments deemed necessary to contemplate new or updated information are reflected in current operations.

Debt Issuance Costs

Debt issuance costs are those costs that have been incurred in connection with the issuance of long-term debt and are offset

against long-term debt in the consolidated balance sheets. Such costs are being amortized over the term of the underlying debt using the straight-line method, as the difference between that and the effective interest method are immaterial.

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performed the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation. Medicaid and Medicare capitation revenues are based on a per member, per month ("PMPM") capitation rates under the PACE program. For a discussion of our revenue recognition policies, please see Note 3 "Revenue Recognition."

Professional Liability Claims

The Company records a liability for medical malpractice claims based on estimated probable losses and costs associated with settling these claims and a receivable to reflect the estimated insurance recoveries, if any. See Note 9 "Commitments and Contingencies."

Advertising Costs

The Company's purchased services and contracts expenses include media advertising, tactical advertising, and promotion costs. The creative portion of these activities is expensed as incurred. Production costs of advertising and promotional materials are expensed when the advertising is first run, unless such costs support direct-response advertising campaigns. In that case, these costs are capitalized and amortized over the period estimated to benefit from the campaign. Total advertising expenses were \$6.8 million and \$5.6 million for the fiscal years ended June 30, 2024 and 2023, respectively.

Stock-based Compensation

The Company and its principal shareholder have long-term equity incentive plans that provide for stock-based compensation, including the granting of stock options, profits interests units and restricted stock units to employees, directors, consultants, or advisers, as determined by each of the respective plans.

The Company utilizes the Black-Scholes option-pricing model to determine the fair value of the stock options on the date of grant. This model derives the fair value of the options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate, and dividend yield. The Company uses the Monte Carlo option model to determine the fair value of the granted profits interests units.

weight:400;line-height:120%>For service-vesting awards (i.e., restricted stock units), we recognize stock-based compensation expense over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. If the award was, in substance, multiple awards, we recognize stock-based compensation expense over the requisite service period for each separately vesting portion of the awards. For performance-vesting awards (i.e., performance stock units), we recognize stock-based compensation expense when it is probable that the performance condition will be achieved. We analyze if a performance condition is probable for each reporting period through the settlement date for awards subject to

performance vesting. Stock-based compensation is included in corporate, general and administrative expenses on our consolidated statements of operations.

Shares issued pursuant to our equity incentive plan are issued from authorized but unissued shares or from shares held by the Company as treasury stock, if any. See Note 10 “Stock-based Compensation.”

Income Taxes

The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Senior Housing Thornton, LLC (“SH1”) and InnovAge Sacramento have elected to be taxed as partnerships, and no provision (benefit) for income taxes for SH1 or InnovAge Sacramento is included in these consolidated financial statements. Further, InnovAge Orlando entered into a joint venture on May 28, 2024 and its members elected to be taxed as a partnership. No provision (benefit) for income taxes for InnovAge Orlando is included in these consolidated financial statements for activity occurring from joint venture formation date through the balance of the fiscal year.

A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.

Variable Interest Entities (VIE)

A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk or whose equity owners lack certain decision-making and economic rights. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity. The primary beneficiary

is required to consolidate the VIE. InnovAge Senior Housing Thornton, LLC ("SH1") and Pinewood Lodge, LLP ("PWD") are considered to be VIEs. The Company is not considered the primary beneficiary of PWD but is considered the primary beneficiary of SH1. On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including the Senior Housing unit. The sale closed on May 2, 2024, and as a result, the Company ceased providing senior housing services through PWD.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company's consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Adopted Accounting Pronouncements

Financial Instruments

In April 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-04, "Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments" ("ASU 2019-04"), which requires entities to use a current expected credit loss ("CECL") model to measure impairment for most financial assets that are not recorded at fair value through net income. Under the CECL model, an entity will estimate lifetime expected credit losses considering available relevant information about historical events, current conditions and supportable forecasts. The CECL model does not apply to available-for-sale debt securities. The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the standard on July 1, 2023. Our adoption of the standard did not have a material impact on the

consolidated financial statements. The Company makes estimates of expected credit losses based on a combination of factors, including historical losses adjusted for current market conditions, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Recent Accounting Pronouncements Not Yet Adopted

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures

. ASU 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual segment disclosures be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is evaluating the impact of ASU 2023-07 on our consolidated financial statements.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

. ASU 2023-09 requires additional disclosures related to rate reconciliation, income taxes paid, and other disclosures. ASU 2023-09 requires public companies to annually (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. Additionally, ASU 2023-09 requires public companies to annually disclose the amount of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as the amount of income taxes paid by individual jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2025. The Company is currently evaluating the impact of ASU 2023-09 on our consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

Basis of Preparation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (VIEs) for which it is the primary beneficiary and entities for which it is the controlling general partner. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and

disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in accounting for, among other things, the allowance for uncollectible accounts; revenue reserves; useful lives of property and equipment and the valuation of goodwill and intangible assets; risk-score adjustments to participant revenues; reported and estimated claims; accruals; the determination of assumptions for stock-based compensation costs; deferred taxes, including the determination of a need for a valuation allowance; legal contingencies, including medical malpractice claims; the determination of fair value of net assets acquired in a business combination; and other fair value measurements. Actual results may differ from previously estimated amounts.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and financial instruments issued by major financial institutions that have an original maturity of less than three months. Amounts are reported in the consolidated balance sheets at cost, which approximates fair value.

The Company's cash and cash equivalents are deposited with high credit quality financial institutions and are primarily in demand deposit accounts. The FDIC insurance coverage is \$250,000 on the aggregate of interest bearing and non-interest bearing accounts. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Investments

Cost method investments do not have a readily determinable fair value and are carried at cost, less impairment plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.

The Company uses the equity method to account for investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. The Company's investments in these nonconsolidated entities are reflected in the Company's consolidated balance sheets under the equity method, and the Company's proportionate net income (loss), if any, is included in the Company's consolidated statements of operations under the equity method.

The Company evaluates its investments for impairment whenever events or changes in circumstances indicate that a decline in value has occurred that is other than temporary. Evidence considered in this evaluation includes, but would not necessarily be limited to, the financial condition and near-term prospects of the investee, recent operating trends and forecasted performance of the investee, market conditions in the geographic area or industry in which the investee operates and the Company's strategic plans for holding the investment in relation to the period of time expected for an anticipated recovery of its carrying value. If the investment is determined to have a decline in value deemed to be other than temporary it is written down to estimated fair value.

Short-term Investments

Short-term investments consist of investments in

managed income fund securities managed by major financial institutions. These securities are measured at fair value on a recurring basis with changes in fair value recognized in earnings. The estimated fair value of the short-term investments is valued using quoted market prices in active markets and classified as Level 1 of the fair value hierarchy. Dividend income is reported within other income (expense) in the Company's consolidated statement of operations. Dividends received are reinvested in fund securities. We may sell these securities at any time for use in current operations. As a result, we classify our short-term investments as current assets on the Company's consolidated balance sheets.

Restricted Cash

Restricted cash includes cash held for participants who have established a personal-needs account to pay for nonmedical personal expenses, payment of which only occurs upon participant authorization, in the amount of approximately \$0.01 million and \$0.02 million as of June 30, 2024 and 2023, respectively. The Company records a related deposit liability for any participant contributions to these personal-needs accounts in accounts payable and accrued expenses in the consolidated balance sheets.

	10000.00	20000.00

Accounts Receivable

The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company's best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts.

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful lives or lease terms, if the assets are being leased.

Property and equipment were comprised of the following as of June 30:

	2024	2023	2022	2021	2020
Land	\$—	\$—	\$—	\$—	\$—
Buildings	\$12.081M	\$12.081M	\$12.081M	\$12.081M	\$12.081M
Furniture and fixtures	\$0.406M	\$0.406M	\$0.406M	\$0.406M	\$0.406M
Leasehold improvements	\$1.0M	\$1.0M	\$1.0M	\$1.0M	\$1.0M
Equipment	\$12.084M	\$12.084M	\$12.084M	\$12.084M	\$12.084M
Total	\$25.561M	\$25.561M	\$25.561M	\$25.561M	\$25.561M

dollars in thousands

Estimated

Useful Lives			
2024			
2023			
Land			
N/A			
\$			
11,970			
2px 0; text-align: right; vertical-align: bottom			
2px 0; text-align: right; vertical-align: bottom			
\$			
11,970			
2px 0; text-align: right; vertical-align: bottom			
Buildings and leasehold improvements			
10 - 40 years			
156,064			
124,262			
Software			
3 - 5 years			
2px 0 2px 1pt; text-align: right; vertical-align: bottom			

	30,678		
	26,656		
	Equipment and vehicles		
3 - 7 years			
	69,495		
	57,754		
	Construction in progress		
	N/A		
	12,234		
	42,223		
	280,441		
	262,865		

Less accumulated depreciation and amortization	(87,419)	(70,677)	
Total property and equipment, net	\$193,022	\$192,188	

Depreciation of \$18.3 million and \$14.8 million was recorded during the fiscal years ended June 30, 2024 and 2023, respectively. Land is not depreciated, and construction in progress is not depreciated until ready for service. Costs of enhancements or modifications that substantially extend the capacity or useful life of an asset are capitalized and depreciated accordingly. Ordinary repairs and maintenance are expensed as incurred.

The costs of acquiring or developing internal-use software, including directly related payroll costs for internal resources, are capitalized. Software maintenance and training costs are expensed in the period incurred.

Interest is capitalized on construction projects, including internal-use software development projects, while in progress. During the fiscal years ended June 30, 2024 and 2023, the Company capitalized interest of

approximately \$0.01 million and \$1.0 million, respectively.

When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets, and the resulting gain or loss, if any, is reflected in the consolidated statements of operations. Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable.

Property and equipment																	
As of June 30:	dollars in thousands				Estimated	Useful Lives			2024	2023	Land	N/A	\$	11,970		\$	11,970

Buildings and leasehold improvements			10 - 40 years			156,064			124,262		
Software			3 - 5 years			30,678			26,656		
Equipment and vehicles			3 - 7 years			69,495			57,754		
Construction in progress			N/A								

12,234			42,223		280,441	
262,865			Less accumulated depreciation and amortization		(87,419)	
(70,677)			\$		193,022	
Total property and equipment, net						

	192,188

11970000 11970000 P10Y P40Y 156064000 124262000 P3Y P5Y 30678000 26656000 P3Y P7Y 69495000 57754000 12234000 42223000 280441000 262865000 87419000 70677000 193022000 192188000 18300000 14800000 10000.00 1000000.0 0 0 0

Goodwill and Intangible Assets

Intangible assets primarily consist of customer relationships acquired through business acquisitions. Goodwill represents the excess of consideration paid over the fair value of net assets acquired through business acquisitions. Goodwill is not amortized but is tested for impairment at least annually.

The Company tests goodwill for impairment annually on April 1st or more frequently if triggering events occur or other impairment indicators arise which might impair recoverability. These events or circumstances would include a significant change in the business climate, legal factors, operating performance indicators, competition, sale, disposition of a significant portion of the business, or other factors. Impairment of goodwill is evaluated at the reporting unit level. A reporting unit is defined as an operating segment (i.e. before aggregation or combination), or one level below an operating segment (i.e. a component). A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component. The Company has two reporting units, East and West, for evaluating goodwill impairment.

ASC 350, Intangibles — Goodwill and Other (“ASC 350”), allows entities to first use a qualitative approach to test goodwill for impairment. When the reporting units where the Company performs the quantitative goodwill impairment are tested, the Company compares the fair value of the reporting unit, which the Company primarily determines using an income approach based on the present value of discounted cash flows, to the respective carrying value, which includes goodwill. If the fair value of the reporting unit exceeds its carrying value, the goodwill is not considered impaired. If the carrying value is higher than the fair value, the difference would be recognized as an impairment loss. There were no goodwill impairments recorded during the years ended June 30, 2024 and 2023.

Customer relationships represent the estimated values of customer relationships of acquired businesses and have definite lives. The Company amortizes these intangible assets on a straight-line basis over their ten-year estimated useful life. Intangible assets are reviewed for impairment in conjunction with long-lived assets.

2 0 0 P10Y 0 0

Reported and Estimated Claims

Reported and estimated claims consist of unpaid claims reported as of the balance sheet date and estimates of claims incurred on or before June 30 that have not been reported by that date (IBNR). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of healthcare

services, historical payment patterns, cost trends, and other factors. These complex estimation methods and the resulting reserves are continually reviewed and updated, and any adjustments deemed necessary to contemplate new or updated information are reflected in current operations.

Debt Issuance Costs

Debt issuance costs are those costs that have been incurred in connection with the issuance of long-term debt and are offset against long-term debt in the consolidated balance sheets. Such costs are being amortized over the term of the underlying debt using the straight-line method, as the difference between that and the effective interest method are immaterial.

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performed the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation. Medicaid and Medicare capitation revenues are based on a per member, per month ("PMPM") capitation rates under the PACE program.

Professional Liability Claims

The Company records a liability for medical malpractice claims based on estimated probable losses and costs associated with settling these claims and a receivable to reflect the estimated insurance recoveries, if any.

Advertising Costs

The Company's purchased services and contracts expenses include media advertising, tactical advertising, and promotion costs. The creative portion of these activities is expensed as incurred. Production costs of advertising and promotional materials are expensed when the advertising is first run, unless such costs support direct-response advertising campaigns. In that case, these costs are capitalized and amortized over the period estimated to benefit from the campaign.

Stock-based Compensation

The Company and its principal shareholder have long-term equity incentive plans that provide for stock-based compensation, including the granting of stock options, profits interests units and restricted stock units to employees, directors, consultants, or advisers, as determined by each of the respective plans.

The Company utilizes the Black-Scholes option-pricing model to determine the fair value of the stock options on the date of grant. This model derives the fair value of the options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate, and dividend yield. The Company uses the Monte Carlo option model to determine the fair value of the granted profits interests units.

For service-

vesting awards (i.e., restricted stock units), we recognize stock-based compensation expense over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. If the award was, in substance, multiple awards, we recognize stock-based compensation expense over the requisite service period for each separately vesting portion of the awards. For performance-vesting awards (i.e., performance stock units), we recognize stock-based compensation expense when it is probable that the performance condition will be achieved. We analyze if a performance condition is probable for each reporting period through the settlement date for awards subject to

performance vesting. Stock-based compensation is included in corporate, general and administrative expenses on our consolidated statements of operations.

Shares issued pursuant to our equity incentive plan are issued from authorized but unissued shares or from shares held by the Company as treasury stock, if any.

Income Taxes

The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Senior Housing Thornton, LLC ("SH1") and InnovAge Sacramento have elected to be taxed as partnerships, and no provision (benefit) for income taxes for SH1 or InnovAge Sacramento is included in these consolidated financial statements. Further, InnovAge Orlando entered into a joint venture on May 28, 2024 and its members elected to be taxed as a partnership. No provision (benefit) for income taxes for InnovAge Orlando is included in these consolidated financial statements for activity occurring from joint venture formation date through the balance of the fiscal year.

A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.

Variable Interest Entities (VIE)

A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk or whose equity owners lack certain decision-making and economic rights. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity. The primary beneficiary is required to consolidate the VIE. InnovAge Senior Housing Thornton, LLC ("SH1") and Pinewood Lodge, LLP ("PWD") are considered to be VIEs. The Company is not considered the primary beneficiary of PWD but is considered the primary beneficiary of SH1. On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including the Senior Housing unit. The sale closed on May 2, 2024, and as a result, the Company ceased providing senior housing services through PWD.

Recently Adopted Accounting Pronouncements

Financial Instruments

In April 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-04, **Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments** ("ASU 2019-04"), which requires entities to use a current expected credit loss ("CECL") model to measure impairment for most financial assets that are not recorded at fair value through net income. Under the CECL model, an entity will estimate lifetime expected credit losses considering available relevant information about historical events, current conditions and supportable forecasts. The CECL model does not apply to available-for-sale debt securities. The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the standard on July 1, 2023. Our adoption of the standard did not have a material impact on the

consolidated financial statements. The Company makes estimates of expected credit losses based on a combination of factors, including historical losses adjusted for current market conditions, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Recent Accounting Pronouncements Not Yet Adopted

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, **Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures**. ASU 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual segment disclosures be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is evaluating the impact of ASU 2023-07 on our consolidated financial statements.

Income Taxes

In December 2023, the FASB issued ASU 2023-09,

Income Taxes (Topic 740): Improvements to Income Tax Disclosures

ASU 2023-09 requires additional disclosures related to rate reconciliation, income taxes paid, and other disclosures. ASU 2023-09 requires public companies to annually (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. Additionally, ASU 2023-09 requires public companies to annually disclose the amount of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as the amount of income taxes paid by individual jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2025. The Company is currently evaluating the impact of ASU 2023-09 on our consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

Revenue Recognition

Capitation Revenue and Accounts Receivable

Our capitation revenue relates to contracts with participants in which our performance obligation is to provide healthcare services to the participants. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type. The Company contracts directly with Medicare and Medicaid on a PMPM basis. We receive 100% of the pooled capitated payment to directly provide or manage the healthcare needs of our participants.

Fees are recorded gross in revenues because the Company is acting as a principal in providing for or overseeing comprehensive care provided to the participants. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.

In general, a participant enrolls in the PACE program and is considered a customer of InnovAge. The Company considers all contracts with participants as a single performance obligation to provide comprehensive medical, health, and social services that integrate acute and long-term care. The Company identified that contracts with customers in the PACE program have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied over time as the Company provides comprehensive care to its participants.

Our revenues are based on the estimated PMPM amounts we expect to be entitled to receive from the capitated fees per participant that are paid monthly by Medicaid, Medicare, the VA, and private pay sources. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. VA is included in "Private Pay and other" and is also capitated. Private pay includes direct payments from participants who do not qualify for the full capitated rate and have to pay all or a portion of the capitated rate. Costs to obtain contracts consist of sales commissions for new enrollees and are included in deposits and other on our consolidated balance sheets. These costs are amortized over a three-

year period which corresponds to the average time a participant is

enrolled in the PACE program. As of June 30, 2024 and 2023, contract assets included within deposits and other were \$2.8 million and \$1.0 million, respectively.

The Company disaggregates capitation revenue from the following sources for the year ended June 30:				
	2024	2023		
Medicaid	54			
Medicare	46			
Private pay and other				

Total	100	100	%

The Company determined the transaction price for these contracts is the amount we expect to be entitled to, which is the most likely amount. For certain capitation payments, the Company is subject to retroactive premium risk adjustment payments according to the CMS risk adjustment payment timeline. Specifically, there is a midyear true up payment based on updated risk score calculations and a final true up payment to allow for complete diagnosis submission. The Company estimates the amount of the adjustment and records it monthly on a straight-line basis. These adjustments are not expected to be material.

The capitation revenues are recognized based on the estimated PMPM transaction price to transfer the service for a distinct increment of the series (i.e. month). We recognize revenue over time in the month in which participants are entitled to receive comprehensive care benefits during the contract term. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company also provides prescription drug benefits in accordance with Medicare Part D. Monthly payments received from CMS and the participants represent the bid amount for providing prescription drug coverage. The portion received from CMS is subject to risk sharing through Medicare Part D risk-sharing corridor provisions. These risk-sharing corridor provisions compare costs targeted in the Company's bid to actual prescription drug costs. The Company estimates and records a monthly adjustment to Medicare Part D revenues associated with these risk-sharing corridor provisions. Medicare Part D comprised (i) 12% and

13% of capitation revenues for the years ended June 30, 2024 and 2023, respectively, and (ii) 24% and 23% of external provider costs for the years ended June 30, 2024 and 2023, respectively.

The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA, and private pay sources. The concentration of net receivables from participants and third-party payers as of June 30, 2024 and 2023 was as follows:

	2024	2023	Medicaid	Medicare	%
	71	71	22	29	%
	61	61	22	29	%

Private pay and other		7	%	10	%
Total		100	%	100	%

The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company's best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. The balance of the allowance for uncollectible accounts was \$6.7 million as of June 30, 2024, compared to \$4.2 million as of June 30, 2023. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts.

Other Service Revenue and Accounts Receivable

Other service revenue primarily consists of revenues derived from state food grants and rent revenues. Accounts receivable related to other service revenue were not significant as of both June 30, 2024 and June 30, 2023.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to change, as well as government review. Failure to comply with these laws can expose the entity to significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. See Note 9, "Commitments and Contingencies."

1 P3Y 2800000

1000000.0

The Company disaggregates capitation revenue from the following sources for the year ended June 30:

	2024	2023
Medicaid	54	%
Medicare	46	%
Private pay and other	*%	

colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:right;vertical-align:bottom">*</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="margin-top:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt">*Less than 1%</div> 0.54 0.54 0.46 0.46 1 1 0.12 0.13 0.24 0.23 The concentration of net receivables from participants and third-party payers as of June 30, 2024 and 2023 was as follows:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid</td><td colspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div>

[illegible]

[illegible]

2,645			
\$			
5,493			

Nonconsolidated Entities

Cost Method Investments

As of June 30, 2024 and 2023, the Company maintained one investment and two investments, respectively, that were accounted for using the cost method. The Company's ownership interests are less than 20% of the voting stock of the investments and the Company does not have the ability to exercise significant influence over the operating and financial policies of the investments.

The investments do not have a readily determinable fair value and the Company has elected to record the investments at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.

JetDoc

In August 2021, the Company acquired a minority interest equal to 806,481 shares of the outstanding common stock of Jetdoc, Inc. ("Jetdoc"), a telehealth and virtual urgent care app dedicated to effectively connecting users with medical professionals, for cash consideration of \$2.0 million. We determined that indicators of impairment were present as of December 31, 2023, and recognized an impairment loss of \$1.9 million during the three months then ended. During the three months ended March 31, 2024, we determined that the remaining balance of our investment in Jetdoc was impaired and recognized an additional impairment loss of \$0.1 million. Impairment losses are included in gain on cost and equity method investments on our consolidated statements of operations. During the year ended June 30, 2023, there were no observable price changes or impairments recorded. As of June 30, 2024, the Company does not have any ownership interest in JetDoc.

Dispatch Health

On June 14, 2019, the Company invested \$1.5 million in DispatchHealth Holdings, Inc., ("DispatchHealth") through the purchase of a portion of its outstanding Series B Preferred Stock. On April 2, 2020, the Company invested an additional \$1.1 million through the purchase of a portion of its outstanding Series C Preferred Stock. As of

June 30, 2024, the balance of the Company's investment was \$2.6 million which represents the maximum exposure to loss. The investment does not have a readily determinable fair value and the Company has elected to record the investment at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. During the years ended June 30, 2024 and 2023, there were no observable price changes or impairments.

Equity Method Investments

Pinewood Lodge

Through May 2, 2024, the Company's operations included a Senior Housing unit that primarily included the accounts of Continental Community Housing ("CCH"), a wholly-owned subsidiary of the Company and the general partner of PWD, which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older.

PWD was a VIE, but the Company was not the primary beneficiary. The Company did not have the power to direct the activities that most significantly impacted the economic performance of PWD. Accordingly, the Company did not consolidate PWD. PWD was accounted for using the equity method of accounting. The equity earnings of PWD were

insignificant. As of June 30, 2023, the balance of the Company's investment in PWD was \$0.8 million, which represented the maximum exposure to loss.

On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including the Senior Housing unit. On May 2, 2024, PWD closed on the sale of its Senior Housing property for \$9.5 million. Upon completion of the sale, PWD ceased providing senior housing services and in June 2024 was dissolved. Following the dissolution, the remaining proceeds from the sale were distributed in accordance with the partnership agreement and as otherwise agreed by the partners.

Consolidated Entities

Controlling Interest

InnovAge Florida PACE – Orlando

On May 28, 2024, the Company entered into a Joint Venture Agreement with Orlando Health ("OHI") to develop and manage PACE centers to serve communities in Orlando, Florida. In connection with the joint venture, the joint venture, InnovAge Florida PACE – Orlando was formed. The Company contributed \$26.1 million for its controlling membership interest of 90%. As result, the joint venture's results are consolidated in the Company's consolidated financial statements. OHI contributed \$2.9 million in cash for its 10% interest.

Noncontrolling Interest

Prepaid expenses and other			5
			1
Property, plant and equipment, net			9,465
Deposits and other, net			409
Liabilities			
Accounts payable and accrued expenses			295

whereby, if certain conditions are met, the joint venture may be required to purchase, at fair market value, certain members' interests or certain members may be required to purchase, at fair market value, the interests of certain other members. The Company's investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As of June 30, 2024, none of the conditions specified in the JV Agreement had been met. Accordingly, these put rights held by the noncontrolling interests of the joint venture are required to be presented as temporary equity. As of June 30, 2024 and 2023, the Company's redeemable noncontrolling interest was recorded at fair value of \$22.2 million and carrying value of \$12.7 million, respectively.

	2024	2023	
Cost method investments	\$	\$	
Equity method investments	2,645	4,645	

[illegible]

Cash and cash equivalents			
\$		816	
\$		648	
Prepaid expenses and other			
5			
		1	
Property, plant and equipment, net			
9,465			
		9,933	
Deposits and other, net			
409			

[illegible]

3000000.0 0.264 0.137 52000 0.001 22200000 12700000 Goodwill and Intangible Assets

Goodwill represents the excess of cost over the fair value of net assets acquired. Goodwill amounted to \$139.9 million and \$124.2 million as of June 30, 2024 and June 30, 2023, respectively. The Company had one acquisition resulting in goodwill during the year ended June 30, 2024, see additional information in Note 11 "Acquisitions," and did not have any acquisitions resulting in goodwill during the year ended June 30, 2023. Goodwill is not amortized.

Pursuant to ASC 350, "Intangibles — Goodwill and Other," we review the recoverability of goodwill annually as of April 1 or whenever significant events or changes occur which might impair the recovery of recorded amounts. For purposes of the annual goodwill impairment assessment for fiscal year 2024, the Company identified two reporting units, East and West. There were no indicators of impairment identified and no goodwill impairments recorded during the years ended June 30, 2024 and 2023.

The following table summarizes the changes in goodwill for the fiscal years ended June 30:

	in thousands			2024			2023				
	Balance as of beginning of period									\$	124,217
										\$	124,217

[illegible]

[illegible]

Accumulated amortization

(4,062)	(3,402)	

Balance as of end of period

\$	4,538	

Intangible assets with a finite useful life continue to be amortized over their useful lives. The Company recorded amortization expense of \$0.7 million for each of the years ended June 30, 2024 and 2023.

The total expected future annual amortization expense for the next 5 years ended June 30, is as follows:

in thousands				
Amortization Expense				

2025

\$	660	

2026

	660	

2027

	630	

2028

	540	

2029

48		

We review the recoverability of other intangible assets in conjunction with long-lived assets whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. There were no intangible asset impairments recorded during the years ended June 30, 2024 and 2023.

139900000 124200000 1 0 2 0 0

The following table summarizes the changes in goodwill for the fiscal years ended June 30:

in thousands		
2024		
2023		
Balance as of beginning of period		
\$	124,217	
\$	124,217	
Goodwill acquired during the period		
	15,732	
—		
Balance as of end of period		
\$	139,949	

2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">124,217</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 124217000 124217000 15732000 0 139949000 124217000 <div style="margin-top:10pt;text-align:justify;text-indent:18pt">Intangible assets consisted of the following as of June 30:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-lived intangible assets</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Customer relationships</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,600</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,600</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-lived intangible assets</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-lived intangible assets</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-lived intangible assets</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-lived intangible assets</td></tr></table></div>

[illegible]

color:#eceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#eceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,198 </td><td style="background-color:#eceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6600000 6600000 2000000 2000000 8600000 8600000 4062000 3402000 4538000 5198000 700000 700000 <div style="margin-top:10pt;text-align:justify;text-indent:18pt">The total expected future annual amortization expense for the next 5 years ended June 30, is as follows:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortization Expense</td></tr><tr><td colspan="3" style="background-color:#eceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="background-color:#eceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#eceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">660 </td><td colspan="3" style="background-color:#eceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">660 </td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#eceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">630 </td><td colspan="2" style="background-color:#eceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">540 </td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

2029	48	

660000 660000 630000 540000 48000 0 0 Leases

Leasing Arrangements as Lessee

The Company leases certain property and equipment under various third-party operating and finance lease agreements. The Company determines if an arrangement is or contains a lease at the lease inception date by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. The leases are noncancelable and expire on various terms from 2024 through 2034. We determine if an arrangement is a lease upon commencement of the contract. If an arrangement is determined to be a long-term lease (greater than 12 months), we recognize a right-of-use ("ROU") asset and lease liability based on the present value of the future minimum lease payments over the lease term at the commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Our lease terms may also include options to extend or terminate the lease when it is reasonably certain that we will exercise those options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have elected to apply the short-term lease exception for contracts that have a lease term of twelve months or less and do not include an option to purchase the underlying asset. Therefore, we do not recognize a ROU asset or lease liability for such contracts. We recognize short-term lease payments as expense on a straight-line basis over the lease term. Variable lease payments that do not depend on an index or rate are recognized as expense. Certain leases include escalations based on inflation indexes and fair market value adjustments. Operating lease liabilities are calculated using the prevailing index or rate at lease commencement for such leases.

On March 20, 2023, we consolidated our Germantown center in Pennsylvania with two of our existing centers. Upon consolidation, we terminated our Germantown center lease and recognized lease termination costs of \$0.6 million. Lease termination costs are included in other income (expense) on our consolidated statements of operations.

The following table presents the components of our ROU assets and their classification in our Balance Sheet as of June 30

[illegible]

weight:400;line-height:120%">Finance lease assets</td><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,908 </td><td style="background-color:#e6e6ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,378 </td><td style="background-color:#e6e6ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total leased assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">44,324 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37,588 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt">The following table presents the components of our lease cost and the classification of such costs in our Statement of Operations for the years ended June 30.</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td></tr></table></div>

Component of Lease Cost			Statement of Operations Line Items		
2024			2023		
			in thousands		
Operating lease cost			Cost of care excluding depreciation and amortization and Corporate, general and administrative		
\$			5,402		
\$			4,642		
Finance lease expense:					
Amortization of leased assets			Depreciation and amortization		

Total	1,984				
	3,080				
Interest on lease liabilities					
Interest expense, net					
	—				
	1,255				
Variable lease cost					
Cost of care excluding depreciation and amortization and Corporate, general and administrative					
	93				
	82				
Short-term lease cost					
Cost of care excluding depreciation and amortization and Corporate, general and administrative					
	172				

108

Total lease expense:	7,651			
	9,167			

The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of June 30.

	June 30, 2024	June 30, 2023
Weighted average remaining lease term:	2024	2023

Operating leases			7.7 years	7.9 years		
Finance leases			3.5 years	3.9 years		

Weighted average discount rate			2024			2023			Operating leases		
		6.86		%					6.60		
		%									

weight:400;line-height:120%">Finance leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.80 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.80 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to June 30, 2024. </div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;text-align:center;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Lease</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Lease</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cfe2f3;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,023 </td><td style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,023 </td></tr></table></div></div>

6,631			
12,654			
2026	5,988		
5,389			
11,377			
2027	5,742		
4,514			
10,256			
2028	4,952		

2,461		
		7,413
2029		
		4,097
555		
4,652		
Thereafter		
		11,582
—		
11,582		
Total lease payments		
		38,384
19,550		

		57,934
Less liability accretion / imputed interest		
	(7,964)	
		(2,208)
		(10,172)
Total lease liabilities		
		30,420
		17,342
		47,762
Less: Current lease liabilities		
		4,145
		4,599

</td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">8,744</td><td style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-color: #ceeeff; padding: 2px 1pt 2px 13pt; text-align: left; vertical-align: bottom">Total long-term lease liabilities</td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">26,275</td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ceeeff; padding: 0 1pt"></td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">12,743</td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ceeeff; padding: 0 1pt"></td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">39,018</td><td style="background-color: #ceeeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table> Leases Leasing Arrangements as Lessee The Company leases certain property and equipment under various third-party operating and finance lease agreements. The Company determines if an arrangement is or contains a lease at the lease inception date by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. The leases are noncancelable and expire on various terms from 2024 through 2034. We determine if an arrangement is a lease upon commencement of the contract. If an arrangement is determined to be a long-term lease (greater than 12 months), we recognize a right-of-use ("ROU") asset and lease liability based on the present value of the future minimum lease payments over the lease term at the commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of

future payments. Our lease terms may also include options to extend or terminate the lease when it is reasonably certain that we will exercise those options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have elected to apply the short-term lease exception for contracts that have a lease term of twelve months or less and do not include an option to purchase the underlying asset. Therefore, we do not recognize a ROU asset or lease liability for such contracts. We recognize short-term lease payments as expense on a straight-line basis over the lease term. Variable lease payments that do not depend on an index or rate are recognized as expense. Certain leases include escalations based on inflation indexes and fair market value adjustments. Operating lease liabilities are calculated using the prevailing index or rate at lease commencement for such leases.

On March 20, 2023, we consolidated our Germantown center in Pennsylvania with two of our existing centers. Upon consolidation, we terminated our Germantown center lease and recognized lease termination costs of \$0.6 million. Lease termination costs are included in other income (expense) on our consolidated statements of operations.

The following table presents the components of our ROU assets and their classification in our Balance Sheet as of June 30:

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	164

Assets:			
Operating lease assets			
Operating lease assets			
\$			
28,416			
\$			
21,210			
Finance lease assets			
Property and equipment, net			
15,908			
16,378			
Total leased assets			
\$			

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%>44,324 </td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">37,588 </td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table></div><div style="margin-top: 10pt; text-indent: 18pt">The following table presents the components of our lease cost and the classification of such costs in our Statement of Operations for the years ended June 30. </div><div style="margin-top: 10pt"><table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: text-bottom; width: 100.000%"><tr><td style="width: 1.0%"></td><td style="width: 34.506%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 35.718%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.081%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.083%"></td><td style="width: 0.1%"></td></tr><tr><td colspan="3" style="padding: 2px 1pt; text-align: left; vertical-align: bottom">Component of Lease Cost</td><td colspan="3" style="padding: 2px 1pt; text-align: left; vertical-align: bottom">Statement of Operations Line Items</td><td colspan="3" style="padding: 0 1pt"></td><td colspan="3" style="padding: 2px 1pt; text-align: center; vertical-align: bottom">2024</td><td colspan="3" style="padding: 0 1pt"></td><td colspan="3" style="border-bottom: 1pt solid #000; padding: 2px 1pt; text-align: center; vertical-align: bottom">2023</td></tr><tr><td colspan="3" style="padding: 0 1pt"></td><td colspan="3" style="padding: 0 1pt"></td><td colspan="3" style="padding: 0 1pt"></td><td colspan="3" style="border-top: 1pt solid #000; padding: 2px 1pt; text-align: center; vertical-align: bottom">in thousands</td></tr><tr><td colspan="3" style="background-color: #e6e6ff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Operating lease cost</td><td colspan="3" style="background-color: #e6e6ff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Cost of care excluding depreciation and amortization and Corporate, general and administrative</td><td colspan="3" style="background-

[illegible]

			Variable lease cost			Cost of care excluding depreciation and amortization and Corporate, general and administrative						93														
Short-term lease cost			Cost of care excluding depreciation and amortization and Corporate, general and administrative						172																	
108																										
Total lease expense:									\$			7,651									\$					

0;text-align:right;vertical-align:bottom">9,167 </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of June 30.</div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Weighted average remaining lease term:</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">7.7 years</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">7.9 years</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.5 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.9 years</td></tr></table></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td></tr></table></div>

[illegible]

in thousands			Operating Lease		
Finance Lease			Total		
2025			\$		
6,023			6,631		
\$			12,654		
2026			5,988		
5,389					

11,377

2027		
5,742		
4,514		
10,256		
2028		
4,952		
2,461		
7,413		
2029		
4,097		
555		
4,652		

Thereafter	11,582	—	11,582
Total lease payments	38,384	19,550	57,934
Less liability accretion / imputed interest	(7,964)	(2,208)	(10,172)

Total lease liabilities		30,420	17,342	47,762
Less: Current lease liabilities		4,145	4,599	8,744
Total long-term lease liabilities		\$	\$	\$

weight:400;line-height:120%">12,743 </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,018 </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 600000 <div style="margin-top:10pt;text-align:justify;text-indent:18pt">The following table presents the components of our ROU assets and their classification in our Balance Sheet as of June 30. </div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:33.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Component of Lease Balances</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Balance Sheet Line Items</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">in thousands</td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">

Operating lease assets		
\$		
28,416		
21,210		
Finance lease assets		
Property and equipment, net		
15,908		
16,378		
Total leased assets		
\$		
44,324		

37,588

28416000

21210000 15908000 16378000 44324000 37588000

The following table presents the components of our lease cost and the classification of such costs in our Statement of Operations for the years ended

June 30

	2024	2023	
Operating lease cost			
Cost of care excluding depreciation and amortization and Corporate, general and administrative			
	\$		
	5,402		

[illegible]

serif;font-size:10pt;font-weight:400;line-height:120%">Cost of care excluding depreciation and amortization and Corporate, general and administrative</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93 </td><td style="background-color:#e6e6ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82 </td><td style="background-color:#e6e6ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term lease cost</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of care excluding depreciation and amortization and Corporate, general and administrative</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">172 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total lease expense:</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,651 </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">9,167 </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5402000 4642000 1984000 3080000 0 1255000 93000 82000 172000 108000 7651000 9167000 <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-

The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of June 30.

Weighted average remaining lease term:	2024	2023	Operating leases	7.7 years	7.9 years
			Finance leases	3.5 years	3.9 years
Weighted average discount rate					

[illegible]

Operating Lease		
Finance Lease		
Total	2025	\$6,023
		\$6,631
		\$12,654
2026	5,988	11,377

2027		5,742		4,514		10,256	
2028		4,952		2,461		7,413	
2029		4,097		555		4,652	
Thereafter							

			11,582
Total lease payments			38,384
Less liability accretion / imputed interest			(7,964)
Total lease liabilities			30,420

		17,342
		47,762
Less: Current lease liabilities		
	4,145	
	4,599	
		8,744
Total long-term lease liabilities		
\$		
	26,275	
		\$
	12,743	

2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,018 </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to June 30, 2024. </div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Lease</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Lease</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,023 </td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,631 </td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

\$	12,654	2026	5,988	5,389	11,377	2027	5,742	4,514	10,256	2028	4,952	2,461

7,413		
2029		
4,097		
555		
4,652		
Thereafter		
11,582		
—		
11,582		
Total lease payments		
38,384		
19,550		
57,934		

Less liability accretion / imputed interest			(7,964)	(2,208)	(2,208)	(10,172)	
Total lease liabilities			30,420	30,420	17,342	17,342	47,762
Less: Current lease liabilities			4,145	4,145	4,599	4,599	8,744

[illegible]

in thousands		
Senior secured borrowings:		
Term Loan Facility	\$	63,750
	\$	67,500
Convertible term loan		2,239
		2,284
Total debt		65,989
		69,784
Less unamortized debt issuance costs		

716		
1,145		
Less current maturities		
3,795		
3,795		
Noncurrent maturities		
\$		
61,478		
\$		
64,844		

2021 Credit Agreement

On March 8, 2021, the Company entered into a credit agreement (as amended, the “2021 Credit Agreement”) that replaced its prior credit agreement. The 2021 Credit Agreement consists of a senior secured term loan (the “Term Loan Facility”) of \$75.0 million principal amount and a revolving credit facility (the “Revolving Credit Facility”) of \$100.0 million maximum borrowing capacity, each with a maturity date of March 8, 2026. Borrowing capacity under the Revolving Credit Facility is subject to (i) any issued amounts under our letters of credit, which as of June 30, 2024 was \$3.9 million,

and (ii) applicable covenant compliance restrictions and any other conditions precedent to borrowing. Loans under the 2021 Credit Agreement are secured by substantially all of the Company's assets. Principal on the Term Loan Facility is paid each calendar quarter in an amount equal to 1.25% of the initial term loan on closing date.

Outstanding principal amounts under the 2021 Credit Agreement accrue interest at a variable interest rate. As of June 30, 2024 and 2023, the interest rate on the Term Loan Facility was 7.18% and 6.95%, respectively. Under the terms of the 2021 Credit Agreement, the Revolving Credit Facility fee accrues at 0.25% of the average daily unused amount and is paid quarterly. As of June 30, 2024, we had no borrowings outstanding, \$3.9 million of letters of credit issued, and \$96.1 million of remaining capacity under the Revolving Credit Facility.

The 2021 Credit Agreement requires the Company to meet certain operational and reporting requirements, including, but not limited to, a secured net leverage ratio. Additionally, annual capital expenditures and permitted investments, including acquisitions, are limited to amounts specified in the 2021 Credit Agreement. The 2021 Credit Agreement also provides certain restrictions on dividend payments and other equity transactions and requires the Company to make prepayments under specified circumstances. The Company was in compliance with the covenants of the 2021 Credit Agreement as of June 30, 2024 and 2023.

The deferred financing costs of \$2.0 million are amortized over the term of the underlying debt and unamortized amounts have been offset against long-term debt in the consolidated balance sheets. Total amortization of deferred financing costs was \$0.4 million and \$0.4 million for the years ended June 30, 2024 and 2023, respectively.

Convertible Term Loan

On June 29, 2015, SH1 entered into a convertible term loan. Principal and interest payments of \$0.02 million are due monthly. The loan bears interest at an annual rate of 6.68%, with the remaining principal balance due upon maturity at August 20, 2030. The loan is secured by a deed of trust to Public Trustee, assignment of leases and rents, security agreements, and SH1's fixture filing.

Aggregate maturities of our debt as of June 30, 2024 were as follows:

			Long-term debt		
			in thousands		
			Year ending June 30:		

2025		
		\$
	3,795	
2026		
	60,059	
2027		
	63	
2028		
	67	
2029		
	72	
Thereafter		
	1,933	
Total debt		
\$		

65,989

The components of our long-term debt are as follows:

June 30, 2024	June 30, 2023				
in thousands					
Senior secured borrowings:					
Term Loan Facility					
	\$				
Convertible term loan					

			2,284		
Total debt			65,989		
Less unamortized debt issuance costs			716		
Less current maturities			1,145		
Less noncurrent maturities			\$		
			61,478		

bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64,844 </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 63750000 67500000 2239000 2284000 65989000 69784000 716000 1145000 3795000 3795000 61478000 64844000 75000000.0 100000000.0 3900000 0.0125 0.0718 0.0695 0.0025 0 3900000 96100000 2000000.0 400000 400000 20000.00 0.0668 <div style="margin-top:10pt;text-align:justify;text-indent:18pt">Aggregate maturities of our debt as of June 30, 2024 were as follows:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Long-term
debt</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">in thousands</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Year ending June 30:</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,059 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2028</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

63		
2028	67	
2029	72	
Thereafter	1,933	
Total debt	\$	65,989

3795000 60059000 63000 67000 72000 1933000 65989000 Fair Value Measurements

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company's own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant.

The three levels of inputs that may be used to measure fair value are:

Level 1

Unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date

Level 2

Quoted prices in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the assets or liabilities

Level 3

Unobservable inputs to the valuation techniques that are significant to the fair value measurements of the assets or liabilities

The following table shows the Company's cash, cash equivalents and marketable securities by significant investment category as of June 30, 2024.

	Cash	Cash Equivalents	Marketable Securities	Total
Amortized Cost	\$1.0%	\$51.021%	\$0.1%	\$52.121%
Fair Value	\$1.0%	\$10.415%	\$0.1%	\$11.526%
Cash and Cash Equivalents	\$1.0%	\$10.416%	\$0.1%	\$11.527%
Short-term Investments				
Cash				

[illegible]

31,153		
—		
Mutual funds		
45,556		
45,833		
45,833		
Total		
\$		
102,502		
\$		
102,779		

\$	56,946	\$	45,833

Recurring Measurements

The Company's investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As a result, at each fiscal period end the Company reports this put right at the greater of (i) carrying value of the redeemable noncontrolling interest or (ii) fair value of the redeemable noncontrolling interest. Because this asset does not have observable inputs, Level 3 inputs are used to measure fair value. The fair value of

the redeemable noncontrolling interest is determined utilizing a discounted cash flow model. As of June 30, 2024 and 2023, the Company's redeemable noncontrolling interest was recorded at carrying value of \$22.2 million and \$12.7 million, respectively.

There were no transfers in and out of Level 3 during the fiscal years ended June 30, 2024 and 2023. The Company's policy is to recognize transfers as of the actual date of the event or change in circumstances.

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company's own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant.

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company's own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant.

[illegible]

Cash	\$	25,793
	\$	25,793
	\$	25,793
	\$	25,793
	\$	—
Level 1		
Money market funds		
		31,153

[illegible]

**bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">56,946</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">45,833</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>
25793000 25793000 25793000 0 31153000 31153000 31153000 0 45556000 45833000 0 45833000 102502000 102779000 56946000 45833000 22200000 12700000 Commitments and Contingencies<div style="margin-top:10pt">Professional Liability</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company pays fixed premiums for annual professional liability insurance coverage under a claims-made policy. Under such policy, only claims made and reported to the insurer are covered during the policy term, regardless of when the incident giving rise to the claim occurred. The Company records claim liabilities and expected recoveries, if any, at gross amounts. The Company is not currently aware of any unasserted claims or unreported incidents that are expected to exceed medical malpractice insurance coverage limits.</div><div style="margin-top:10pt;text-align:justify">Litigation</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">From time to time, the Company may be involved in various legal proceedings and be subject to claims. The Company regularly evaluates the status of claims and legal proceedings in which it is involved in order to assess whether a loss is probable or there is a reasonable possibility that a loss may have been incurred, and to determine whether accruals are appropriate. The Company expenses legal costs as such costs are incurred.</div><div style="margin-top:10pt;text-align:justify">Civil Investigative Demands</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In July 2021, the Company received a civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act. The demand requests information and documents regarding Medicaid billing, patient services and referrals in connection with the Company's PACE program in Colorado. We continue to fully cooperate with the Attorney General . We are currently unable to predict the outcome of this investigation.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">We are currently unable to predict the outcome of this investigation.</div>**

indent:18pt">In February 2022, the Company received a civil investigative demand from the Department of Justice ("DOJ") under the Federal False Claims Act on similar subject matter. The demand requests information and documents regarding audits, billing, orders tracking, and quality and timeliness of patient services in connection with the Company's PACE programs in the states where the Company operated as of 2022 (California, Colorado, New Mexico, Pennsylvania, and Virginia). In December 2022, the Company received a supplemental civil investigative demand requesting supplemental information on the same matters. The Company continues to fully cooperate with the DOJ. We are currently unable to predict the outcome of this investigation.</div><div style="margin-top:10pt;text-align:justify">Stockholder Lawsuits</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On October 14, 2021, and subsequently amended on June 21, 2022, the Company was named as a defendant in a putative class action complaint filed in the District Court for the District of Colorado on behalf of individuals who purchased or acquired shares of the Company's common stock during a specified period (the "Securities Action"). Through the complaint, plaintiffs are asserting claims against the Company, certain of the Company's officers and directors, Apax Partners, L.P., Welsh, Carson, Anderson & Stowe and the underwriters in the Company's IPO, alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 for making allegedly inaccurate and misleading statements and omissions in connection with the Company's IPO and subsequent earnings calls and public filings, and seeking compensatory damages, among other things. On September 13, 2022, the Company and the officer and director defendants and Apax Partners, L.P. and Welsh, Carson, Anderson & Stowe filed a motion to dismiss the amended complaint for failure to state a claim upon which relief can be granted. On December 22, 2023, the District Court granted in part and denied in part the motion to dismiss. The action is now in discovery.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On April 20, 2022, the Board of Directors of the Company received a books and records demand pursuant to Section 220 of the Delaware General Corporation Law, from a purported stockholder of the Company, Brian Hall, in connection with the stockholder's investigation of, among other matters, potential breaches of fiduciary duty, mismanagement, self-dealing, corporate waste or other violations of law by the Company's Board with respect to these matters. On May 15, 2023, Mr. Hall filed a lawsuit in the Delaware Court of Chancery asserting derivative claims for breach of fiduciary duty against certain of the Company's current and former officers and directors generally relating to alleged failures by the defendants to take remedial actions to address the matters that resulted in sanctions by CMS at certain of the Company's </div><div style="margin-top:10pt;text-align:justify">centers, and alleged misstatements in the Company's public filings relating to those matters. On June 28, 2023, upon stipulation of the parties, the court entered an order staying the litigation pending the resolution of the motion to dismiss in the Securities Action or upon fifteen days' notice by any party to the litigation. On January 22, 2024, upon stipulation of the parties, the court entered an order further staying the litigation pending the close of fact discovery in the Securities Action. </div><div style="margin-top:10pt;text-indent:18pt">We are currently unable to predict the outcome of these matters.</div><div style="margin-top:10pt;text-align:justify">Other Matters</div><div style="margin-

In the third fiscal quarter of 2023, the Company agreed to settle a wage and hour class action lawsuit in the State of California for a cash payment of \$1.2 million. Subsequently, the Company was notified of certain additional individual claims and agreed to include such claims within the class. In October 2023, the Company agreed to increase the settlement amount to a total of \$1.3 million, reflecting the additional individual claim. The Court entered the final approval of the settlement on April 2, 2024 and the payout occurred on June 7, 2024. The matter will remain open for 180 days to allow the class members to settle their checks, after which time the case is expected to officially close.

Because the results of legal proceedings and claims are inherently unpredictable and uncertain, we are currently unable to predict whether the legal proceedings we are involved in will, either individually or in the aggregate, have a material adverse effect on our business, financial condition, or cash flows. The outcomes of legal proceedings and claims could be material to the Company's operating results for any particular period, depending in part, upon the operating results of such period. Regardless of the outcome, litigation has the potential to have an adverse impact on us due to any related defense and settlement costs, diversion of management resources, and other factors.

P15D 1200000 1300000 P180D Stock-based Compensation

A summary of our aggregate stock-based compensation expense is set forth below. Stock-based compensation expense is included in corporate, general and administrative expenses on our consolidated statements of operations.

	Year ended June 30,	2024	2023	
				in thousands
Stock options	\$			

	802	
	\$	1,010
Profits interests units	861	
		867
Restricted stock units	5,169	
		3,116
Total stock-based compensation expense	\$	6,832
		\$
		\$
		\$
		\$

[illegible]

[illegible]

[illegible]

	\$		
Vested	(703,395)		
Outstanding balance, June 30, 2024	1,287,113		
	\$	5.52	

Performance-based unit awards	Number of units	Weighted average grant date fair value

Outstanding balance, June 30, 2023	2,118,558	\$	0.57
Granted	1,106,850		
Forfeited	(1,853,737)		
Vested	—		

\$

			Outstanding balance, June 30, 2024
			1,371,671
			\$
			1.55

The total unrecognized compensation cost related to profits interests units outstanding as of June 30, 2024 was \$3.9 million, comprised (i) \$1.8 million related to time-based unit awards expected to be recognized over a weighted-average period of 2.8 years and (ii) \$2.1 million related to performance-based unit awards, which will be recorded when it is probable that the performance-based criteria will be met.

2021 Omnibus Incentive Plan

In March 2021, the Compensation Committee of the Board of Directors approved the InnovAge Holding Corp. 2021 Omnibus Incentive Plan ("2021 Omnibus Incentive Plan"), pursuant to which various stock-based awards may be granted to employees, directors, consultants, and advisers. The total number of shares of the Company's common stock authorized under the 2021 Omnibus Incentive Plan is 14,700,000. The Company has issued time-based restricted stock units under this plan to its employees which generally (i) vested on March 4, 2023, the second anniversary of the grant date, or (ii) vest over a three-year period with one-third vesting on each anniversary of the date of grant. Certain other vesting periods have also been used. The grant date fair value of restricted stock units with time-based vesting is based on the closing market price of our common stock on the date of grant. Certain other awards, including units and stock options under this plan vest upon achieving specific share price performance criteria and are determined to have performance-based vesting conditions. The Company has also issued time-based vesting stock options under this plan to its employees which generally vest in equal parts over a three-year period.

Restricted Stock Units

A summary of time-based vesting restricted stock units activity for the year ended June 30, 2024, was as follows:

[illegible]

	\$	5.25	
Granted			
1,854,786			
	\$		
4.84			
Outstanding balance, June 30, 2024			
2,864,319			
\$			
8.15			
The total unrecognized compensation cost related to time-based restricted stock units outstanding as of June 30, 2024, was \$11.3 million and is expected to be recognized over a weighted-average period of 2.0 years.			
A summary of performance-based vesting restricted stock units activity for the year ended June 30, 2024, was as follows:			
Year ended	Performance-based vesting restricted stock units granted	Performance-based vesting restricted stock units forfeited	Performance-based vesting restricted stock units expired
2023	1,854,786	1,854,786	1,854,786
2024	1,854,786	1,854,786	1,854,786
Total	3,709,572	3,709,572	3,709,572

Restricted stock units – performance based		
Number of awards		
Weighted average grant-date fair value per share		
Outstanding balance, June 30, 2023		
258,767		
\$		
5.18		
Forfeited		
—		
\$		
—		
Vested		
—		
\$		
—		

Granted

Outstanding balance, June 30, 2024	258,767		\$
			5.18

The total unrecognized compensation cost related to performance-based vesting restricted stock units outstanding as of June 30, 2024, was \$0.4 million and is expected to be recognized over a weighted-average period of 1.5 years.

Nonqualified Stock Options

A summary of time-based vesting stock option activity for the year ended June 30, 2024, was as follows:

	Number of options	Weighted average exercise price	Weighted average remaining contractual term in years	Aggregate intrinsic value
Stock options – time based				
Number of				

Weighted			average		
			grant-date		
			value		
Outstanding balance, June 30, 2023					
716,661					
\$					
1.43					
Granted					
—					
\$					
—					
Forfeited					
(108,108)					
\$					
0.31					
Exercised					

[illegible]

\$

	0.17	

The total unrecognized compensation costs related to time-based vesting stock options outstanding as of June 30, 2024, was \$0.09 million and is expected to be recognized over a weighted-average period of 1.4 years.

The fair value of the time-based stock options granted during the year ended June 30, 2023, was based upon the Black-Scholes option pricing model using the assumptions in the following table:

	2023		
Expected volatility	34.5		
	%		
Weighted-average expected life (years) - time vesting units	2.9		
Interest rate	1.56		
	%		
Dividend yield	0		

[illegible]

[illegible]

776,299

			Year ended June 30,								
			2024								
			2023								
			in thousands								
			Stock options								
			\$								
			802								
			\$								

1,010		
Profits interests units		
861		
867		
Restricted stock units		
5,169		
3,116		
Total stock-based compensation expense		
\$		
6,832		
\$		
4,993		

802000 1010000 861000 867000 5169000 3116000 6832000 4993000 16162177 15222837 0 2213700

The assumptions under the Monte Carlo model related to the profits interests units for fiscal 2024, presented on a weighted-average basis, are provided below:

[illegible]

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%">1.59 - 2.17</td><td colspan="3" style="background-color: #ccccff; padding: 0 1pt"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Fair value of underlying stock</td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom">\$</td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom"><div style="text-align: right">5.52 - 7.27</div></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td></tr></table></div><div style="margin-top: 10pt; text-align: justify; text-indent: 18pt">The fair value of the time-based stock options granted during the year ended June 30, 2023, was based upon the Black-Scholes option pricing model using the assumptions in the following table:</div><div style="margin-top: 10pt"><table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: text-bottom; width: 100.000%"><tr><td style="width: 1.0%"></td><td style="width: 85.718%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.082%"></td><td style="width: 0.1%"></td></tr><tr><td colspan="3" style="padding: 0 1pt"></td><td colspan="3" style="padding: 2px 1pt; text-align: center; vertical-align: bottom">2023</td></tr><tr><td colspan="3" style="background-color: #ccccff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Expected volatility</td><td colspan="3" style="background-color: #ccccff; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">34.5</td><td colspan="3" style="background-color: #ccccff; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom">%</td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Weighted-average expected life (years) - time vesting units</td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom">2.9</td></tr><tr><td colspan="3" style="background-color: #ccccff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Interest rate</td><td colspan="3" style="background-color: #ccccff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">1.56</td><td colspan="3" style="background-color: #ccccff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom">%</td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Dividend yield</td><td colspan="3" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">

Weighted-average fair values

\$	0.80	Fair value of underlying stock	\$	3.70
0.680	0.760	P2Y8M12D P3Y1M6D 0.0423	0.0457	0
1.59	2.17	5.52	7.27	

A summary of profits interests activity for the year ended June 30, 2024, was as follows:

Time-based unit awards	Number of units	Weighted average grant date fair value
Outstanding balance, June 30, 2023	1,264,337	

					\$	
	1.28					
Granted						
1,106,850						
\$						
6.21						
Forfeited						
(380,679)						
\$						
1.28						
Vested						
(703,395)						
\$						
1.28						
Outstanding balance, June 30, 2024						

			1,287,113						\$			5.52		

Performance-based unit awards			Number of units			Weighted average grant date fair value		

Outstanding balance, June 30, 2023			2,118,558			\$			0.57					

Granted			1,106,850					

align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.78 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:right;vertical-align:bottom">(1,853,737)</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:bottom">0.57 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding balance, June 30, 2024</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,371,671</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:bottom">1.55 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1264337 1.28 1106850 6.21 380679 1.28 703395 1.28 1287113 5.52 2118558 0.57 1106850 1.78 1853737 0.57 0 0 1371671 1.55 3900000 1800000 P2Y9M18D 2100000 14700000 P3Y P3Y <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span

A summary of time-based vesting restricted stock units activity for the year ended June 30, 2024, was as follows:				
Restricted stock units – time based	Number of awards	Weighted average grant-date fair value per share	Outstanding balance, June 30, 2023	Outstanding balance, June 30, 2024
			1,873,794	\$10.10
			Forfeited	(143,935)
			\$	5.49
			Vested	

[illegible]

Restricted stock units – performance based		
Number of awards		
Weighted average grant-date fair value per share		
Outstanding balance, June 30, 2023		
258,767		
\$		
5.18		
Forfeited		
—		
\$		
—		
Vested		
—		
\$		
—		

color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding balance, June 30, 2024</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">258,767</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">5.18</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1873794 10.10 143935 5.49 720326 5.25 1854786 4.84 2864319 8.15 11300000 P2Y 258767 5.18 0 0 0 0 0 258767 5.18 400000 P1Y6M <div style="margin-top:10pt;text-align:justify;text-indent:18pt">A summary of time-based vesting stock option activity for the year ended June 30, 2024, was as follows:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options - time based</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of
awards</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
average
grant-date fair
value per share</td></tr><tr><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"></td></tr></table></div>

[illegible]

[illegible]

A summary of performance-based vesting stock option activity for the year ended June 30, 2024, was as follows:

																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						</

	—	
\$	—	
Vested		—
\$	—	—
Outstanding balance, June 30, 2024		
	776,299	\$
	3.08	

716661 1.43 0 0 108108 0.31 54054 0.19 0 0 554499 1.77 346560 0.17 90000.00 P1Y4M24D 0.345 P2Y10M24D 0.0156 0 0.80 3.70 776299 3.08 0 0 0 0 0 776299 3.08 800000 P1Y7M6D

Acquisitions

On December 1, 2023, the Company acquired all of the issued and outstanding membership interests of two California-based PACE programs, ConcertoCare PACE of Bakersfield, LLC and ConcertoHealth PACE of Los Angeles, LLC (collectively "Concerto"), from Perfect Health, Inc. d/b/a ConcertoCare, a tech-enabled, value-based provider of at-home, comprehensive care for seniors and other adults with unmet health and social needs, for \$23.9 million. We believe the Concerto acquisition complements our California

PACE centers. The acquisition was funded through cash on hand. Results of operations from the acquired centers are included in our consolidated statements of operations for the year ended June 30, 2024 beginning with the date of acquisition and were not significant to our results. We incurred costs related to the acquisition of approximately \$0.1 million during the year ended June 30, 2024. Acquisition related costs were expensed as incurred and have been recorded in corporate, general and administrative expenses in our consolidated statements of operations.

The Concerto acquisition was accounted for using the purchase method of accounting. The purchase price has been preliminarily allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. The fair values of assets acquired and liabilities assumed may change as the valuation of intangible assets, working capital adjustments, and overall purchase price allocation are being finalized. Goodwill represents the excess of the purchase price over the fair value of net assets acquired. Goodwill recognized represents the

estimated future economic benefits arising from expected growth opportunities for the Company and is not deductible for income tax purposes.

The following table presents a preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:

Purchased Intangible Assets	Estimated Fair Value	Weighted Average Amortization Period	Goodwill
Cash Consideration	\$1,000,000		
Identifiable Intangible Assets	(100,000)		
Liabilities Assumed	(50,000)		
Total	\$850,000		\$150,000

Preliminary allocation

Measurement period adjustments	Adjusted Allocation
Cash Consideration	\$1,000,000
Identifiable Intangible Assets	(100,000)
Liabilities Assumed	(50,000)
Total	\$850,000

Adjusted allocation

Cash Consideration

[illegible]

[illegible]

Operating lease assets	6,892	923	7,815
Goodwill	17,348	(1,616)	15,732
Deposits and other	343	—	343

Accounts payable and accrued expenses		
	(353)	78
	(275)	
Reported and estimated claims		
	(111)	
		—
	(111)	
Operating lease obligations		
	(8,941)	
		—
	(8,941)	
Finance lease obligations		

[illegible]

[illegible]

[illegible]

739		
1,069		
Property and equipment, net		
7,969		
—		
7,969		
Operating lease assets		
6,892		
923		
7,815		
Goodwill		
17,348		
(1,616)		

15,732				
Deposits and other				
343				
—				
343				
Accounts payable and accrued expenses				
(353)				
78				
(275)				
Reported and estimated claims				
(111)				
(111)				

Operating lease obligations			(8,941)		—
			(8,941)		—
Finance lease obligations			(124)		—
			(124)		—
			(124)		—
Fair value of assets and liabilities			\$		\$
			23,916		\$
					—

color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,916 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt">The following table presents a preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:</div> <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:38.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Preliminary
allocation</td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Measurement period adjustments</td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Adjusted
allocation</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">in thousands</td></tr><tr><td colspan="3" style="background-color:#cfe2f3;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash Consideration</td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td style="background-color:#cfe2f3;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cfe2f3;padding:2px 0;text-align:right;vertical-align:bottom">23,916 </td><td style="background-color:#cfe2f3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cfe2f3;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cfe2f3;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cfe2f3;padding:2px 0;text-align:right;vertical-align:bottom">— </td></tr></table></div>

	\$	23,916	Total Consideration	\$	23,916	\$	\$	—		\$	23,916	Accounts receivable, net	\$	563	\$

	(124)		\$	439	
Prepaid expenses					
				330	
				739	
				1,069	
Property and equipment, net					
				7,969	
				7,969	
Operating lease assets					
				6,892	

923			
		7,815	
Goodwill			
		17,348	
		(1,616)	
		15,732	
Deposits and other			
		343	
		—	
		343	
Accounts payable and accrued expenses			
		(353)	
		78	

	(275)	
Reported and estimated claims	(111)	
Operating lease obligations	(8,941)	
Finance lease obligations	(124)	

[illegible]

2023				
in thousands				
Statutory rate				
\$	(4,581)			
\$	(10,667)			
IRC Section 162(m) limitation (a)				
504				
588				
Change in valuation allowance				
6,543				
4,297				
Permanent adjustments				
614				

	457		Prior year true-up and other	(349)		157		Income from entities not subject to taxation	404		605		State tax	(1,733)		Provision (benefit) for income taxes	\$	1,402

(7,241)

Reflects the permanent addback for the Section 162(m) limitation, which limits the deduction of compensation for the five highest paid officers to \$1.0 million per officer.

Provision (benefit) for income taxes consisted of the following for the years ended June 30, 2024 and 2023:

	2024	2023
in thousands	Current:	Federal

[illegible]

	State	779
		(1,262)
	Total deferred tax expense	1,224
		(11,525)
	Total provision (benefit) for income taxes	\$
		1,402
		(7,241)

The significant components of deferred tax assets and liabilities were as follows for the years ended June 30, 2024 and 2023:									
Year ended June 30,			2024			2023			
Deferred tax assets:									
Amortization									
\$									
573									
\$									
629									
Federal net operating losses									
22,873									

[illegible]

weight:400;line-height:120%">1,164			
Stock-based compensation			511
449			
Accrued bonuses			1,180
582			
Interest Expense			1,943
791			
Lease liability			9,260
6,784			

Total deferred tax assets	48,122					35,196													
Valuation allowance										(15,948)					(8,347)				
Deferred tax assets, net of valuation allowance										32,174									
Deferred tax liabilities:																			
Goodwill										(9,207)									

[illegible]

Other	(54)	(4)
Total deferred tax liabilities	(39,634)	(33,085)
Net deferred tax liability	\$	(7,460)
		(6,236)

Carryforwards

The Company had state net operating loss carryforwards of \$185.8 million and \$117.9 million at June 30, 2024 and 2023, respectively, which will begin to expire in 2037 if not utilized. Included in this is a city net operating loss which will

begin to expire in 2025 if not utilized. Additionally, the Company has federal net operating loss carryforwards of \$108.9 million and \$81.7 million as of June 30, 2024 and 2023, respectively which do not expire.

Valuation Allowance

The Company has provided \$15.9 million and \$8.3 million at June 30, 2024 and June 30, 2023, respectively, as a valuation allowance against its deferred tax assets for federal and state net operating losses and state 163(j) interest expense limitations where there is not sufficient positive evidence to substantiate that these deferred tax assets will be realized at a more-likely-than-not level of assurance.

Other

The Company had no uncertain tax positions at June 30, 2024 and 2023.

The Company files income tax returns as a consolidated group, excluding SH1, InnovAge Sacramento, and InnovAge Orlando, in the U.S. federal jurisdiction and various states and is subject to examination by taxing authorities in all of those jurisdictions. From time to time, the Company's tax returns are reviewed or audited by U.S. federal and various U.S. state-taxing authorities.

The Company believes that adjustments, if any, resulting from these reviews or audits would not be material, individually or in the aggregate, to the Company's consolidated financial position, results of operations, or liquidity. The Company is subject to income tax examinations by U.S. federal and state jurisdictions for the period ended June 30, 2021 and forward. The Company is subject to income tax examinations by California, Colorado and New Mexico state jurisdictions for the period ended June 30, 2020 and forward.

The Company's effective income tax rate for the years ended June 30, 2024 and 2023 was (6.4)% and 14.3%, respectively, which differed from the amount computed by applying the applicable U.S. federal statutory corporate income tax rate of 21% in each period as a result of the following factors:

	2024	2023	Statutory rate	Change due to:	
State income taxes	12.083%	12.081%	21.000%	(8.917)%	
Research and development credit	(0.100)%	(0.100)%	21.000%	20.900%	
Charitable contribution deduction	(0.100)%	(0.100)%	21.000%	20.900%	
Other	(0.406)%	(0.406)%	21.000%	20.594%	
	(6.403)%	14.300%	21.000%	(27.403)%	
Effective rate	(6.403)%	14.300%			

Year ended June 30,

2024

2023

2023									
in thousands									
Statutory rate									
\$									
(4,581)									
\$									
(10,667)									
IRC Section 162(m) limitation (a)									
504									
588									
Change in valuation allowance									
6,543									
Permanent adjustments									

weight:400;line-height:120%">614				

weight:400;line-height:120%">1,402 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(7,241)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"></div>(a)Reflects the permanent addback for the Section 162(m) limitation, which limits the deduction of compensation for the five highest paid officers to \$1.0 million per officer. -0.064 0.143 -4581000 -10667000 504000 588000 6543000 4297000 614000 457000 -349000 157000 -404000 -605000 -1733000 -2678000 1402000 -7241000 5 1000000.0 <div style="margin-top:10pt;text-align:justify;text-indent:18pt">Provision (benefit) for income taxes consisted of the following for the years ended June 30, 2024 and 2023:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">in thousands</td></tr><tr><td colspan="3" style="background-color:#cfe2f3;padding:2px 1pt;text-align:left;vertical-align:bottom">Current:</td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Federal</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td></tr></table></div>

	\$	
—		
	\$	
		3,709
State		
		178
		575
Total current tax expense		178
		4,284
Deferred:		
Federal		445

	(10,263)	
State	779	
Total deferred tax expense	1,224	
Total provision (benefit) for income taxes	\$ (11,525)	
	1,402	
	(7,241)	
0 3709000 178000 575000 178000 4284000 445000 -10263000 779000		

-1262000 -1224000 -11525000 1402000 -7241000

The significant components of deferred tax assets and liabilities were as follows for the years ended June 30, 2024 and 2023:

			Year ended June 30,								
			2024			2023			in thousands		
Deferred tax assets:											
Amortization			\$			573			22,873		
Federal net operating losses			629		Federal net operating losses						

	17,147		
State net operating losses	8,053		
	5,701		
Provision for uncollectible accounts	1,755		
	1,114		
Accrued vacation	469		
	835		
Reported and estimated claims	1,505		

1,164		
Stock-based compensation	511	
449		
Accrued bonuses	1,180	
582		
Interest Expense	1,943	
791		
Lease liability	9,260	
6,784		

Total deferred tax assets 48,122 35,196		
Valuation allowance (15,948) (8,347)		
Deferred tax assets, net of valuation allowance 32,174		
Deferred tax liabilities:		
Goodwill (9,207)		

	(6,697)	
Depreciation	(16,288)	
	(13,137)	
Equity investment	(4,696)	
	(5,019)	
Prepaid expenses	(705)	
	(1,792)	
ROU asset	(8,684)	
	(6,436)	

[illegible]

PWD VIE

Pursuant to the PWD Amended and Restated Agreement of Limited Partnership, CCH helped fund operating deficits and shortfalls of PWD in the form of a loan (the “PWD Loan”). The PWD Loan did not accrue interest. Additionally, CCH was paid an administration fee of \$35,000 per year. At June 30, 2023, \$0.7 million was recorded in Deposits and other related to the PWD Loan. On March 13, 2024, PWD entered into a Purchase and Sale Agreement for the sale of all of PWD's property, including the Senior Housing unit.

On May 2, 2024, PWD closed on the sale of its Senior Housing property for \$9.5 million. Upon completion of the sale, PWD ceased providing senior housing services and was dissolved. Following the dissolution, the remaining proceeds from the sale were distributed in accordance with the partnership agreement and as otherwise agreed by the partners. The Company received net proceeds of \$4.8 million in connection with the dissolution.

35000 700000 9500000 4800000

Segment Reporting

The Company applies ASC Topic 280, “Segment Reporting,” which establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about operations, major customers and the geographies in which the entity holds material assets and reports revenue. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the Company's chief executive officer, who is the chief operating decision maker (“CODM”), and for which discrete financial information is available. The Company has determined that it has three operating segments, two of which are related to the Company's PACE offering. The PACE-related operating segments are based on two geographic divisions, which are East and West. Due to the similar economic characteristics, nature of services, and customers, we have aggregated our East and West operating segments into one reportable segment for PACE. The Company's remaining operating segment primarily relates to Senior Housing, which is an immaterial operating segment, and shown below as “Other” along with certain corporate unallocated expenses.

As of June 30, 2024, the Company served approximately 7,020 PACE participants, making it the largest PACE provider in the U.S. based upon participants served, and operated 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania and Virginia.

PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, in a community-based service model. InnovAge provides all needed healthcare services through an all-inclusive, coordinated model of care and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, VA and private pay sources. Additionally, under the Medicare Prescription Drug Plan, CMS shares part of the risk for providing prescription medication to the Company's participants.

The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The Company does not review assets by segment and therefore assets by segment are not disclosed below. For the periods presented, all of the Company's long-lived assets were located in the United

[illegible]

All other (1)		
Totals		
Capitation revenue \$ 762,570		
\$ —		
\$ 762,570		
\$ 686,836		
\$ —		

	\$	686,836	
Other service revenue		310	
		975	
		1,285	
		347	
		904	
		1,251	
Total revenues		762,880	
		975	

763,855	687,183	904	688,087	External provider costs	403,010	—	374,528	—	374,528

[illegible]

						340							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			
						101,288							101,288			

Depreciation and amortization		18,477	473	18,950	14,959	460	15,419
Interest expense, net		3,845	178	4,023	1,342		

[illegible]

	(2,542)	(124)	(21,555)	(264)	(21,819)
Loss Before Income Taxes	\$				

(50, 493)

(300)

(50, 793)

Center-level Contribution Margin from a segment below the quantitative thresholds is attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.

(2) Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.

The following table summarizes the operating results regularly provided to the CODM by segment for the years ended June 30, 2024 and 2023:

[illegible]

	\$	—		\$	762,570		\$	686,836		\$	686,836		—		Other service revenue	310	975	

		1,285			
		347			
		904			
		1,251			
	Total revenues				
		762,880			
		975			
		763,855			
		687,183			
		904			
		688,087			

External provider costs			403,010	—	374,528	374,528	374,528	374,528
Cost of care, excluding depreciation and amortization			228,203	578	228,781	228,781	228,781	211,707

				564						212,271				
Center-Level Contribution Margin			131,667							397				
132,064								100,948						
340								101,288				Overhead costs (2)		

[illegible]

[illegible]

[illegible]

[illegible]

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;> \$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">(50, 793)</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table></div><div style="margin-top: 10pt"></div><div style="margin-top: 10pt; padding-left: 18pt; text-align: justify; text-indent: -18pt">(1)Center-level Contribution Margin from a segment below the quantitative thresholds is attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.</div><div style="margin-top: 10pt; padding-left: 18pt; text-align: justify; text-indent: -18pt">(2)Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.</div>762570000 0 762570000 686836000 0 686836000 310000 975000 1285000 347000 904000 1251000 762880000 975000 763855000 687183000 904000 688087000 403010000 0 403010000 374528000 0 374528000 228203000 578000 228781000 211707000 564000 212271000 131667000 397000 132064000 100948000 340000 101288000 136284000 10000 136294000 135264000 0 135264000 18477000 473000 18950000 14959000 460000 15419000 -3845000 -178000 -4023000 -1342000 -180000 -1522000 2842000 0 2842000 0 0 0 2542000 0 2542000 124000 0 124000 -21555000 -264000 -21819000 -50493000 -300000 -50793000 Earnings per Share<div style="margin-top: 10pt; text-align: justify; text-indent: 18pt">Basic earnings (loss) per share ("EPS") is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options and other equity awards, using the treasury stock method and the average market price of the Company's common stock during the applicable period. When a loss from continuing operations exists, all dilutive securities and potentially dilutive securities are anti-dilutive and are therefore excluded from the computation of diluted earnings per share. When net income from continuing operations exists, performance-based units, are omitted from the calculation of diluted EPS until it is determined that the performance criteria has been met at the end of the reporting period. As of June 30, 2024 and 2023, there were 1,035,066 performance-based awards excluded from the calculation of diluted EPS.</div><div style="margin-top: 10pt; text-align: justify; text-indent: 18pt">The following table sets forth the computation of basic and diluted net loss per common share:</div><div style="margin-top: 10pt; text-align: justify"><table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: text-bottom; width: 100.000%"><tr><td style="width: 1.0%"></td><td style="width: 71.930%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.081%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.083%"></td><td style="width: 0.1%"></td></tr><tr><td colspan="3"></td><td></td></tr></table></div>

Year ended June 30,		
in thousands, except share values		
2024	2023	
Net loss attributable to InnovAge Holding Corp.		
\$	(21,338)	
\$	(40,673)	
Weighted average common shares outstanding (basic)		
135,902,214	135,593,824	
EPS (basic)		
\$		
\$	(0.16)	

	Dilutive shares	(0.30)	
	—		
	Weighted average common shares outstanding (diluted)	135,902,214	
		135,593,824	
	EPS (diluted)	\$	
	(0.16)		
		(0.30)	

1035066 1035066

The following table sets forth the computation of basic and diluted net loss per common share:

	Basic	Diluted
Year ended June 30,		
in thousands, except share values		
2024	2023	
Net loss attributable to InnovAge Holding Corp.	\$	(21,338)
\$	(40,673)	
Weighted average common shares outstanding (basic)	135,902,214	
	135,593,824	

[illegible]

style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.30)</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>-21338000-40673000-135902214-135593824-0.16-0.30-0.0-135902214-135593824-0.16-0.30 Share Repurchase ProgramOn June 14, 2024, our Board authorized up to \$5.0 million of share repurchases. As of June 30, 2024, the Company had repurchased approximately 45,023 shares of its common stock for \$0.2 million, of which 36,559 were placed in Treasury. 5000000.0 45023 200000 36559 Subsequent Event<div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company has evaluated subsequent events through September 10, 2024, the date on which the consolidated financial statements were issued.</div><div style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2024, Nicole D'Amato, the Company's Chief Legal Officer and Corporate Secretary, adopted a Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the sale of up to 47,574 shares of the Company's common stock through September 16, 2025, or upon the earlier completion of all authorized transactions under the plan.</div> June 13, 2024 Nicole D'Amato Chief Legal Officer and Corporate Secretary true 47574 September 16, 2025

Q?CD·M·Y(%) MN^NMJM2I=·@REXZN3/&GRGQ^UCONBN8P6LBIU/I^A1H 9IPO·84+2VZGIU, M>R*MG3=E(PP\$1=+Q5WYN>·@('0>\$@=:@23@CH8"RI?2R·3,;J"FEHXT5P M·4@#C@)*)3?>XPIV"G#1·1+45"V51DI@?F61+8·RITZ&·M/JXV@>*J/I·I0IS·#RD2875H7C6(9+>J03B·=169425M(CI>@HB\$W·"61\$ M)·K\$PHI2(+·=:2DDDLY%IGC1255KPI8%2H5DA1·D7I7*·A13C*3/RD2=MSX326T1Z504L6\$%IGICGY·=·JINCNDM8K·L7>PS·6\$^X8\$9GT·1·78K\$C)E=DI4WSC5B#&J>S@N% M?·L·B·99N·A5AQ^YISVC@/I·4E>H+I·U·V(\$6PLPY/B·L·G55,P"=·<4K?·UGK M^V?·7·L1H1H#·E·X·#2MIQ·9=·B·77·6W1·5EQ>2XO·\$S\$NV8D8)7OB>QDB'D·J6T^HM 9C,JBPY8J INP\$+D,B I|?'·MG2M3·O?FR4·R?CH1;20H1T7IP|CXKN^M·@·0P^·4?I0#IVS1"5E(5C7OA M1^L6I<+Q·U·ZIN(I·MAQWV·2K)IS27·HEI(·W0@BR|O|U<I\$G·MNEI·2·MAT·XM=1H?2DHQ\$?6R1)·\$S^8>=EN0·EIG9\$8IG?IK·I=R(GYC8?&K^I19+QI5·M·J·=·C5I+@0@1DBBHHA"=·L·MY·SS·*·I·U·KJ809·IC|E?E^@·4·2&PA28U4^H|OPN·VNW·JM22)·^·NX#1)8L1·6R·ZRE·*·MAJ74SS=WD"JH0G1\$·TMO·4MC·IQ^@#·G|KE·X|BI@·F8·S4YKIA9 M·+K·%2·AZV·Q|@/DH?·\$·\$BWK1&73OW(I)9·^CY9·AB^?J|·\$·=·0PYMV1Y·4·M·YD|N#^>3·I·ZV3TUE·C0DG^|JDC\$·YX·#P0XU·2GXV29G5T·M|IRKV6·^·200B·I·L·Z8T·=·(H?7WIGCOJ<P6WVAMS·+·\$C(C=·,·5K?·)MOVH1^0(O·K@OY+O&T6\$^Q·51528UH(3G+Z&R7212WK·^·(HV·T·O815C^R·MIJD·R307^PR#4>=1529^RF7G8V>@·(I\$6L08I0·GZ^SW=·'G^E|UL·MLB^V1^*QIP^W6B·K^V|I·520=Q5I09O1V4(S>O#0Y^5H)·8AM5XTUA724#·MOKKEH6^I·+·J·#P|>12W·CPIWMA·VPEY+K2M5>VUHX5,P=GGQ·3>EIP·MIU9K/·@·LR?%M;7Y7W^=C0EA91162I0I6ZD(90\$?@QIRSL6%K8·NEZK·MA(GAP·T·#·+D|G^+F·MCXB·S<45)I>·%KG^M5<C>=>7CG8+GVR<^\$XIZ\$XZ>D·^IQ^P%QXMK90GG^06G\$1RT17VNBPS?A1%196C·PW MH1\$·+PIH|U·(RO=50AI·835+38UOPFEZIKN%G6F1^972D^IA·M·(MC·2·M5·|G2N9·^H·#·1?·|WV9E>C06MC·M·P6M+>I<·Z·%6^%0%·C\$DU·6#M|'IO\$DSU·U2·6·I58^Q·2<I·%·MLI=·E|J(3·=PCUCI%>USVIM/I·O·)·U·M#H(G·WYQ^K·NIVE·9SDYE115=PV82>6#·KA^5CH·N|@FLIASD(6=D6@=D5 MK+VH·1·H9AW@+I·D&RQ0AA>E|·I·(·=·(8M·606·ZQ·O8P·E9·Y6XD·Y82Y2^8=4I7F·6)·L·ME34K5D>I·L·V1<+·XP7T@>^CHI"8MN·^·%26·TZ·ZCEZV1^HY0^VE·&93G M(VVH0>58)D>ON<·(O·UJ08·LR·RB6·9I·A2·64UH^K|FIUFU>I·L·O·50·AY>^1·IC·M")4N42IK0I·+1·3ZT^O·(I8·I16·?2TI4QZIT·I·O·L0I6·I·VY·L·Y6&·&·MIH\$>@J9Z>5E@·U·GXAW·O·8S·L1·/384Y1·179·M1^O8K7^90XQ·>9FWDMYCAE·21E60&C+@·<@·0FARH|G·W12C·M")4KNE1MI·HRZ?·M1·M(2I5\$X@·OCZ|IIM>3F7P·LCLEA·OSB·(U1+SC09=^78R/X?>=M|>=·1\$19@I\$<>CT9^R=SA2^4E3\$P05T@H&UEN,>F/Q·W2X5^I·9·A|K>K·MAQ^AI2·D·MEAK2CG·8+Q^+·@·O/QEFWS·4>0XXHG^8Y13E|·=V3C·@TV&·M2L·OANX>1W20T|T|B|ICY?2I)MCLMK2\$P·=1KGT+I·(AM2B41ANNF1V|SVZ1·MCR)=·I·S·C·86I?2%I^+·222M^BAYY<^Y8UEG+P|P%?L\$|·@·BZ%\$T·HA·I>JB·M1JA·XO·POZ?·FUABV&5V5FC4^·O·MM·Z·#STW|H^@·@I·U5^41I3?>·(6Y58UW·M/ZV+2EQ2A2%28Y·A·MC·3^NU196Q3(I·A?·8·UB^9^FIUUD<@Y·F?CZ>7(I0·O|QI((>E0B|&&·MB·B?Q·9·6)·(I·08·I)S\$%KFS·48CN·|·^·A·O8E|8R815MH·QOIZB<3·@·MOQO·Q·A?·^·^·11"FSJ|HQAIG<M·I·%·%2YH19·4F·^&48^*^T·INV?>VDC·ME·1C43N%KM%\$L4VIO?·=·4^<7^=·(48BT)·A3·>·\$·FLT\$S2·BIQ^2RW·TAL·MD|OSMZH|D1·FQWM24VNB·D·=·#8)F94@J2^E/W@·4FK1259?>0E28^I8YV·M|VACD·0XOI^·T·T2B|GKW?U&M(GWM&D·PJ|O4K^73>4J8ZT1M)J^I^SX42C·M821=^E#T^I·^U6M|XIHUP·U(T4G·N1·O9HVX·TW^I·M6XQO·I·90^>26Y19·M·MIEEX·W·G6Q89V·@·F7W5344^·@O8RK2\$F·H00^L·C·B·H6%YNN\$J·P#>G·8·M6I>Z>JBC1^7N62WAO/2WU5H1·I1+·7B·Z|S·IC·I|MIJ·^496C=16F1·2·I·M&Y·@EHNT|MG>3·MR<6|X|C9·I\$@=E@·KE|MG|C|PLZ5CIU^ELO35%·H·MWRCB(M·Z>I·Q6906I·PL#D@·>9=F·#2ZHRH0Q^JVL10>H^19Y8B·WB·6·MR|XZ=7&(8·B5·(M\$%9M·I·TNTNZ^XNDT·HB^>·B|GON·00·I·V#P4+J8=U7·M<Q0R8L00IA9=+·W·V1=V2>@IOPTX@1PD·Q6VT9479·JBEI|GCN5LCOY+UIA·M+4OU>=·J2|WQ/C|UQ=UQ=WM|FQBU·G8Z4D^M·2I05I5+J|CVAM|2^N7·M5UV<@J\$T0@GWM·BA|BD·(C·L·2N@5%)(XZV|F·M6I/O·D@2·3UCOW9^SZ·MA·5·%9Q1N·6H|AQOWC=·\#P9VC@QO·RI·CN·M·A@·I·^L·VZ\$%·T·P|FK^N92(\$·U·ISM1<22BIYCL·PVD|·J|D3K6·OW·M·^·I·UO)B6@MAB·&G·9·V1·O·C·I·MG·DUEC|J·X\$N^CS·(NNU·E·4MYP·M&M&ZMDXH8HOULF|OECX·PD8\$·)·ZV·A·AA·K>L212Z7·I·(AO·M2^900Q9A#4Y·715^\$·@·I·Z0·9%+WEACB·MZ·X·RQF=I0R|U)·=·2B6SE·HE·NXC0·N1·MC@·I8·B>R<|TSE3B2>B·6·\$·3E%O·MBT·FS·W+OK·M2·|QD9U?A·BS7^T·U·S+Z6MUT>?Q&IDG33H4N@·W3RTZ·S·A071^CN·9VVE·Z1U2UTG·V·G9#0·%29A0A·*04M12I·C^\$6I·MA·>Q·Z12I·U·X·O·F|R·K1K3<·&9%·SS/I·O·I·ZL^I87Y^C8%3|TW·RWXVZ·9^=I\$JYUSFG·MA·^·C·Q|ZUVI|LAD+AXT·S5I87Z·M1F1H|J3\$·NH|·^I·T5M^#·VZO+I9^>I·Z+X8·&@<7?>2IG+I·N·MW·HO|WPIQ0KTHFY·E|8T·F=08=·A837F·%I7Z553^I\$A>|C|C|/IC^MC>W&·9·6IE#S·C·I·F·OE?C/O·9^@·L^I·N·(·+B·MOM?8RHN^I·3K6G1\$=6%&2^I·K0^MBUUCR?GO|I·N^31PIH^WC09W<·R·7E3283N|B67>=·(R·6&I·MU|OQI·V1>2&8·6|8B2I·7F·I6·AM·M·I?·4MPS0IAB0?IHDS·?<2D09B|TD?>79CLWJ3M@·B/J·9>D\$8I>·M|K|@·MNNP1B·J·S·E·T·QEIW>^9EZFA·YUSPO10Q9H<@·C·AUO|SYZ·Z·GK>X·8·M·^·J·3·F·PAVZ=2%FMVEZ2PD·+QD|S·>JN·+K#J3W1·MRP7Y5V5FC4^·O·MM·Z·#STW|H^@·@I·U5^41I3?>·(6Y58UW·M/ZV+2EQ2A2%28Y·A·MC·3^NU196Q3(I·A?·8·UB^9^FIUUD<@Y·F?CZ>7(I0·O|QI((>E0B|&&·MB·B?Q·9·6)·(I·08·I)S\$%KFS·48CN·|·^·A·O8E|8R815MH·QOIZB<3·@·MOQO·Q·A?·^·^·11"FSJ|HQAIG<M·I·%·%2YH19·4F·^&48^*^T·INV?>VDC·ME·1C43N%KM%\$L4VIO?·=·4^<7^=·(48BT)·A3·>·\$·FLT\$S2·BIQ^2RW·TAL·MD|OSMZH|D1·FQWM24VNB·D·=·#8)F94@J2^E/W@·4FK1259?>0E28^I8YV·M|VACD·0XOI^·T·T2B|GKW?U&M(GWM&D·PJ|O4K^73>4J8ZT1M)J^I^SX42C·M821=^E#T^I·^U6M|XIHUP·U(T4G·N1·O9HVX·TW^I·M6XQO·I·90^>26Y19·M·MIEEX·W·G6Q89V·@·F7W5344^·@O8RK2\$F·H00^L·C·B·H6%YNN\$J·P#>G·8·M6I>Z>JBC1^7N62WAO/2WU5H1·I1+·7B·Z|S·IC·I|MIJ·^496C=16F1·2·I·M&Y·@EHNT|MG>3·MR<6|X|C9·I\$@=E@·KE|MG|C|PLZ5CIU^ELO35%·H·MWRCB(M·Z>I·Q6906I·PL#D@·>9=F·#2ZHRH0Q^JVL10>H^19Y8B·WB·6·MR|XZ=7&(8·B5·(M\$%9M·I·TNTNZ^XNDT·HB^>·B|GON·00·I·V#P4+J8=U7·M<Q0R8L00IA9=+·W·V1=V2>@IOPTX@1PD·Q6VT9479·JBEI|GCN5LCOY+UIA·M+4OU>=·J2|WQ/C|UQ=UQ=WM|FQBU·G8Z4D^M·2I05I5+J|CVAM|2^N7·M5UV<@J\$T0@GWM·BA|BD·(C·L·2N@5%)(XZV|F·M6I/O·D@2·3UCOW9^SZ·MA·5·%9Q1N·6H|AQOWC=·\#P9VC@QO·RI·CN·M·A@·I·^L·VZ\$%·T·P|FK^N92(\$·U·ISM1<22BIYCL·PVD|·J|D3K6·OW·M·^·I·UO)B6@MAB·&G·9·V1·O·C·I·MG·DUEC|J·X\$N^CS·(NNU·E·4MYP·M&M&ZMDXH8HOULF|OECX·PD8\$·)·ZV·A·AA·K>L212Z7·I·(AO·M2^900Q9A#4Y·715^\$·@·I·Z0·9%+WEACB·MZ·X·RQF=I0R|U)·=·2B6SE·HE·NXC0·N1·MC@·I8·B>R<|TSE3B2>B·6·\$·3E%O·MBT·FS·W+OK·M2·|QD9U?A·BS7^T·U·S+Z6MUT>?Q&IDG33H4N@·W3RTZ·S·A071^CN·9VVE·Z1U2UTG·V·G9#0·%29A0A·*04M12I·C^\$6I·MA·>Q·Z12I·U·X·O·F|R·K1K3<·&9%·SS/I·O·I·ZL^I87Y^C8%3|TW·RWXVZ·9^=I\$JYUSFG·MA·^·C·Q|ZUVI|LAD+AXT·S5I87Z·M1F1H|J3\$·NH|·^I·T5M^#·VZO+I9^>I·Z+X8·&@<7?>2IG+I·N·MW·HO|WPIQ0KTHFY·E|8T·F=08=·A837F·%I7Z553^I\$A>|C|C|/IC^MC>W&·9·6IE#S·C·I·F·OE?C/O·9^@·L^I·N·(·+B·MOM?8RHN^I·3K6G1\$=6%&2^I·K0^MBUUCR?GO|I·N^31PIH^WC09W<·R·7E3283N|B67>=·(R·6&I·MU|OQI·V1>2&8·6|8B2I·7F·I6·AM·M·I?·4MPS0IAB0?IHDS·?<2D09B|TD?>79CLWJ3M@·B/J·9>D\$8I>·M|K|@·MNNP1B·J·S·E·T·QEIW>^9EZFA·YUSPO10Q9H<@·C·AUO|SYZ·Z·GK>X·8·M·^·J·3·F·PAVZ=2%FMVEZ2PD·+QD|S·>JN·+K#J3W1·MRP7Y5V5FC4^·O·MM·Z·#STW|H^@·@I·U5^41I3?>·(6Y58UW·M/ZV+2EQ2A2%28Y·A·MC·3^NU196Q3(I·A?·8·UB^9^FIUUD<@Y·F?CZ>7(I0·O|QI((>E0B|&&·MB·B?Q·9·6)·(I·08·I)S\$%KFS·48CN·|·^·A·O8E|8R815MH·QOIZB<3·@·MOQO·Q·A?·^·^·11"FSJ|HQAIG<M·I·%·%2YH19·4F·^&48^*^T·INV?>VDC·ME·1C43N%KM%\$L4VIO?·=·4^<7^=·(48BT)·A3·>·\$·FLT\$S2·BIQ^2RW·TAL·MD|OSMZH|D1·FQWM24VNB·D·=·#8)F94@J2^E/W@·4FK1259?>0E28^I8YV·M|VACD·0XOI^·T·T2B|GKW?U&M(GWM&D·PJ|O4K^73>4J8ZT1M)J^I^SX42C·M821=^E#T^I·^U6M|XIHUP·U(T4G·N1·O9HVX·TW^I·M6XQO·I·90^>26Y19·M·MIEEX·W·G6Q89V·@·F7W5344^·@O8RK2\$F·H00^L·C·B·H6%YNN\$J·P#>G·8·M6I>Z>JBC1^7N62WAO/2WU5H1·I1+·7B·Z|S·IC·I|MIJ·^496C=16F1·2·I·M&Y·@EHNT|MG>3·MR<6|X|C9·I\$@=E@·KE|MG|C|PLZ5CIU^ELO35%·H·MWRCB(M·Z>I·Q6906I·PL#D@·>9=F·#2ZHRH0Q^JVL10>H^19Y8B·WB·6·MR|XZ=7&(8·B5·(M\$%9M·I·TNTNZ^XNDT·HB^>·B|GON·00·I·V#P4+J8=U7·M<Q0R8L00IA9=+·W·V1=V2>@IOPTX@1PD·Q6VT9479·JBEI|GCN5LCOY+UIA·M+4OU>=·J2|WQ/C|UQ=UQ=WM|FQBU·G8Z4D^M·2I05I5+J|CVAM|2^N7·M5UV<@J\$T0@GWM·BA|BD·(C·L·2N@5%)(XZV|F·M6I/O·D@2·3UCOW9^SZ·MA·5·%9Q1N·6H|AQOWC=·\#P9VC@QO·RI·CN·M·A@·I·^L·VZ\$%·T·P|FK^N92(\$·U·ISM1<22BIYCL·PVD|·J|D3K6·OW·M·^·I·UO)B6@MAB·&G·9·V1·O·C·I·MG·DUEC|J·X\$N^CS·(NNU·E·4MYP·M&M&ZMDXH8HOULF|OECX·PD8\$·)·ZV·A·AA·K>L212Z7·I·(AO·M2^900Q9A#4Y·715^\$·@·I·Z0·9%+WEACB·MZ·X·RQF=I0R|U)·=·2B6SE·HE·NXC0·N1·MC@·I8·B>R<|TSE3B2>B·6·\$·3E%O·MBT·FS·W+OK·M2·|QD9U?A·BS7^T·U·S+Z6MUT>?Q&IDG33H4N@·W3RTZ·S·A071^CN·9VVE·Z1U2UTG·V·G9#0·%29A0A·*04M12I·C^\$6I·MA·>Q·Z12I·U·X·O·F|R·K1K3<·&9%·SS/I·O·I·ZL^I87Y^C8%3|TW·RWXVZ·9^=I\$JYUSFG·MA·^·C·Q|ZUVI|LAD+AXT·S5I87Z·M1F1H|J3\$·NH|·^I·T5M^#·VZO+I9^>I·Z+X8·&@<7?>2IG+I·N·MW·HO|WPIQ0KTHFY·E|8T·F=08=·A837F·%I7Z553^I\$A>|C|C|/IC^MC>W&·9·6IE#S·C·I·F·OE?C/O·9^@·L^I·N·(·+B·MOM?8RHN^I·3K6G1\$=6%&2^I·K0^MBUUCR?GO|I·N^31PIH^WC09W<·R·7E3283N|B67>=·(R·6&I·MU|OQI·V1>2&8·6|8B2I·7F·I6·AM·M·I?·4MPS0IAB0?IHDS·?<2D09B|TD?>79CLWJ3M@·B/J·9>D\$8I>·M|K|@·MNNP1B·J·S·E·T·QEIW>^9EZFA·YUSPO10Q9H<@·C·AUO|SYZ·Z·GK>X·8·M·^·J·3·F·PAVZ=2%FMVEZ2PD·+QD|S·>JN·+K#J3W1·MRP7Y5V5FC4^·O·MM·Z·#STW|H^@·@I·U5^41I3?>·(6Y58UW·M/ZV+2EQ2A2%28Y·A·MC·3^NU196Q3(I·A?·8·UB^9^FIUUD<@Y·F?CZ>7(I0·O|QI((>E0B|&&·MB·B?Q·9·6)·(I·08·I)S\$%KFS·48CN·|·^·A·O8E|8R815MH·QOIZB<3·@·MOQO·Q·A?·^·^·11"FSJ|HQAIG<M·I·%·%2YH19·4F·^&48^*^T·INV?>VDC·ME·1C43N%KM%\$L4VIO?·=·4^<7^=·(48BT)·A3·>·\$·FLT\$S2·BIQ^2RW·TAL·MD|OSMZH|D1·FQWM24VNB·D·=·#8)F94@J2^E/W@·4FK1259?>0E28^I8YV·M|VACD·0XOI^·T·T2B|GKW?U&M(GWM&D·PJ|O4K^73>4J8ZT1M)J^I^SX42C·M821=^E#T^I·^U6M|XIHUP·U(T4G·N1·O9HVX·TW^I·M6XQO·I·90^>26Y19·M·MIEEX·W·G6Q89V·@·F7W5344^·@O8RK2\$F·H00^L·C·B·H6%YNN\$J·P#>G·8·M6I>Z>JBC1^7N62WAO/2WU5H1·I1+·7B·Z|S·IC·I|MIJ·^496C=16F1·2·I·M&Y·@EHNT|MG>3·MR<6|X|C9·I\$@=E@·KE|MG|C|PLZ5CIU^ELO35%·H·MWRCB(M·Z>I·Q6906I·PL#D@·>9=F·#2ZHRH0Q^JVL10>H^19Y8B·WB·6·MR|XZ=7&(8·B5·(M\$%9M·I·TNTNZ^XNDT·HB^>·B|GON·00·I·V#P4+J8=U7·M<Q0R8L00IA9=+·W·V1=V2>@IOPTX@1PD·Q6VT9479·JBEI|GCN5LCOY+UIA·M+4OU>=·J2|WQ/C|UQ=UQ=WM|FQBU·G8Z4D^M·2I05I5+J|CVAM|2^N7·M5UV<@J\$T0@GWM·BA|BD·(C·L·2N@5%)(XZV|F·M6I/O·D@2·3UCOW9^SZ·MA·5·%9Q1N·6H|AQOWC=·\#P9VC@QO·RI·CN·M·A@·I·^L·VZ\$%·T·P|FK^N92(\$·U·ISM1<22BIYCL·PVD|·J|D3K6·OW·M·^·I·UO)B6@MAB·&G·9·V1·O·C·I·MG·DUEC|J·X\$N^CS·(NNU·E·4MYP·M&M&ZMDXH8HOULF|OECX·PD8\$·)·ZV·A·AA·K>L212Z7·I·(AO·M2^900Q9A#4Y·715^\$·@·I·Z0·9%+WEACB·MZ·X·RQF=I0R|U)·=·2B6SE·HE·NXC0·N1·MC@·I8·B>R<|TSE3B2>B·6·\$·3E%O·MBT·FS·W+OK·M2·|QD9U?A·BS7^T·U·S+Z6MUT>?Q&IDG33H4N@·W3RTZ·S·A071^CN·9VVE·Z1U2UTG·V·G9#0·%29A0A·*04M12I·C^\$6I·MA·>Q·Z12I·U·X·O·F|R·K1K3<·&9%·SS/I·O·I·ZL^I87Y^C8%3|TW·RWXVZ·9^=I\$JYUSFG·MA·^·C·Q|ZUVI|LAD+AXT·S5I87Z·M1F1H|J3\$·NH|·^I·T5M^#·VZO+I9^>I·Z+X8·&@<7?>2IG+I·N·MW·HO|WPIQ0KTHFY·E|8T·F=08=·A837F·%I7Z553^I\$A>|C|C|/IC^MC>W&·9·6IE#S·C·I·F·OE?C/O·9^@·L^I·N·(·+B·MOM?8RHN^I·3K6G1\$=6%&2^I·K0^MBUUCR?GO|I·N^31PIH^WC09W<·R·7E3283N|B67>=·(R·6&I·MU|OQI·V1>2&8·6|8B2I·7F·I6·AM·M·I?·4MPS0IAB0?IHDS·?<2D09B|TD?>79CLWJ3M@·B/J·9>D\$8I>·M|K|@·MNNP1B·J·S·E·T·QEIW>^9EZFA·YUSPO10Q9H<@·C·AUO|SYZ·Z·GK>X·8·M·^·J·3·F·PAVZ=2%FMVEZ2PD·+QD|S·>JN·+K#J3W1·MRP7Y5V5FC4^·O·MM·Z·#STW|H^@·@I·U5^41I3?>·(6Y58UW·M/ZV+2EQ2A2%28Y·A·MC·3^NU196Q3(I·A?·8·UB^9^FIUUD<@Y·F?CZ>7(I0·O|QI((>E0B|&&·MB·B?Q·9·6)·(I·08·I)S\$%KFS·48CN·|·^·A·O8E|8R815MH·QOIZB<3·@·MOQO·Q·A?·^·^·11"FSJ|HQAIG<M·I·%·%2YH19·4F·^&48^*^T·INV?>VDC·ME·1C43N%KM%\$L4VIO?·=·4^<7^=·(48BT)·A3·>·\$·FLT\$S2·BIQ^2RW·TAL·MD|OSMZH|D1·FQWM24VNB·D·=·#8)F94@J2^E/W@·4FK1259?>0E28^I8YV·M|VACD·0XOI^·T·T2B|GKW?U&M(GWM&D·PJ|O4K^73>4J8ZT1M)J^I^SX42C·M821=^E#T^I·^U6M|XIHUP·U(T4G·N1·O9HVX·TW^I·M6XQO·I·90^>26Y19·M·MIEEX·W·G6Q89V·@·F7W5344^·@O8RK2\$F·H00^L·C·B·H6%YNN\$J·P#>G·8·M6I>Z>JBC1^7N62WAO/2WU5H1·I1+·7B·Z|S·IC·I|MIJ·^496C=16F1·2·I·M&Y·@EHNT|MG>3·MR<6|X|C9·I\$@=E@·KE|MG|C|PLZ5CIU^ELO35%·H·MWRCB(M·Z>I·Q6906I·PL#D@·>9=F·#2ZHRH0Q^JVL10>H^19Y8B·WB·6·MR|XZ=7&(8·B5·(M\$%9M·I·TNTNZ^XNDT·HB^>·B|GON·00·I·V#P4+J8=U7·M<Q0R8L00IA9=+·W·V1=V2>@IOPTX@1PD·Q6VT9479·JBEI|GCN5LCOY+UIA·M+4OU>=·J2|WQ/C|UQ=UQ=WM|FQBU·G8Z4D^M·2I05I5+J|CVAM|2^N7·M5UV<@J\$T0@GWM·BA|BD·(C·L·2N@5%)(XZV|F·M6I/O·D@2·3UCOW9^SZ·MA·5·%9Q1N·6H|AQOWC=·\#P9VC@QO·RI·CN·M·A@·I·^L·VZ\$%·T·P|FK^N92(\$·U·ISM1<22BIYCL·PVD|·J|D3K6·OW·M·^·I·UO)B6@MAB·&G·9·V1·O·C·I·MG·DUEC|J·X\$N^CS·(NNU·E·4MYP·M&M&ZMDXH8HOULF|OECX·PD8\$·)·ZV·A·AA·K>L212Z7·I·(AO·M2^900Q9A#4Y·715^\$·@·I·Z0·9%+WEACB·MZ·X·RQF=I0R|U)·=·2B6SE·HE·NXC0·N1·MC@·I8·B>R<|TSE3B2>B·6·\$·3E%O·MBT·FS·W+OK·M2·|QD9U?A·BS7^T·U·S+Z6MUT>?Q&IDG33H4N@·W3RTZ·S·A071^CN·9VVE·Z1U2UTG·V·G9#0·%29A0A·*04M12I·C^\$6I·MA·>Q·Z12I·U·X·O·F|R·K1K3<·&9%·SS/I·O·I·ZL^I87Y^C8%3|TW·RWXVZ·9^=I\$JYUSFG·MA·^·C·Q|ZUVI|LAD+AXT·S5I87Z·M1F1H|J3\$·NH|·^I·T5M^#·VZO+I9^>I·Z+X8·&@<7?>2IG+I·N·MW·HO|WPIQ0KTHFY·E|8T·F=08=·A837F·%I7Z553^I\$A>|C|C|/IC^MC>W&·9·6IE#S·C·I·F·OE?C/O·9^@·L^I·N·(·+B·MOM?8RHN^I·3K6G1\$=6%&2^I·K0^MBUUCR?GO|I·N^31PIH^WC09W<·R·7E3283N|B67>=·(R·6&I·MU|OQI·V1>2&8·6|8B2I·7F·I6·AM·M·I?·4MPS0IAB0?IHDS·?<2D09B|TD?>79CLWJ3M@·B/J·9>D\$8I>·M|K|@·MNNP1B·J·S·E·T·QEIW>^9EZFA·YUSPO10Q9H<@·C·AUO|SYZ·Z·GK>X·8·M·^·J·3·F·PAVZ=2%FMVEZ2PD·+QD|S·>JN·+K#J3W1·MRP7Y5V5FC4^·O·MM·Z·#STW|H^@·@I·U5^41I3?>·(6Y58UW·M/ZV+2EQ2A2%28Y·A·MC·3^NU196Q3(I·A?·8·UB^9^FIUUD<@Y·F?CZ>7(I0·O|QI((>E0B|&&·MB·B?Q·9·6)·(I·08·I)S\$%KFS·48CN·|·^·A·O8E|8R815MH·QOIZB<3·@·MOQO·Q·A?·^·^·11"FSJ|HQAIG<M·I·%·%2YH19·4F·^&48^*^T·INV?>VDC·ME·1C43N%KM%\$L4VIO?·=·4^<7^=·(48BT)·A3·>·\$·FLT\$S2·BIQ^2RW·TAL·MD|OSMZH|D1·FQWM24VNB·D·=·#8)F94@J2^E/W@·4FK1259?>0E28^I8YV·M|VACD·0XOI^·T·T2B|GKW?U&M(GWM&D·PJ|O4K^73>4J8ZT1M)J^I^SX42C·M821=^E#T^I·^U6M|XIHUP·U(T4G·N1·O9HVX·TW^I

[illegible]

07571NGR160KY2>N^F7 M7E@>@2%L0@>P1P0Q1%3CIP3%RBMNYXGIB1>82Z^*F8*G 9J6IE1 MLR54M,FHJS #=>_HM72?1-E^QV2SW2%1(XN#_EK0_&1\$0AQ_62B^3B0R0A9TSG6VU27N141^>#WL@>W^WBKUZ>B/PPX1Z^11#L NLG& M^H26%FTF0A8 ER<W.W&C<70-R^5Y^C 3.RL25OZ&+V#0D-A>Y+MC M7/1<L51DRIA6HT@1L1#16 N+ZV116G.021>9^S^K^AGH1^76LRL MFL^6&Q6L4FX8R>X^*G N1D2VX1PT M301^>ZCE@F0Q00S1^0^81S1>5^Z T^H5G_2VR 4U.S7&+O2S.IS&ERR MR^#>@FH8CK&? HD+>06<<^A1VD01^1.KHN#>L1E1392&2_&4-A_ X\$2D M+1/3\$21K<=>ELQPS/QH10>#>YD1/IC 14100/21>+61A.G1L26IN

0X1E:OP1ADNCEB1CA>G&DQGINVQ_117W15%G<PIMUK7R2P/28%U>5C&A M^#FE^RPAK<=>Y121Y1Y1P1 U1 />E11-XOC&S<=>O.F516@.36MUY1R KA? M26F_7TLP01-B P%02P.\$%>O

0X1L65LQ6Q6G10 @AC1D IX^W.M.W&K&L1541^1LX&XK1<=M1UJ UP^NL1YV M1TQD.Q1Y1HB.12D1+4G&ROW210 Q ZEAS<=HIJK>U^R<=>7X\$1FRX>^K

M7&X&1X1.WD26BG&QDXFE 1BL@Q121.ORRXV1C^51&>M5(3SHD1FE.L21Q>14)51&1^*B1=>S60+Z<=>1-1/7+E2>FIR.UF341 M26M/22N141=1L(K6D0&1%Y41(X**U78D1V7>=141Q&6

MOU7P6R1K12Q2Q60B^>^ET911<=>K3^T21K-TK>X&S2Q<=>8PD>27M2Z1M<=>4AGEY101/ZTR10+9Q<=>XC1C2P101K23474>TV.FUEAM1J2D1D&0HEZERD1JHO

W0672A@HNNW1^>+82.6(H2%(250-M4#_YRLG1CBW^FE=1M11H%XG7&K1+8<1\$B&1ZL8R31P=>_6 1L^A PP@1B.M^DG@>@<=1S1NFT1(%Q5SDS&5E&R45%>XK1LYXX&+T1YU8&EKM4%Q.N0+1

111M1&1&1&2P1^5U21J1>=>O0>MUU1W^V.QW11/K12181C2+35U5SRN^M.X@1U1V4^110Y<=>+1ZEON= 03M^<=>G1ICAPL +149 ZF.30.77^#Z M^B1Q 7W2Q101(A12) 1

1^S/B9^BBX1BXR7-J1=>S1E15KM^>O.D0P6 M1^J.HL<1X21@T1:1QC^1P^S8011U1.BMATR135H&@<=H1U1T0^<R MOH1B&75SC^

1YM^>V#D051AMR6H74LWZ06@114DXZ3M11DX.YN1YTSXZG1M0BWSQ>BV31830.8<=>A1C%>X21P121C1701M1LUNN M2^<=11@<5Z^Z<=>1<=>S1C^#11^C.PIY1%05MX.KN

1YOP1S^H0C6@1%=>N+M1NYO.U6 W0113G^U>Z>@F^T^1D1 M1>8P.1R>0A0P1M10&1UJ.FOM6S1F1^?2 AFNM4.8T2K&B.EW>TR212101.<02Q1<41/81L1=>YS16 A15X0

50/0=WTUQ1.C8U51M0<=>O M1^#YH1BYW1^6B1+>O1(AH4%1KW21CA3K01LQ3R%G7E>+>1W1J1K<=>B0T1B XDU1L191K109Z.TK1T1A1>G.N1&5H&XO^>Y1^M1<=>VFGV1U1^P04^

11BR191U40 M141#^1JP10&1A1^V10<3Q1OTE1B21N2>5MO1YER1 M=1011LB1^<L3%TMS1DNR1M&SV NV11 MPRI1<=>Q102^22=Q (1QOEBW6G6FULW&L1Y01/51L)

*GD25P20^5Z^1>BAY1FB4P12M^CAZPR>@H0S.N1 M6K^<=>C1&1<1SOR31XQO2^E.X^S^H1C21P1>HPE>+<5^9311 YREA.L0C0 M61815G88UX1>M^+K11B^A2_O^KO1 M1.SC&^Z52^1M>D1H

G41P221.N1G@7E2F>F1%>DXG4RBEX9A^7^OT^SG6 M1Q0+0<=>1&3>F801T1F1S90+0<4<=>1&B1H1X2E30B M06183>N5D63K13G01H1=>W^WS^M.81T1PLUC51JUW1^?>B1SMK1+6%

M1RGM122C^5&8<=>V326^GBUX3CTFW1UJ.V1^1HUB72>>9101T1P1@SAV13 M^M1RTZ1^@1C^F81U1RG3714Q^C.G1HAY111S1K1W1P M1H1 UD 141V1 4P21PSMSWE^OC^11W71=>VE

8K1VGV^V5D1T1 51K021<41V1X20< 511 P041^11BR19A1^<=>M1Q1^Y1@<1&1A1^W=0.802^7&5 A1VFS 17P2S1M1QX S1F<=>C^YH2T1<31>2916UR1P1D1N13^1H251G1E1V1U800+16R

MW1=>5(DRB1A6C.M1.O9S^WHZ&K457^=>1E7%=>101H1QCB81QOB212R^M2Z1Q1G1CA^WEY1ND1Y2<5R1@50C1%1@1#Z1&1AX^#<=>61U1V^YH1N1VDP91>V1C3^M

>181L&K31K1V1E1H1L1E1 H1&K<=>8#>E M1<113R1/11Y1H1&S1Z1>=>OZO V 51D0D0C691KZ1 SXW5=>V1^110<=>IV MOH1G1Y1T1H16MND1LW6S21E1=>O0BF431.540?

G1^4QOSD2^<M0N@811>56<1MT120131U1 P04 M1^11BR191R31V3D@<=>1%>10&1A1^W=OC& MRN=>@15&NR16^V03.P8RQ13 1141M^S1X1V0^5%11<=>V1&1141^G1 M1P2?

E1N1U1W^>R1F1D02^F1C1RMD_V19<6P121^E41@<1^C1JUK12^V1H1T1@<1^MHA1Y13KHT1@<1P418131T1>@<1K1D18DPS^A921CG1S N03B1FE1@<1E15 16<1L M1^Y1H5^U8S1R141^>Y13T?

CH111O2^8 T<=>K1S1<1 916310S1&10151Q&C M21Q0>1W1W1H1&1B08^T1EXG&S1>074R11>Z<=>L1E HA1A1D1Z1H&=>101W1V1W1M1P1E5^5XUB1T1E87P1D0T1EE1E1W1@10&3F0B1U1JH00 MKD

14&552&192&HG1A31XD<@1H1CX&F3T1R3K>B0A2^411N1C20<0>8% M^<=>H1W1^<=>RDF121_11^=>P^MC911^<=>A19218C9S0^H0=31131<=>8&1FBZ&11^<=>N00&1%=>P1K0X19TGY9

M170010V1WAK9^C1B1 K^=>=>3<=>4N1V141L1M1V&S.R&1J211 9Z<=>1H0H1T1BN11T1J2P41Y1P711>K P&OCU&+B+Q1H0B1@1E10&=>N1AY%413YD1@1H

M1W12M1>7121>GW&K&H1.KX.CU1X&V/H101181U 51L1H1(PAB.PXH #=>@8HP MV1^11>=>3^XK11&11.8521L84C22.M1P1<11D1>=>E3041490V1>=>R6C^S1ERV MU1U1

7245K1YB.PP&815ZGEL61A11B1C&G1C1+OZS^H1UJ6E1>V1D15G MDU11H9Z>51OZ.BF7A 2DS72D1Q1YWC.N1U1N1V&K&1Q1W M1V1T9C1Z11^>T1U1Z1M1M1#11^<=>O.A117B1_0B1^<=>86N1

<=>M1J1E1A111K&S1 M1T1P.M83K11(3H&S1N>X1V1P&A1UM^<=>D&S1<=>6&4&5&OZ1Y@1S1N1A1T1Y1A11N&S1 M1>8Z11^>F&GH691V1R1Z1B5^<=>1&AT24^>Y1U1P1M1^<=>21&11&S1>=>17K1Z1E1(YK M1W1P

11K&G1C.#<=>S1R01>T1UG23K1N1L1C11P1W31U91&161KH1H161X512P1Z1 M3A1W1C1>11>H31^<=>C1 Q1M1D

[illegible]

[illegible]

[illegible]

(Tables)Sheethhttp://www.innovage.com/role/StockbasedCompensationTablesStock-based-Compensation
(Tables)Tableshttp://www.innovage.com/role/StockbasedCompensation35 falsefalseR36.htm9954480 - Disclosure - Acquisitions
(Tables)Sheethhttp://www.innovage.com/role/AcquisitionsTablesAcquisitions (Tables)Tableshttp://www.innovage.com/role/Acquisitions36 falsefalseR37.htm9954481-
Disclosure - Income Taxes (Tables)Sheethhttp://www.innovage.com/role/IncomeTaxesTablesIncome Taxes (Tables)Tableshttp://www.innovage.com/role/IncomeTaxes37
falsefalseR38.htm9954482 - Disclosure - Segment Reporting (Tables)Sheethhttp://www.innovage.com/role/SegmentReportingTablesSegment-Reporting
(Tables)Tableshttp://www.innovage.com/role/SegmentReporting38 falsefalseR39.htm9954483 - Disclosure - Earnings per Share
(Tables)Sheethhttp://www.innovage.com/role/EarningsperShareTablesEarnings per Share (Tables)Tableshttp://www.innovage.com/role/EarningsperShare39
falsefalseR40.htm9954484 - Disclosure - Business (Details)Sheethhttp://www.innovage.com/role/BusinessDetailsBusiness
(Details)Detailshttp://www.innovage.com/role/Business40 falsefalseR41.htm9954485 - Disclosure - Summary of Significant Accounting Policies - Investments
(Details)Sheethhttp://www.innovage.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetailsSummary of Significant Accounting Policies - Investments
(Details)Details41 falsefalseR42.htm9954486 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash
(Details)Sheethhttp://www.innovage.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetailsSummary of Significant Accounting Policies - Restricted Cash
(Details)Details42 falsefalseR43.htm9954487 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment
(Details)Sheethhttp://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetailsSummary of Significant Accounting Policies - Property and
Equipment (Details)Details43 falsefalseR44.htm9954488 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Intangible Assets
(Details)Sheethhttp://www.innovage.com/role/SummaryofSignificantAccountingPoliciesGoodwillandIntangibleAssetsDetailsSummary of Significant Accounting Policies -
Goodwill and Intangible Assets (Details)Details44 falsefalseR45.htm9954489 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs
(Details)Sheethhttp://www.innovage.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetailsSummary of Significant Accounting Policies - Advertising Costs
(Details)Details45 falsefalseR46.htm9954490 - Disclosure - Revenue Recognition - Narrative
(Details)Sheethhttp://www.innovage.com/role/RevenueRecognitionNarrativeDetailsRevenue Recognition - Narrative (Details)Details46 falsefalseR47.htm9954491 - Disclosure -
Revenue Recognition - Schedule of Source of Revenue (Details)Sheethhttp://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetailsRevenue
Recognition - Schedule of Source of Revenue (Details)Details47 falsefalseR48.htm9954492 - Disclosure - Revenue Recognition - Schedule of Concentration of Net Receivable
(Details)Sheethhttp://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetailsRevenue Recognition - Schedule of Concentration of Net
Receivable (Details)Details48 falsefalseR49.htm9954493 - Disclosure - Cost and Equity Method Investments - Schedule of Equity Method and Cost Method Investments
(Details)Sheethhttp://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofEquityMethodandCostMethodInvestmentsDetailsCost and Equity Method
Investments - Schedule of Equity Method and Cost Method Investments (Details)Details49 falsefalseR50.htm9954494 - Disclosure - Cost and Equity Method Investments -
Narrative (Details)Sheethhttp://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetailsCost and Equity Method Investments - Narrative (Details)Details50
falsefalseR51.htm9954495 - Disclosure - Cost and Equity Method Investments - Schedule of Variable Interest Entity
(Details)Sheethhttp://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetailsCost and Equity Method Investments - Schedule of
Variable Interest Entity (Details)Details51 falsefalseR52.htm9954496 - Disclosure - Goodwill and Intangible Assets - Narrative
(Details)Sheethhttp://www.innovage.com/role/GoodwillandIntangibleAssetsNarrativeDetailsGoodwill and Intangible Assets - Narrative (Details)Details52
falsefalseR53.htm9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Changes in Goodwill
(Details)Sheethhttp://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofChangesinGoodwillDetailsGoodwill and Intangible Assets - Schedule of Changes in
Goodwill (Details)Details53 falsefalseR54.htm9954498 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Asset
(Details)Sheethhttp://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetailsGoodwill and Intangible Assets - Schedule of Intangible Asset
(Details)Details54 falsefalseR55.htm9954499 - Disclosure - Goodwill and Intangible Assets - Schedule of Expected Future Annual Amortization Expense
(Details)Sheethhttp://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofExpectedFutureAnnualAmortizationExpenseDetailsGoodwill and Intangible Assets -
Schedule of Expected Future Annual Amortization Expense (Details)Details55 falsefalseR56.htm9954500 - Disclosure - Leases - Narrative
(Details)Sheethhttp://www.innovage.com/role/LeasesNarrativeDetailsLeases - Narrative (Details)Details56 falsefalseR57.htm9954501 - Disclosure - Leases - Schedule of Assets
and Liabilities Related to Leases (Details)Sheethhttp://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetailsLeases - Schedule of Assets and
Liabilities Related to Leases (Details)Details57 falsefalseR58.htm9954502 - Disclosure - Leases - Schedule of Lease Cost
(Details)Sheethhttp://www.innovage.com/role/LeasesScheduleofLeaseCostDetailsLeases - Schedule of Lease Cost (Details)Details58 falsefalseR59.htm9954503 - Disclosure -
Leases - Schedule of Weighted Average Lease Terms and Discount Rates
(Details)Sheethhttp://www.innovage.com/role/LeasesScheduleofWeightedAverageLeaseTermsandDiscountRatesDetailsLeases - Schedule of Weighted Average Lease Terms and
Discount Rates (Details)Details59 falsefalseR60.htm9954504 - Disclosure - Leases - Schedule of Future Maturities of Lease Payments
(Details)Sheethhttp://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetailsLeases - Schedule of Future Maturities of Lease Payments
(Details)Details60 falsefalseR61.htm9954505 - Disclosure - Long-term Debt - Schedule of Long-term Debt
(Details)Sheethhttp://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetailsLong-term Debt - Schedule of Long-term Debt (Details)Details61
falsefalseR62.htm9954506 - Disclosure - Long-term Debt - Narrative (Details)Sheethhttp://www.innovage.com/role/LongtermDebtNarrativeDetailsLong-term Debt - Narrative
(Details)Details62 falsefalseR63.htm9954507 - Disclosure - Long-term Debt - Schedule of Aggregate Maturities of the Total Debt Outstanding
(Details)Sheethhttp://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetailsLong-term Debt - Schedule of Aggregate
Maturities of the Total Debt Outstanding (Details)Details63 falsefalseR64.htm9954508 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Cash, Cash
Equivalents and Marketable Securities by Significant Investment Category
(Details)Sheethhttp://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDeta
Value Measurements - Schedule of Fair Value of Cash, Cash Equivalents and Marketable Securities by Significant Investment Category (Details)Details64
falsefalseR65.htm9954509 - Disclosure - Fair Value Measurements - Narrative (Details)Sheethhttp://www.innovage.com/role/FairValueMeasurementsNarrativeDetailsFair-Value
Measurements - Narrative (Details)Details65 falsefalseR66.htm9954510 - Disclosure - Commitments and Contingencies
(Details)Sheethhttp://www.innovage.com/role/CommitmentsandContingenciesDetailsCommitments and Contingencies
(Details)Details66 falsefalseR67.htm9954511 - Disclosure - Stock-based Compensation - Schedule of Stock-
based Compensation Expense (Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetailsStock-based
Compensation - Schedule of Stock-based Compensation Expense (Details)Details67 falsefalseR68.htm9954512 - Disclosure - Stock-based Compensation - Equity Incentive Plan
(Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetailsStock-based Compensation - Equity Incentive Plan (Details)Details68
falsefalseR69.htm9954513 - Disclosure - Stock-based Compensation - Schedule of Weighted-Average Assumptions
(Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetailsStock-based Compensation - Schedule of Weighted-
Average Assumptions (Details)Details69 falsefalseR70.htm9954514 - Disclosure - Stock-based Compensation - Schedule of Profits Interests Transactions and Number of Units
Outstanding (Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetailsStock-based
Compensation - Schedule of Profits Interests Transactions and Number of Units Outstanding (Details)Details70 falsefalseR71.htm9954515 - Disclosure - Stock-based
Compensation - 2021 Omnibus Incentive Plan and Restricted Stock Units
(Details)Sheethhttp://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetailsStock-based Compensation - 2021 Omnibus
Incentive Plan and Restricted Stock Units (Details)Details71 falsefalseR72.htm9954516 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units Activity
(Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetailsStock-based Compensation - Schedule of Restricted Stock
Units Activity (Details)Details72 falsefalseR73.htm9954517 - Disclosure - Stock-based Compensation - Schedule of Time-based Awards
(Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetailsStock-based Compensation - Schedule of Time-based Awards
(Details)Details73 falsefalseR74.htm9954518 - Disclosure - Stock-based Compensation - Schedule of Black-Scholes Option Pricing Model
(Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetailsStock-based Compensation - Schedule of Black-
Scholes Option Pricing Model (Details)Details74 falsefalseR75.htm9954519 - Disclosure - Stock-based Compensation - Schedule of Performance-based Awards
(Details)Sheethhttp://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetailsStock-based Compensation - Schedule of Performance-based
Awards (Details)Details75 falsefalseR76.htm9954520 - Disclosure - Acquisitions - Narrative
(Details)Sheethhttp://www.innovage.com/role/AcquisitionsNarrativeDetailsAcquisitions - Narrative (Details)Details76 falsefalseR77.htm9954521 - Disclosure - Acquisitions -
Schedule of Business Acquisitions, by Acquisition (Details)Sheethhttp://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetailsAcquisitions -
Schedule of Business Acquisitions, by Acquisition (Details)Details77 falsefalseR78.htm9954522 - Disclosure - Income Taxes - Effective Income Tax Reconciliation
(Details)Sheethhttp://www.innovage.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetailsIncome Taxes - Effective Income Tax Reconciliation (Details)Details78
falsefalseR79.htm9954523 - Disclosure - Income Taxes - Schedule of Effective Income Tax Reconciliation
(Details)Sheethhttp://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetailsIncome Taxes - Schedule of Effective Income Tax Reconciliation
(Details)Details79 falsefalseR80.htm9954524 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes
(Details)Sheethhttp://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetailsIncome Taxes - Schedule of Provision for Income Taxes (Details)Details80
falsefalseR81.htm9954525 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities
(Details)Sheethhttp://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetailsIncome Taxes - Schedule of Components of Deferred
Tax Assets and Liabilities (Details)Details81 falsefalseR82.htm9954526 - Disclosure - Income Taxes - Carryforwards
(Details)Sheethhttp://www.innovage.com/role/IncomeTaxesCarryforwardsDetailsIncome Taxes - Carryforwards (Details)Details82 falsefalseR83.htm9954527 - Disclosure -
Related Parties (Details)Sheethhttp://www.innovage.com/role/RelatedPartiesDetailsRelated Parties (Details)Details83 falsefalseR84.htm9954528 - Disclosure - Segment Reporting - Narrative (Details)Sheethhttp://www.innovage.com/role/SegmentReportingNarrativeDetailsSegment-Reporting -
Narrative (Details)Details84 falsefalseR85.htm9954529 - Disclosure - Segment Reporting - Schedule of Operating Results by Reportable Segments
(Details)Sheethhttp://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetailsSegment-Reporting - Schedule of Operating Results
by Reportable Segments (Details)Details85 falsefalseR86.htm9954530 - Disclosure - Earnings per Share
(Details)Sheethhttp://www.innovage.com/role/EarningsperShareDetailsEarnings per Share (Details)Details86 falsefalseR87.htm9954531 - Disclosure - Share Repurchase Program (Details)Sheethhttp://www.innovage.com/role/ShareRepurchaseProgramDetailsShare-Repurchase Program
(Details)Details87 falsefalseR88.htm9954532 - Disclosure - All Reports Book All Reports innv-20240630.htminnv-20240630.xsdinnv-
20240630-cal.xmlinnv-20240630-def.xmlinnv-20240630-lab.xmlinnv-20240630-pre.xml innv-20240630-g1.jpg http://fasb.org/20240630-us-
gaap/20240630.htm" xbrl:sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024trueJSON-115 MetaLinks.jsonIDEA:XBRL-DOCUMENT {"version": "2.2", "instance": {"innv-
20240630.htm": {"nsprefix": "innv", "nsuri": "http://www.innovage.com/20240630", "dts": {"inline": {"local": {"innv-20240630.htm": {"schema": {"local": {"innv-
20240630.xsd": {"remote": {"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd": {"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd": {"http://www.xbrl.org/2003/xl-
2003-12-31.xsd": {"http://www.xbrl.org/2003/xlink-2003-12-31.xsd": {"http://www.xbrl.org/2005/xbrldt-2005.xsd": {"http://www.xbrl.org/2006/ref-2006-02-27.xsd":
{"http://www.xbrl.org/ir/role/negated-2009-12-16.xsd": {"http://www.xbrl.org/ir/role/net-2009-12-16.xsd": {"http://www.xbrl.org/ir/role/reference-2009-12-16.xsd":
{"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd": {"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd": {"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd":
{"https://xbrl.fashb.org/srt/2024/elts/srt-2024.xsd": {"https://xbrl.fashb.org/srt/2024/elts/srt-roles-2024.xsd": {"https://xbrl.fashb.org/srt/2024/elts/srt-types-2024.xsd":
{"https://xbrl.fashb.org/us-gaap/2024/elts/us-gaap-2024.xsd": {"https://xbrl.fashb.org/us-gaap/2024/elts/us-roles-2024.xsd": {"https://xbrl.fashb.org/us-gaap/2024/elts/us-types-
2024.xsd": {"https://xbrl.sec.gov/country/2024/country-2024.xsd": {"https://xbrl.sec.gov/dei/2024/dei-2024.xsd": {"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd":
{"https://xbrl.sec.gov/spr/2024/spr-2024.xsd": {"calculationLink": {"local": {"innv-20240630-cal.xml": {"definitionLink": {"local": {"innv-20240630-def.xml": {"
labelLink": {"local": {"innv-20240630-lab.xml": {"presentationLink": {"local": {"innv-20240630-pre.xml": {"keyStandard": 389, "keyCustom": 71, "axisStandard": 30,
"axisCustom": 0, "memberStandard": 37, "memberCustom": 36, "hidden": {"total": 10, "http://fasb.org/us-gaap/2024": 5, "http://xbrl.sec.gov/dei/2024": 4,
"http://xbrl.sec.gov/ecd/2024": 1, "contextCount": 20, "entityCount": 1, "segmentCount": 75, "elementCount": 774, "unitCount": 13, "baseTaxonomies": {"http://fasb.org/us-
gaap/2024": 824, "http://xbrl.sec.gov/dei/2024": 40, "http://xbrl.sec.gov/ecd/2024": 11, "http://fasb.org/us-gaap/2024": 1, "report": {"R1": {"role":
"http://www.innovage.com/role/Cover": {"longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "subGroupType": ""

```

menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R2": { "role": "http://www.innovage.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R3": { "role": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "longName": "9952151 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R4": { "role": "http://www.innovage.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R5": { "role": "http://www.innovage.com/role/ConsolidatedStatementsOfOperations", "longName": "9952153 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "isContinuation": "ix", "continuation": "body", "html": " ", "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingAndMarketingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R6": { "role": "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity", "longName": "9952154 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R7": { "role": "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows", "longName": "9952155 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnDispositionOfAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R8": { "role": "http://www.innovage.com/role/Business", "longName": "9952156 - Disclosure - Business", "shortName": "Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R9": { "role": "http://www.innovage.com/role/SummaryOfSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R10": { "role": "http://www.innovage.com/role/RevenueRecognition", "longName": "9952158 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R11": { "role": "http://www.innovage.com/role/CostandEquityMethodInvestments", "longName": "9952159 - Disclosure - Cost and Equity Method Investments", "shortName": "Cost and Equity Method Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R12": { "role": "http://www.innovage.com/role/GoodwillandIntangibleAssets", "longName": "9952160 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillandIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillandIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R13": { "role": "http://www.innovage.com/role/Leases", "longName": "9952161 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseesOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseesFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "
```

innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R23": { "role": "http://www.innovage.com/role/ShareRepurchaseProgram", "longName": "9952171 - Disclosure - Share Repurchase Program", "shortName": "Share Repurchase Program", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R24": { "role": "http://www.innovage.com/role/SubsequentEvent", "longName": "9952172 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R25": { "role": "http://www.innovage.com/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-200", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-200", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R26": { "role": "http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R27": { "role": "http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R28": { "role": "http://www.innovage.com/role/RevenueRecognitionTables", "longName": "9954473 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R29": { "role": "http://www.innovage.com/role/GoodwillAndIntangibleAssetsTables", "longName": "9954475 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R30": { "role": "http://www.innovage.com/role/LeasesTables", "longName": "9954476 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "innv:ScheduleOfLeaseAssetsAndLiabilitiesClassificationInBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "innv:ScheduleOfLeaseAssetsAndLiabilitiesClassificationInBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R31": { "role": "http://www.innovage.com/role/LongtermDebtTables", "longName": "9954477 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R32": { "role": "http://www.innovage.com/role/FairValueMeasurementsTables", "longName": "9954478 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R33": { "role": "http://www.innovage.com/role/StockbasedCompensationTables", "longName": "9954479 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "innv:ScheduleOfAllocatedShareBasedCompensationExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "innv:ScheduleOfAllocatedShareBasedCompensationExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R34": { "role": "http://www.innovage.com/role/IncomeTaxTables", "longName": "9954481 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R35": { "role": "http://www.innovage.com/role/SegmentReportingTables", "longName": "9954482 - Disclosure - Segment Reporting (Tables)", "

```

Accounting Policies - Property and Equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation": "ix:continuation", "body": "html" } },
"reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-
gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation": "ix:continuation", "body": "html" } },
"reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R44": { "role":
"http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesGoodwillandIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Summary of Significant
Accounting Policies - Goodwill and Intangible Assets (Details)", "shortName": "Summary of Significant Accounting Policies - Goodwill and Intangible Assets (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:NumberOffReportingUnits", "unitRef": "reporting unit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "ix:continuation", "body": "html" } },
"reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "ix:continuation", "span": "div", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-
20240630.htm", "unique": true }, "R45": { "role": "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails", "longName": "9954489 -
Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)", "shortName": "Summary of Significant Accounting Policies - Advertising Costs
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1,
"baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true,
"unique": true }, "R46": { "role": "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails", "longName": "9954490 - Disclosure - Revenue Recognition - Narrative
(Details)", "shortName": "Revenue Recognition - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"46", "firstAnchor": { "contextRef": "c-1", "name": "innv:PercentageOfPooledCapitatedPaymentReceived", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals":
"2", "ancestors": { "span": "div", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c-1", "name": "innv:PercentageOfPooledCapitatedPaymentReceived", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {
"span": "div", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R47": { "role":
"http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails", "longName": "9954491 - Disclosure - Revenue Recognition - Schedule of Source of
Revenue (Details)", "shortName": "Revenue Recognition - Schedule of Source of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-58", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-
US", "decimals": "2", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1,
"baseRef": "innv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-54", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil":
"false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation": "ix:continuation", "body": "html" } },
"reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R48": { "role":
"http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails", "longName": "9954492 - Disclosure - Revenue Recognition - Schedule of
Concentration of Net Receivable (Details)", "shortName": "Revenue Recognition - Schedule of Concentration of Net Receivable (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:ConcentrationRiskPercentage1",
"unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "ix:continuation", "body": "html" } },
"reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:ConcentrationRiskPercentage1",
"unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "ix:continuation", "body": "html" } },
"reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R49": { "role":
"http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofEquityMethodandCostMethodInvestmentsDetails", "longName": "9954493 - Disclosure - Cost and
Equity Method Investments - Schedule of Equity Method and Cost Method Investments (Details)", "shortName": "Cost and Equity Method Investments - Schedule of Equity
Method and Cost Method Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor":
{ "contextRef": "c-4", "name": "innv:CostMethodInvestment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div":
"us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "innv:CostMethodInvestment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3",
"ancestors": { "span": "td", "tr": "table", "div": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1,
"baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R50": { "role": "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails",
"longName": "9954494 - Disclosure - Cost and Equity Method Investments - Narrative (Details)", "shortName": "Cost and Equity Method Investments - Narrative (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name":
"innv:NumberOfInvestmentsAccountedUnderCostMethod", "unitRef": "investment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div",
"ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name":
"innv:NumberOfInvestmentsAccountedUnderCostMethod", "unitRef": "investment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div",
"ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R51": { "role":
"http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetails", "longName": "9954495 - Disclosure - Cost and Equity Method
Investments - Schedule of Variable Interest Entity (Details)", "shortName": "Cost and Equity Method Investments - Schedule of Variable Interest Entity (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body",
"html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfVariableInterestEntitiesTableTextBlock",
"ix:continuation": "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R52": { "role":
"http://www.innovage.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "longName": "9954496 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
"shortName": "Goodwill and Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"52", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr":
"table", "div": "body", "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":
"innv:NumberOfAcquisitionResultingInGoodwill", "unitRef": "acquisition", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation":
"ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R53": { "role":
"http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofChangesinGoodwillDetails", "longName": "9954497 - Disclosure - Goodwill and Intangible Assets -
Schedule of Changes in Goodwill (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" } }, "reportCount": 1, "baseRef": "innv-
```


"innv-20240630.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails", "longName": "9954504 - Disclosure - Leases - Schedule of Future Maturities of Lease Payments (Details)", "shortName": "Leases - Schedule of Future Maturities of Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R61": { "role": "http://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetails", "longName": "9954505 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details)", "shortName": "Long-term Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R62": { "role": "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "longName": "9954506 - Disclosure - Long-term Debt - Narrative (Details)", "shortName": "Long-term Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R63": { "role": "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails", "longName": "9954508 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Cash, Cash Equivalents and Marketable Securities by Significant Investment Category (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value of Cash, Cash Equivalents and Marketable Securities by Significant Investment Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R64": { "role": "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails", "longName": "9954509 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R65": { "role": "http://www.innovage.com/role/CommitmentsandContingenciesDetails", "longName": "9954510 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R66": { "role": "http://www.innovage.com/role/CommitmentsandContingenciesDetails", "longName": "9954511 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-124", "name": "innv:LossContingencyPendingLitigationMotionToDismissResolutionNoticePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "innv:LossContingencyPendingLitigationMotionToDismissResolutionNoticePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R67": { "role": "http://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails", "longName": "9954511 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "innv:ScheduleOfAllocatedShareBasedCompensationExpensesTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "innv:ScheduleOfAllocatedShareBasedCompensationExpensesTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R68": { "role": "http://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetails", "longName": "9954512 - Disclosure - Stock-based Compensation - Equity Incentive Plan (Details)", "shortName": "Stock-based Compensation - Equity Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-133", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R69": { "role": "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails", "longName": "9954513 - Disclosure - Stock-based Compensation - Schedule of Weighted-Average Assumptions (Details)", "shortName": "Stock-based Compensation - Schedule of Weighted-Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-129", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "div", "td", "tr": "table", "div": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-129", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "div", "td", "tr": "table", "div": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R70": { "role": "http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails", "longName": "9954514 - Disclosure - Stock-based Compensation - Schedule of Profits Interests Transactions and Number of Units Outstanding (Details)", "shortName": "Stock-based Compensation - Schedule of Profits Interests Transactions and Number of Units Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R71": { "role": "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails", "longName": "9954515 - Disclosure - Stock-based Compensation - 2021 Omnibus Incentive Plan and Restricted Stock Units (Details)", "shortName": "Stock-based Compensation - 2021 Omnibus Incentive Plan and Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-156", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-156", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R72": { "role": "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "longName": "9954516 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details)", "shortName": "Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-149", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "unique": true }, "R73": { "role": "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails", "longName": "9954517 - Disclosure - Stock-based Compensation - Schedule of Time-based Awards (Details)", "shortName": "Stock-based Compensation - Schedule of Time-based Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-157", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-1NF", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "R74": { "role": "http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails", "longName": "9954518 - Disclosure - Stock-based Compensation - Schedule of Black-Scholes Option Pricing Model (Details)", "shortName": "Stock-based Compensation - Schedule of Black-Scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-160", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-160", "name": "us-

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber, "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails", "longName": "9954519 - Disclosure - Stock-based Compensation - Schedule of Performance-based Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-162", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.innovage.com/role/AcquisitionsNarrativeDetails", "longName": "9954520 - Disclosure - Acquisitions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "longName": "9954521 - Disclosure - Acquisitions - Schedule of Business Acquisitions by Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.innovage.com/role/IncomeTaxEffectiveIncomeTaxReconciliationDetails", "longName": "9954522 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.innovage.com/role/IncomeTaxEffectiveIncomeTaxReconciliationDetails", "longName": "9954523 - Disclosure - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails", "longName": "9954524 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails", "longName": "9954525 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-4", "name": "innv:DeferredTaxAssetsAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails", "longName": "9954526 - Disclosure - Income Taxes - Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.innovage.com/role/RelatedPartiesDetails", "longName": "9954527 - Disclosure - Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-182", "name": "us-gaap:ProceedsFromSaleOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954528 - Disclosure - Segment Reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.innovage.com/role/EarningsperShareDetails", "longName": "9954530 - Disclosure - Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954529 - Disclosure - Segment Reporting - Schedule of Operating Results by Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": { "id": "tr", "table": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954531 - Disclosure - Share Repurchase Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-197", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954532 - Disclosure - Segment Reporting - Schedule of Operating Results by Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-197", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954533 - Disclosure - Segment Reporting - Schedule of Operating Results by Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-197", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954534 - Disclosure - Segment Reporting - Schedule of Operating Results by Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-197", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954535 - Disclosure - Segment Reporting - Schedule of Operating Results by Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-197", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": { "div": { "ix:continuation": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "innv-20240630.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "longName": "9954536 - Disclosure - Segment Reporting - Schedule of Operating Results by

```

property, plant and equipment cost basis." } } }, "auth_ref": { } }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": { "r967" } }, "us-gaap-AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": { "r94", "r906", "r1235" } }, "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r764", "r1064", "r1065", "r1066", "r1067", "r1169", "r1236" } }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": { "r980" } }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation.", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": { "r980" } }, "ecd_AdjToNonPeeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": { "r980" } }, "ecd_AdjToPeeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": { "r980" } }, "us-gaap-AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax withholding related to the net share settlements of stock-based compensation awards", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax-withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": { } }, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { } }, "innv_AdministrativeFeePerYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "AdministrativeFeePerYearMember", "presentation": { "http://www.innovage.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Administrative Fee Per Year", "label": "Administrative Fee Per Year [Member]", "documentation": "Administrative Fee Per Year" } } }, "auth_ref": { } }, "innv_AdventistHealthSystemWestJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "AdventistHealthSystemWestJointVentureMember", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Adventist Health System/West Joint Venture", "label": "Adventist Health System/West Joint Venture", "documentation": "Represents the information pertaining to Adventist Health System/West Joint Venture." } } }, "auth_ref": { } }, "us-gaap-AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Advertising Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": { "r165" } }, "us-gaap-AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Advertising expenses", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": { "r522", "r888" } }, "ecd_AggtChngPnsnYalnSummryCompstnTblForApbllyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnYalnSummryCompstnTblForApbllyrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r1014" } }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r938", "r949", "r959", "r992" } }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": { "r941", "r952", "r962", "r995" } }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r1015" } }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": { "r980" } }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": { "r987" } }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": { "r942", "r953", "r963", "r987", "r996", "r1000", "r1008" } }, "us-gaap-AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": { "http://www.innovage.com/role/SegmentReportingNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Segments", "label": "Other Segments", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": { "r266", "r285", "r286", "r287", "r288", "r289", "r292", "r858", "r859" } }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": { "r1006" } }, "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r515", "r520" } }, "us-gaap-AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r208", "r299", "r339", "r342", "r344", "r1197" } }, "dei-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { } }, "us-gaap-AmortizationOffinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffinancingCosts", "crdr": "debit", "presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred
```

Securities, Name {Domain}, "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r24" } }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Impairment charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": { "r5", "r34" } }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r145", "r160", "r204", "r230", "r263", "r269", "r287", "r291", "r336", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r572", "r576", "r614", "r701", "r788", "r858", "r859", "r906", "r927", "r1116", "r1117", "r1186" } }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r198", "r210", "r230", "r336", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r572", "r576", "r614", "r1116", "r1117", "r1186" } }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current {Abstract}" } } }, "auth_ref": { "innv_AssetsLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innovage.com/role/20240630", "localname": "AssetsLesseeAbstract", "presentation": { "http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Assets, Lessee {Abstract}", "documentation": "Assets, Lessee" } } }, "auth_ref": { "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": { "r230", "r336", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r572", "r576", "r614", "r1116", "r1117", "r1186" } }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Assets", "label": "Assets, Noncurrent {Abstract}" } } }, "auth_ref": { "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": { "http://www.innovage.com/role/AuditInformation": { "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": { "r932", "r933", "r945" } }, "innv_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "label": "Auditor Information {Abstract}", "documentation": "Auditor Information" } } }, "auth_ref": { "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": { "http://www.innovage.com/role/AuditInformation": { "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": { "r932", "r933", "r945" } }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": { "http://www.innovage.com/role/AuditInformation": { "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": { "r932", "r933", "r945" } }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": { "r1003" } }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": { "r1004" } }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures {Line Items}" } } }, "auth_ref": { "r999" } }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing How MNPI Considered", "label": "Award Timing, How MNPI Considered {Text Block}" } } }, "auth_ref": { "r999" } }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method {Text Block}" } } }, "auth_ref": { "r999" } }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered {Flag}" } } }, "auth_ref": { "r999" } }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure {Text Block}" } } }, "auth_ref": { "r999" } }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined {Flag}" } } }, "auth_ref": { "r999" } }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Type {Axis}", "label": "Award Type {Axis}", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" } }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": { "r1002" } }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": { "r1001" } }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures {Table Text Block}" } } }, "auth_ref": { "r1000" } }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies {Text Block}", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r118" } }, "innv_BuildingAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BuildingAndLeaseholdImprovementsMember", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Buildings and leasehold improvements", "label": "Buildings and leasehold improvements", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": { "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree {Domain}", "label": "Business Acquisition, Acquiree {Domain}", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": { "r369", "r370", "r371", "r372", "r373", "r566", "r883", "r884" } }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition {Axis}", "label": "Business Acquisition {Axis}", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": { "r46", "r48", "r369", "r370", "r371", "r372", "r373", "r566", "r883", "r884" } }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition {Line Items}", "label": "Business Acquisition {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r566" } }, "innv_BusinessAcquisitionNumberOfProgramsAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessAcquisitionNumberOfProgramsAcquired", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of programs acquired", "label": "Business Acquisition, Number of Programs Acquired", "documentation": "Business Acquisition, Number of Programs Acquired" } } }, "auth_ref": { "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of additional membership interest", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": { "r47" } }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill expected to be deductible for income tax purposes", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes." } } }, "auth_ref": { "r52" } }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Costs incurred related to the acquisition", "label": "Business

Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": { "r45" } }, "us-gaap-BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": { "r1" } }, "us-gaap-BusinessCombinationConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred", "crdr": "credit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total Consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": { "r1", "r2", "r8" } }, "us-gaap-BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": { "http://www.innovage.com/role/Acquisitions": { "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": { "r337", "r567" } }, "innv-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Measurement period, adjustments accounts receivable, net", "terseLabel": "Measurement period, adjustments accounts receivable, net", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable, Net", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable, Net" } } }, "auth_ref": { "r1" } }, "us-gaap-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "crdr": "credit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "totalLabel": "Measurement period adjustments, fair value of assets and liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": { "r51" } }, "innv-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Measurement period adjustments, accounts payable and accrued expenses", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities, Accounts Payable", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities, Accounts Payable" } } }, "auth_ref": { "r1" } }, "innv-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOperatingLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOperatingLeaseAssets", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Measurement period adjustments, operating lease assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Operating Lease Assets" } } }, "auth_ref": { "r1" } }, "innv-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Measurement period adjustments, prepaid expenses", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses" } } }, "auth_ref": { "r1" } }, "innv-BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedFinanceLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedFinanceLeaseObligation", "crdr": "credit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Finance lease obligations", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Finance Lease Obligation", "documentation": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Finance Lease Obligation" } } }, "auth_ref": { "r1" } }, "innv-BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseAssets", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease Assets", "documentation": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease Assets" } } }, "auth_ref": { "r1" } }, "innv-BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseObligation", "crdr": "credit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease obligations", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease Obligation", "documentation": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease Obligation" } } }, "auth_ref": { "r1" } }, "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": { "r50" } }, "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": { "r50" } }, "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts payable and accrued expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": { "r50" } }, "innv-BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDepositsAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDepositsAndOther", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deposits and other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deposits And Other", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deposits And Other" } } }, "auth_ref": { "r1" } }, "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": { "r49", "r50" } },

us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReportedAndEstimatedClaims": {"xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReportedAndEstimatedClaims", "crdr": "credit", "calculation": {"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {"parentTag": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 4.0 }}, "presentation": {"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Reported and estimated claims", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reported And Estimated Claims", "documentation": "Amount of reported and estimated claims assumed at the acquisition date." }}, "auth ref": "r11" }, "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": {"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {"parentTag": null, "weight": null, "order": null, "root": true }}, "presentation": {"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {"lang": {"en-us": {"role": {"totalLabel": "Fair value of assets and liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." }}, "auth ref": "r50" }}, "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": {"http://www.innovage.com/role/Business": {"lang": {"en-us": {"role": {"terseLabel": "Business", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). }}, "auth ref": {"r77", "r118", "r119" }}, "innv:CapitationRevenueMember": {"xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "CapitationRevenueMember", "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": {"http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Capitation revenue", "label": "Capitation revenue", "documentation": "Represents information pertaining to capitation revenue." }}, "auth ref": "r11" }, "us-gaap:CashAndCashEquivalentsAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap:AssetsCurrent", "weight": 1.0, "order": 5.0 }}, "presentation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." }}, "auth ref": {"r21", "r200", "r844" }}, "us-gaap:CashAndCashEquivalentsFairValueDisclosure": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": {"http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }}, "auth ref": {"r171", "r172" }}, "us-gaap:CashAndCashEquivalentsPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": {"http://www.innovage.com/role/SummaryofSignificantAccountingPolicies": {"lang": {"en-us": {"role": {"verboseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." }}, "auth ref": {"r22" }}, "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": {"http://www.innovage.com/role/SummaryofSignificantAccountingPolicies": {"lang": {"en-us": {"role": {"verboseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." }}, "auth ref": {"r22", "r143" }}, "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"periodStartLabel": "CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD", "periodEndLabel": "CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }}, "auth ref": {"r21", "r114", "r227" }}, "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": {"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": {"parentTag": null, "weight": null, "order": null, "root": true }}, "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "DECREASE IN CASH, CASH EQUIVALENTS & RESTRICTED CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }}, "auth ref": {"r3", "r114" }}, "us-gaap:CashMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": {"http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." }}, "auth ref": {"r200" }}, "ecd:ChangedPeerGroupFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]", "auth ref": {"r978" }}, "ecd:ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "auth ref": {"r975" }}, "ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "auth ref": {"r973" }}, "del:CityAreaCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/del/2024", "localname": "CityAreaCode", "presentation": {"http://www.innovage.com/role/Cover": {"lang": {"en-us": {"role": {"terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city", "auth ref": "r11", "ecd:CoSelectedMeasureAmt": {"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount", "auth ref": {"r979" }}, "ecd:CoSelectedMeasureName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name", "auth ref": {"r979" }}, "us-gaap:CommitmentsAndContingencies": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap:LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 }}, "presentation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Commitments and Contingencies (See Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." }}, "auth ref": {"r87", "r149", "r704", "r775" }}, "us-gaap:CommitmentsAndContingenciesDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": {"en-us": {"role": {"terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]", "auth ref": "r11", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock":

an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } "auth_ref": { "r92" } } } "us-gaap:CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheetsParentetical", "http://www.innovage.com/role/ConsolidatedStatementofStockholdersEquity" } } } "lang": { "en-us" } } "role": { "terseLabel": "Common stock outstanding (in shares)", "periodStartLabel": "Beginning, balances (in shares)", "periodEndLabel": "Ending, balances (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } "auth_ref": { "r10", "r92", "r776", "r794", "r1236", "r1237" } } } "us-gaap:CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 2.0 } } } "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us" } } "role": { "terseLabel": "Common stock, \$0.001 par value: 500,000,000 authorized as of June100a030, 2024 and 2023; 136,152,858 issued and 136,116,299 outstanding as of June 30, 2024 and 135,639,845 issued and outstanding as of June100a030, 2023." } } } "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock for common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } "auth_ref": { "r92", "r705", "r906" } } } "ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us" } } "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } } "auth_ref": { "r984" } } } "ecd:CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us" } } "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } } "auth_ref": { "r983" } } } "ecd:CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us" } } "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } } "auth_ref": { "r985" } } } "ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us" } } "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } } "auth_ref": { "r982" } } } "us-gaap:CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us" } } "role": { "verboseLabel": "Stock-based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } } "auth_ref": { "r132", "r135" } } } "us-gaap:ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us" } } "role": { "verboseLabel": "Deferred tax assets", "label": "Components of Deferred Tax Assets [Abstract]" } } } "auth_ref": { "r1" } } } "us-gaap:ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us" } } "role": { "verboseLabel": "Deferred tax liabilities", "label": "Components of Deferred Tax Liabilities [Abstract]" } } } "auth_ref": { "r1" } } } "us-gaap:ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails": { "lang": { "en-us" } } "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } } "auth_ref": { "r26", "r27", "r70", "r71", "r297", "r835" } } } "us-gaap:ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails": { "lang": { "en-us" } } "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } } "auth_ref": { "r26", "r27", "r70", "r71", "r297", "r750", "r835" } } } "us-gaap:ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails": { "lang": { "en-us" } } "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } } "auth_ref": { "r26", "r27", "r70", "r71", "r297", "r835", "r1026" } } } "us-gaap:ConcentrationRiskPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails": { "lang": { "en-us" } } "role": { "verboseLabel": "Risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the 'benchmark' for denominator) in the equation, this concept represents the concentration percentage derived from the division." } } } "auth_ref": { "r26", "r27", "r70", "r71", "r297" } } } "us-gaap:ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails": { "lang": { "en-us" } } "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } } "auth_ref": { "r26", "r27", "r70", "r71", "r297", "r835" } } } "innv:ConcertoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "ConcertoMember", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsByAcquisitionDetails": { "lang": { "en-us" } } "role": { "terseLabel": "Concerto", "label": "Concerto [Member]", "documentation": "Concerto" } } } "auth_ref": { "r1" } } } "srt:ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": { "http://www.innovage.com/role/ConsolidatedEntitiesDomain": { "http://www.innovage.com/role/ConsolidatedEntitiesDetails": { "lang": { "en-us" } } "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } } "auth_ref": { "r176", "r188", "r236", "r572", "r573", "r576", "r577", "r654", "r837", "r1037", "r1038", "r1039", "r1115", "r1118", "r1119" } } } "srt:ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": { "http://www.innovage.com/role/ConsolidatedEntitiesDetails": { "http://www.innovage.com/role/ConsolidatedEntitiesDetails": { "lang": { "en-us" } } "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } } "auth_ref": { "r176", "r188", "r236", "r572", "r573", "r576", "r577", "r654", "r837", "r1037", "r1038", "r1039", "r1115", "r1118", "r1119" } } } "us-gaap:ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us" } } "role": { "terseLabel": "Basis of Preparation and Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } } "auth_ref": { "r58", "r850" } } } "us-gaap:ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us" } } "role": { "verboseLabel": "Variable Interest Entities (VIE)", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity: the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors

limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments." } } } ,
"auth_ref": { "http://www.innovage.com/role/InvestmentImpairmentLoss", "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname":
"CostMethodInvestmentImpairmentLoss", "crdr": "debit", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails",
"http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesInvestmentsDetails", "lang": "en-us", "role": "verboseLabel", "Impairment loss in investments",
"terseLabel": "Cost method investment impairment losses", "label": "Cost Method Investment Impairment Loss", "documentation": "Cost Method Investment Impairment
Loss" } } } , "auth_ref": { "http://www.innovage.com/role/InvestmentMaximumExposureToLoss", "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630",
"localname": "CostMethodInvestmentMaximumExposureToLoss", "crdr": "credit", "presentation": {
"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Maximum exposure to loss of the cost method
investments", "label": "Cost Method Investment Maximum Exposure to Loss", "documentation": "The amount of maximum exposure to loss under the cost method
investments" } } } , "auth_ref": { "http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsByReportableSegmentsDetails", "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630",
"localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsByReportableSegmentsDetails", "parentTag": "us-
gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 1.0 } } , "presentation": {
"http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsByReportableSegmentsDetails", "lang": "en-us", "role": "terseLabel": "Depreciation and
amortization", "label": "Cost, Depreciation and Amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful
lives directly used in production of good and rendering of service." } } } , "auth_ref": { "http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsByReportableSegmentsDetails", "xbrltype":
"monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "CostOfGoodsAndServicesSoldOverhead", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsByReportableSegmentsDetails", "parentTag": "us-
gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 } } , "presentation": {
"http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsByReportableSegmentsDetails", "lang": "en-us", "role": "verboseLabel": "Overhead costs",
"label": "Cost, Overhead", "documentation": "Indirect cost incurred related to good produced and service rendered." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype":
"us-gaap_CostOfGoodsProductLineMember", "domainItemType": "nsuri": "http://www.innovage.com/20240630", "localname": "CostOfGoodsProductLineMember",
"presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Cost of Goods and Service, Product and
Service Benchmark", "label": "Cost of Goods and Service, Product and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered from
specified product or service, when it serves as benchmark in concentration of risk calculation." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype":
"monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } } , "presentation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "totalLabel": "Total expenses", "label": "Costs and Expenses",
"documentation": "Total costs of sales and operating expenses for the period." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "stringItemType",
"nsuri": "http://www.innovage.com/20240630", "localname": "CounterpartyNameAxis", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails",
"lang": "en-us", "role": "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A
counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "stringItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "CoverAbstract", "lang": "en-us", "role": "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover
page." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "CreditAgreement2021CreditFacilityMember",
"presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "terseLabel":
"2021 Credit Agreement", "label": "2021 Credit Agreement", "documentation": "Represents information pertaining to 2021 credit agreement." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "stringItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "CreditFacilityAxis", "presentation": {
"http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]",
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } } ,
"auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "CurrentFederalTaxExpenseBenefitAbstract",
"presentation": { "http://www.innovage.com/role/IncomeTaxExpenseBenefitAbstract", "lang": "en-us", "role": "terseLabel": "Current Federal Tax Expense (Benefit)", "label": "Current Federal Tax Expense (Benefit)",
"documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations.
Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "monetaryItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/IncomeTaxExpenseBenefitAbstract", "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": -1.0, "order":
1.0 } } , "presentation": { "http://www.innovage.com/role/IncomeTaxExpenseBenefitAbstract", "lang": "en-us", "role": "verboseLabel": "Federal",
"label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations.
Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "monetaryItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/IncomeTaxExpenseBenefitAbstract", "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": -1.0, "order": 1.0 } } ,
"presentation": { "http://www.innovage.com/role/IncomeTaxExpenseBenefitAbstract", "lang": "en-us", "role": "totalLabel": "Total current tax
expense", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from
continuing operations." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "monetaryItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/IncomeTaxExpenseBenefitAbstract", "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": -1.0, "order": 2.0 } } ,
"presentation": { "http://www.innovage.com/role/IncomeTaxExpenseBenefitAbstract", "lang": "en-us", "role": "verboseLabel": "State",
"label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from
continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } } ,
"auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "CustomerConcentrationRiskMember",
"presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails",
"http://www.innovage.com/role/RevenueRecognitionScheduleOfConcentrationOfNetReceivableDetails",
"http://www.innovage.com/role/RevenueRecognitionScheduleOfSourceOfRevenueDetails", "lang": "en-us", "role": "terseLabel": "Customer Concentration Risk", "label":
"Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues,
as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } } ,
"auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "stringItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DebtDisclosureAbstract",
"presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]",
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable,
commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying
arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or
not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt
covenants." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "textBlockItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DebtDisclosureTextBlock",
"presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "verboseLabel": "Long-term Debt", "label": "Debt Disclosure Text Block",
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable,
commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying
arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or
not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt
covenants." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "monetaryItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": {
"http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Total debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium
and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated
debt and other types of debt." } } } , "auth_ref": { "http://www.innovage.com/20240630", "xbrltype": "monetaryItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails",
"lang": "en-us", "role": "terseLabel": "Loan amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of
issuance." } } } , "auth_ref": { "http://www.innovage.com/2

"http://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": { "r15", "r39", "r40", "r75", "r129", "r130", "r236", "r409", "r410", "r411", "r412", "r413", "r415", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r433", "r867", "r868", "r869", "r870", "r871", "r904", "r1060", "r1179", "r1181" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": { "http://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Less unamortized debt issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": { "r420", "r436", "r621", "r622", "r623", "r868", "r869", "r904" }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Debt Issuance Costs", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": { "r7" } }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": { "r1062", "r1163", "r1164" } }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Deferred", "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": { "r5", "r172", "r1062" } }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": { "r88", "r89", "r147", "r544" } }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability, net", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": { "r527", "r528", "r702" } }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": { "r117" } }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": { "r1062", "r1163", "r1164" } }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetInterestCarryforward", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Deferred Tax Asset, Interest Carryforward", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward." } } }, "auth_ref": { "r1161" } }, "innv_DeferredTaxAssetLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxAssetLeaseLiability", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Deferred Tax Asset, Lease Liability", "documentation": "Deferred Tax Asset, Lease Liability" } } }, "auth_ref": { "r1161" } }, "innv_DeferredTaxAssetsAccruedBonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxAssetsAccruedBonuses", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued bonuses", "label": "Deferred Tax Assets, Accrued Bonuses", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible accrued bonuses." } } }, "auth_ref": { "r1161" } }, "innv_DeferredTaxAssetsAccruedVacation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxAssetsAccruedVacation", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued vacation", "label": "Deferred Tax Assets, Accrued Vacation", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible accrued vacation." } } }, "auth_ref": { "r1161" } }, "innv_DeferredTaxAssetsAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxAssetsAmortization", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Deferred Tax Assets, Amortization", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible amortization." } } }, "auth_ref": { "r1161" } }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": { "r545" } }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, net of valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": { "r1157" } }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Federal net operating losses", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": { "r1161" } }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "State net operating losses", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": { "r1161" } }, "innv_DeferredTaxAssetsReportedAndEstimatedClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxAssetsReportedAndEstimatedClaims", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reported and estimated claims", "label": "Deferred Tax Assets, Reported and Estimated Claims", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible reported and estimated claims." } } }, "auth_ref": { "r1161" } }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": { "r1161" } }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Provision for uncollectible accounts", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r1161" } }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": {

"http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails", "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "verboseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": { "r546" }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Net deferred tax liability", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": { "r1157" }, "innv_DeferredTaxLiabilitiesDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxLiabilitiesDepreciation", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": -1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Depreciation", "label": "Deferred Tax Liabilities, Depreciation", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from depreciation." } } }, "auth_ref": { }, "innv_DeferredTaxLiabilitiesEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxLiabilitiesEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Equity investment", "label": "Deferred Tax Liabilities, Equity Method Investments", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from equity investment." } } }, "auth_ref": { }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Goodwill", "label": "Deferred Tax Liabilities, Goodwill", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill." } } }, "auth_ref": { "r53", "r54", "r1161" }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": -1.0, "order": 6.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": { "r1161" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": -1.0, "order": 4.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Deferred Tax Liabilities, Prepaid Expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": { "r1161" }, "innv_DeferredTaxLiabilitiesRightsOfUseOfAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DeferredTaxLiabilitiesRightsOfUseOfAsset", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": -1.0, "order": 5.0 }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "ROU asset", "label": "Deferred Tax Liabilities Rights of Use of Asset", "documentation": "Deferred Tax Liabilities Rights of Use of Asset" } } }, "auth_ref": { }, "innv_DepositsAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DepositsAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": -1.0, "order": 4.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "verboseLabel": "Deposits and other", "terseLabel": "Deposits and other, net", "label": "Deposits and Other Assets, Noncurrent", "documentation": "The amount of non current portion of deposits and other assets as at the end of the reporting period." } } }, "auth_ref": { }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r5", "r35" }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 5.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": { "r5", "r263", "r274", "r291", "r859", "r859" }, "innv_DepreciationDepletionAndAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DepreciationDepletionAndAmortizationMember", "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization [Member]", "documentation": "Depreciation, Depletion and Amortization" } } }, "auth_ref": { }, "us-gaap_DirectOperatingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectOperatingCosts", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Cost of care, excluding depreciation and amortization", "label": "Direct Operating Costs", "documentation": "The aggregate direct operating costs incurred during the reporting period." } } }, "auth_ref": { "r103" }, "innv_DirectOperatingCostsAndGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DirectOperatingCostsAndGeneralAndAdministrativeExpenseMember", "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cost of care excluding depreciation and amortization and Corporate, general and administrative", "label": "Direct Operating Costs and General and Administrative Expense [Member]", "documentation": "Direct Operating Costs and General and Administrative Expense" } } }, "auth_ref": { }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r473", "r873", "r874", "r875", "r876", "r877", "r878", "r879" }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r473", "r873", "r874", "r875", "r876", "r877", "r878", "r879" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": { "http://www.innovage.com/role/RevenueRecognitionTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Source of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r1124" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.innovage.com/role/StockbasedCompensation": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r485", "r488", "r516", "r517", "r519", "r886" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": { }, "innv_DispatchHealthHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DispatchHealthHoldingsIncMember", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Dispatch Health Holdings, Inc.", "label": "Dispatch Health Holdings, Inc.", "documentation": "Represents information pertaining to Dispatch Health Holdings, Inc." } } }, "auth_ref": { }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": { "r932", "r933", "r945" }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction Flag", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": { "r932", "r933", "r945", "r988" }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { }, "dei_DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r966" }, "dei_DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": {

"http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.' } } }, "auth_ref": { "dei_DocumentsIncorporatedByReferenceTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": { "r930"/, "us-gaap_DomesticCountryMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": { "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Domestic Tax Authority", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": { "r530"/, "innv_DueToStateAndFederalHealthPrograms", "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "DueToStateAndFederalHealthPrograms", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets"/, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets"/, "lang": { "en-us": { "role": { "terseLabel": "Due to Medicaid and Medicare", "label": "Due to State and Federal Health Programs", "documentation": "Amounts payable to state and federal health programs such as Medicare and Medicaid." } } }, "auth_ref": { "r570", "r587", "r588", "r697", "r717", "r851"/, "us-gaap_EarningsPerShareDiluted", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdNtOthrrsRfctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"/, "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r977"/, "us-gaap_EarningsPerShareAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r217", "r242", "r243", "r244", "r245", "r246", "r247", "r252", "r254", "r256", "r257", "r258", "r262", "r564", "r570", "r587", "r588", "r697", "r717", "r851"/, "us-gaap_EarningsPerShareTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfOperations"/, "http://www.innovage.com/role/EarningsperShareDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Net loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r217", "r242", "r243", "r244", "r245", "r246", "r247", "r254", "r256", "r257", "r258", "r262", "r564", "r570", "r587", "r588", "r697", "r717", "r851"/, "us-gaap_EarningsPerShareTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.innovage.com/role/EarningsperShare"/, "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r251", "r259", "r260", "r261"/, "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": { "http://www.innovage.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate (as a percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r530", "r690"/, "innv_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPaid", "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPaid", "crdr": "debit", "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Nondeductible compensation paid", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Paid", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible compensation paid." } } }, "auth_ref": { "r518"/, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails"/, "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails"/, "http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails"/, "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDfnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r518"/, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails"/, "http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails"/, "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r1153"/, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails"/, "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": { "r1153"/, "us-gaap_EmployeeStockOptionMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"/, "http://xbrl.sec.gov/ecd/index/AwardTimingDisclosure"/, "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { "dei_EntityAddressAddressLine1", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { "dei_EntityAddressAddressLine2", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { "dei_EntityAddressCityOrTown", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { "dei_EntityAddressPostalZipCode", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { "dei_EntityAddressStateOrProvince", "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { "dei_EntityCentralIndexKey", "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "dei_EntityCommonStockSharesOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { "dei_EntityCurrentReportingStatus", "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityDomain", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails"/, "http://www.innovage.com/role/RelatedPartiesDetails"/, "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { "dei_EntityEmergingGrowthCompany", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "dei_EntityExTransitionPeriod", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": { "dei_EntityFileNumber", "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory", "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityIncorporationStateCountryCode", "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.innovage.com/role/Cover"/, "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or

[illegible]

fair value hierarchy and fair value measured at net asset value per share as practical expedient. } } } , "auth_ref": { "r422", "r477", "r478", "r479", "r480", "r481", "r482", "r589", "r590", "r591", "r592", "r593", "r602", "r603", "r605", "r660", "r661", "r662", "r688", "r689", "r880", "r881", "r882", "r893", "r897" } } , "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } } , "auth_ref": { } } , "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } } , "auth_ref": { "r422", "r477", "r482", "r590", "r603", "r660", "r880", "r881", "r882", "r893" } } } , "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reported information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "r594", "r595", "r596", "r597", "r598", "r599" } } } , "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } } , "auth_ref": { "r594", "r595", "r596", "r597", "r598", "r599", "r604" } } } } , "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } } , "auth_ref": { } } } , "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } } , "auth_ref": { "r422", "r477", "r478", "r479", "r480", "r481", "r482", "r589", "r590", "r591", "r592", "r593", "r602", "r603", "r605", "r660", "r661", "r662", "r688", "r689", "r880", "r881", "r882", "r893", "r897" } } } , "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } } , "auth_ref": { "r631", "r635", "r905" } } } } , "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance Lease", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } } , "auth_ref": { } } } , "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "innv_LeaseLiability", "weight": 1.0, "order": 1.0 } } , "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } } , "auth_ref": { "r629", "r642" } } } , "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } } , "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } } } , "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Current portion of finance lease obligations", "verboseLabel": "Less: Current lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } } , "auth_ref": { "r629" } } } } } , "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.innovage.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Maturities of Lease Payments for Finance Leases", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } } , "auth_ref": { "r1184" } } } } , "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } } , "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } } } , "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance lease obligations", "verboseLabel": "Total long-term lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } } , "auth_ref": { "r629" } } } } } , "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } } , "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails_2": { "parentTag": "innv_LeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } } , "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } } } , "presentation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } , "auth_ref": { "r642" } } } , "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } } , "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } , "auth_ref": { "r642" } } } , "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } } , "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } , "auth_ref": { "r642" } } } , "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } } , "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel":


```

2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r642", "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "innv_LeaseLiabilityUndiscountedExcessAmount", "weight": 1.0, "order": 2.0 }, "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Less liability accretion / imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "auth_ref": "r642", "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Payments for finance lease obligations", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease.", "auth_ref": "r632", "r639", "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "innv_RightOfUseAsset", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance lease assets", "label": "Finance Lease, Right of Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "auth_ref": "r629", "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization of leased assets", "label": "Finance Lease, Right of Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "auth_ref": "r631", "r635", "r905", "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right of Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right of Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "auth_ref": "r630", "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.innovage.com/role/LeasesScheduleofWeightedAverageLeaseTermsandDiscountRatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "auth_ref": "r641", "r905", "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.innovage.com/role/LeasesScheduleofWeightedAverageLeaseTermsandDiscountRatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": "r640", "r905", "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument.", "auth_ref": "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r340", "r341", "r345", "r346", "r347", "r348", "r349", "r350", "r433", "r450", "r584", "r610", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r674", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r716", "r864", "r893", "r895", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r907", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1079", "r1080", "r1081", "r1082", "r1170", "r1173", "r1174", "r1175", "r1176", "r1177", "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesGoodwillandIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, useful life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "auth_ref": "r376", "r840", "r866", "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "auth_ref": "r203", "r353", "r374", "r866", "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofExpectedFutureAnnualAmortizationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r376", "r840", "r866", "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofExpectedFutureAnnualAmortizationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r376", "r840", "r866", "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofExpectedFutureAnnualAmortizationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r376", "r840", "r866", "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofExpectedFutureAnnualAmortizationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r376", "r840", "r866", "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofExpectedFutureAnnualAmortizationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r376", "r840", "r866", "us-gaap
```

"http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } },
"presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of assets", "label":
"Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment,
intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": { "r1057" } }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Corporate, general and administrative", "label": "General
and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting
entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r105", "r798" } }, "us-
gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": -1.0, "order": 1.0 },
"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": "http://www.innovage.com/role/ConsolidatedBalanceSheets",
"http://www.innovage.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
"http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofChangesinGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel":
"Balance as of beginning of period", "periodEndLabel": "Balance as of end of period", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of
asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually
identified and separately recognized." } } }, "auth_ref": { "r202", "r355", "r696", "r859", "r865", "r894", "r906", "r1087", "r1094" } }, "us-gaap_GoodwillAcquiredDuringPeriod": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": {
"http://www.innovage.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
"http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofChangesinGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired during the
period", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired
in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": { "r359", "r865" } }, "us-
gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and
Intangible Assets Disclosure [Abstract]", "auth_ref": { "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": {
"http://www.innovage.com/role/GoodwillandIntangibleAssets": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible
Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": { "r1085", "r1097" } }, "us-
gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role":
{ "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting
policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is
allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": { "r354", "r366", "r865" } }, "us-gaap_GoodwillImpairmentLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": {
"http://www.innovage.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
"http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesGoodwillandIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Goodwill,
impairment charges", "terseLabel": "Impairment of goodwill", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing
future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately
recognized." } } }, "auth_ref": { "r5", "r356", "r362", "r366", "r865", "r894" } }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-
gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0, "order": 4.0 } }, "presentation": {
"http://www.innovage.com/role/AcquisitionsNarrativeDetails": "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "lang": {
"en-us": { "role": { "negatedLabel": "Measurement period adjustments, goodwill", "terseLabel": "Measurement period adjustments, goodwill", "label": "Goodwill, Measurement
Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other
asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": { "r0", "r1093"
} }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": {
"http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofChangesinGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]",
"label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": {
"us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": {
"http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "parentTag": "us-
gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Center-Level
Contribution Margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the
revenue generation activity." } } }, "auth_ref": { "r100", "r103", "r159", "r230", "r336", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r614", "r853",
"r858", "r1069", "r1071", "r1072", "r1073", "r1074", "r1116" } }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "IcfrAuditorAttestationFlag", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag",
"label": "ICFR Auditor Attestation Flag", "auth_ref": { "us-gaap_ImpairmentOfIntangibleAssetsFiniteLived": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFiniteLived", "crdr": "debit", "presentation": {
"http://www.innovage.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
"http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesGoodwillandIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Intangible
assets, impairment charges", "terseLabel": "Intangible asset impairments", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of
impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": { "r368",
"r1057", "r1101" } }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 },
"http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfOperations",
"http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Loss Before Income
Taxes", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "documentation": "Amount, before tax, of income (loss) including
portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method
investments." } } }, "auth_ref": { "r101", "r1051" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]", "auth_ref": { "us-
gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
"http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of
Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": {
"r380", "r387", "r388", "r595", "r599", "r604", "r741", "r743", "r803", "r840", "r896", "r1199" } }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
"http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of
Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r387", "r388",
"r595", "r599", "r604", "r741", "r743", "r803", "r840", "r896", "r1199" } }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": { "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": { "r226",
"r530", "r531", "r540", "r549", "r890", "r1160" } }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxAuthorityDomain", "presentation": { "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Income Tax Authority [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": { "r226", "r530", "r531", "r540",
"r549", "r890", "r1160" } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]", "auth_ref": {
"us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock",
"presentation": { "http://www.innovage.com/role/IncomeTaxes": { "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]",
"documentation": "The entire disclosure for income tax." } } }, "auth_ref": { "r231", "r523", "r530", "r537", "r538", "r539", "r542", "r548", "r555", "r557", "r558", "r559",
"r758", "r890" } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit",
"crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 },
"http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true },
"http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails",
"http://www.innovage.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Provision (Benefit) for Income Taxes",
"totalLabel": "Provision (benefit) for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred
income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r164", "r173", "r249", "r250", "r263", "r277", "r291", "r329", "r530", "r556", "r719",
"r890" } }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock",
"presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label":
"Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and
measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and
other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } },
"auth_ref": { "r213", "r523", "r526", "r542", "r543", "r547", "r551", "r755" } }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr":
"debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-
gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Change in valuation
allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference
between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax

income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. } } }, "auth_ref": { "r534", "r890", "r1154" } }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": { "r530", "r890" } }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "IRC Section 162(m) limitation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": { "r535", "r536", "r1154" } }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Permanent adjustments", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": { "r890", "r1154", "r1156" } }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Prior year true-up and other", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": { "r1154", "r1155" } }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "State tax", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": { "r533", "r890", "r1154" } }, "us-gaap_IncomeTaxReconciliationTaxExemptIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxExemptIncome", "crdr": "credit", "calculation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Income from entities not subject to taxation", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes." } } }, "auth_ref": { "r535", "r536", "r1154" } }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": { "r23", "r116", "r1058", "r1158", "r1159" } }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Income tax receivable", "label": "Income Taxes Receivable, Current", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": { "r144", "r1048" } }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r841" } }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Deposits and other", "label": "Increase (Decrease) in Deposit Assets", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } }, "auth_ref": { "r44" } }, "imv_IncreaseDecreaseInDueToStateAndFederalHealthPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "IncreaseDecreaseInDueToStateAndFederalHealthPrograms", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Due to Medicaid and Medicare", "label": "Increase (Decrease) in Due to State and Federal Health Programs", "documentation": "The increase (decrease) during the reporting period in the amounts of due to Medicaid and Medicare." } } }, "auth_ref": { "I", "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Income tax receivable", "label": "Increase (Decrease) in Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of acquisitions", "label": "Increase (Decrease) in Operating Assets [Abstract]", "documentation": "The increase (decrease) during the reporting period in amounts of operating assets and liabilities, net of acquisitions." } } }, "auth_ref": { "I", "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": { "r1028", "r1056" } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": { "r4" } }, "imv_IncreaseDecreaseInReportedAndEstimatedClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "IncreaseDecreaseInReportedAndEstimatedClaims", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Reported and estimated claims", "label": "Increase (Decrease) in Reported and Estimated Claims", "documentation": "The increase (decrease) during the reporting period in the amounts of reported and estimated claims." } } }, "auth_ref": { "I", "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "I", "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interests (Temporary Equity)", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "I", "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails": { "lang": { "en-us": { "role": {

```

verboseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": { "r353", "r377", "r866" } }, "ecd_individualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us" }, "role": { "terseLabel": "Individual", "label": "Individual [Axis]" } } }, "auth_ref": { "r42", "r53", "r63", "r87", "r96", "r100", "r108" } }, "innv_innovAgeFloridaPACEOrlandoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "InnovAgeFloridaPACEOrlandoMember", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "Orlando Health", "label": "InnovAge Florida PACE w/2013 Orlando [Member]", "documentation": "InnovAge Florida PACE w/2013 Orlando" } } }, "auth_ref": { "r11", "innv_innovAgeSacramentoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "InnovAgeSacramentoMember", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "InnovAge Sacramento", "label": "InnovAge Sacramento", "documentation": "Represents information relating to InnovAge Sacramento." } } }, "auth_ref": { "ecd_insiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us" }, "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": { "r1006" } }, "ecd_insiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us" }, "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": { "r934", "r1012" } }, "ecd_insiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" } }, "lang": { "en-us" }, "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r934", "r1012" } }, "ecd_insiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" } }, "lang": { "en-us" }, "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r934", "r1012" } }, "us_gaap_intangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails" } }, "lang": { "en-us" }, "role": { "totalLabel": "Total intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": { "r202" } }, "us_gaap_intangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails" } }, "lang": { "en-us" }, "role": { "totalLabel": "Balance as of end of period", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": { "r367", "r1098", "r1100" } }, "us_gaap_intangibleAssetsNetIncludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwillAbstract", "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "Intangible Assets, Net (Including Goodwill) [Abstract]", "label": "Intangible Assets, Net (Including Goodwill) [Abstract]" } } }, "auth_ref": { "r11", "us_gaap_interestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": { "r13" } }, "us_gaap_interestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations" } }, "lang": { "en-us" }, "role": { "terseLabel": "Interest expense, net", "label": "Interest expense, net", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": { "r858", "r1055", "r1071" } }, "us_gaap_interestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows" } }, "lang": { "en-us" }, "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r221", "r224", "r225" } }, "us_gaap_investmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsTables" } }, "lang": { "en-us" }, "role": { "terseLabel": "Schedule of Equity Method and Cost Method Investments", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": { "r1229", "r1230", "r1231", "r1232", "r1233", "r1234" } }, "us_gaap_investmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies" } }, "lang": { "en-us" }, "role": { "verboseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": { "r718", "r751", "r752", "r753", "r754", "r827", "r828" } }, "us_gaap_investmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us" }, "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": { "r11", "us_gaap_investmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestments" } }, "lang": { "en-us" }, "role": { "verboseLabel": "Cost and Equity Method Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": { "r156", "r175", "r300", "r301", "r611", "r612", "r1194" } }, "innv_jetdocInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "JetdocInc.Member", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "Jetdoc, Inc.", "label": "Jetdoc, Inc.", "documentation": "Represents information pertaining to Jetdoc, Inc." } } }, "auth_ref": { "r11", "innv_june2024RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "June2024RepurchaseProgramMember", "presentation": { "http://www.innovage.com/role/ShareRepurchaseProgramDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "June 2024 Repurchase Program", "label": "June 2024 Repurchase Program [Member]", "documentation": "June 2024 Repurchase Program" } } }, "auth_ref": { "r11", "us_gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Land", "crdr": "debit", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": { "r1043" } }, "us_gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": { "r1125" } }, "us_gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails" } }, "lang": { "en-us" }, "role": { "totalLabel": "Total lease expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": { "r634", "r905" } }, "us_gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails" } }, "lang": { "en-us" }, "role": { "terseLabel": "Component of Lease Cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": { "r11", "us_gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock",
```

"LeaseLiabilityPaymentsDueYearFive","crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityPaymentsDue","weight":1.0,"order":4.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"lang":{"en-us":{"role":{"totalLabel":"2029","label":"Lease Liability, Payments Due, Year Five"},"documentation":"Lease Liability, Payments Due, Year Five"}}},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"monetaryItemType","nsuri":{"http://www.innovage.com/20240630"},"localname":"LeaseLiabilityPaymentsDueYearFour"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityPaymentsDue","weight":1.0,"order":5.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"lang":{"en-us":{"role":{"totalLabel":"2028","label":"Lease Liability, Payments Due, Year Four"},"documentation":"Lease Liability, Payments Due, Year Four"}}},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"xbrltype":"monetaryItemType","nsuri":{"http://www.innovage.com/20240630"},"localname":"LeaseLiabilityPaymentsDueYearOne"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityPaymentsDue","weight":1.0,"order":6.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"lang":{"en-us":{"role":{"totalLabel":"2025","label":"Lease Liability, Payments Due, Year One"},"documentation":"Lease Liability, Payments Due, Year One"}}},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"xbrltype":"monetaryItemType","nsuri":{"http://www.innovage.com/20240630"},"localname":"LeaseLiabilityPaymentsDueYearThree"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityPaymentsDue","weight":1.0,"order":2.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"lang":{"en-us":{"role":{"totalLabel":"2027","label":"Lease Liability, Payments Due, Year Three"},"documentation":"Lease Liability, Payments Due, Year Three"}}},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"xbrltype":"monetaryItemType","nsuri":{"http://www.innovage.com/20240630"},"localname":"LeaseLiabilityPaymentsDueYearTwo"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityPaymentsDue","weight":1.0,"order":3.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"lang":{"en-us":{"role":{"totalLabel":"2026","label":"Lease Liability, Payments Due, Year Two"},"documentation":"Lease Liability, Payments Due, Year Two"}}},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"innv_LeaseLiabilityUndiscountedExcessAmount"},"xbrltype":"monetaryItemType","nsuri":{"http://www.innovage.com/20240630"},"localname":"LeaseLiabilityUndiscountedExcessAmount"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityPaymentsDue","weight":1.0,"order":1.0},"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"lang":{"en-us":{"role":{"negatedTotalLabel":"Less liability accretion / imputed interest"},"label":"Lease Liability Undiscounted Excess Amount"},"documentation":"Lease Liability Undiscounted Excess Amount"},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"LeasesAbstract"},"lang":{"en-us":{"role":{"terseLabel":"Leases [Abstract]"},"label":"Leases [Abstract]"},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"innv_LeasesWeightedAverageDiscountRateAbstract"},"xbrltype":"stringItemType","nsuri":{"http://www.innovage.com/20240630"},"localname":"LeasesWeightedAverageDiscountRateAbstract"},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"lang":{"en-us":{"role":{"terseLabel":"Weighted average discount rate"},"label":"Leases, Weighted Average Discount Rate [Abstract]"},"documentation":"Leases, Weighted Average Discount Rate"},"auth_ref":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"LegalEntityAxis"},"presentation":{"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails"},"http://www.innovage.com/role/RelatedPartiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Legal Entity [Axis]"},"label":"Legal Entity [Axis]"},"documentation":"The set of legal entities associated with a report"},"auth_ref":{"http://www.innovage.com/role/RelatedPartiesDetails":{"innv_LegalSettlementSettlementPeriod"},"xbrltype":"durationItemType","nsuri":{"http://www.innovage.com/20240630"},"localname":"LegalSettlementSettlementPeriod"},"presentation":{"http://www.innovage.com/role/CommitmentsandContingenciesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Legal settlement, settlement period"},"label":"Legal Settlement, Settlement Period"},"documentation":"Legal Settlement, Settlement Period"},"auth_ref":{"http://www.innovage.com/role/CommitmentsandContingenciesDetails":{"us-gaap_LesseeFinanceLeasesTextBlock"},"xbrltype":"textBlockItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeFinanceLeasesTextBlock"},"presentation":{"http://www.innovage.com/role/Leases"},"lang":{"en-us":{"role":{"terseLabel":"Leases"},"label":"Lessee, Finance Leases [Text Block]"},"documentation":"The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."},"auth_ref":{"r626"},"us-gaap_LesseeLeaseDescriptionLineItems":{"xbrltype":"stringItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeLeaseDescriptionLineItems"},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeaseCostDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lessee, Lease, Description [Line Items]"},"label":"Lessee, Lease, Description [Line Items]"},"documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."},"auth_ref":{"r633","r644"},"us-gaap_LesseeLeaseDescriptionTable":{"xbrltype":"stringItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeLeaseDescriptionTable"},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeaseCostDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lessee, Lease, Description [Table]"},"label":"Lessee, Lease, Description [Table]"},"documentation":"Disclosure of information about lessee's leases."},"auth_ref":{"r633","r644"},"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityMaturityTableTextBlock"},"presentation":{"http://www.innovage.com/role/LeasesTables"},"lang":{"en-us":{"role":{"terseLabel":"Schedule of Future Maturities of Lease Payments for Operating Leases"},"label":"Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]"},"documentation":"Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."},"auth_ref":{"r1184"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDue"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails_2"},"parentTag":"innv_LeaseLiabilityPaymentsDue","weight":1.0,"order":1.0},"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails_1"},"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total lease payments"},"label":"Lessee, Operating Lease, Liability, to be Paid"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":6.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Thereafter"},"label":"Lessee, Operating Lease, Liability, to be Paid, After Year Five"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityPaymentsDueYearOne","weight":1.0,"order":2.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2025"},"label":"Lessee, Operating Lease, Liability, to be Paid, Year One"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearFive"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":2.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2029"},"label":"Lessee, Operating Lease, Liability, to be Paid, Year Five"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearFour"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":3.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2028"},"label":"Lessee, Operating Lease, Liability, to be Paid, Year Four"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearThree"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":4.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2027"},"label":"Lessee, Operating Lease, Liability, to be Paid, Year Three"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":5.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2026"},"label":"Lessee, Operating Lease, Liability, to be Paid, Year Two"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearOne":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearOne"},"crdr":"credit","calculation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails":{"parentTag":"innv_LeaseLiabilityUndiscountedExcessAmount","weight":1.0,"order":1.0},"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails_1"},"parentTag":"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":1.0},"presentation":{"http://www.innovage.com/role/LeasesScheduleoffFutureMaturitiesofLeasePaymentsDetails"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Less liability accretion / imputed interest"},"label":"Lessee, Operating Lease, Liability, Undiscounted Excess Amount"},"documentation":"Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."},"auth_ref":{"r642"},"us-gaap_LesseeOperatingLeasesTextBlock":{"xbrltype":"textBlockItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LesseeOperatingLeasesTextBlock"},"presentation":{"http://www.innovage.com/role/Leases"},"lang":{"en-us":{"role":{"terseLabel":"Leases"},"label":"Lessee, Operating Leases [Text Block]"},"documentation":"The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."},"auth_ref":{"r626"},"us-gaap_Liabilities":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"Liabilities"},"crdr":"credit","calculation":{"http://www.innovage.com/role/ConsolidatedBalanceSheets"},"parentTag":"us-gaap_LiabilitiesAndStockholdersEquity","weight":1.0,"order":1.0},"presentation":{"http://www.innovage.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"totalLabel":"Total liabilities"},"label":"Liabilities"},"documentation":"Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."},"auth_ref":{"r15","r80","r81","r82","r85","r86","r87","r90","r230","r336","r399","r400","r401","r402","r403","r404","r405","r406","r407","r573","r576","r614","r774","r852","r927","r1116","r1186","r1187"},"us-gaap_LiabilitiesAbstract":{"xbrltype":"stringItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"LiabilitiesAbstract"},"presentation":{"http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Liabilities"},"label":"Liabilities [Abstract]"},"auth_ref":{"http://www.innovage.com/role/ConsolidatedBalanceSheets"},"crdr":"credit","calculation":{"http://www.innovage.com/role/ConsolidatedBalanceSheets"},"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.innovage.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"totalLabel":"Total liabilities"}}

and stockholders in 2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "auth_ref": "r98", "r151", "r708", "r906", "r1061", "r1084", "r1178", "us-gaap_LiabilitiesAndStockholdersEquityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]", "auth_ref": "r1", "us-gaap_LiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0, "presentation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "totalLabel", "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "auth_ref": "r82", "r199", "r230", "r336", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r573", "r576", "r577", "r614", "r1116", "r1186", "r1187", "us-gaap_LiabilitiesCurrentAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Current liabilities", "label": "Liabilities, Current [Abstract]", "auth_ref": "r1", "us-gaap_LiabilitiesNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": "http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetails", "lang": "en-us", "role": "terseLabel", "Noncurrent liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "auth_ref": "r15", "r85", "r86", "r87", "r90", "r230", "r336", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r573", "r576", "r577", "r614", "r1116", "r1186", "r1187", "us-gaap_LiabilitiesNoncurrentAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Noncurrent liabilities", "label": "Liabilities, Noncurrent [Abstract]", "auth_ref": "r1", "us-gaap_LimitedLiabilityCompanyLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LimitedLiabilityCompanyLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest", "presentation": "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Controlling membership interest", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest", "documentation": "Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP).", "auth_ref": "r25", "us-gaap_LimitedLiabilityCompanyLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LimitedLiabilityCompanyLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "presentation": "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Membership interest (as a percent)", "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest", "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).", "auth_ref": "r25", "us-gaap_LineOfCreditFacilityCommitmentFeePercentage", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "verboseLabel", "Revolving credit facility fee", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "auth_ref": "r1", "innv_LineOfCreditFacilityIssuedAmount", "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "LineOfCreditFacilityIssuedAmount", "crdr": "credit", "presentation": "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Letters of credit, issued amounts", "label": "Line Of Credit Facility Issued Amount", "documentation": "Issued amounts under letters of credit.", "auth_ref": "r1", "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "auth_ref": "r79", "r84", "r398", "us-gaap_LitigationSettlementAmountAwardedToOtherParty", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": "http://www.innovage.com/role/CommitmentsandContingenciesDetails", "lang": "en-us", "role": "terseLabel", "Settlement agreement amount subject to court approval", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "auth_ref": "r1", "us-gaap_LoansAndLeasesReceivableRelatedParties", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableRelatedParties", "crdr": "debit", "presentation": "http://www.innovage.com/role/RelatedPartiesDetails", "lang": "en-us", "role": "terseLabel", "Loans and leases receivable, related parties", "label": "Loans and Leases Receivable, Related Parties", "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.", "auth_ref": "r73", "r154", "dei_LocalPhoneNumber", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": "http://www.innovage.com/role/Govern", "lang": "en-us", "role": "terseLabel", "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity.", "auth_ref": "r1", "us-gaap_LongTermDebt", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "totalLabel", "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "auth_ref": "r15", "r148", "r421", "r437", "r868", "r869", "r904", "r1195", "us-gaap_LongTermDebtByMaturityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByMaturityAbstract", "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "terseLabel", "Long-term debt", "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "auth_ref": "r1", "us-gaap_LongTermDebtCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0, "presentation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "verboseLabel": "Less current maturities", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "auth_ref": "r206", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0, "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "terseLabel", "Thereafter", "label": "Long-Term Debt, Maturity, After Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r7", "r236", "r1121", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0, "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "terseLabel", "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r7", "r236", "r426", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0, "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "terseLabel", "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r7", "r236", "r426", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0, "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "terseLabel", "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r7", "r236", "r426", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0, "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "terseLabel", "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r7", "r236", "r426", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0, "presentation": "http://www.innovage.com/role/LongtermDebtScheduleofAggregateMaturitiesoftheTotalDebtOutstandingDetails", "lang": "en-us", "role": "terseLabel", "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r7", "r236", "r426", "us-gaap_LongTermDebtNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0, "presentation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetails", "http://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetails", "lang": "en-us", "role": "terseLabel", "Long-term debt, net of debt issuance costs", "verboseLabel": "Noncurrent maturities", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "auth_ref": "r207", "us-gaap_LongTermInvestments", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "calculation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0, "http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofEquityMethodandCostMethodInvestmentsDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.innovage.com/role/ConsolidatedBalanceSheets",

"http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofEquityMethodandCostMethodInvestmentsDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Investments", "totalLabel": "Total investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": { "r201" } }, "us-gaap-LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "http://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": { "r15", "r106", "r107", "r108" } }, "us-gaap-LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails", "http://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": { "r15", "r36", "r106", "r107", "r108" } }, "innv-LossContingencyPendingLitigationMotionToDismissResolutionNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "LossContingencyPendingLitigationMotionToDismissResolutionNoticePeriod", "presentation": { "http://www.innovage.com/role/CommitmentsandContingenciesDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Pending litigation, motion to dismiss resolution, notice period", "label": "Loss Contingency, Pending Litigation, Motion to Dismiss Resolution, Notice Period", "documentation": "Loss Contingency, Pending Litigation, Motion to Dismiss Resolution, Notice Period" } } }, "auth_ref": { "srt-MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": { "r297", "r875", "r909", "r914", "r1124", "r1198", "r1200", "r1201", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227" } }, "us-gaap-MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": { "r152", "r1045" } }, "innv-MarketableSecuritiesAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "MarketableSecuritiesAmortizedCost", "crdr": "debit", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Marketable Securities, Amortized Cost", "documentation": "Marketable Securities, Amortized Cost" } } }, "auth_ref": { "srt-MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails", "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": { "r177", "r178", "r179", "r180", "r181", "r192", "r193", "r393", "r394", "r395", "r396", "r484", "r521", "r593", "r692", "r740", "r742", "r749", "r766", "r767", "r826", "r829", "r830", "r831", "r832", "r838", "r839", "r863", "r872", "r883", "r897", "r898", "r902", "r903", "r910", "r1120", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193" } }, "ecd-MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]", "documentation": "Measure [Axis]", "auth_ref": { "r979" } }, "ecd-MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": { "r979" } }, "innv-MedicareCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "MedicareCustomerMember", "presentation": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Medicaid", "label": "Medicaid", "documentation": "Represents information pertaining to Medicaid customer." } } }, "auth_ref": { "srt-MedicareCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "MedicareCustomerMember", "presentation": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Medicare", "label": "Medicare", "documentation": "Represents information pertaining to Medicare customer." } } }, "auth_ref": { "srt-MedicarePartDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "MedicarePartDMember", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Medicare Part D", "label": "Medicare Part D", "documentation": "Represents the information pertaining to Medicare Part D." } } }, "auth_ref": { "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails", "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": { "r177", "r178", "r179", "r180", "r181", "r192", "r193", "r393", "r394", "r395", "r396", "r484", "r521", "r593", "r692", "r740", "r742", "r749", "r766", "r767", "r826", "r829", "r830", "r831", "r832", "r838", "r839", "r863", "r872", "r883", "r897", "r898", "r902", "r910", "r1120", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193" } }, "us-gaap-MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": { "r97", "r150", "r230", "r336", "r399", "r401", "r402", "r403", "r406", "r407", "r614", "r707", "r778" } }, "ecd-MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" |, "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "documentation": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": { "r999" } }, "us-gaap-MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": { "r1126" } }, "ecd-MtrTermsOfFrdArTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOfFrdArTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" |, "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]", "documentation": "Material Terms of Trading Arrangement" } } }, "auth_ref": { "r1007" } }, "us-gaap-MutualFundMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MutualFundMember", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Mutual funds", "label": "Mutual Fund [Member]", "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective." } } }, "auth_ref": { "r1126" } }, "srt-NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleofSourceofRevenueDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": { "r297", "r875", "r909", "r914", "r1124", "r1198", "r1200", "r1201", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227" } }, "ecd-NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]", "documentation": "Named Executive Officers, Footnote" } } }, "auth_ref": { "r980" } }, "us-gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows" |, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r223" } }, "us-gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows" |, "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "documentation": "Net Cash Provided by (Used in) Financing Activities" } } }, "auth_ref": { "srt-NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows" |, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r223" } }, "us-gaap-NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows" |, "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "documentation": "Net Cash Provided by (Used in) Operating Activities" } } }, "auth_ref": { "srt-NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows" |, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r114", "r115", "r117" } }, "us-gaap-NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows" |, "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "documentation": "Net Cash Provided by (Used in) Operating Activities" } } }, "auth_ref": { "srt-NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations" |, "lang": { "en-us": { "role": { "totalLabel": "Net Loss Attributable to Innovag Holding Corp.", "label": "Net Loss Attributable to Innovag Holding Corp.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r104", "r117", "r155", "r197", "r211", "r212", "r216", "r230", "r240", "r242", "r243", "r244", "r245", "r246", "r249", "r250", "r255", "r336", "r399", "r400", "r401", "r402",

"r403","r404","r405","r406","r407","r564","r570","r588","r614","r714","r796","r816","r817","r925","r1116"}}, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": {"parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0}}, "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": {"lang": {"en-us": {"role": {"verboseLabel": "Less: net loss attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."}}, "auth_ref": {"r69", "r140", "r211", "r212", "r246", "r249", "r250", "r713", "r1051"}}, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "calculation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"parentTag": "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "weight": -1.0, "order": 2.0}}, "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"lang": {"en-us": {"role": {"terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest."}}, "auth_ref": {"r102"}}, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "crdr": "credit", "calculation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"lang": {"en-us": {"role": {"totalLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity."}}, "auth_ref": {"r16", "r140", "r141"}}, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": {"http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesPolicies": {"lang": {"en-us": {"role": {"terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"innv_NicoleDAmatoMember": {"xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "NicoleDAmatoMember", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"label": "Nicole Diu2019Amato [Member]", "documentation": "Nicole Diu2019Amato"}}, "auth_ref": {"ecd_NonGaapMeasureDescriptionTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"ecd_NonNeosMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": {"http://xbrl.sec.gov/ecd/role/ExtCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"ecd_NonPeoNeoAvgCompActuallyPaidAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-PEO-NEO Average Compensation Actually Paid Amount", "label": "Non-PEO-NEO Average Compensation Actually Paid Amount", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"ecd_NonPeoNeoAvgTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-PEO-NEO Average Total Compensation Amount", "label": "Non-PEO-NEO Average Total Compensation Amount", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"ecd_NonPeoNeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-PEO-NEO", "label": "Non-PEO-NEO [Member]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"ecd_NonRule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"ecd_NonRule10b51ArrTrmmtDFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmmtDFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, "auth_ref": {"us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"lang": {"en-us": {"role": {"terseLabel": "Contribution from joint venture partner", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders."}}, "auth_ref": {"us-gaap_NoncontrollingInterestMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"lang": {"en-us": {"role": {"terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."}}, "auth_ref": {"us-gaap_NonoperatingIncomeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": {"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": {"parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 1.0}}, "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": {"lang": {"en-us": {"role": {"totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."}}, "auth_ref": {"innv_NumberOfAcquisitionResultingInGoodwill": {"xbrltype": "integerItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "NumberOfAcquisitionResultingInGoodwill", "presentation": {"http://www.innovage.com/role/GoodwillAndIntangibleAssetsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of acquisition resulting in goodwill", "label": "Number of Acquisition Resulting In Goodwill", "documentation": "Number of Acquisition Resulting In Goodwill"}}, "auth_ref": {"innv_NumberOfCentersExcludingNonConsolidatingJointVentures": {"xbrltype": "integerItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "NumberOfCentersExcludingNonConsolidatingJointVentures", "presentation": {"http://www.innovage.com/role/BusinessDetails": {"http://www.innovage.com/role/SegmentReportingNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of PACE centers excluding non-consolidating joint ventures", "label": "Number of Centers Excluding Non-consolidating Joint Ventures", "documentation": "Represents information pertaining to number of centers excluding non-consolidating joint ventures."}}, "auth_ref": {"innv_NumberOfGeographicDivisions": {"xbrltype": "integerItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "NumberOfGeographicDivisions", "presentation": {"http://www.innovage.com/role/SegmentReportingNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of geographic divisions", "label": "Number of Geographic Divisions", "documentation": "Number of geographic divisions."}}, "auth_ref": {"innv_NumberOfInvestmentsAccountedUnderCostMethod": {"xbrltype": "integerItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "NumberOfInvestmentsAccountedUnderCostMethod", "presentation": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of investments", "label": "Number of Investments Accounted Under Cost Method", "documentation": "The number of investments held by company which are accounted under cost method."}}, "auth_ref": {"innv_NumberOfOfficersHighestCompensationPaid": {"xbrltype": "integerItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "NumberOfOfficersHighestCompensationPaid", "presentation": {"http://www.innovage.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxReconciliationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Highest compensation paid, officers", "label": "Number of Officers, Highest Compensation Paid", "documentation": "The number of officers whom highest compensation paid."}}, "auth_ref": {"us-gaap_NumberOfOperatingSegments": {"xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": {"http://www.innovage.com/role/SegmentReportingNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."}}, "auth_ref": {"innv_NumberOfParticipants": {"xbrltype": "integerItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "NumberOfParticipants", "presentation": {"http://www.innovage.com/role/BusinessDetails": {"http://www.innovage.com/role/SegmentReportingNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of PACE participants", "label": "Number of Participants", "documentation": "Number of participants."}}, "auth_ref": {"us-gaap_NumberOfReportableSegments": {"xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": {"http://www.innovage.com/role/BusinessDetails": {"http://www.innovage.com/role/SegmentReportingNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."}}, "auth_ref": {"us-gaap_NumberOfReportingUnits": {"xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportingUnits", "presentation": {"http://www.innovage.com/role/GoodwillAndIntangibleAssetsNarrativeDetails": {"http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of reporting units", "label": "Number of Reporting Units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."}}, "auth_ref": {"innv_OmnibusIncentivePlan2021Member": {"xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "OmnibusIncentivePlan2021Member", "presentation": {"http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2021 Omnibus Incentive Plan", "label": "2021 Omnibus Incentive Plan", "documentation": "Represents information pertaining to omnibus incentive plan 2021."}}, "auth_ref": {"us-gaap_OperatingExpensesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfOperations": {"lang": {"en-us": {"role": {"verboseLabel": "Expenses", "label": "Operating Expenses [Abstract]", "documentation": "The net result for the period of deducting operating expenses from operating revenues."}}, "auth_ref": {"us-gaap_OperatingLeaseCost": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": {"http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": {"parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0}}, "presentation": {"http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": {"lang": {"en-us": {"role": {"terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."}}, "auth_ref": {"us-gaap_OperatingLeaseExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": {"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0}}, "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Operating lease rentals", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income."}}, "auth_ref": {"innv_OperatingLeaseLeaseTerminationCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "OperatingLeaseLeaseTerminationCosts", "crdr": "debit", "presentation": {"http://www.innovage.com/role/LeasesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Lease termination costs", "label": "Operating Lease, Lease Termination Costs", "documentation": "Operating Lease, Lease Termination Costs"}}, "auth_ref": {"us-

gaap-OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Lease", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": { "us-gaap-OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "innv-LeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r629": { "us-gaap-OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "innv-LeaseLiabilityCurrent", "weight": 1.0, "order": 1.0 }, "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 8.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "verboseLabel": "Current portion of operating lease obligations", "terseLabel": "Less: Current lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r629": { "us-gaap-OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "parentTag": "us-gaap-OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "http://www.innovage.com/role/LeasesScheduleofFutureMaturitiesofLeasePaymentsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Operating lease obligations", "terseLabel": "Total long-term lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r629": { "us-gaap-OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails": { "parentTag": "innv-RightOfUseAsset", "weight": 1.0, "order": 2.0 }, "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-AssetsNoncurrent", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Operating lease assets", "terseLabel": "Operating lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r628": { "us-gaap-OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.innovage.com/role/LeasesScheduleofWeightedAverageLeaseTermsandDiscountRatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r641", "r905": { "us-gaap-OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.innovage.com/role/LeasesScheduleofWeightedAverageLeaseTermsandDiscountRatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r640", "r905": { "us-gaap-OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": { "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": { "r550": { "us-gaap-OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": { "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r550": { "us-gaap-OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": { "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": { "r550": { "us-gaap-OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "documentation": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { "us-gaap-OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-AssetsNoncurrent", "weight": 1.0, "order": 5.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "label": "Other Intangible Assets, Net", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": { "us-gaap-OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r86": { "us-gaap-OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "parentTag": "us-gaap-IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfOperations": { "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other income", "negatedTerseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": { "r219": { "us-gaap-OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Other income (Expense)", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": { "us-gaap-OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": { "ecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": { "r979": { "innv-OtherServiceRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "OtherServiceRevenueMember", "presentation": { "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other service revenue", "label": "Other service revenue", "documentation": "Represents information pertaining to other service revenue." } } }, "auth_ref": { "ecd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r940", "r951", "r961", "r994": { "ecd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": { "r943", "r954", "r964", "r997": { "ecd-OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": { "r943", "r954", "r964", "r997": { "srt-OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": { "srt-OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": { "ecd-PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": { "r968": { "us-gaap-PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": { "http://www.innovage.com/role/ShareRepurchaseProgramDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payments for repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": { "r112": { "us-gaap-PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Taxes paid related to net settlements of stock-based compensation awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": { "r220": { "us-gaap-PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "us-gaap-BusinessCombinationConsiderationTransferred", "weight": 1.0, "order": 1.0 }, "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails": { "http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of business", "verboseLabel": "Acquisition of business", "terseLabel": "Cash Consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": { "r19", "r568": { "us-gaap-PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": { "r110": { "us-gaap-PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype":

```

monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }
presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": "en-us", "role": "negatedLabel", "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } }
auth_ref": { "r111": { "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }
presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": { "lang": "en-us", "role": "negatedLabel", "Purchases of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } }
auth_ref": { "r110": { "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } }
auth_ref": { "r978": { "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } }
auth_ref": { "r978": { "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } }
auth_ref": { "r970": { "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "PEO", "label": "PEO [Member]" } }
auth_ref": { "r987": { "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "PEO Name", "label": "PEO Name" } }
auth_ref": { "r980": { "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } }
auth_ref": { "r969": { "innv_PercentageOfHealthCareCostsIncurred": { "xbrltype": "percentItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "PercentageOfHealthCareCostsIncurred", "presentation": { "http://www.innovage.com/role/BusinessDetails": { "lang": "en-us", "role": "terseLabel", "Percentage of obligation for health care costs", "label": "Percentage of Health Care Costs Incurred", "documentation": "Percentage of health care cost incurred." } }
auth_ref": { "r1": { "innv_PercentageOfPooledCapitatedPaymentReceived": { "xbrltype": "percentItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "PercentageOfPooledCapitatedPaymentReceived", "presentation": { "http://www.innovage.com/role/RevenueRecognitionNarrativeDetails": { "lang": "en-us", "role": "terseLabel", "Pooled capitated payment", "label": "Percentage of pooled capitated payment received." } }
auth_ref": { "r1": { "innv_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "PerformanceBasedRestrictedStockUnitsMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": "en-us", "role": "terseLabel", "Restricted stock units - performance based", "label": "Performance-Based Restricted Stock Units", "documentation": "Represents the information pertaining to performance based restricted stock units." } }
auth_ref": { "r1": { "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": { "http://www.innovage.com/role/EarningsperShareDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": "en-us", "role": "terseLabel", "Stock options - performance based", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } }
auth_ref": { "r1": { "innv_PerformanceVestingUnitsProfitInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "PerformanceVestingUnitsProfitInterestsMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": "en-us", "role": "terseLabel", "Performance-based unit awards", "label": "Performance Vesting Units", "documentation": "Represents the information pertaining to performance vesting units of profit interests." } }
auth_ref": { "r1": { "innv_PinewoodLodgeLLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "PinewoodLodgeLLPMember", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "http://www.innovage.com/role/RelatedPartiesDetails": { "lang": "en-us", "role": "terseLabel", "Pinewood Lodge L L P", "label": "Pinewood Lodge L L P [Member]", "documentation": "Pinewood Lodge L L P" } }
auth_ref": { "r1": { "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": { "http://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetails": { "lang": "en-us", "role": "terseLabel", "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } }
auth_ref": { "r1127": "r1128": "r1129": "r1130": "r1131": "r1132": "r1133": "r1134": "r1135": "r1136": "r1137": "r1138": "r1139": "r1140": "r1141": "r1142": "r1143": "r1144": "r1145": "r1146": "r1147": "r1148": "r1149": "r1150": "r1151": "r1152": { "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": { "http://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetails": { "lang": "en-us", "role": "terseLabel", "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } }
auth_ref": { "r1127": "r1128": "r1129": "r1130": "r1131": "r1132": "r1133": "r1134": "r1135": "r1136": "r1137": "r1138": "r1139": "r1140": "r1141": "r1142": "r1143": "r1144": "r1145": "r1146": "r1147": "r1148": "r1149": "r1150": "r1151": "r1152": { "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } }
auth_ref": { "r971": { "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } }
auth_ref": { "r1016": { "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } }
auth_ref": { "r970": { "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetails": { "lang": "en-us", "role": "terseLabel", "Prepaid expenses and other", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } }
auth_ref": { "r1050": { "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": "http://www.innovage.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }
presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets": { "lang": "en-us", "role": "verboseLabel", "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } }
auth_ref": { "r209": "r351": "r352": "r846": { "innv_PrivatePayAndOtherCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "PrivatePayAndOtherCustomerMember", "presentation": { "http://www.innovage.com/role/RevenueRecognitionScheduleofConcentrationofNetReceivableDetails": { "lang": "en-us", "role": "terseLabel", "Private pay and other", "label": "Private pay and other", "documentation": "Represents information pertaining to private pay and other customer." } }
auth_ref": { "r1": { "us-gaap_ProceedsFromContributionsFromParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromContributionsFromParent", "crdr": "debit", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": "en-us", "role": "terseLabel", "Cash contributions", "label": "Proceeds from Contributions from Parent", "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital." } }
auth_ref": { "r20": { "us-gaap_ProceedsFromRepurchaseOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepurchaseOfEquity", "crdr": "debit", "calculation": "http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows", "parentTag
```

[illegible]

"RedeemableNoncontrollingInterestEquityCarryingAmount": {"crdr": "credit", "calculation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 }}, "presentation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"http://www.innovage.com/role/FairValueMeasurementsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Redeemable Noncontrolling Interests (See Note 4)", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "verboseLabel": "Redeemable noncontrolling interest, equity, carrying amount", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity. } } }, "auth_ref": {"r37", "r38", "r126", "r127"} }}, "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityFairValue", "crdr": "credit", "presentation": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Redeemable noncontrolling interests", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value", "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity. } } }, "auth_ref": {"r37", "r38", "r126", "r127"} }}, "innv_RedeemableNoncontrollingInterestFairValueCarryingAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "RedeemableNoncontrollingInterestFairValueCarryingAmount", "crdr": "credit", "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"lang": {"en-us": {"role": {"terseLabel": "Fair value adjustment for redeemable noncontrolling interests", "label": "Redeemable Noncontrolling Interest, Fair Value, Carrying Amount", "documentation": "Redeemable Noncontrolling Interest, Fair Value, Carrying Amount" } } }, "auth_ref": {} }}, "us-gaap_RelatedPartyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party {Domain}", "label": "Related and Nonrelated Parties {Domain}", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": {"r298", "r483", "r649", "r650", "r703", "r709", "r769", "r770", "r771", "r772", "r773", "r793", "r795", "r825"} }}, "us-gaap_RelatedPartyMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party {Member}", "label": "Related Party {Member}", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": {"r232", "r233", "r649", "r650", "r651", "r652", "r703", "r709", "r769", "r770", "r771", "r772", "r773", "r793", "r795", "r825"} }}, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": {"http://www.innovage.com/role/RelatedPartiesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Administrative fee per year", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": {"r74", "r649"} }}, "us-gaap_RelatedPartyTransactionAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": {"http://www.innovage.com/role/RelatedPartiesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction {Axis}", "label": "Related Party Transaction {Axis}", "documentation": "Information by type of related party transaction." } } }, "auth_ref": {"r649", "r650", "r1185"} }}, "us-gaap_RelatedPartyTransactionDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": {"http://www.innovage.com/role/RelatedPartiesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction {Domain}", "label": "Related Party Transaction {Domain}", "documentation": "Transaction between related party." } } }, "auth_ref": {} }}, "us-gaap_RelatedPartyTransactionLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": {"http://www.innovage.com/role/RelatedPartiesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction {Line Items}", "label": "Related Party Transaction {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {"r298", "r799", "r800", "r803"} }}, "us-gaap_RelatedPartyTransactionsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": {"en-us": {"role": {"terseLabel": "Related Party Transactions {Abstract}", "label": "Related Party Transactions {Abstract}" } } }, "auth_ref": {} }}, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party {Axis}", "label": "Related and Nonrelated Parties {Axis}", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": {"r298", "r483", "r649", "r650", "r703", "r709", "r769", "r770", "r771", "r772", "r773", "r793", "r795", "r825", "r1185"} }}, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": {"http://www.innovage.com/role/RelatedParties": {"lang": {"en-us": {"role": {"terseLabel": "Related Parties", "label": "Related Party Transactions Disclosure {Text Block}", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": {"r646", "r647", "r648", "r650", "r653", "r759", "r760", "r761", "r801", "r802", "r803", "r822", "r824"} }}, "us-gaap_RepaymentsOfLongTermDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": {"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 }}, "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"negatedLabel": "Principal payments on long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": {"r113", "r756"} }}, "innv_ReportedAndEstimatedClaimsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "ReportedAndEstimatedClaimsCurrent", "crdr": "credit", "calculation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }}, "presentation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Reported and estimated claims", "label": "Reported and Estimated Claims, Current", "documentation": "Carrying value as of the balance sheet date of the portion of reported and estimated claims due within one year or the operating cycle, if longer." } } }, "auth_ref": {} }}, "srt_RepurchaseAgreementCounterpartyNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": {"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Counterparty Name {Domain}", "label": "Counterparty Name {Domain}", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": {"r189", "r190", "r234", "r235", "r412", "r440", "r652", "r676", "r700", "r848", "r849"} }}, "ecd_RestatementDateAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date {Axis}", "documentation": "The date of the restatement determination." } } }, "auth_ref": {"r936", "r947", "r957", "r990"} }}, "ecd_RestatementDeterminationDate": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date", "documentation": "The date of the restatement determination." } } }, "auth_ref": {"r937", "r948", "r958", "r991"} }}, "ecd_RestatementDoesNotRequireRecoveryTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery {Text Block}", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": {"r78", "r79", "r963", "r998"} }}, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": {"http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {"lang": {"en-us": {"role": {"terseLabel": "Restricted Cash and Cash Equivalents {Axis}", "label": "Restricted Cash and Cash Equivalents {Axis}", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": {"r78", "r79"} }}, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": {"http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {"lang": {"en-us": {"role": {"terseLabel": "Cash and Cash Equivalents {Domain}", "label": "Cash and Cash Equivalents {Domain}", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": {"r200"} }}, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "presentation": {"http://www.innovage.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {"lang": {"en-us": {"role": {"terseLabel": "Restricted Cash and Cash Equivalents Items {Line Items}", "label": "Restricted Cash and Cash Equivalents Items {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {"r1196"} }}, "us-gaap_RestrictedCashCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }}, "presentation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": {"r1044", "r1059"} }}, "us-gaap_RestrictedStockUnitsRSUMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": {"http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": {"http://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) {Member}", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": {} }}, "innv_RestrictedStockUnitsRSUsTimeBasedMember": {"xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "RestrictedStockUnitsRSUsTimeBasedMember", "presentation": {"http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Time-based restricted stock units (RSUs)", "label": "Restricted Stock Units (RSUs), Time Based {Member}", "documentation": "Restricted Stock Units (RSUs), Time Based" } } }, "auth_ref": {} }}, "us-gaap_RetainedEarningsAccumulatedDeficit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 }}, "presentation": {"http://www.innovage.com/role/ConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Retained deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)."} } } }, "auth_ref": {"r95", "r131", "r706", "r747", "r748", "r757", "r777", "r906"} }}, "us-gaap_RetainedEarningsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": {"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity": {"lang": {"en-us": {"role": {"terseLabel": "Retained Earnings (Deficit)", "label": "Retained Earnings {Member}", "documentation": "Accumulated undistributed earnings (deficit)."} } } }, "auth_ref": {"r194", "r237", "r238", "r239", "r241", "r246", "r250",

"r337", "r338", "r379", "r553", "r554", "r561", "r562", "r563", "r565", "r569", "r570", "r578", "r580", "r581", "r583", "r586", "r624", "r627", "r744", "r746", "r764", "r1236" } } ,
"us-gaap-RevenueFromContractWithCustomerAbstract" : { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract
with Customer [Abstract]" } } }, "auth_ref": { "us-gaap-RevenueFromContractWithCustomerExcludingAssessedTax" : { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsbyReportableSegmentsDetails" : { "parentTag": "us-gaap-GrossProfit", "weight": 1.0, "order": 1.0
} , "http://www.innovage.com/role/ConsolidatedStatementsOfOperations" : { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } } , "presentation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfOperations",
"http://www.innovage.com/role/SegmentReportingScheduleOfOperatingResultsbyReportableSegmentsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Total revenues",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of
performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on
and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r157", "r158", "r263",
"r270", "r271", "r285", "r291", "r294", "r296", "r297", "r472", "r473", "r693" } } , "us-gaap-RevenueFromContractWithCustomerMember" : { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": {
"http://www.innovage.com/role/RevenueRecognitionNarrativeDetails", "http://www.innovage.com/role/RevenueRecognitionScheduleOfSourceofRevenueDetails" } , "lang": { "en-
us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation":
"Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk
calculation." } } }, "auth_ref": { "r297", "r1025" } } , "us-gaap-RevenueFromContractWithCustomerPolicyTextBlock" : { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": {
"http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies" } , "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from
Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": { "r174", "r464",
"r465", "r466", "r467", "r468", "r469", "r470", "r471", "r042" } } , "us-gaap-RevenueFromContractWithCustomerTextBlock" : { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://www.innovage.com/role/RevenueRecognition" } , "lang":
{ "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue
from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized
from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with
customer. Excludes insurance and lease contracts." } } }, "auth_ref": { "r174", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r475" } } , "us-
gaap-RevenuesAbstract" : { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": {
"http://www.innovage.com/role/ConsolidatedStatementsOfOperations" } , "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "label": "Revenues [Abstract]" } } } ,
"auth_ref": { "us-gaap-RevolvingCreditFacilityMember" : { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevolvingCreditFacilityMember", "presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Revolving
Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but
the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": { "inny-RightOfUseAsset" : { "xbrltype": "monetaryItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "RightOfUseAsset", "crdr": "debit", "calculation": {
"http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails" : { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": {
"http://www.innovage.com/role/LeasesScheduleofAssetsandLiabilitiesRelatedtoLeasesDetails" } , "lang": { "en-us": { "role": { "totalLabel": "Total leased assets", "label":
"Right-of-Use Asset", "documentation": "Right-of-Use Asset" } } }, "auth_ref": { "ecd-Rule10b51ArrAdoptedFlag" : { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us": {
"role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r1007" } } } ,
"ecd-Rule10b51ArrTrmtdFlag" : { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1
Arrangement Terminated [Flag]" } } }, "auth_ref": { "r1007" } } } , "us-gaap-ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" : { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": {
"http://www.innovage.com/role/RevenueRecognitionTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Concentration of Net Receivable", "label": "Schedule of
Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and
for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified
receivables." } } }, "auth_ref": { "r93", "r99" } } , "inny-ScheduleOfAllocatedShareBasedCompensationExpensesTableTextBlock" : { "xbrltype": "textBlockItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "ScheduleOfAllocatedShareBasedCompensationExpensesTableTextBlock", "presentation": {
"http://www.innovage.com/role/StockbasedCompensationTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expense", "label":
"Schedule of Allocated Share-Based Compensation Expenses [Table Text Block]", "documentation": "Tabular disclosure of allocated share based compensation expenses." } } }
} , "auth_ref": { "us-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" : { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": {
"http://www.innovage.com/role/EarningsperShareDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of
Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could
potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": { "r24" } } } , "us-
gaap-ScheduleOfBusinessAcquisitionsByAcquisitionTable" : { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": { "http://www.innovage.com/role/AcquisitionsNarrativeDetails",
"http://www.innovage.com/role/AcquisitionsScheduleofBusinessAcquisitionsByAcquisitionDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business
Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business
combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": { "r46", "r48", "r566" } } , "us-
gaap-ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" : { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": { "http://www.innovage.com/role/AcquisitionsTables" } , "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Preliminary Allocation of the Purchase Price", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular
disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include
leveraged buyouts." } } }, "auth_ref": { "r46", "r48" } } , "us-gaap-ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" : { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": {
"http://www.innovage.com/role/IncomeTaxesTables" } , "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Provision for Income Taxes", "label": "Schedule of Components
of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for
each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of
operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent
intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and
adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of
the related deferred tax asset in future years." } } }, "auth_ref": { "r1162" } } , "us-gaap-ScheduleOfDebtInstrumentsTextBlock" : { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": { "http://www.innovage.com/role/LongtermDebtTables" } , "lang": { "en-
us": { "role": { "terseLabel": "Schedule of Long-term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of
long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are
debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } } ,
"auth_ref": { "r15", "r39", "r40", "r75", "r129", "r130", "r068", "r70", "r1063", "r179" } } , "us-gaap-ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" : { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": {
"http://www.innovage.com/role/IncomeTaxesTables" } , "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities", "label":
"Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized
in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance
recognized for deferred tax assets." } } }, "auth_ref": { "r157" } } , "us-gaap-ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" : { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": {
"http://www.innovage.com/role/EarningsperShareTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings per Share", "label": "Schedule of Earnings Per
Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation
of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": { "r1068" } } , "us-
gaap-ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" : { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": { "http://www.innovage.com/role/IncomeTaxesTables" } , "lang": { "en-us": { "role": {
"verboseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation":
"Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year
to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": {
"r532", "r090", "r1154" } } , "srt-ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" : { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": {
"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label":
"Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": { "r333",
"r334", "r335", "r560", "r1020", "r1021", "r1022", "r1165", "r1166", "r1167", "r1168" } } ,
"inny-ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock" : { "xbrltype": "textBlockItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "presentation": {
"http://www.innovage.com/role/GoodwillandIntangibleAssetsTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Finite
Lived And Indefinite Lived Intangible Assets By Major Class [Table Text Block]", "documentation": "Tabular disclosure of amortizable finite-lived intangible assets, including
the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization, excluding goodwill." } } }, "auth_ref": { "us-
gaap-ScheduleOfGoodwillTextBlock" : { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": {
"http://www.innovage.com/role/GoodwillandIntangibleAssetsTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Goodwill", "label": "Schedule of
Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": {
"r065", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096" } } } ,
"inny-ScheduleOfLeaseAssetsAndLiabilitiesClassificationInBalanceSheetTableTextBlock" : { "xbrltype": "textBlockItemType", "nsuri": "http://www.innovage.com/20240630",
"localname": "ScheduleOfLeaseAssetsAndLiabilitiesClassificationInBalanceSheetTableTextBlock", "presentation": { "http://www.innovage.com/role/LeasesTables" } , "lang": {
"en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Related to Leases", "label": "Schedule of Lease Assets and Liabilities Classification in Balance Sheet [Table
Text Block]", "documentation": "Schedule of Lease Assets and Liabilities Classification in Balance Sheet" } } } , "auth_ref": { "us-
gaap-ScheduleOfMaturitiesOffLongTermDebtTableTextBlock" : { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfMaturitiesOffLongTermDebtTableTextBlock", "presentation": { "http://www.innovage.com/role/LongtermDebtTables" } , "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Aggregate Maturities of the Total Debt Outstanding", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular
disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": { "r7" } } , "us-

gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "presentation": { "http://www.innovage.com/role/StockbasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Profits Interests Transactions and Number of Units Outstanding", "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award." } } }, "auth_ref": { "r134": { "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r6": { "r643": { "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": { "http://www.innovage.com/role/AcquisitionsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": { "r138": { "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": { "http://www.innovage.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": { "r72": { "r74": { "r799": { "r800": { "r803": { "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "presentation": { "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]", "label": "Restrictions on Cash and Cash Equivalents [Table]", "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": { "r14": { "r143": { "r1196": { "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": { "http://www.innovage.com/role/SegmentReportingNarrativeDetails": { "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": { "r31": { "r32": { "r33": { "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": { "http://www.innovage.com/role/SegmentReportingTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Results by Reportable Segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": { "r31": { "r32": { "r33": { "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.innovage.com/role/ShareRepurchaseProgramDetails": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": { "http://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails": { "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r486": { "r487": { "r489": { "r490": { "r491": { "r492": { "r493": { "r494": { "r495": { "r496": { "r497": { "r498": { "r499": { "r500": { "r501": { "r502": { "r503": { "r504": { "r505": { "r506": { "r507": { "r508": { "r509": { "r510": { "r511": { "r512": { "r513": { "r514": { "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": { "http://www.innovage.com/role/StockbasedCompensationTables": { "lang": { "en-us": { "role": { "verboselabel": "Schedule of Restricted Stock Units Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { "r133": { "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.innovage.com/role/StockbasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r11": { "r12": { "r133": { "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.innovage.com/role/StockbasedCompensationTables": { "lang": { "en-us": { "role": { "verboselabel": "Schedule of Weighted-Average Assumptions and Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments; (b) expected volatility of the entity's shares; (c) expected dividends; (d) risk-free rate(s); and (e) discount for post-vesting restrictions." } } }, "auth_ref": { "r136": { "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsScheduleofVariableInterestEntityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of assets and liabilities", "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": { "r59": { "r60": { "r62": { "r65": { "r67": { "r572": { "r573": { "r576": { "r577": { "r671": { "r672": { "r673": { "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entity", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": { "r59": { "r60": { "r62": { "r65": { "r67": { "inv_ScheduleOfWeightedAverageLeaseTermAndDiscountRatesOffLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "ScheduleOfWeightedAverageLeaseTermAndDiscountRatesOffLeasesTableTextBlock", "presentation": { "http://www.innovage.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted-Average Lease Terms and Discount Rates", "label": "Schedule of Weighted-Average Lease Term and Discount Rates of Leases [Table Text Block]", "documentation": "Schedule of Weighted-Average Lease Term and Discount Rates of Leases" } } }, "auth_ref": { "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://www.innovage.com/role/GoodwillandIntangibleAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Future Annual Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": { "r866": { "r1099": { "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r928": { "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.innovage.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r931": { "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://www.innovage.com/role/SegmentReportingNarrativeDetails": { "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsbyReportableSegmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r157": { "r158": { "r159": { "r160": { "r263": { "r266": { "r269": { "r270": { "r271": { "r272": { "r273": { "r274": { "r275": { "r276": { "r277": { "r278": { "r279": { "r280": { "r282": { "r283": { "r284": { "r285": { "r286": { "r287": { "r288": { "r289": { "r291": { "r292": { "r293": { "r297": { "r357": { "r358": { "r359": { "r360": { "r361": { "r362": { "r363": { "r364": { "r365": { "r378": { "r389": { "r390": { "r390": { "r420": { "r421": { "r422": { "r423": { "r424": { "r425": { "r426": { "r427": { "r428": { "r429": { "r430": { "r431": { "r432": { "r433": { "r434": { "r435": { "r436": { "r437": { "r438": { "r439": { "r440": { "r441": { "r442": { "r443": { "r444": { "r445": { "r446": { "r447": { "r448": { "r449": { "r450": { "r451": { "r452": { "r453": { "r454": { "r455": { "r456": { "r457": { "r458": { "r459": { "r460": { "r461": { "r462": { "r463": { "r464": { "r465": { "r466": { "r467": { "r468": { "r469": { "r470": { "r471": { "r472": { "r473": { "r474": { "r475": { "r476": { "r477": { "r478": { "r479": { "r480": { "r481": { "r482": { "r483": { "r484": { "r485": { "r486": { "r487": { "r488": { "r489": { "r490": { "r491": { "r492": { "r493": { "r494": { "r495": { "r496": { "r497": { "r498": { "r499": { "r500": { "r501": { "r502": { "r503": { "r504": { "r505": { "r506": { "r507": { "r508": { "r509": { "r510": { "r511": { "r512": { "r513": { "r514": { "r515": { "r516": { "r517": { "r518": { "r519": { "r520": { "r521": { "r522": { "r523": { "r524": { "r525": { "r526": { "r527": { "r528": { "r529": { "r530": { "r531": { "r532": { "r533": { "r534": { "r535": { "r536": { "r537": { "r538": { "r539": { "r540": { "r541": { "r542": { "r543": { "r544": { "r545": { "r546": { "r547": { "r548": { "r549": { "r550": { "r551": { "r552": { "r553": { "r554": { "r555": { "r556": { "r557": { "r558": { "r559": { "r560": { "r561": { "r562": { "r563": { "r564": { "r565": { "r566": { "r567": { "r568": { "r569": { "r570": { "r571": { "r572": { "r573": { "r574": { "r575": { "r576": { "r577": { "r578": { "r579": { "r580": { "r581": { "r582": { "r583": { "r584": { "r585": { "r586": { "r587": { "r588": { "r589": { "r590": { "r591": { "r592": { "r593": { "r594": { "r595": { "r596": { "r597": { "r598": { "r599": { "r600": { "r601": { "r602": { "r603": { "r604": { "r605": { "r606": { "r607": { "r608": { "r609": { "r610": { "r611": { "r612": { "r613": { "r614": { "r615": { "r616": { "r617": { "r618": { "r619": { "r620": { "r621": { "r622": { "r623": { "r624": { "r625": { "r626": { "r627": { "r628": { "r629": { "r630": { "r631": { "r632": { "r633": { "r634": { "r635": { "r636": { "r637": { "r638": { "r639": { "r640": { "r641": { "r642": { "r643": { "r644": { "r645": { "r646": { "r647": { "r648": { "r649": { "r650": { "r651": { "r652": { "r653": { "r654": { "r655": { "r656": { "r657": { "r658": { "r659": { "r660": { "r661": { "r662": { "r663": { "r664": { "r665": { "r666": { "r667": { "r668": { "r669": { "r670": { "r671": { "r672": { "r673": { "r674": { "r675": { "r676": { "r677": { "r678": { "r679": { "r680": { "r681": { "r682": { "r683": { "r684": { "r685": { "r686": { "r687": { "r688": { "r689": { "r690": { "r691": { "r692": { "r693": { "r694": { "r695": { "r696": { "r697": { "r698": { "r699": { "r700": { "r701": { "r702": { "r703": { "r704": { "r705": { "r706": { "r707": { "r708": { "r709": { "r710": { "r711": { "r712": { "r713": { "r714": { "r715": { "r716": { "r717": { "r718": { "r719": { "r720": { "r721": { "r722": { "r723": { "r724": { "r725": { "r726": { "r727": { "r728": { "r729": { "r730": { "r731": { "r732": { "r733": { "r734": { "r735": { "r736": { "r737": { "r738": { "r739": { "r740": { "r741": { "r742": { "r743": { "r744": { "r745": { "r746": { "r747": { "r748": { "r749": { "r750": { "r751": { "r752": { "r753": { "r754": { "r755": { "r756": { "r757": { "r758": { "r759": { "r760": { "r761": { "r762": { "r763": { "r764": { "r765": { "r766": { "r767": { "r768": { "r769": { "r770": { "r771": { "r772": { "r773": { "r774": { "r775": { "r776": { "r777": { "r778": { "r779": { "r780": { "r781": { "r782": { "r783": { "r784": { "r785": { "r786": { "r787": { "r788": { "r789": { "r790": { "r791": { "r792": { "r793": { "r794": { "r795": { "r796": { "r797": { "r798": { "r799": { "r800": { "r801": { "r802": { "r803": { "r804": { "r805": { "r806": { "r807": { "r808": { "r809": { "r810": { "r811": { "r812": { "r813": { "r814": { "r815": { "r816": { "r817": { "r818": { "r819": { "r820": { "r821": { "r822": { "r823": { "r824": { "r825": { "r826": { "r827": { "r828": { "r829": { "r830": { "r831": { "r832": { "r833": { "r834": { "r835": { "r836": { "r837": { "r838": { "r839": { "r840": { "r841": { "r842": { "r843": { "r844": { "r845": { "r846": { "r847": { "r848": { "r849": { "r850": { "r851": { "r852": { "r853": { "r854": { "r855": { "r856": { "r857": { "r858": { "r859": { "r860": { "r861": { "r862": { "r863": { "r864": { "r865": { "r866": { "r867": { "r868": { "r869": { "r870": { "r871": { "r872": { "r873": { "r874": { "r875": { "r876": { "r877": { "r878": { "r879": { "r880": { "r881": { "r882": { "r883": { "r884": { "r885": { "r886": { "r887": { "r888": { "r889": { "r890": { "r891": { "r892": { "r893": { "r894": { "r895": { "r896": { "r897": { "r898": { "r899": { "r900": { "r901": { "r902": { "r903": { "r904": { "r905": { "r906": { "r907": { "r908": { "r909": { "r910": { "r911": { "r912": { "r913": { "r914": { "r915": { "r916": { "r917": { "r918": { "r919": { "r920": { "r921": { "r922": { "r923": { "r924": { "r925": { "r926": { "r927": { "r928": { "r929": { "r930": { "r931": { "r932": { "r933": { "r934": { "r935": { "r936": { "r937": { "r938": { "r939": { "r940": { "r941": { "r942": { "r943": { "r944": { "r945": { "r946": { "r947": { "r948": { "r949": { "r950": { "r951": { "r952": { "r953": { "r954": { "r955": { "r956": { "r957": { "r958": { "r959": { "r960": { "r961": { "r962": { "r963": { "r964": { "r965": { "r966": { "r967": { "r968": { "r969": { "r970": { "r971": { "r972": { "r973": { "r974": { "r975": { "r976": { "r977": { "r978": { "r979": { "r980": { "r981": { "r982": { "r983": { "r984": { "r985": { "r986": { "r987": { "r988": { "r989": { "r990": { "r991": { "r992": { "r993": { "r994": { "r995": { "r996": { "r997": { "r998": { "r999": { "r1000": { "r1001": { "r1002": { "r1003": { "r1004": { "r1005": { "r1006": { "r1007": { "r1008": { "r1009": { "r1010": { "r1011": { "r1012": { "r1013": { "r1014": { "r1015": { "r1016": { "r1017": { "r1018": { "r1019": { "r1020": { "r1021": { "r1022": { "r1023": { "r1024": { "r1025": { "r1026": { "r1027": { "r1028": { "r1029": { "r1030": { "r1031": { "r1032": { "r1033": { "r1034": { "r1035": { "r1036": { "r1037": { "r1038": { "r1039": { "r1040": { "r1041": { "r1042": { "r1043": { "r1044": { "r1045": { "r1046": { "r1047": { "r1048": { "r1049": { "r1050": { "r1051": { "r1052": { "r1053": { "r1054": { "r1055": { "r1056": { "r1057": { "r1058": { "r1059": { "r1060": { "r1061": { "r1062": { "r1063": { "r1064": { "r1065": { "r1066": { "r1067": { "r1068": { "r1069": { "r1070": { "r1071": { "r1072": { "r1073": { "r1074": { "r1075": { "r1076": { "r1077": { "r1078": { "r1079": { "r1080": { "r1081": { "r1082": { "r1083": { "r1084": { "r1085": { "r1086": { "r1087": { "r1088": { "r1089": { "r1090": { "r1091": { "r1092": { "r1093": { "r1094": { "r1095": { "r1096": { "r1097": { "r1098": { "r1099": { "r1100": { "r1101": { "r1102": { "r1103": { "r1104": { "r1105": { "r1106": { "r1107": { "r1108": { "r1109": { "r1110": { "r1111": { "r1112": { "r1113": { "r1114": { "r1115": { "r1116": { "r1117": { "r1118": { "r1119": { "r1120": { "r1121": { "r1122": { "r1123": { "r1124": { "r1125": { "r1126": { "r1127": { "r1128": { "r1129": { "r1130": { "r1131": { "r1132": { "r1133": { "r1134": { "r1135": { "r1136": { "r1137": { "r1138": { "r1139": { "r1140": { "r1141": { "r1142": { "r1143": { "r1144": { "r1145": { "r1146": { "r1147": { "r1148": { "r1149": { "r1150": { "r1151": { "r1152": { "r1153": { "r1154": { "r1155": { "r1156": { "r1157": { "r1158": { "r1159": { "r1160": { "r1161": { "r1162": { "r1163": { "r1164": { "r1165": { "r1166": { "r1167": { "r1168": { "r1169": { "r1170": { "r1171": { "r1172": { "r1173": { "r1174": { "r1175": { "r1176": { "r1177": { "r1178": { "r1179": { "r1180": { "r1181": { "r1182": { "r1183": { "r1184": { "r1185": { "r1186": { "r1187": { "r1188": { "r1189": { "r1190": { "r1191": { "r1192": { "r1193": { "r1194": { "r1195": { "r1196": { "r1197": { "r1198": { "r1199": { "r1200": { "r1201": { "r1202": { "r1203": { "r1204": { "r1205": { "r1206": { "r1207": { "r1208": { "r1209": { "r1210": { "r1211": { "r1212": { "r1213": { "r1214": { "r1215": { "r1216": { "r1217": { "r1218": { "r1219": { "r1220": { "r1221": { "r1222": { "r1223": { "r1224": { "r1225": { "r1226": { "r1227": { "r1228": { "r1229": { "r1230": { "r1231": { "r1232": { "r1233": { "r1234": { "r1235": { "r1236": { "r1237": { "r1238": { "r1239": { "r1240": { "r1241": { "r1242": { "r1243": { "r1244": { "r1245": { "r1246": { "r1247": { "r1248": { "r1249": { "r1250": { "r1251": { "r1252": { "r1253": { "r1254": { "r1255": { "r1256": { "r1257": { "r1258": { "r1259": { "r1260": { "r1261": { "r1262": { "r1263": { "r1264": { "r1265": { "r1266": { "r1267": { "r1268": { "r1269": { "r1270": { "r1271": { "r1272": { "r1273": { "r1274": { "r1275": { "r1276": { "r1277": { "r1278": { "r1279": { "r1280": { "r1281": { "r1282": { "r1283": { "r1284": { "r1285": { "r1286": { "r1287": { "r1288": { "r1289": { "r1290": { "r1291": { "r1292": { "r1293": { "r1294": { "r1295": { "r1296": { "r1297": { "r1298": { "r1299": { "r1300": { "r1301": { "r1302": { "r1303": { "r1304": { "r1305": { "r1306": { "r1307": { "r1308": { "r1309": { "r1310": { "r1311": { "r1312": { "r1313": { "r1314": { "r1315": { "r1316": { "r1317": { "r1318": { "r1319": { "r1320": { "r1321": { "r1322": { "r1323": { "r1324": { "r1325": { "r1326": { "r1327": { "r1328": { "r1329": { "r1330": { "r1331": { "r1332": { "r1333": { "r1334": { "r1335": { "r1336": { "r1337": { "r1338": { "r1339": { "r1340": { "r1341": { "r1342": { "r1343": { "r1344": { "r1345": { "r1346": { "r1347": { "r1348": { "r1349": { "r1350": { "r1351": { "r1352": { "r1353": { "r1354": { "r1355": { "r1356": { "r1357": { "r1358": { "r1359": { "r1360": { "r1361": { "r1362": { "r1363": { "r1364": { "r1365": { "r1366": { "r1367": { "r1368": { "r1369": { "r1370": { "r1371": { "r1372": { "r1373": { "r1374": { "r1375": { "r1376": { "r1377": { "r1378": { "r1379": { "r1380": { "r1381": { "r1382": { "r1383": { "r1384": { "r1385": { "r1386": { "r1387": { "r1388": { "r1389": { "r1390": { "r1391": { "r1392": { "r1393": { "r1394": { "r1395": { "r1396": { "r1397": { "r1398": { "r1399": { "r1400": { "r1401": { "r1402": { "r1403": { "r1404": { "r1405": { "r1406": { "r1407": { "r1408": { "r1409": { "r1410": { "r1411": { "r1412": { "r1413": { "r1414": { "r1415": { "r1416": { "r1417": { "r1418": { "r1419": { "r1420": { "r1421": { "r1422": { "r1423": { "r1424": { "r1425": { "r1426": { "r1427": { "r1428": { "r1429": { "r1430": { "r1431": { "r1432": { "r1433": { "r1434": { "r1435": { "r1436": { "r1437": { "r1438": { "r1439": { "r1440": { "r1441": { "r1442": { "r1443": { "r1444": { "r1445": { "r1446": { "r1447": { "r1

data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } } "auth_ref": "r160", "r263", "r265", "r266", "r267", "r268", "r269", "r281", "r283", "r284", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r854", "r856", "r857", "r858", "r860", "r861", "r862" } } "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": { "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsByReportableSegmentsDetails": { "lang": "en-us", "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "lang": "en-us", "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": { "us-gaap_SeniorLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorLoansMember", "presentation": { "http://www.innovage.com/role/LongtermDebtNarrativeDetails": "http://www.innovage.com/role/LongtermDebtScheduleofLongtermDebtDetails" } } }, "lang": "en-us", "role": { "terseLabel": "Term Loan Facility", "label": "Senior Loans [Member]", "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive repayment prior] relative to junior and unsecured (general) creditors." } } }, "auth_ref": { "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": "en-us", "role": { "terseLabel": "Series B Preferred Stock", "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": { "r1046", "r1047", "r1122" } } }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesCPreferredStockMember", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails": { "lang": "en-us", "role": { "terseLabel": "Series C Preferred Stock", "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": { "r1046", "r1047", "r1122" } } }, "us-gaap_ServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceOtherMember", "presentation": { "http://www.innovage.com/role/RelatedPartiesDetails": { "lang": "en-us", "role": { "terseLabel": "Service. Other", "label": "Service. Other [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other." } } }, "auth_ref": { "r1125" } } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofCashFlows": { "lang": "en-us", "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r4" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "verboseLabel": "Vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in PnYnMnDnFnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r886" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "terseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r505" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "verboseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r505" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."} } } }, "auth_ref": { "r503" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."} } } }, "auth_ref": { "r503" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "periodStartLabel": "Unvested balance, beginning (in shares)", "periodEndLabel": "Unvested balance, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r500", "r501" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "terseLabel": "Number of units", "verboseLabel": "Number of awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "r504" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "periodStartLabel": "Unvested balance, beginning (in dollars per share)", "periodEndLabel": "Unvested balance, ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r500", "r501" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "periodStartLabel": "Unvested balance, beginning (in dollars per share)", "periodEndLabel": "Unvested balance, ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r504" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails": { "lang": "en-us", "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r504" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://www.innovage.com/role

"presentation": f"http://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Dividend yield",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } }, {"auth_ref": f"r512" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": f"xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"presentation": f"http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails" }, {"lang": f"en-us", f"role": f"terseLabel",
"Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation":
"The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } }, {"auth_ref": f"r511" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": f"xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Maximum expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation":
"The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } }, {"auth_ref": f"r511" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": f"xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Minimum expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation":
"The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } }, {"auth_ref": f"r511" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": f"xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Maximum interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation":
"The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } }, {"auth_ref": f"r511" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": f"xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
"presentation": f"http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, {"lang": f"en-us", f"role": f"terseLabel",
"Minimum interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
"documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } }, {"auth_ref": f"r511" }, {"inv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue": f"xbrltype": "perShareItemType", "nsuri":
"http://www.innovage.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue",
"presentation": f"http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Weighted-average fair values (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value",
"documentation": "The estimated weighted average fair value." } }, {"auth_ref": f"r511" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": f"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"presentation": f"http://www.innovage.com/role/ShareRepurchaseProgramDetails";
"http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails";
"http://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, {"auth_ref": f"r486", "r487", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberofSharesAuthorized": f"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberofSharesAuthorized", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails";
"http://www.innovage.com/role/StockbasedCompensationEquityIncentivePlanDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } }, {"auth_ref": f"r487" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": f"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Exercisable balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } }, {"auth_ref": f"r494" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": f"xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"presentation": f"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Exercisable balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } }, {"auth_ref": f"r494" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": f"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"negatedLabel", "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } }, {"auth_ref": f"r499" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": f"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"negatedLabel", "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } }, {"auth_ref": f"r498" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": f"xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } }, {"auth_ref": f"r496" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": f"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"periodStartLabel", "Outstanding balance, beginning (in shares)", "periodEndLabel": "Outstanding balance, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } }, {"auth_ref": f"r492", "r493" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": f"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": f"
"http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"terseLabel", "Number of awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } }, {"auth_ref": f"r492" }, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": f"xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": f"http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails";
"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, {"lang": f"en-us", f"role": f"periodStartLabel", "Outstanding balance, beginning (in dollars per share)", "periodEndLabel": "Outstanding balance, ending (in dollars per share)", "terseLabel": "Outstanding balance, beginning (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation":
"Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } }, {"auth_ref": f"r492", "r493" }, {"us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"; { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value per share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": { "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r497" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": { "r499" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r498" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r496" } }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of Vesting, Second Anniversary", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": { "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of vesting Year 2", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": { "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of vesting Year 1", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": { "innv_ShareBasedPaymentArrangementTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "ShareBasedPaymentArrangementTrancheFourMember", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of vesting Year 3", "label": "Share-Based Payment Arrangement, Tranche Four [Member]", "documentation": "Share-Based Payment Arrangement, Tranche Four" } } }, "auth_ref": { "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair value of underlying stock (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": { "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": { "http://www.innovage.com/role/ShareRepurchaseProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": { "r1123" } }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": { "http://www.innovage.com/role/ShareRepurchaseProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": { "r1123" } }, "innv_ShareRepurchaseProgramNumberOfSharesRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "ShareRepurchaseProgramNumberOfSharesRepurchased", "presentation": { "http://www.innovage.com/role/ShareRepurchaseProgramDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share repurchase program, number of shares repurchased (in shares)", "label": "Share Repurchase Program, Number of Shares Repurchased", "documentation": "Share Repurchase Program, Number of Shares Repurchased" } } }, "auth_ref": { "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of vesting", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": { "r1127" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofBlackScholesOptionPricingModelDetails", "http://www.innovage.com/role/StockbasedCompensationScheduleofWeightedAverageAssumptionsDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Expected life (years) - time vesting units", "terseLabel": "Weighted average expected life (years) - time vesting units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r510" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } }, "auth_ref": { "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.innovage.com/role/StockbasedCompensationScheduleofPerformancebasedAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant date fair value of options vested." } } }, "auth_ref": { "innv_SharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "SharesAcquired", "presentation": { "http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares acquired (in shares)", "label": "Shares Acquired", "documentation": "The number of shares acquired." } } }, "auth_ref": { "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax withholding related to the net share settlements of stock-based compensation awards (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": { "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.innovage.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available for sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": { "r152", "r153", "r1049" } }, "innv_ShortTermInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "ShortTermInvestmentsFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Short-Term Investments, Fair Value Disclosure", "documentation": "Short-Term Investments, Fair Value Disclosure" } } }, "auth_ref": { "innv_ShortTermInvestmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innovage.com/20240630",

"localname": "ShortTermInvestmentsPolicyTextBlock", "presentation": "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "ShortTermInvestments", "label": "Short-Term Investments [Policy Text Block]", "documentation": "Short-Term Investments", "auth_ref": "us-gaap ShortTermLeaseCost", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails", "parentTag": "us-gaap LeaseCost", "weight": 1.0, "order": 3.0, "presentation": "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails", "lang": "en-us", "role": "terseLabel", "Short-term lease cost", "label": "Short-Term Lease Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less", "auth_ref": "r637", "r905", "us-gaap SoftwareAndSoftwareDevelopmentCostsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "lang": "en-us", "role": "terseLabel", "Software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use", "auth_ref": "innv SpecificPurposeRestrictedCashMember", "xbrltype": "domainItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "SpecificPurposeRestrictedCashMember", "presentation": "http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails", "lang": "en-us", "role": "terseLabel", "Personal-Needs Account", "label": "Personal-needs account", "documentation": "Represents information pertaining to cash held for specific purpose", "auth_ref": "us-gaap StateAndLocalJurisdictionMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": "http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails", "lang": "en-us", "role": "terseLabel", "State and Local Jurisdiction", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax", "auth_ref": "r530", "us-gaap StatementBusinessSegmentsAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": "http://www.innovage.com/role/SegmentReportingNarrativeDetails", "http://www.innovage.com/role/SegmentReportingScheduleofOperatingResultsByReportableSegmentsDetails", "lang": "en-us", "role": "terseLabel", "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments", "auth_ref": "r157", "r158", "r159", "r160", "r196", "r263", "r266", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r297", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r378", "r381", "r389", "r390", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r855", "r858", "r859", "r865", "r913", "r1198", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "us-gaap StatementEquityComponentsAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.innovage.com/role/ShareRepurchaseProgramDetails", "lang": "en-us", "role": "terseLabel", "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity", "auth_ref": "r10", "r92", "r96", "r97", "r194", "r214", "r215", "r216", "r237", "r238", "r239", "r241", "r246", "r248", "r250", "r264", "r337", "r338", "r379", "r452", "r553", "r554", "r561", "r562", "r563", "r565", "r569", "r570", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r615", "r616", "r617", "r618", "r619", "r620", "r624", "r627", "r645", "r715", "r744", "r745", "r746", "r764", "r810", "us-gaap StatementLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": "http://www.innovage.com/role/ConsolidatedStatementsOfOperations", "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity", "lang": "en-us", "role": "terseLabel", "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": "r237", "r238", "r239", "r264", "r627", "r693", "r751", "r765", "r768", "r769", "r770", "r771", "r772", "r773", "r776", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r793", "r795", "r797", "r798", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r818", "r920", "us-gaap StatementOfCashFlowsAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": "en-us", "role": "terseLabel", "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]", "auth_ref": "us-gaap StatementOfFinancialPositionAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": "en-us", "role": "terseLabel", "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]", "auth_ref": "us-gaap StatementOfStockholdersEquityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": "en-us", "role": "terseLabel", "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]", "auth_ref": "us-gaap StatementTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": "http://www.innovage.com/role/ConsolidatedStatementsOfOperations", "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity", "lang": "en-us", "role": "terseLabel", "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity", "auth_ref": "r237", "r238", "r239", "r264", "r298", "r627", "r693", "r751", "r765", "r768", "r769", "r770", "r771", "r772", "r773", "r776", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r793", "r795", "r797", "r798", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r818", "r920", "ecd StkPrCrOrTsrEstimationMethodTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCrOrTsrEstimationMethodTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]", "auth_ref": "r939", "r950", "r960", "r993", "us-gaap StockAppreciationRightsSARSMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period", "auth_ref": "us-gaap StockIssuedDuringPeriodSharesShareBasedCompensation", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity", "lang": "en-us", "role": "terseLabel", "Stock-based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)", "auth_ref": "r10", "r91", "r92", "r131", "us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": "http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails", "lang": "en-us", "role": "negatedLabel", "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period", "auth_ref": "r10", "r91", "r92", "r131", "r497", "us-gaap StockIssuedDuringPeriodValueShareBasedCompensation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": "http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity", "lang": "en-us", "role": "terseLabel", "Stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)", "auth_ref": "r144", "r91", "r92", "r131", "srt StockRepurchaseProgramAuthorizedAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount", "crdr": "credit", "presentation": "http://www.innovage.com/role/ShareRepurchaseProgramDetails", "lang": "en-us", "role": "terseLabel", "Share repurchase program, authorized, amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership", "auth_ref": "r1423", "us-gaap StockholdersEquity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": "http://www.in


```

xbrl:"domainItemType","nsuri":"http://www.innovage.com/20240630","localname":"","TimeBasedStockOptionsMember","presentation":f
"http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails","http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}
"lang":"en-us","role":"terseLabel","Time-based stock options","label":"Time Based Stock Options [Member]","documentation":"Time Based Stock Options"}
"auth_ref":f,"innv-TimeVestingAwardsMember","xbrltype":"domainItemType","nsuri":"http://www.innovage.com/20240630","localname":
"TimeVestingAwardsMember","presentation":f"http://www.innovage.com/role/StockbasedCompensationScheduleofTimebasedAwardsDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}
"lang":"en-us","role":"terseLabel":"Stock options - time based","label":"Time-based options awards",
"documentation":"Represents the information pertaining to Time Vesting Awards."}}
"auth_ref":f,"innv-TimeVestingUnitsProfitInterestsMember","xbrltype":
"domainItemType","nsuri":"http://www.innovage.com/20240630","localname":"TimeVestingUnitsProfitInterestsMember","presentation":f
"http://www.innovage.com/role/StockbasedCompensationScheduleofProfitsInterestsTransactionsandNumberofUnitsOutstandingDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}
"lang":"en-us","role":"terseLabel":"Time-based unit awards","label":"Time Vesting Units","documentation":
"Represents the information pertaining to time vesting units of profit interests."}}
"auth_ref":f,"ecd-TotalShareholderRtnAmt","xbrltype":"monetaryItemType",
"nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"TotalShareholderRtnAmt","presentation":f"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}
"lang":"en-us","role":"terseLabel":"Total Shareholder Return Amount","label":"Total Shareholder Return Amount"}
"auth_ref":f,"r978"}
"ecd-TotalShareholderRtnVsPeerGroupTextBlock","xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":
"TotalShareholderRtnVsPeerGroupTextBlock","presentation":f"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}
"lang":"en-us","role":"terseLabel":"Total Shareholder Return Vs Peer Group","label":"Total Shareholder Return Vs Peer Group [Text Block]"}
"auth_ref":f,"r985"}
"us-gaap-TradeAndOtherAccountsReceivablePolicy","xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"TradeAndOtherAccountsReceivablePolicy","presentation":f
"http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies"}
"lang":"en-us","role":"terseLabel":"Accounts Receivable","label":"Accounts Receivable [Policy Text Block]","documentation":"Disclosure of accounting policy for accounts receivable."}}
"auth_ref":f,"r161","r162","r163","r1076","r1077",
"r1078"}
"ecd-TradingArrAxis","xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"TradingArrAxis","presentation":f
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Trading Arrangement","label":"Trading Arrangement [Axis]"}
"auth_ref":f,"r1006"}
"ecd-TradingArrByIndTable","xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"TradingArrByIndTable",
"presentation":f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Trading Arrangements by Individual","label":
"Trading Arrangements by Individual [Table]"}
"auth_ref":f,"r1008"}
"dei-TradingSymbol","xbrltype":"tradingSymbolItemType","nsuri":
"http://xbrl.sec.gov/dei/2024","localname":"TradingSymbol","presentation":f"http://www.innovage.com/role/Cover"}
"lang":"en-us","role":"terseLabel":"Trading Symbol","label":"Trading Symbol","documentation":"Trading symbol of an instrument as listed on an exchange."}}
"auth_ref":f,"us-
gaap-TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain","xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024",
"localname":"TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain","presentation":f
"http://www.innovage.com/role/CostandEquityMethodInvestmentsNarrativeDetails",
"http://www.innovage.com/role/FairValueMeasurementsScheduleofFairValueofCashCashEquivalentsandMarketableSecuritiesbySignificantInvestmentCategoryDetails"}
"lang":"en-us","role":"terseLabel":"Financial Instruments fDomain","label":"Financial Instruments fDomain","documentation":"Instrument or contract that
imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a
contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."}}
"auth_ref":f,"r302","r303",
"r304","r305","r306","r307","r308","r309","r310","r311","r312","r313","r314","r315","r316","r317","r318","r319","r320","r321","r322","r323","r324","r325",
"r326","r327","r328","r329","r330","r331","r333","r343","r350","r584","r610","r657","r659","r660","r661","r662","r663","r664","r665","r666","r667","r668",
"r669","r670","r674","r677","r678","r679","r680","r681","r682","r683","r684","r685","r686","r687","r688","r689","r690","r691","r716","r893","r895","r897",
"r898","r899","r900","r901","r902","r903","r907","r1030","r1031","r1032","r1033","r1034","r1035","r1036","r1079","r1080","r1081","r1082","r1170","r1173",
"r1174","r1175","r1176","r1177"}
"ecd-TrdArrAdoptionDate","xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"TrdArrAdoptionDate",
"presentation":f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Adoption Date","label":"Trading Arrangement Adoption Date"}
"auth_ref":f,"r1009"}
"ecd-TrdArrDuration","xbrltype":"durationItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"TrdArrDuration",
"presentation":f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Arrangement Duration","label":"Trading Arrangement Duration"}
"auth_ref":f,"r1010"}
"ecd-TrdArrExpirationDate","xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":
"TrdArrExpirationDate","presentation":f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Expiration Date","label":
"Trading Arrangement Expiration Date"}
"auth_ref":f,"r1010"}
"ecd-TrdArrIndName","xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024",
"localname":"TrdArrIndName","presentation":f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Name","label":
"Trading Arrangement Individual Name"}
"auth_ref":f,"r1008"}
"ecd-TrdArrIndTitle","xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024",
"localname":"TrdArrIndTitle","presentation":f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Title","label":
"Trading Arrangement Individual Title"}
"auth_ref":f,"r1008"}
"ecd-TrdArrSecuritiesAggAvailAmt","xbrltype":"sharesItemType","nsuri":
"http://xbrl.sec.gov/ecd/2024","localname":"TrdArrSecuritiesAggAvailAmt","presentation":f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Aggregate Available","label":"Trading Arrangement Securities Aggregate Available Amount"}
"auth_ref":f,"r1011"}
"ecd-TrdArrTerminationDate","xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"TrdArrTerminationDate","presentation":f
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}
"lang":"en-us","role":"terseLabel":"Termination Date","label":"Trading Arrangement Termination Date"}
"auth_ref":f,"r1009"}
"us-gaap-TreasuryStockCommonMember","xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"TreasuryStockCommonMember","presentation":f"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity",
"http://www.innovage.com/role/ShareRepurchaseProgramDetails"}
"lang":"en-us","role":"terseLabel":"Treasury Stock","label":"Treasury Stock, Common [Member]","documentation":"Previously issued common shares repurchased by the issuing entity and held in treasury."}}
"auth_ref":f,"r42"}
"us-
gaap-TreasuryStockCommonShares","xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"TreasuryStockCommonShares","presentation":f
"http://www.innovage.com/role/ConsolidatedBalanceSheetsParenthetical","http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity"}
"lang":"en-us","role":"terseLabel":"Treasury stock at cost (in shares)","label":"Treasury Stock, Common, Shares","documentation":"Number of previously issued common shares
repurchased by the issuing entity and held in treasury."}}
"auth_ref":f,"r42"}
"us-gaap-TreasuryStockCommonValue","xbrltype":"monetaryItemType","nsuri":
"http://fasb.org/us-gaap/2024","localname":"TreasuryStockCommonValue","presentation":"debit","calculation":f"http://www.innovage.com/role/ConsolidatedBalanceSheets",
"parentTag":"us-gaap-TreasuryStockCommonShares","weight":1.0,"order":4.0}}
"credit":f"http://www.innovage.com/role/ConsolidatedBalanceSheets"}
"lang":"en-us","role":"negatedTerseLabel":"Treasury stock at cost, 36,559 shares as of June 30, 2024","label":"Treasury Stock, Common, Value","documentation":"Amount allocated to
previously issued common shares repurchased by the issuing entity and held in treasury."}}
"auth_ref":f,"r42","r43","r96"}
"us-gaap-TreasuryStockSharesAcquired","xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"TreasuryStockSharesAcquired","presentation":f
"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity","http://www.innovage.com/role/ShareRepurchaseProgramDetails"}
"lang":"en-us","role":"terseLabel":"Shares repurchased at cost (in shares)","label":"Treasury Stock, Shares, Acquired","documentation":"Number of shares that have been repurchased during
the period and are being held in treasury."}}
"auth_ref":f,"r10","r92","r131"}
"us-gaap-TreasuryStockValueAcquiredCostMethod","xbrltype":"monetaryItemType",
"nsuri":"http://fasb.org/us-gaap/2024","localname":"TreasuryStockValueAcquiredCostMethod","credit":"debit","presentation":f
"http://www.innovage.com/role/ConsolidatedStatementsOfStockholdersEquity"}
"lang":"en-us","role":"negatedTerseLabel":"Shares repurchased at cost","label":
"Treasury Stock, Value, Acquired, Cost Method","documentation":"Equity impact of the cost of common and preferred stock that were repurchased during the period.
Recorded using the cost method."}}
"auth_ref":f,"r10","r42","r131"}
"ecd-UndrlygSecurityMktPriceChngPct","xbrltype":"pureItemType","nsuri":
"http://xbrl.sec.gov/ecd/2024","localname":"UndrlygSecurityMktPriceChngPct","presentation":f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}
"lang":"en-us","role":"terseLabel":"Underlying Security Market Price Change","label":"Underlying Security Market Price Change, Percent"}
"auth_ref":f,"r1005"}
"us-
gaap-UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy","xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy","presentation":f"http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies"}
"lang":"en-
us","role":"terseLabel":"Reported and Estimated Claims","label":"Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]","documentation":
"Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date
(ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have
been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and
(c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees, outside adjuster fees, and costs to
record, process, and adjust claims."}}
"auth_ref":f,"r737","r738","r911"}
"us-gaap-UnrecognizedTaxBenefits","xbrltype":"monetaryItemType","nsuri":
"http://fasb.org/us-gaap/2024","localname":"UnrecognizedTaxBenefits","credit":"credit","presentation":f"http://www.innovage.com/role/IncomeTaxesCarryforwardsDetails",
"lang":"en-us","role":"terseLabel":"Uncertain tax positions","label":"Unrecognized Tax Benefits","documentation":"Amount of unrecognized tax benefits."}}
"auth_ref":f,"r524","r541","r889"}
"us-gaap-UseOfEstimates","xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"UseOfEstimates",
"presentation":f"http://www.innovage.com/role/SummaryofSignificantAccountingPoliciesPolicies"}
"lang":"en-us","role":"terseLabel":"Use of Estimates","label":
"Use of Estimates, Policy [
```

power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": { "r59": { "r572": { "r573": { "r576": { "r577": { "r578": { "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.innovage.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": { "r638": { "r905": { "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": { "r1127": { "r1128": { "r1129": { "r1130": { "r1131": { "r1132": { "r1133": { "r1134": { "r1135": { "r1136": { "r1137": { "r1138": { "r1139": { "r1140": { "r1141": { "r1142": { "r1143": { "r1144": { "r1145": { "r1146": { "r1147": { "r1148": { "r1149": { "r1150": { "r1151": { "r1152": { "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": { "http://www.innovage.com/role/StockbasedCompensation2021OmnibusIncentivePlanandRestrictedStockUnitsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": { "r1127": { "r1128": { "r1129": { "r1130": { "r1131": { "r1132": { "r1133": { "r1134": { "r1135": { "r1136": { "r1137": { "r1138": { "r1139": { "r1140": { "r1141": { "r1142": { "r1143": { "r1144": { "r1145": { "r1146": { "r1147": { "r1148": { "r1149": { "r1150": { "r1151": { "r1152": { "ecd_VrEndFrValOfEqtyAwrdsGrntdAndUnvstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VrEndFrValOfEqtyAwrdsGrntdAndUnvstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PyPDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "auth_ref": { "r974": { "r975": { "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.innovage.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.innovage.com/role/EarningsperShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Dilutive shares (in shares)", "label": "Weighted Average Number of Shares Outstanding - Diluted - Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": { "r1068": { "r1069": { "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.innovage.com/role/EarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "http://www.innovage.com/role/EarningsperShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares outstanding - diluted (in shares)", "totalLabel": "Weighted average common shares outstanding (diluted) (in shares)", "label": "Weighted Average Number of Shares Outstanding - Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": { "r253": { "r258": { "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.innovage.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.innovage.com/role/ConsolidatedStatementsofOperations": { "http://www.innovage.com/role/EarningsperShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares outstanding - basic (in shares)", "verboseLabel": "Weighted average common shares outstanding (basic) (in shares)", "label": "Weighted Average Number of Shares Outstanding - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r252": { "r258": { "innv_WeightedAverageRemainingLeaseTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innovage.com/20240630", "localname": "WeightedAverageRemainingLeaseTermAbstract", "presentation": { "http://www.innovage.com/role/LeasesScheduleofWeightedAverageLeaseTermsandDiscountRatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term.", "label": "Weighted Average Remaining Lease Term [Abstract]", "documentation": "Weighted Average Remaining Lease Term" } } }, "auth_ref": { "r1": { "r2": { "r3": { "r4": { "r5": { "r6": { "r7": { "r8": { "r9": { "r10": { "r11": { "r12": { "r13": { "r14": { "r15": { "r16": { "r17": { "r18": { "r19": { "r20": { "r21": { "r22": { "r23": { "r24": { "r25": { "r26": { "r27": { "r28": { "r29": { "r30": { "r31": { "r32": { "r33": { "r34": { "r35": { "r36": { "r37": { "r38": { "r39": { "r40": { "r41": { "r42": { "r43": { "r44": { "r45": { "r46": { "r47": { "r48": { "r49": { "r50": { "r51": { "r52": { "r53": { "r54": { "r55": { "r56": { "r57": { "r58": { "r59": { "r60": { "r61": { "r62": { "r63": { "r64": { "r65": { "r66": { "r67": { "r68": { "r69": { "r70": { "r71": { "r72": { "r73": { "r74": { "r75": { "r76": { "r77": { "r78": { "r79": { "r80": { "r81": { "r82": { "r83": { "r84": { "r85": { "r86": { "r87": { "r88": { "r89": { "r90": { "r91": { "r92": { "r93": { "r94": { "r95": { "r96": { "r97": { "r98": { "r99": { "r100": { "r101": { "r102": { "r103": { "r104": { "r105": { "r106": { "r107": { "r108": { "r109": { "r110": { "r111": { "r112": { "r113": { "r114": { "r115": { "r116": { "r117": { "r118": { "r119": { "r120": { "r121": { "r122": { "r123": { "r124": { "r125": { "r126": { "r127": { "r128": { "r129": { "r130": { "r131": { "r132": { "r133": { "r134": { "r135": { "r136": { "r137": { "r138": { "r139": { "r140": { "r141": { "r142": { "r143": { "r144": { "r145": { "r146": { "r147": { "r148": { "r149": { "r150": { "r151": { "r152": { "r153": { "r154": { "r155": { "r156": { "r157": { "r158": { "r159": { "r160": { "r161": { "r162": { "r163": { "r164": { "r165": { "r166": { "r167": { "r168": { "r169": { "r170": { "r171": { "r172": { "r173": { "r174": { "r175": { "r176": { "r177": { "r178": { "r179": { "r180": { "r181": { "r182": { "r183": { "r184": { "r185": { "r186": { "r187": { "r188": { "r189": { "r190": { "r191": { "r192": { "r193": { "r194": { "r195": { "r196": { "r197": { "r198": { "r199": { "r200": { "r201": { "r202": { "r203": { "r204": { "r205": { "r206": { "r207": { "r208": { "r209": { "r210": { "r211": { "r212": { "r213": { "r214": { "r215": { "r216": { "r217": { "r218": { "r219": { "r220": { "r221": { "r222": { "r223": { "r224": { "r225": { "r226": { "r227": { "r228": { "r229": { "r230": { "r231": { "r232": { "r233": { "r234": { "r235": { "r236": { "r237": { "r238": { "r239": { "r240": { "r241": { "r242": { "r243": { "r244": { "r245": { "r246": { "r247": { "r248": { "r249": { "r250": { "r251": { "r252": { "r253": { "r254": { "r255": { "r256": { "r257": { "r258": { "r259": { "r260": { "r261": { "r262": { "r263": { "r264": { "r265": { "r266": { "r267": { "r268": { "r269": { "r270": { "r271": { "r272": { "r273": { "r274": { "r275": { "r276": { "r277": { "r278": { "r279": { "r280": { "r281": { "r282": { "r283": { "r284": { "r285": { "r286": { "r287": { "r288": { "r289": { "r290": { "r291": { "r292": { "r293": { "r294": { "r295": { "r296": { "r297": { "r298": { "r299": { "r300": { "r301": { "r302": { "r303": { "r304": { "r305": { "r306": { "r307": { "r308": { "r309": { "r310": { "r311": { "r312": { "r313": { "r314": { "r315": { "r316": { "r317": { "r318": { "r319": { "r320": { "r321": { "r322": { "r323": { "r324": { "r325": { "r326": { "r327": { "r328": { "r329": { "r330": { "r331": { "r332": { "r333": { "r334": { "r335": { "r336": { "r337": { "r338": { "r339": { "r340": { "r341": { "r342": { "r343": { "r344": { "r345": { "r346": { "r347": { "r348": { "r349": { "r350": { "r351": { "r352": { "r353": { "r354": { "r355": { "r356": { "r357": { "r358": { "r359": { "r360": { "r361": { "r362": { "r363": { "r364": { "r365": { "r366": { "r367": { "r368": { "r369": { "r370": { "r371": { "r372": { "r373": { "r374": { "r375": { "r376": { "r377": { "r378": { "r379": { "r380": { "r381": { "r382": { "r383": { "r384": { "r385": { "r386": { "r387": { "r388": { "r389": { "r390": { "r391": { "r392": { "r393": { "r394": { "r395": { "r396": { "r397": { "r398": { "r399": { "r400": { "r401": { "r402": { "r403": { "r404": { "r405": { "r406": { "r407": { "r408": { "r409": { "r410": { "r411": { "r412": { "r413": { "r414": { "r415": { "r416": { "r417": { "r418": { "r419": { "r420": { "r421": { "r422": { "r423": { "r424": { "r425": { "r426": { "r427": { "r428": { "r429": { "r430": { "r431": { "r432": { "r433": { "r434": { "r435": { "r436": { "r437": { "r438": { "r439": { "r440": { "r441": { "r442": { "r443": { "r444": { "r445": { "r446": { "r447": { "r448": { "r449": { "r450": { "r451": { "r452": { "r453": { "r454": { "r455": { "r456": { "r457": { "r458": { "r459": { "r460": { "r461": { "r462": { "r463": { "r464": { "r465": { "r466": { "r467": { "r468": { "r469": { "r470": { "r471": { "r472": { "r473": { "r474": { "r475": { "r476": { "r477": { "r478": { "r479": { "r480": { "r481": { "r482": { "r483": { "r484": { "r485": { "r486": { "r487": { "r488": { "r489": { "r490": { "r491": { "r492": { "r493": { "r494": { "r495": { "r496": { "r497": { "r498": { "r499": { "r500": { "r501": { "r502": { "r503": { "r504": { "r505": { "r506": { "r507": { "r508": { "r509": { "r510": { "r511": { "r512": { "r513": { "r514": { "r515": { "r516": { "r517": { "r518": { "r519": { "r520": { "r521": { "r522": { "r523": { "r524": { "r525": { "r526": { "r527": { "r528": { "r529": { "r530": { "r531": { "r532": { "r533": { "r534": { "r535": { "r536": { "r537": { "r538": { "r539": { "r540": { "r541": { "r542": { "r543": { "r544": { "r545": { "r546": { "r547": { "r548": { "r549": { "r550": { "r551": { "r552": { "r553": { "r554": { "r555": { "r556": { "r557": { "r558": { "r559": { "r560": { "r561": { "r562": { "r563": { "r564": { "r565": { "r566": { "r567": { "r568": { "r569": { "r570": { "r571": { "r572": { "r573": { "r574": { "r575": { "r576": { "r577": { "r578": { "r579": { "r580": { "r581": { "r582": { "r583": { "r584": { "r585": { "r586": { "r587": { "r588": { "r589": { "r590": { "r591": { "r592": { "r593": { "r594": { "r595": { "r596": { "r597": { "r598": { "r599": { "r600": { "r601": { "r602": { "r603": { "r604": { "r605": { "r606": { "r607": { "r608": { "r609": { "r610": { "r611": { "r612": { "r613": { "r614": { "r615": { "r616": { "r617": { "r618": { "r619": { "r620": { "r621": { "r622": { "r623": { "r624": { "r625": { "r626": { "r627": { "r628": { "r629": { "r630": { "r631": { "r632": { "r633": { "r634": { "r635": { "r636": { "r637": { "r638": { "r639": { "r640": { "r641": { "r642": { "r643": { "r644": { "r645": { "r646": { "r647": { "r648": { "r649": { "r650": { "r651": { "r652": { "r653": { "r654": { "r655": { "r656": { "r657": { "r658": { "r659": { "r660": { "r661": { "r662": { "r663": { "r664": { "r665": { "r666": { "r667": { "r668": { "r669": { "r670": { "r671": { "r672": { "r673": { "r674": { "r675": { "r676": { "r677": { "r678": { "r679": { "r680": { "r681": { "r682": { "r683": { "r684": { "r685": { "r686": { "r687": { "r688": { "r689": { "r690": { "r691": { "r692": { "r693": { "r694": { "r695": { "r696": { "r697": { "r698": { "r699": { "r700": { "r701": { "r702": { "r703": { "r704": { "r705": { "r706": { "r707": { "r708": { "r709": { "r710": { "r711": { "r712": { "r713": { "r714": { "r715": { "r716": { "r717": { "r718": { "r719": { "r720": { "r721": { "r722": { "r723": { "r724": { "r725": { "r726": { "r727": { "r728": { "r729": { "r730": { "r731": { "r732": { "r733": { "r734": { "r735": { "r736": { "r737": { "r738": { "r739": { "r740": { "r741": { "r742": { "r743": { "r744": { "r745": { "r746": { "r747": { "r748": { "r749": { "r750": { "r751": { "r752": { "r753": { "r754": { "r755": { "r756": { "r757": { "r758": { "r759": { "r760": { "r761": { "r762": { "r763": { "r764": { "r765": { "r766": { "r767": { "r768": { "r769": { "r770": { "r771": { "r772": { "r773": { "r774": { "r775": { "r776": { "r777": { "r778": { "r779": { "r780": { "r781": { "r782": { "r783": { "r784": { "r785": { "r786": { "r787": { "r788": { "r789": { "r790": { "r791": { "r792": { "r793": { "r794": { "r795": { "r796": { "r797": { "r798": { "r799": { "r800": { "r801": { "r802": { "r803": { "r804": { "r805": { "r806": { "r807": { "r808": { "r809": { "r810": { "r811": { "r812": { "r813": { "r814": { "r815": { "r816": { "r817": { "r818": { "r819": { "r820": { "r821": { "r822": { "r823": { "r824": { "r825": { "r826": { "r827": { "r828": { "r829": { "r830": { "r831": { "r832": { "r833": { "r834": { "r835": { "r836": { "r837": { "r838": { "r839": { "r840": { "r841": { "r842": { "r843": { "r844": { "r845": { "r846": { "r847": { "r848": { "r849": { "r850": { "r851": { "r852": { "r853": { "r854": { "r855": { "r856": { "r857": { "r858": { "r859": { "r860": { "r861": { "r862": { "r863": { "r864": { "r865": { "r866": { "r867": { "r868": { "r869": { "r870": { "r871": { "r872": { "r873": { "r874": { "r875": { "r876": { "r877": { "r878": { "r879": { "r880": { "r881": { "r882": { "r883": { "r884": { "r885": { "r886": { "r887": { "r888": { "r889": { "r890": { "r891": { "r892": { "r893": { "r894": { "r895": { "r896": { "r897": { "r898": { "r899": { "r900": { "r901": { "r902": { "r903": { "r904": { "r905": { "r906": { "r907": { "r908": { "r909": { "r910": { "r911": { "r912": { "r913": { "r914": { "r915": { "r916": { "r917": { "r918": { "r919": { "r920": { "r921": { "r922": { "r923": { "r924": { "r925": { "r926": { "r927": { "r928": { "r929": { "r930": { "r931": { "r932": { "r933": { "r934": { "r935": { "r936": { "r937": { "r938": { "r939": { "r940": { "r941": { "r942": { "r943": { "r944": { "r945": { "r946": { "r947": { "r948": { "r949": { "r950": { "r951": { "r952": { "r953": { "r954": { "r955": { "r956": { "r957": { "r958": { "r959": { "r960": { "r961": { "r962": { "r963": { "r964": { "r965": { "r966": { "r967": { "r968": { "r969": { "r970": { "r971": { "r972": { "r973": { "r974": { "r975": { "r976": { "r977": { "r978": { "r979": { "r980": { "r981": { "r982": { "r983": { "r984": { "r985": { "r986": { "r987": { "r988": { "r989": { "r990": { "r991": { "r992": { "r993": { "r994": { "r995": { "r996": { "r997": { "r998": { "r999": { "r1000": { "r1001": { "r1002": { "r1003": { "r1004": { "r1005": { "r1006": { "r1007": { "r1008": { "r1009": { "r1010": { "r1011": { "r1012": { "r1013": { "r1014": { "r1015": { "r1016": { "r1017": { "r1018": { "r1019": { "r1020": { "r1021": { "r1022": { "r1023": { "r1024": { "r1025": { "r1026": { "r1027": { "r1028": { "r1029": { "r1030": { "r1031": { "r1032": { "r1033": { "r1034": { "r1035": { "r1036": { "r1037": { "r1038": { "r1039": { "r1040": { "r1041": { "r1042": { "r1043": { "r1044": { "r1045": { "r1046": { "r1047": { "r1048": { "r1049": { "r1050": { "r1051": { "r1052": { "r1053": { "r1054": { "r1055": { "r1056": { "r1057": { "r1058": { "r1059": { "r1060": { "r1061": { "r1062": { "r1063": { "r1064": { "r1065": { "r1066": { "r1067": { "r1068": { "r1069": { "r1070": { "r1071": { "r1072": { "r1073": { "r1074": { "r1075": { "r1076": { "r1077": { "r1078": { "r1079": { "r1080": { "r1081": { "r1082": { "r1083": { "r1084": { "r1085": { "r1086": { "r1087": { "r1088": { "r1089": { "r1090": { "r1091": { "r1092": { "r1093": { "r1094": { "r1095": { "r1096": { "r1097": { "r1098": { "r1099": { "r1100": { "r1101": { "r1102": { "r1103": { "r1104": { "r1105": { "r1106": { "r1107": { "r1108": { "r1109": { "r1110": { "r1111": { "r1112": { "r1113": { "r1114": { "r1115": { "r1116": { "r1117": { "r1118": { "r1119": { "r1120": { "r1121": { "r1122": { "r1123": { "r1124": { "r1125": { "r1126": { "r1127": { "r1128": { "r1129": { "r1130": { "r1131": { "r1132": { "r1133": { "r1134": { "r1135": { "r1136": { "r1137": { "r1138": { "r1139": { "r1140": { "r1141": { "r1142": { "r1143": { "r1144": { "r1145": { "r1146": { "r1147": { "r1148": { "r1149": { "r1150": { "r1151": { "r1152": { "r1153": { "r1154": { "r1155": { "r1156": { "r1157": { "r1158": { "r1159": { "r1160": { "r1161": { "r1162": { "r1163": { "r1164": { "r1165": { "r1166": { "r1167": { "r1168": { "r1169": { "r1170": { "r1171": { "r1172": { "r1173": { "r1174": { "r1175": { "r1176": { "r1177": { "r1178": { "r1179": { "r1180": { "r1181": { "r1182": { "r1183": { "r1184": { "r1185": { "r1186": { "r1187": { "r1188": { "r1189": { "r1190": { "r1191": { "r1192": { "r1193": { "r1194": { "r1195": { "r1196": { "r1197": { "r1198": { "r1199": { "r1200": { "r1201": { "r1202": { "r1203": { "r1204": { "r1205": { "r1206": { "r1207": { "r1208": { "r1209": { "r1210": { "r1211": { "r1212": { "r1213": { "r1214": { "r1215": { "r1216": { "r1217": { "r1218": { "r1219": { "r1220": { "r1221": { "r1222": { "r1223": { "r1224": { "r1225": { "r1226": { "r1227": { "r1228": { "r1229": { "r1230": { "r1231": { "r1232": { "r1233": { "r1234": { "r1235": { "r1236": { "r1237": { "r1238": { "r1239": { "r1240": { "r1241": { "r1242": { "r1243": { "r1244": { "r1245": { "r1246": { "r1247": { "r1248": { "r1249": { "r1250": { "r1251": { "r1252": { "r1253": { "r1254": { "r1255": { "r1256": { "r1257": { "r1258": { "r1259": { "r1260": { "r1261": { "r1262": { "r1263": { "r1264": { "r1265": { "r1266": { "r1267": { "r1268": { "r1269": { "r1270": { "r1271": { "r1272": { "r1273": { "r1274": { "r1275": { "r1276": { "r1277": { "r1278": { "r1279": { "r1280": { "r1281": { "r1282": { "r1283": { "r1284": { "r1285": { "r1286": { "r1287": { "r1288": { "r1289": { "r1290": { "r1291": { "r1292": { "r1293": { "r1294": { "r1295": { "r1296": { "r1297": { "r1298": { "r1299": { "r1300": { "r1301": { "r1302": { "r1303": { "r1304": { "r1305": { "r1306": { "r1307": { "r1308": { "r1309": { "r1310": { "r1311": { "r1312": { "r1313": { "r1314": { "r1315": { "r1316": { "r1317": { "r1318": { "r1319": { "r1320": { "r1321": { "r1322": { "r1323": { "r1324": { "r1325": { "r1326": { "r1327": { "r1328": { "r1329": { "r1330": { "r1331": { "r1332": { "r1333": { "r1334": { "r1335": { "r1336": { "r1337": { "r1338": { "r1339": { "r1340": { "r1341": { "r1342": { "r1343": { "r1344": { "r1345": { "r1346": { "r1347": { "r1348": { "r1349": { "r1350": { "r1351": { "r1352": { "r1353": { "r1354": { "r1355": { "r1356": { "r1357": { "r1358": { "r1359": { "r1360": { "r1361": { "r1362": { "r1363": { "r1364": { "r1365": { "r1366": { "r1367": { "r1368": { "r1369": { "r1370": { "r1371": { "r1372": { "r1373": { "r1374": { "r1375": { "r1376": { "r1377": { "r1378": { "r1379": { "r1380": { "r1381": { "r1382": { "r1383": { "r1384": { "r1385": { "r1386": { "r1387": { "r1388": { "r1389": { "r1390": { "r1391": { "r1392": { "r1393": { "r1394": { "r1395": { "r1396": { "r1397": { "r1398": { "r1399": { "r1400": { "r1401": { "r1402": { "r1403": { "r1404": { "r

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "944", "SubTopic", "80", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2",
"Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r1228", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "205", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "4",
"Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478009/946-205-45-4", "r1229", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "210", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "1",
"Subparagraph", "(b)(2)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478795/946-210-50-1", "r1230", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "210", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "6",
"Subparagraph", "(a)(1)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478795/946-210-50-6", "r1231", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "210", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "6",
"Subparagraph", "(a)(2)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478795/946-210-50-6", "r1232", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "210", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "6",
"Subparagraph", "(a)(3)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478795/946-210-50-6", "r1233", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "210", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "6",
"Subparagraph", "(a)(4)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478795/946-210-50-6", "r1234", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "210", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "6",
"Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478795/946-210-50-6", "r1235", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "210", "Name", "Accounting Standards Codification", "Section", "599", "Paragraph", "1",
"Subparagraph", "(SX 210.6-04(18))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479170/946-210-599-1", "r1236", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "220", "Name", "Accounting Standards Codification", "Section", "599", "Paragraph", "3",
"Subparagraph", "(SX 210.6-09(4)(b))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479134/946-220-599-3", "r1237", "f", "role",
http://www.xbrl.org/2009/role/commonPracticeRef, "Topic", "946", "SubTopic", "220", "Name", "Accounting Standards Codification", "Section", "599", "Paragraph", "3",
"Subparagraph", "(SX 210.6-09(7))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479134/946-220-599-3", "r1238", "f", "role",
IDEA: XBRL DOCUMENT begin 644 0001834376-24-000074-xbrl.zip M4\$!#10 (\$ + ^ EGY# UF> OP > VJ> 97@O.#\$Y+7)E=FES961F M;W)M;V9R97-TF2G\$;Z!+
M=Q;E;R50^47\$D\$D\$-D51 M;/H-L0 AE2;V3;3QJ!E;@D\$4C;V10I0P5 M!>3GES;EXY Z-0 > R(UUE4SE\$;B^A7LE^Q*(U-1^2^6)EKL-CKSK)LM<M3V>V%
0=0;1/9UO!P2<1+V1LGGVY< >D=ZRM;0B!JAGK&ZCGVYH MP-1@IWD41YX^A L!H^0^>2IUB-IDB!>378IR?>W6M+H+E>
(HEH6GZWW;BYFL1E=W7Y4JLKYE.X^>P513R &N^E42I8LAS3L C M66<=>G2 B:6PX4IHW>ZE/O^>V^Q^K<N=NB;(BRX1^VY4 Q C SD3=;A M^OM(SY4Y^I67&9SF?
Z19V1+HS^I800-APB!H^OHR>@I6G\$2GRJL L^>+M/CL QW< /54^>QY0Z9^>BY+R=>M^YZO;Z+>#>O#>EPYB!F2V8N=955 M^OM(MHXZ+^>T<+!^=VHO:
^13^SIOM(H^>S^>)/F?<=\$MF (180R?>7HTN MSTY&Z >U>CBV? N. SD3B &VY<G.(%6)P W^Q^ G9JW=7XNSV1V1=^< M5+OJ;SS?
KC@>UGG^Z4H2Y^>Y^T^>Q%F7BMR!R;R29F+L^>F^D^>U^>MWM1N1^>3JBD2^>KMS^>INDDFIRJDNOPVK^>Z+>X^BDQ9E;DH;R@RHOIC MF#WFFJZ7IURE^>6
<7>1-8JBE.KOOTG^E%5K!6^>I(OB;2TUT;BQ1+L^>M C4GZPZ!F;A.X4^>XOW7QOQD&ZUP!>23FI(KB5=IY=V!
M!#D8N;BSIAI9LE^OF@<5!>H4^>Y M!>2^S01BID;M<@>ED>JORIEB^442N MA->8T4BET. MDACZOG=N^>L^>J9H913^>IN10^>C^>72^>3^>KE/461^>*.WW8+^>O3^>DI@
MD1>7^F8E60^>P^>L6D9Y^>X6^>A^>J L^>8CLHLSN!>T^>V1G<O^>M^>RQD^>2^>8OR MA->B^>T@>V>IOVY MA^>98P3>V15^>NP2550&EQCGX+3+<
M^>KAO CS+>^>IN^>N F!A^>6FWAF;0\$M.C!>+@8R ST>>2.Y286 ^>I?>(LOL= MSLX!5?I+16^>W2VY^>7HT/9&EBF;YE2@>B+PG G^>+OD.FDV3K6C92U;X;SS\$VEFIV/!
ZJHJ46COKNMG6D13.CZ1>2>HEH3Z^>TAUCXW^>OY>WYXN!>^>X14 G9YV^>P5!>K^>C^>P^>MU8TA^>ZG^>G^>RC%>=>1JF6^>DHSY6&8H1F^>2^>8U@A^>W\$HBF6G^KZYH
MCRK^>Q57HMD0^>T2838^>U3L&P^>OQ410^>X^>P^>F3D3AOYXZ^>D;0B55^>P^>V0Y3^>M3Y2^>@J8ZBL^>CBG^>M^>=>#>A40^>0L^>X^>P^>9^>F^>=>1^>SH2^>MGE9RCLM^>Z^>1^>#>JLG^>FTMLL@6?
1:0G^>RXD5^>2JVV^>U11-D^>1PH;TH0^> . M.OQL<6R5^>J0^>+>36N^>2^>S3^>3^>5^>H6B^>OF^>X^>F^>L^>H^>J^>Z^>KH^>MN^>A^>VJUD0&SBLEA RZKNZB!>S0 ^>LK-GJ=>^>IDB2<@>UVU);
N31^>QEG^>M^>XNRM1G^>G^>KZKN^>R^>J^>K^>X^>GOEBO B0^>W^>6^>GOW/!#L IK1L^>=>(S\$B6F^>XLH/L^>ME^>F^>L^>H^>L^>Z^>69.L^>UWOB8L^>Z66N!>XLEGNO<6^>I^>X^>D^>4B^>I^>X^>D^>MS5^>7G\$;FV^>=
Z^>#^>X^>IZWDT^>H^>H^>OQI^>^>AJLXX6^>+QH6\$E=5!5?>)U+V12 MQ?>6JZV^>HJ\$;GORU5-T& &KW^>1MQ1BM9^>YL>(6^>N\$!>G^>V^>+>C/4L^>)>^>GT^>MZ^>7I^>^>H^>E5^>G&W^>6^>7^>2^>RO^>2^>F!
H^>G^>F^>Z^>771H^> L^>#A^>L^>E^>O\$;63B^>M^>F^>1>=>V^>P^>9U^>P^>3^>7^>DR12^>F5^>X^>K^>4K^>L^>CS^>W^>N^>L^>1R2^>SU^>V^>S^>E^>M^>X^>K6501R5^>^>K46F^>J8;P^>L^>EG^>H6&X^>I6^>Z^&gt

[illegible]